<SEC-DOCUMENT>0001055726-25-000012.txt : 20250318
<SEC-HEADER>0001055726-25-000012.hdr.sgml : 20250318
<ACCEPTANCE-DATETIME>20250318160037
ACCESSION NUMBER:		0001055726-25-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250318
DATE AS OF CHANGE:		20250318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		25748097

	BUSINESS ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ino-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:17b32d98-3816-4b9f-8e66-a2aab92f0705,g:04b54f73-b42b-4be7-b731-92d690b75cab,d:cae65948681042dba847429b32ecbd7c-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ino="http://www.inovio.com/20241231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-33">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-36">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-37">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="c-49" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-355">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-67" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-417">0.0833</ix:nonFraction><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-574">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-222" decimals="INF" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" scale="-2" id="f-826">50</ix:nonFraction><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-1019">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-67" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-1057">0.0833</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ino:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="position"><xbrli:measure>ino:position</xbrli:measure></xbrli:unit><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="defendent"><xbrli:measure>ino:defendent</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-16</xbrli:startDate><xbrli:endDate>2024-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-16</xbrli:startDate><xbrli:endDate>2024-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:April2024OfferingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:April2024OfferingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-18</xbrli:startDate><xbrli:endDate>2024-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-24</xbrli:startDate><xbrli:endDate>2024-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-16</xbrli:startDate><xbrli:endDate>2024-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-16</xbrli:startDate><xbrli:endDate>2024-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-16</xbrli:startDate><xbrli:endDate>2024-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-16</xbrli:startDate><xbrli:endDate>2024-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-13</xbrli:startDate><xbrli:endDate>2024-08-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis">ino:PerformanceRSUsSpecifiedThresholdPercentileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis">ino:PerformanceRSUsTargetPercentileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis">ino:PerformanceRSUsSpecifiedMaximumPercentileMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ino:December2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ino:December2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:StockOptionsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:StockOptionsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3107Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3107Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO5401AndOtherImmunoOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO5401AndOtherImmunoOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:EngineeringAndDeviceRelatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:EngineeringAndDeviceRelatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:StockBasedCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:StockBasedCompensationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherUnallocatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherUnallocatedExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-12</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icae65948681042dba847429b32ecbd7c_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> FOR THE FISCAL YEAR ENDED <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">DECEMBER 31</ix:nonNumeric>, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.465%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-14888</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><img src="ino-20241231_g1.jpg" alt="inoviologosw.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Plymouth Meeting</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-13">Pennsylvania</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">19462</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">440-4200</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.965%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.799%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric>  Capital Market</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#168;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity (which consists solely of shares of Common Stock) held by non-affiliates of the Registrant as of June&#160;30, 2024 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-30">208.0</ix:nonFraction> million based on $8.08 per share, the closing price on that date of the Registrant&#8217;s Common Stock on the Nasdaq Capital Market.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">36,667,221</ix:nonFraction> as of March&#160;12, 2025.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2025 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2024.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:81.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_10">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_13">ITEM&#160;1. BUSINESS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_16">ITEM&#160;1A. RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_16">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_19">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_19">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_22">ITEM&#160;1C. CYBERSECURITY</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_19">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_25">ITEM&#160;2. PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_25">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_28">ITEM&#160;3. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_28">55</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_31">ITEM&#160;4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_31">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_34">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_34">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_37">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_37">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_40">ITEM&#160;6. [RESERVED]</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_40">58</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_43">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_43">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_61">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_61">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_64">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_64">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_67">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_67">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_70">ITEM&#160;9A. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_70">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_76">ITEM 9B. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_76">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_79">ITEM 9C.  </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_79">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_79">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_82">PART III</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_82">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_85">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_85">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_88">ITEM&#160;11. EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_88">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_91">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_91">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_94">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_94">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_97">ITEM&#160;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_97">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_100">PART IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_100">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_103">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_103">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_106">ITEM 16. FORM 10-K SUMMARY</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_106">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_109">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_109">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_112">CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_112">1</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K (including the following section regarding Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading &#8220;Risk Factors&#8221; below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report includes trademarks and registered trademarks of INOVIO Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners. References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;INOVIO&#8221; or the &#8220;Company&#8221; refer to INOVIO Pharmaceuticals, Inc. and its consolidated subsidiaries. References herein to &#8220;DNA medicines&#8221; refers to our product candidates in development for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Part I, Item 1A., Risk Factors herein. These risk factors include, but are not limited to, the following: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to obtain FDA approval of our proprietary devices and DNA medicine candidates, we will not be able to commercialize them in the United States. In particular, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory authorities do not provide marketing authorization for our CELLECTRA delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a novel approach to administering medicines. Negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary devices and DNA medicine candidates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have agreements with government agencies that are subject to termination and uncertain future funding. Termination or cessation of funding could have a negative impact on our ability to develop some of the product candidates in our pipeline and/or require us to seek alternative funding sources to advance those candidates. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have entered into collaborations with Chinese companies and may rely on clinical materials manufactured in China for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. Our platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease.  Our proprietary investigational CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> devices are designed to deliver the plasmids into the body&#8217;s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP) a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. RRP is characterized by the recurring growth of small wart-like growths called papillomas in the respiratory tract. Although mostly benign, these papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. The standard of care for RRP is repeated invasive surgery and patients have expressed that even one less surgery would be life-changing. The most widely cited U.S. epidemiology data, published in 1995, estimated that there were 14,000 active cases for both adults and juveniles, and about 1.8 new cases per 100,000 adults each year.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRP patients are unable to mount an effective immune response to HPV-6 and HPV-11, leading to chronic disease. INO-3107 has the potential to induce a targeted immune response, enabling the body to generate new T-cells that travel to HPV-infected airway tissue to seek out and kill HPV-6 and HPV-11 infected cells. In a Phase 1/2 trial (RRP-001) of 32 participants, INO-3107 reduced the number of surgeries patients faced by helping prevent or slow papilloma growth. Of the 32 participants in the trial, 26 of them (81.3%) experienced a reduction in the number of surgical interventions in the year following administration of INO-3107 when compared with the year prior to treatment. Of these 32 patients, nine did not require surgical intervention during or after the dosing window. Patients in the trial had a median of 4 surgeries (range of 2-8) in the year prior to dosing. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior to treatment. Treatment with INO-3107 generated a strong immune response in the trial, inducing activated CD4 T cells and activated CD8 T cells with lytic potential. T-cell responses were also observed at Week 52, indicating a persistent cellular memory response. A retrospective analysis (RRP-002) of 28 participants from the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRP-001 trial showed extended durability of response and further reduction in surgical burden when patients were evaluated up to three years after initial dosing, including 50% (14/28) of patients meeting the criteria for Complete Response during Year 2 vs. 28% (9/32) during Year 1. INO-3107 was well tolerated by participants in the trial, resulting in mostly low-grade (Grade 1) treatment-emergent adverse effects such as injection site pain and fatigue. In the fourth quarter of 2023, we received feedback from the U.S. Food and Drug Administration, or FDA, that the data from the completed Phase 1/2 trial could be used to support the submission of a Biologic License Application, or BLA, for review under the FDA&#8217;s accelerated approval program. As part of submitting our BLA under the accelerated program, we will need to satisfy all FDA filing requirements and initiate a confirmatory clinical trial prior to BLA submission. We previously expected to be able to submit our BLA by the end of 2024; however, during our device testing process we identified a manufacturing issue involving the single-use disposable administration component of the CELLECTRA 5PSP device that we will use in the confirmatory trial and will be submitted for approval for commercial use. We resolved the manufacturing issue in the first quarter of 2025 and are currently on track to begin a rolling submission of the BLA in mid-2025 and to request priority review, with a goal of receiving file acceptance by the FDA by the end of 2025.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing INO-3112, a DNA medicine candidate targeting HPV 16 /18 combined with a DNA plasmid encoding for human IL-12 as an immune activator, for the treatment of high-risk, HPV-16 or 18 positive oropharyngeal squamous cell carcinoma, or OPSCC, a type of head and neck cancer commonly known as throat cancer. The incidence of HPV-related throat cancer has increased rapidly in recent years in the United States, with an estimated 20,000 new cases each year. In 2024 HPV-related throat cancer surpassed cervical cancer as the most common HPV-related cancer. In the United States, men are four to five times more likely to be diagnosed with HPV-associated oropharyngeal cancers than women.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a clinical collaboration and supply agreement with Coherus BioSciences, Inc., or Coherus, to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) in a clinical trial for patients with locoregionally advanced, high-risk, HPV16/18 positive OPSCC. Under the terms of the supply agreement, Coherus will provide LOQTORZI for a planned Phase 3 clinical trial. We have also gained alignment with the FDA on the design of the planned Phase 3 trial in the United States and received initial feedback from European regulatory authorities on the proposed design of the trial in Europe. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing INO-5401, an immunotherapy consisting of three DNA plasmids encoding for three tumor associated antigens, for the treatment of glioblastoma multiforme, or GBM, an aggressive type of brain cancer that accounts for more than 50% of all primary malignant brain tumors. GBM is one of the most complex, deadly, and treatment-resistant cancers. In the United States, nearly 15,000 people were expected to receive a GBM diagnosis in 2023, and it is estimated that more than 10,000 individuals will succumb to the disease each year.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our development efforts with the product candidates described above, we, or with partners, are actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia; cancers in people with certain gene mutations; and a potential vaccine booster to protect against the Ebola virus. We were previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions, or HSIL, but announced in 2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Characteristics of DNA Medicines </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines are optimized DNA plasmids containing a gene encoding for a protein that is expressed once these plasmids are delivered into cells. We can design our plasmids to teach the body&#8217;s cells to produce a wide range of proteins, including antigens to elicit a specific immune response, monoclonal antibodies to fight a specific pathogen, or therapeutic proteins to replace defective or missing proteins in the body. These DNA medicines can generate antigen-targeted humoral and cellular immune responses based on the indication, including antigen-specific cytotoxic, or killer, T cell responses that are important for fighting cancer and viral infections. Some of the key characteristics of our DNA medicines include:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">T Cell Responses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have demonstrated the ability to generate high levels of T cell (CD4+, CD8+, and memory) response along with antibody response. CD8+ T cell responses are thought to play an important role in clearing tumors or virally infected cells.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Safety and Tolerability: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have been well tolerated by clinical trial participants when evaluated against multiple disease targets. Our DNA medicines have been administered over 19,000 times across nearly 6,000 participants to date.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Ability to Re-dose: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have been used in clinical trials to boost or sustain immune response via repeat administration </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Versatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our DNA medicines technology can be utilized to produce in vivo proteins or antigens key to treating or preventing various human diseases, such as cancer, viral infections or protein deficiencies. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Stability of Product: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines do not require frozen storage or shipping.&#8239;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt">Design and Manufacture: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines can be rapidly designed and scaled, with ease of manufacturing providing a potential cost advantage.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Delivery Mechanism:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our proprietary delivery devices use electroporation to increase cellular uptake and overcome the barrier posed by cell membranes that can hinder the entry of large molecules, such as DNA plasmids. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Our DNA Medicines Platform</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines platform consists of DNA plasmids and our CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. These two components combine to create a versatile platform that has the potential to target multiple diseases and conditions. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA Plasmid Design Technology </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our precisely designed DNA plasmids are circular double-stranded DNA constructs that have been optimized, using our proprietary technology and algorithms, to express a protein. Our plasmids can be designed to enable the body&#8217;s cells to produce a wide range of proteins, including antigens to elicit a specific immune response, monoclonal antibodies to fight a specific pathogen, or therapeutic proteins to replace defective or missing proteins in the body. In the area of HPV-related diseases, for example, the expressed proteins are viral antigens that elicit antigen-specific T cell responses to fight HPV. We start by identifying one or more viral antigens that we believe are the best targets for directing the immune system toward HPV and then apply our design process, which analyzes the genetic make-up of the selected antigens from multiple strains of the virus.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each antigen, we create a new genetic sequence that represents a nucleotide consensus sequence of the targeted antigen. In doing so, we believe we can create a differentiated sequence to help the immune system better recognize the target antigen and potentially variations of the target antigen. We have generated immune responses, including CD4+, CD8+, and memory T cells, with our DNA medicines against various tumor-associated antigens, as well as against different strains of certain infectious diseases in human clinical trials. Because the engineered genetic sequences are substantially similar to the original sequences, without matching them exactly, we believe they are patentable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a sequence is designed and optimized with our proprietary gene optimization algorithm, which we refer to as GOAL, the sequence is synthesized and inserted into a circular DNA plasmid with its own promoter. Promoters serve a vital role in promoting the expression of the protein once the DNA medicine has entered the cell. Using our technology, the DNA plasmids have been optimized to enable high expression in human cells. We believe these design capabilities allow us to better target appropriate immune system mechanisms and produce a higher level of protein expression compared to traditional approaches, potentially enhancing the overall ability to induce the desired immune response.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plasmids are then manufactured in a bacterial fermentation process using scalable manufacturing technology. We have recently developed a high-yield manufacturing process which we anticipate using to manufacture our DNA medicines. The manufactured DNA medicines do not require ultracold or frozen storage or thawing prior to injection and are refrigerator stable at 2 to 8 degrees Celsius, which are key factors for both distribution and administration. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Delivery Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines need a pathway into the cell to work effectively. To help DNA plasmids, which are relatively large molecules, pass through the cell membrane, we use our proprietary CELLECTRA delivery technology. After injecting the DNA medicine either intramuscularly (IM) or intradermally (ID), CELLECTRA devices use electroporation (EP), or brief electrical pulses, to reversibly open small pores in the cell membrane, allowing DNA plasmids to enter. Through this process, the cellular uptake of the DNA plasmids can be substantially increased compared to the in vivo injection of DNA plasmids alone. This improved cellular uptake has enabled the immune responses and efficacy results observed in our clinical trials to date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CELLECTRA device portfolio currently consists of two models (CELLECTRA 5PSP AND CELLECTRA 3PSP) designed for late-stage clinical use and potentially for eventual commercial use, and one device (CELLECTRA 2000) that we primarily utilize in earlier-stage clinical trials. These devices have been designed to optimize delivery of our DNA medicine candidates depending on the target disease. Our CELLECTRA 5PSP model provides intramuscular EP and is designed to be used with candidates addressing cancers and HPV-related pre-cancers. It uses a prefilled drug cartridge and delivers both the DNA medicine and the EP to the patient. CELLECTRA 5PSP was used in our Phase 3 trials (REVEAL1/REVEAL2) for cervical HSIL and will be used in our planned confirmatory trial for INO-3107, our DNA medicine candidate for RRP. Our CELLECTRA 3PSP model was developed with support from the U.S. Department of Defense, the Center for Epidemic Preparedness Innovations, and the Bill &amp; Melinda Gates Foundation for intradermal EP delivery. The small, handheld design is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intended for mass administration and commercial use and will mainly be used with DNA medicine candidates addressing infectious disease. CELLECTRA 3PSP only delivers EP, after a separate DNA medicine injection into the skin. The EP is delivered around the intradermal injection site.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CELLECTRA devices are validated and manufactured under Current Good Manufacturing Practices (cGMP). We have used CELLECTRA devices in global human clinical trials. We have CE-marked the CELLECTRA 5PSP model in the EU, which allows us to commercialize the device in the EU and other geographies that recognize CE-marking.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for administration of our DNA medicines is illustrated in the following graphic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><img src="ino-20241231_g2.jpg" alt="Picture2.jpg" style="height:247px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA Medicines and HPV-related Diseases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are more than 200 known types of HPV. It is believed that nearly all humans will become infected with at least some type of HPV during their lifetime, but most people are able to eliminate the virus before it causes disease. Certain types of HPV are known for being more difficult to clear and have a greater likelihood of leading to disease. For example, HPV-6 and HPV-11 may lead to benign growths (either warts or papillomas) that can develop into conditions such as RRP, while HPV-16 and HPV-18 may lead to cell changes and lesions, also known as precancerous dysplasia, that can become malignant and lead to cervical cancer. HPV causes nearly all cervical cancers and many cancers of the vagina, vulva, penis, anus, rectum, and oropharynx.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are currently vaccines available to prevent HPV infection, challenges with acceptance, accessibility, and patient compliance have resulted in many vaccine-eligible people remaining unvaccinated and at risk. It is estimated that even in the United States, only 50-60% of the eligible population has been vaccinated against HPV. In addition, current preventive HPV vaccines cannot treat or protect those already infected with the same HPV genotypes. As a result, there is still an urgent need for the development of HPV therapies that can treat existing infections and prevent the development of HPV-related diseases. The current standard of care for many HPV-related diseases, including RRP and many cancers, is surgery. These surgeries can be invasive and may be needed repeatedly because the underlying HPV infection is not eliminated. In addition to surgery, other options are being explored to treat HPV-related diseases, including the usage of immune checkpoint inhibitors and other immunotherapies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our DNA Medicines in Development</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The chart below provides an overview of our DNA medicines pipeline. We have focused our efforts and resources on those product candidates that we believe have the greatest potential to reach the market. The programs identified in the chart are described in more detail below. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><img src="ino-20241231_g3.jpg" alt="Pipeline updated (002).jpg" style="height:392px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(DMAb = DNA-encoded monoclonal antibody; DPROT = DNA-encoded protein technology; dLNP = DNA-launched nanoparticle)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">INO-3107 for HPV-related RRP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRP is a life-long, rare disease characterized by the growth of small tumors, or papillomas, in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although mostly benign, these papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. A distinguishing aspect of RRP is the tendency for the papillomas to recur after surgical procedures to remove them. If RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease, also known as bronchiectasis, and, ultimately, progressive pulmonary failure. In approximately 2% of cases, RRP can develop into squamous cell carcinoma. Additional symptoms of RRP can include a hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in children than in adults. The standard of care for RRP is repeated surgery. The most widely cited U.S. epidemiology data, published in 1995, estimated that there were 14,000 active cases for both adults and juveniles, and about 1.8 new cases per 100,000 adults each year.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing our lead product candidate, INO-3107, for the treatment of HPV-6 and HPV-11-associated RRP. INO-3107 is an immunotherapy composed of plasmids encoding for HPV-6 and HPV-11 antigens, as well as human interleukin-12 (IL-12). In May 2023, preliminary results from an open-label, multicenter Phase 1/2 trial (RRP-001; NCT:04398433) evaluating the efficacy, safety, tolerability and immunogenicity of INO-3107 in 32 patients with HPV 6 and/or HPV 11-associated RRP were presented at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts. The trial included a first cohort of 21 patients dosed with a standard injection needle and a second cohort of 11 patients dosed with an exploratory side port injection needle. We plan to use the standard needle in our planned confirmatory trial and for delivery of the commercial product, should it be approved. In both cohorts of the trial, our proprietary CELLECTRA 2000 electroporation device was used to deliver the product candidate. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim analysis was published in a scientific peer-reviewed journal, The Laryngoscope, in 2023. The full safety and efficacy results from the RRP-001 trial were presented in October 2024 at the International Society of Vaccines Congress and published in the scientific journal Nature Communications in February 2025. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RRP-001 trial evaluated the reduction in the number of surgical interventions in the year following initial administration of INO-3107 compared to the year prior to treatment. For this trial, adult patients first underwent surgical removal of their papillomas and then received four doses of INO-3107, once every three weeks. The primary endpoint of this trial was safety and tolerability. At the outset of the study (Day 0), patients could have RRP tissue surgically removed, but any surgery performed after Day 0 during the dosing window was counted against the efficacy endpoint.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the trial, 81.3% (26/32) of patients had a decrease in number of surgical interventions in the year after INO-3107 administration compared to the prior year, including 28.1% (9/32) that required no surgical intervention during or after the dosing window. Patients in the trial had a median of 4 surgeries (overall range of 2-8) in the year prior to dosing. After dosing, there was a statistically significant median decrease of 3 surgical interventions (95% confidence interval: -3 to -2). Treatment with INO-3107 generated a strong cellular immune response in the trial, inducing activated CD4 T cells and activated CD8 T cells with lytic potential. T-cell responses were also observed at Week 52, indicating a persistent cellular memory response. INO-3107 was well tolerated by participants in the trial, resulting in mostly low-grade (Grade 1) treatment-emergent adverse effects such as injection site pain and fatigue. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, immunology data from the RRP-001 trial were presented at the American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and the Immunotherapy and the International Papillomavirus Conference. These data support the mechanism of action of INO-3107 and demonstrated the ability of INO-3107 to induce antigen-specific T cell responses against HPV-6 and HPV-11 and drive recruitment of those T cells into airway tissues and papilloma of RRP patients, resulting in the slowing or elimination of papilloma regrowth. The immunology data showed that INO-3107 induced significant clonal T cell expansion in the blood, including antigen-specific killer T cells and T cell infiltration into airway tissue, which was positively associated with clinical response. The immunology data was consistent with the clinical effect observed in the RRP-001 trial, which showed an elimination or reduction in the incidence of papilloma in the airway of RRP patients. In the immunological assessment, the T cell infiltration observed in airway tissues of clinical responders was predominantly comprised of a T cell population detectable only after administration of INO-3107.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further data reported in 2024 showed that patients exhibited extended durability of clinical response and further reduction in surgical burden when evaluated two and three years after initial dosing. In a retrospective trial (RRP-002) of 28 participants from the Phase 1/2 RRP-001 trial, half of the patients treated with INO-3107 achieved a complete response (CR) and required no surgery when evaluated at the end of year two and into year three post initial treatment, increasing from the initial CR rate of 28% at the end of the first year. The retrospective analysis showed that of those patients who had an initial CR, 88% maintained their CR by end of the second year and 63% into the third year. Of the patients included in the retrospective analysis, 95% maintained or enhanced their original Overall Response Rate (&#8220;ORR,&#8221; defined as those patients who achieved either a CR or a partial response) after two years, while 86% of patients maintained or enhanced their ORR into year three.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted INO-3107 Orphan Drug Designation (ODD) in July 2020 and Breakthrough Therapy Designation in 2023. The European Commission has also granted INO-3107 Orphan Drug Designation. In 2024, INO-3107, was designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP). In 2024, the European Medicines Agency's Committee for Advanced Therapies (CAT) certified the quality and non-clinical data for INO-3107, confirming that the chemistry, manufacturing and controls (CMC) data and nonclinical results available to date comply with the scientific and technical standards that would be used for evaluating a European Marketing Authorization application. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-3112 is a DNA immunotherapy consisting of two plasmids targeting HPV 16/18 combined with a DNA plasmid encoding for human IL-12 as an immune activator. Results from a Phase 1/2a trial of INO-3112 alone in 22 HPV-positive head and neck squamous cell carcinoma (HNSCC) patients, published in Clinical Cancer Research in 2019, included the observation of T cell responses and infiltration of CD8+ T cells into the head and neck tumors. In early 2023, updated results were published in Clinical Cancer Research from a Phase 1b/2a trial of INO-3112 in combination with AstraZeneca&#8217;s PD-L1 immune checkpoint inhibitor, durvalumab, showing an ORR of 27.6% with 4 complete responses and 4 partial responses in the overall group of 29 evaluable patients and increased presence of peripheral HPV-specific T cells and tumoral CD8+ T cells. Further, the efficacy of the combination of INO-3112 with durvalumab resulted in a median overall survival, or OS, of more than 29 months. This is an improvement over historical data for immune-checkpoint blockade therapy alone, or in combination with other HPV therapeutic vaccines and almost three times the historical overall survival period for monotherapy durvalumab in a similar patient population. Objective responses, including complete responses, occurred independently of PD-L1 expression, which contrasts with historical data for durvalumab. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we announced a clinical collaboration and supply agreement with Coherus. to evaluate the combination of INO-3112 and LOQTORZI&#8482; as a potential treatment for patients with locoregionally advanced, high-risk, HPV-16/-18 positive OPSCC. Under the terms of the supply agreement, Coherus will provide LOQTORZI for a planned Phase 3 clinical trial to be conducted by us. We have submitted our Phase 3 trial design to the FDA and European regulators and gained alignment with FDA on the proposed trial design. We have also received initial feedback from European regulatory authorities on the proposed design of the trial. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 for the Treatment of HPV-related Cervical HSIL</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we announced the discontinuance of our U.S. development program of VGX-3100 for the treatment of HPV-related cervical HSIL. This decision followed final analysis of the data from our second Phase 3 trial of VGX-3100. In this trial, statistical significance was not achieved in the investigational biomarker-selected population for the endpoint of lesion </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regression and viral clearance. However, statistical significance was achieved in the all-participants population for the endpoint of lesion regression and viral clearance. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ad hoc integrated efficacy analysis of the results for the two completed Phase 3 trials of VGX-3100 showed statistical significance in the biomarker-selected and all-participants populations for lesion regression and viral clearance. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in both Phase 3 trials, administration of VGX-3100 by the CELLECTRA 5PSP device was well tolerated and there were no treatment-related serious adverse events, with most adverse events considered to be mild to moderate. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combined data set from the two Phase 3 trials will be used as supportive data in any future regulatory interactions involving VGX-3100. Our collaborator ApolloBio Corporation is conducting a Phase 3 clinical trial of VGX-3100 for cervical HSIL in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. See &#8220;Collaborations and Alliances&#8221; below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 for the Treatment of Anal or Perianal HSIL  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV-16 and HPV-18 can cause precancerous lesions of the anus (anal HSIL). Left untreated, anal HSIL may progress to cancer. Spontaneous regression of anal HSIL is observed in approximately 20% of patients. Persistent infection with one or more high-risk HPV genotypes is responsible for a large portion of anal cancer. In the United States, about 55% to 80% of anal HSIL cases are associated with HPV-16/-18, and worldwide about 80% of anal HSIL cases are associated with HPV-16/18. In the United States, over 90% of anal cancer is attributable to HPV, and about 87% of those HPV anal cancers are attributable to HPV-16/-18 specifically. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no validated screening tests or a general consensus for screening recommendations for anal HSIL. Treatment usually consists of repeated ablation, most commonly radiofrequency ablation (RFA), resections or laser therapy. However, recurrence rates are high, up to 49% one year after treatment, as ablation does not clear the underlying HPV infection, resulting in an unmet medical need. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted a Phase 2 clinical trial (HPV-203) to evaluate VGX-3100 in participants who were HIV-negative with histologically confirmed anal or perianal HSIL, or anal intraepithelial neoplasia (AIN), associated with HPV-16 and/or HPV-18. This open-label trial enrolled 24 participants who received three doses of VGX-3100 delivered by our CELLECTRA 5PSP device. The primary endpoint of the trial was histologic clearance of the high-grade lesions and virologic clearance of the HPV-16/18 virus in anal/perianal tissue samples. In 2020, we announced Phase 2 results from this trial. One-half of the 22 participants treated with VGX-3100 showed resolution of HPV-16/18-associated anal HSIL at six months following the start of treatment. Administration of VGX-3100 by our CELLECTRA-5PSP device was also well tolerated in the trial. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A separate Phase 2 trial of VGX-3100 is currently being sponsored by the AIDS Malignancy Consortium. The trial is evaluating VGX-3100 in participants with histologically confirmed anal or perianal HSIL associated with HPV-16 and/or HPV-18 who are HIV-positive. This open-label single-arm trial has enrolled approximately 90 participants who will receive up to four doses of VGX-3100 delivered by CELLECTRA 5PSP. The primary endpoint of the trial is histological regression of high-grade anal lesions to low-grade SIL or normal histology. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5401 for the Treatment of Glioblastoma Multiforme (GBM) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glioblastoma multiforme, or GBM, is the most common aggressive type of brain cancer. In the United States, the median age at diagnosis is 65 years, and the incidence rate increases thereafter. Prognosis is extremely poor, and a limited number of new therapies have been approved over the last 10 years; average survival for U.S. patients has been reported to be as low as 8 months with a five-year survival rate of 6.9% for all ages combined. The overall incidence of GBM varies worldwide but is highest in North America, Australia and Northern and Western Europe. In the United States, the average age-adjusted incidence rate of GBM is 3.19 cases per 100,000 persons. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our immunotherapy candidate INO-5401 consists of three DNA plasmids encoding for three tumor-associated antigens: human Telomerase Reverse Transcriptase (hTERT), Wilms Tumor gene-1 (WT1) and Prostate-Specific Membrane Antigen (PSMA). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted a Phase 1/2 immuno-oncology trial of INO-5401 and INO-9012 (a DNA plasmid encoding for IL-12) in 52 participants with newly diagnosed GBM, in combination with cemiplimab (Libtayo&#174;), a PD-1 immune checkpoint inhibitor developed by Regeneron Pharmaceuticals. The primary endpoint was safety and tolerability, and the trial also evaluated immunogenicity as well as efficacy based on OS rates. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented the OS data at the 2022 American Society of Clinical Oncology (ASCO). Median OS in patients with an unmethylated MGMT promoter (Cohort A) was 17.9 months, which compared favorably to historical durations between 14.6 and 16 months. Median OS in patients with an MGMT methylated promoter (Cohort B) was 32.5 months, which also compared favorably to historical durations between 23.2 and 25 months. Overall, co-administration of INO-5401 with INO-9012 and with Libtayo and RT/TMZ (radiation and temozolomide) was well tolerated. Treatment was also observed to be immunogenic, eliciting antigen-specific T cells that may infiltrate GBM tumors. As of the end of 2024, GBM patients in the trial remained on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug treatment. We are considering various options for continuing clinical investigation of INO-5401 and INO-9012 in patients with GBM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with researchers at the University of Pennsylvania to conduct a Phase 1b investigator-sponsored trial to evaluate the tolerability and immunogenicity of INO-5401 alone or in combination with INO-9012, in each case delivered with our CELLECTRA device, for adult cancer and non-cancer patients with BRCA1 or BRCA2 mutations. This trial is ongoing. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All humans have BRCA1 and BRCA2 genes, but some people are born with an error, or mutation, in one of these genes. People with a gene mutation in either BRCA1 or BRCA2 are at heightened risk for certain cancers, including breast, ovarian, prostate, and pancreatic cancers. These gene mutations can be passed on to children by either men or women. </span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infectious Disease Product Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4800 for COVID-19 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2/3 Clinical Trial &#8211; SOLIDARITY TRIAL VACCINES (STV)  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-4800 is one of two initial COVID-19 vaccine candidates included in the World Health Organization (WHO) sponsored Solidarity Trial Vaccines, or STV, which is designed to evaluate the efficacy and safety of vaccine candidates selected by an independent vaccine prioritization advisory group composed of leading scientists and experts. The conduct of the STV is wholly under the WHO&#8217;s control and any announcement regarding that trial will be made by the WHO. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INO-4800 in China </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborator Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous booster vaccine trials in China. The trials are designed to evaluate safety, tolerability and immunogenicity of INO-4800 as a homologous booster where INO-4800 was administered as the primary vaccine and as a heterologous booster where an inactivated vaccine was administered as the primary vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 DNA-encoded Monoclonal Antibodies (DMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our GOAL technology, we are able to create precisely designed DNA plasmids that encode for specific monoclonal antibodies (mAbs). They are delivered directly into cells of the body using our CELLECTRA delivery system, enabling the body to manufacture its own DNA encoded mAbs (DMAbs) in vivo, as opposed to conventional recombinant mAb production </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe this approach provides potentially significant advantages in terms of design simplicity, rapidity of execution and lower production costs. We expect to design DMAb product candidates for new disease targets that may not be currently addressable with conventional recombinant mAbs and also targets of existing, commercially available mAb products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we, along with a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), a research and development agency of the DoD and the JPEO-CBRND, to use our DMAb technology to develop anti-SARS-CoV-2-specific DMAbs that function as both a therapeutic and potentially preventive treatment for COVID-19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Wistar announced the dosing of the first participant in a Phase 1, open-label, single-center, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic profile of the mAb product candidates encoded on our DNA plasmid, administered intramuscularly followed immediately by electroporation using our CELLECTRA 2000 device in a 1- dose (Day 0), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2-dose (Days 0 and 3) and 4-dose regimen (Days 0, 3, 28 and 31) in healthy adults (NCT05293249). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March of 2025 interim results from the trial were shared in preprint on Research Square. In the trial, 100% (24/24) of participants who have reached week 72 maintained biologically relevant levels of DMAbs, confirming the durability of in vivo antibody production. Notably, no participant developed anti-drug antibodies, a common challenge observed in other gene-based delivery platforms, such as adeno-associated virus (AAV) )-mediated antibody expression. Additionally, the DMAbs were well tolerated in the trial, with the most common side effects being mild, temporary injection site reactions, such as pain and redness. The study is ongoing and we and our collaborators plan to present and publish the interim clinical data this year.   </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4201 for Ebola Virus Disease</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ebola virus (EBOV) causes one of the most virulent viral diseases, with case fatality rates averaging approximately 50% but approaching up to 90% in past outbreaks in areas with no or under-developed health care. EBOV can spread through human-to-human transmission by direct contact with the blood, secretions, organs or bodily fluids of an infected individual and with surfaces or materials that contain the contaminated fluids of an infected person, such as bedding and clothing. It is capable of causing death within 2 to 21 days of exposure. In 2019, the European Medicines Agency (EMA) conditionally approved the preventative vaccine ERVEBO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the World Health Organization pre-qualified that vaccine for use in high-risk countries and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approved the vaccine for use in the United States. However, ERVEBO has not been approved for repeat dosing and there are currently no approved booster vaccines available in the United States.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we announced complete enrollment of a 46-participant Phase 1b trial (NCT04906629) in which our DNA medicine candidate INO-4201 was assessed as a heterologous booster in healthy volunteers previously vaccinated with ERVEBO. In 2023, we announced results from the Phase 1b trial. INO-4201 was well tolerated and boosted humoral responses in all 36 participants treated in the trial. In 2024 we announced new antibody response data from the Phase 1b trial. Utilizing the FANG assay, which allows us to more accurately benchmark our data against the primary vaccines on the market, we observed that INO-4201 elicited strong antibody responses, comparable to the ERVEBO primary series vaccination. We and our collaborators plan to publish the data from this Phase 1b trial in a peer-reviewed scientific journal.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we also submitted a proposed Phase 2 trial design to the FDA. We have been advised that the FDA is in alignment with our proposal to use a non-human primate (NHP) challenge study to immunobridge to the Phase 2 clinical study. Results from these two studies would subsequently inform the design of a potential Phase 3 study.   </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-6160 for HIV</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing our DNA medicine candidate INO-6160 as a prophylactic vaccine against human immunodeficiency virus, or HIV. INO-6160 is composed of one plasmid encoding for an HIV trimer and one encoding for human IL-12. INO-6160 is being evaluated in a Phase 1 trial that is externally sponsored and funded by the National Institute of Allergy and Infectious Diseases, or NIAID. The trial is a randomized, 20-participant, open-label Phase 1 trial evaluating the safety and immunogenicity of INO-6160.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA-Launched Nanoparticles (DLNPs) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators at the Wistar Institute are applying our experience in DNA vaccine development toward the development of the next generation of DNA medicine technology, by investigating DNA-launched nanoparticles, or DLNPs, initially targeting infectious diseases vaccines. INO-6172, our first DLNP to enter clinical trials, is in a Phase 1 trial sponsored and funded by NIAID. INO-6172 contains two plasmids, one encoding for the DLNP and one encoding for human IL-12. The trial is a randomized, 45-participant, open-label Phase 1 trial evaluating the safety and immunogenicity of INO-6172 in adults without HIV. The trial is ongoing, as is additional preclinical work with DLNP technology and additional vaccine candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA Encoded Protein Technology (DPROT) </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our DNA-encoded protein technology, or DPROT platform is a new approach to therapeutic protein replacement that aims to address some of the shortcomings of conventional therapeutic protein replacement that uses either repeated recombinant protein injections, infusions or viral based gene therapy. Similar to our DMAb technology, DPROT targets long-term protein expression with the ability to re-dose due to the lack of anti-vector immunity. Research is currently in the preclinical stage for various targets.  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Alliances</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our current collaboration with ApolloBio Corporation described below, our other partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences (PLS), Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2017, we entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with ApolloBio Corporation ("ApolloBio"), which was amended in June 2023. Under the terms of the ApolloBio Agreement, we granted to ApolloBio the exclusive right to develop and commercialize VGX-3100, our DNA immunotherapy product candidate designed to treat pre-cancers caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in accordance with the ApolloBio Agreement. In the event that VGX-3100 is approved for marketing, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the low- to mid-teens, subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the last-to-expire patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloBio dosed its first participant in a separate Phase 3 trial in China (HPV-303CHN) in 2021, and the trial remains ongoing as of the date of this report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop and seek to ultimately commercialize our product candidates, we face and will continue to encounter competition with an array of existing or development-stage drug and immunotherapy approaches targeting diseases we are pursuing. We are aware of various established enterprises, including major bio-pharmaceutical companies, broadly engaged in immunotherapy/vaccine research and development. These include AbbVie, AstraZeneca, BioNTech, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen Pharmaceuticals (part of J&amp;J), Merck, Moderna, Novartis, Pfizer, Roche, and Sanofi-Aventis. There are also various development-stage biotechnology companies involved in different immunotherapy and vaccine technologies, including but not limited to Agenus, AIVITA, Barinthus Biotherapeutics (formerly Vaccitech), BL Corp,  BlueSphere Bio, Dynavax, Entos Pharma, Flow Pharma, Frantz Viral Therapeutics, Immunocore, Immunome, Imunon, ImVax, Iovance, Genexine, HOOKIPA, Mimivax, Nektar, Northwest Therapeutics, Novavax, Nykode, Precigen, and PapiVax. If these companies are successful in developing their technologies, it could materially and adversely affect our business and our future growth prospects. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are also seeking to treat early HPV infections. For RRP, Precigen is developing a product candidate, PRG-2012, based on a Gorilla adenovirus-based vector. Precigen reported that they submitted a BLA in December 2024 based on their Phase 1/2 trial of PRG-2012 for the treatment of RRP, have initiated a confirmatory trial and believe that no additional randomized, placebo-controlled trial will be required to support their BLA submission under FDA&#8217;s accelerated approval pathway. Other companies have started to explore RRP as a disease target, including Nykode, Merck and Cytovation. For head and neck cancers, AstraZeneca is developing a bispecific antibody targeting PD-1 and TIGIT for locoregionally advanced head and neck squamous cell carcinoma, while the National Cancer Institute is conducting a Phase 3 study with the immunotherapy nivolumab (Bristol-Myers Squibb&#8217;s Opdivo) in HPV-positive oropharyngeal cancer. Other companies are pursuing different approaches to pre-cancers and cancers we are targeting. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid delivery to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. These competitive technologies have shown promise, but they each also have their own unique obstacles to overcome.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viral Vector-based Vaccine Delivery </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This technology utilizes a virus as a carrier, or vector, to deliver genetic material into target cells. The method is efficient for delivering immunotherapy antigens and has the advantage of mimicking real viral infection so that the recipient will mount a broad immune response against the immunotherapy. A potential limitation of the technology stems from problems with unwanted immune responses against components of the viral vector itself, making repeated administration to boost or maintain immune responses difficult. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lipid Nanoparticle DNA/RNA Delivery</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lipid formulations have been developed that increase the effect of DNA/RNA immunotherapies, most notably with COVID-19 mRNA vaccines. These work by either increasing uptake of the DNA/RNA into cells and/or by acting as an adjuvant, alerting the immune system.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA Immunotherapy Delivery with Electroporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other companies with electroporation intellectual property and devices. We believe we have competitive advantages over other companies focused on electroporation for multiple reasons: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have an extensive history and experience in developing the methods and devices that optimize the use of electroporation in conjunction with DNA medicine. This experience has been validated with multiple sets of data from clinical trials assessing DNA medicine against cancers and infectious disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have a broad product line of electroporation instruments designed to enable DNA delivery, including our intradermal and intramuscular devices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have been proactive in filing for patents, as well as acquiring and licensing additional patents, to expand our global patent estate.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive or result in treatments or cures superior to ours.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position will be affected by the disease indications addressed by our product candidates as compared to those of our competitors, as well as the timing of market introduction for these products and the stage of development of other technologies to address these disease indications. For us and our competitors, proprietary technologies, the ability to complete clinical trials on a timely basis and with the desired results, and the ability to obtain timely regulatory approvals to market these product candidates are likely to be significant competitive factors. Other important competitive factors will include efficacy, safety, ease of use, reliability, availability and price of products and the ability to fund operations during the period between technological conception and commercial sales.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies may expand current requirements for public disclosure of DNA-based product development data, which may harm our competitive position with foreign and United States companies developing DNA-based products for similar indications. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties for the manufacture of clinical supplies for all of our product candidates. We have service agreements in place for multiple manufacturers for drug substance and drug product depending on the product and clinical stage, including Richter BioLogics, Kaneka Eurogentec, Gedeon Richter and Alliance Medical Products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replacement of any third-party manufacturers would require us to qualify new manufacturers and negotiate and execute contractual agreements with them. If any of our supply or service agreements with third-party manufacturers are terminated, we would likely experience delays and additional expenses.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production processes for biological products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended shutdowns at one of our own facilities, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our plasmids can be produced in commercial quantities through uniform methods of fermentation and processing that are applicable to all plasmids. We believe we will be able to obtain sufficient supplies of plasmids for all foreseeable planned clinical trials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture materials for our CELLECTRA device at our device manufacturing facilities located in San Diego.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we have single source suppliers for molded plastic parts, machined metal parts and fully assembled printed circuit boards (PCBs). In the event one of these suppliers was unable to provide the materials or product, we would generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier, it is possible that we could experience an interruption in supply until we can establish new sources or, in some cases, implement alternative processes.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no approved products in the United States or any country. We cannot market or promote a new product in a country until a marketing application has been approved by the appropriate regulatory authority for that jurisdiction. Subject to receiving marketing authorization in a jurisdiction, we believe we will be able to commercialize in that market because of the broad potential applications of our technologies. We intend to develop and commercialize products both on our own and through our collaborators and licensees. We intend to develop and commercialize products in well-defined specialty markets, such as HPV-related diseases, infectious diseases, and cancer. Where appropriate, we intend to rely on strategic marketing and distribution alliances. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we continued to advance the development of our commercialization plans for INO-3107 in the United States based on the notification from the FDA that the data from our completed Phase 1/2 trial (RRP-001) could be used to submit a BLA under the FDA&#8217;s accelerated approval program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not fully established a sales, marketing or distribution infrastructure. If we are unable to enter into a third-party commercial arrangement with respect to the United States, we believe that we could establish an appropriately sized organization to commercialize INO-3107 and any other approved products. Outside the United States, our strategy is to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are essential to our business. We file patent applications to protect our technologies, inventions and improvements to our inventions that we consider important to the development of our business. We file for patent registration extensively in the United States and in key foreign markets. Although our patent filings include claims covering various features of our products and product candidates, including composition, methods of manufacture and use, our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents do not provide us with complete protection, or guarantee, against the development of competing products. In addition, some of our know-how and technology are not patentable. We thus also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We also require employees, consultants, advisors and collaborators to enter into confidentiality agreements, but such agreements may provide limited protection for our trade secrets, know-how or other proprietary information. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, our patent portfolio included approximately 60 issued U.S. patents and approximately 80 U.S. patent applications as well as approximately 590 issued foreign counterpart patents and approximately 770 counterpart foreign patent applications. These are comprised, in part, of: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">one issued U.S. patent, three U.S. patent applications and approximately 40 counterpart foreign patent applications directed to treatment of RRP; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">eight issued U.S. patents and five U.S. patent applications, as well as approximately 80 issued foreign counterpart patents and approximately 30 counterpart foreign patent applications, directed to treatment of GBM; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">approximately 50 issued U.S. patents and approximately 65 U.S. patent applications, as well as approximately 425 issued foreign counterpart patents and approximately 490 counterpart foreign patent applications, directed to our other earlier-stage product candidates; and </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">three issued U.S. patents and four U.S. patent applications, as well as approximately 160 issued foreign counterpart patents and approximately 45 counterpart foreign patent applications, directed to our device delivery systems. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications directed to treatment of RRP, if issued, would expire between about 2040 and 2043. Our issued patents directed to treatment of GBM expire between about 2027 and 2037 and our pending patent applications, if issued, would expire between about 2027 and 2040. Our issued patents directed to our other product candidates expire between about 2027 and 2036 and our pending patent applications, if issued, would expire between about 2027 and 2042. Our issued patents directed to our device delivery systems expire between about 2025 and 2036 and our pending patent applications, if issued, would expire between about 2025 and 2042. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual patent terms extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In most countries in which we file patent applications, including the United States, the patent term is 20 years from the date of filing of the first non-provisional patent application to which priority is claimed. In some instances, a patent term can be extended under certain circumstances, such as patent term extension or patent term adjustment; alternatively, a patent term may be shortened, for example in the United States, if a patent is terminally disclaimed over an earlier-filed patent. Protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to protect our intellectual property rights adequately our competitors might gain access to our technology and our business would thus be harmed. In addition, defending our intellectual property rights might entail significant expense. Any of our intellectual property rights may be challenged by others or invalidated through administrative processes or litigation through the courts. In addition, our patents, or any other patents that may be issued to us in the future, may not provide us with any competitive advantages, or may be challenged by third parties. Furthermore, legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain. Effective patent, trademark, copyright and trade secret protection may not be available to us in each country where we operate. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and domestic and international mechanisms for enforcement of intellectual property rights in those countries may be inadequate. Accordingly, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our intellectual property or otherwise gaining access to our technology. We may be required to expend significant resources to monitor and protect our intellectual property rights. We may initiate claims or litigation against third parties for infringement of our proprietary rights or to establish the validity of our proprietary rights. Any such litigation, whether or not it is ultimately resolved in our favor, would result in significant expense to us and divert the efforts of our technical and management personnel. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be rights we are not aware of, including applications that have been filed but not published that, when issued, could be asserted against us. These third parties could bring claims against us, and that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic drug candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important legal issues remain to be resolved as to the extent and scope of available patent protection for biologic products, including vaccines, and processes in the United States and other important markets outside the United States, such as Europe and Japan. Foreign markets may not provide the same level of patent protection as provided under the United States patent system. We recognize that litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others&#8217; proprietary rights. Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to interrupt our operations, redesign our products or processes, or negotiate a license agreement, all of which would adversely affect our revenue. Furthermore, changes in, or different interpretations of, patent laws in the United States and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, or biologics, and medical devices, such as our product candidates. Generally, before a new biologic or medical device can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority. These requirements are continually updated by regulatory authorities to address changes in science, manufacturing and potential new threats, such as cybersecurity concerns.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Review and Approval of Combination Products in the United States</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">two or more separate products packaged together in a single package or as a unit and comprised of drug and device products; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any investigational drug, device, or biological packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products comprising an electroporation device for delivery of a biologic. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product, which means the mode of action expected to make the greatest contribution to the overall intended therapeutic effects. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biologic product, that is, if it acts by means of a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, the FDA center responsible for premarket review of the biologic product would have primary jurisdiction for the combination product. We believe that all of our product candidates will have a biologic primary mode of action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Biological Product Development</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates biologics under FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to establish the safety and efficacy of the proposed product candidate for its proposed indication;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">submission to the FDA of a BLA;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">potential FDA audit of the pre-clinical and/or clinical trial sites that generated the data in support of the BLA; and </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data required to support a BLA is generated in two distinct development stages: pre-clinical and clinical. The pre-clinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the pre-clinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the product candidate to healthy participants under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research participants provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, participant selection and exclusion criteria, and the parameters to be used to monitor participant safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial participant or his or her legal representative and must monitor the clinical trial until completed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. The FDA requires sponsors to disclose the results of most, but not all, trials after completion.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a product candidate. The primary purpose of these clinical trials is to assess the action, side effect tolerability and safety of the product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in patients to determine the dose required to produce the desired benefits. At the same time, safety and preliminary evaluation of efficacy is assessed. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries (from several hundred to several thousand participants) and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may grant conditional approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials, such as these post-approval trials, to further assess the biologic&#8217;s safety and effectiveness after BLA approval. Under the accelerated approval pathway, FDA may require the conduct of confirmatory trials before full approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important rate increase of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA and FDA Review Process</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following trial completion, trial data is analyzed to assess safety and efficacy. The results of pre-clinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the product candidate, and other relevant information. The BLA is a request for approval to market the biologic in combination with the device, if applicable, for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive pre-clinical and clinical testing. The application includes positive findings from pre-clinical and clinical trials as well as ambiguous or negative results. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual program fee for approved products. Fee waivers or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business or a waiver of fee based on orphan drug status.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA has been accepted for filing, which occurs, if at all, 60 days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The review process is often significantly extended by FDA requests for additional information or clarification. If not accepted for filing, the sponsor must resubmit the BLA and begin the FDA&#8217;s review process again, including the initial 60-day review to determine if the application is sufficiently complete to permit substantive review.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also accept the submission of a BLA under its Accelerated Approval Program, which was instituted to allow for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but may not it itself be the final measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. Companies are still required to conduct studies to confirm the anticipated clinical benefit. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA would grant provisional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to the removal of the drug from the market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and an applicant may not receive a timely approval, if at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the FDA will ultimately approve a product for marketing in the United States and applicants may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track, Breakthrough Therapy and Priority Review Designations</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need for such diseases or condition. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first section of the application. In addition, fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may designate a biologic as a &#8220;breakthrough therapy&#8221; upon a request made by the IND sponsor. A breakthrough therapy is a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor, which are intended to expedite the development and review of an application for approval of a breakthrough therapy.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the FDA may designate an application for priority review if it is for a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness over existing therapy. The FDA determines at the time that the marketing application is submitted, on a case- by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on an original marketing application from ten months to six months from the date of filing.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated Approval Pathway</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA will require that a sponsor of a product receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug or biologic, such as an effect on IMM.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a program or development candidate approved on this basis is typically subject to rigorous post-marketing compliance requirements, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the completion of Phase 4 or post-approval clinical trials to establish the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, may allow the FDA to withdraw approval of the drug. The FDA may require the sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The sponsor must also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports are published on FDA&#8217;s website.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All promotional materials for products approved under the accelerated approval program are subject to prior review by the FDA.  </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a biologic product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a biologic for this type of disease or condition will be recovered from sales in the United States for that biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use will be disclosed publicly by the FDA; the posting will also indicate whether the biologic is no longer designated as an orphan drug. More than one program or development candidate may receive an orphan drug designation for the same indication. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to seven years of orphan product exclusivity. During the seven-year exclusivity period, the FDA may not approve any other applications to market a product containing the same active moiety for the same disease, except in very limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A product is clinically superior if it is safer, more effective or makes a major contribution to patient care. Thus, orphan drug exclusivity could block the approval of one of our potential products for seven years if a competitor obtains approval of the same product as defined by the FDA and we are not able to show the clinical superiority of our program or development candidate or if our program or development candidate&#8217;s indication is determined to be contained within the competitor&#8217;s product orphan indication. In addition, the FDA will not recognize orphan drug exclusivity if a sponsor fails to demonstrate upon approval that the product is clinically superior to a previously approved product containing the same active moiety for the same orphan condition, regardless of whether or not the previously approved product was designated an orphan drug or had orphan drug exclusivity. A product that has received orphan drug designation may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received the designation. Orphan exclusivity does not prevent the FDA from approving a different drug or biological product for the same disease or condition, or the same product for a different disease or condition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Marketing Requirements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, also known as off-label use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Moreover, the constituent parts of a combination product retain their regulatory status, for example, as a biologic or device, and as such, we may be subject to additional requirements in the Quality System Regulation, or QSR, applicable to medical devices, such as design controls, purchasing controls, and corrective and preventive action. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and Reference Product Exclusivity</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic without such alteration or switch. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biosimilar applicant must demonstrate that the product is biosimilar based on data from (1) analytical studies showing that the biosimilar product is highly similar to the reference product; (2) animal studies (including toxicity); and (3) one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and vaccines. Accordingly, a pharmaceutical company&#8217;s ability to commercialize its products successfully depends in part on the extent to which private health insurers, other third-party payors, and governmental authorities, including Medicare and Medicaid, establish appropriate coverage and reimbursement levels for its product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that products be approved for marketing by the FDA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are available. The process for obtaining coverage for a product or service is separate from the process to obtain the associated reimbursement. Reimbursement levels can affect the adoption of products and services by physicians and patients. Additionally, products used in connection with medical procedures may not be reimbursed separately, but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for a product or the treatment or procedure in which the product is used may not be available.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products and vaccines can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which may require the provision of scientific and clinical support for the use of the product to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system that impact the ability to sell pharmaceutical products profitably. In the United States, the federal government enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. The ACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70 percent, effective as of January 1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been amendments to and judicial and Congressional challenges to certain aspects of the ACA. For example, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and by creating a newly established manufacturer discount program. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect until 2032 unless additional Congressional action is taken. Additionally, on March 11, 2021 the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source biologics that have been on the market for at least 11 years covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon prices of the first ten drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare drug price negotiation program. Further, on December 7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Laws</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to the business of a pharmaceutical company. The laws that may affect a pharmaceutical company&#8217;s ability to operate include: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the purchasing, ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A pharmaceutical company will need to spend substantial time and money to ensure that its business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that its business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If a pharmaceutical company&#8217;s operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to it, it may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm and the curtailment or restructuring of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Regulations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers and Research and Development</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, we derived 100% and 29%, respectively, of our revenue from ApolloBio. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, virtually all of our activities have consisted of research and development efforts related to developing our electroporation technologies and immunotherapies. Research and development expense consists of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Our research and development expense was $75.6 million in 2024 and $86.7 million in 2023.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue for the years ended December&#160;31, 2024 and 2023 was earned in the United States. All of our long-lived assets are located in the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462, and our main telephone number is (267) 440-4200. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet website address is www.inovio.com. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make our annual report on Form&#8239;10-K, quarterly reports on Form&#8239;10-Q, current reports on Form&#8239;8-K and amendments to those reports filed or furnished pursuant to Section&#8239;13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our corporate governance, including the charters of our audit committee, our nomination and corporate governance committee and our compensation committee, our Code of Business Conduct and Ethics, our Corporate Governance Guidelines, and information for contacting our board of directors is available on our website. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Code of Business Conduct and Ethics includes our Code of Ethics applicable to our Chief Executive Officer and Chief Financial Officer, who also serves as our principal accounting officer. Any amendments to or waivers of the Code of Ethics will be promptly posted on our website or in a report on Form 8-K, as required by applicable law. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 14, 2025, we employed 134 people on a full-time basis. Of the total, 99 were in product research, which includes research and development, quality assurance, clinical, engineering and manufacturing, and 35 were in general and administrative functions, which includes corporate development, information technology, legal, commercial, investor relations, finance and corporate administration. Approximat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely one-half of our workforce is comprised of women and approximately one-half is comprised of individuals with ethnically diverse backgrounds. In addition, four of the eight members of our board of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">directors are women. None of our employees are subject to collective bargaining agreements. We consider our relationship with our employees to be good.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the highly competitive biotechnology industry. Attracting, developing and retaining talented people in research, quality assurance, clinical, engineering, manufacturing and other positions is crucial to executing our strategy and our ability to compete effectively. Our ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and work environment. To that end, we invest in our employees to be an employer of choice. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Engagement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we work to make an impact on how healthcare is delivered, we believe it is critical that our employees are informed and engaged. We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings, employee surveys and our company intranet, and acknowledge individual contributions to our company&#8217;s success through several rewards and recognition initiatives. We believe these engagement efforts keep employees informed about our strategy, culture and purpose and motivated to do their best work.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The physical health, financial well-being, life balance and mental health of our employees is vital to our success. We have a company-wide comprehensive wellness program inclusive of financial, physical, and mental well-being. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our environmental, health and safety team stays abreast of local, regional and global concerns and trends and ensures safety procedures are in place to mitigate workplace injuries and safety risks. Employees are required to complete training in various safety procedures for the laboratories and manufacturing facilities and specialized safety training based on particular job duties. Designated Safety Officers and response teams oversee safety-related initiatives and a safety committee provides input on safety procedures, practices, and policies. Employees are required to wear personal protective equipment relevant for their particular job duties. Occupational injuries at our workplace have historically been very low and are always investigated to determine if any environmental or other changes need to be implemented. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following factors regarding information included in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of December 31, 2024 our accumulated deficit was $1.7 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA medicine candidates or proprietary device technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently generate any revenue from the commercial sale of products. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our DNA medicine candidates, including securing regulatory approval for conducting clinical trials with DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">developing our proprietary device technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary device and DNA medicine candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our proprietary device and DNA medicine candidates as combination products before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of proprietary devices and DNA medicine products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past we have derived a significant portion of our revenue from a limited number of licensing partners and government grants and contracts, and we expect that a significant portion of our revenue will continue to be derived from a limited number of licensing partners and/or government grants and contracts unless and until we are able to commercialize our product candidates. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our DNA medicine candidates and proprietary device technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost to commercialize any product that obtains regulatory approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of geopolitical turmoil, inflation and rising interest rates, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. In particular, biotech and small-cap companies tend to feel these difficulties acutely. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Rising interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our proprietary devices and DNA medicine candidates, we will not be able to commercialize them in the United States. In particular, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory authorities do not provide marketing authorization for our CELLECTRA delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our proprietary device and DNA medicine candidates as combination products in the United States. If we fail to obtain FDA approval to market our proprietary device and DNA medicine candidates as combination products, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our combination products as well as the evaluation of our device design, manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our proprietary device and DNA medicine candidates are both safe and effective for each indication for which approval is sought. In determining what is needed to demonstrate the safety and effectiveness of a combination product, the FDA takes into account the questions and considerations, reflected in the statutory and regulatory provisions associated with each constituent part in the FDA&#8217;s review of the combination product as a whole and its constituent parts. This includes how the constituent parts may interact and interrelate and is a complex process. To the extent that our DNA medicine candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our proprietary device and any of our DNA medicine candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our proprietary device and DNA medicine candidates. If the FDA does not consider or approve our application, it may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our product candidates or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because our product candidates are drug-device combination products comprising an electroporation device for delivery of a biologic, additional time may be required to obtain regulatory approval for our product candidates because of the complexity involved with developing and manufacturing a drug-device combination product. In addition, if the FDA and similar regulatory authorities do not provide marketing authorization for our delivery devices, then we will not be able to bring to market our DNA medicines that rely on delivery by such a device. Such delays or failure to obtain marketing authorization for our devices would result in significant harm to our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pursuing accelerated approval for INO-3107 or any of our other product candidates may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to pursue accelerated approval for our product candidate INO-3107 and may in the future decide to pursue accelerated approval for one or more of our other product candidates. Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug or biologic for a serious or life-threatening disease or condition that provides a meaningful advantage over available therapies based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. For drugs or biologics granted accelerated approval, post-marketing confirmatory trials are required to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence, and the FDA may require that the trial be designed, initiated, and/or fully enrolled prior to approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we pursue accelerated approval for INO-3107 for the treatment or RRP, or a future product candidate for another disease or condition, we would do so on the basis that there is no available therapy for that disease or condition or that our product candidate provides a benefit over available therapy. If standard of care were to evolve or if any of our competitors were to receive full approval on the basis of a confirmatory trial for a drug or biologic for a disease or condition for which we are seeking accelerated approval before we receive accelerated approval, the disease or condition would no longer qualify as one for which there is no available therapy, and accelerated approval of our product candidate would not occur without a showing of benefit over available therapy. The treatment landscape can change quickly as the FDA converts accelerated approvals to full approvals on the basis of successful confirmatory trials. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received feedback from the FDA that data from our completed Phase 1/2 clinical trial of INO-3107 for the treatment of RRP can be used to support the submission of a BLA for review under the accelerated approval program; however, whether any trial is sufficient to receive FDA approval under the accelerated approval pathway will depend on the safety and efficacy results of such trial and will only be determined by the FDA upon review of a submitted BLA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA may withdraw approval of INO-3107 or any future product candidate approved under the accelerated approval pathway if, for example:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the trial or trials required to verify the predicted clinical benefit of our product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with such product;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">we fail to conduct any required post-approval trial of our product candidate with due diligence; or</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">we disseminate false or misleading promotional materials relating to the relevant product candidate.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may terminate the accelerated approval program or change the standards under which accelerated approvals are considered and granted in response to public pressure or other concerns regarding the accelerated approval program. Changes to or termination of the accelerated approval program could prevent or limit our ability to obtain accelerated approval of any of our clinical development programs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States, and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any proprietary device and DNA medicine candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our DNA medicine candidates may not be approved for all indications requested, which could limit the uses of our DNA medicine candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain, particularly when the clinical testing involves drug and device combination products such as ours. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and DNA medicine candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any products for use in humans.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our proprietary device meets the standard of reasonable assurance of safety and effectiveness or that our product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary device or DNA medicine candidates' clinical and other benefits outweigh their safety risks; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary device or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our DNA medicine candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or that of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulations or marketing authorization and approval policies of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for marketing authorization or approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third-party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our proprietary device and DNA medicine candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining Institutional Review Board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, the conflict between Israel and Hamas, bank failures and other economic and other external factors beyond our control.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to clinical trials of product candidates for rare diseases, such as our planned confirmatory trial of INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, we may encounter difficulties in recruiting a sufficient number of patients to enroll in the trial due to the small number of patients with the disease. Because RRP is caused by specific HPV types, 6 and 11, and there is currently no standard protocol for diagnostic/screening of RRP patients unless there are symptoms of dysphonia, respiratory distress or other symptoms related to the presence of papillomas, it may be difficult to identify and diagnose patients for whom INO-3107 may be a potential treatment.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our proprietary device and our DNA medicine candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DNA medicines programs are in various stages of research and development, and currently include DNA medicine candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of DNA medicine candidates compared with conventional therapies, including vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our DNA medicine candidates. The success of our efforts to develop and commercialize our DNA medicine candidates could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our DNA medicine candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale, particularly given the complexity concerning the manufacturing of combination products, or uneconomical to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are now only pursuing development in collaboration with third parties, as both a primary and heterologous booster vaccine, but there can be no assurance that our candidate will ever receive regulatory approval as a primary vaccine or a booster in any country, whether by Emergency Use Authorization or otherwise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we expended significant resources on the clinical development of a COVID-19 vaccine candidate, INO-4800. We were previously conducting a Phase 2/3 clinical trial of INO-4800 called INNOVATE. Based on regulatory feedback and the competitive landscape for COVID-19 vaccines, in 2022 we discontinued the INNOVATE trial and pursued a strategy to develop our COVID-19 vaccine as a potential heterologous booster following administration of other primary vaccines. Following an assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines, in the fourth quarter of 2022 we discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are no longer conducting any active clinical trials of INO-4800 and do not expect that it will ever receive regulatory approval in the United States. Our collaborator Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous booster vaccine trials in China. They may seek an Emergency Use Authorization, or EUA, from regulatory authorities in China and other countries in Asia for the use of INO-4800 as a heterologous booster. However, any such decision would be made by Advaccine, and there is no guarantee that Advaccine will apply for an EUA or other similar authorization or, if it does apply, that Advaccine will be able to obtain such authorization. An EUA may not be available if countries are no longer in a state of public health emergency, in which case full approval would need to be sought. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We await the results of our COVID-19 vaccine candidate's participation in the World Health Organization&#8217;s Solidarity Trial Vaccines. Depending on the results of that trial, we could also pursue a strategy of seeking EUA for the vaccine candidate in other countries outside of the United States. Even if an EUA or other authorization is ultimately granted, we will rely on the applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our vaccine candidate. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. Regulatory authorities may also terminate an EUA if safety issues or other concerns about our product arise or if we or Advaccine fail to comply with the conditions of authorization. If we or Advaccine apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our and Advaccine&#8217;s ability to market and sell our COVID-19 vaccine.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a novel approach to administering medicines. Negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No DNA medicines have been granted EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to other nucleic acid based vaccines such as mRNA vaccines, gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our pipeline of DNA medicine candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, even if our product candidates receive regulatory approval from the FDA and similar regulatory authorities, the novelty of our CELLECTRA delivery devices may make it difficult to demonstrate to physicians and third-party payors that this delivery system is an appropriate approach for DNA medicines and provides advantages compared to the current standards of care. Further, if we or our commercialization and collaboration partners are not successful in conveying to physicians, patients and third-party payors that our CELLECTRA delivery devices provide useful patient outcomes, we or our commercialization and collaboration partners may experience reluctance, or refusal, on the part of physicians to order and use, and third-party payors to cover and provide adequate reimbursement for, our DNA medicines. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We manufacture some components of our proprietary devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our DNA medicine candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our DNA medicine candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls that meet the relevant current good manufacturing practice (cGMP) requirements for combination products. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and DNA medicine candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our proprietary device to our partners and to supply DNA medicine candidates for clinical trials or to commercially launch a product would be jeopardized. For example, as part of the testing process required for BLA submission for INO-3107, we identified a manufacturing issue in the single use administration component of our CELLECTRA 5PSP device that we are working to resolve. However, the timeline on which we expect to be able to commence our confirmatory trial and submit our BLA for INO-3107 has been delayed as a result. There can be no assurance we will be able to rectify this manufacturing issue on the timeline we expect or at all or that we will not identify additional issues with our device that could further delay our planned regulatory submission or impair our ability to receive regulatory approval.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we previously relied on VGXI to manufacture DNA plasmids for our DNA medicine candidates before they became unable to produce the necessary plasmids due to a lack of manufacturing capacity. As a result, we had to engage several additional third-party contract manufacturers. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity for any of our DNA medicine candidates on commercially reasonable terms. Our inability to secure sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for our DNA medicine candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to pass preapproval inspection of our manufacturing facilities and obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the quality system regulations, and any amendments thereto, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our proprietary device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our proprietary device and DNA medicine candidates. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that may not be interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays to the development timelines for our development candidates or investigational medicines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a lack of long-term supply arrangements for key components with our suppliers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage to our reputation caused by defective components produced by our suppliers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Even if our product candidates receive regulatory approval, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any of our product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if FDA regulatory approval is obtained, regulators may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory authorities do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and devices and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our DNA medicine candidates, or the manufacturing facilities for our DNA medicine candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate injunction actions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA and comparable foreign regulatory authorities&#8217; policies may also change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, the U.S. Supreme Court&#8217;s June 2024 decision in Loper Bright Enterprises v. Raimondo overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper decision could result in additional legal challenges to regulations and decisions issued by federal agencies, including the FDA, on which we rely. Any such legal challenges, if successful, could have a material impact on our business. Additionally, the Loper decision may result in increased regulatory uncertainty, inconsistent judicial interpretations, and other impacts to the agency rulemaking process, any of which could adversely impact our business and operations. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. Certain policies of any administration may impact our business and industry. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing some of our investigational DNA medicines using new endpoints or methodologies for the treatment of diseases in which there is little clinical experience. As a result, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. For example, our product candidate INO-3107 is being developed for RRP, a rare condition for which there are no approved non-surgical treatments. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our DNA medicine candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional DNA medicine candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of RRP. We have sought and may continue to seek Orphan Drug Designation for one or more of our other DNA medicine candidates, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of RRP, and even if we obtain Orphan Drug Designation for our other DNA medicine candidates in specific indications, we may not be the first to obtain marketing approval of these DNA medicine candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our DNA medicine candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our DNA medicine candidates, we may never receive such designations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have received breakthrough therapy designation for INO-3107 and may seek this designation for one or more of our other investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our DNA medicine candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies that are subject to termination and uncertain future funding. Termination or cessation of funding could have a negative impact on our ability to develop some of the product candidates in our pipeline and/or require us to seek alternative funding sources to advance those candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases (NIH NIAID), Defense Advanced Research Projects Agency (DARPA), Medical CBRN Defense Consortium (MCDC) and the Department of Defense (DoD) Joint Program Executive Office (JPEO) for Chemical, Biological, Radiological and Nuclear Defense (CBRN), and we intend to continue entering into these types of agreements with government agencies in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in 2021 the DoD discontinued funding for the planned Phase 3 trial of our COVID-19 product candidate, which resulted in increased expenditures by us.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our DNA medicine candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our proprietary device and DNA medicine candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our DNA medicine candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our DNA medicine candidates. As a result, our financial results and the commercial prospects for our DNA medicine candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees&#8217; exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our DNA Medicine Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have only a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, if approved, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only a small commercial organization to support pre-commercial activities for our proprietary device and DNA medicine candidates, if approved, and we do not currently have a sales organization. In order to successfully commercialize INO-3107 or any other products that may receive regulatory approval, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of a sales force, either on our own or in conjunction with third parties, will be expensive and time-consuming and could delay any product launch, and we may not be able to successfully develop or acquire this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In the event we are unable to successfully develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our DNA medicine candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our proprietary device and DNA medicine candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our DNA medicine candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration, including the acceptance and usage of our proprietary device by the medical community; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential public perception of new therapies and the reputational challenges that the industry is facing related to drug costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our proprietary device and DNA medicine candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our DNA medicine candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our DNA medicine candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our proprietary device and DNA medicine candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our DNA medicine candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, co-payments may be required that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products. Even if we obtain coverage for our products, the revenue generated may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our DNA medicine candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our DNA medicine candidates or procedures using our DNA medicine candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more products, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, numerous purported shareholder class action and shareholder derivative complaints were filed against us beginning in 2020, naming us and our directors and executive officers as defendants, alleging that we made materially false and misleading statements in violation of federal securities laws. Although we have resolved these actions, there can be no guarantee that we will not become subject to similar claims in the future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. There can be no assurance that we will ultimately prevail in the ongoing litigation matters described in this report or in future litigation matters. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our DNA medicine candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and DNA medicine candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines were negatively impacted. Similar events could result in future business and manufacturing disruption, or in reduced operations, any of which would materially affect our business, financial condition and results of operations. The COVID-19 pandemic also caused supply chain disruptions and supply shortages globally. As a result, we experienced delays and disruptions in obtaining clinical supplies, manufacturing supplies and components, and had to secure new vendors for certain supplies and components at higher prices. There can be no assurance that we will not encounter similar difficulties in the future.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future health epidemics could adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure if an outbreak occurs in their geography. Trial participants may not be able to or may not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for our clinical trials. Further, future epidemics could also result in delays in our clinical trials due to prioritization of hospital resources toward the disease, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting disease or other health conditions. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates and introduce new, disruptive technology, we may not be able to complete the development of or commercialize our product candidates, and sales of any commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or product candidates obsolete or non-competitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors and potential competitors include large pharmaceutical companies broadly engaged in vaccine/immunotherapy research and development, such as Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline, Merck, Pfizer, Roche, AbbVie, Novartis, Bristol-Myers Squibb, and AstraZeneca, as well as various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, such as CureVac, Dynavax, Genexine, Hookipa, Iovance, Nektar, Nykode, Precigen, Zydus, and Vir Biotechnology. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care in the United States and other high income countries for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is developing a potential treatment for RRP based on a gorilla adenovirus vector and announced in late 2024 that it has submitted a BLA based on a completed Phase 1/2 study. As a result, Precigen could receive marketing approval for its RRP product candidate before we can obtain regulatory approval for INO-3107, which could put us at a competitive disadvantage in this indication. Advaxis, Genexine, and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small biotechnology companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or those of third parties upon which we rely or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to, regulatory investigations and actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse consequences.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential, proprietary or otherwise sensitive information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls designed to maintain the confidentiality, availability and integrity of such information as appropriate. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the compromise of information stored in our or our third-party providers' systems, portable media or storage devices. Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten our information and information technology systems and those of third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect and come from a variety of sources such as traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through error or malfeasance), sophisticated national states and nation-state support actors (for example, in conjunction with military conflicts). During times of war and other major conflicts, we may be vulnerable to a heightened risk of these attacks. We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to: business interruption, loss of information, theft of information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), social-engineering attacks (including through deep fakes and phishing attacks), malicious code (such as viruses and worms), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, telecommunications failures, natural disasters, and other similar threats, any of which may compromise our system infrastructure or lead to data compromise. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, loss of data, reputational harm and diversion of funds. Extortion payments may alleviate some of the negative impact of a ransomware attack but we may be unwilling or unable to make such payments. Remote work has also become more common and increased risks to our information technology systems and data. Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities as our systems could be negatively affected by vulnerabilities resent in acquired or integrated entities&#8217; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">systems and technologies. Furthermore, we may discover security issues that were not found during diligence of such acquired or integrated entities and it may be difficult to integrate such entities into our programs. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on service providers and third-party technologies to operate critical business systems to process sensitive information in a variety of contexts, including without limitation, cloud-based infrastructure, personnel email, data hosting, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited and these service providers may not have adequate information security measures in place. If our service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our service providers fail to satisfy their privacy or security-related obligations to us, any aware may be insufficient or we may be unable to recover such award.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented measures designed to protect our data and information technology systems, there can be no assurance that our efforts will be effective (including, without limitation prevent service interruptions or security incidents). We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems (such as our hardware and software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities on a timely or effective basis. Vulnerabilities could be exploited and result in a security incident. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific or reasonable security measures.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.  Additionally, sensitive information of ours could be leaked, disclosed, or revealed as a result of or in connection with our personnel&#8217;s or vendors&#8217; use of artificial intelligence (AI) technologies, including generative AI, and machine learning (ML) technologies (collectively, AI/ML technologies).  Any sensitive information (including confidential, competitive, proprietary, or personal data) that we input into a third-party generative AI/ML platform could be leaked or disclosed to others, including if sensitive information is used to train the third parties&#8217; AI/ML model.  Additionally, where an AI/ML model ingests personal data and makes connections using such data, those technologies may reveal other personal or sensitive information generated by the model.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, regulators, and other stakeholders of security incidents.  Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our proprietary device and DNA medicine candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. The ACA, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70 percent, effective as of January 1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been amendments to and executive, judicial, and Congressional challenges to certain aspects of the ACA. For example., on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 included reductions to Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute will remain in effect until 2032, unless Congressional action is taken. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, at the federal level, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source biologics that have been on the market for at least 11 years covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon prices of the first ten drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare drug price negotiation program. Further, on December 7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December 8, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act (HIPAA), which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug and Cosmetic Act (FDCA), which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our DNA medicine candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and may rely on clinical materials manufactured in China for our development efforts. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a license and collaboration agreement with a China-based company, ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, China's "zero COVID" policy caused delays in Advaccine&#8217;s conduct of clinical trials for INO-4800 in China under our collaboration with them, which in turn resulted in delays in obtaining clinical data to evaluate the safety and potential efficacy of INO-4800. In addition, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on ApolloBio or Advaccine, which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, including the threat of a trade war between the United States and China, could lead to supply chain disruptions or increased costs for clinical materials manufactured in China that are necessary for our development efforts. Certain Chinese biotechnology companies and contract development and manufacturing organizations may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could potentially impact our ability to secure the materials we need for our product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the recently proposed BIOSECURE Act that was passed by the U.S. House of Representatives in September 2024, as well as a substantially similar bill in the U.S. Senate, target U.S. government contracts, grants, and loans for entities that use equipment and services from certain named Chinese biotech companies, and authorize the U.S. government to name additional Chinese biotechnology companies of concern. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of companies </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to work with certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We may also be exposed to fluctuations in the value of the local currency in China. These disruptions, failures or uncertainties may have adverse impacts on the development of our product candidates, our ability to commercialize our DNA medicine candidates, if approved, our business operations, our ability to enforce the contracts we have entered into and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our proprietary device and DNA medicine candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our DNA medicine candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Capital Market, we cannot be certain that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, the conflict between Israel and Hamas, bank failures, and other economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general can experience relatively large price and volume fluctuations from time to time. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. For example, our operating expenses increased significantly from 2020 to 2022 due to development and manufacturing activities for our COVID-19 vaccine program, for which we discontinued internal funding in the fourth quarter of 2022. We may not deploy our current capital resources effectively. The failure by our management to apply our funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our product candidates. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes in laws and regulations, such as alternative minimum taxes or suspensions on the use </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our proprietary device, DNA medicine candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our proprietary device and DNA medicine candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our DNA medicine candidates receive regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns due to reasons including, among other things, inflation, rising interest rates, energy costs, geopolitical issues, political changes and trends such as protectionism, economic nationalism resulting in government actions impacting international trade agreements or imposing trade restrictions such as tariffs and retaliatory counter measures, global pathogen outbreaks or pandemics, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in 2023, several banking institutions were closed or seized by the Federal Deposit Insurance Corporation, leading to significant liquidity concerns in the broader financial services industry. </span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we did not have any deposits at any of the banks impacted by the adverse developments in 2023, we maintain deposits at financial institutions as a part of doing business that could be at risk if another similar event were to occur. Our ongoing cash management strategy is to maintain the majority of our deposit accounts in large financial institutions, but there can be no assurance this strategy will be successful. Increasing concerns regarding the U.S. or international financial systems, including bank failures and bailouts, and their potential broader effects and potential systemic risk on the banking sector generally, may adversely affect our access to capital. Any decline in available funding or access to our cash and liquidity resources could, among other risks, limit our ability to meet our capital needs and fund future growth or fulfill our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other obligations, or result in breaches of our financial and/or contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In 2017, tax legislation commonly known as the Tax Cuts and Jobs Act, or Tax Act, was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, resulted in significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). It is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or legislative changes proposed or implemented, could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.  Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, and financial information (collectively, sensitive data).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws).  In the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), applies to personal data of consumers, business representatives, and employees who are California residents, and requires certain businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages.  Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security.  For example, the European Union&#8217;s General Data Protection Regulation (&#8220;EU GDPR&#8221;), the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or &#8220;LGPD&#8221;) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal data. For example, under GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows.  Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.  In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate.  Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.  Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.  If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.  Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities groups.  Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.  Other jurisdictions have adopted and may adopt stringent data localization and cross-border data transfer laws.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we may be contractually subject to certain industry standards adopted by industry groups.  We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.  We publish statements regarding data privacy and security. Regulators in the United States have scrutinized and are increasingly scrutinizing these statements and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personnel and certain third parties with whom we work may use generative AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages. Due to inaccuracies or flaws in the inputs, outputs, or logic of the AI/ML, AI models could be biased and could lead us to make decisions that could bias certain individuals (or classes of individuals), and adversely impact their rights, employment, and ability to obtain certain pricing, products, services, or benefits.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty.  Additionally, these obligations may be subject to differing applications and interpretations, which has in the past and may in the future be inconsistent or conflict among jurisdictions.  Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations.  Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations.  If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data.  In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands.  Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations.  Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C.&#160;&#160;&#160;&#160;CYBERSECURITY</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk management and strategy</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-38" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-39" continuedAt="f-39-1" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-40">third party hosted services</ix:nonNumeric>, communications systems, hardware and software, and our critical data (including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data) (collectively, &#8220;Information Systems and Data&#8221;).  </span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-39-1">Our Information Technology department (&#8220;IT Department&#8221;) (including its Senior Director), with support from service providers, helps identify, assess and manage our cybersecurity threats and risks. The IT Department identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment and our risk profile using various methods. For example, the methods include manual and automated tools; subscriptions to reports and services that identify cybersecurity threats; analysis of threat and threat actor reports; threat environment scans; law enforcement coordination; audits; threat assessments; and vulnerability assessments.</ix:continuation>  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: security incident response strategies; tools designed to detect and respond to security incidents; data encryption strategies; access controls; physical security controls; asset management strategies; systems monitoring; personnel training; penetration testing; and cybersecurity insurance.    </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-41">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes.</ix:nonNumeric>  For example, the IT Department works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business and our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example: professional services firms (including legal counsel); cybersecurity consultants; cybersecurity software providers; managed cybersecurity service providers; and penetration testing firms.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-42">We use service providers to perform a variety of functions throughout our business, such as application providers; hosting providers; and contract research organizations. Depending on the nature of the services provided, in order to analyze the cybersecurity processes of certain vendors we review their internal security assessment reports and certifications, if available.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-43">For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including in particular under the caption &#8220;if our information technology systems or those of third parties upon which we rely or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to, regulatory investigations and actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse consequences.&#8221;</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-45" continuedAt="f-45-1" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-46" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-44" escape="true">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</ix:nonNumeric></ix:nonNumeric>  </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-47" continuedAt="f-47-1" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including the Senior Director of the IT Department. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-48" escape="true">This individual has previously held roles as a head of cybersecurity, cybersecurity consultant and information security specialist for other organizations. This individual holds several certifications related to cybersecurity including Certified Information Systems Security Professional (CISSP).</ix:nonNumeric>  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-49" escape="true">The IT Department reports to our Chief Financial Officer (CFO) who is responsible for helping the IT Department hire appropriate personnel, integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-50">Senior Director of the IT Department</ix:nonNumeric> is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CFO.   The Senior Director of IT and the CFO work with our incident response team to help mitigate and remediate cybersecurity incidents of which they </span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-47-1"><ix:continuation id="f-45-1"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are notified.  In addition, our incident response and vulnerability management processes include reporting to the audit committee of the board of directors for certain cybersecurity incidents. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-51" escape="true">As indicated above, the audit committee receives reports from the Senior Director of IT or other designee concerning significant cybersecurity threats and risk and the processes we have implemented to address them.</ix:nonNumeric> The <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-52">audit committee</ix:nonNumeric> also receives various written reports, summaries or presentations related to cybersecurity threats, risk and mitigation. In turn, the audit committee routinely provides reports to the board on cybersecurity matters.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own no real property and have no plans to acquire any real property in the future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">San Diego Leases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a lease agreement, or the New San Diego Lease, for research and development space in San Diego, California. The total space under the New San Diego Lease is approximately 5,600 square feet and the initial term continues through June 2028.We have also entered into an office lease, or the First San Diego Lease, for other property in San Diego, California that we use for office, manufacturing and research and development purposes. The total space under the First San Diego Lease is approximately 51,000 square feet and the term continues through May 2027.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent payments under both leases include base rent with an annual increase of approximately three percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $95,000 in connection with the First San Diego Lease. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth Meeting Lease </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a lease, or the Plymouth Meeting Lease, for our corporate headquarters in Plymouth Meeting, Pennsylvania. We have amended the Plymouth Meeting Lease on multiple occasions to increase the total leased space to approximately 57,400 square feet and extend the lease term through December 31, 2029.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent payments under the Plymouth Meeting Lease include base rent with an annual increase of approximately two percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid security deposits totaling $124,000. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into four agreements to sublease a total of approximately 25,000 square feet in our Plymouth Meeting headquarters, with two sublease terms through December 31, 2026, one through December 31, 2027 and one through December 31, 2029. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current and future planned facilities will be adequate to meet our operating needs for the foreseeable future. Should we need additional space, we believe we will be able to secure additional space at commercially reasonable rates.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, we filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our appeal, in July 2020, VGXI filed counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI, but VGXI later discontinued its third-party claims. We filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneOne. We terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. We filed preliminary objections to the complaint, which were overruled. In September 2021, we filed an answer to the complaint, new matter, and counterclaims. Our counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. In October 2021, GeneOne filed its answer to our counterclaims and new matter. In 2024, we filed a motion for summary judgment, which was denied. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="icae65948681042dba847429b32ecbd7c_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, par value $0.001 per share, began trading on the Nasdaq Global Select Market on September 15, 2014 under the symbol "INO," having previously traded on the NYSE MKT exchange. On November 2, 2023, the listing of our common stock was transferred to the Nasdaq Capital Market.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, we implemented a 1-for-12 reverse stock split of our common stock. As of March 12, 2025, we had approximately 65 common stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price per share of our common stock on March 12, 2025 was $2.05, as reported on the Nasdaq Capital Market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment of any dividends on our common stock is within the discretion of our board of directors. We have never paid cash dividends on our common stock and the board of directors does not expect to declare cash dividends on the common stock in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the performance of our common stock with the performance of the NYSE American Index, the S&amp;P SuperCap Biotechnology index and the Nasdaq Composite Index for the five years ended December 31, 2024. The graph assumes a $100 investment on December 31, 2019 in our common stock and in each index, with the reinvestment of all dividends, if any.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><img src="ino-20241231_g4.jpg" alt="1701" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:558px"/></div><div style="padding-left:108pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*$100 invested on 12/31/19 in stock or index, including reinvestment of dividends.<br/>Fiscal year ended December 31.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/24</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NYSE American</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nasdaq Composite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P SuperCap Biotechnology Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The stock price performance included in this graph is not necessarily indicative of future stock price performance. The performance graph is furnished solely to accompany this Form 10-K annual report and shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Parties </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Annual Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this Annual Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;I of this Annual Report under the caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our proprietary device technology and DNA medicine candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our DNA medicine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INOVIO, CELLECTRA, the INOVIO logo, and our other trademarks or service marks appearing in this Annual Report are our property. Solely for convenience, the trademarks and trade names in this report are referred to without the &#174; and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. Products or service names of other companies mentioned in this Annual Report may be trademarks, trade names or service marks of their respective owners.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;INOVIO&#8221; or the &#8220;Company&#8221; refer to INOVIO Pharmaceuticals, Inc. and its consolidated subsidiaries. References herein to &#8220;DNA medicines&#8221; refers to our product candidates in development.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_46"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. Our platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary investigational CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> devices are designed to deliver the plasmids into the body&#8217;s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, a chronic, rare and debilitating disease characterized by the growth of small tumors, or papillomas, in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although mostly benign, these papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. The standard of care for RRP is repeated invasive surgery. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we received feedback from the U.S. Food and Drug Administration, or FDA, that the data from this completed trial could be used to support the submission of a Biologic License Application, or BLA, for review under the FDA&#8217;s accelerated approval program. As part of submitting our BLA under the accelerated program, we will need to satisfy all FDA filing requirements and initiate a confirmatory clinical trial prior to BLA submission. We previously expected to be able to submit our BLA by the end of 2024; however, during our device testing process we identified a manufacturing issue involving the single-use disposable administration component of the CELLECTRA 5PSP device that we plan to use in the confirmatory trial and that will be submitted for approval for commercial use. We resolved the manufacturing issue in the first quarter of 2025 and are currently on track to begin a rolling submission of the BLA in mid-2025 and to request priority review, with a goal of receiving file acceptance by the FDA by the end of 2025.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing INO-3112, a DNA medicine candidate targeting HPV 16/18 combined with a DNA plasmid encoding for human IL-12 as an immune activator, for the treatment of oropharyngeal squamous cell carcinoma, or OPSCC, a type of head and neck cancer commonly known as throat cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) in a clinical trial for patients with locoregionally advanced, high-risk, HPV16/18 positive OPSCC. Under the terms of the supply agreement, Coherus will provide LOQTORZI for a planned Phase 3 clinical trial. We have also gained alignment with FDA on the design of the planned Phase 3 trial in the United States and received initial feedback from European regulatory authorities on the proposed design of the trial in Europe. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing INO-5401, an immunotherapy consisting of three DNA plasmids encoding for three tumor associated antigens, for the treatment of glioblastoma multiforme, or GBM, an aggressive type of brain cancer that accounts for more than 50% of all primary malignant brain tumors. GBM is one of the most complex, deadly, and treatment-resistant cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our development efforts with the product candidates described above, we are actively developing or planning to develop DNA medicines for other indications, including HPV-related anal dysplasia; cancers in people with certain gene mutations; and a potential vaccine booster to protect against the Ebola virus. We were previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions, or HSIL, but announced in 2023 that we were ceasing development for this indication in the United States. However, our collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any material revenues unless and until we obtain marketing approval for and successfully commercialize INO-3107 and our other product candidates. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All DNA medicine candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had an accumulated deficit of $1.7 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC defines critical accounting policies as those that are, in management&#8217;s view, important to the portrayal of our financial condition and results of operations and require management&#8217;s judgment. Our discussion and analysis of our financial condition and results of operations are based on our audited consolidated financial statements, which have been prepared in accordance with U.S.&#160;GAAP. Our significant accounting policies are outlined in Note 2 to the consolidated financial statements included in this report.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. We believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements:</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our activities have largely consisted of research and development efforts related to developing proprietary device technologies, DNA medicine candidates and dMABs. For clinical trial expenses, judgments used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to our results of operations. </span></div><div><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;2 to the consolidated financial statements, included elsewhere in this report.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial data for the years ended December&#160;31, 2024 and 2023 is presented in the following table and the results of these periods are used in the discussion thereafter.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.516%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,  </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2024 vs. 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity<br/></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,620,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,676,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,056,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,996,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,582,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,585,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,513,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,616,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,772,038&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,155,360)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,398,922)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,940,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,541,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,366,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,222,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,808,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,808,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,166,443)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,939,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,773,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,163,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,711,596)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,352)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,863,226&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Not meaningful</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue was primarily derived under collaborative arrangements and other contracts, including arrangements with affiliated entity, for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We derived 100% and 29%, respectively, of our revenue from a single collaborator, ApolloBio, in those years.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations and other consultants, and outside expenses. We utilize a labor reporting system to record employee compensation on a project-by-project basis. Unallocated research and development expenses include engineering and device-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related expenses that are not allocable to a specific project, as well as stock-based compensation, other employee-related expenses that are not related to a specific project, and facilities and depreciation expenses.     </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize our research and development expense by product candidate for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-3107</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-5401 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development programs (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engineering and device-related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated expenses (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,057)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div><div style="padding-left:36pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Includes impairment of intangible assets of $2.0 million recorded in 2023.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $11.1 million overall decrease in research and development expenses year over year was primarily the result of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$12.3 million in lower employee compensation, including stock-based compensation, due to lower headcount following our corporate restructuring undertaken in 2023; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$8.1 million in lower drug manufacturing expenses for other programs; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$7.5 million in lower drug manufacturing and clinical study expenses related to INO-4800 after we discontinued this program in 2022;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$3.4 million in lower drug manufacturing and engineering services related to other COVID-19 studies that we ceased after we discontinued development of INO-4800;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$2.0 million related to the impairment charge on intangible assets in 2023 which did not recur;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.9 million in lower immunology and clinical study expenses related to INO-3107;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.3 million in lower clinical study expenses related to VGX-3100 as we discontinued development of this product candidate in the third quarter of 2023; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.3 million in lower clinical study and subcontractor expenses related to our CEPI LASSA and MERS grants.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were offset by:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$10.6 million in higher drug manufacturing related to INO-3107; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$6.8 million in higher engineering professional and outside services related to our device development; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$4.7 million of lower contra-research and development expense recorded from grant agreements; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$4.6 million of higher expensed inventory.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $2.1 million and $6.8 million for the years ended December&#160;31, 2024 and 2023, respectively. The decrease was primarily due to decreases of $3.6 million and $553,000, respectively, in reimbursements from Advaccine and expenses earned under the sub-grants through Wistar.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses, which include business development expenses and patent expenses, were $37.0 million for the year ended December&#160;31, 2024 as compared to $47.6 million in 2023. The $10.6 million overall decrease was primarily the result of:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$5.4 million in lower employee compensation, including employee and consultant stock-based compensation, as a result of lower headcount and lower weighted average grant date fair value for the awards granted during 2024; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">$4.7 million in lower legal expenses related to litigation matters settled in 2023 that did not recur in 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Impairment of Goodwill  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we concluded that our goodwill was impaired due to a sustained decline in our stock price and related market capitalization, and a general decline in equity values in the biotechnology industry. Based on this analysis, we recognized a non-cash, pre-tax goodwill impairment charge of $10.5 million during the three months ended September 30, 2023. For more information, see Note 8 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Intangible Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the consolidated financial statements included in this report.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Stock-based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Total employee stock-based compensation cost for the years ended December&#160;31, 2024 and 2023 was $6.4 million and $10.4 million, of which $2.8 million and $4.5 million was included in research and development expenses and $3.6 million and $5.9 million was included in general and administrative expenses, respectively. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3.4 million decrease in interest income for the year ended December&#160;31, 2024 as compared to 2023 was primarily due to a lower short-term investment balance.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.0 million decrease in interest expense for the year ended December&#160;31, 2024 as compared to 2023 was primarily due to our senior convertible promissory notes that were repaid in full on March 1, 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Common Stock Warrant Liability</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a gain of $2.8 million from a decrease in the fair value of our common stock warrant liability for the year ended December 31, 2024. This change was related to the revaluation of the liability associated with the Warrants, as defined below, we issued in December 2024 and was primarily the result of a decrease in our stock price during the period between the issuance date and December 31, 2024. We will continue to estimate the fair value of these Warrants at each balance sheet date and will record gain or loss on the statement of operations for changes between balance sheet dates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Loss) Gain on Investment in Affiliated Entity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (loss) gain on investment in affiliated entity resulted from the change in the fair market value of our investment in PLS of $(1.2) million and $773,000 for the years ended December&#160;31, 2024 and 2023, respectively. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the consolidated statements of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Unrealized Gain on Available-for-Sale Equity Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gain on available-for-sale equity securities for the years ended December&#160;31, 2024 and 2023 was $2.1 million and $5.9 million, respectively, which resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense, net </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net, of $3.2 million for the year ended December 31, 2024 was primarily due to a realized loss on our short-term investments sold during the year, as well as the financing costs we incurred in connection with the issuance of the  Warrants, as defined below, in December 2024. Other expense, net, of $4.7 million for the year ended December 31, 2023 was primarily the result of realized losses on short-term investments sold during the year.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred operating losses and accordingly have not recorded a provision for U.S. income taxes for any of the periods presented. Utilization of net operating losses and tax credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended, or IRC. As of December&#160;31, 2024, we had net operating loss carry forwards for U.S. federal, California and Pennsylvania income tax purposes of $1.1 billion, $259.9 million and $88.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. We also had U.S. federal and state research and development tax credits of $46.1 million and $7.9 million, respectively, net of the federal research and development credits that will expire due to IRC Section&#160;383 limitations. The net operating losses and credits began to expire during 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash are to finance research and development activities, including clinical trial activities for the advancement of our DNA medicine candidates. We have satisfied our cash requirements principally from proceeds from the sale of equity and debt securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had cash and short-term investments of $94.1 million and working capital of $62.5 million, as compared to $145.3 million and $110.5 million as of December&#160;31, 2023, respectively. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $104.1 million and $124.4 million for the years ended December&#160;31, 2024 and 2023, respectively. The variance was primarily due to the timing and changes in working capital balances, offset by decreased operating expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $104.1 million and $87.4 million for the years ended December&#160;31, 2024 and 2023, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financing Activities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $51.5 million and $5.0 million for the years ended December&#160;31, 2024 and 2023, respectively. The variance was primarily due to the aggregate net proceeds of $60.8 million from the April 2024 Offering and December 2024 Offering (described below) and net proceeds of $6.1 million from the sale of common stock under at-the-market sales agreements, offset by the repayment of our convertible senior notes of $16.4 million in March 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering of Common Stock and Warrants</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, we closed an underwritten public offering, or the December 2024 Offering, relating to the issuance and sale of 10,000,000 shares of the common stock, and accompanying warrants to purchase 10,000,000 shares of common stock, or the Warrants, at an offering price of $3.00 per share and accompanying Warrant. The net proceeds from the December 2024 Offering were $27.6 million, after deducting the underwriting discounts and commissions and offering expenses paid by us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offering of Common Stock and Pre-Funded Warrants</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, we closed an underwritten registered direct offering, or the April 2024 Offering, relating to the issuance and sale of 2,536,258 shares of common stock at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock, or the Pre-Funded Warrants, at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2 million, after deducting the underwriting discounts and commissions and offering expenses paid by us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-The-Market Sales Agreements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2024, we entered into an Equity Distribution Agreement, or the 2024 Sales Agreement, with an outside sales agent, or Sales Agent, for the offer and sale of our common stock for an aggregate offering price of up to $60.0&#160;million. The 2024 Sales Agreement provides that the Sales Agent is entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agent under the 2024 Sales Agreement, and we have provided the Sales Agent with certain indemnification rights. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, we sold 133,900 shares of common stock under the 2024 Sales Agreement. The sales were made at a weighted average price of $7.02 per share, resulting in aggregate net proceeds of $925,000. As of December&#160;31, 2024, there was $59.1 million of remaining capacity under the 2024 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, we entered into an ATM Equity Offering Sales Agreement, or the 2021 Sales Agreement, with outside sale</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s agents, under which we were able to offer and sell shares of our common stock with aggregate gross proceeds of up to $300.0 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we sold 543,620 shares of our common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2 million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we sold 875,305 shares of our common stock under the 2021 Sales Agreement at a weighted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average price of $6.33 per share, resulting in aggregate net proceeds of $5.5&#160;million. We terminated the 2021 Sales Agreement in August 2024 in connection with the entry into the 2024 Sales Agreement described above.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock options to purcha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">se 8,159</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock were exercised for aggregate net proceeds to us of $68,000, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $421,000. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, no stock options were exercised and tax payments of $467,000 were made related to the net sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are settlement of RSU awards. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we issued 760,083 shares of common stock pursuant to a securities class action settlement, as described in Note 11 to our consolidated financial statements included in this report.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Requirements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had an accumulated deficit of $1.7 billion and we expect to continue to operate at a loss in the near term. The amount of our accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. Our current cash resources </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will not be sufficient to complete the clinical development of our product candidates beyond INO-3107, and we anticipate that additional financing will be required in order to complete the development of and to commercialize and generate revenues from the sale of INO-3107 or any other product candidates that may receive regulatory approval. If these activities are successful and if we receive approval from the FDA to market our DNA medicine candidates, then we will need to raise additional funding to market and sell the approved products and equipment. In addition to the potential issuance of equity or debt securities in order to raise capital, we are also evaluating potential collaborations as an additional way to fund our operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We expect our cash runway to extend through the fourth quarter of 2025, without giving effect to any further capital raising activities that we may undertake.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue operations is dependent upon our ability to obtain additional capital in the future and achieve profitable operations. We expect to continue to rely on outside sources of financing to meet our capital needs and we may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about our ability to continue as a going concern beyond the fourth quarter of 2025. The consolidated financial statements as of and for the year ended December&#160;31, 2024 do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, future minimum payments due under our contractual obligations are set forth in the table below. We expect to be able to satisfy these obligations, both in the short-term and in the longer-term, with cash on hand.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than<br/>1&#160;year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1&#160;&#8211;&#160;3&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,435,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,510,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,442,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing commitments (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) We have entered into operating leases for our facilities, which expire from 2027 to 2029, and operating leases for office equipment, which expire in 2025. We have four active subleases for portions of our Plymouth Meeting corporate headquarters facility with two sublease periods through December 31, 2026, one through December 31, 2027 and one through December 31, 2029. As of December&#160;31, 2024, we expect to receive aggregate future minimum lease payments totaling $2.4 million (non-discounted) over the duration of the sublease agreements, which expected payments are not included in the table above.&#160;</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Purchase obligations from supply agreements with contract manufacturers.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_61"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in short-term investment-grade securities. Over the past several years, there has been a pronounced overall increase in prevailing interest rates in the United States, which has contributed to the accumulated unrealized loss of $1.9 million in the market value of our investment portfolio as of December 31, 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate primarily in the United States and most transactions during the year ended December&#160;31, 2024 were made in United States dollars. Accordingly, we do not have any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor. Although inflation has increased generally in the United States in recent years, we do not believe that inflation has had a material effect on our business, financial condition or results of operations during the year ended December&#160;31, 2024. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;8 is incorporated by reference to our Consolidated Financial Statements and the Report of Independent Registered Public Accounting Firm beginning at page&#160;F-1 of this report.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Annual Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of December&#160;31, 2024 at the reasonable assurance level.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting and Attestation Report of Registered Public Accounting Firm</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in &#8220;Internal Control&#8212;Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management determined that we maintained effective internal control over financial reporting as of December&#160;31, 2024.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm regarding the effectiveness of internal control over financial reporting as required by Section 404(b) of the Sarbanes-Oxley Act of 2002. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit smaller reporting companies to provide only management&#8217;s report in this Annual Report.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the fourth quarter of our fiscal year ended December&#160;31, 2024, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Trading Plans</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fiscal quarter ended December 31, 2024, none of our officers or directors, as defined in Rule 16a-1(f), <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-53"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-54">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-55"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-56">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Item 408 of Regulation S-K.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_79"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.            DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">          </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="icae65948681042dba847429b32ecbd7c_82"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;10 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2024 fiscal year, under the captions &#8220;Election of Directors,&#8221; &#8220;Corporate Governance&#8221; and &#8220;Executive Officers and Other Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item&#160;11 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2024 fiscal year, under the captions &#8220;Executive Compensation&#8221; (excluding the information under the subheading &#8220;Pay Versus Performance Disclosure&#8221;) and &#8220;Director Compensation."</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;12 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2024 fiscal year, under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director independence and other information required by this Item&#160;13 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2024 fiscal year, under the captions &#8220;Executive Officers and Other Information - Certain Relationships and Related Party Transactions&#8221; and &#8220;Election of Directors.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;14 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2024 fiscal year, under the caption &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm.&#8221;</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="icae65948681042dba847429b32ecbd7c_103"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statements</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated financial statements required to be filed hereunder begin on Page&#160;F-1 in this report.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules not listed herein have been omitted because the information required to be set forth therein is not applicable or is included in the Financial Statements or notes thereto.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report on Form&#160;10-K:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments prior to December 31, 2023 (incorporated by reference to Exhibit&#160;3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312524015380/d736726dex31.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312524015380/d736726dex31.htm">Certificate of Amendment to Certificate of Incorporation, effective as of January 24, 2024 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s current report on Form 8-K filed on January 25, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August&#160;10, 2011 (incorporated by reference to Exhibit&#160;3.2 to the registrant&#8217;s Form&#160;8-K current report filed on August&#160;12, 2011).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.9 to the registrant&#8217;s annual report on Form 10-K filed with the SEC on March 12, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001055726/000119312524099067/d817715d8k.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001055726/000119312524099067/d817715d8k.htm">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 8-K filed on April 17, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001055726/000119312524279061/d899983d8k.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001055726/000119312524279061/d899983d8k.htm">Form of Warrant issued in December 2024 (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 8-K filed on December 16, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">10.1&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">R&amp;D Alliance Agreement dated December&#160;19, 2005 by and between Ganial Immunotherapeutics,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by Novation and Amendment Agreement by and between VGX Pharmaceuticals, Inc., Ganial Immunotherapeutics, Inc., and Onconox (incorporated by reference to Exhibit&#160;10.31 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">10.2&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">R&amp;D Collaboration and License Agreement dated December&#160;18, 2006 by and between VGX International,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated October&#160;31, 2007 and as amended by Second Amendment dated August&#160;4, 2008 (incorporated by reference to Exhibit&#160;10.39 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">10.3&#8224;&#160;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">Patent License Agreement dated April&#160;27, 2007 by and between The Trustees of the University of Pennsylvania and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated June&#160;12, 2008 (incorporated by reference to Exhibit&#160;10.50 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">10.4&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">License Agreement dated May&#160;9, 2007 by and between Baylor University and VGX Pharmaceuticals,&#160;Inc. (incorporated by reference to Exhibit&#160;10.34 as filed with the registrant&#8217;s registration statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001055726/000119312524199331/d761691d8k.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001055726/000119312524199331/d761691d8k.htm">Equity Distribution Agreement, dated August 13, 2024, by and between Inovio Pharmaceuticals, Inc. and Oppenheimer &amp; Co. Inc. (incorporated by reference to Exhibit 1.1 of the Registrant&#8217;s Current Report on Form 8-K filed on August 13, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">10.6&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">License and Collaboration Agreement dated March&#160;24, 2010 between Inovio Pharmaceuticals, Inc. and VGX International, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended March&#160;31, 2010 filed on May&#160;17, 2010).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">10.7&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">Collaborative Development and License Agreement dated October 7, 2011 between VGX International, Inc. and Inovio Pharmaceuticals, Inc., as amended by First Amendment dated August 21, 2013, and Second Amendment dated October 7, 2013 (incorporated by reference to Exhibit 10.1 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended September&#160;30, 2011 filed on November&#160;7, 2011).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">10.10&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">Amended and Restated License and Collaboration Agreement, dated December 29, 2017, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (incorporated by reference to Exhibit 10.12 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2017 filed on March 14, 2018).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">10.11</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">First Amendment to the Amended and Restated License and Collaboration Agreement, dated June 14, 2023, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (incorporated by reference to Exhibit 10.11 of the registrant's Form 10-K annual report for the year ended December 31, 2023 filed on March 6, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm">Office Lease Agreement dated October 10, 2016 by and between 6759 Mesa Ridge Road Holdings, LLC and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2016 filed on November 9, 2016).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm">Sublease dated June 21, 2017 between Accolade, Inc. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">10.14+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">Employment Agreement dated as of December&#160;27, 2010 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Form 10-K report for the year ended December&#160;31, 2010 filed on March&#160;16, 2011).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">10.15+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit&#160;10.42 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">10.16+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">Second Amendment to Employment Agreement dated November 7, 2014 by and between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.2 of the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2014 filed on November 10, 2014).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">10.17+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">Inovio Pharmaceuticals, Inc. Severance Plan and Summary Plan Description (incorporated by reference to Exhibit 10.17+ of the registrant's Form 10-K annual report for the year ended December 31, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">3 filed on March 6, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">10.18+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">Participation Agreement under Severance Plan for Jacqueline Shea (incorporated by reference to Exhibit 10.18+ of the registrant's Form 10-K annual report for the year ended December 31, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">3 filed on March 6, 2024).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">10.19+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">Participation Agreement under Severance Plan for Laurent Humeau  (incorporated by reference to Exhibit 10.19+ of the registrant's Form 10-K annual report for the year ended December 31, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">3 filed on March 6, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">10.20+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">Participation Agreement under Severance Plan for Michael Sumner (incorporated by reference to Exhibit 10.20+ of the registrant's Form 10-K annual report for the year ended December 31, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">3 filed on March 6, 2024).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">10.21+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">Form of Indemnification Agreement for Directors and Officers of Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit&#160;10.1 to the registrant&#8217;s Form&#160;10-Q quarterly report for the quarterly period ended June&#160;30, 2009, filed on August&#160;19, 2009).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">10.22+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">Amended and Restated 2007 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.12 to the registrant's Form 10-K report for the year ended December 31, 2015 filed on March 14, 2016).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">10.23+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">Form of Incentive and Non-Qualified Stock Option Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit&#160;4.4 to the registrant&#8217;s Registration Statement on Form&#160;S-8 filed on May&#160;14, 2007).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">10.24+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the registrant's Form 8-K filed on May 10, 2019).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">10.25+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">Form of Incentive Stock Option Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.55 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">10.26+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">Form of Nonqualified Stock Option Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.56 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">10.27+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">Form of Restricted Stock Unit Award Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.54 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex991.htm">10.28+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex991.htm">Inovio Pharmaceuticals, Inc. 2022 Inducement Plan (incorporated by reference to Exhibit 99.1 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex992.htm">10.29+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex992.htm">Form of Option Grant Package under 2022 Inducement Plan (incorporated by reference to Exhibit 99.2 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex993.htm">10.30+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex993.htm">Form of RSU Grant Package under 2022 Inducement Plan (incorporated by reference to Exhibit 99.3 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312523148122/d458280dex101.htm">10.31+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000119312523148122/d458280dex101.htm">Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed on May 18, 2023).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex102.htm">10.32+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex102.htm">Form of Option Grant Package under 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s quarterly report on Form 10-Q filed on August 9, 2023).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex103.htm">10.33+</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572623000051/ino-63023x10qex103.htm">Form of RSU Grant Package under 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the registrant&#8217;s quarterly report on Form 10-Q filed on August 9, 2023).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex191.htm">19.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex191.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-57">Insider Trading Policy (filed herewith)</ix:nonNumeric></a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex211.htm">Subsidiaries of the registrant (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex231.htm">Consent of Independent Registered Public Accounting Firm (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_109">24.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_109">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex311.htm">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex312.htm">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex321.htm">32.1&#x5E;</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312024x10kex312.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">97.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1055726/000105572624000011/ino-20231231.htm">Incentive Compensation Recoupment Policy, adopted on November 14, 2023 (incorporated by reference to Exhibit 97.1 of the registrant's Form 10-K annual report for the year ended December 31, 2023 filed on March 6, 2024).</a></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema with Embedded Linkbase Documents.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designates management contract, compensatory plan or arrangement.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted for certain portions omitted from this exhibit (indicated by asterisks) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential portions of this exhibit have been separately filed with the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain confidential portions of this exhibit (indicated by asterisks) were omitted because the identified confidential portions are not material and are of the type that the registrant treats as private or confidential. </span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:4.635%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#x5E;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March&#160;18, 2025.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JACQUELINE E. SHEA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea<br/>President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jacqueline E. Shea and Peter Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the United States Securities and Exchange Commission in connection with the Annual Report on Form&#160;10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JACQUELINE E. SHEA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SIMON X. BENITO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Simon X. Benito</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ROGER D. DANSEY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Roger D. Dansey</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ANN C. MILLER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ann C. Miller</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JAY SHEPARD</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jay Shepard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DAVID B. WEINER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">David B. Weiner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;WENDY L. YARNO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wendy L. Yarno</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;LOTA S. ZOTH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lota S. Zoth</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div id="icae65948681042dba847429b32ecbd7c_115"></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_118">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-58">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_118">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_121">Consolidated Balance Sheets </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_121">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_127">Consolidated Statements of Operations </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_127">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_133">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_133">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_136">Consolidated Statements of Stockholders' Equity </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_136">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_142">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_142">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_145">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#icae65948681042dba847429b32ecbd7c_145">9</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Stockholders and the Board of Directors of Inovio Pharmaceuticals, Inc. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Inovio Pharmaceuticals, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s Ability to Continue as a Going Concern</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations, has negative cash flows from operating activities, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrual of clinical trial expenses</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2024, the Company accrued $2.0 million for clinical trial expenses. Clinical trial expenses primarily consists of external costs to be paid to clinical research organizations (&#8220;CROs&#8221;) which are accrued and expensed based upon actual work completed in accordance with signed agreements. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Auditing management&#8217;s accounting for accrued clinical trial expenses is especially challenging because the evaluation is dependent upon data and inputs exchanged between clinical personnel and third-party service providers, such as the number of sites activated, the number of patients enrolled, and the number of patient visits, which is tracked in spreadsheets and other end user computing programs.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">How We Addressed the Matter in our Audit</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding of the accounting for accrued clinical trial expenses including management&#8217;s process for measuring estimated accrued clinical study costs such as patient enrollment and total cost incurred to date from third-parties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To test the completeness of the Company&#8217;s accrued clinical trial expenses, we obtained from third-parties, confirmation of patient enrollment and direct service cost to date for significant clinical trials. We attended internal clinical trial and project status meetings with accounting personnel and the clinical project manager to understand the status of significant clinical trial activities. To assess the appropriate measurement of accrued clinical trial expenses, we inspected key terms, timelines of completion, activities and costs for a sample of vendor contracts, including amendments, and compared these to management&#8217;s analyses used in tracking the progress of service agreements. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.220%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-59">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2002.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-60">San Diego, California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-61">65,813,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-62">14,310,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-63">28,300,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-64">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-65">1,199,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="f-66">2,405,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets, including with affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-67">2,517,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-68">5,414,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-69">97,830,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-70">153,113,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-71">3,659,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-72">4,960,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in affiliated entity </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-73">1,613,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-74">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-75">8,113,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-76">9,491,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-77">1,979,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-78">605,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-79">113,197,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-80">170,951,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-81">16,200,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-82">19,847,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-83">1,351,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-84">1,070,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-85">2,021,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-86">2,365,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-87">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="0" id="f-88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-89">2,497,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-90">2,406,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:fixed-zero" scale="0" id="f-91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-92">109,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:fixed-zero" scale="0" id="f-93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:ConvertibleDebtCurrent" format="ixt:num-dot-decimal" scale="0" id="f-94">16,770,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-95">35,325,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-96">42,570,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-97">9,367,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-98">11,032,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-99">44,693,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-100">53,602,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-101"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-102"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-103"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-104">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-106">10,000,000</ix:nonFraction></ix:nonFraction>, issued and outstanding shares: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-110">9</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at December&#160;31, 2024 and 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-113"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-114">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-115"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-116">600,000,000</ix:nonFraction></ix:nonFraction> at December 31, 2024 and 2023, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-117"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-118">36,099,991</ix:nonFraction></ix:nonFraction> at December&#160;31, 2024 and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-119"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-120">22,793,075</ix:nonFraction></ix:nonFraction> at December&#160;31, 2023 </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-121">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-122">22,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-123">1,799,362,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-124">1,740,954,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-125">1,730,219,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-126">1,622,965,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-127">675,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-128">662,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-129">68,503,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-130">117,349,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-131">113,197,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-132">170,951,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:11pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-133">217,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-134">832,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-135">75,620,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-136">86,676,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-137">36,996,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-138">47,582,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="0" id="f-140">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-141">112,616,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-142">144,772,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-143">112,398,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-144">143,940,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-145">4,766,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-146">8,133,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="0" id="f-147">177,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="0" id="f-148">1,222,789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-149">2,808,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-151">1,166,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-152">773,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-153">2,077,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-154">5,850,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-155">3,163,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-156">4,711,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-157">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-158">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-159"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-160">3.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-161"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-162">6.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-163"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-164">27,160,863</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-165"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-166">22,173,662</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"/><td style="width:68.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.591%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.616%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-167">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-168">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-169">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-170">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Unrealized (loss) gain on short-term investments, net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-171">45,469</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-172">40,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-173">107,267,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-174">135,081,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_136"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.321%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common stock </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-175">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-177">21,090,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-178">21,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-179">1,710,888,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-180">1,487,847,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-181">698,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-182">222,362,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for legal settlement</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-183">760,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="f-184">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-185">13,999,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="f-186">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-187">875,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="f-188">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-189">5,460,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-190">5,461,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-191">66,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-192">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-193">466,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-194">466,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-195">11,072,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-196">11,072,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-197">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-198">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-199">40,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-200">40,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-201">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-202">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-203">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-205">22,793,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-206">22,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-207">1,740,954,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-208">1,622,965,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-209">662,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-210">117,349,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-211">13,213,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-212">13,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-213">36,020,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-214">36,033,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of pre-funded warrants for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-215">16,146,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="0" id="f-216">16,146,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-217">93,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="f-218">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-219">353,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-220">353,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-221">6,595,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-222">6,595,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-223">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-224">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-225">45,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-226">45,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-227">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-228">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-229">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-231">36,099,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-232">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-233">1,799,362,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-234">1,730,219,262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-235">675,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-236">68,503,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_142"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:73.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.137%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-237">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-238">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-239">1,752,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-240">2,621,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-242">145,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-243">1,377,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-244">736,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-245">2,808,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="f-246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="0" id="f-248">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="0" id="f-250">1,984,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-252">32,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-253">6,595,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-254">11,072,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest on senior convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-255">355,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-256">155,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of discounts on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="f-257">1,690,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="f-258">4,686,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized loss on sales of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-259">1,905,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="f-260">4,805,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gain) loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="f-261">22,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="f-262">317,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on equity investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-263">1,166,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-264">773,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-265">2,077,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-266">5,850,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-267">1,206,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="f-268">9,332,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-269">1,483,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-270">39,020,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-271">38,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="f-272">78,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses, including due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-273">3,367,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-274">45,989,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-275">343,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="f-276">8,228,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-277">1,573,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="f-278">2,020,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant funding liability, including from affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-279">109,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="f-280">2,453,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-281">104,076,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-282">124,365,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-283">54,138,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-284">203,475,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-285">158,637,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-286">284,932,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-287">487,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-288">320,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of capital assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-289">59,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-290">6,219,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-291">104,071,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-292">87,355,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="f-293">16,415,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="0" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of pre-funded warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ino:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-295">16,146,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="ino:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" format="ixt:fixed-zero" scale="0" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-297">36,033,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-298">5,461,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-299">16,063,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="0" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-301">67,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-303">420,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="f-304">466,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-305">51,475,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-306">4,995,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-307">32,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-308">3,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-309">51,502,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-310">32,018,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-311">14,310,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-312">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-313">65,813,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-314">14,310,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-315">533,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-316">1,066,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock as part of litigation settlement</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="0" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="0" id="f-318">14,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="icae65948681042dba847429b32ecbd7c_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="icae65948681042dba847429b32ecbd7c_148"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-319" continuedAt="f-319-1" escape="true">The Company</ix:nonNumeric></span></div><ix:continuation id="f-319-1"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body's cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA),  HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div id="icae65948681042dba847429b32ecbd7c_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-320" continuedAt="f-320-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-321" continuedAt="f-321-1" escape="true"><ix:continuation id="f-320-1" continuedAt="f-320-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-322">107.3</ix:nonFraction> million for the year ended December&#160;31, 2024. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ino:WorkingCapital" scale="6" id="f-323">62.5</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="f-324">1.7</ix:nonFraction> billion as of December&#160;31, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-325">94.1</ix:nonFraction> million as of December 31, 2024 are not sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements.  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-326">10,000,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-37" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-327">0.001</ix:nonFraction> per share, and warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-328">10,000,000</ix:nonFraction> shares of common stock (the &#8220;Warrants&#8221;), at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-39" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-329">3.00</ix:nonFraction> per share and accompanying Warrant. The exercise price of the Warrants is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-39" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-330">3.76</ix:nonFraction> per share. The net proceeds from the December 2024 Offering were $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-331">27.6</ix:nonFraction>&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;April 2024 Offering&#8221;), relating to the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-332">2,536,258</ix:nonFraction> shares (the &#8220;Shares&#8221;) of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-333">0.001</ix:nonFraction> per share, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-43" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-334">7.693</ix:nonFraction> per share and pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-335">2,135,477</ix:nonFraction> shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-336">7.692</ix:nonFraction> per Pre-Funded Warrant, which represents the per share price for the Shares less the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-337">0.001</ix:nonFraction> per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-338">33.2</ix:nonFraction>&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-339">94.1</ix:nonFraction> million as of December&#160;31, 2024 are expected to be sufficient to support the Company's planned operations through the fourth quarter of 2025. The Company's current </span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-320-2" continuedAt="f-320-3"><ix:continuation id="f-321-1" continuedAt="f-321-2"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-340">60.8</ix:nonFraction>&#160;million from equity offerings during the year ending December 31, 2024, and $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-341">6.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-342">5.5</ix:nonFraction>&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2024 and 2023, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the fourth quarter of 2025. The Company's consolidated financial statements as of and for the year ended December&#160;31, 2024 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-321-2">The Company is, and from time to time in the future may be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#8217; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-343" continuedAt="f-343-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-343-1">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-344" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM"), the President and Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-345">one</ix:nonFraction> segment operating primarily within the United States, as further described in Note 16.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-346" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-347" continuedAt="f-347-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-320-3" continuedAt="f-320-4"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-347-1">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-348" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses and common stock warrant liability. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The estimated fair value of the common stock warrant liability is determined by using the Black-Scholes pricing model, as discussed in Note 5.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-349" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2024 and 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-350" continuedAt="f-350-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2024 and 2023. </span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><ix:continuation id="f-350-1" continuedAt="f-350-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-350-2">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-351" continuedAt="f-351-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Affiliated Entities</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-351-1">Accounts receivable from affiliated entities are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-352"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-353">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts for potential credit losses as of December&#160;31, 2024 or 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-354" continuedAt="f-354-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:f-355">three</span> to <ix:nonNumeric contextRef="c-50" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-356">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-354-1">The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable.</ix:continuation> No impairment losses have been recognized related to long-lived assets for the years ended December 31, 2024 or 2023.</span></div><ix:nonNumeric contextRef="c-1" name="ino:WarrantsPolicyPolicyTextBlock" id="f-357" continuedAt="f-357-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-320-4" continuedAt="f-320-5"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-357-1">reporting period while the warrants are outstanding. The Pre-Funded Warrants issued in April 2024 met all the criteria for equity classification and were recorded as a component of additional paid-in capital on issuance. However, the Warrants issued in December 2024 did not meet all the criteria for equity classification and were recorded as a liability at fair value upon issuance. The Warrants met the definition of a derivative and did not meet any scope exceptions under ASC 815. As a result, the fair value of the liability associated with the Warrants will be remeasured at the end of each reporting period while the Warrants are outstanding, and any change in fair value between reporting periods will be recognized as gain or loss on the consolidated statement of operations for that reporting period.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs associated with the issuance of the Warrants classified as a liability were expensed at the time of issuance and have been included as part of other expense, net, on the consolidated statement of operations for the year ended December 31, 2024. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-358" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carryforwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-359">349.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-360">327.5</ix:nonFraction> million at December&#160;31, 2024 and 2023, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-362" continuedAt="f-362-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-361" continuedAt="f-361-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="f-362-1"><ix:continuation id="f-361-1">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).</ix:continuation></ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="ino:GrantRevenuePolicyTextBlock" id="f-363" continuedAt="f-363-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="f-363-1" continuedAt="f-363-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-363-2">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-364" continuedAt="f-364-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="f-364-1" continuedAt="f-364-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-364-2"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-365" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-366" continuedAt="f-366-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-320-5" continuedAt="f-320-6"><ix:continuation id="f-366-1"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. The outstanding Pre-Funded Warrants (see Note 10) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the year ended December 31, 2024 given their nominal exercise price.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 9) was considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, basic and diluted net loss per share are the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" id="f-367" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the year ended December 31, 2024 and 2023 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-368">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-369">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ino:WeightedAverageNumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-370">25,655,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="ino:WeightedAverageNumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-371">22,173,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" format="ixt:num-dot-decimal" scale="0" id="f-372">1,505,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" format="ixt:fixed-zero" scale="0" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-374"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-375">27,160,863</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-376"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-377">22,173,662</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-378"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-379">3.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-380"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-381">6.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-382" escape="true"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-383">10,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-385">1,337,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-386">1,128,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-387">337,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-388">274,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-389">128,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-391">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-392">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-394">254,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-395">11,804,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-396">1,658,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-397" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-320-6" continuedAt="f-320-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-398" continuedAt="f-398-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><ix:continuation id="f-398-1" continuedAt="f-398-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-and market-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-398-2">The Company recognizes forfeitures as they occur.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-399" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-400">4.22</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-401">4.05</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-402">105</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-403">100</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-63" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-404">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-64" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-405">5.5</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-406">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-64" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-407">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-408">4.21</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-409">3.90</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-410">100</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-411">89</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-65" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-412">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-66" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-413">10.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-65" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-414">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-66" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-415">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-416" continuedAt="f-416-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-07. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company has adopted ASU 2023-07 and included the segment disclosures in Note 16 below.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance its consolidated financial statements. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2024-03. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-416-1"><ix:continuation id="f-320-7"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024-03 requires public business entities to disaggregate operating expenses into specific categories such as employee compensation, depreciation, and intangible asset amortization, by relevant expense caption on the statement of operations. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on the consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_157"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-418" continuedAt="f-418-1" escape="true">Revenue Recognition and Concentration of Credit Risk</ix:nonNumeric></span></div><ix:continuation id="f-418-1" continuedAt="f-418-2"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the years ended December&#160;31, 2024 and 2023, the Company recognized revenue from various license and other agreements. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-419" continuedAt="f-419-1" escape="true">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="f-419-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.407%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-420">217,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-421">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-422">245,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-423">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-426">586,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-427">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-428">217,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-429">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-430">832,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-431">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="0" id="f-432">No</ix:nonFraction> revenue recognized during the years ended December&#160;31, 2024 and 2023 was in deferred revenue as of December 31, 2023 and 2022, respectively. </span></div></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-418-2">As of December&#160;31, 2024 and 2023, the Company had no accounts receivable balance.</ix:continuation> </span></div><div><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-433" continuedAt="f-433-1" escape="true">Collaborative Agreements  </ix:nonNumeric></span></div><ix:continuation id="f-433-1" continuedAt="f-433-2"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated in 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. The 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounts for the 2021 amendment under ASC Topic 808. Reimbursements from Advaccine are recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility is assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="0" id="f-434">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-435">3.6</ix:nonFraction>&#160;million respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), which was amended in June 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="f-436">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="c-80" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:duryear" id="f-437">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-438">218,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="f-439">245,000</ix:nonFraction>, respectively, from the ApolloBio Agreement that was recorded as revenue. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-433-2"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations (CEPI)</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-440">56</ix:nonFraction>&#160;million of costs over a <ix:nonNumeric contextRef="c-83" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" format="ixt-sec:durwordsen" id="f-441">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="f-442">1.6</ix:nonFraction> million in connection with the final close-out of these grants, which was recorded as contra-research and development expense. During the year ended December 31, 2023, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="f-443">1.8</ix:nonFraction> million in connection with these grants.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-444">2.2</ix:nonFraction>&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="f-445">1.1</ix:nonFraction>&#160;million for the project. During the years ended December&#160;31, 2024 and 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="f-446">39,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="f-447">70,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant.</span></div></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-449" continuedAt="f-449-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-448" continuedAt="f-448-1" escape="true">Short-term Investments and Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-449-1" continuedAt="f-449-2"><ix:continuation id="f-448-1" continuedAt="f-448-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-450" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2024 and 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-451">25,926,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-453">1,445,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-454">24,480,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-91" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-455">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-456">2,980,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-457">9,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-458">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-459">2,989,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-460">1,260,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-462">430,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-463">829,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-464">30,167,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-465">9,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-466">1,876,951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-467">28,300,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-468">55,389,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-470">3,522,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-471">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-95" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-472">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-473">75,164,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-474">24,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-476">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="c-95" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="f-477">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-478">2,978,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-479">11,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="f-480">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-481">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-482">1,340,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-484">403,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-485">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-486">134,873,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-487">36,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-488">3,927,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-489">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and 2023, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-2" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="f-490">900</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="f-491">1,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-492">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="f-493">4.8</ix:nonFraction> million, respectively. During the years ended December&#160;31, 2024 and 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-494">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-495">5.9</ix:nonFraction>&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2024 and&#160;2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2024, the Company had&#160;<ix:nonFraction unitRef="position" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-496">19</ix:nonFraction>&#160;available-for-sale securities with an aggregate total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="6" id="f-497">1.9</ix:nonFraction> million. All of the securities had been in a loss position for longer than 12 months as of December&#160;31, 2024. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-449-2" continuedAt="f-449-3"><ix:continuation id="f-448-2" continuedAt="f-448-3"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2024&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2024, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-498" escape="true"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-499">24,480,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-500">24,480,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-503">2,989,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-505">2,989,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-507">829,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-509">829,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-511">28,300,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-512">24,480,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-513">3,819,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" id="f-515">1,613,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" id="f-516">1,613,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" id="f-517">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="f-519">29,914,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="f-520">26,094,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="f-521">3,819,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" id="f-522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:num-dot-decimal" id="f-523">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:fixed-zero" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:fixed-zero" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="ino:CommonStockWarrantLiabilityFairValue" format="ixt:num-dot-decimal" id="f-526">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" id="f-527">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" id="f-530">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-531">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-532">51,866,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-535">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-536">75,189,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-539">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-541">2,990,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-543">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-545">936,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-547">130,982,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-548">127,056,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-549">3,926,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-551">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="f-552">2,780,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-555">133,763,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-556">129,836,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-557">3,926,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2024 consisted of mutual funds and the Company&#8217;s investment in its affiliated entity, PLS. Level 1 assets at December 31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-449-3"><ix:continuation id="f-448-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-559"><ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-560">597,808</ix:nonFraction></ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2024 and 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of December&#160;31, 2024 or 2023. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 liabilities held as of December 31, 2024 consisted of liabilities associated with the Warrants to purchase  common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 10 for additional information about the liability-classified warrants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-561" continuedAt="f-561-1" escape="true">The following assumptions were used to estimate the fair value of the warrant liability:</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-561-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">On Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="3" name="ino:WarrantLiabilityMeasurementInput" scale="-2" id="f-562">4.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-138" decimals="3" name="ino:WarrantLiabilityMeasurementInput" scale="-2" id="f-563">4.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-139" decimals="3" name="ino:WarrantLiabilityMeasurementInput" scale="-2" id="f-564">111</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="3" name="ino:WarrantLiabilityMeasurementInput" scale="-2" id="f-565">111</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="y" contextRef="c-141" decimals="0" name="ino:WarrantLiabilityMeasurementInput" id="f-566">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="y" contextRef="c-142" decimals="0" name="ino:WarrantLiabilityMeasurementInput" id="f-567">5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-143" decimals="3" name="ino:WarrantLiabilityMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-568">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="number" contextRef="c-144" decimals="3" name="ino:WarrantLiabilityMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-569">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#8217;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="6" id="f-570">2.8</ix:nonFraction>&#160;million on the consolidated statement of operations for the year ended December 31, 2024. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-571" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s total Level 3 financial liabilities for the year ended December 31, 2024:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock warrants in December 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="0" id="f-573">16,063,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-574">Decrease in fair value of liability</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="0" id="f-575">2,808,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="0" id="f-576">13,255,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentAssetsTextBlock" id="f-577" continuedAt="f-577-1" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="f-578" continuedAt="f-578-1" escape="true"><ix:continuation id="f-577-1" continuedAt="f-577-2"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-577-2"><ix:continuation id="f-578-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="ino:PrepaidClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-579">627,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="ino:PrepaidClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-580">3,410,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-581">1,889,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-582">2,003,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-583">2,517,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-584">5,414,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-585" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-586">5,091,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-587">3,577,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-588">10,007,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-589">9,837,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-590">1,101,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-591">6,432,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-592">16,200,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-593">19,847,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt">As of December 31, 2024 and 2023, balance included $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ino:PrepaidManufacturingExpenseCurrent" scale="0" id="f-594">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="ino:PrepaidManufacturingExpenseCurrent" format="ixt:num-dot-decimal" scale="6" id="f-595">1.5</ix:nonFraction>&#160;million, respectively, of prepaid manufacturing expenses.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As of December 31, 2024 and 2023, balance included $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ino:GrantLiability" scale="0" id="f-596">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="ino:GrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-597">4.3</ix:nonFraction>&#160;million, respectively, of liability for unused grant funding.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-598" continuedAt="f-598-1" escape="true">Fixed Assets</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-599" escape="true"><ix:continuation id="f-598-1" continuedAt="f-598-2"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-600">11,761,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-601">8,390,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-602">3,370,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-603">2,835,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-604">2,571,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-605">263,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-606">2,431,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-607">2,416,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-608">15,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-609">3,093,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-610">3,083,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-611">9,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-612">20,122,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-613">16,462,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-614">3,659,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-615">15,917,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-616">11,753,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-617">4,164,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-618">3,538,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-619">3,078,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-620">460,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-621">2,827,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-622">2,816,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-623">10,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-624">3,529,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-625">3,204,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-626">325,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-627">25,812,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-628">20,851,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-629">4,960,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-598-2">Depreciation expense for the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-630">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-631">2.6</ix:nonFraction> million, respectively. The Company determined that the carrying value of its fixed assets was not impaired during the periods presented. During the year ended December 31, 2024, the Company sold fixed assets with no net book value for a gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ino:GainLossOnSaleOfFixedAssetsNoNetBookValue" format="ixt:num-dot-decimal" scale="0" id="f-632">59,000</ix:nonFraction> and disposed of fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="0" id="f-633">37,000</ix:nonFraction>. During the year ended December 31, 2023, the Company sold fixed assets with no net book value for a gain of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ino:GainLossOnSaleOfFixedAssetsNoNetBookValue" format="ixt:num-dot-decimal" scale="0" id="f-634">148,000</ix:nonFraction> and disposed of fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="0" id="f-635">466,000</ix:nonFraction>.</ix:continuation> </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-636" continuedAt="f-636-1" escape="true">Goodwill and Intangible Assets </ix:nonNumeric></span></div><ix:continuation id="f-636-1" continuedAt="f-636-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, and a general decline in equity values in the biotechnology industry, the Company performed a quantitative impairment assessment of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-636-2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">its goodwill and long-lived assets. The goodwill was determined to be fully impaired as of September 30, 2023, and the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-637">10.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company also recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-638">2.0</ix:nonFraction>&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_175"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-639" continuedAt="f-639-1" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="f-639-1" continuedAt="f-639-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-640">78.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-641"><ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-642">6.50</ix:nonFraction></ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="f-643">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-644">6.50</ix:nonFraction>% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="f-645">16.9</ix:nonFraction>&#160;million obligation in full, including accrued interest.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-639-2">For the years ended December&#160;31, 2024 and 2023, &#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="0" id="f-646">178,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="6" id="f-647">1.2</ix:nonFraction>&#160;million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="f-648">178,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-649">1.1</ix:nonFraction> million, respectively, related to the contractual interest coupon.</ix:continuation> </span></div><div><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-650" continuedAt="f-650-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="margin-top:3pt"><span><br/></span></div><ix:continuation id="f-650-1" continuedAt="f-650-2"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-651" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $<ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-652"><ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-653">0.001</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-654">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-655">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-656">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-657">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2024, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $<ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" scale="0" id="f-658">326.40</ix:nonFraction> per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="f-659">275</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Offerings of Common Stock and Warrants</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed the December 2024 Offering (see &#8220;Basis of Presentation and Liquidity&#8221; in Note 2 above). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Warrant issued in the December 2024 Offering has an initial exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-163" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-660">3.76</ix:nonFraction>, subject to certain adjustments. The Warrants may be exercised at any time, in whole or in part, until expiration on December 16, 2029. In the event there is no effective registration statement covering the shares of common stock underlying a Warrant exercise, the Warrants may be exercised via cashless exercise. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than <ix:nonFraction unitRef="number" contextRef="c-163" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPercent" scale="-2" id="f-661">4.99</ix:nonFraction>% (or, for certain holders who so elected prior to the issuance of the Warrants, <ix:nonFraction unitRef="number" contextRef="c-163" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" scale="-2" id="f-662">9.99</ix:nonFraction>%) of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of <ix:nonFraction unitRef="number" contextRef="c-163" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" scale="-2" id="f-663">19.99</ix:nonFraction>% upon 61 days&#8217; notice to the Company subject to the terms of the Warrants. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Warrants are not indexed to the Company&#8217;s common stock, the Company recorded a liability for the Warrants at fair value upon issuance on the Company's consolidated balance sheet. The common stock warrant liability is remeasured to fair value at the end of each reporting period. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, no Warrants issued in the December 2024 Offering had been exercised.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed the April 2024 Offering (see &#8220;Basis of Presentation and Liquidity&#8221; in Note 2 above). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Pre-Funded Warrant issued in the April 2024 Offering has an initial exercise price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-664">0.001</ix:nonFraction>, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than <ix:nonFraction unitRef="number" contextRef="c-165" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPercent" scale="-2" id="f-665">9.99</ix:nonFraction>% of the Company&#8217;s outstanding Common </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-650-2" continuedAt="f-650-3"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of <ix:nonFraction unitRef="number" contextRef="c-166" decimals="4" name="ino:ClassOfWarrantOrRightCommonStockOwnershipPercent" scale="-2" id="f-666">19.99</ix:nonFraction>% upon 61 days&#8217; notice to the Company subject to the terms of the Pre-Funded Warrants. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Pre-Funded Warrants issued in the April 2024 Offering are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of December 31, 2024.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, no Pre-Funded Warrants had been exercised.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market Sales Agreements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2024, the Company entered into an Equity Distribution Agreement (the "2024 Sales Agreement") with an outside sales agent (the "Sales Agent") for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-667">60.0</ix:nonFraction>&#160;million. The 2024 Sales Agreement provides that the Sales Agent is entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="c-167" decimals="3" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="f-668">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agent under the 2024 Sales Agreement, and the Company has provided the Sales Agent with certain indemnification rights. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-669">133,900</ix:nonFraction> shares of its common stock under the 2024 Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-670">7.02</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="0" id="f-671">925,000</ix:nonFraction>. As of December 31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="ino:StockSaleAgreementRemainingCapacityAmount" format="ixt:num-dot-decimal" scale="6" id="f-672">59.1</ix:nonFraction>&#160;million of remaining capacity under the 2024 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-673">300.0</ix:nonFraction>&#160;million. The 2021 Sales Agreement provides that the sales agents were entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="c-170" decimals="INF" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="f-674">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-675">543,620</ix:nonFraction> shares of its common stock under the 2021 Sales Agreement at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-171" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-676">9.76</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="f-677">5.2</ix:nonFraction>&#160;million. During the year ended December 31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-678">875,305</ix:nonFraction> shares of its common stock under the 2021 Sales Agreement at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="f-679">6.33</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="f-680">5.5</ix:nonFraction>&#160;million. The 2021 Sales Agreement was terminated in August 2024 in connection with the entry into the 2024 Sales Agreement described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="ino:LitigationSettlementAmountAwardedToOtherPartyShares" format="ixt:num-dot-decimal" scale="0" id="f-681">760,083</ix:nonFraction> shares of common stock pursuant to a securities class action litigation settlement, as described in Note 11.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#8220;2023 Plan&#8221;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed the sum of <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-682">1,166,666</ix:nonFraction> shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#8220;2016 Plan&#8221;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At December&#160;31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-683">800,526</ix:nonFraction> shares of common stock available for future grant under the 2023 Plan, <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-684">188,082</ix:nonFraction> shares underlying outstanding but unvested RSUs and <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-685">282,579</ix:nonFraction> shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over <ix:nonNumeric contextRef="c-176" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-686">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-176" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-687">ten years</ix:nonNumeric>. The 2023 Plan terminates by its terms on March&#160;24, 2033.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. At December&#160;31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" format="ixt:num-dot-decimal" scale="0" id="f-688">129,000</ix:nonFraction> shares underlying outstanding but unvested RSU and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-689">904,669</ix:nonFraction> shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over <ix:nonNumeric contextRef="c-177" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-690">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-177" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-691">ten years</ix:nonNumeric>. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-692">166,666</ix:nonFraction> shares. At December&#160;31, 2024 the Company had <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-693">84,328</ix:nonFraction> shares of common stock available for future grant under the 2022 Inducement Plan, <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-694">20,829</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-695">53,684</ix:nonFraction> shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-650-3" continuedAt="f-650-4"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2024, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-696">96,296</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vested over <ix:nonNumeric contextRef="c-182" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-697">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="c-182" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="f-698">ten years</ix:nonNumeric>. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-699">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-700">10.4</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-701">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-702">4.5</ix:nonFraction> million was included in research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-703">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-704">5.9</ix:nonFraction> million was included in general and administrative expenses, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024 and 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-705">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-706">4.3</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-707">1.5</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-11" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-708">1.3</ix:nonNumeric> years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024 and 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-709">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-710">3.5</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-189" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-711">1.6</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-190" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-712">1.5</ix:nonNumeric> years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-713">226,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-714">669,000</ix:nonFraction>, respectively. As of December&#160;31, 2024, options to purchase <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-715">66,056</ix:nonFraction> shares of common stock granted to non-employees remained outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-716" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2024:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-717">1.78</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-194" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-718">18.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-719">568,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-194" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-720">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-721">10.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-722">205,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-195" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-723">12.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-724">18.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-196" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-725">39.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-726">249,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-196" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-727">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-728">35.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-729">191,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-730">35.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-731">39.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-732">52.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-733">152,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-198" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-734">3.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-735">44.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-736">151,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-737">44.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-738">52.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-739">90.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-740">126,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-200" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-741">3.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-201" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-742">76.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-743">123,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-201" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-744">77.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-745">90.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-746">130.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-747">112,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-202" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-748">3.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-749">98.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-750">112,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-751">98.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-204" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-752">130.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-204" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-753">233.28</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-754">128,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-204" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-755">5.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-205" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-756">137.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-757">128,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-205" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-758">137.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-759">1,337,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-760">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-761">45.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-762">913,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-763">59.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the aggregate intrinsic value of options outstanding was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-764">1,000</ix:nonFraction>, the aggregate intrinsic value of options exercisable was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="f-765">0</ix:nonFraction>, and the weighted average remaining contractual term of options exercisable was <ix:nonNumeric contextRef="c-1" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-766">5.5</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, the aggregate intrinsic value of unvested RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="0" id="f-767">618,000</ix:nonFraction> and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="f-768">1.3</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, options to purchase <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-769">1,337,228</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-770">337,911</ix:nonFraction> RSUs were expected to vest.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-771" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2024 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-772">1,128,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-773">58.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-774">328,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-775">8.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-776">8,159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-777">8.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-778">111,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-779">76.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-780">1,337,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-781">45.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-782" continuedAt="f-782-1" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2024 was as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-650-4" continuedAt="f-650-5"><ix:continuation id="f-782-1"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-783">274,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-784">214,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-785">126,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-786">24,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-787">337,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-788">139.02</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-789">38,503</ix:nonFraction> options which expired during the year ended December&#160;31, 2024 and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-790">38.86</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-791">9,357</ix:nonFraction> options which expired during the year ended December&#160;31, 2023. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-792">6.69</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-793">11.19</ix:nonFraction> for options granted during the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-189" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-794">8.30</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-190" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-795">10.34</ix:nonFraction> per share for RSUs granted during the years ended December&#160;31, 2024 and 2023, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-796">68,000</ix:nonFraction> in proceeds from the exercise of stock options during the years ended December&#160;31, 2024. <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-797">No</ix:nonFraction> stock options were exercised during the year ended December 31, 2023. The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-798">39,000</ix:nonFraction> during the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance- and Market-Based RSUs </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company granted performance- and-market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. As of December 31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-206" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-799">83,800</ix:nonFraction> performance- and market-based RSUs were outstanding.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the target number of RSUs underlying each PSU Award, up to <ix:nonFraction unitRef="number" contextRef="c-207" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" scale="-2" id="f-800">70</ix:nonFraction>% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#8217;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining <ix:nonFraction unitRef="number" contextRef="c-207" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" scale="-2" id="f-801">30</ix:nonFraction>% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#8217;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#8220;Relative TSR&#8221;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#8220;Performance Period&#8221;), expressed as a percentile ranking.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Market-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from <ix:nonFraction unitRef="number" contextRef="c-208" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-802">50</ix:nonFraction>% of the target number of RSUs for performance at a specified threshold percentile, to <ix:nonFraction unitRef="number" contextRef="c-209" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-803">100</ix:nonFraction>% of the target number of RSUs for performance at the target percentile, and up to <ix:nonFraction unitRef="number" contextRef="c-210" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" scale="-2" id="f-804">150</ix:nonFraction>% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#8217;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#8217;s total stockholder return is negative for the Performance Period.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value was affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the <ix:nonNumeric contextRef="c-211" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-805">three-year</ix:nonNumeric> period ranging from <ix:nonFraction unitRef="number" contextRef="c-212" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" format="ixt-sec:numwordsen" id="f-806">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-213" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" scale="-2" id="f-807">150</ix:nonFraction>% of the target number of awards granted. </span></div><ix:nonNumeric contextRef="c-1" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="f-808" continuedAt="f-808-1" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-650-5"><ix:continuation id="f-808-1"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-211" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-809">4.60</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-211" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-810">90</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-211" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-811">3.61</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-211" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-812">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Milestone-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-813">643,000</ix:nonFraction> based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-814">10.96</ix:nonFraction>. As of December 31, 2024, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and <ix:nonFraction unitRef="usd" contextRef="c-215" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" id="f-815">no</ix:nonFraction> stock-based compensation expense was recognized for the year then ended.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Market-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-816">269,000</ix:nonFraction> based on the fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-211" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-817">10.69</ix:nonFraction> per share as determined using the Monte Carlo simulation method. For the year ended December 31, 2024, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-818">44,000</ix:nonFraction> in stock-based compensation for the Market-based RSUs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2024 Performance-Based Awards</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company granted performance-based stock options and RSUs (such performance-based grants, the "December 2024 Awards") to key employees under the 2023 Plan. Each award was expressed as a target number of stock options and RSUs. With respect to the December 2024 Awards, the Company's Board of Directors established specified performance goals and a corresponding performance period over which the goals must be attained, the satisfaction of which are conditions to earning the December 2024 Awards and vesting of the underlying stock options and RSUs. As of December 31, 2024, December 2024 Awards were outstanding covering <ix:nonFraction unitRef="shares" contextRef="c-217" decimals="0" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-819">25,686</ix:nonFraction> shares of common stock underlying stock options and <ix:nonFraction unitRef="shares" contextRef="c-218" decimals="0" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-820">19,314</ix:nonFraction> shares of common stock underlying RSUs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-821">34,000</ix:nonFraction> based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-219" decimals="2" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" scale="0" id="f-822">1.78</ix:nonFraction>. The grant date fair value of the performance-based stock options was $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-823">38,000</ix:nonFraction> based on the Black-Scholes per share value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-221" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-824">1.46</ix:nonFraction>. As of December 31, 2024, the underlying performance milestones of the December 2024 Awards were determined to be not probable of achievement, and <ix:nonFraction unitRef="usd" contextRef="c-215" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" id="f-825">no</ix:nonFraction> stock-based compensation expense was recognized for the year then ended.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-827" continuedAt="f-827-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-827-1" continuedAt="f-827-2"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="c-223" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-828">56,600</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and approximately <ix:nonFraction unitRef="sqft" contextRef="c-224" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-829">57,400</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2024 of <ix:nonNumeric contextRef="c-49" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-830">2.4</ix:nonNumeric> to <ix:nonNumeric contextRef="c-50" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-831">5.0</ix:nonNumeric> years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the leases. Rent payments under the leases include base rent with annual increases of approximately <ix:nonFraction unitRef="number" contextRef="c-225" decimals="2" name="ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" format="ixt-sec:numwordsen" scale="-2" id="f-832">two</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-226" decimals="2" name="ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" format="ixt-sec:numwordsen" scale="-2" id="f-833">three</ix:nonFraction> percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-834" continuedAt="f-834-1" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the maturities of the Company's operating lease liabilities were as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-827-2" continuedAt="f-827-3"><ix:continuation id="f-834-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-835">3,483,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-836">3,555,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-837">2,955,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="f-838">2,310,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="f-839">2,132,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-840">14,435,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-841">2,570,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-842">11,865,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-843">2,497,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-844">9,368,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-845">4.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-846">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2024 and 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-847">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="f-848">3.5</ix:nonFraction> million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Company entered into agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="c-227" decimals="-2" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="f-849">11,400</ix:nonFraction> square feet in its Plymouth Meeting headquarters with sublease terms through December 31, 2026.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, the Company amended the sublease agreements for its Plymouth Meeting headquarters to extend one sublease term through December 31, 2027 and the other through December 31, 2029.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a purported shareholder class action complaint was filed naming the Company and its former President and Chief Executive Officer as defendants and alleging that the Company made materially false and misleading statements in violation of certain federal securities laws. In 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-850">30.0</ix:nonFraction>&#160;million in cash and issued <ix:nonFraction unitRef="shares" contextRef="c-228" decimals="0" name="ino:LitigationSettlementAmountAwardedToOtherPartyShares" format="ixt:num-dot-decimal" scale="0" id="f-851">760,083</ix:nonFraction> shares of its common stock, with a value of $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="ino:LossContingencyEstimateOfPossibleLossValueOfShares" format="ixt:num-dot-decimal" scale="6" id="f-852">14.0</ix:nonFraction>&#160;million at the time, to settle all outstanding claims. The Company's insurance carriers paid the $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-853">30.0</ix:nonFraction>&#160;million cash component of the settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a purported shareholder derivative complaint was filed naming <ix:nonFraction unitRef="defendent" contextRef="c-229" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="f-854">eight</ix:nonFraction> current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff sought unspecified monetary damages on behalf of the Company as well as governance reforms. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 2020 and 2022, additional shareholder derivative complaints were filed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the court entered an order preliminarily approving a proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="6" id="f-855">1.2</ix:nonFraction>&#160;million to plaintiffs&#8217; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-827-3"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI, but VGXI later discontinued its third-party claims. The Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#8217;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-856" continuedAt="f-856-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-856-1" continuedAt="f-856-2"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-857" continuedAt="f-857-1" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-856-2" continuedAt="f-856-3"><ix:continuation id="f-857-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="f-858">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="f-859">134,979,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" id="f-860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="f-861">137,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="f-862">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="f-863">135,117,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-864"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-865"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-866">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for or benefit from income taxes for the years ended December 31, 2024 and 2023. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-867" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2024 and 2023, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-868">22,523,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-869">28,375,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="f-870">1,543,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="f-871">3,922,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-872">21,749,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-873">28,394,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="f-874">5,846,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="f-875">2,139,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-876">1,579,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-877">2,099,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="f-878">2,344,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="f-879">861,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="0" id="f-880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:num-dot-decimal" scale="0" id="f-881">1,962,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-882">4,687,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-883">1,352,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-884">2,056,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="f-885">997,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-886">403,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="0" id="f-887">365,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="0" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="f-889">4,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-890">1,206,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="f-891">404,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-894" continuedAt="f-894-1" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2024 and 2023 are shown below:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-856-3" continuedAt="f-856-4"><ix:continuation id="f-894-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-895">54,204,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-896">50,143,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-897">250,336,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-898">235,624,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-899">31,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-900">27,734,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="0" id="f-901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="0" id="f-902">22,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-903">3,060,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-904">3,683,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ino:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-905">774,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ino:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-906">907,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="0" id="f-907">1,651,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="0" id="f-908">1,406,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ino:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-909">2,492,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ino:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-910">2,822,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-911">441,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-912">337,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="f-913">6,720,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="f-914">6,808,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-915">350,928,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-916">329,486,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-917">349,224,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-918">327,493,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-919">1,704,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-920">1,993,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-921">1,704,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-922">1,993,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-923">1,704,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-924">1,993,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="0" id="f-925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="0" id="f-926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, the Company had federal, California and other state tax net operating loss (NOL) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" scale="9" id="f-927">1.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" scale="6" id="f-928">259.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" scale="6" id="f-929">88.6</ix:nonFraction> million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-930">801.9</ix:nonFraction> million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2025, and the California and other state NOL carryforwards will begin and have begun to expire in 2028 and 2025, respectively, unless previously utilized. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also had Korean NOL carryforward of $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-931">1.0</ix:nonFraction>&#160;million as of December 31, 2024.  The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2035, unless previously utilized.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2024, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-932">46.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-933">7.9</ix:nonFraction> million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><ix:nonNumeric contextRef="c-1" name="ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" id="f-934" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInNextFiscalYear" scale="6" id="f-935">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInNextFiscalYear" scale="6" id="f-936">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInNextFiscalYear" format="ixt:fixed-zero" scale="6" id="f-937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInNextFiscalYear" format="ixt:fixed-zero" scale="6" id="f-938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInNextFiscalYear" format="ixt:fixed-zero" scale="6" id="f-939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="f-940">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="f-941">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="f-942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="f-943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="f-944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="f-945">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="f-946">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" format="ixt:fixed-zero" scale="6" id="f-947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInThreeYears" format="ixt:fixed-zero" scale="6" id="f-948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInThreeYears" format="ixt:fixed-zero" scale="6" id="f-949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="f-950">245.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="f-951">333.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="f-952">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInFourYears" scale="6" id="f-953">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInFourYears" format="ixt:fixed-zero" scale="6" id="f-954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" scale="6" id="f-955">801.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" scale="6" id="f-956">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" format="ixt:fixed-zero" scale="6" id="f-957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" format="ixt:fixed-zero" scale="6" id="f-958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" scale="6" id="f-959">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-960">1,087.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-961">348.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-962">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-963">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-964">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2024. As a result of the analysis, the Company estimates that approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="ino:TaxBenefitsExpired" scale="6" id="f-965">5.3</ix:nonFraction> million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-856-4"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes, could further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2024 and 2023, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-966" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-967">22,114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-968">21,139,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-969">2,297,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-970">1,816,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-971">197,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="f-972">841,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-973">24,608,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="f-974">22,114,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="f-975">22.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="f-976">20.5</ix:nonFraction> million as of December&#160;31, 2024 and 2023, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2021 and state and local income tax examinations before 2020. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#8220;IRS&#8221;), state, local or foreign tax examination.</span></div></ix:continuation><div><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-977" continuedAt="f-977-1" escape="true">401(k) Plan</ix:nonNumeric></span></div><ix:continuation id="f-977-1"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-978">50</ix:nonFraction>% of its employees&#8217; contributions, up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-979">6</ix:nonFraction>% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="0" id="f-980">961,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-981">1.4</ix:nonFraction> million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_196"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-982" continuedAt="f-982-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-982-1" continuedAt="f-982-2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned <ix:nonFraction unitRef="shares" contextRef="c-241" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-983"><ix:nonFraction unitRef="shares" contextRef="c-242" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="f-984">597,808</ix:nonFraction></ix:nonFraction> shares of common stock in PLS as of December 31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a <ix:nonFraction unitRef="number" contextRef="c-241" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-985">17.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-242" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-986">17.8</ix:nonFraction>% ownership interest, respectively. The Company's investment in PLS is recorded as investment in affiliated entity on the consolidated balance sheet as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and was valued at $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-987">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-988">2.8</ix:nonFraction>&#160;million, respectively, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the closing price of the shares on the Korea New Exchange Market at the applicable balance sheet date</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" scale="6" id="f-989">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="c-245" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-990">five-year</ix:nonNumeric> term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-982-2"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon expiration of the 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the exclusive right to in-license new intellectual property developed under this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-991">10.7</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2021 to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="f-992">13.6</ix:nonFraction>&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19. In August 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the sub-grant was amended to a total of $<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="f-993">12.5</ix:nonFraction>&#160;million in funding through September 2025. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company received a $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="f-994">1.2</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2024 to $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="f-995">2.4</ix:nonFraction>&#160;million with funding through November 2024, with an option for an additional $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="f-996">4.2</ix:nonFraction>&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2024 and 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="f-997">482,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="ino:GrantProceedsReceived" scale="6" id="f-998">1.0</ix:nonFraction> million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements. Research and development expenses recorded from Wistar for the years ended December&#160;31, 2024 and 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-999">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1000">1.8</ix:nonFraction> million, respectively. At December&#160;31, 2024 and 2023, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="f-1001">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="f-1002">2.4</ix:nonFraction> million, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="6" id="f-1003">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="6" id="f-1004">1.1</ix:nonFraction> million, respectively, related to Wistar. As of December&#160;31, 2024 and 2023, the Company had a prepaid expense balance of $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="0" id="f-1005">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-1006">20,000</ix:nonFraction>, respectively, and recorded $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" scale="0" id="f-1007">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="f-1008">22,000</ix:nonFraction>, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-1009" continuedAt="f-1009-1" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="f-1009-1" continuedAt="f-1009-2"><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos Therapeutics ("Geneos") to develop and commercialize neoantigen-based personalized cancer therapies. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company held <ix:nonFraction unitRef="number" contextRef="c-256" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-1010">23</ix:nonFraction>% of the outstanding equity of Geneos, on an as-converted to common stock basis. The Company accounts for its common stock investment in Geneos as an equity method investment under ASC 323. Due to continuing net losses of Geneos, the Company&#8217;s investment had been reduced to $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-1011"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="f-1012">0</ix:nonFraction></ix:nonFraction> as of each of December 31, 2024 and 2023. The Company has not made any further investment in Geneos. The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="ino:EquityMethodInvestmentsMinimum" scale="0" id="f-1013">0</ix:nonFraction> and will not record its share of further net losses of Geneos, as the Company has no obligation to fund Geneos.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1009-2">The Company continues to exclusively license its immunotherapy platform and CELLECTRA&#160;technology to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_1607"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1014" continuedAt="f-1014-1" escape="true">Segment Information</ix:nonNumeric></span></div><ix:continuation id="f-1014-1" continuedAt="f-1014-2"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1015">one</ix:nonFraction> reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1016" continuedAt="f-1016-1" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1016-1"><ix:continuation id="f-1014-2"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:69.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.187%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,  </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity<br/></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-1017">217,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-1018">832,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1019">Research and development:</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3107</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1020">29,930,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1021">17,840,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-5401 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1022">6,293,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1023">11,758,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other programs (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="0" sign="-" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1024">77,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1025">18,701,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Engineering and device-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1026">19,393,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1027">8,863,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1028">2,821,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1029">4,606,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other unallocated expenses (b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1030">17,259,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-1031">24,905,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-1032">36,996,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-1033">47,582,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="0" id="f-1035">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-1036">112,616,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-1037">144,772,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-1038">4,766,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-1039">8,133,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="0" id="f-1040">177,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="0" id="f-1041">1,222,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" name="ino:ChangeInFairValueOfCommonStockWarrants" format="ixt:num-dot-decimal" scale="0" id="f-1042">2,808,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="ino:ChangeInFairValueOfCommonStockWarrants" format="ixt:fixed-zero" scale="0" id="f-1043">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-1044">1,166,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="f-1045">773,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-1046">2,077,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-1047">5,850,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-1048">3,163,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-1049">4,711,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-1050">107,254,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-1051">135,117,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          (b) Includes impairment of intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1052">2.0</ix:nonFraction>&#160;million recorded in 2023.</span></div></ix:continuation></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div id="icae65948681042dba847429b32ecbd7c_202"></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1053" continuedAt="f-1053-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-1053-1"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2025 through the date of these financial statements, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1054">512,518</ix:nonFraction> shares of common stock under the 2024 Sales Agreement at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-273" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1055">2.16</ix:nonFraction> per share, for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1056">1.1</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>ino-12312024x10kex191.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ifa62cb9fd1ac4abb9a0aa5a73a9b0c22_36"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exhibit 19.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Insider Trading</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Policy</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Amended and Restated on May 16, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">MEMORANDUM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">TO&#58;                 All Company Personnel </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">FROM&#58;            Inovio Pharmaceuticals, Inc. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">DATE&#58;            May 16, 2023 (Amended and Restated)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">RE&#58;                  Compliance with the Company&#8217;s Insider Trading Policy</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a director, officer, employee, consultant or contractor of Inovio Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), your ability to purchase, sell or otherwise transfer the Company&#8217;s securities is subject to various limitations under federal and state securities laws.  In particular, Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), creates potential liability for you if you trade in the Company&#8217;s securities while aware of material, non-public information (so-called &#8220;insider trading&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To help ensure that you comply with the federal securities laws relating to insider trading, the Company has adopted a Pre-clearance and Blackout Policy, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, (which incorporates the Company&#8217;s Insider Trading Policy, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">).  You are required to comply with this program, the material terms of which are summarized below, but you understand that compliance of this policy does not necessarily insulate you from liability under the securities laws and thus continued vigilance and sound judgment should be used in any transaction of Company&#8217;s securities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Please note that the last page of this Memorandum contains a certification that you have read and understand the attached Pre-clearance and Blackout Policy along with the Insider Trading Policy.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">You are required to sign and return a copy of the signed certification to the Company&#8217;s General Counsel</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Insider Trading</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Summary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  Rule 10b-5 of the Exchange Act prohibits the purchase or sale of Company securities while you are aware of material non-public information (such terms are discussed in the attached Insider Trading Policy).  This potential liability also extends to your immediate family members, including your spouse, children or others living in your home and any entities under your control. In addition, the federal securities laws prohibit you from disclosing any material non-public information to others (or recommending that others purchase the Company&#8217;s securities), including your family members, friends or social acquaintances who trade in the Company&#8217;s securities.  This prohibition applies whether or not you receive any benefit from the other person&#8217;s use of that information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Penalties for Insider Trading</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  If you trade on, or tip others regarding, material non-public information involving the Company, you may subject yourself, as well as the Company and its officers and directors to civil and criminal liability.  The SEC has various means to enforce the federal securities laws, including administrative proceedings for any violation of the federal securities laws (including Rule </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10b-5) or cease-and-desist orders.  An individual who is convicted of trading on, or tipping others regarding, material non-public information can face significant monetary fines and penalties, as well as imprisonment.  Violation of the Company&#8217;s policies may subject you to immediate discipline by the Company, including discharge from the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, the Insider Trading and Securities Fraud Enforcement Act of 1988 contains a number of measures designed to limit insider trading.  Perhaps most noteworthy, the Act imposes liability on &#8220;controlling persons&#8221; (including employees, officers and members of the Board of Directors) if the SEC can establish that the controlling persons knew or recklessly disregarded that an employee (not just a corporate insider) was likely to engage in insider trading and failed to take action to prevent insider trading violations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">OUR COMPLIANCE PROGRAM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a result of the federal securities laws discussed above, we have adopted a Pre-clearance and Blackout Policy and an Insider Trading Policy that you and your immediate family must follow when conducting transactions in the Company&#8217;s securities.  The following summarizes the key components of these policies and programs&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.15pt">Prohibition of Insider Trading</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  All Company personnel are prohibited from&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)        buying or selling the Company&#8217;s securities while in possession of material non-public information&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)        communicating material non-public information to others&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(c)        assisting anyone engaged in any of the above activities.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.15pt">Mandatory Pre-clearance Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  All directors, officers, CEO, EVPs, SVPs, VPs and other employees of the Company subject to Section 16 of the Exchange Act (together with their family members), and such other employees of the Company as may be designated in writing in advance by the Company&#8217;s Chief Executive Officer, Chief Financial Officer or General Counsel, may not engage in any transaction in the Company&#8217;s securities (including option exercises, purchases, sales, gifts, contributions to a trust, or similar transfers) without first obtaining written pre-clearance of the transaction from the either of the Company&#8217;s Chief Financial Officer or its General Counsel (each, a &#8220;Compliance Officer&#8221; and together, the &#8220;Compliance Officers&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.15pt">Quarterly Blackout Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  As described in greater detail in the attached Pre-clearance and Blackout Policy, you are restricted from conducting transactions involving the purchase or sale of the Company&#8217;s securities during a blackout period for the quarter.  The Company&#8217;s blackout period with respect to each fiscal quarter of the Company begins on the close of business on the fifteenth (15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) calendar day of the month following the month in which the close of the quarter occurs and ends on the opening of the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) business day following the Company&#8217;s filing with the SEC of the Company&#8217;s quarterly or annual financial reports (or public release of quarterly or annual financial information).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">It is important to note that when purchasing or selling the Company&#8217;s securities, you must continue to comply with other federal laws in addition to Rule 10b-5 as discussed above.  For example, if you are considered an &#8220;affiliate&#8221; of the Company (i.e., all directors, executive officers and other officers in charge of a principal unit or function), you must comply with all applicable requirements of Rule 144 before you sell Company securities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To the extent that you have any questions about this Memorandum, the Company&#8217;s Pre-clearance and Blackout Policy or Insider Trading Policy, please contact a Compliance Officer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Inovio Pharmaceuticals</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Insider Trading Policy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Certification</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">I certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.         I have read and understand the Company&#8217;s Pre-clearance and Blackout Policy and Insider Trading Policy.  I understand that a Compliance Officer is available to answer any questions I have regarding the new procedures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.         I will comply with the procedures required by the Company&#8217;s Pre-clearance and Blackout Policy and Insider Trading Policy for as long as I am subject to such policies.</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.332%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Date</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Name (Print)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">EXHIBIT A</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">PRE-CLEARANCE AND BLACKOUT POLICY</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">INOVIO PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">PRE-CLEARANCE AND BLACKOUT POLICY</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All Company personnel (including directors, officers and employees and, at the discretion of a Compliance Officer, consultants and contractors of the Company) are subject to the Insider Trading Policy of Inovio Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;) attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and incorporated herein by reference.  The attached Insider Trading Policy provides guidelines to all Company personnel as to transactions in the Company&#8217;s securities and the handling of confidential information about the Company and the companies with which it does business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the restrictions contained in the attached Insider Trading Policy, (i) all personnel are subject to the blackout period restrictions described below, and (ii) all directors, officers, CEO EVPs, SVPs, VPs and employees subject to Section 16 of the Securities Exchange Act of 1934, as amended, together with such other employees of the Company as may be designated from time to time in writing with advance notice by the Company&#8217;s Chief Executive Officer, Chief Financial Officer or General Counsel (collectively an &#8220;Insider&#8221;) are subject to the mandatory pre-clearance restrictions described below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Personnel with any questions about the application of these provisions when considering a transaction involving the Company&#8217;s securities should contact a Compliance Officer before undertaking the transaction and follow his instructions.  This Pre-Clearance and Blackout Policy is supersedes and replaces any other Pre-Clearance and Blackout Policy of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Blackout Period Trading Prohibition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The release of earnings is a particularly sensitive period of time for transactions in the Company&#8217;s stock, because Company personnel may possess material non-public information about the expected financial results for the quarter.  Accordingly, Company personnel may not conduct transactions involving the purchase or sale of the Company&#8217;s securities during a &#8220;blackout period&#8221; for the quarter.  The Company&#8217;s &#8220;blackout period&#8221; with respect to each fiscal quarter begins on the close of business on the fifteenth (15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) calendar day of the month following the month in which the close of the quarter occurs and ends on the opening of the second (2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) business day following the Company&#8217;s filing with the SEC of the Company&#8217;s quarterly or annual financial reports or public release of quarterly or annual financial information (the &#8220;Earnings Release Date&#8221;).  If an individual&#8217;s employment, or services as a director, consultant or contractor, terminates during a blackout period, the individual may not trade in the Company&#8217;s securities until that blackout period has ended.  The Company will inform individuals of the anticipated date of public disclosure of each quarter&#8217;s financial results upon request.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">From time to time, the Company may also determine that Company personnel should suspend trading because of developments known to the Company and not yet disclosed to the public.  In such event, such persons may not engage in any transaction involving the purchase or sale of the Company&#8217;s securities during such period and should not disclose to others the fact of such suspension of trading.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Even outside of the blackout period trading prohibition, any person possessing material non- public information concerning the Company should not engage in any transactions in the Company&#8217;s securities until such information has been known publicly for at least two (2) trading days, whether or not the Company has recommended a suspension of trading to that person.  If an individual is aware of material non-public information when his or her employment or services as a director, consultant or contractor terminates, the individual may not trade in the Company&#8217;s securities until that information has become </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">public or is no longer material.  Trading in the Company&#8217;s securities outside of the blackout period should not be considered a &#8220;safe harbor,&#8221; and all individuals should use good judgment at all times to make sure that their trades are not effected while they are in possession of material non- public information about the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Mandatory Pre-clearance of Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Prior to any transaction involving the Company&#8217;s securities, all Insiders must receive written pre-clearance from a Compliance Officer.  A Compliance Officer will make every effort to respond to requests for pre- clearance as quickly and expeditiously as possible.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Pension Fund Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To the extent that the Company has any pension funds subject to &#8220;pension blackout periods&#8221; as defined below, then directors and executive officers are prohibited from purchasing, selling or otherwise acquiring or transferring, during any &#8220;pension blackout period,&#8221; any equity security of the Company, if the director or executive officer has received such security in connection with his or her service or employment as a director or executive officer of the Company.  A &#8220;pension blackout period&#8221; is a period of more than three (3) consecutive business days during which the ability of fifty percent (50%) or more of the participants in the Company&#8217;s 401(k) plans (and other ERISA individual account plans) to trade Company stock held in such plans is temporarily suspended by the Company or a fiduciary of any such plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Option Exercises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Directors, officers and other employees may exercise options for cash granted under the Company&#8217;s stock option plans without restriction to any particular period.  However, the subsequent sale of the stock (including sales of stock in a cashless exercise) acquired upon the exercise of options is subject to all provisions of this policy.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">EXHIBIT B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">INSIDER TRADING POLICY</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">INSIDER TRADING POLICY</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Insider Trading Policy provides guidelines to all personnel, including employees (both domestic and international), directors and officers of Inovio Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;) for transactions in the Company&#8217;s securities and the handling of confidential information about the Company and the companies with which it does business.  In the discretion of a Compliance Officer, the Insider Trading Policy may also apply to consultants and contractors to the Company who may come into possession of such information as a result of their work for the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For purposes of this Insider Trading Policy, the Company&#8217;s securities include common stock, options to purchase common stock and any other securities the Company may issue from time to time, such as preferred stock, warrants and convertible debentures.  The Company&#8217;s securities also include derivative securities relating to the Company&#8217;s stock, even if not issued by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company&#8217;s personnel are also subject to additional limitations, including pre-clearance and blackout restrictions, described separately in the Company&#8217;s Pre-clearance and Blackout Policy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Insider Trading Policy supersedes and replaces any other Insider Trading Policy of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Policy</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">It is the policy of the Company to comply with all insider trading laws and regulations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Responsibility</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Employees, officers and directors of the Company may create, use or have access to material information about the Company that is not generally available to the investing public (such information is referred to in this Insider Trading Policy as &#8220;material non-public information,&#8221; as explained in more detail below).  Each individual has an important ethical and legal obligation to maintain the confidentiality of such information and not to engage in any transactions in the Company&#8217;s securities while in possession of material non-public information.  Each individual and the Company may be subject to severe civil and criminal penalties as a result of unauthorized disclosure of or trading in the Company&#8217;s securities while in possession of material non-public information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Compliance Officers are responsible for the administration of this Insider Trading Policy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Guidelines</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:9.75pt">Prohibition.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Every employee, officer and director of the Company is prohibited from&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.8pt">trading in the Company&#8217;s securities while in possession of material non-public information, except as provided in Section 8 below&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.18pt">communicating such information to third parties other than those who need to know such information in connection with doing business with or for the Company&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.8pt">recommending the purchase or sale of the Company&#8217;s securities while in the possession of material information that has not been publicly disclosed by the Company&#59; and </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.18pt">assisting anyone engaged in any of the above activities.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This prohibition also applies to information about, and the securities of, other companies (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> customers or suppliers) with which the Company has a relationship</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">There are no exceptions to this Insider Trading Policy other than those described in Section 8 below.  Engaging in transactions in the Company&#8217;s securities that are otherwise necessary for personal reasons, such as personal financial commitments, are still prohibited if you possess material non-public information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2.    Transactions by Family Members&#59; Entities Controlled by You.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The prohibitions outlined in this Policy also apply to your &#8220;immediate family&#8221; members, including your spouse, minor children or others living in your home and any entities under your control.  &#8220;Immediate family&#8221; also includes any child, stepchild, grandchild, parent, stepparent, grandparent, sibling, mother or father-in-law, son or daughter-in-law, or brother or sister-in-law (as well as other adoptive relationships) who shares your same household.  The Company will hold you responsible for the conduct of your immediate family and any entities under your control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">3.   Tipping Information to Others.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may not disclose any material non-public information to others, including your family members, friends or social acquaintances.  This prohibition applies whether or not you receive any benefit from the other person&#8217;s use of that information.  The Securities and Exchange Commission (the &#8220;SEC&#8221;) has imposed large penalties even when the disclosing person did not profit from the trading.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">4.   Material Non-Public Information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Material Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Information is considered &#8220;material&#8221; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to purchase, hold or sell the Company&#8217;s securities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">, information regarding a possible merger or acquisition involving the Company, the introduction of important products or major marketing changes).  In addition, any information that could affect the market for the Company&#8217;s securities is material.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Non-public Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Non-public information is any information that has not been disclosed generally to the investing public.  Disclosure by press release or in the Company&#8217;s periodic reports filed with the SEC is necessary to make the information public.  However, even after the Company has released information to the public, you should generally allow at least two (2) full business days (that is, days on which national stock exchanges and Nasdaq are open for trading) for the investing public to absorb and evaluate the information before you trade in the Company&#8217;s securities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Although it is not possible to list all types of material information, the following are a few examples of information that is particularly sensitive and should be treated as material&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">clinical trial results or material changes to clinical trial timelines&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">changes in estimates of earnings or sales&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">increases or decreases in dividend payments&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">stock splits or securities offerings&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">possible mergers, acquisitions or joint ventures&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">significant contracts and technology licenses&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">changes in management&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">changes in auditors&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">the introduction of important products or services&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">major marketing changes&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">unusual gains or losses in major operations&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">public or private sales by the Company of a significant amount of securities&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">purchase or sale of a significant asset&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">significant labor dispute&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">financial liquidity problems&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">establishment of a repurchase program for the Company&#8217;s securities.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If you have any question as to whether particular information is material or non-public, you should not trade or communicate the information to anyone without prior approval by the Chief Financial Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">5.   Inadvertent Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If material non-public information is inadvertently disclosed by any employee, officer or director to a person outside the Company who is not obligated to keep the information confidential, you should immediately report all the facts to a Compliance Officer so that the Company may take appropriate remedial action.  Under SEC rules, the Company generally has only 24 hours after learning of an inadvertent disclosure of material non-public information to publicly disclose such information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">6.   Short-term, Speculative Transactions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Company has determined that there is a substantial likelihood for the appearance of improper conduct by Company personnel when they engage in short-term or speculative securities transactions.  Therefore, Company personnel are prohibited from engaging in any of the following activities involving the Company&#8217;s shares, except with the prior written consent of the Compensation Committee of the Board of Directors&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.8pt">purchasing the Company&#8217;s securities on margin&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.18pt">pledging Company securities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.8pt">short sales&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.18pt">buying or selling puts or calls&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.8pt">engaging in derivative transactions relating to the Company&#8217;s securities.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, all officers, directors and employees are subject to the Company&#8217;s anti-hedging policy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">See</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#8220;Restrictions on Pledging, Hedging and Other Transactions in Company Securities&#8221; in the Code of Business Conduct and Ethics.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">7.   Further Prohibition.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">From time to time, effective immediately upon notice or as otherwise provided by the Company, the Company may determine that other types of transactions, or all transactions, by Company personnel in the Company&#8217;s securities shall be prohibited or shall be permitted only with the prior written consent of the Chief Financial Officer. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">8.   Option Exercises&#59; Pre-cleared, Pre-Planned Trading Programs Pursuant to Rule 10b5-1</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Notwithstanding any other guidelines contained herein, it shall not be a violation of this Insider Trading Policy or the Company&#8217;s Pre-clearance and Blackout Policy for Company personnel to (i) exercise stock options granted under the Company&#8217;s stock option plans for cash (provided that the subsequent sale of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">stock, including sales by cashless exercise, acquired upon exercise of options remains subject to the terms of this policy) or (ii) sell (or purchase) securities of the Company under certain pre-planned trading programs adopted to purchase or sell securities in the future  (a &#8220;Trading Plan&#8221;), provided that the Trading Plan is properly established. To be properly established, a Trading Plan must be established in compliance with the requirements of Rule 10b5-1 of the Exchange Act and the Company&#8217;s 10b5-1 trading plan guidelines (the &#8220;10b5-1 Guidelines&#8221;) at a time when the plan entrant was unaware of any material nonpublic information relating to the Company and when the Company was not otherwise in a blackout period.   Moreover, all Trading Plans must be reviewed and approved by a Compliance Officer before being established to confirm that the Trading Plan complies with all pertinent company policies and applicable securities laws. The Company may be aware of material non-public information (that the individual is unaware of) that may make it imprudent for the Compliance Officers (as defined in the 10b5-1 Guidelines) to pre-clear the trading program at that time. Please see the 10b5-1 Guidelines for more information. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Each director, officer, CEO, EVP, SVP, VP and other Section 16 insider understands that the approval or adoption of a pre-planned selling program in no way reduces or eliminates such person&#8217;s obligations under Section 16 of the Securities Exchange Act of 1934, as amended, including such person&#8217;s disclosure and short-swing trading liabilities thereunder.  If any questions arise, such person should consult with their own counsel in designing a trading program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">9.  Confidentiality Guidelines.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">To provide more effective protection against the inadvertent disclosure of material non-public information about the Company or the companies with which it does business, the Company has adopted the following guidelines in addition to the prohibition in paragraph 3 above.  These guidelines are not intended to be exhaustive.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Additional measures to secure the confidentiality of information should be undertaken as deemed necessary under the circumstances.  If you have any doubt as to your responsibilities with respect to confidential information, please seek clarification and guidance from the Chief Financial Officer before you act.  Do not try to resolve any uncertainties on your own.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following guidelines establish procedures with which every employee, officer and director should comply in order to maximize the security of confidential information&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.8pt">Do not discuss any Company matter in public places, such as elevators, hallways, restrooms or eating facilities, where conversations might be overheard.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.18pt">Use passwords to restrict access to the information on computers.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.8pt">Limit access to particular physical areas where material non-public information is likely to be documented or discussed.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:5.18pt">Maintain records in accordance with the Company&#8217;s Document Retention Policy. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">10.  Authorized Disclosure of Material Non-Public Information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Under certain circumstances, the Chief Financial Officer may authorize the immediate release of material non-public information.  If disclosure is authorized, the form and content of all public disclosures shall be approved by the Chief Financial Officer and Company legal counsel pursuant to the terms of the Company&#8217;s Disclosure Policy.  In the case of material non-public information which is not disclosed, such information is not to be disclosed or discussed except on a strict &#8220;need-to-know&#8221; basis.  All requests for information, comments, or interviews (other than routine product inquiries) made to any officer, director or employee of the Company should be directed to the Chief Financial Officer, who will clear all proposed responses, which must be in compliance with the Company&#8217;s Disclosure Policy.  It is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">anticipated that most questions raised can be answered by the Chief Financial Officer or another company representative to whom the Chief Financial Officer refers the request.  All officers, directors and employees must comply with the Company&#8217;s Disclosure Policy and should not respond to such requests directly, unless expressly instructed otherwise by the Chief Financial Officer.  In particular, great care should be taken not to comment on the Company&#8217;s expected future financial results.  If the Company wishes to give some direction to investors or securities professionals, it must do so only in compliance with the Company&#8217;s Disclosure Policy.  All communications with representatives of the media and securities analysts shall be directed to the Chief Financial Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">11.  Company Assistance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If you have any questions about specific information or proposed transactions, or as to the applicability or interpretation of this Insider Trading Policy or the propriety of any desired action, you are encouraged to contact a Compliance Officer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ino-12312024x10kex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3dae0d63b1084d07831ca3a92f02964f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Subsidiary Name(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inovio Asia, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ino-12312024x10kex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4845b389fd054e1ba3a9fcbd6371d673_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-275445) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 Nos. 333-142938, 333-150769, 333-161559, 333-166906, 333-174353, 333-181532, 333-192318, 333-196325, 333-209155, and 333-216061) pertaining to the 2007 Omnibus Incentive Plan, as amended, of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 Nos. 333-216059, 333-223776, 333-230337, 333-231872, 333-236201, 333-253736, 333-263167 and 333-272047) pertaining to the 2016 Omnibus Incentive Plan, as amended, of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-265944) pertaining to the Inovio Pharmaceuticals, Inc. 2022 Inducement Plan, and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-272045) pertaining to the Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our report dated March&#160;18, 2025, with respect to the consolidated financial statements of Inovio Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Inovio Pharmaceuticals, Inc. for the year ended December 31, 2024.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">March&#160;18, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ino-12312024x10kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i30453ff95c564d06a41e28ff51bc6d54_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jacqueline E. Shea, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JACQUELINE E. SHEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ino-12312024x10kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if5945eaff719493b968acd87283ca9ef_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ino-12312024x10kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i18a60781e9f042ad8d72c26b9b3bec6c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ending December&#160;31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JACQUELINE E. SHEA</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ino-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:17b32d98-3816-4b9f-8e66-a2aab92f0705,g:04b54f73-b42b-4be7-b731-92d690b75cab-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.inovio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>9952154 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952155 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompany" roleURI="http://www.inovio.com/role/TheCompany">
        <link:definition>9952157 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRisk" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk">
        <link:definition>9952159 - Disclosure - Revenue Recognition and Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>9952160 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurements" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements">
        <link:definition>9952161 - Disclosure - Short-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.inovio.com/role/CertainBalanceSheetItems">
        <link:definition>9952162 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssets" roleURI="http://www.inovio.com/role/FixedAssets">
        <link:definition>9952163 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>9952164 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>9952165 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>9952166 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.inovio.com/role/CommitmentsandContingencies">
        <link:definition>9952167 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>9952168 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.inovio.com/role/A401kPlan">
        <link:definition>9952169 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>9952170 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>9952171 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.inovio.com/role/SegmentInformation">
        <link:definition>9952172 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.inovio.com/role/SubsequentEvents">
        <link:definition>9952173 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskTables" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables">
        <link:definition>9955513 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables">
        <link:definition>9955515 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsTables" roleURI="http://www.inovio.com/role/FixedAssetsTables">
        <link:definition>9955516 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>9955517 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955518 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.inovio.com/role/IncomeTaxesTables">
        <link:definition>9955519 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.inovio.com/role/SegmentInformationTables">
        <link:definition>9955520 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955521 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955522 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
        <link:definition>9955523 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails">
        <link:definition>9955525 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails">
        <link:definition>9955526 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>9955527 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails">
        <link:definition>9955528 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>9955529 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955530 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails">
        <link:definition>9955531 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails">
        <link:definition>9955532 - Disclosure - Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company&#8217;s Total Level 3 Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails">
        <link:definition>9955533 - Disclosure - Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>9955534 - Disclosure - Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsDetails" roleURI="http://www.inovio.com/role/FixedAssetsDetails">
        <link:definition>9955535 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>9955536 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>9955537 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails">
        <link:definition>9955538 - Disclosure - Stockholders' Equity - Schedule of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>9955539 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" roleURI="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails">
        <link:definition>9955540 - Disclosure - Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAtTheMarketSalesAgreementsDetails" roleURI="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails">
        <link:definition>9955541 - Disclosure - Stockholders' Equity - At-The-Market Sales Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityOtherIssuancesofCommonStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails">
        <link:definition>9955542 - Disclosure - Stockholders' Equity - Other Issuances of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" roleURI="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails">
        <link:definition>9955543 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionsOutstandingDetails" roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails">
        <link:definition>9955544 - Disclosure - Stockholders' Equity - Schedule of Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails">
        <link:definition>9955545 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails">
        <link:definition>9955546 - Disclosure - Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails">
        <link:definition>9955547 - Disclosure - Stockholders' Equity - Significant Assumption Used in Monte Carlo Simulation Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPerformanceandMarketBasedRSUsDetails" roleURI="http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails">
        <link:definition>9955548 - Disclosure - Stockholders' Equity - Performance-and Market-Based RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDecember2024PerformanceBasedAwardsDetails" roleURI="http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails">
        <link:definition>9955549 - Disclosure - Stockholders' Equity - December 2024 Performance-Based Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>9955550 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails">
        <link:definition>9955551 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1">
        <link:definition>9955551 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofPretaxLossfromOperationsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails">
        <link:definition>9955552 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails">
        <link:definition>9955553 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955554 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955555 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails">
        <link:definition>9955556 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails">
        <link:definition>9955557 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.inovio.com/role/A401kPlanDetails">
        <link:definition>9955558 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955559 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>9955560 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.inovio.com/role/SegmentInformationDetails">
        <link:definition>9955561 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.inovio.com/role/SubsequentEventsDetails">
        <link:definition>9955562 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestIncomeExpense" abstract="false" name="NonCashInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" abstract="false" name="ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CertainBalanceSheetItemsAbstract" abstract="true" name="CertainBalanceSheetItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_WarrantsPolicyPolicyTextBlock" abstract="false" name="WarrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_GrantRevenuePolicyTextBlock" abstract="false" name="GrantRevenuePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" abstract="false" name="ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ino_December2024OfferingMember" abstract="true" name="December2024OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_April2024OfferingMember" abstract="true" name="April2024OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_December2024OfferingWarrantsMember" abstract="true" name="December2024OfferingWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_April2024OfferingWarrantsMember" abstract="true" name="April2024OfferingWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_WeightedAverageNumberOfSharesOutstanding" abstract="false" name="WeightedAverageNumberOfSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" abstract="false" name="IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" abstract="true" name="AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_ApolloBioCorporationMember" abstract="true" name="ApolloBioCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AllOtherCustomersMember" abstract="true" name="AllOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CommonStockWarrantLiabilityFairValue" abstract="false" name="CommonStockWarrantLiabilityFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_WarrantLiabilityMeasurementInput" abstract="false" name="WarrantLiabilityMeasurementInput" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="ino_PrepaidClinicalExpensesCurrent" abstract="false" name="PrepaidClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesTable" abstract="true" name="AccountsPayableAndAccruedExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesLineItems" abstract="true" name="AccountsPayableAndAccruedExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_PrepaidManufacturingExpenseCurrent" abstract="false" name="PrepaidManufacturingExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantLiability" abstract="false" name="GrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GainLossOnSaleOfFixedAssetsNoNetBookValue" abstract="false" name="GainLossOnSaleOfFixedAssetsNoNetBookValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" abstract="false" name="ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ino_UnderwrittenRegisteredDirectOfferingMember" abstract="true" name="UnderwrittenRegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" abstract="false" name="ClassOfWarrantOrRightCommonStockOwnershipPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" abstract="false" name="ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" abstract="false" name="ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_A2024SalesAgreementMember" abstract="true" name="A2024SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_A2021SalesAgreementMember" abstract="true" name="A2021SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" abstract="false" name="SaleOfStockSalesProceedsOfAnyCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementRemainingCapacityAmount" abstract="false" name="StockSaleAgreementRemainingCapacityAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" abstract="true" name="McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_LitigationSettlementAmountAwardedToOtherPartyShares" abstract="false" name="LitigationSettlementAmountAwardedToOtherPartyShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_A2023IncentivePlanMember" abstract="true" name="A2023IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2022InducementPlanMember" abstract="true" name="A2022InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_FormerPresidentAndChiefExecutiveOfficerMember" abstract="true" name="FormerPresidentAndChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" abstract="false" name="NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_RangeOfExercisePricesOneMember" abstract="true" name="RangeOfExercisePricesOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesTwoMember" abstract="true" name="RangeOfExercisePricesTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesThreeMember" abstract="true" name="RangeOfExercisePricesThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFourMember" abstract="true" name="RangeOfExercisePricesFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFiveMember" abstract="true" name="RangeOfExercisePricesFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesSixMember" abstract="true" name="RangeOfExercisePricesSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsRSUsMarketBasedMember" abstract="true" name="RestrictedStockUnitsRSUsMarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RestrictedStockUnitsRSUsMilestoneBasedMember" abstract="true" name="RestrictedStockUnitsRSUsMilestoneBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PerformanceRSUsSpecifiedThresholdPercentileMember" abstract="true" name="PerformanceRSUsSpecifiedThresholdPercentileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PerformanceRSUsTargetPercentileMember" abstract="true" name="PerformanceRSUsTargetPercentileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PerformanceRSUsSpecifiedMaximumPercentileMember" abstract="true" name="PerformanceRSUsSpecifiedMaximumPercentileMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RestrictedStockUnitsPerformanceBasedMember" abstract="true" name="RestrictedStockUnitsPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockOptionsPerformanceBasedMember" abstract="true" name="StockOptionsPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_December2024Member" abstract="true" name="December2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_BehestiVKimEtAlMember" abstract="true" name="BehestiVKimEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" abstract="false" name="LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_LossContingencyEstimateOfPossibleLossValueOfShares" abstract="false" name="LossContingencyEstimateOfPossibleLossValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncomeTaxReconciliationStatuteLimitations" abstract="false" name="IncomeTaxReconciliationStatuteLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CaliforniaIncomeTaxAuthorityMember" abstract="true" name="CaliforniaIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_PennsylvaniaStateIncomeTaxAuthorityMember" abstract="true" name="PennsylvaniaStateIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" abstract="false" name="OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxBenefitsExpired" abstract="false" name="TaxBenefitsExpired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxAssetsIntangibleAssets" abstract="false" name="DeferredTaxAssetsIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" abstract="false" name="OperatingLossCarryforwardsExpiringInNextFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinTwoYears" abstract="false" name="OperatingLossCarryforwardsExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinThreeYears" abstract="false" name="OperatingLossCarryforwardsExpiringinThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinFourYears" abstract="false" name="OperatingLossCarryforwardsExpiringinFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsIndefinitelyCarryforward" abstract="false" name="OperatingLossCarryforwardsIndefinitelyCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInNextFiscalYear" abstract="false" name="TaxCreditCarryforwardExpiringInNextFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinTwoYears" abstract="false" name="TaxCreditCarryforwardExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInThreeYears" abstract="false" name="TaxCreditCarryforwardExpiringInThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInFourYears" abstract="false" name="TaxCreditCarryforwardExpiringInFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardCarryforwardIndefinitely" abstract="false" name="TaxCreditCarryforwardCarryforwardIndefinitely" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAmendedAmount" abstract="false" name="CollaborativeAgreementAmendedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ino_EquityMethodInvestmentsMinimum" abstract="false" name="EquityMethodInvestmentsMinimum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ReportableSegmentsMember" abstract="true" name="ReportableSegmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ResearchAndDevelopmentCostAxis" abstract="true" name="ResearchAndDevelopmentCostAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_ResearchAndDevelopmentCostDomain" abstract="true" name="ResearchAndDevelopmentCostDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_INO3107Member" abstract="true" name="INO3107Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_INO5401AndOtherImmunoOncologyMember" abstract="true" name="INO5401AndOtherImmunoOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_OtherProgramsMember" abstract="true" name="OtherProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_EngineeringAndDeviceRelatedMember" abstract="true" name="EngineeringAndDeviceRelatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockBasedCompensationMember" abstract="true" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_OtherUnallocatedExpensesMember" abstract="true" name="OtherUnallocatedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ChangeInFairValueOfCommonStockWarrants" abstract="false" name="ChangeInFairValueOfCommonStockWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ino-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:17b32d98-3816-4b9f-8e66-a2aab92f0705,g:04b54f73-b42b-4be7-b731-92d690b75cab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0c6e2d30-eaa5-4588-be86-b173c1607ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f72bcb5-80a2-449c-9165-8694081de562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c6e2d30-eaa5-4588-be86-b173c1607ec4" xlink:to="loc_us-gaap_LiabilitiesCurrent_9f72bcb5-80a2-449c-9165-8694081de562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eedd1973-136d-4d55-a4f4-0dd46051ab13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0c6e2d30-eaa5-4588-be86-b173c1607ec4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eedd1973-136d-4d55-a4f4-0dd46051ab13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4f0947d9-c460-4470-a6fc-05ead56905d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_58c09c1a-cf09-48d8-befa-1e04078869a7" xlink:href="ino-20241231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f0947d9-c460-4470-a6fc-05ead56905d7" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_58c09c1a-cf09-48d8-befa-1e04078869a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9d49211a-8106-403f-aefd-442be091e907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f0947d9-c460-4470-a6fc-05ead56905d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9d49211a-8106-403f-aefd-442be091e907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0ccd0057-af2f-46eb-ad15-09d1d8d9429c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f0947d9-c460-4470-a6fc-05ead56905d7" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0ccd0057-af2f-46eb-ad15-09d1d8d9429c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_4e23db34-66a8-4036-b982-63515d1cd93a" xlink:href="ino-20241231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f0947d9-c460-4470-a6fc-05ead56905d7" xlink:to="loc_ino_DeferredGrantFundingCurrent_4e23db34-66a8-4036-b982-63515d1cd93a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_64fa7039-a44a-40ba-92e0-59577e50871c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f0947d9-c460-4470-a6fc-05ead56905d7" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_64fa7039-a44a-40ba-92e0-59577e50871c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_7808547e-a335-4c05-83fa-c4ab73d49ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f0947d9-c460-4470-a6fc-05ead56905d7" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_7808547e-a335-4c05-83fa-c4ab73d49ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7d4ea407-7d11-49be-8407-814d0fcb0cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f51d4751-5104-4872-be7d-20de22af0416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7d4ea407-7d11-49be-8407-814d0fcb0cca" xlink:to="loc_us-gaap_AssetsCurrent_f51d4751-5104-4872-be7d-20de22af0416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_26164bd3-eb8f-4d0d-8afe-857c8781bcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7d4ea407-7d11-49be-8407-814d0fcb0cca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_26164bd3-eb8f-4d0d-8afe-857c8781bcc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f8cadb4e-47d6-4442-a18c-1c496974b994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7d4ea407-7d11-49be-8407-814d0fcb0cca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f8cadb4e-47d6-4442-a18c-1c496974b994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d2a8f59d-d86e-4ec5-9233-828f8250f071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7d4ea407-7d11-49be-8407-814d0fcb0cca" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d2a8f59d-d86e-4ec5-9233-828f8250f071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f15e2a60-a639-4a7b-a696-48cc6f221f41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7d4ea407-7d11-49be-8407-814d0fcb0cca" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f15e2a60-a639-4a7b-a696-48cc6f221f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15eb6410-16a6-4671-8279-aa0babd524ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9634563-b2f0-4e77-bc63-e4dfd6fabb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_15eb6410-16a6-4671-8279-aa0babd524ee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9634563-b2f0-4e77-bc63-e4dfd6fabb29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_59c68c43-664a-4c51-95d1-d354a551b7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_15eb6410-16a6-4671-8279-aa0babd524ee" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_59c68c43-664a-4c51-95d1-d354a551b7e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c9255798-8cb7-49f6-92b2-217edc619b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_15eb6410-16a6-4671-8279-aa0babd524ee" xlink:to="loc_us-gaap_ShortTermInvestments_c9255798-8cb7-49f6-92b2-217edc619b3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0b474697-f91d-4bb3-b7b3-1e6325e24024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_15eb6410-16a6-4671-8279-aa0babd524ee" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0b474697-f91d-4bb3-b7b3-1e6325e24024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b547c7a6-8600-4a30-b560-2ecbe927c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3ccd7324-a1fd-475e-9325-f1f593894c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b547c7a6-8600-4a30-b560-2ecbe927c09a" xlink:to="loc_us-gaap_StockholdersEquity_3ccd7324-a1fd-475e-9325-f1f593894c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ffc538c1-4bf2-4c5f-9a1e-204a305ca1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b547c7a6-8600-4a30-b560-2ecbe927c09a" xlink:to="loc_us-gaap_Liabilities_ffc538c1-4bf2-4c5f-9a1e-204a305ca1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4e043c12-f155-443f-8bec-568539af52ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b547c7a6-8600-4a30-b560-2ecbe927c09a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4e043c12-f155-443f-8bec-568539af52ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e0bf6b4-846b-44f9-8a06-f5254ad9e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ee27e652-4201-456e-ad90-69103f23bc65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bf6b4-846b-44f9-8a06-f5254ad9e85b" xlink:to="loc_us-gaap_CommonStockValue_ee27e652-4201-456e-ad90-69103f23bc65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_65bc55c8-d9d0-4d1f-938c-4a014f32472c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bf6b4-846b-44f9-8a06-f5254ad9e85b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_65bc55c8-d9d0-4d1f-938c-4a014f32472c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bc7d2acd-7656-41d2-9355-c5e0eaee67a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bf6b4-846b-44f9-8a06-f5254ad9e85b" xlink:to="loc_us-gaap_PreferredStockValue_bc7d2acd-7656-41d2-9355-c5e0eaee67a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4fc8a440-a4b5-4b84-ac83-93bbc3685d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bf6b4-846b-44f9-8a06-f5254ad9e85b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4fc8a440-a4b5-4b84-ac83-93bbc3685d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4d76716-b9ef-4115-a4e5-a935acdaf457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bf6b4-846b-44f9-8a06-f5254ad9e85b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b4d76716-b9ef-4115-a4e5-a935acdaf457" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8911f577-cc22-4acf-a8e7-f75cf53fefbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b4d0774a-d614-4a61-a006-2355a687306e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8911f577-cc22-4acf-a8e7-f75cf53fefbf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b4d0774a-d614-4a61-a006-2355a687306e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0d446141-a750-445b-add5-e5f6e55ef16c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8911f577-cc22-4acf-a8e7-f75cf53fefbf" xlink:to="loc_us-gaap_OperatingExpenses_0d446141-a750-445b-add5-e5f6e55ef16c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d1c27828-a582-4eca-9b8b-7453024dd5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_20b32e2e-5a9d-49a4-8839-015140025b13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1c27828-a582-4eca-9b8b-7453024dd5fd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_20b32e2e-5a9d-49a4-8839-015140025b13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2fa9ae0c-5cac-4c0b-83a5-dd00061eaff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1c27828-a582-4eca-9b8b-7453024dd5fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2fa9ae0c-5cac-4c0b-83a5-dd00061eaff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9726d577-8bec-4da8-80a4-7ff8d3ad53a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d1c27828-a582-4eca-9b8b-7453024dd5fd" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9726d577-8bec-4da8-80a4-7ff8d3ad53a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49791541-a452-4c83-969b-40751dbd349f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_975f6169-7b5b-47cc-a87e-e0e16e75f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49791541-a452-4c83-969b-40751dbd349f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_975f6169-7b5b-47cc-a87e-e0e16e75f80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d59ad963-be0c-47ab-8878-5d383d73cd15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49791541-a452-4c83-969b-40751dbd349f" xlink:to="loc_us-gaap_OperatingIncomeLoss_d59ad963-be0c-47ab-8878-5d383d73cd15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_4ea5ab43-831b-4be6-8444-faa5f9491450" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49791541-a452-4c83-969b-40751dbd349f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_4ea5ab43-831b-4be6-8444-faa5f9491450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_1a8d9a62-0169-4400-91c7-658ffac4c2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49791541-a452-4c83-969b-40751dbd349f" xlink:to="loc_us-gaap_InterestExpenseNonoperating_1a8d9a62-0169-4400-91c7-658ffac4c2d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_678d4c5c-2306-487d-a093-866093f291fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49791541-a452-4c83-969b-40751dbd349f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_678d4c5c-2306-487d-a093-866093f291fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a9a6b706-f927-4bfb-98d4-b8d4db553b88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49791541-a452-4c83-969b-40751dbd349f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a9a6b706-f927-4bfb-98d4-b8d4db553b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_222a77c0-1875-4ceb-8345-28b0394e2a6f" xlink:href="ino-20241231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49791541-a452-4c83-969b-40751dbd349f" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_222a77c0-1875-4ceb-8345-28b0394e2a6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b5841c3-76b3-47ed-9d07-ffa98e63c23b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_585658ad-1205-401d-a3bf-eddf0b9f71b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b5841c3-76b3-47ed-9d07-ffa98e63c23b" xlink:to="loc_us-gaap_NetIncomeLoss_585658ad-1205-401d-a3bf-eddf0b9f71b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8be0192e-878e-4084-8cf8-b30d9ca70edf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b5841c3-76b3-47ed-9d07-ffa98e63c23b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8be0192e-878e-4084-8cf8-b30d9ca70edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a2c4ecfe-9c99-494d-b0bf-1fa33f2b09fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b5841c3-76b3-47ed-9d07-ffa98e63c23b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a2c4ecfe-9c99-494d-b0bf-1fa33f2b09fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6be9e899-3290-4c0e-bb26-e2a0b6e3a115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_008dbedc-79d6-4c56-9852-48807d0f2410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6be9e899-3290-4c0e-bb26-e2a0b6e3a115" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_008dbedc-79d6-4c56-9852-48807d0f2410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_bb525e0c-7f63-4a42-80ea-674af40e81e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6be9e899-3290-4c0e-bb26-e2a0b6e3a115" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_bb525e0c-7f63-4a42-80ea-674af40e81e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3ac21d7b-aeb6-4d14-94d2-5a3388fed3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6be9e899-3290-4c0e-bb26-e2a0b6e3a115" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3ac21d7b-aeb6-4d14-94d2-5a3388fed3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d18583cc-0e6d-4655-9c0a-106cec39100a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6be9e899-3290-4c0e-bb26-e2a0b6e3a115" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d18583cc-0e6d-4655-9c0a-106cec39100a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_3b0cae6d-dccb-4b41-8534-44a39093bd14" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_3b0cae6d-dccb-4b41-8534-44a39093bd14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e16aa557-1b59-4c7f-aead-caeacde2d67f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e16aa557-1b59-4c7f-aead-caeacde2d67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_2965aa67-ac00-4bfa-a5de-f043ea051ec8" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_2965aa67-ac00-4bfa-a5de-f043ea051ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49e7b7a4-f184-4809-a37d-a79d18822e16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_NetIncomeLoss_49e7b7a4-f184-4809-a37d-a79d18822e16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d690ae64-ff45-49f5-a338-499c507ee382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d690ae64-ff45-49f5-a338-499c507ee382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_9d0334d8-f0e8-4563-bbcc-935772c2e9b4" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_9d0334d8-f0e8-4563-bbcc-935772c2e9b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8d3754ee-453a-4790-9e5a-52458bd2c6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8d3754ee-453a-4790-9e5a-52458bd2c6ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ec1493e2-51de-4645-a431-8ecba386d268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ec1493e2-51de-4645-a431-8ecba386d268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_32e5e20b-17f7-4489-8927-b5ba4882c122" xlink:href="ino-20241231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_32e5e20b-17f7-4489-8927-b5ba4882c122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1a0e675c-5318-471c-958e-8e8b539e76be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_ShareBasedCompensation_1a0e675c-5318-471c-958e-8e8b539e76be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_04f0c495-4768-47db-be15-8cf7008f6701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_04f0c495-4768-47db-be15-8cf7008f6701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_614d5dd0-8df4-4670-96b6-33c3dafe4f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_614d5dd0-8df4-4670-96b6-33c3dafe4f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a0ed010a-0287-4a6b-822f-866e581c8d32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_Depreciation_a0ed010a-0287-4a6b-822f-866e581c8d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d042656f-3a46-431c-b3e1-5109cd7e0f82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d042656f-3a46-431c-b3e1-5109cd7e0f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_23673875-c52d-4b58-a0ad-b7f150664a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_23673875-c52d-4b58-a0ad-b7f150664a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_47f62cf7-9bbf-4fbc-b060-e33e82118065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_47f62cf7-9bbf-4fbc-b060-e33e82118065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2e78798d-11b7-4c55-add7-868ad3d9ba95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2e78798d-11b7-4c55-add7-868ad3d9ba95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_51aa17ca-a47f-42ec-bb12-b17da6fe7274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_51aa17ca-a47f-42ec-bb12-b17da6fe7274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_1025f44f-07a5-44d9-8100-f9e41d7ebf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_1025f44f-07a5-44d9-8100-f9e41d7ebf9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ceb35869-61f5-4ecb-80b1-09b573606c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ceb35869-61f5-4ecb-80b1-09b573606c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_4428a973-a600-4ef2-8ede-c16033302e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_4428a973-a600-4ef2-8ede-c16033302e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_bdcc573e-59ac-4c8b-96fe-c327822c90dd" xlink:href="ino-20241231.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39ad822a-2f2d-40e5-a51f-74b107093358" xlink:to="loc_ino_NonCashInterestIncomeExpense_bdcc573e-59ac-4c8b-96fe-c327822c90dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1cec474-557b-45d3-9785-b27e9bb2d0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4ef4a19-fb57-4291-a9c8-3de43c48b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1cec474-557b-45d3-9785-b27e9bb2d0c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4ef4a19-fb57-4291-a9c8-3de43c48b44d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e41d8249-6d82-4d46-996f-b4c63389b1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1cec474-557b-45d3-9785-b27e9bb2d0c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e41d8249-6d82-4d46-996f-b4c63389b1b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_847d062d-9a15-4918-b836-ee28e4dc7736" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1cec474-557b-45d3-9785-b27e9bb2d0c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_847d062d-9a15-4918-b836-ee28e4dc7736" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb7d8c5f-933c-452f-97f4-e7fddd283f06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1cec474-557b-45d3-9785-b27e9bb2d0c0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eb7d8c5f-933c-452f-97f4-e7fddd283f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34f4ff20-1a5f-45f1-9615-1b9d21d54601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_9cef04c6-46b8-48c9-997a-9cfd0b4a0f89" xlink:href="ino-20241231.xsd#ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34f4ff20-1a5f-45f1-9615-1b9d21d54601" xlink:to="loc_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_9cef04c6-46b8-48c9-997a-9cfd0b4a0f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c0fa88cb-9cd4-4a53-95c3-3b20e599142f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34f4ff20-1a5f-45f1-9615-1b9d21d54601" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c0fa88cb-9cd4-4a53-95c3-3b20e599142f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_d10bc7db-0102-4d52-848e-b3ede747eed0" xlink:href="ino-20241231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34f4ff20-1a5f-45f1-9615-1b9d21d54601" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_d10bc7db-0102-4d52-848e-b3ede747eed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a06f6ca6-e3fc-4ec4-bb64-6a348a1513d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34f4ff20-1a5f-45f1-9615-1b9d21d54601" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a06f6ca6-e3fc-4ec4-bb64-6a348a1513d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_f0e4145b-8e82-43b1-ba8b-1fd4ba676955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34f4ff20-1a5f-45f1-9615-1b9d21d54601" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_f0e4145b-8e82-43b1-ba8b-1fd4ba676955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_5817aa28-c69e-4222-b4bd-0e309985000f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34f4ff20-1a5f-45f1-9615-1b9d21d54601" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_5817aa28-c69e-4222-b4bd-0e309985000f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a0d4a72c-c23b-4c04-8641-2b2b0a68d229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_561120cd-4de4-4f31-ac47-400f3058a766" xlink:href="ino-20241231.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a0d4a72c-c23b-4c04-8641-2b2b0a68d229" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_561120cd-4de4-4f31-ac47-400f3058a766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_cc850930-43f5-436b-922e-bb05e93b55f0" xlink:href="ino-20241231.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a0d4a72c-c23b-4c04-8641-2b2b0a68d229" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_cc850930-43f5-436b-922e-bb05e93b55f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_836172f2-41c1-4e0e-b647-53eca967a385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_4d229643-5b1d-4b97-b88f-5da0b0861d2c" xlink:href="ino-20241231.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_836172f2-41c1-4e0e-b647-53eca967a385" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_4d229643-5b1d-4b97-b88f-5da0b0861d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_952494ec-2bb2-4711-ba07-4d9e62f338a8" xlink:href="ino-20241231.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_836172f2-41c1-4e0e-b647-53eca967a385" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_952494ec-2bb2-4711-ba07-4d9e62f338a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_450106f5-3d6c-43a9-90a0-11b170c8abdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d50a0ebe-0946-4d1e-a362-27cbee697616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_450106f5-3d6c-43a9-90a0-11b170c8abdf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d50a0ebe-0946-4d1e-a362-27cbee697616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8687619-ec33-40d1-b85f-63adf1d64fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_450106f5-3d6c-43a9-90a0-11b170c8abdf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f8687619-ec33-40d1-b85f-63adf1d64fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74a512e3-5b4f-458b-86f8-bb4d6535c655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_450106f5-3d6c-43a9-90a0-11b170c8abdf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74a512e3-5b4f-458b-86f8-bb4d6535c655" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1cbbc412-2248-4d7a-8527-cb6708656285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockWarrantLiabilityFairValue_265e02c3-b2eb-4287-ab1b-d4630f0f9f7f" xlink:href="ino-20241231.xsd#ino_CommonStockWarrantLiabilityFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1cbbc412-2248-4d7a-8527-cb6708656285" xlink:to="loc_ino_CommonStockWarrantLiabilityFairValue_265e02c3-b2eb-4287-ab1b-d4630f0f9f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a3d60116-0b2e-4e64-a6b6-db979bf7d5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94dc6676-2588-46af-9228-0477151ed5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a3d60116-0b2e-4e64-a6b6-db979bf7d5cf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94dc6676-2588-46af-9228-0477151ed5c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e3545f59-430e-42f4-8cfb-c0e1d93554ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a3d60116-0b2e-4e64-a6b6-db979bf7d5cf" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e3545f59-430e-42f4-8cfb-c0e1d93554ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ebbf087-06bc-4159-9772-10d5ae00c7da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_3019d02b-13b7-4262-a7d6-8a7e90d0d2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ebbf087-06bc-4159-9772-10d5ae00c7da" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_3019d02b-13b7-4262-a7d6-8a7e90d0d2c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent_9e212aed-8b55-4fbc-b3e1-8d042cf5324e" xlink:href="ino-20241231.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ebbf087-06bc-4159-9772-10d5ae00c7da" xlink:to="loc_ino_PrepaidClinicalExpensesCurrent_9e212aed-8b55-4fbc-b3e1-8d042cf5324e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e2b7c184-15b0-43c9-92e0-afb7c7a4815d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_577c68ed-c62e-49fd-ae79-cf7f92dbec7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e2b7c184-15b0-43c9-92e0-afb7c7a4815d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_577c68ed-c62e-49fd-ae79-cf7f92dbec7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_771b09c6-b96d-4293-88a9-d2f5b0a29dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e2b7c184-15b0-43c9-92e0-afb7c7a4815d" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_771b09c6-b96d-4293-88a9-d2f5b0a29dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_a484391f-5e81-434c-a57a-209cd85adc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e2b7c184-15b0-43c9-92e0-afb7c7a4815d" xlink:to="loc_us-gaap_AccruedSalariesCurrent_a484391f-5e81-434c-a57a-209cd85adc9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#FixedAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0352381a-3141-4c7c-9609-816b6ac34a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d3828b96-b0ca-4c96-a8ee-d10d22da1594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0352381a-3141-4c7c-9609-816b6ac34a2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d3828b96-b0ca-4c96-a8ee-d10d22da1594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2c6a1f1-0b27-4869-8ee9-778ceef91ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0352381a-3141-4c7c-9609-816b6ac34a2f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2c6a1f1-0b27-4869-8ee9-778ceef91ecd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2d878c94-cc3e-4e2b-93c5-aea4a19521ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_733b42ad-848a-412f-89d7-25a908bc86da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2d878c94-cc3e-4e2b-93c5-aea4a19521ce" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_733b42ad-848a-412f-89d7-25a908bc86da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5151c15-44f9-4706-abd4-50b711bc3b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2d878c94-cc3e-4e2b-93c5-aea4a19521ce" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5151c15-44f9-4706-abd4-50b711bc3b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df3d7313-97b1-4003-8032-e063c62c9db0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_29246720-feff-41ce-8b09-c5a130167c36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df3d7313-97b1-4003-8032-e063c62c9db0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_29246720-feff-41ce-8b09-c5a130167c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c0a54630-d512-4207-9c00-1a32d144220d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_df3d7313-97b1-4003-8032-e063c62c9db0" xlink:to="loc_us-gaap_OperatingLeaseLiability_c0a54630-d512-4207-9c00-1a32d144220d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20241231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0f6fcf9-f3b4-432b-b5d0-e622af605697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ba9bf9b1-c115-4bde-9c4a-487d09c5f9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0f6fcf9-f3b4-432b-b5d0-e622af605697" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ba9bf9b1-c115-4bde-9c4a-487d09c5f9bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3fadb9a3-d9d6-4569-bfcc-817efb6642eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0f6fcf9-f3b4-432b-b5d0-e622af605697" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3fadb9a3-d9d6-4569-bfcc-817efb6642eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c9c82720-cf20-40f8-87b7-c5faf01e076f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0f6fcf9-f3b4-432b-b5d0-e622af605697" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c9c82720-cf20-40f8-87b7-c5faf01e076f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3c1b32d3-0901-4502-a024-6543b40b7ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0f6fcf9-f3b4-432b-b5d0-e622af605697" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3c1b32d3-0901-4502-a024-6543b40b7ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fe570f3e-38cb-48e7-a625-535e43ccbd59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0f6fcf9-f3b4-432b-b5d0-e622af605697" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fe570f3e-38cb-48e7-a625-535e43ccbd59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71611681-e736-4b72-b4c4-3abab9352a07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_dbcd3bc4-ac7f-4125-9cba-904385f87c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71611681-e736-4b72-b4c4-3abab9352a07" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_dbcd3bc4-ac7f-4125-9cba-904385f87c91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_139d9197-15c4-4c0d-bafd-5acfa1929046" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71611681-e736-4b72-b4c4-3abab9352a07" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_139d9197-15c4-4c0d-bafd-5acfa1929046" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_380cda47-3785-47ca-bfcf-63bd10f1f939" xlink:href="ino-20241231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_380cda47-3785-47ca-bfcf-63bd10f1f939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e2f8403e-8d62-4f19-8a0a-e412998c2327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e2f8403e-8d62-4f19-8a0a-e412998c2327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0336995e-904b-4fb5-bc37-2403e65a10a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0336995e-904b-4fb5-bc37-2403e65a10a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_e3665812-1417-43c6-95b4-840acd57ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_e3665812-1417-43c6-95b4-840acd57ab50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cd11db47-a69c-4fa0-a37d-a9156b2e8607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cd11db47-a69c-4fa0-a37d-a9156b2e8607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_734d35b0-c58b-45aa-9857-8753a8384af0" xlink:href="ino-20241231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_734d35b0-c58b-45aa-9857-8753a8384af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b46bc285-2863-46f9-bc8c-04fa11db9e34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b46bc285-2863-46f9-bc8c-04fa11db9e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_fb3c7b89-ef87-489a-975f-34e32636ecdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_fb3c7b89-ef87-489a-975f-34e32636ecdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_056e386e-f1ab-4177-bef6-eb6ce2573a01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_056e386e-f1ab-4177-bef6-eb6ce2573a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_ba96c51f-10f9-4afa-8603-52e97c0cf38b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_ba96c51f-10f9-4afa-8603-52e97c0cf38b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_a4bdd072-d711-4a0c-9d5b-cc1ddcefd991" xlink:href="ino-20241231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_a4bdd072-d711-4a0c-9d5b-cc1ddcefd991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_f083f82e-4baf-4e08-aa9c-29df13f5243a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_e66d8a33-300b-477c-ba71-48caa3be2a7f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_f083f82e-4baf-4e08-aa9c-29df13f5243a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_cad303e9-259e-404a-9d31-dcd97a5e8b83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_3b667c7f-d283-47ed-9722-e793d4430066" xlink:href="ino-20241231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_cad303e9-259e-404a-9d31-dcd97a5e8b83" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_3b667c7f-d283-47ed-9722-e793d4430066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2875a217-bfb1-4109-85f3-d8627221764b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_474c711a-9eb8-41e1-a416-40ed46a92e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2875a217-bfb1-4109-85f3-d8627221764b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_474c711a-9eb8-41e1-a416-40ed46a92e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_14d27e1b-05b3-4bcb-a2a3-231b5815f5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2875a217-bfb1-4109-85f3-d8627221764b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_14d27e1b-05b3-4bcb-a2a3-231b5815f5e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ca1b5164-2c85-43e0-9c72-95aad0405d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1b8cb007-dfb4-49f9-a147-5184d10a87d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ca1b5164-2c85-43e0-9c72-95aad0405d25" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1b8cb007-dfb4-49f9-a147-5184d10a87d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_58a29ffc-4825-4d63-b1db-974f1c4d246b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ca1b5164-2c85-43e0-9c72-95aad0405d25" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_58a29ffc-4825-4d63-b1db-974f1c4d246b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f4d1d180-ae61-417d-870d-7615d26f6a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f4d1d180-ae61-417d-870d-7615d26f6a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b5fead1e-5d06-4d74-b5cd-ef945c9e2496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b5fead1e-5d06-4d74-b5cd-ef945c9e2496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_849974cd-8a20-4e16-9149-b81fc978d2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_849974cd-8a20-4e16-9149-b81fc978d2aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_cef1130b-a103-4621-a913-45b5841be936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_cef1130b-a103-4621-a913-45b5841be936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_852a7b65-34dc-4878-8051-d0fd659e5f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_852a7b65-34dc-4878-8051-d0fd659e5f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_867f7a05-712a-4fb9-8ba5-a6ec3d45489e" xlink:href="ino-20241231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_867f7a05-712a-4fb9-8ba5-a6ec3d45489e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_c2b7ec4a-e02d-49e7-a1bd-c6d325a5540b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_c2b7ec4a-e02d-49e7-a1bd-c6d325a5540b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_7dc1ff2e-47e5-4e98-94a1-06e1c4c39077" xlink:href="ino-20241231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_7dc1ff2e-47e5-4e98-94a1-06e1c4c39077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_263be9b1-8843-405e-9c20-caf6af9c4166" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_263be9b1-8843-405e-9c20-caf6af9c4166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_e8af2533-774e-45ba-8f8e-657348bb858f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_22657682-5436-461a-a94e-a6cc5eba48d9" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_e8af2533-774e-45ba-8f8e-657348bb858f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a0903aa0-2204-4759-8ce3-786e19c93118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_4297437e-de98-4f4e-9769-eee48241749b" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_a0903aa0-2204-4759-8ce3-786e19c93118" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_4297437e-de98-4f4e-9769-eee48241749b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_d199f486-6cb1-42b8-8392-71cf4d191d8a" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_a0903aa0-2204-4759-8ce3-786e19c93118" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_d199f486-6cb1-42b8-8392-71cf4d191d8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_bfb72bf8-76f3-4b8e-a361-e7e8b64a0454" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_a0903aa0-2204-4759-8ce3-786e19c93118" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_bfb72bf8-76f3-4b8e-a361-e7e8b64a0454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_70fa8260-5ea1-4c72-beec-99928c46cc04" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_a0903aa0-2204-4759-8ce3-786e19c93118" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_70fa8260-5ea1-4c72-beec-99928c46cc04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_ef047498-4836-460d-b239-9bbbed469b0b" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInNextFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_a0903aa0-2204-4759-8ce3-786e19c93118" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_ef047498-4836-460d-b239-9bbbed469b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_53c906f9-4809-48f7-bbc0-fa5f8a0fc660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_f6eaf6c7-01cf-4b0a-b26b-f844022c758e" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_53c906f9-4809-48f7-bbc0-fa5f8a0fc660" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_f6eaf6c7-01cf-4b0a-b26b-f844022c758e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_b2bfab01-f91c-4f43-a577-faa852bfb05a" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_53c906f9-4809-48f7-bbc0-fa5f8a0fc660" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_b2bfab01-f91c-4f43-a577-faa852bfb05a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_2f6bbdfb-7868-44c9-86c5-278321e7cc08" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_53c906f9-4809-48f7-bbc0-fa5f8a0fc660" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_2f6bbdfb-7868-44c9-86c5-278321e7cc08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_5affe7e7-9d54-47d0-bc02-b79dfc3fa6c9" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_53c906f9-4809-48f7-bbc0-fa5f8a0fc660" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_5affe7e7-9d54-47d0-bc02-b79dfc3fa6c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_08261b3d-0daa-4f35-9bde-f4db54de51c1" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringInNextFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_53c906f9-4809-48f7-bbc0-fa5f8a0fc660" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_08261b3d-0daa-4f35-9bde-f4db54de51c1" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ino-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:17b32d98-3816-4b9f-8e66-a2aab92f0705,g:04b54f73-b42b-4be7-b731-92d690b75cab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_240a87d5-d355-428a-b243-ee616d8d5133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_467dd741-7083-49b0-b89e-d7b4dbd7c38b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_240a87d5-d355-428a-b243-ee616d8d5133" xlink:to="loc_us-gaap_StatementTable_467dd741-7083-49b0-b89e-d7b4dbd7c38b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_467dd741-7083-49b0-b89e-d7b4dbd7c38b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50" xlink:to="loc_us-gaap_RelatedPartyDomain_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_66db659b-db3e-4bed-a816-783c6a32dffe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50" xlink:to="loc_us-gaap_RelatedPartyDomain_66db659b-db3e-4bed-a816-783c6a32dffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_721d3b75-ec66-4060-8eff-60664bba02b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_66db659b-db3e-4bed-a816-783c6a32dffe" xlink:to="loc_us-gaap_NonrelatedPartyMember_721d3b75-ec66-4060-8eff-60664bba02b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_e5671939-a64e-40d7-97b4-8233114e1f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_66db659b-db3e-4bed-a816-783c6a32dffe" xlink:to="loc_us-gaap_RelatedPartyMember_e5671939-a64e-40d7-97b4-8233114e1f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_240a87d5-d355-428a-b243-ee616d8d5133" xlink:to="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3030cccc-00da-4377-8808-a680e514b15d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3030cccc-00da-4377-8808-a680e514b15d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a04d4ef9-9b29-408b-a8f5-7610060f488b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_ShortTermInvestments_a04d4ef9-9b29-408b-a8f5-7610060f488b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_04567f62-b7b3-432b-8a50-ac3db3b57c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_04567f62-b7b3-432b-8a50-ac3db3b57c43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5368c6c-46fd-4ee7-a1ef-bb95a4f4b413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5368c6c-46fd-4ee7-a1ef-bb95a4f4b413" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_98ac2eeb-3650-4ae9-9f73-c4088bd8badf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_AssetsCurrent_98ac2eeb-3650-4ae9-9f73-c4088bd8badf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e56cba8-596e-4bca-b236-3d891f39e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e56cba8-596e-4bca-b236-3d891f39e30f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d57c6eec-d019-4c7b-993a-ac7213bf7abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d57c6eec-d019-4c7b-993a-ac7213bf7abe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc4efc44-e793-4175-b1a7-887d8b6d8aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc4efc44-e793-4175-b1a7-887d8b6d8aaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5a10b5dc-a2d6-4e05-8ed5-60faceb5960d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5a10b5dc-a2d6-4e05-8ed5-60faceb5960d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b46b2f8b-2ecc-456f-ac7f-0e2058a3dc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_Assets_b46b2f8b-2ecc-456f-ac7f-0e2058a3dc4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_240a87d5-d355-428a-b243-ee616d8d5133" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e3baa97c-ea47-49a2-a0d7-fc3160beb419" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e3baa97c-ea47-49a2-a0d7-fc3160beb419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_2fc338f5-63c7-4e58-8717-487302831a96" xlink:href="ino-20241231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_2fc338f5-63c7-4e58-8717-487302831a96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_525f8a46-1154-4437-99b4-65eed52fd567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_525f8a46-1154-4437-99b4-65eed52fd567" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c661a5f6-8909-4722-bef0-5d51073f208c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c661a5f6-8909-4722-bef0-5d51073f208c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_92bc2001-6825-4dd5-b7eb-de0ec6c307a7" xlink:href="ino-20241231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_ino_DeferredGrantFundingCurrent_92bc2001-6825-4dd5-b7eb-de0ec6c307a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_7b5f3b8b-69b7-480c-a37e-eb43e14568f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_7b5f3b8b-69b7-480c-a37e-eb43e14568f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e17f9e18-fd91-4f65-b0b2-353f7b2c54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_LiabilitiesCurrent_e17f9e18-fd91-4f65-b0b2-353f7b2c54c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c69e8f88-a719-459c-b1d1-8931b5ed1d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c69e8f88-a719-459c-b1d1-8931b5ed1d6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bc3bb252-c219-491a-b9a1-abbcd8d3ddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_Liabilities_bc3bb252-c219-491a-b9a1-abbcd8d3ddc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4781a13a-5020-44e6-8b72-6e665a154353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4781a13a-5020-44e6-8b72-6e665a154353" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_684ae8ee-8fa4-4bf8-9b6e-0cb2e58f6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_PreferredStockValue_684ae8ee-8fa4-4bf8-9b6e-0cb2e58f6a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0d5b7ea3-41f8-4593-8d07-d10cc5684b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_CommonStockValue_0d5b7ea3-41f8-4593-8d07-d10cc5684b30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e7ed6259-a17b-4832-ab9c-5a84686a4534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e7ed6259-a17b-4832-ab9c-5a84686a4534" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43b2661f-ddf9-4ff9-bc80-194f0e23c30e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43b2661f-ddf9-4ff9-bc80-194f0e23c30e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f9a1a04-b527-4188-90c1-dbdc082f64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f9a1a04-b527-4188-90c1-dbdc082f64ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db6b0b13-e6bb-4f96-9789-fa27f2fe2091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_StockholdersEquity_db6b0b13-e6bb-4f96-9789-fa27f2fe2091" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5221d3d6-a9a3-4764-9f2f-a6c72634b552" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5221d3d6-a9a3-4764-9f2f-a6c72634b552" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bfdf46ce-8297-4bd3-881e-92a6fd1a86a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3dc8dca9-ae30-4225-b338-e6bb503e527f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bfdf46ce-8297-4bd3-881e-92a6fd1a86a0" xlink:to="loc_us-gaap_StatementTable_3dc8dca9-ae30-4225-b338-e6bb503e527f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_76f3d074-0675-4528-9469-7e0cf7666d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3dc8dca9-ae30-4225-b338-e6bb503e527f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_76f3d074-0675-4528-9469-7e0cf7666d7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76f3d074-0675-4528-9469-7e0cf7666d7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76f3d074-0675-4528-9469-7e0cf7666d7a" xlink:to="loc_us-gaap_EquityComponentDomain_76f3d074-0675-4528-9469-7e0cf7666d7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76f3d074-0675-4528-9469-7e0cf7666d7a" xlink:to="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_13249820-9329-4e53-b488-a430eb32eac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_PreferredStockMember_13249820-9329-4e53-b488-a430eb32eac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_29fb8304-280d-4f11-b9a1-e03cc29823b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_CommonStockMember_29fb8304-280d-4f11-b9a1-e03cc29823b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1b5c0f85-3c03-4e97-9d00-4824eeaa1a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1b5c0f85-3c03-4e97-9d00-4824eeaa1a64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ea5a22cb-9589-4830-9733-13ad13d43a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_RetainedEarningsMember_ea5a22cb-9589-4830-9733-13ad13d43a6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_90b293ce-9532-4317-a425-a71dd203b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_90b293ce-9532-4317-a425-a71dd203b4fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bfdf46ce-8297-4bd3-881e-92a6fd1a86a0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_82a8652a-11c0-4b11-a43d-f90f9af11002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_82a8652a-11c0-4b11-a43d-f90f9af11002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ac88819e-ec0f-4968-83f4-846d155bb8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ac88819e-ec0f-4968-83f4-846d155bb8ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7cabb347-9f21-4e55-aad9-1ca83dab27ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockholdersEquity_7cabb347-9f21-4e55-aad9-1ca83dab27ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2861879c-f91b-4745-9628-c5a995ac593d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2861879c-f91b-4745-9628-c5a995ac593d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4905057c-6f1d-430c-ac8a-226a01724419" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4905057c-6f1d-430c-ac8a-226a01724419" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93884981-087c-4304-ada7-e4003a532918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93884981-087c-4304-ada7-e4003a532918" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bc3f980f-1453-4fc1-bc1a-96fedcb2fc00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bc3f980f-1453-4fc1-bc1a-96fedcb2fc00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_57ab51ae-e057-4786-b371-b330a26ea62b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_57ab51ae-e057-4786-b371-b330a26ea62b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_49d7f556-e510-434c-9bb6-c025286e3b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_49d7f556-e510-434c-9bb6-c025286e3b7c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a07e93c2-6723-4375-9f55-e5f21d097970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a07e93c2-6723-4375-9f55-e5f21d097970" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_23376a79-188e-4978-b925-1a23de20e7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_23376a79-188e-4978-b925-1a23de20e7c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94fd0eac-017c-47f6-aaa5-edf4a0bd1118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_NetIncomeLoss_94fd0eac-017c-47f6-aaa5-edf4a0bd1118" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_76b8a5e5-1a79-4255-a202-ad123a4d10d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_76b8a5e5-1a79-4255-a202-ad123a4d10d0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_95ccd6a3-dd93-4e39-b8d5-62797a053f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_95ccd6a3-dd93-4e39-b8d5-62797a053f84" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d48b0262-543f-479d-a3f0-b7791e9f288d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9335ce9d-d82c-4381-b5e0-afb100b36645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d729a76-eafe-49f7-8278-2d08492f8d32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_46ec630d-82bc-430b-9362-ccf71ae15964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_46ec630d-82bc-430b-9362-ccf71ae15964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_46ec630d-82bc-430b-9362-ccf71ae15964_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46ec630d-82bc-430b-9362-ccf71ae15964" xlink:to="loc_us-gaap_EquityComponentDomain_46ec630d-82bc-430b-9362-ccf71ae15964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_426b033e-ef87-427b-afe2-a606322892c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46ec630d-82bc-430b-9362-ccf71ae15964" xlink:to="loc_us-gaap_EquityComponentDomain_426b033e-ef87-427b-afe2-a606322892c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_30d78974-262d-426a-bbd4-3687b3b2cbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_426b033e-ef87-427b-afe2-a606322892c8" xlink:to="loc_us-gaap_CommonStockMember_30d78974-262d-426a-bbd4-3687b3b2cbfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_bb925a3c-9854-40d2-af94-0d2765cfdb43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_426b033e-ef87-427b-afe2-a606322892c8" xlink:to="loc_us-gaap_WarrantMember_bb925a3c-9854-40d2-af94-0d2765cfdb43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_64a3ef2b-7ec5-4280-aabd-a492151c7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_64a3ef2b-7ec5-4280-aabd-a492151c7b10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64a3ef2b-7ec5-4280-aabd-a492151c7b10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_64a3ef2b-7ec5-4280-aabd-a492151c7b10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64a3ef2b-7ec5-4280-aabd-a492151c7b10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_64a3ef2b-7ec5-4280-aabd-a492151c7b10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingMember_5a81a6b9-2a5d-44c5-950b-d678824c2186" xlink:href="ino-20241231.xsd#ino_December2024OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:to="loc_ino_December2024OfferingMember_5a81a6b9-2a5d-44c5-950b-d678824c2186" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_April2024OfferingMember_60c8229a-74e7-4994-834c-9ca57f19ac63" xlink:href="ino-20241231.xsd#ino_April2024OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:to="loc_ino_April2024OfferingMember_60c8229a-74e7-4994-834c-9ca57f19ac63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_4a7e9050-c3e6-45eb-bbd9-40f3df7f361f" xlink:href="ino-20241231.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:to="loc_ino_SalesAgreementMember_4a7e9050-c3e6-45eb-bbd9-40f3df7f361f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_202ada00-4719-4e7f-9cd0-03dd87420f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_202ada00-4719-4e7f-9cd0-03dd87420f7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_202ada00-4719-4e7f-9cd0-03dd87420f7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_202ada00-4719-4e7f-9cd0-03dd87420f7c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_202ada00-4719-4e7f-9cd0-03dd87420f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c289eb07-6cc0-4c95-a11d-02a4b93af3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_202ada00-4719-4e7f-9cd0-03dd87420f7c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c289eb07-6cc0-4c95-a11d-02a4b93af3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember_67040baf-312c-4089-bd22-a35516cb42ca" xlink:href="ino-20241231.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c289eb07-6cc0-4c95-a11d-02a4b93af3dc" xlink:to="loc_ino_December2024OfferingWarrantsMember_67040baf-312c-4089-bd22-a35516cb42ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_April2024OfferingWarrantsMember_72fc2892-e029-40ee-bf36-decf6665f1db" xlink:href="ino-20241231.xsd#ino_April2024OfferingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c289eb07-6cc0-4c95-a11d-02a4b93af3dc" xlink:to="loc_ino_April2024OfferingWarrantsMember_72fc2892-e029-40ee-bf36-decf6665f1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e9247f92-b716-4bb0-9b62-e708f68463c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_srt_RangeAxis_e9247f92-b716-4bb0-9b62-e708f68463c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9247f92-b716-4bb0-9b62-e708f68463c2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e9247f92-b716-4bb0-9b62-e708f68463c2" xlink:to="loc_srt_RangeMember_e9247f92-b716-4bb0-9b62-e708f68463c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b83a7e3a-41bc-4a7a-b51c-aa54c31ac5e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e9247f92-b716-4bb0-9b62-e708f68463c2" xlink:to="loc_srt_RangeMember_b83a7e3a-41bc-4a7a-b51c-aa54c31ac5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f03dc90c-3927-4547-abd6-f32761a47aaa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b83a7e3a-41bc-4a7a-b51c-aa54c31ac5e2" xlink:to="loc_srt_MinimumMember_f03dc90c-3927-4547-abd6-f32761a47aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_53a24b7a-ffa3-4f4b-8823-1bdc0e65e5bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b83a7e3a-41bc-4a7a-b51c-aa54c31ac5e2" xlink:to="loc_srt_MaximumMember_53a24b7a-ffa3-4f4b-8823-1bdc0e65e5bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed5257f8-3b9f-440b-a820-5ad04c86f630" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_NetIncomeLoss_ed5257f8-3b9f-440b-a820-5ad04c86f630" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_2709627b-01ca-40dd-ba67-14019069cf8f" xlink:href="ino-20241231.xsd#ino_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_ino_WorkingCapital_2709627b-01ca-40dd-ba67-14019069cf8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5bfef70-a088-4e10-96fd-2ab7fcc35afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5bfef70-a088-4e10-96fd-2ab7fcc35afa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4d240f8a-9e7b-461e-8a7b-9d510e5573d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4d240f8a-9e7b-461e-8a7b-9d510e5573d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17a20d77-074a-4782-aa75-9d18c7f2fa10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17a20d77-074a-4782-aa75-9d18c7f2fa10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9ff7f39a-eaa1-4e00-a055-f5b37c367d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9ff7f39a-eaa1-4e00-a055-f5b37c367d7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bc166eaf-9fc2-4f25-a2a8-b45c648f06cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bc166eaf-9fc2-4f25-a2a8-b45c648f06cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5442e028-f2bb-4c52-a9f8-9d3a99d0422f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5442e028-f2bb-4c52-a9f8-9d3a99d0422f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97138ce3-9156-46de-bbfa-3e04f265e273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97138ce3-9156-46de-bbfa-3e04f265e273" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e8365e5c-6ea3-44ec-bb70-a7e1238b9ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e8365e5c-6ea3-44ec-bb70-a7e1238b9ad8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f5714d8-eb32-40d5-86a6-2fccd6dca9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f5714d8-eb32-40d5-86a6-2fccd6dca9eb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a8bcc33e-de5e-4803-8b81-ca07553ada24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a8bcc33e-de5e-4803-8b81-ca07553ada24" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_83573090-f5a1-425e-8332-a726074ecf59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_NumberOfReportableSegments_83573090-f5a1-425e-8332-a726074ecf59" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_253a4d38-f0ef-4f36-bf50-43b470638578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_253a4d38-f0ef-4f36-bf50-43b470638578" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3e2d8f2a-62e6-4256-8477-4f9f19671543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3e2d8f2a-62e6-4256-8477-4f9f19671543" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7dce8e06-c3c8-49c4-a2d9-9b738d0ef18c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7dce8e06-c3c8-49c4-a2d9-9b738d0ef18c" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57cce3cb-7bd6-4e99-882a-0864b85959ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57cce3cb-7bd6-4e99-882a-0864b85959ac" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4427bd9c-b6ce-47ce-ae22-bf2350c9eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_WarrantMember_4427bd9c-b6ce-47ce-ae22-bf2350c9eeb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_70cab780-ccdc-4886-9763-4bf723a249cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_70cab780-ccdc-4886-9763-4bf723a249cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_8ec77fbe-6b6c-4b5e-a925-204e2b21d3de" xlink:href="ino-20241231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_8ec77fbe-6b6c-4b5e-a925-204e2b21d3de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4f68f80f-a63d-4d1e-8976-bd81a82a485f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4f68f80f-a63d-4d1e-8976-bd81a82a485f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_da33a500-d610-42cb-b4ca-4056361b5756" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_da33a500-d610-42cb-b4ca-4056361b5756" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_46c33c8d-9669-4823-a6ba-068aa8dcf441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_46c33c8d-9669-4823-a6ba-068aa8dcf441" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2ceb8990-7aab-48df-9230-7a412f125445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:to="loc_us-gaap_DebtInstrumentAxis_2ceb8990-7aab-48df-9230-7a412f125445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ceb8990-7aab-48df-9230-7a412f125445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ceb8990-7aab-48df-9230-7a412f125445" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ceb8990-7aab-48df-9230-7a412f125445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e93fe351-8fad-4b9f-903e-8a54fc46db2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ceb8990-7aab-48df-9230-7a412f125445" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e93fe351-8fad-4b9f-903e-8a54fc46db2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_80d8325c-4b5c-43d5-a455-fa16807c1f6f" xlink:href="ino-20241231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e93fe351-8fad-4b9f-903e-8a54fc46db2a" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_80d8325c-4b5c-43d5-a455-fa16807c1f6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_149284f5-9457-4c23-99a8-c952e5e384dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57cce3cb-7bd6-4e99-882a-0864b85959ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_149284f5-9457-4c23-99a8-c952e5e384dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599253f5-2f2f-4beb-94a5-eb7bc1a4920a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599253f5-2f2f-4beb-94a5-eb7bc1a4920a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b9d97096-e7d3-47a1-b9a0-989216ad146d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:to="loc_srt_TitleOfIndividualAxis_b9d97096-e7d3-47a1-b9a0-989216ad146d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b9d97096-e7d3-47a1-b9a0-989216ad146d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b9d97096-e7d3-47a1-b9a0-989216ad146d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b9d97096-e7d3-47a1-b9a0-989216ad146d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bf440637-8a2c-4597-b3fd-3b2ae29833e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b9d97096-e7d3-47a1-b9a0-989216ad146d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bf440637-8a2c-4597-b3fd-3b2ae29833e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_d4886813-0412-4947-bf86-c61da3decbd6" xlink:href="ino-20241231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bf440637-8a2c-4597-b3fd-3b2ae29833e2" xlink:to="loc_ino_EmployeesAndDirectorsMember_d4886813-0412-4947-bf86-c61da3decbd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_7522dc0a-52bb-4e91-94d3-3b8124ca6c6a" xlink:href="ino-20241231.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bf440637-8a2c-4597-b3fd-3b2ae29833e2" xlink:to="loc_ino_NonEmployeeMember_7522dc0a-52bb-4e91-94d3-3b8124ca6c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_feffb7b6-1983-448a-a0bc-071471fdd8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:to="loc_us-gaap_AwardTypeAxis_feffb7b6-1983-448a-a0bc-071471fdd8d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_feffb7b6-1983-448a-a0bc-071471fdd8d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_feffb7b6-1983-448a-a0bc-071471fdd8d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_feffb7b6-1983-448a-a0bc-071471fdd8d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c98efc87-537b-4f59-859d-6daff653a8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_feffb7b6-1983-448a-a0bc-071471fdd8d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c98efc87-537b-4f59-859d-6daff653a8ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d219db34-8eef-4ce0-93f0-fb41d9cbfb12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c98efc87-537b-4f59-859d-6daff653a8ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d219db34-8eef-4ce0-93f0-fb41d9cbfb12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:href="ino-20241231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599253f5-2f2f-4beb-94a5-eb7bc1a4920a" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32e81ec7-170c-4a24-a809-aff25d221f15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32e81ec7-170c-4a24-a809-aff25d221f15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4da3afc6-e07b-431b-a9ae-bf02989784ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4da3afc6-e07b-431b-a9ae-bf02989784ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4512737f-da7e-46ea-95ff-7734ee3d97ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4512737f-da7e-46ea-95ff-7734ee3d97ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cbe9b4f4-4186-4e5e-8306-2c5a48ba26bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cbe9b4f4-4186-4e5e-8306-2c5a48ba26bb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e845aa7e-1751-48b1-be9e-43f7829848d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e845aa7e-1751-48b1-be9e-43f7829848d5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_14118168-a13a-4181-a75a-e621adf65abc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:to="loc_srt_MajorCustomersAxis_14118168-a13a-4181-a75a-e621adf65abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_14118168-a13a-4181-a75a-e621adf65abc_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_14118168-a13a-4181-a75a-e621adf65abc" xlink:to="loc_srt_NameOfMajorCustomerDomain_14118168-a13a-4181-a75a-e621adf65abc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_323357e5-5f32-45b8-87e1-7da63f5fe204" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_14118168-a13a-4181-a75a-e621adf65abc" xlink:to="loc_srt_NameOfMajorCustomerDomain_323357e5-5f32-45b8-87e1-7da63f5fe204" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioCorporationMember_e4325b4e-8bd2-4946-9d31-d08f04a8ce75" xlink:href="ino-20241231.xsd#ino_ApolloBioCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_323357e5-5f32-45b8-87e1-7da63f5fe204" xlink:to="loc_ino_ApolloBioCorporationMember_e4325b4e-8bd2-4946-9d31-d08f04a8ce75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_318335e9-4285-4c26-9758-e06bda6492ab" xlink:href="ino-20241231.xsd#ino_AllOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_323357e5-5f32-45b8-87e1-7da63f5fe204" xlink:to="loc_ino_AllOtherCustomersMember_318335e9-4285-4c26-9758-e06bda6492ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15b98877-ffad-4350-8fd3-b86d78d8705c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15b98877-ffad-4350-8fd3-b86d78d8705c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15b98877-ffad-4350-8fd3-b86d78d8705c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15b98877-ffad-4350-8fd3-b86d78d8705c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_15b98877-ffad-4350-8fd3-b86d78d8705c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_18ce15e0-451e-4c1c-adeb-b7cbc25b9332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15b98877-ffad-4350-8fd3-b86d78d8705c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_18ce15e0-451e-4c1c-adeb-b7cbc25b9332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_32ae672b-c2da-4fd5-8783-872cab256a95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_18ce15e0-451e-4c1c-adeb-b7cbc25b9332" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_32ae672b-c2da-4fd5-8783-872cab256a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1b5c8e31-7d4b-4786-b054-4293f577e1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1b5c8e31-7d4b-4786-b054-4293f577e1ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1b5c8e31-7d4b-4786-b054-4293f577e1ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b5c8e31-7d4b-4786-b054-4293f577e1ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1b5c8e31-7d4b-4786-b054-4293f577e1ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bc7bc308-3b5c-4f54-b078-f291631970b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b5c8e31-7d4b-4786-b054-4293f577e1ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bc7bc308-3b5c-4f54-b078-f291631970b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5788e4f7-86e9-4dd1-99f6-9f7ac28d1b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bc7bc308-3b5c-4f54-b078-f291631970b9" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5788e4f7-86e9-4dd1-99f6-9f7ac28d1b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6aaa8e26-6ebe-452b-ad8c-e3a580d7b2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e845aa7e-1751-48b1-be9e-43f7829848d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6aaa8e26-6ebe-452b-ad8c-e3a580d7b2f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2fe23874-8c8a-4e2e-9efc-b67c23e394af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e845aa7e-1751-48b1-be9e-43f7829848d5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2fe23874-8c8a-4e2e-9efc-b67c23e394af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_306666c9-badf-4181-83f7-92cf7e62b2eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:to="loc_srt_CounterpartyNameAxis_306666c9-badf-4181-83f7-92cf7e62b2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_306666c9-badf-4181-83f7-92cf7e62b2eb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_306666c9-badf-4181-83f7-92cf7e62b2eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_306666c9-badf-4181-83f7-92cf7e62b2eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_306666c9-badf-4181-83f7-92cf7e62b2eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_17cc07f8-2df1-4ae1-9d8b-9aaa050056a5" xlink:href="ino-20241231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:to="loc_ino_AdvaccineMember_17cc07f8-2df1-4ae1-9d8b-9aaa050056a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_69f428d0-b602-47d7-ac8d-0cdb96fe0cd2" xlink:href="ino-20241231.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:to="loc_ino_ApolloBioMember_69f428d0-b602-47d7-ac8d-0cdb96fe0cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_9e6b86cc-7c69-46fb-b209-c97e9b781781" xlink:href="ino-20241231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_9e6b86cc-7c69-46fb-b209-c97e9b781781" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_525a91d4-5c65-4f87-9330-18efcaf305a8" xlink:href="ino-20241231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_525a91d4-5c65-4f87-9330-18efcaf305a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_977710db-690c-4f70-9236-97173b5f5098" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:to="loc_us-gaap_TypeOfArrangementAxis_977710db-690c-4f70-9236-97173b5f5098" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_977710db-690c-4f70-9236-97173b5f5098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_977710db-690c-4f70-9236-97173b5f5098" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_977710db-690c-4f70-9236-97173b5f5098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d008b66e-3048-43d2-a83b-cd6f4243b7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_977710db-690c-4f70-9236-97173b5f5098" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d008b66e-3048-43d2-a83b-cd6f4243b7f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_25ef6b59-81d1-448a-908f-116e8b9016b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d008b66e-3048-43d2-a83b-cd6f4243b7f8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_25ef6b59-81d1-448a-908f-116e8b9016b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0663ae23-af36-4c9c-863d-76acf31dc8f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:to="loc_srt_ProductOrServiceAxis_0663ae23-af36-4c9c-863d-76acf31dc8f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0663ae23-af36-4c9c-863d-76acf31dc8f7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0663ae23-af36-4c9c-863d-76acf31dc8f7" xlink:to="loc_srt_ProductsAndServicesDomain_0663ae23-af36-4c9c-863d-76acf31dc8f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_851ee33f-8bff-4ca2-9414-84326d41c429" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0663ae23-af36-4c9c-863d-76acf31dc8f7" xlink:to="loc_srt_ProductsAndServicesDomain_851ee33f-8bff-4ca2-9414-84326d41c429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_cd499a17-ba6a-4486-9ca0-1ddf1b023b74" xlink:href="ino-20241231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_851ee33f-8bff-4ca2-9414-84326d41c429" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_cd499a17-ba6a-4486-9ca0-1ddf1b023b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_5160e081-620a-4802-a816-d2ef418bdafb" xlink:href="ino-20241231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_851ee33f-8bff-4ca2-9414-84326d41c429" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_5160e081-620a-4802-a816-d2ef418bdafb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_87ae4603-4348-43aa-8ae3-e9d0f5006240" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_87ae4603-4348-43aa-8ae3-e9d0f5006240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_afa507f6-a27e-4891-ad2c-abce343f0734" xlink:href="ino-20241231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_afa507f6-a27e-4891-ad2c-abce343f0734" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_3b6120c9-b9ec-4122-891b-2b3e17d407fa" xlink:href="ino-20241231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_3b6120c9-b9ec-4122-891b-2b3e17d407fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_89edbbfb-362f-4297-a059-2cbe670ea46e" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_89edbbfb-362f-4297-a059-2cbe670ea46e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_957f8e22-af77-4711-8eb1-5f6b55b914de" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_957f8e22-af77-4711-8eb1-5f6b55b914de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_6bd6e48c-cbc3-4ac0-9133-1629da96307c" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_6bd6e48c-cbc3-4ac0-9133-1629da96307c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_79eb4a53-c603-4cb0-b510-6e833272664a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_79eb4a53-c603-4cb0-b510-6e833272664a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_0b2ff77e-e35f-4493-8399-f58e604a9236" xlink:href="ino-20241231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:to="loc_ino_MutualFundsMember_0b2ff77e-e35f-4493-8399-f58e604a9236" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_4dae95dc-b06d-4088-b32d-ad2ccb919cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_4dae95dc-b06d-4088-b32d-ad2ccb919cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f1dd8b1d-664a-4754-88cd-47b814659378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f1dd8b1d-664a-4754-88cd-47b814659378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_f4649bf2-58bf-4e57-8e06-727fb9d5d2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_f4649bf2-58bf-4e57-8e06-727fb9d5d2c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:to="loc_srt_RangeAxis_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1" xlink:to="loc_srt_RangeMember_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1fed439-6a3c-4f1a-b2ab-e45534ae99d1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1" xlink:to="loc_srt_RangeMember_d1fed439-6a3c-4f1a-b2ab-e45534ae99d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_24f8f8b7-bf63-4d5d-bfa1-10ba02c69f3b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d1fed439-6a3c-4f1a-b2ab-e45534ae99d1" xlink:to="loc_srt_MaximumMember_24f8f8b7-bf63-4d5d-bfa1-10ba02c69f3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_98bb3ce6-dba9-4d68-b8fc-ebee15dc8b75" xlink:href="ino-20241231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_79eb4a53-c603-4cb0-b510-6e833272664a" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_98bb3ce6-dba9-4d68-b8fc-ebee15dc8b75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_79eb4a53-c603-4cb0-b510-6e833272664a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ad93061c-4fb1-48ef-82e4-f65bdaad599c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ad93061c-4fb1-48ef-82e4-f65bdaad599c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_543e298a-6cb6-4911-9c58-0d3458f641ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_543e298a-6cb6-4911-9c58-0d3458f641ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_eb3e4ddd-5fb5-4d7d-aa90-630ff8ae19a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_eb3e4ddd-5fb5-4d7d-aa90-630ff8ae19a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e6177957-185f-4271-93d2-522c25ffc334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e6177957-185f-4271-93d2-522c25ffc334" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_98ba8c04-2833-4091-813f-e5fb95766510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_98ba8c04-2833-4091-813f-e5fb95766510" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c520b2c8-ab11-4583-9979-3998e34e391c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_98ba8c04-2833-4091-813f-e5fb95766510" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c520b2c8-ab11-4583-9979-3998e34e391c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c520b2c8-ab11-4583-9979-3998e34e391c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c520b2c8-ab11-4583-9979-3998e34e391c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c520b2c8-ab11-4583-9979-3998e34e391c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_132fd930-6941-4cc3-aeca-c2ca33bdae52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c520b2c8-ab11-4583-9979-3998e34e391c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_132fd930-6941-4cc3-aeca-c2ca33bdae52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_53bd5753-9421-452b-b9db-178b8b3463d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_132fd930-6941-4cc3-aeca-c2ca33bdae52" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_53bd5753-9421-452b-b9db-178b8b3463d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_dbedbd3a-cc50-4684-a7a4-8a4db7f2483d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_dbedbd3a-cc50-4684-a7a4-8a4db7f2483d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_c01a4d82-e971-4222-86ad-5c517a2035ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_c01a4d82-e971-4222-86ad-5c517a2035ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_33701154-0afb-4ea4-b45a-3162f54c952d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_33701154-0afb-4ea4-b45a-3162f54c952d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_82ecbc0f-4010-40ba-8d31-9b164e7aab5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_82ecbc0f-4010-40ba-8d31-9b164e7aab5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_4e75a31f-3dab-4029-b484-6ac5a7f47d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_4e75a31f-3dab-4029-b484-6ac5a7f47d8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_ddc4eb02-85c0-4d3c-a337-bec277dcb0da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_ddc4eb02-85c0-4d3c-a337-bec277dcb0da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_240ca828-3a1b-4ece-a3f3-9a192982b750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_240ca828-3a1b-4ece-a3f3-9a192982b750" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c80c60c0-e057-44ec-a59f-196754933dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c80c60c0-e057-44ec-a59f-196754933dde" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2bace38c-0f7d-4c85-88d8-8847bf807588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2bace38c-0f7d-4c85-88d8-8847bf807588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2bace38c-0f7d-4c85-88d8-8847bf807588_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2bace38c-0f7d-4c85-88d8-8847bf807588" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2bace38c-0f7d-4c85-88d8-8847bf807588_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_91a576b0-33dd-4c83-97ea-2b4256d6e717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2bace38c-0f7d-4c85-88d8-8847bf807588" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_91a576b0-33dd-4c83-97ea-2b4256d6e717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_02876c10-d916-4026-8e31-0f06d06c0e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_91a576b0-33dd-4c83-97ea-2b4256d6e717" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_02876c10-d916-4026-8e31-0f06d06c0e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_6cfb7c76-696b-4d2a-81c5-1c22f646d7a7" xlink:href="ino-20241231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:to="loc_ino_MutualFundsMember_6cfb7c76-696b-4d2a-81c5-1c22f646d7a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f30cbe19-b266-421e-9c35-e51bc710c517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f30cbe19-b266-421e-9c35-e51bc710c517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_16782278-5e1a-491c-8e42-c220e0027f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:to="loc_us-gaap_CertificatesOfDepositMember_16782278-5e1a-491c-8e42-c220e0027f29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3d357a24-62b6-4664-bd73-87bb6c03e403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3d357a24-62b6-4664-bd73-87bb6c03e403" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ade004f-000f-46cc-ae9f-262f45f43071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ade004f-000f-46cc-ae9f-262f45f43071" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ade004f-000f-46cc-ae9f-262f45f43071_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ade004f-000f-46cc-ae9f-262f45f43071" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5ade004f-000f-46cc-ae9f-262f45f43071_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ade004f-000f-46cc-ae9f-262f45f43071" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5069add9-90ae-4b51-9231-a96dea285df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5069add9-90ae-4b51-9231-a96dea285df5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_41f5e07f-e714-4b2e-8bfa-380f9abf0456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_41f5e07f-e714-4b2e-8bfa-380f9abf0456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0d47c157-42ec-4623-aaab-fadfcb11bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0d47c157-42ec-4623-aaab-fadfcb11bd0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c32cb65a-f534-4c41-92f7-61a967318e66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c80c60c0-e057-44ec-a59f-196754933dde" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c32cb65a-f534-4c41-92f7-61a967318e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c32cb65a-f534-4c41-92f7-61a967318e66" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5ebb3fa-178d-4777-a865-71ce98b9ce06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5ebb3fa-178d-4777-a865-71ce98b9ce06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a3045875-3bab-4f9c-8671-093dceb74f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a3045875-3bab-4f9c-8671-093dceb74f1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_abf5a80d-097c-46ac-8fa5-f404d2fa5e87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_abf5a80d-097c-46ac-8fa5-f404d2fa5e87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ae638080-c7f9-4175-ba43-3dd0827885d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c32cb65a-f534-4c41-92f7-61a967318e66" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ae638080-c7f9-4175-ba43-3dd0827885d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockWarrantLiabilityFairValue_cecf3e01-e15b-40f5-b21f-5734bf691bd1" xlink:href="ino-20241231.xsd#ino_CommonStockWarrantLiabilityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ae638080-c7f9-4175-ba43-3dd0827885d0" xlink:to="loc_ino_CommonStockWarrantLiabilityFairValue_cecf3e01-e15b-40f5-b21f-5734bf691bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_52dbdcf3-e0b0-4b43-9464-728602902cde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ae638080-c7f9-4175-ba43-3dd0827885d0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_52dbdcf3-e0b0-4b43-9464-728602902cde" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6c3a2ea-531b-4178-950c-d23fb5150338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_068006ad-c19c-4d1c-9c70-bcc6253be38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6c3a2ea-531b-4178-950c-d23fb5150338" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_068006ad-c19c-4d1c-9c70-bcc6253be38e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3cc36366-e909-4d6d-ad5f-ccc3596002dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_068006ad-c19c-4d1c-9c70-bcc6253be38e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3cc36366-e909-4d6d-ad5f-ccc3596002dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3cc36366-e909-4d6d-ad5f-ccc3596002dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3cc36366-e909-4d6d-ad5f-ccc3596002dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3cc36366-e909-4d6d-ad5f-ccc3596002dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3cc36366-e909-4d6d-ad5f-ccc3596002dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ac29808d-4cc4-4132-809e-4ad78b2abcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ac29808d-4cc4-4132-809e-4ad78b2abcf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_aa919cbd-5d70-4cec-b4dd-22564ba7ba2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_aa919cbd-5d70-4cec-b4dd-22564ba7ba2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_26575553-eb4d-4d0f-89d1-067bf6857958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_26575553-eb4d-4d0f-89d1-067bf6857958" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_e4d6e461-7652-4f95-b268-ab96259b52b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_e4d6e461-7652-4f95-b268-ab96259b52b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WarrantLiabilityMeasurementInput_9d71b588-67e7-40fe-8949-243914fd6eb5" xlink:href="ino-20241231.xsd#ino_WarrantLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6c3a2ea-531b-4178-950c-d23fb5150338" xlink:to="loc_ino_WarrantLiabilityMeasurementInput_9d71b588-67e7-40fe-8949-243914fd6eb5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:href="ino-20241231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_b4b84d3e-6ab4-42f7-8867-9bd7a4e708cc" xlink:href="ino-20241231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_b4b84d3e-6ab4-42f7-8867-9bd7a4e708cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_b4b84d3e-6ab4-42f7-8867-9bd7a4e708cc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4" xlink:to="loc_us-gaap_RelatedPartyDomain_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ca78a69e-21a3-4383-8fee-82f85aed2ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4" xlink:to="loc_us-gaap_RelatedPartyDomain_ca78a69e-21a3-4383-8fee-82f85aed2ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_3537f4d0-e4e8-4316-8930-1c285a483ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ca78a69e-21a3-4383-8fee-82f85aed2ce8" xlink:to="loc_us-gaap_NonrelatedPartyMember_3537f4d0-e4e8-4316-8930-1c285a483ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_2cfb4743-833a-4e84-a5cb-0a943d866cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_2cfb4743-833a-4e84-a5cb-0a943d866cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_8b75b2bf-174a-486d-a1e6-b4652809af08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_us-gaap_AccruedSalariesCurrent_8b75b2bf-174a-486d-a1e6-b4652809af08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_9bed5267-dabe-45f7-a27a-518eb7647772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_9bed5267-dabe-45f7-a27a-518eb7647772" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ca461efd-38f4-48e6-9cb2-257acb920647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ca461efd-38f4-48e6-9cb2-257acb920647" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpenseCurrent_3e84b87e-32cc-4b7f-8376-cc1d0f8380bd" xlink:href="ino-20241231.xsd#ino_PrepaidManufacturingExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_ino_PrepaidManufacturingExpenseCurrent_3e84b87e-32cc-4b7f-8376-cc1d0f8380bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability_54fbbe4e-2fcb-42ab-858f-60e76f8140e6" xlink:href="ino-20241231.xsd#ino_GrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_ino_GrantLiability_54fbbe4e-2fcb-42ab-858f-60e76f8140e6" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#FixedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b508e7ae-dffe-4f66-a001-5b5c1e13ffcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b508e7ae-dffe-4f66-a001-5b5c1e13ffcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b508e7ae-dffe-4f66-a001-5b5c1e13ffcf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_05cbe6e8-060f-4949-8014-7425db1d721a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_05cbe6e8-060f-4949-8014-7425db1d721a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_aedb3d23-cfb9-496b-a5a9-30200ede7bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:to="loc_us-gaap_OfficeEquipmentMember_aedb3d23-cfb9-496b-a5a9-30200ede7bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9f3a1168-c4ee-48e5-beca-8c70cfd66945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9f3a1168-c4ee-48e5-beca-8c70cfd66945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_c1cb670c-78bb-4b20-9c43-0f0e3ddcddad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_c1cb670c-78bb-4b20-9c43-0f0e3ddcddad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d39184a1-d8eb-4e04-afb4-6cec36b0fe04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d39184a1-d8eb-4e04-afb4-6cec36b0fe04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d715eb15-48e2-4674-ad76-eef26ff88175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d715eb15-48e2-4674-ad76-eef26ff88175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_54fa4222-0062-4557-bcfd-3527884148b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_54fa4222-0062-4557-bcfd-3527884148b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_79233d99-861c-4d8a-9fd7-1c6a8205f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_Depreciation_79233d99-861c-4d8a-9fd7-1c6a8205f56f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue_c629092d-860f-45ed-b409-80bb6f67b572" xlink:href="ino-20241231.xsd#ino_GainLossOnSaleOfFixedAssetsNoNetBookValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue_c629092d-860f-45ed-b409-80bb6f67b572" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_fe9c7a7f-99d7-4396-ac49-3b8018932490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_fe9c7a7f-99d7-4396-ac49-3b8018932490" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_fc8be8a9-50af-444f-8ca0-0dcc5e2cbb39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_4bd7d447-b6fc-4618-9228-5e0c8b6ed97d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_fc8be8a9-50af-444f-8ca0-0dcc5e2cbb39" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_4bd7d447-b6fc-4618-9228-5e0c8b6ed97d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a83f7db2-9f83-4a84-918a-cc137cd48743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_4bd7d447-b6fc-4618-9228-5e0c8b6ed97d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a83f7db2-9f83-4a84-918a-cc137cd48743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a83f7db2-9f83-4a84-918a-cc137cd48743_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a83f7db2-9f83-4a84-918a-cc137cd48743" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a83f7db2-9f83-4a84-918a-cc137cd48743_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ab29938-920f-4123-b469-7eec821a1476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a83f7db2-9f83-4a84-918a-cc137cd48743" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ab29938-920f-4123-b469-7eec821a1476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_a83023d5-a1fc-41a9-8e47-04b04048c54e" xlink:href="ino-20241231.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ab29938-920f-4123-b469-7eec821a1476" xlink:to="loc_ino_BiojectMember_a83023d5-a1fc-41a9-8e47-04b04048c54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cdcf3576-8030-425d-96ba-9014f417e0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_fc8be8a9-50af-444f-8ca0-0dcc5e2cbb39" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cdcf3576-8030-425d-96ba-9014f417e0d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_87adf84b-ad87-44a6-b85e-e7ddfb367707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_fc8be8a9-50af-444f-8ca0-0dcc5e2cbb39" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_87adf84b-ad87-44a6-b85e-e7ddfb367707" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f64e227b-aea1-4e72-9eb2-97e6d9000913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:to="loc_us-gaap_DebtInstrumentAxis_f64e227b-aea1-4e72-9eb2-97e6d9000913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f64e227b-aea1-4e72-9eb2-97e6d9000913_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f64e227b-aea1-4e72-9eb2-97e6d9000913" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f64e227b-aea1-4e72-9eb2-97e6d9000913_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3b38cd5-5e40-40d1-8bd9-2fc7a212e5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f64e227b-aea1-4e72-9eb2-97e6d9000913" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3b38cd5-5e40-40d1-8bd9-2fc7a212e5ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7f0ef9ad-5f2b-41b8-9325-011de466061f" xlink:href="ino-20241231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b38cd5-5e40-40d1-8bd9-2fc7a212e5ad" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7f0ef9ad-5f2b-41b8-9325-011de466061f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bab74529-a29e-4938-8ade-6fccbde08a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bab74529-a29e-4938-8ade-6fccbde08a7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bab74529-a29e-4938-8ade-6fccbde08a7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bab74529-a29e-4938-8ade-6fccbde08a7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bab74529-a29e-4938-8ade-6fccbde08a7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d175df89-73f0-4386-8114-b1eff4b9ca60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bab74529-a29e-4938-8ade-6fccbde08a7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d175df89-73f0-4386-8114-b1eff4b9ca60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_aec260c4-5fe4-4dc5-a8e7-f80cf769adca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d175df89-73f0-4386-8114-b1eff4b9ca60" xlink:to="loc_us-gaap_ConvertibleDebtMember_aec260c4-5fe4-4dc5-a8e7-f80cf769adca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3bf82052-5dfa-421e-b71a-8eddb3244967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3bf82052-5dfa-421e-b71a-8eddb3244967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c32b281-3ced-495f-a8f1-c8e9ce14b35c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c32b281-3ced-495f-a8f1-c8e9ce14b35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_94919d20-f6dc-4603-8231-e64e135fe9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_94919d20-f6dc-4603-8231-e64e135fe9f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_14cc5fce-2f0e-4ea3-9ad2-53b5f1b1002b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_14cc5fce-2f0e-4ea3-9ad2-53b5f1b1002b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_a36500a3-12dc-48d3-b35b-fc80caee0d41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_InterestExpenseNonoperating_a36500a3-12dc-48d3-b35b-fc80caee0d41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c9267435-df8e-4371-9492-ece940341b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_InterestExpenseDebt_c9267435-df8e-4371-9492-ece940341b8b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityScheduleofPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2e84e50a-c1e2-491e-9fdf-5b953e31bdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fdbabc2c-b28b-439c-8280-b5eaa2cab1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2e84e50a-c1e2-491e-9fdf-5b953e31bdfb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fdbabc2c-b28b-439c-8280-b5eaa2cab1de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b66b927a-9b27-4264-bd85-5bbb17279b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fdbabc2c-b28b-439c-8280-b5eaa2cab1de" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b66b927a-9b27-4264-bd85-5bbb17279b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b66b927a-9b27-4264-bd85-5bbb17279b26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b66b927a-9b27-4264-bd85-5bbb17279b26" xlink:to="loc_us-gaap_ClassOfStockDomain_b66b927a-9b27-4264-bd85-5bbb17279b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0291b076-45c6-4df6-b731-f9109e8aa50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b66b927a-9b27-4264-bd85-5bbb17279b26" xlink:to="loc_us-gaap_ClassOfStockDomain_0291b076-45c6-4df6-b731-f9109e8aa50b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_a64d6013-43cd-4e23-9cd4-474cad775d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0291b076-45c6-4df6-b731-f9109e8aa50b" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_a64d6013-43cd-4e23-9cd4-474cad775d5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2e84e50a-c1e2-491e-9fdf-5b953e31bdfb" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5b682f8f-bd60-470e-b719-8332f33eed95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5b682f8f-bd60-470e-b719-8332f33eed95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6d178ac9-c129-4e74-94fd-14262ac9913d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6d178ac9-c129-4e74-94fd-14262ac9913d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_87eb326f-6430-4b2a-88cd-c24774b6cbba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_87eb326f-6430-4b2a-88cd-c24774b6cbba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8eab8df0-d9c6-4db5-9f57-0e83110c9257" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8eab8df0-d9c6-4db5-9f57-0e83110c9257" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e8ca9f68-4199-432f-af60-bf98464603a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_42010e26-da1c-4bfa-8886-46c86d0f74c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8ca9f68-4199-432f-af60-bf98464603a4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_42010e26-da1c-4bfa-8886-46c86d0f74c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7b6cfe4c-738a-4f35-8d46-bf98f21bad62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42010e26-da1c-4bfa-8886-46c86d0f74c1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7b6cfe4c-738a-4f35-8d46-bf98f21bad62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7b6cfe4c-738a-4f35-8d46-bf98f21bad62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b6cfe4c-738a-4f35-8d46-bf98f21bad62" xlink:to="loc_us-gaap_ClassOfStockDomain_7b6cfe4c-738a-4f35-8d46-bf98f21bad62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4c6513e1-a050-4e15-b7f6-9225e5fd16ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b6cfe4c-738a-4f35-8d46-bf98f21bad62" xlink:to="loc_us-gaap_ClassOfStockDomain_4c6513e1-a050-4e15-b7f6-9225e5fd16ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_bff59990-6822-4c5c-a5e8-f186883c6a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4c6513e1-a050-4e15-b7f6-9225e5fd16ca" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_bff59990-6822-4c5c-a5e8-f186883c6a80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_f6796ce0-e985-4113-bf57-2f09ea628dab" xlink:href="ino-20241231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8ca9f68-4199-432f-af60-bf98464603a4" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_f6796ce0-e985-4113-bf57-2f09ea628dab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b28d9b46-bef8-4f12-b0ee-0eecf8120d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8ca9f68-4199-432f-af60-bf98464603a4" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b28d9b46-bef8-4f12-b0ee-0eecf8120d76" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_badd0a45-4233-416d-9389-13695ba62852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_badd0a45-4233-416d-9389-13695ba62852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_badd0a45-4233-416d-9389-13695ba62852_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_badd0a45-4233-416d-9389-13695ba62852" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_badd0a45-4233-416d-9389-13695ba62852_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0f115e13-ba6d-4e8b-8f6d-3d4645fcb5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_badd0a45-4233-416d-9389-13695ba62852" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0f115e13-ba6d-4e8b-8f6d-3d4645fcb5fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember_07c271cf-6205-4939-a979-ee8e8da860a4" xlink:href="ino-20241231.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0f115e13-ba6d-4e8b-8f6d-3d4645fcb5fc" xlink:to="loc_ino_December2024OfferingWarrantsMember_07c271cf-6205-4939-a979-ee8e8da860a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b9c02a74-d38c-4799-b67e-d78905c45a13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b9c02a74-d38c-4799-b67e-d78905c45a13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b9c02a74-d38c-4799-b67e-d78905c45a13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b9c02a74-d38c-4799-b67e-d78905c45a13" xlink:to="loc_us-gaap_EquityComponentDomain_b9c02a74-d38c-4799-b67e-d78905c45a13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_64e3c7f8-6f46-4fca-9c98-778fc44fe979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b9c02a74-d38c-4799-b67e-d78905c45a13" xlink:to="loc_us-gaap_EquityComponentDomain_64e3c7f8-6f46-4fca-9c98-778fc44fe979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_24341b19-d41f-4508-9007-693289420365" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64e3c7f8-6f46-4fca-9c98-778fc44fe979" xlink:to="loc_us-gaap_WarrantMember_24341b19-d41f-4508-9007-693289420365" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6f9416dc-89df-46a7-bf5c-1c9f7fe5123b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64e3c7f8-6f46-4fca-9c98-778fc44fe979" xlink:to="loc_us-gaap_CommonStockMember_6f9416dc-89df-46a7-bf5c-1c9f7fe5123b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ddecb612-ff4a-4f1e-bfae-e0a6413bb389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ddecb612-ff4a-4f1e-bfae-e0a6413bb389" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ddecb612-ff4a-4f1e-bfae-e0a6413bb389_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ddecb612-ff4a-4f1e-bfae-e0a6413bb389" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ddecb612-ff4a-4f1e-bfae-e0a6413bb389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e470e830-2e25-4334-ada1-ce79046ac96d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ddecb612-ff4a-4f1e-bfae-e0a6413bb389" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e470e830-2e25-4334-ada1-ce79046ac96d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_7875bc66-530b-44bc-9dd7-f953b4c3013c" xlink:href="ino-20241231.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e470e830-2e25-4334-ada1-ce79046ac96d" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_7875bc66-530b-44bc-9dd7-f953b4c3013c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9fce45b1-4f33-4c81-acb0-469730e40bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9fce45b1-4f33-4c81-acb0-469730e40bd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_a571ec2a-47f7-49f0-bc02-ae0d68458cab" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_a571ec2a-47f7-49f0-bc02-ae0d68458cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_e7e2cb90-8e1b-485c-acb3-e0be7ce198f4" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_e7e2cb90-8e1b-485c-acb3-e0be7ce198f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_a22114c2-8d73-4f6f-9341-dd664e80d142" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_a22114c2-8d73-4f6f-9341-dd664e80d142" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityAtTheMarketSalesAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6c7587df-08c9-43a2-aa15-a78e10d461fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6c7587df-08c9-43a2-aa15-a78e10d461fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c7587df-08c9-43a2-aa15-a78e10d461fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6c7587df-08c9-43a2-aa15-a78e10d461fe" xlink:to="loc_us-gaap_EquityComponentDomain_6c7587df-08c9-43a2-aa15-a78e10d461fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad32fc49-205d-4fe7-acb1-20fad851f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6c7587df-08c9-43a2-aa15-a78e10d461fe" xlink:to="loc_us-gaap_EquityComponentDomain_ad32fc49-205d-4fe7-acb1-20fad851f60e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ba505002-51f7-4479-bb99-cdfb2f90e0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad32fc49-205d-4fe7-acb1-20fad851f60e" xlink:to="loc_us-gaap_CommonStockMember_ba505002-51f7-4479-bb99-cdfb2f90e0f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_07ffedef-791a-43b6-87f3-4b1547160bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_07ffedef-791a-43b6-87f3-4b1547160bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember_ca992c94-8b2b-4b6f-9c00-a3acb990dbcf" xlink:href="ino-20241231.xsd#ino_A2024SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_07ffedef-791a-43b6-87f3-4b1547160bd7" xlink:to="loc_ino_A2024SalesAgreementMember_ca992c94-8b2b-4b6f-9c00-a3acb990dbcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_2fa007e2-21fa-4d46-bdbf-c1c21d086843" xlink:href="ino-20241231.xsd#ino_A2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_07ffedef-791a-43b6-87f3-4b1547160bd7" xlink:to="loc_ino_A2021SalesAgreementMember_2fa007e2-21fa-4d46-bdbf-c1c21d086843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_9f122bf3-d3a3-404d-881a-998cff117c9d" xlink:href="ino-20241231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_9f122bf3-d3a3-404d-881a-998cff117c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_f3a8739c-da40-4ac5-a52c-b1dd1011f631" xlink:href="ino-20241231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_f3a8739c-da40-4ac5-a52c-b1dd1011f631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_2816cdaf-c1f6-49ca-b8ed-3e660765952c" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_2816cdaf-c1f6-49ca-b8ed-3e660765952c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_f406a868-230a-4c30-a589-3bc24ad16b65" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_f406a868-230a-4c30-a589-3bc24ad16b65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_dac649c0-e90a-439a-8ae0-52ba3a95eb3c" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_dac649c0-e90a-439a-8ae0-52ba3a95eb3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementRemainingCapacityAmount_9c5c13c9-b620-4f16-9f4d-500582b1adf2" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementRemainingCapacityAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSaleAgreementRemainingCapacityAmount_9c5c13c9-b620-4f16-9f4d-500582b1adf2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityOtherIssuancesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_97fd48fb-959e-4153-a995-3ad821f7a6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8a893fc2-3711-4ce2-8807-0f1a4dadd101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_97fd48fb-959e-4153-a995-3ad821f7a6a3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8a893fc2-3711-4ce2-8807-0f1a4dadd101" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8a893fc2-3711-4ce2-8807-0f1a4dadd101" xlink:to="loc_srt_LitigationCaseAxis_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d" xlink:to="loc_srt_LitigationCaseTypeDomain_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ac456234-074c-4e5e-a49c-664f1e9d7030" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d" xlink:to="loc_srt_LitigationCaseTypeDomain_ac456234-074c-4e5e-a49c-664f1e9d7030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_d3a4f092-dd15-4c8a-86cb-413028f2a7c9" xlink:href="ino-20241231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ac456234-074c-4e5e-a49c-664f1e9d7030" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_d3a4f092-dd15-4c8a-86cb-413028f2a7c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_0f33563c-a841-4ad5-b924-cb47f61cf702" xlink:href="ino-20241231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_97fd48fb-959e-4153-a995-3ad821f7a6a3" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_0f33563c-a841-4ad5-b924-cb47f61cf702" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c4d3dd89-0263-42cd-8727-4a9146e656da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_PlanNameAxis_c4d3dd89-0263-42cd-8727-4a9146e656da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c4d3dd89-0263-42cd-8727-4a9146e656da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c4d3dd89-0263-42cd-8727-4a9146e656da" xlink:to="loc_us-gaap_PlanNameDomain_c4d3dd89-0263-42cd-8727-4a9146e656da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c4d3dd89-0263-42cd-8727-4a9146e656da" xlink:to="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember_562d2d7b-ae74-4df9-8bdc-86c21571c276" xlink:href="ino-20241231.xsd#ino_A2023IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:to="loc_ino_A2023IncentivePlanMember_562d2d7b-ae74-4df9-8bdc-86c21571c276" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_7b855453-3e30-4d03-ba67-956db3bf704a" xlink:href="ino-20241231.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:to="loc_ino_A2016IncentivePlanMember_7b855453-3e30-4d03-ba67-956db3bf704a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_11c8e31d-bb30-41ec-9601-a6e92e044fef" xlink:href="ino-20241231.xsd#ino_A2022InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:to="loc_ino_A2022InducementPlanMember_11c8e31d-bb30-41ec-9601-a6e92e044fef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_9003e9d3-b301-441e-a9db-369dc9c2dec2" xlink:href="ino-20241231.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:to="loc_ino_A2007IncentivePlanMember_9003e9d3-b301-441e-a9db-369dc9c2dec2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_abbbacb9-777f-421f-a352-9511edf3d40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_abbbacb9-777f-421f-a352-9511edf3d40e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_abbbacb9-777f-421f-a352-9511edf3d40e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abbbacb9-777f-421f-a352-9511edf3d40e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_abbbacb9-777f-421f-a352-9511edf3d40e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_284e43ae-ec72-4398-b70c-93dc3e505ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abbbacb9-777f-421f-a352-9511edf3d40e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_284e43ae-ec72-4398-b70c-93dc3e505ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9589808c-a08c-41cb-952d-6cb71f6c4d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_284e43ae-ec72-4398-b70c-93dc3e505ad8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9589808c-a08c-41cb-952d-6cb71f6c4d83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1664602d-ca4a-4a54-8749-82e8ae02be4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_284e43ae-ec72-4398-b70c-93dc3e505ad8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1664602d-ca4a-4a54-8749-82e8ae02be4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d5fdba06-eb23-46f1-bd05-33708f0ba110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_AwardTypeAxis_d5fdba06-eb23-46f1-bd05-33708f0ba110" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5fdba06-eb23-46f1-bd05-33708f0ba110_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d5fdba06-eb23-46f1-bd05-33708f0ba110" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5fdba06-eb23-46f1-bd05-33708f0ba110_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc542369-5ee1-4f7f-8929-135c60e95f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d5fdba06-eb23-46f1-bd05-33708f0ba110" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc542369-5ee1-4f7f-8929-135c60e95f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_df4b7161-9d39-46e9-a3d5-b3d41516da8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc542369-5ee1-4f7f-8929-135c60e95f3c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_df4b7161-9d39-46e9-a3d5-b3d41516da8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_2e820429-27f8-4ddb-9fef-96d2873f45cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_GranteeStatusAxis_2e820429-27f8-4ddb-9fef-96d2873f45cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_2e820429-27f8-4ddb-9fef-96d2873f45cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_2e820429-27f8-4ddb-9fef-96d2873f45cf" xlink:to="loc_us-gaap_GranteeStatusDomain_2e820429-27f8-4ddb-9fef-96d2873f45cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_decc0077-cfd7-48f6-882c-f611dc3f1555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_2e820429-27f8-4ddb-9fef-96d2873f45cf" xlink:to="loc_us-gaap_GranteeStatusDomain_decc0077-cfd7-48f6-882c-f611dc3f1555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d80f79eb-000d-4025-b060-3cb86c595964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_decc0077-cfd7-48f6-882c-f611dc3f1555" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d80f79eb-000d-4025-b060-3cb86c595964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1c9e19cd-4405-40b5-9004-4c0e09a83574" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_srt_TitleOfIndividualAxis_1c9e19cd-4405-40b5-9004-4c0e09a83574" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1c9e19cd-4405-40b5-9004-4c0e09a83574_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1c9e19cd-4405-40b5-9004-4c0e09a83574" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1c9e19cd-4405-40b5-9004-4c0e09a83574_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_caaf07ea-b872-424c-ba1e-76ebd9d43e7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1c9e19cd-4405-40b5-9004-4c0e09a83574" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_caaf07ea-b872-424c-ba1e-76ebd9d43e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_a24cea8c-ef8a-41d8-9a09-d217c7615366" xlink:href="ino-20241231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_caaf07ea-b872-424c-ba1e-76ebd9d43e7c" xlink:to="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_a24cea8c-ef8a-41d8-9a09-d217c7615366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5e814f1b-7ffd-40f6-b55d-6861fae701b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5e814f1b-7ffd-40f6-b55d-6861fae701b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e34d5402-2c5e-43ad-8787-fecb3aa2b616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e34d5402-2c5e-43ad-8787-fecb3aa2b616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9759e43c-3219-4beb-8b81-f8e4ad6e9c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9759e43c-3219-4beb-8b81-f8e4ad6e9c59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_1f38c3a1-c8c1-447e-99c4-9701da417899" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_1f38c3a1-c8c1-447e-99c4-9701da417899" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19305917-93d1-44fa-b852-ea7180daf7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19305917-93d1-44fa-b852-ea7180daf7a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_6bf488de-cc9a-453e-88ea-3662683274ce" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_6bf488de-cc9a-453e-88ea-3662683274ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_fcf6dd89-89d0-4ab3-a55d-915bcf815382" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_fcf6dd89-89d0-4ab3-a55d-915bcf815382" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_c29bc600-098e-4988-ac1e-09e68fe00517" xlink:href="ino-20241231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_c29bc600-098e-4988-ac1e-09e68fe00517" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_474f04b3-94d1-412b-b720-53d09eac2dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_474f04b3-94d1-412b-b720-53d09eac2dfd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_aa461e30-a8e8-499f-9e3f-d9ca2793c67d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_aa461e30-a8e8-499f-9e3f-d9ca2793c67d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9911cfb8-7a34-4b0b-b309-98588e2bd55b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9911cfb8-7a34-4b0b-b309-98588e2bd55b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c1204a80-24b9-4e5b-a0d7-c8a2b17fd119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c1204a80-24b9-4e5b-a0d7-c8a2b17fd119" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_993a1e16-d6e4-4c7e-beac-a56c6c4009a1" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_993a1e16-d6e4-4c7e-beac-a56c6c4009a1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ab9ddc33-3f9b-472d-868b-27085429369b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ab9ddc33-3f9b-472d-868b-27085429369b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_b1e33187-7164-4135-8aa8-50db16b44830" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_b1e33187-7164-4135-8aa8-50db16b44830" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c1a1b8d0-3f8c-4102-a9ca-727defe55b61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c1a1b8d0-3f8c-4102-a9ca-727defe55b61" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_8ae90322-dacc-447b-9cc9-89e18f3e8016" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_8ae90322-dacc-447b-9cc9-89e18f3e8016" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_f982ef75-bff1-4d23-b503-dbc8f3b7dd43" xlink:href="ino-20241231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_f982ef75-bff1-4d23-b503-dbc8f3b7dd43" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_cd4df652-f667-4a8a-bf1c-47519f088bba" xlink:href="ino-20241231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_cd4df652-f667-4a8a-bf1c-47519f088bba" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9a21c5ef-0c5a-41b9-842b-432f5cf7c843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9a21c5ef-0c5a-41b9-842b-432f5cf7c843" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_29f95a36-74ef-45ae-9e2a-67b2efe7f3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_29f95a36-74ef-45ae-9e2a-67b2efe7f3f0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80efbff4-9bb9-412a-943f-6210ab730fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80efbff4-9bb9-412a-943f-6210ab730fb6" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d23564e-4e3f-4a19-a8bb-490b971eb044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d23564e-4e3f-4a19-a8bb-490b971eb044" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5092729d-4085-468b-952b-2647434d73e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5092729d-4085-468b-952b-2647434d73e3" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_446e8569-142c-42ee-98cc-5a8746d7dd34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_446e8569-142c-42ee-98cc-5a8746d7dd34" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityScheduleofStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_2ff993c5-9736-4a87-a9ab-67fb1b42e84e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_2ff993c5-9736-4a87-a9ab-67fb1b42e84e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ddbf9300-da76-43ab-862d-66a580f69a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_2ff993c5-9736-4a87-a9ab-67fb1b42e84e" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ddbf9300-da76-43ab-862d-66a580f69a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ddbf9300-da76-43ab-862d-66a580f69a87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ddbf9300-da76-43ab-862d-66a580f69a87" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ddbf9300-da76-43ab-862d-66a580f69a87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ddbf9300-da76-43ab-862d-66a580f69a87" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_9495474b-8ee2-4db2-83a4-829c167b4fca" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesOneMember_9495474b-8ee2-4db2-83a4-829c167b4fca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_2a57b4a5-89a1-42af-b531-9c8be99cee6a" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_2a57b4a5-89a1-42af-b531-9c8be99cee6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_10651bf4-9cd9-4e8a-a4bf-ec14aa4141eb" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_10651bf4-9cd9-4e8a-a4bf-ec14aa4141eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_12a7ad72-5f81-415a-a106-2267f1abfdec" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesFourMember_12a7ad72-5f81-415a-a106-2267f1abfdec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_85dfbf36-acda-4f63-942d-873164d294db" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_85dfbf36-acda-4f63-942d-873164d294db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_801becf8-06c9-469e-b9a0-10e9ba4efd32" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesSixMember_801becf8-06c9-469e-b9a0-10e9ba4efd32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_42997676-b902-4ad0-b37c-d2b4cb5ef09e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_42997676-b902-4ad0-b37c-d2b4cb5ef09e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_26600a6d-efab-4cc1-bf10-bc3fd5633dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_26600a6d-efab-4cc1-bf10-bc3fd5633dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_bda3848a-e8d5-4506-841b-477883912148" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_bda3848a-e8d5-4506-841b-477883912148" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7514be6f-9c86-40f3-8805-d3b42ff5bc57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7514be6f-9c86-40f3-8805-d3b42ff5bc57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2660228a-0fad-470f-8c75-7dbc4692a32c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2660228a-0fad-470f-8c75-7dbc4692a32c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_db36f7d3-868b-4138-a219-aef5a594992d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_db36f7d3-868b-4138-a219-aef5a594992d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_298fa958-6561-4ce5-b921-86ac94123752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_298fa958-6561-4ce5-b921-86ac94123752" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa495bc6-1774-4f40-89a9-53ae2980da84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab56be9d-c34f-498d-bcb0-f61269ea768a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa495bc6-1774-4f40-89a9-53ae2980da84" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab56be9d-c34f-498d-bcb0-f61269ea768a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e47a353-85b6-46f6-b8e9-f8764ed014a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab56be9d-c34f-498d-bcb0-f61269ea768a" xlink:to="loc_us-gaap_AwardTypeAxis_7e47a353-85b6-46f6-b8e9-f8764ed014a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e47a353-85b6-46f6-b8e9-f8764ed014a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7e47a353-85b6-46f6-b8e9-f8764ed014a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e47a353-85b6-46f6-b8e9-f8764ed014a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81205044-58c9-42cb-b1b7-db63c6312370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7e47a353-85b6-46f6-b8e9-f8764ed014a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81205044-58c9-42cb-b1b7-db63c6312370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0a7f0942-a594-4a77-b8be-78495063bba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81205044-58c9-42cb-b1b7-db63c6312370" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0a7f0942-a594-4a77-b8be-78495063bba3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa495bc6-1774-4f40-89a9-53ae2980da84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0c662923-4a47-4755-bf83-0eeb741c89d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0c662923-4a47-4755-bf83-0eeb741c89d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82d4af3a-c906-4272-9f8b-3ceae4d24a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82d4af3a-c906-4272-9f8b-3ceae4d24a4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_524adb5b-79b1-4c97-9091-a4bc5be1adca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_524adb5b-79b1-4c97-9091-a4bc5be1adca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_27a94619-8bce-475b-b7a0-7696538b39f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_27a94619-8bce-475b-b7a0-7696538b39f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a6869cc-62e8-4a40-b477-d86f1ee2ad62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15575da6-823e-47bd-a644-d12acc4a5edb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15575da6-823e-47bd-a644-d12acc4a5edb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83751d2f-bc5e-4824-9396-a1f260221102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15575da6-823e-47bd-a644-d12acc4a5edb" xlink:to="loc_us-gaap_AwardTypeAxis_83751d2f-bc5e-4824-9396-a1f260221102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83751d2f-bc5e-4824-9396-a1f260221102_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_83751d2f-bc5e-4824-9396-a1f260221102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_83751d2f-bc5e-4824-9396-a1f260221102_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d62217b5-8091-4d61-84b5-0498194b4506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_83751d2f-bc5e-4824-9396-a1f260221102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d62217b5-8091-4d61-84b5-0498194b4506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_cab2ac69-6e42-447c-8634-73a7b3ee60ea" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d62217b5-8091-4d61-84b5-0498194b4506" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_cab2ac69-6e42-447c-8634-73a7b3ee60ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b81c71a0-7939-4fd7-b6a6-0139226a5fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b81c71a0-7939-4fd7-b6a6-0139226a5fdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d7ef528c-3f68-4931-a6c0-58b45cd2e87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d7ef528c-3f68-4931-a6c0-58b45cd2e87e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8e75b641-516b-4bf7-bb1c-6d6ea2307595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8e75b641-516b-4bf7-bb1c-6d6ea2307595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24de2a34-c644-4cdf-bf20-65fcd9a10633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24de2a34-c644-4cdf-bf20-65fcd9a10633" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityPerformanceandMarketBasedRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d696954-eff2-4e49-8c69-be243611f510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:to="loc_us-gaap_AwardTypeAxis_5d696954-eff2-4e49-8c69-be243611f510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d696954-eff2-4e49-8c69-be243611f510_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5d696954-eff2-4e49-8c69-be243611f510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d696954-eff2-4e49-8c69-be243611f510_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5d696954-eff2-4e49-8c69-be243611f510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8988747b-3610-4c9d-a667-7a9b1b195b99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:to="loc_us-gaap_PerformanceSharesMember_8988747b-3610-4c9d-a667-7a9b1b195b99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fa18a5e3-0667-410f-a262-8f77702774c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fa18a5e3-0667-410f-a262-8f77702774c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_3a24ea04-f1b4-488f-831a-bd1bcc131fc7" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_3a24ea04-f1b4-488f-831a-bd1bcc131fc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_b18c7b6d-17f1-4cf7-a450-feadd202d62d" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:to="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_b18c7b6d-17f1-4cf7-a450-feadd202d62d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_2567123c-b8d1-498c-a6cf-c60c782c3ea5" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_2567123c-b8d1-498c-a6cf-c60c782c3ea5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_2567123c-b8d1-498c-a6cf-c60c782c3ea5_default" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_2567123c-b8d1-498c-a6cf-c60c782c3ea5" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_2567123c-b8d1-498c-a6cf-c60c782c3ea5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_2567123c-b8d1-498c-a6cf-c60c782c3ea5" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsSpecifiedThresholdPercentileMember_b54aa8bd-d65f-4ce7-87bd-2772dc0a9f5b" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsSpecifiedThresholdPercentileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:to="loc_ino_PerformanceRSUsSpecifiedThresholdPercentileMember_b54aa8bd-d65f-4ce7-87bd-2772dc0a9f5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsTargetPercentileMember_7309a99a-cbd4-409f-b8aa-24df438a5833" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsTargetPercentileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:to="loc_ino_PerformanceRSUsTargetPercentileMember_7309a99a-cbd4-409f-b8aa-24df438a5833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsSpecifiedMaximumPercentileMember_265abd3d-df30-4097-8df7-57dad98911ab" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsSpecifiedMaximumPercentileMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:to="loc_ino_PerformanceRSUsSpecifiedMaximumPercentileMember_265abd3d-df30-4097-8df7-57dad98911ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_71208795-32fa-4346-ba73-ad3e8f6d619d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:to="loc_srt_RangeAxis_71208795-32fa-4346-ba73-ad3e8f6d619d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_71208795-32fa-4346-ba73-ad3e8f6d619d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_71208795-32fa-4346-ba73-ad3e8f6d619d" xlink:to="loc_srt_RangeMember_71208795-32fa-4346-ba73-ad3e8f6d619d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b00cb8eb-2779-4429-8bd5-2c3042727056" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_71208795-32fa-4346-ba73-ad3e8f6d619d" xlink:to="loc_srt_RangeMember_b00cb8eb-2779-4429-8bd5-2c3042727056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37e20f09-8107-46fe-a15d-7f42efa1b419" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b00cb8eb-2779-4429-8bd5-2c3042727056" xlink:to="loc_srt_MinimumMember_37e20f09-8107-46fe-a15d-7f42efa1b419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05f12a49-3250-48ff-baee-c2ac35f64829" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b00cb8eb-2779-4429-8bd5-2c3042727056" xlink:to="loc_srt_MaximumMember_05f12a49-3250-48ff-baee-c2ac35f64829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d41e588b-5aa3-4121-bef7-f67a08a0cf50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d41e588b-5aa3-4121-bef7-f67a08a0cf50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased_af3de1a5-42d4-4a6d-bdac-773b49919687" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased_af3de1a5-42d4-4a6d-bdac-773b49919687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased_1875d179-b217-43ba-85b6-87be69e64d77" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased_1875d179-b217-43ba-85b6-87be69e64d77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_6df1edda-29b1-4df6-a641-4b27eec66334" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_6df1edda-29b1-4df6-a641-4b27eec66334" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d8c281c0-7b92-4922-b945-1131820e880b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d8c281c0-7b92-4922-b945-1131820e880b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards_a7d50adf-438a-42af-80dd-6072766f4bc6" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards_a7d50adf-438a-42af-80dd-6072766f4bc6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_97d36d60-116f-4830-8feb-e5490e288720" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_97d36d60-116f-4830-8feb-e5490e288720" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59d806ea-dbf6-4e71-af2c-a5a1fc5cc84e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59d806ea-dbf6-4e71-af2c-a5a1fc5cc84e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e2c74aee-560b-4ef6-a6aa-0212f917dc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e2c74aee-560b-4ef6-a6aa-0212f917dc1e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityDecember2024PerformanceBasedAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:to="loc_us-gaap_AwardTypeAxis_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b595ba49-a153-4361-9424-a2cd91959905" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b595ba49-a153-4361-9424-a2cd91959905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e71ea2f0-9683-47b0-83eb-6ec8bbfc29ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e71ea2f0-9683-47b0-83eb-6ec8bbfc29ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsPerformanceBasedMember_9cb19694-9469-43f8-aa0b-e164d1e2eab0" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:to="loc_ino_RestrictedStockUnitsPerformanceBasedMember_9cb19694-9469-43f8-aa0b-e164d1e2eab0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockOptionsPerformanceBasedMember_7fc3c4c5-200e-4614-ba1c-49317c1ad87a" xlink:href="ino-20241231.xsd#ino_StockOptionsPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:to="loc_ino_StockOptionsPerformanceBasedMember_7fc3c4c5-200e-4614-ba1c-49317c1ad87a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_890f81b2-8473-40d6-8d4d-4c2013a4ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:to="loc_us-gaap_AwardDateAxis_890f81b2-8473-40d6-8d4d-4c2013a4ce26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_890f81b2-8473-40d6-8d4d-4c2013a4ce26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_890f81b2-8473-40d6-8d4d-4c2013a4ce26" xlink:to="loc_us-gaap_AwardDateDomain_890f81b2-8473-40d6-8d4d-4c2013a4ce26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_467266ed-b599-4692-9622-53d79b99dc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_890f81b2-8473-40d6-8d4d-4c2013a4ce26" xlink:to="loc_us-gaap_AwardDateDomain_467266ed-b599-4692-9622-53d79b99dc5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024Member_0c600f6d-1d58-4eb5-905e-dc7c0b8f780c" xlink:href="ino-20241231.xsd#ino_December2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_467266ed-b599-4692-9622-53d79b99dc5b" xlink:to="loc_ino_December2024Member_0c600f6d-1d58-4eb5-905e-dc7c0b8f780c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_c7e7c868-572a-46fd-9ac8-0e864ffa8f29" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_c7e7c868-572a-46fd-9ac8-0e864ffa8f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_fb71e937-a8e6-4cbf-99ef-857bc8556005" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_fb71e937-a8e6-4cbf-99ef-857bc8556005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_11429a60-f3e2-4884-b889-c9101558a1e0" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_11429a60-f3e2-4884-b889-c9101558a1e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34bf4c61-dd2f-404e-a3b8-87e1088aeac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34bf4c61-dd2f-404e-a3b8-87e1088aeac5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6bcbc4d6-cc20-4a2a-8cca-e361652bcc97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6bcbc4d6-cc20-4a2a-8cca-e361652bcc97" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ca43fa81-25d1-437e-b844-84a8b9138000" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ca43fa81-25d1-437e-b844-84a8b9138000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ca43fa81-25d1-437e-b844-84a8b9138000_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ca43fa81-25d1-437e-b844-84a8b9138000" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ca43fa81-25d1-437e-b844-84a8b9138000_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_123589f4-c147-4a09-8e12-48f1c546e3a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ca43fa81-25d1-437e-b844-84a8b9138000" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_123589f4-c147-4a09-8e12-48f1c546e3a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_ca697f05-7f36-439c-9230-997b33b5568b" xlink:href="ino-20241231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_123589f4-c147-4a09-8e12-48f1c546e3a0" xlink:to="loc_ino_SanDiegoCaliforniaMember_ca697f05-7f36-439c-9230-997b33b5568b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_0cf3df32-0261-4237-b952-84c9e919dbc0" xlink:href="ino-20241231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_123589f4-c147-4a09-8e12-48f1c546e3a0" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_0cf3df32-0261-4237-b952-84c9e919dbc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7f19be1-794d-4272-9d46-160db75190cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:to="loc_srt_RangeAxis_a7f19be1-794d-4272-9d46-160db75190cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7f19be1-794d-4272-9d46-160db75190cc_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a7f19be1-794d-4272-9d46-160db75190cc" xlink:to="loc_srt_RangeMember_a7f19be1-794d-4272-9d46-160db75190cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a1591e71-2d23-4125-a2a1-9854832cebb9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a7f19be1-794d-4272-9d46-160db75190cc" xlink:to="loc_srt_RangeMember_a1591e71-2d23-4125-a2a1-9854832cebb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9be195f7-fa32-45a7-b6f2-43f4eac5cb49" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a1591e71-2d23-4125-a2a1-9854832cebb9" xlink:to="loc_srt_MinimumMember_9be195f7-fa32-45a7-b6f2-43f4eac5cb49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c8453c3-8521-4c31-ab18-53b8ac10a2a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a1591e71-2d23-4125-a2a1-9854832cebb9" xlink:to="loc_srt_MaximumMember_2c8453c3-8521-4c31-ab18-53b8ac10a2a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_aba7fd64-6696-4868-aa8d-d477736b5047" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:to="loc_srt_LitigationCaseAxis_aba7fd64-6696-4868-aa8d-d477736b5047" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aba7fd64-6696-4868-aa8d-d477736b5047_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_aba7fd64-6696-4868-aa8d-d477736b5047" xlink:to="loc_srt_LitigationCaseTypeDomain_aba7fd64-6696-4868-aa8d-d477736b5047_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bc3a8ff6-e10e-4d42-8170-d6ba11e76b40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_aba7fd64-6696-4868-aa8d-d477736b5047" xlink:to="loc_srt_LitigationCaseTypeDomain_bc3a8ff6-e10e-4d42-8170-d6ba11e76b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c9c5b4d3-e385-4276-b798-53d6413eb989" xlink:href="ino-20241231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_bc3a8ff6-e10e-4d42-8170-d6ba11e76b40" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c9c5b4d3-e385-4276-b798-53d6413eb989" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember_fffe6922-4ad1-4fd7-b657-faed74de2f1d" xlink:href="ino-20241231.xsd#ino_BehestiVKimEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_bc3a8ff6-e10e-4d42-8170-d6ba11e76b40" xlink:to="loc_ino_BehestiVKimEtAlMember_fffe6922-4ad1-4fd7-b657-faed74de2f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4802fc66-4c1c-4901-b16f-47afde28043b" xlink:href="ino-20241231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4802fc66-4c1c-4901-b16f-47afde28043b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_3258c34a-18da-43b7-8a2f-23e8a73d4503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_3258c34a-18da-43b7-8a2f-23e8a73d4503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_fedf6d98-6156-4217-81d8-4c2f9df4dd5e" xlink:href="ino-20241231.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_fedf6d98-6156-4217-81d8-4c2f9df4dd5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9f07eb64-b9a5-4cdd-896e-b3b3e44726dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LeaseCost_9f07eb64-b9a5-4cdd-896e-b3b3e44726dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_da04529f-b833-4aac-885a-4a1570c4f93c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_da04529f-b833-4aac-885a-4a1570c4f93c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_fccbe0e9-dc6c-4fce-9092-3e195e0232ed" xlink:href="ino-20241231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_fccbe0e9-dc6c-4fce-9092-3e195e0232ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_e32b1532-3a72-40fb-ae87-3f0bb65eafee" xlink:href="ino-20241231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_e32b1532-3a72-40fb-ae87-3f0bb65eafee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_8ad793d4-8fff-40f4-a0d0-c095581b9030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_8ad793d4-8fff-40f4-a0d0-c095581b9030" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_474bd446-92c8-40e7-b6cd-b68583ffd91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_474bd446-92c8-40e7-b6cd-b68583ffd91d" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_84824232-728c-458a-bcd8-d657c4b78525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_84824232-728c-458a-bcd8-d657c4b78525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_84824232-728c-458a-bcd8-d657c4b78525_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_84824232-728c-458a-bcd8-d657c4b78525" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_84824232-728c-458a-bcd8-d657c4b78525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_84824232-728c-458a-bcd8-d657c4b78525" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_8a4f9074-339e-4209-88d5-6d01e7aaab69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_8a4f9074-339e-4209-88d5-6d01e7aaab69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_7c2bae79-11ca-4a8a-a2b3-ad789528f042" xlink:href="ino-20241231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_7c2bae79-11ca-4a8a-a2b3-ad789528f042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_b2a6ccf8-7467-43a2-944b-5143c1c0d690" xlink:href="ino-20241231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_b2a6ccf8-7467-43a2-944b-5143c1c0d690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_b84553bb-7a05-4f3a-b788-366afe6a689b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_us-gaap_DomesticCountryMember_b84553bb-7a05-4f3a-b788-366afe6a689b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_7be40439-54fd-4c67-9e26-3cd9e7c96d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_us-gaap_ForeignCountryMember_7be40439-54fd-4c67-9e26-3cd9e7c96d98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4af53d04-7827-459d-9fac-406869392261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4af53d04-7827-459d-9fac-406869392261" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_d73cc8a8-4115-4050-ba58-23ef9fa4c476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_d73cc8a8-4115-4050-ba58-23ef9fa4c476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d73cc8a8-4115-4050-ba58-23ef9fa4c476_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d73cc8a8-4115-4050-ba58-23ef9fa4c476" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d73cc8a8-4115-4050-ba58-23ef9fa4c476_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c4d4014e-9d05-47ba-be14-7c0f418b8aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d73cc8a8-4115-4050-ba58-23ef9fa4c476" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c4d4014e-9d05-47ba-be14-7c0f418b8aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_d4af3cf3-342f-4b35-b3f5-e766567d7803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_c4d4014e-9d05-47ba-be14-7c0f418b8aca" xlink:to="loc_us-gaap_ResearchMember_d4af3cf3-342f-4b35-b3f5-e766567d7803" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6e28e8b4-5cc8-4fa5-9433-e6ff208092cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6e28e8b4-5cc8-4fa5-9433-e6ff208092cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_6d64ca80-d827-46d6-9af5-d48e4b56edd9" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_6d64ca80-d827-46d6-9af5-d48e4b56edd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_89f5cd71-f18f-42cf-bdbc-ef77ebe7da51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_OperatingLossCarryforwards_89f5cd71-f18f-42cf-bdbc-ef77ebe7da51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d30e3c98-833f-4185-89f0-af1e753d200f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d30e3c98-833f-4185-89f0-af1e753d200f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_6122aaaa-e088-4b5b-bc35-a7e89a7b6601" xlink:href="ino-20241231.xsd#ino_TaxBenefitsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_ino_TaxBenefitsExpired_6122aaaa-e088-4b5b-bc35-a7e89a7b6601" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cc7f200a-733f-4a22-8d45-424b4d0403b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cc7f200a-733f-4a22-8d45-424b4d0403b2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_85e3dbc5-0bd3-4d29-8747-93745482d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_85e3dbc5-0bd3-4d29-8747-93745482d3c0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_3ff9906d-887e-4c9f-993a-632fca2f4452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_3ff9906d-887e-4c9f-993a-632fca2f4452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3ff9906d-887e-4c9f-993a-632fca2f4452_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3ff9906d-887e-4c9f-993a-632fca2f4452" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3ff9906d-887e-4c9f-993a-632fca2f4452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ded5cf43-e6ff-4c95-a783-748a8348686f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3ff9906d-887e-4c9f-993a-632fca2f4452" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ded5cf43-e6ff-4c95-a783-748a8348686f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_496bcff3-d11a-48d4-8203-7906a5e97bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ded5cf43-e6ff-4c95-a783-748a8348686f" xlink:to="loc_us-gaap_ResearchMember_496bcff3-d11a-48d4-8203-7906a5e97bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_897074cd-5aaf-4bda-9db6-5ff1a98d10fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_897074cd-5aaf-4bda-9db6-5ff1a98d10fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_897074cd-5aaf-4bda-9db6-5ff1a98d10fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_897074cd-5aaf-4bda-9db6-5ff1a98d10fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_897074cd-5aaf-4bda-9db6-5ff1a98d10fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_897074cd-5aaf-4bda-9db6-5ff1a98d10fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_aa0eace8-b7e8-4278-8770-480083900bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:to="loc_us-gaap_DomesticCountryMember_aa0eace8-b7e8-4278-8770-480083900bcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a7147028-2714-4baa-a6f2-1d792f9c3ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a7147028-2714-4baa-a6f2-1d792f9c3ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_83d492be-374c-4105-8c79-3d83a7d296d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:to="loc_us-gaap_ForeignCountryMember_83d492be-374c-4105-8c79-3d83a7d296d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_85e3dbc5-0bd3-4d29-8747-93745482d3c0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_8f2b9fdd-59fb-434c-a05f-9d7c1611fb00" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringInNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_8f2b9fdd-59fb-434c-a05f-9d7c1611fb00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_7a5d300f-4a5e-44b5-80c3-0d418f2bcb0f" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_7a5d300f-4a5e-44b5-80c3-0d418f2bcb0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_8a2754da-27e6-443a-8b91-b0b71424bac7" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_8a2754da-27e6-443a-8b91-b0b71424bac7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_0760ee5b-5021-478b-84cd-b7d53f70b7ef" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_0760ee5b-5021-478b-84cd-b7d53f70b7ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_4ecfa24f-9067-45b6-9489-3c5c36473c87" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_4ecfa24f-9067-45b6-9489-3c5c36473c87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ee9e4cbe-598b-4396-b31e-aad22d3b5b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ee9e4cbe-598b-4396-b31e-aad22d3b5b68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_85e3dbc5-0bd3-4d29-8747-93745482d3c0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_1ed2175a-ca6c-4859-9542-23699758df06" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_1ed2175a-ca6c-4859-9542-23699758df06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_f8b85dd7-6d2b-4211-9be6-a81bbd1bbb24" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_f8b85dd7-6d2b-4211-9be6-a81bbd1bbb24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_85bcc3e0-e51e-4aad-a552-abdfc0883814" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_85bcc3e0-e51e-4aad-a552-abdfc0883814" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_70bae01c-4da8-4387-96e4-83b8fa1cfd48" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_70bae01c-4da8-4387-96e4-83b8fa1cfd48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_52414470-baa9-4043-a5c2-67b65d176209" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_52414470-baa9-4043-a5c2-67b65d176209" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_789455d3-e364-4655-a239-27815a08cf11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_789455d3-e364-4655-a239-27815a08cf11" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_64b57950-73d6-47e4-966c-735e5b53eba2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:to="loc_srt_OwnershipAxis_64b57950-73d6-47e4-966c-735e5b53eba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_64b57950-73d6-47e4-966c-735e5b53eba2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_64b57950-73d6-47e4-966c-735e5b53eba2" xlink:to="loc_srt_OwnershipDomain_64b57950-73d6-47e4-966c-735e5b53eba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ffbdb11b-fb97-4ae3-ba2f-d9cbafcc9658" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_64b57950-73d6-47e4-966c-735e5b53eba2" xlink:to="loc_srt_OwnershipDomain_ffbdb11b-fb97-4ae3-ba2f-d9cbafcc9658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_7fd08598-5e1c-4311-87e8-ddaac2a38eb3" xlink:href="ino-20241231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ffbdb11b-fb97-4ae3-ba2f-d9cbafcc9658" xlink:to="loc_ino_PlumblineLifeSciencesMember_7fd08598-5e1c-4311-87e8-ddaac2a38eb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6156eada-1455-4188-9b81-5d4edca6fed0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:to="loc_srt_CounterpartyNameAxis_6156eada-1455-4188-9b81-5d4edca6fed0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6156eada-1455-4188-9b81-5d4edca6fed0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6156eada-1455-4188-9b81-5d4edca6fed0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6156eada-1455-4188-9b81-5d4edca6fed0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722af4d1-bafd-4cf0-9693-923c56d358ea" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6156eada-1455-4188-9b81-5d4edca6fed0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722af4d1-bafd-4cf0-9693-923c56d358ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_5348cf63-961d-4d8c-9361-7dedaed69419" xlink:href="ino-20241231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722af4d1-bafd-4cf0-9693-923c56d358ea" xlink:to="loc_ino_PlumblineLifeSciencesMember_5348cf63-961d-4d8c-9361-7dedaed69419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_56ebfc6e-978b-4440-a876-4a034790448a" xlink:href="ino-20241231.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722af4d1-bafd-4cf0-9693-923c56d358ea" xlink:to="loc_ino_TheWistarInstituteMember_56ebfc6e-978b-4440-a876-4a034790448a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6b4abfe-d907-4aae-9887-11d391927f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6b4abfe-d907-4aae-9887-11d391927f1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f6b4abfe-d907-4aae-9887-11d391927f1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6b4abfe-d907-4aae-9887-11d391927f1b" xlink:to="loc_us-gaap_RelatedPartyDomain_f6b4abfe-d907-4aae-9887-11d391927f1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a5b7726f-2e53-433b-aae1-34037e66f06d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6b4abfe-d907-4aae-9887-11d391927f1b" xlink:to="loc_us-gaap_RelatedPartyDomain_a5b7726f-2e53-433b-aae1-34037e66f06d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_3be7073c-0489-4c12-9ac6-b7f628a01cc7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a5b7726f-2e53-433b-aae1-34037e66f06d" xlink:to="loc_srt_AffiliatedEntityMember_3be7073c-0489-4c12-9ac6-b7f628a01cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_63569ab8-5715-4d68-95d8-65a39324ede0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_63569ab8-5715-4d68-95d8-65a39324ede0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_756812bd-1be8-40c7-be31-c3154125727f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_756812bd-1be8-40c7-be31-c3154125727f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6b4f2486-5188-472d-a2fa-67acacf07601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6b4f2486-5188-472d-a2fa-67acacf07601" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_91a29f16-1592-4042-990a-7975eb7b3821" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_91a29f16-1592-4042-990a-7975eb7b3821" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_179635c9-c2c5-499c-b7c2-f7813b045f80" xlink:href="ino-20241231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeArrangementTerm_179635c9-c2c5-499c-b7c2-f7813b045f80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_143a9a8f-1f89-44ac-895c-29e91f9c1931" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_143a9a8f-1f89-44ac-895c-29e91f9c1931" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_60b3a835-9388-44f7-a1a7-bfcfd4d92308" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_60b3a835-9388-44f7-a1a7-bfcfd4d92308" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_1d421e61-e969-4b6a-8ede-277908e3be7c" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_1d421e61-e969-4b6a-8ede-277908e3be7c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_5a8ff594-8308-40b5-914c-5dd5c17f772c" xlink:href="ino-20241231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_GrantProceedsReceived_5a8ff594-8308-40b5-914c-5dd5c17f772c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d0bcde58-ca12-4329-beba-43e2c9e060e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d0bcde58-ca12-4329-beba-43e2c9e060e3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_23dd8d6f-13eb-4f67-8195-e0ee80505bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_AccountsReceivableNet_23dd8d6f-13eb-4f67-8195-e0ee80505bde" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2302c4f6-cb16-45fa-919f-9a76947ddd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2302c4f6-cb16-45fa-919f-9a76947ddd1f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_e71d4633-dc7b-4f20-a163-75abc5be0989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_e71d4633-dc7b-4f20-a163-75abc5be0989" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_a6aafbcb-f750-4d67-ba0b-7f53ea6ad02b" xlink:href="ino-20241231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_a6aafbcb-f750-4d67-ba0b-7f53ea6ad02b" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_b3765188-a177-4b25-b25b-c4a45542d627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:to="loc_us-gaap_MinorityInterestTable_b3765188-a177-4b25-b25b-c4a45542d627" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_61104cad-0179-4c14-adea-6e7ac6c78b24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_b3765188-a177-4b25-b25b-c4a45542d627" xlink:to="loc_srt_OwnershipAxis_61104cad-0179-4c14-adea-6e7ac6c78b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_61104cad-0179-4c14-adea-6e7ac6c78b24_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_61104cad-0179-4c14-adea-6e7ac6c78b24" xlink:to="loc_srt_OwnershipDomain_61104cad-0179-4c14-adea-6e7ac6c78b24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e807611d-bfda-493c-9b47-f145d0c7b2a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_61104cad-0179-4c14-adea-6e7ac6c78b24" xlink:to="loc_srt_OwnershipDomain_e807611d-bfda-493c-9b47-f145d0c7b2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_ddf15cd1-6c0b-4890-97cc-4185631fc162" xlink:href="ino-20241231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e807611d-bfda-493c-9b47-f145d0c7b2a7" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_ddf15cd1-6c0b-4890-97cc-4185631fc162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d31978ef-df3c-4ab5-866d-a5a293977585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d31978ef-df3c-4ab5-866d-a5a293977585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a1d95c03-6682-4653-a865-e35de603d081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:to="loc_us-gaap_EquityMethodInvestments_a1d95c03-6682-4653-a865-e35de603d081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentsMinimum_117b4757-8694-4cd1-9773-afa356a09bd6" xlink:href="ino-20241231.xsd#ino_EquityMethodInvestmentsMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:to="loc_ino_EquityMethodInvestmentsMinimum_117b4757-8694-4cd1-9773-afa356a09bd6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_40cd6eaa-a26c-4aaf-a221-528a9971529c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_40cd6eaa-a26c-4aaf-a221-528a9971529c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_40cd6eaa-a26c-4aaf-a221-528a9971529c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_40cd6eaa-a26c-4aaf-a221-528a9971529c" xlink:to="loc_us-gaap_SegmentDomain_40cd6eaa-a26c-4aaf-a221-528a9971529c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2b1867f4-0ecd-46ee-af44-99abdf4a59b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_40cd6eaa-a26c-4aaf-a221-528a9971529c" xlink:to="loc_us-gaap_SegmentDomain_2b1867f4-0ecd-46ee-af44-99abdf4a59b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ReportableSegmentsMember_90bb59df-3eda-40f8-9f6a-6947ba6c25d6" xlink:href="ino-20241231.xsd#ino_ReportableSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2b1867f4-0ecd-46ee-af44-99abdf4a59b2" xlink:to="loc_ino_ReportableSegmentsMember_90bb59df-3eda-40f8-9f6a-6947ba6c25d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostAxis_1f18de6a-a570-43e6-9168-27ca96614e36" xlink:href="ino-20241231.xsd#ino_ResearchAndDevelopmentCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:to="loc_ino_ResearchAndDevelopmentCostAxis_1f18de6a-a570-43e6-9168-27ca96614e36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostDomain_1f18de6a-a570-43e6-9168-27ca96614e36_default" xlink:href="ino-20241231.xsd#ino_ResearchAndDevelopmentCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ino_ResearchAndDevelopmentCostAxis_1f18de6a-a570-43e6-9168-27ca96614e36" xlink:to="loc_ino_ResearchAndDevelopmentCostDomain_1f18de6a-a570-43e6-9168-27ca96614e36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:href="ino-20241231.xsd#ino_ResearchAndDevelopmentCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ino_ResearchAndDevelopmentCostAxis_1f18de6a-a570-43e6-9168-27ca96614e36" xlink:to="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3107Member_eb2aac7d-862d-448a-8d95-f2d4b15ea4a5" xlink:href="ino-20241231.xsd#ino_INO3107Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_INO3107Member_eb2aac7d-862d-448a-8d95-f2d4b15ea4a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO5401AndOtherImmunoOncologyMember_21dcb4a4-3a39-41c6-a34d-815a9f832e76" xlink:href="ino-20241231.xsd#ino_INO5401AndOtherImmunoOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_INO5401AndOtherImmunoOncologyMember_21dcb4a4-3a39-41c6-a34d-815a9f832e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherProgramsMember_3f670df8-e061-4eec-bd8d-d4d20d15c46a" xlink:href="ino-20241231.xsd#ino_OtherProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_OtherProgramsMember_3f670df8-e061-4eec-bd8d-d4d20d15c46a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EngineeringAndDeviceRelatedMember_12ccf775-c586-4e7f-8953-141a461efcd8" xlink:href="ino-20241231.xsd#ino_EngineeringAndDeviceRelatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_EngineeringAndDeviceRelatedMember_12ccf775-c586-4e7f-8953-141a461efcd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockBasedCompensationMember_47842eb7-e99f-45b3-9396-ecc56113e0f0" xlink:href="ino-20241231.xsd#ino_StockBasedCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_StockBasedCompensationMember_47842eb7-e99f-45b3-9396-ecc56113e0f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherUnallocatedExpensesMember_507ee646-66f5-4240-9aa3-8ba4cba93a8f" xlink:href="ino-20241231.xsd#ino_OtherUnallocatedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_OtherUnallocatedExpensesMember_507ee646-66f5-4240-9aa3-8ba4cba93a8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_255cc652-357f-4739-83b3-76d4be7634de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_255cc652-357f-4739-83b3-76d4be7634de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6203e7cb-1b6d-4d16-8723-1b5feece4bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6203e7cb-1b6d-4d16-8723-1b5feece4bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1374ccf0-d214-4d2d-a72a-c97936af81fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1374ccf0-d214-4d2d-a72a-c97936af81fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c489784c-d882-471c-83d0-31190c8c3966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c489784c-d882-471c-83d0-31190c8c3966" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_baffeb57-8fcf-4453-85cd-439ee623d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_baffeb57-8fcf-4453-85cd-439ee623d4bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9cd8e64f-f787-4877-867d-9d4f4d003b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_OperatingExpenses_9cd8e64f-f787-4877-867d-9d4f4d003b7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_028c9c82-84d2-4604-97af-8b4d7b567f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_InvestmentIncomeInterest_028c9c82-84d2-4604-97af-8b4d7b567f3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_481205b8-fa16-42d5-a1d2-17dd17c70cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_InterestExpenseNonoperating_481205b8-fa16-42d5-a1d2-17dd17c70cbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_f67bdb7c-9a5d-4951-a8fa-0b729ea7ccd0" xlink:href="ino-20241231.xsd#ino_ChangeInFairValueOfCommonStockWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_f67bdb7c-9a5d-4951-a8fa-0b729ea7ccd0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cadec33f-7d6a-4a63-984f-7f7657a02e28" xlink:href="ino-20241231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cadec33f-7d6a-4a63-984f-7f7657a02e28" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ffe6018e-fae1-4bba-99ed-392820f0f4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ffe6018e-fae1-4bba-99ed-392820f0f4cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_070c5dc1-7e6b-4136-a746-b5d5a2dd3249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_070c5dc1-7e6b-4136-a746-b5d5a2dd3249" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9d730eb-9e16-4468-af77-8aa97ca4d017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_NetIncomeLoss_a9d730eb-9e16-4468-af77-8aa97ca4d017" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_70805761-1d4f-44f6-a6cb-eab5935aa92f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_70805761-1d4f-44f6-a6cb-eab5935aa92f" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_97ed47c1-4028-49ac-8f97-c56316f5a19b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_DebtInstrumentAxis_97ed47c1-4028-49ac-8f97-c56316f5a19b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97ed47c1-4028-49ac-8f97-c56316f5a19b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_97ed47c1-4028-49ac-8f97-c56316f5a19b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_97ed47c1-4028-49ac-8f97-c56316f5a19b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_12221db3-041f-4853-bf6d-6ce1d79ea659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_97ed47c1-4028-49ac-8f97-c56316f5a19b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_12221db3-041f-4853-bf6d-6ce1d79ea659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_f73187b8-23d8-4395-bd71-74cb74f380ab" xlink:href="ino-20241231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_12221db3-041f-4853-bf6d-6ce1d79ea659" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_f73187b8-23d8-4395-bd71-74cb74f380ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_741adc70-c6fb-4136-96e0-a14e91a5e993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_741adc70-c6fb-4136-96e0-a14e91a5e993" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_741adc70-c6fb-4136-96e0-a14e91a5e993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_741adc70-c6fb-4136-96e0-a14e91a5e993" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_741adc70-c6fb-4136-96e0-a14e91a5e993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_887948f2-dd56-4849-8eca-6c13790161f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_741adc70-c6fb-4136-96e0-a14e91a5e993" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_887948f2-dd56-4849-8eca-6c13790161f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_77b89954-7000-482a-ad3c-ddfce7112c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_887948f2-dd56-4849-8eca-6c13790161f9" xlink:to="loc_us-gaap_ConvertibleDebtMember_77b89954-7000-482a-ad3c-ddfce7112c0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8b2b3be1-eb30-4fba-9c6b-bc7c44327329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8b2b3be1-eb30-4fba-9c6b-bc7c44327329" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8b2b3be1-eb30-4fba-9c6b-bc7c44327329_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b2b3be1-eb30-4fba-9c6b-bc7c44327329" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8b2b3be1-eb30-4fba-9c6b-bc7c44327329_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_abbb47e8-a7cd-4257-b096-f515b8d9fcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b2b3be1-eb30-4fba-9c6b-bc7c44327329" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_abbb47e8-a7cd-4257-b096-f515b8d9fcc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5c2e955d-5d3c-4f1d-b653-aafe006741e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_abbb47e8-a7cd-4257-b096-f515b8d9fcc0" xlink:to="loc_us-gaap_SubsequentEventMember_5c2e955d-5d3c-4f1d-b653-aafe006741e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_811199b7-e54c-4341-a822-f9cc517326f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_811199b7-e54c-4341-a822-f9cc517326f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_811199b7-e54c-4341-a822-f9cc517326f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_811199b7-e54c-4341-a822-f9cc517326f9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_811199b7-e54c-4341-a822-f9cc517326f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647988cd-28c3-4c90-92b6-3e11191c3f18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_811199b7-e54c-4341-a822-f9cc517326f9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647988cd-28c3-4c90-92b6-3e11191c3f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_6b345d00-8c17-4036-adc2-fa6f75700524" xlink:href="ino-20241231.xsd#ino_A2021SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647988cd-28c3-4c90-92b6-3e11191c3f18" xlink:to="loc_ino_A2021SalesAgreementMember_6b345d00-8c17-4036-adc2-fa6f75700524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember_ddce2088-1331-4f48-8b78-603ff0487c1e" xlink:href="ino-20241231.xsd#ino_A2024SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647988cd-28c3-4c90-92b6-3e11191c3f18" xlink:to="loc_ino_A2024SalesAgreementMember_ddce2088-1331-4f48-8b78-603ff0487c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_273be13a-6c67-41f4-ae71-efade0e59caa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_273be13a-6c67-41f4-ae71-efade0e59caa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b75ba5d7-a216-45e6-96b8-27dc4083cf69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b75ba5d7-a216-45e6-96b8-27dc4083cf69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0063bb58-919d-4d61-b06b-4a10ebccf1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0063bb58-919d-4d61-b06b-4a10ebccf1e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_b9f6ac43-2c10-48ab-a213-743e335ec0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_b9f6ac43-2c10-48ab-a213-743e335ec0f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6d037d0f-880a-481d-a626-83e78aa80ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6d037d0f-880a-481d-a626-83e78aa80ef0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="691"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="692"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ino-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:17b32d98-3816-4b9f-8e66-a2aab92f0705,g:04b54f73-b42b-4be7-b731-92d690b75cab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_705c6cf2-738e-4113-8e42-d23703c1b163_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_25ef5dd2-79c4-485e-aadb-4f64a2e0bedf_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_042631b3-414c-4ab0-a3c4-58cde9ce9517_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_718440e5-aeae-4323-b316-b85f9c836860_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit from income taxes at statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_caee95db-fac3-4fdc-b3b3-2c4091e7ab8c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_50efff2b-6fec-4cae-80b1-87e3cc790b21_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Maturities Of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0a3cc1bb-1638-48ba-a3f7-89f9067144a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5719320a-5aa1-4466-be99-fc3ab21dbb0a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_37f3a9f4-2baf-4d82-adfc-6e61855b3c23_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$18.01-$39.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesTwoMember" xlink:to="lab_ino_RangeOfExercisePricesTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_88ccb5d8-638d-4ec2-ac74-4e2b768e202c_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU's expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20241231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_86778aed-aba4-49fb-bb4f-87497a3fbdad_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_4fe206f6-b3fc-4668-83a0-5b92c93ef2a9_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20241231.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c9ee7672-8bd8-4e52-a424-edf46494565e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO3107Member_21998716-c886-4c8e-9227-77c716f05d09_terseLabel_en-US" xlink:label="lab_ino_INO3107Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INO-3107</link:label>
    <link:label id="lab_ino_INO3107Member_label_en-US" xlink:label="lab_ino_INO3107Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INO-3107 [Member]</link:label>
    <link:label id="lab_ino_INO3107Member_documentation_en-US" xlink:label="lab_ino_INO3107Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INO-3107</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3107Member" xlink:href="ino-20241231.xsd#ino_INO3107Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO3107Member" xlink:to="lab_ino_INO3107Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_d8c50dce-4b6b-4054-ac0d-c6521a3a4d4a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_55f1a52f-998e-4609-be99-2b617596f03b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_67ff0546-d96e-487c-96e3-fa8626361fcf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_53db25eb-e0da-44b9-b01c-c6703fdf51b1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_23812a94-c70a-4a7d-9e61-5bab00b4e32e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b6f21e96-cfd2-4e9e-8337-e280ada0348a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_5a89cb1e-382b-43c8-b190-a11a77edacaa_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_ec4c2780-ded4-47ca-898b-cafb88acc8b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c022a06a-e6d0-49fd-8a66-3327d4bb263e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_e09820a5-b980-4f56-bd51-d7f4f7f19948_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_8642b56b-997e-416d-8d75-28b03d835ae7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4d41c04a-e228-4b70-a04c-f69c15846ede_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a8ad0488-c806-411e-9c89-2b25df850dfe_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5675ad63-4215-49b9-aa9b-4b6649908a35_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_4bebdb51-371d-4765-b1fa-62885f619851_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_4aea8153-2478-4afe-8cdc-fbcc6e206143_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_40a3d307-b0d4-4b93-b6fd-d4bb37a11bb1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a18f745-02e8-4a34-aa31-f07ee5a0d667_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3c08380c-edbe-4ecf-91ed-dbabe3639e7d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_d7be1615-6272-41a6-88b3-b054a899e3fb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_fff4e267-1441-45d3-b54e-f952fdd04104_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ffcbd291-4aab-4dcb-a459-240aebfe1dc9_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_823a4f51-2975-49d9-9914-e6a2e8f18cf0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a24644f2-3e82-4c6d-b33e-623b92c5d916_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_1130aaf8-91ce-4379-8410-d065363e6dff_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_27dfc999-985f-45f1-9034-175a61503040_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20241231.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7bb3fc34-783f-4ed4-9255-137ed36104dc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_57cf1e45-750d-49ad-9daa-4e5aa508f7de_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_dc82cfcb-dd63-464f-80c4-ad9cf708fdca_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_d9d413ec-80b2-48c0-8acc-5ed61945b4b3_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20241231.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5182d93e-8eda-4804-bae9-bf720fe487fb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cf8fdc7-b6a9-4a48-bda2-13e088b981c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2bd99df2-5ef2-4dee-b942-fa8a4e42c7c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_d6ca0e56-a016-477a-956e-9326da27668b_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8636a3ed-c754-42bb-a0fb-907ca46f7e85_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantLiability_f4a696b9-af85-4005-85ab-04c018d66fe0_terseLabel_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused grant funding</link:label>
    <link:label id="lab_ino_GrantLiability_label_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Liability</link:label>
    <link:label id="lab_ino_GrantLiability_documentation_en-US" xlink:label="lab_ino_GrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability" xlink:href="ino-20241231.xsd#ino_GrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantLiability" xlink:to="lab_ino_GrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_bed18ef3-be28-4440-947f-ba196070b376_terseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20241231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bfe04c7c-74c1-4c04-ac55-c455186e4170_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_f22b5a23-46b5-4f2d-bbc0-873eedf94f61_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20241231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_7b3c502b-9d69-4b73-a396-864dd76b6881_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$130.01-$233.28</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Six [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesSixMember" xlink:to="lab_ino_RangeOfExercisePricesSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_93d12bf1-2412-4b8e-9896-846006ec7c47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b6f8a58a-872e-4e20-93e9-faae33af2a31_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a8693595-7cb3-49ab-897e-865b7d990eb5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f692cff3-4a4f-45dd-8faa-4b7a5d464294_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_33538cf8-9e84-4d55-b4c1-c1b200c4653e_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c75c1a4f-a024-47b8-a6fe-56d373d31296_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_ffcf4a1c-36aa-499f-97f4-a41d1a830781_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20241231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_26795ce5-0e05-4237-9e67-e4f3fe021fe0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3a146707-dc62-4ec4-a41b-1453ca90ed6d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_81f8c30a-c46c-4d1a-9c5f-bac533420d43_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_f2a4a0eb-f90a-4625-b03f-1fc467936b6a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_c6d4b473-5224-4448-8bf3-037bb6318df2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2021SalesAgreementMember_c4be62bc-c403-4e97-b714-4665215a7cc5_terseLabel_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:label id="lab_ino_A2021SalesAgreementMember_label_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_A2021SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_A2021SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember" xlink:href="ino-20241231.xsd#ino_A2021SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2021SalesAgreementMember" xlink:to="lab_ino_A2021SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ee4e05a2-84f1-4f90-b9bf-e36a62b4c21e_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_df6abc71-c68a-4822-abc2-db0843bcb366_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0b53e76f-bbf8-4002-a460-be8c76e89446_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7f880eb3-ad6c-4bcd-93e9-8b9d1e675a9a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_3e84ae19-2f5d-4710-8f80-6ae2e2857f71_verboseLabel_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_label_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_documentation_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assumptions used in estimation of fair value of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:href="ino-20241231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:to="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_08fb33c0-eb99-49c0-a889-42705c513761_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_fc26f0b1-66cf-4258-ad3b-71ea1e189846_terseLabel_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="ino-20241231.xsd#ino_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_ino_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1044ec8f-3c88-4a3a-8794-43359cd94def_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8c2966f9-a953-4c2b-b78e-ed25efa25889_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_920aa58f-faed-4b44-906b-526d889a94c1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_95ff6137-b547-4f82-b9ec-ebd2b5bda67a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_71af9eef-5566-45e6-9316-53767390f7db_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ccaf9aa8-fda3-4788-9dd5-a68e9802ffb1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3dd0b707-07fc-48e1-af9d-92b857596a72_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d36c64b5-1bfd-4f36-8e51-e4b83fb7a41e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0404dfc5-7525-4074-b0cc-46a443705bfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_733b8609-2474-475e-9857-727d4bfff74f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_588b5396-5608-4f7b-aa28-207c2060b0ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_75e4add1-eb0d-4263-8ecb-e23218174efd_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage-Backed Security, Issued by US Government-Sponsored Enterprise [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_91513008-5e92-42c3-b519-7536e2e98baf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_27380fc0-5b9f-4cae-9ea0-0d9ec1909de8_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20241231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0d660234-e32a-48b4-9762-73d3f2e12e6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5ee7d100-cfa5-4faf-a1d5-e06938ffc5be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2c316460-0495-4a7d-84dc-ac34a39dfdd1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_ace6838f-e16d-4186-a2c8-c6185efb55af_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limited NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:href="ino-20241231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_694276b6-a2b9-4e9a-8208-0107b106a33a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Liquidity</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4d3b5520-0189-4a8a-ac7d-c9aa8ca7cb0a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_15d74d19-87ee-4924-892f-6e1e411cdb97_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4d465c79-b2bd-488b-b1c8-d02f54eeb8fa_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_af8c050b-cb38-445e-8054-db5612fb5b02_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_550aaa56-6b78-4c45-aa00-46eafe9a647f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_68950bd7-4695-4ef4-a78e-a78227fff7b6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_84174b0c-5237-4cfe-9bfa-879d8ce99273_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8f62e5ee-ee64-4239-8320-1022f17ce4ef_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_276d0f6d-9bed-4db9-8462-527e7a8c1076_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_321587df-8b9c-4593-8c92-e3bda48a4656_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_13928a2b-ac50-40c5-8740-9ba495de79a4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's contribution to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_f71772d9-8fc3-4b61-be04-93b5ffa364bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_48a3c3f5-c83d-431c-9229-79beb184ffec_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of convertible debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_3eaa35db-4221-4456-a51e-f517a4fdcf81_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement, aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_9a72d2fe-771a-4d64-bf2e-ac034a5f6a0e_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Axis]</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Axis]</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_38577a21-c3ce-4e2e-bc6d-0e062837d52a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserved number of shares under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_40491e3b-d1bd-448c-9b79-b9e1a6a206f0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ee0afe58-2338-4bd6-8daf-f7e3a18fe26d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_91722e51-4080-4eb6-bf6f-c376246028d8_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio Corporation</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20241231.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_69521e8c-8a86-4c87-b748-e26bc0e7b60e_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_30b6b18c-0b5a-40a8-bf2d-2bce1661f33f_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d4a64081-f08b-4779-90ba-e7bc7025f0fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_faf044f8-a88d-45b6-9fa7-d8ed5651e0c2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fd31e242-7db9-4ba5-82b6-8646addb1e14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_5f3651aa-6248-4e06-9e72-d8a6cdd5fd8c_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fb36164a-0730-4d22-9f1e-6206ff0a39ae_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_000c3741-093a-4cb3-9f71-a057df7142f7_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred grant funding from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20241231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_f6c7d816-9843-479e-9edf-09211b92aa52_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_0a438655-c82a-4ee3-973a-5edfe8f5482d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CommonStockWarrantLiabilityFairValue_904df049-8aae-480b-a54d-97703833098c_terseLabel_en-US" xlink:label="lab_ino_CommonStockWarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_ino_CommonStockWarrantLiabilityFairValue_label_en-US" xlink:label="lab_ino_CommonStockWarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrant Liability, Fair Value</link:label>
    <link:label id="lab_ino_CommonStockWarrantLiabilityFairValue_documentation_en-US" xlink:label="lab_ino_CommonStockWarrantLiabilityFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrant Liability, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockWarrantLiabilityFairValue" xlink:href="ino-20241231.xsd#ino_CommonStockWarrantLiabilityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CommonStockWarrantLiabilityFairValue" xlink:to="lab_ino_CommonStockWarrantLiabilityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_847afa11-ec62-4f33-878f-7432a814b2a2_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20241231.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_9dbe4146-4d68-4250-8fd1-fd02f479f886_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20e7e0ba-1362-4203-8b5b-754a3eb30871_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_511af2de-9f1a-4ac4-82ba-c1c7943bc043_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="ino-20241231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_e2bec4af-5d99-4b3a-9f74-2b4417805aba_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_94618b93-f787-4e15-94c8-fbd0306a8ffb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_735c21cb-c2a7-44ad-b174-566d0457c6a8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f7016052-5fc8-41ff-83a8-83b7f3edc5fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_b7cbab12-e497-4b32-966e-5a459f5bbf49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_18795267-49fe-418b-b5be-d141cf27fc4a_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_f81b96d1-90da-4496-84e2-6c044032c7c7_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20241231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_60c5db48-74f1-4759-a835-beb5d116e637_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_dd4f42ca-6792-4c5b-aa86-9c7cbaeb9c01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, expirations in period, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_45512dd0-4eda-45ab-bb4f-54f7c940a381_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used To Estimate The Fair Value Of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_d959e686-31e8-467e-99ee-a2c2cc9be644_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_cf0b7933-70f1-47d0-9cb5-4a17e86140b4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90d4a594-daeb-4456-9af1-62015ea1e9dc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_a6b33a64-183e-450a-9212-1dbe76c51eaa_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_33746916-5eb8-4d91-96ae-0ae8c7a0197e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d2521472-bf78-42e7-b2f2-e396169286d7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because of Their Anti-Dilutive Effect</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_65de5d37-9e86-4ace-b96c-1b846db3bebd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_10ef3cc6-a6c0-4988-9db1-29609fb9f497_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_cc2a5f95-e37c-421e-a637-5ddac46afb93_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20241231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_d61466fb-fe2b-456d-ab1a-db258b28db42_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_d2ad02ab-291d-4866-a208-bbf4da49822d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_673c9927-9425-4722-ab99-cd70a468e175_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_57244bd9-fa9c-438c-b44e-404ed8bf4add_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4f4a32d0-1cc5-49fb-9a8b-6c4bd008263c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4afc80fd-8c8e-4344-b1dc-1bec59a24188_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_ba7bf159-3e9a-4698-a7e6-d294fcb77517_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c53d33cb-eb97-4ab0-84ed-c0feaa0c3cbc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_c1e98d3a-2a03-43c1-a439-873aa1333130_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_0a8361fa-543a-4912-9be2-bd62d88440e0_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_9c485233-382b-4e6c-a758-1cbbaefd6f44_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_75188740-c9b1-4423-a157-558c7be79088_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20241231.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_53bd2bd3-b57b-4e7b-becc-1fdd58f97e64_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockBasedCompensationMember_6835f99b-cbce-411a-a784-ea5b44041b5b_terseLabel_en-US" xlink:label="lab_ino_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_ino_StockBasedCompensationMember_label_en-US" xlink:label="lab_ino_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation [Member]</link:label>
    <link:label id="lab_ino_StockBasedCompensationMember_documentation_en-US" xlink:label="lab_ino_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockBasedCompensationMember" xlink:href="ino-20241231.xsd#ino_StockBasedCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockBasedCompensationMember" xlink:to="lab_ino_StockBasedCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_41c076c5-cb7c-4656-be1b-f6f31885feca_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum annual contribution per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3548005d-9d97-445d-ad67-d6cfc074174b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_e2c2c9b2-5128-4225-83fa-1eda31da62c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ec167280-5bd9-4c55-ac51-141a7bd95733_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_908d5b57-4a04-4f7d-9074-2aae3b8ba392_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9020818c-f36c-40ff-99da-e6836a398416_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_af1674af-0de9-478b-bcdf-184f112c3fcd_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20241231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_03d2080d-21e2-46d4-8ffe-3821651316e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized loss on sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_11f2f9e1-05b2-4548-b802-b6013477f880_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="ino-20241231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_429aa214-0f32-4188-863c-e312cdb5f276_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of capital assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e8af4421-f5da-4fcf-ad4f-375d254a449c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a417c455-9c76-4742-975e-ff7588e63427_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f115fe69-36c1-4712-bbea-0865d68faec4_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_66e185e2-e0f4-43f1-a4d7-d1681b04e8fb_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockOptionsPerformanceBasedMember_c8b2c7c9-a003-4a2c-a4fb-7e4869ebe69b_terseLabel_en-US" xlink:label="lab_ino_StockOptionsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Performance-Based</link:label>
    <link:label id="lab_ino_StockOptionsPerformanceBasedMember_label_en-US" xlink:label="lab_ino_StockOptionsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options, Performance-Based [Member]</link:label>
    <link:label id="lab_ino_StockOptionsPerformanceBasedMember_documentation_en-US" xlink:label="lab_ino_StockOptionsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options, Performance-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockOptionsPerformanceBasedMember" xlink:href="ino-20241231.xsd#ino_StockOptionsPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockOptionsPerformanceBasedMember" xlink:to="lab_ino_StockOptionsPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7fbbd1f6-791f-4728-955a-799548aaee36_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dce46949-e4b3-40f4-aff7-4dc35f65c47d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangements and other contracts, including affiliated entity</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f1ae35aa-724e-47c5-8e9d-ce0abd928aa2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_b1190931-374b-4006-93f4-71c86e22dc77_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:href="ino-20241231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e9d6557c-f088-42f3-a6bc-22320735d8d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_fc9220d1-9033-40e2-8b8b-a1be5758f4b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_250b32fb-f514-4eac-8640-7f7b1af76a7d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b954d9fc-4e8f-4c41-b07f-7a55744d3b6f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_09c1669b-fa0c-4700-a9e5-b60ce0fad9d5_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_56e970ef-5959-41ce-af82-404f9642f2bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_657a560c-636e-44a6-8a62-3f6a3be22f0e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_c0983b61-b7fd-4ecc-ab97-009a6200e106_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioCorporationMember_a802be51-c622-4ff9-947a-795d2716d556_terseLabel_en-US" xlink:label="lab_ino_ApolloBioCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio Corporation</link:label>
    <link:label id="lab_ino_ApolloBioCorporationMember_label_en-US" xlink:label="lab_ino_ApolloBioCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ApolloBio Corporation [Member]</link:label>
    <link:label id="lab_ino_ApolloBioCorporationMember_documentation_en-US" xlink:label="lab_ino_ApolloBioCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApolloBio Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioCorporationMember" xlink:href="ino-20241231.xsd#ino_ApolloBioCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioCorporationMember" xlink:to="lab_ino_ApolloBioCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b979168d-0b32-4404-b9e1-a443eb53fa1a_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b6c52138-a67c-4d2e-975f-2086a9da3e11_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7038d3b5-84f0-4be9-9aef-3a3a3790179d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a79d6f50-3895-4511-b7f8-423183a87667_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8f77f9c5-b0cd-4a83-93f2-d18dcf53bc0c_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_facdf5d9-7d9f-4604-874b-17544dcc254a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PerformanceRSUsTargetPercentileMember_861144c0-3df6-4b29-80b3-8fbd6525b2a3_terseLabel_en-US" xlink:label="lab_ino_PerformanceRSUsTargetPercentileMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance RSUs, Target Percentile</link:label>
    <link:label id="lab_ino_PerformanceRSUsTargetPercentileMember_label_en-US" xlink:label="lab_ino_PerformanceRSUsTargetPercentileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance RSUs, Target Percentile [Member]</link:label>
    <link:label id="lab_ino_PerformanceRSUsTargetPercentileMember_documentation_en-US" xlink:label="lab_ino_PerformanceRSUsTargetPercentileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance RSUs, Target Percentile</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsTargetPercentileMember" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsTargetPercentileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PerformanceRSUsTargetPercentileMember" xlink:to="lab_ino_PerformanceRSUsTargetPercentileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_e4a0284b-1101-4e97-a77e-9263347a0d15_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_9a416564-93d5-4789-bd87-a981139c93de_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cfbc314e-f785-45f8-859a-b528c5c55c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2024OfferingMember_82da6559-7503-4be6-b0ed-b20ae6003a2a_terseLabel_en-US" xlink:label="lab_ino_December2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2024 Offering</link:label>
    <link:label id="lab_ino_December2024OfferingMember_label_en-US" xlink:label="lab_ino_December2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2024 Offering [Member]</link:label>
    <link:label id="lab_ino_December2024OfferingMember_documentation_en-US" xlink:label="lab_ino_December2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2024 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingMember" xlink:href="ino-20241231.xsd#ino_December2024OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2024OfferingMember" xlink:to="lab_ino_December2024OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6261d03-ca88-470e-8d28-197828f797ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b89833a8-9da3-468a-961c-965e76d9f5a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_7a280782-1e75-41f6-b488-077e11e575dd_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, remaining contractual term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_18f70b3d-62d2-44b0-9104-139498e168b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_cdaa0bbe-3e81-400e-95c1-f7b56628e441_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:href="ino-20241231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:to="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ed8cff5-c034-4de0-84ed-533da940d8b0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0a650cd6-4233-4f79-baba-1fde3c8bb982_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_101c650d-9ade-43b2-953c-af26cf1b410e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapital_73c334a5-d026-45a9-967e-1dda7a20d656_terseLabel_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_label_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_documentation_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net amount of current assets and current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital" xlink:href="ino-20241231.xsd#ino_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital" xlink:to="lab_ino_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_3a1c3aef-0a84-4ef1-9b34-0f1ac2308519_terseLabel_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:href="ino-20241231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:to="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_7fc3daa5-14ec-4487-8e45-25688d6e40d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_739d82f7-0e17-4d51-a378-a8f5096ed843_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expirations of Tax Credit Carryforwards [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e06fab5e-97c7-4a5c-958f-bdd942a24b16_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_00ef8975-a347-43c3-800c-65a2c9b5f848_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_d58db97d-31a4-494e-a53b-c19691f55801_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9100b9b6-033b-4489-9580-e68ca5b7bb26_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e04d2038-73ce-4b90-8ee1-5b2942704ff2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_b1d6b382-98db-4606-8293-46eaabca1342_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$90.01-$130.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFiveMember" xlink:to="lab_ino_RangeOfExercisePricesFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7dde4e06-ca6e-4618-bb66-ae008170660f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b8f04b78-4594-47a8-95fc-d3ceafed1c61_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_d9b787c1-9a61-4022-993f-484f8c44b6f0_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_e999615d-700f-4c7e-a678-c39ec5d9f25c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_425fcbfa-91a4-42f6-9720-b78f3695381b_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:to="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7e7bf340-e1c0-4e79-93b9-90d762a81f51_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_ded194a4-2680-420f-bc42-3ca38782df21_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20241231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_8fae5531-ff1c-4a81-b02d-d53154f358a3_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_e7668880-08f7-4db0-b757-766097b42fa7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue_3a9b9952-de23-4933-8672-a8bb6053070b_terseLabel_en-US" xlink:label="lab_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of fixed assets, no net book value</link:label>
    <link:label id="lab_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue_label_en-US" xlink:label="lab_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Sale Of Fixed Assets, No Net Book Value</link:label>
    <link:label id="lab_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue_documentation_en-US" xlink:label="lab_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Sale Of Fixed Assets, No Net Book Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue" xlink:href="ino-20241231.xsd#ino_GainLossOnSaleOfFixedAssetsNoNetBookValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue" xlink:to="lab_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_49c56ec5-0e93-4167-a4aa-7c36c6063681_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ReportableSegmentsMember_aa6a0b80-c5fe-40b8-8479-d48dc3218b5f_terseLabel_en-US" xlink:label="lab_ino_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_ino_ReportableSegmentsMember_label_en-US" xlink:label="lab_ino_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segments [Member]</link:label>
    <link:label id="lab_ino_ReportableSegmentsMember_documentation_en-US" xlink:label="lab_ino_ReportableSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ReportableSegmentsMember" xlink:href="ino-20241231.xsd#ino_ReportableSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ReportableSegmentsMember" xlink:to="lab_ino_ReportableSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_d5ba4267-a232-4fcc-b045-c9f575925ba0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_1b907688-7174-4bea-9b7c-b01176cc6d7a_terseLabel_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:href="ino-20241231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:to="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ffcd0bce-52e4-4913-a823-4cadc06c5d28_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_8de75f73-579d-4721-afdf-2191839c1fd3_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7cee282a-e572-4145-9343-82c69e134902_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_961ba7ea-37ad-4507-9bba-7beded8bd516_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0ab1d48c-cfa3-434d-a51b-6534b99ddf77_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_215f75c3-f976-43f9-a0c5-36c989626b0d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_31b93eda-0d09-4c76-87b4-6004c2e2cde3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxBenefitsExpired_d951a116-5464-43b4-aa04-4569fcdadc15_terseLabel_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_label_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_documentation_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired" xlink:href="ino-20241231.xsd#ino_TaxBenefitsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxBenefitsExpired" xlink:to="lab_ino_TaxBenefitsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_eff0618a-3273-46d9-b4d9-453c43938f44_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c502c8f4-bc90-4790-b073-13b11dc0e079_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9742e2c-36af-4830-9c19-8f77ea942eb2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_cc255f82-2c62-494a-a52f-d0ef44091606_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_07ccd50b-e3b7-4edc-8ce6-cf98a07071f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0aefe9ca-36b6-4f69-85ce-afe9d076e6a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_39d745e1-9de6-4d1e-a70c-0b8233ac3393_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:to="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6cea0c69-2335-46cc-a407-983c03b4c5ab_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b16a2730-336f-4b15-a43b-97143526aa2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PerformanceRSUsSpecifiedMaximumPercentileMember_d088072a-8608-4617-a124-fad7a291f47a_terseLabel_en-US" xlink:label="lab_ino_PerformanceRSUsSpecifiedMaximumPercentileMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance RSUs, Specified Maximum Percentile</link:label>
    <link:label id="lab_ino_PerformanceRSUsSpecifiedMaximumPercentileMember_label_en-US" xlink:label="lab_ino_PerformanceRSUsSpecifiedMaximumPercentileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance RSUs, Specified Maximum Percentile [Member]</link:label>
    <link:label id="lab_ino_PerformanceRSUsSpecifiedMaximumPercentileMember_documentation_en-US" xlink:label="lab_ino_PerformanceRSUsSpecifiedMaximumPercentileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance RSUs, Specified Maximum Percentile</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsSpecifiedMaximumPercentileMember" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsSpecifiedMaximumPercentileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PerformanceRSUsSpecifiedMaximumPercentileMember" xlink:to="lab_ino_PerformanceRSUsSpecifiedMaximumPercentileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a0ef4ed0-dc99-4241-b752-96f220c2ba36_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_094a419d-251b-4b1f-b19d-07973479df39_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_April2024OfferingWarrantsMember_a68af787-500d-49dd-b160-4f7878e3bc2e_terseLabel_en-US" xlink:label="lab_ino_April2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2024 Offering Warrants</link:label>
    <link:label id="lab_ino_April2024OfferingWarrantsMember_label_en-US" xlink:label="lab_ino_April2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2024 Offering Warrants [Member]</link:label>
    <link:label id="lab_ino_April2024OfferingWarrantsMember_documentation_en-US" xlink:label="lab_ino_April2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2024 Offering Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_April2024OfferingWarrantsMember" xlink:href="ino-20241231.xsd#ino_April2024OfferingWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_April2024OfferingWarrantsMember" xlink:to="lab_ino_April2024OfferingWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7c8ac77e-d738-40ed-af25-e577fd645172_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_86bce988-7b28-4e62-8374-4d648eda63a8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses, including due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e62ea206-9a29-467a-b16a-e8855ae4a20a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_ffc7c6e1-7be5-496e-9b96-ccd153217b0b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fddc97e3-857d-4adc-8586-ebe659b80b0f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in fair value of liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_846d66f1-c8c1-4be3-93cc-2d184deff404_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in fair value of liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_763bffcc-bfa2-47e2-8b79-edff9ee2d016_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_6da59a5b-7b7a-47da-9811-19f15469ddee_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_aac5b5bb-2024-4b01-b069-0e3d80274e67_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_24e2fd23-770d-4a90-9d1c-5cd61d80ce1c_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8654e236-a90f-4510-9e3f-d18899096253_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Components Of Pretax Loss From Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7c81d0f0-8665-48dd-b737-03e9b29a9a88_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_64065937-5b27-4b36-bc70-5b6673333db6_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_61f27bb6-8bea-444f-bdf1-5048064244ed_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_30b90b58-e47a-4290-a969-d33aafe5af5b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cac9f8c8-5c2c-4db8-a554-97a2ff98b548_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ae55175a-289b-4ddd-b09e-da8aaca60ff8_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1d783fe7-1023-4587-ac75-ed3fa5711634_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_5d92ae35-12fc-4f62-8f5e-e63aeda00127_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_95c583d1-f466-4278-86a1-f221a4c0bfab_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f7f8e681-0683-4456-8a33-5735621c4171_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b7218efd-e530-4acf-8519-1d4f0eb6199f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PerformanceRSUsSpecifiedThresholdPercentileMember_e697d14d-f6b4-4652-850b-46fa4b937290_terseLabel_en-US" xlink:label="lab_ino_PerformanceRSUsSpecifiedThresholdPercentileMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance RSUs, Specified Threshold Percentile</link:label>
    <link:label id="lab_ino_PerformanceRSUsSpecifiedThresholdPercentileMember_label_en-US" xlink:label="lab_ino_PerformanceRSUsSpecifiedThresholdPercentileMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance RSUs, Specified Threshold Percentile [Member]</link:label>
    <link:label id="lab_ino_PerformanceRSUsSpecifiedThresholdPercentileMember_documentation_en-US" xlink:label="lab_ino_PerformanceRSUsSpecifiedThresholdPercentileMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance RSUs, Specified Threshold Percentile</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsSpecifiedThresholdPercentileMember" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsSpecifiedThresholdPercentileMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PerformanceRSUsSpecifiedThresholdPercentileMember" xlink:to="lab_ino_PerformanceRSUsSpecifiedThresholdPercentileMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_7857e8b2-f496-4b5b-9d9d-7abbdd9a54de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_60bc896c-c269-466b-a3ef-0b1da24e8d51_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WarrantLiabilityMeasurementInput_d8c115a3-9a83-44aa-bcee-f272e7cf18c3_terseLabel_en-US" xlink:label="lab_ino_WarrantLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, measurement input</link:label>
    <link:label id="lab_ino_WarrantLiabilityMeasurementInput_label_en-US" xlink:label="lab_ino_WarrantLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Measurement Input</link:label>
    <link:label id="lab_ino_WarrantLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_ino_WarrantLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WarrantLiabilityMeasurementInput" xlink:href="ino-20241231.xsd#ino_WarrantLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WarrantLiabilityMeasurementInput" xlink:to="lab_ino_WarrantLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_cb1608e1-f702-4847-9921-522278625c1c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9d0c9d5f-ef2d-41cb-85a9-5d523cadf9f1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_81e14bf0-2f75-48c0-bdbe-216246003531_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_93f57a5b-4a84-475a-a877-1171ab1b1680_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f269d390-caa8-40ba-8ac1-d0f50c9bf500_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_08ae5c40-8592-442d-82db-c8ac701eb490_terseLabel_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, common stock ownership (percent)</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_label_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Percent</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_documentation_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:to="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f24068e9-8cbb-4309-9a4f-5d7d043d4f88_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_bdd7a712-39d0-41f6-8480-7e646c487f63_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Next Fiscal Year</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_5fd623d5-6c36-4fd6-bf7e-f29d89445701_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_290683ff-623c-4554-87e5-6a3e26f69ce0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_184eafae-8f19-420f-ae85-a50559552502_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4ff75297-fabc-4eb4-bde1-57cba621930b_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d7b022f4-d531-41aa-85ce-c3c47d6b77f1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e60dfebf-0a3b-4471-b51b-11e7a9641779_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_fae4c6d0-09d0-49e7-9e64-e88c37769ce5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_29ceb305-9151-4a91-aeba-6aab9fe694f8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_b81f5da8-ee74-4bda-8854-70da89ee0bec_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0a5c7ae8-9fc8-4b51-99d7-de0d21eac360_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_62d4db0e-c01f-4436-9297-efbbdec12e8f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a9a7c6d2-e477-4505-ab99-fe436ecbb47a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net (gain) loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_c400c5cb-5975-4690-8ba7-f86094477fac_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability, including from affiliated entity</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20241231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_abacadfe-6a4d-4efa-bb6b-d7722f659fe1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_481cee6e-ff00-46a9-9e52-4694d366bf8c_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Next Fiscal Year</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringInNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d1172bf2-9a15-4d35-849a-7b5ad00fb2a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cceab895-a5e8-487e-9560-e79aa118c78a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e9adfeb0-b265-4ff8-9991-ba92eae052b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc333ac9-8f29-44d7-a16c-c5b506be7a1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_b0344bec-f563-4c5f-96e6-2b056e394d67_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering</link:label>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenRegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Registered Direct Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:href="ino-20241231.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:to="lab_ino_UnderwrittenRegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_bafef6e8-2a4e-4e17-859e-db880c519e03_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_134bb770-9647-4af6-adc5-d71bff691e4a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_98dcfd98-251b-420a-955e-34e615840c04_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidManufacturingExpenseCurrent_92694807-0014-4ce7-9a0e-7f144411d3a1_terseLabel_en-US" xlink:label="lab_ino_PrepaidManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid manufacturing expense, current</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpenseCurrent_label_en-US" xlink:label="lab_ino_PrepaidManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Manufacturing Expense, Current</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpenseCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Manufacturing Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpenseCurrent" xlink:href="ino-20241231.xsd#ino_PrepaidManufacturingExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidManufacturingExpenseCurrent" xlink:to="lab_ino_PrepaidManufacturingExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_23f87eee-f033-4cdb-8dbf-44b6cbb11f33_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_b03bfe1a-2d1a-466f-8d58-1b94b77c3494_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_33345b47-9de3-4917-a84e-a1ebed239550_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_34f0e41a-3763-4126-9fca-101f98fbfee0_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ae794d22-dad6-4a1c-b618-462db497794e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_cd8097ce-12b8-4b1c-8aa8-106d70671a78_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6776e606-9d44-468d-903f-6ca84969a202_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_ddea0989-e12f-45b8-9207-6a2b3c4b9edf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_0cd7e6ea-c268-46be-8260-d61427295792_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_8fd5a97a-7f15-44c9-9013-310944c6ca49_verboseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual year term of incentive plan (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c5a7755c-4b18-4bb6-a9ab-a6bed6a109f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_436f83eb-d68f-454b-84eb-084d6dd22c56_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_0e4f2556-0212-45c7-9a6a-675de3e4a3c4_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20241231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0803bd5e-b3cb-42f3-9121-6d4f7c06fa51_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_df8da27d-d4df-4842-b01a-9327d598b16e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_54e50f6d-96f1-44e8-92a1-66ad9e6738a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_a3dca0fc-7ca3-454d-a0fe-ef81eeee3acd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Damages paid</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_49b0fc01-23e1-47b4-a12a-634687026e87_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e7a6ff3d-69cd-4652-b00e-1a1fc599619e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f0ab3f34-c598-4608-ac97-a1b3f638be42_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_bb2e2b0a-f59a-42a8-aff8-85607950144c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for legal settlement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2ad83f6b-a374-4ba0-a299-1fce4b97166f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_634a7a05-9468-4b16-bf0f-ca637346ea2d_terseLabel_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of shares settlement</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_label_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_documentation_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:href="ino-20241231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:to="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_357b9224-ac41-4936-86e3-0f4ef801d676_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_31cf4f96-886d-4674-b744-df8ff719a18f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_72d2aaf9-5fa5-4f55-b965-c1c459413ae5_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss from operations</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_5de00a27-1744-473e-9e12-28335d472388_terseLabel_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_label_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Shares Outstanding</link:label>
    <link:label id="lab_ino_WeightedAverageNumberOfSharesOutstanding_documentation_en-US" xlink:label="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding" xlink:href="ino-20241231.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WeightedAverageNumberOfSharesOutstanding" xlink:to="lab_ino_WeightedAverageNumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_label_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items [Abstract]</link:label>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_documentation_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract" xlink:href="ino-20241231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract" xlink:to="lab_ino_CertainBalanceSheetItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_88e72b44-cacd-4aac-87ad-326f8b858a41_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:href="ino-20241231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:to="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ff6c1590-00fe-465a-bb5a-74af1ca8929e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_db110aad-0dab-4d6a-a24a-954bcd8c8596_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3dcef97f-847c-43f4-b78e-d3955bd839aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1f65844a-8650-4c94-8b07-e62e54d65c9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_da316c07-443f-496b-8f1f-6ef9b1794a57_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ea59a81a-44be-4692-93f6-5d777c2a5ca3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a296439-6879-4db6-af74-52cea5e3b032_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_884af1dc-12c7-4dc2-a153-f0dab31a33c1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1834752d-8c5f-4129-aec6-19c03d0352dd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value for options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_080ff484-3036-492d-aff0-a8300dfa4f8b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_09d242c5-ed8a-4712-92a8-a243a366831a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_8e9f8dee-c87e-4558-8237-da2b28be27c5_terseLabel_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, common stock, prior to issuance (percent)</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_label_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_documentation_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:to="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_5751af18-5da5-4463-b33e-afa0a4a6ac36_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_75856c59-6112-45d2-a79c-4ce650a1e08b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_2a3dc06f-d117-44e5-a5d9-14a7de5320ae_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales made at a weighted average price (in dollars per share)</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_019e4ff6-336f-4e95-8d47-e88da53e70c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_dbecdda2-e830-4d0a-8a95-8ffecb33c03d_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20241231.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO5401AndOtherImmunoOncologyMember_40e305ba-d91f-4ddd-a034-801e7869df7d_terseLabel_en-US" xlink:label="lab_ino_INO5401AndOtherImmunoOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INO-5401 And Other Immuno-oncology</link:label>
    <link:label id="lab_ino_INO5401AndOtherImmunoOncologyMember_label_en-US" xlink:label="lab_ino_INO5401AndOtherImmunoOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INO-5401 And Other Immuno-oncology [Member]</link:label>
    <link:label id="lab_ino_INO5401AndOtherImmunoOncologyMember_documentation_en-US" xlink:label="lab_ino_INO5401AndOtherImmunoOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INO-5401 And Other Immuno-oncology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO5401AndOtherImmunoOncologyMember" xlink:href="ino-20241231.xsd#ino_INO5401AndOtherImmunoOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO5401AndOtherImmunoOncologyMember" xlink:to="lab_ino_INO5401AndOtherImmunoOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_eb387fa5-7daf-4a57-8501-fead800bdb8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock warrants in December 2024</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_daf74f7a-bb51-46ef-a8fc-f51b37e63294_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Preferred Stock Authorized, Issued And Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9978b5f5-81a1-4927-a065-52978b7894de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_68459308-f9e0-471e-8cbe-245d0e46e8d0_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f61ca3a1-adef-405c-87fc-e1aabc0318d9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_749b3cc4-e9d6-46ed-9835-ba2186414588_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9fa6722-c598-4666-b4e5-8f19d3fa72de_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92dd711a-ddec-48bd-ac98-bfb4dcfea035_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d12792cd-610d-4bca-bc9c-c72dfda50c6a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_6e646421-8d3f-41db-8fbb-e3892fa5a845_terseLabel_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in settlement (in shares)</link:label>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_label_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party, Shares</link:label>
    <link:label id="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares_documentation_en-US" xlink:label="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:href="ino-20241231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:to="lab_ino_LitigationSettlementAmountAwardedToOtherPartyShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_e5c84872-f0e0-473a-80cc-f506e8a3b30a_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20241231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_172e7d6e-422b-4c2b-b7cd-e69bebc98a2a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_c9265f89-bf12-4a5f-8841-cd43a35955b7_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_052b76c1-96c0-4cc3-8f96-eda47e96cc57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e5aa55f7-cc1b-44b3-bfc0-877d60cc0c1b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_07ccf2d6-dd74-43e2-8400-de5c5f28a2fa_negatedTerseLabel_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest on senior convertible notes</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_label_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense" xlink:href="ino-20241231.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestIncomeExpense" xlink:to="lab_ino_NonCashInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32ae665f-eaaa-4501-9bf5-78f9550580b0_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_a26d298e-964e-408c-8029-9c8a70e3e9f7_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$52.01-$90.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFourMember" xlink:to="lab_ino_RangeOfExercisePricesFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_541bfe6a-b956-4b0d-aa63-8a40fe9a320d_verboseLabel_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_label_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares of Vested Restricted Stock Outstanding Under Plan</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_documentation_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:href="ino-20241231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:to="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1330d501-91b1-41d9-b45c-d4009a3a5e48_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_ae35e292-d867-484c-9cfd-a2f6072a8852_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6d66bca1-dadf-4b8c-a910-0e8f0085ce0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_8f858cf3-159f-4c0c-9339-54826404c9cb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_c1d336bc-c5de-438a-bcd8-e64c34ab2f0c_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_091a32dc-f98b-4884-b7db-5bd0abff48d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_c05c94b0-1afd-4f52-80bd-1709e22ffa6c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherProgramsMember_dee9cb4a-0b44-4f7c-8d69-39cf1aa56d1c_terseLabel_en-US" xlink:label="lab_ino_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Programs</link:label>
    <link:label id="lab_ino_OtherProgramsMember_label_en-US" xlink:label="lab_ino_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Programs [Member]</link:label>
    <link:label id="lab_ino_OtherProgramsMember_documentation_en-US" xlink:label="lab_ino_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherProgramsMember" xlink:href="ino-20241231.xsd#ino_OtherProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherProgramsMember" xlink:to="lab_ino_OtherProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_0d0cd1cb-d781-4998-83b0-5dd9ed89c7e2_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant proceeds received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20241231.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_61615a50-5dbd-4f11-a5ed-66ca5e80509b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_ce1ed2c9-0f9b-47b1-bdb0-418b2ab52bcb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1a5e5045-d254-40bd-b39e-1873aefc4aca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4fef0151-c760-4758-94cc-4e16394067ec_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8eaa8074-4aca-44e1-8f92-6757e1034a11_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_bdaf04ab-7c67-417e-9902-b57f1eeb5baa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_4a45f4b4-d7c0-4db1-ae9f-db6eca54949c_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_330c74bb-36bd-4956-a6cc-5053d65d254e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a9e2bde8-0d65-4240-89d2-e0ea3932d031_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grants under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_13744e72-49a8-49d3-8395-8ae3394159ac_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_50868f72-f31a-4861-9c74-1dfa1fa34ae5_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_50a6c21b-7dfe-412a-af46-c3fb424976d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_87d7e6e1-845f-4085-80ab-3bcc61876a48_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9dbea537-30d9-4466-a69f-ba90ae036ab3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_57a50861-27e3-4137-bf40-32b9a8631174_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e55effbb-85de-4a4e-9418-ba0c63ec8046_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of discounts on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f75f357-b7f0-44ff-87df-91ba283b00e1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_276a4b49-ec85-4f55-9b95-90e1fccfaa66_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a8c16251-3b8e-4706-8791-deb0df7f7e72_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_00e3b0da-bd25-48e6-8594-61124d89af75_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7d4cdfcd-dbae-4b91-abfe-7dde13c8fe31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_6268f4cd-66ec-4ff2-b434-90ed749766fd_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_label_en-US" xlink:label="lab_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Warrants, Net Of Issuance Costs</link:label>
    <link:label id="lab_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Warrants, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:href="ino-20241231.xsd#ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:to="lab_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased_2beb0444-b58a-4348-b17a-3fe2d03b350f_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market-based RSUs (in percent)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Market-Based</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Market-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_fc552ca1-e508-4ed4-aea1-5f6b0f96b661_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses - Clinical Trial Accruals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d299ebc1-daf1-4070-a4ac-8d920ddb1170_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e7b007d3-2432-41c7-9efa-8ed984f98b9e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_ce3750a8-3fcd-4021-913a-1bf9674531c5_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable from Affiliated Entities</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_dde95433-4010-42e8-b964-f1b587c5bbbd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise&#160;price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_5a3fe0ba-9e03-4bcf-844b-4b5ee44a9bb6_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:to="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_2c3867de-44ce-4e47-91c3-42429b4b722b_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used To Estimate The Fair Value Of Warrants</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d130fef4-7092-4646-a6e8-ccdc0d7b3c12_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_4a459f8b-08e1-4ca2-ae3a-7aa1ce5f05c2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3767cfe1-1689-4885-9fcc-32c4baa0e27c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_8ace08e7-9726-4b04-afc2-b43f3ce7488d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a7dcf5d5-2b29-45b1-bcc1-635b88fbe3d1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e21f64e1-b1f9-423f-b98a-0ba378f5d0cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_7fde5283-f986-42a5-ba66-cbf0adecab64_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementRemainingCapacityAmount_dd338b5c-440f-4201-a58b-df136daf427f_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementRemainingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement, remaining capacity, amount</link:label>
    <link:label id="lab_ino_StockSaleAgreementRemainingCapacityAmount_label_en-US" xlink:label="lab_ino_StockSaleAgreementRemainingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Remaining Capacity, Amount</link:label>
    <link:label id="lab_ino_StockSaleAgreementRemainingCapacityAmount_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementRemainingCapacityAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Remaining Capacity, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementRemainingCapacityAmount" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementRemainingCapacityAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementRemainingCapacityAmount" xlink:to="lab_ino_StockSaleAgreementRemainingCapacityAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_930b8802-52a6-4add-b279-81484d9f2294_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b5ae340-9638-4f84-ade6-1a13cdcb400e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_06798d4f-9c75-4368-bbc8-57ae5f810f17_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_1218068f-616d-4886-a9c6-a2fd9b4dbc85_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_33fe797c-9975-4a6b-bbb2-e9b9ea452b8e_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_label_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_documentation_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:href="ino-20241231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:to="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c7e8bb14-f1fa-4398-8ed3-7b873cb7e133_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BehestiVKimEtAlMember_39a050bb-edc4-416e-ad00-3761678f85a1_terseLabel_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al.</link:label>
    <link:label id="lab_ino_BehestiVKimEtAlMember_label_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al. [Member]</link:label>
    <link:label id="lab_ino_BehestiVKimEtAlMember_documentation_en-US" xlink:label="lab_ino_BehestiVKimEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Behesti v. Kim, et al.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember" xlink:href="ino-20241231.xsd#ino_BehestiVKimEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BehestiVKimEtAlMember" xlink:to="lab_ino_BehestiVKimEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_62313b7e-0276-4f2b-bda1-8d0b6c63fcb5_terseLabel_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_label_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_documentation_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock" xlink:href="ino-20241231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantRevenuePolicyTextBlock" xlink:to="lab_ino_GrantRevenuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_45dd5ead-023e-4116-9288-b38376dcf193_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_fe5dee18-e8dd-438c-a30e-4ef0ef3fb891_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_69b70088-3adf-49a7-89d0-74416e2609e4_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased_53d59c55-bd97-4d61-9b69-2445f4583821_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone-based RSUs (in percent)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Milestone-Based</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Milestone-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ffaec694-796b-41ca-b1ed-2e4b16b85082_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_214f5f64-31f8-41c6-8be7-efb196158873_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e7fd3eda-d561-4990-9a8b-8c7ab2b7587d_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_ad38ec3d-3d42-45af-ae04-ba6be241d09a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7b045834-19a9-4a96-a2da-759c5ab3ac71_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0c38b79c-b3ee-4015-919d-2f6a8c673fd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_64283478-53fe-41ff-ad15-839620f28458_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_0912488f-5cc2-4a4b-afa5-f5a7d8790ff7_terseLabel_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former President and Chief Executive Officer</link:label>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former President and Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former President and Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:href="ino-20241231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:to="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementMember_3a2033b0-735c-40c5-ac8d-9cd9c72ff06a_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_ino_SalesAgreementMember_label_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember" xlink:href="ino-20241231.xsd#ino_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementMember" xlink:to="lab_ino_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_174f86ae-e6b7-4dd5-8e73-edf17f4c7398_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_3130faba-31ee-4e48-bfd5-af475c1d5b39_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0e40f5d0-00ae-4aaa-b129-ef052f4c3b05_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AllOtherCustomersMember_8a0187ea-71cf-4ee2-bcff-619503149c28_terseLabel_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other, including affiliated entity</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_label_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_documentation_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember" xlink:href="ino-20241231.xsd#ino_AllOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AllOtherCustomersMember" xlink:to="lab_ino_AllOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a572f485-f845-4d3f-8b66-e863991f0296_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_63aa3ba2-041a-42bd-a95a-c26847124347_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">%&#160;of&#160;Total Revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_800b7e0d-7e81-4aa5-aaf6-7f5be6b85619_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2024Member_f96b8f3f-d00f-4995-8da1-725082f4e685_terseLabel_en-US" xlink:label="lab_ino_December2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2024</link:label>
    <link:label id="lab_ino_December2024Member_label_en-US" xlink:label="lab_ino_December2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2024 [Member]</link:label>
    <link:label id="lab_ino_December2024Member_documentation_en-US" xlink:label="lab_ino_December2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024Member" xlink:href="ino-20241231.xsd#ino_December2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2024Member" xlink:to="lab_ino_December2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_6591a91d-0b9a-468a-b83a-91cd7bf62a8b_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_43d3f115-4c8f-442e-bf30-ec4675467ed9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e57af57a-d1cb-448f-9b68-be7ab3a2ef28_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_c645f0e8-3eac-4f1e-8943-ecb1050e07b6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_7f1751b9-1f74-4515-90d3-ec7ddb807507_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_c680c1ba-56af-4a85-9933-dff3fc9fbc43_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_75c2d1b7-850e-4335-9250-165391a672ef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_96bf1a95-0374-480a-9691-425d783f4f82_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">(Loss) gain on investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_27b29816-ebef-4b63-a617-0b7f090a248e_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on equity investment in affiliated entity</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_c21e4515-dfa5-42b6-b202-58d5b4cf1dbb_terseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20241231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_7eb4657a-6ff7-49f3-bab0-a9f1ec3eb07e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_0a57ad00-c7c3-4661-94f2-2800624efa94_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0d12f551-3e04-4c4c-89d9-ff75544ca8c5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_a48dfc3e-2e6d-43da-9a49-4e0249c52a71_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9eff301b-370c-430b-8a1c-2e3745d1a597_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_8f6e5dc3-0814-46bc-b7a8-022956715c07_terseLabel_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_label_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_documentation_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:href="ino-20241231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:to="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_a472f496-643e-4ae5-914a-7a48f98a4b78_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b260c8c4-9412-4b51-8b8e-fc03236ec3ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f3395760-bc17-4911-9d9a-d4823f17c2d4_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Domain]</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Domain]</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b441c64a-3b73-470d-8eb6-7d95b2cf30ad_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_c0f63397-c3d5-4022-b914-bf3621837272_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_89516b2d-9d2c-4ed5-857a-8f3cf7fa0c4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7b0e905e-3fa4-4c5c-b6d7-7ab303c4a3a1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_56e1e38c-7e3a-4c73-b772-6a894d322552_terseLabel_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Agents will be entitled to compensation</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_label_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_documentation_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:href="ino-20241231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:to="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_e306aacf-be9f-4f76-a3c6-7e5d6c832c82_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_d0084e2a-84c6-4c2d-9905-284c8ee31a80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a0ce4e27-c2fc-4483-8f30-ec26686c28c5_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_72e174ac-79b7-4973-95cd-7205c93facc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, lower range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f7f2f336-2e8f-4761-813a-f20e2938a978_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8d5a2426-dfb4-40ea-b32a-bc21262425a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0828c773-0118-43dc-94fa-0a6c1950285d_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_0c1abc6e-3c2d-4517-8259-6f42dfcfa29a_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f3c602c4-673c-4a1d-8bca-1c5980c8ed47_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_05453a6a-05c3-4611-8ccf-e9b922bba87d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_dd8c7f11-9e8b-4c75-8c0e-e34c83972939_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_31201deb-1561-4b69-b90e-18733d3244b2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e9f91ff6-9bc0-417c-96c5-fd9d003a499c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_e0415b0b-075c-4ef6-81ca-255f3522410d_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market-Based RSUs</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Market-Based [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Market-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:to="lab_ino_RestrictedStockUnitsRSUsMarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_50d5ebe3-e922-4aa3-be36-0a8bf5346e2d_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$39.01-$52.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesThreeMember" xlink:to="lab_ino_RangeOfExercisePricesThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_591d4580-7b7e-493b-9fef-6781580c0331_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e6f73c57-b485-4e51-9f63-1bb56fdf73f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aef62f6d-5a42-4a8f-9b5d-5b3116fa4c6e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d517f3a5-a184-4931-a862-06da97ef6642_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_90f34aad-e214-4f53-8271-43bf097d5e09_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_840c69b8-37e7-4bbc-865e-b7c6f12dd02b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_ab4a4f82-b276-4b05-b591-f07ae7e65c02_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_56596d57-2660-4b2b-99e3-6757939f72da_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c6c754b4-0c92-4f7d-b787-e16e85adb340_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_b641ebd9-d85f-47ff-923b-c2b48cd23302_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_52f428bf-acb9-4982-bbb2-09c89e0f4ccf_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b0045595-0f1b-4d28-bce7-0ba70d966a37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_771dbb69-c201-4e9c-92ea-86ee75a3c61a_verboseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_382d19f3-5ca5-435e-983e-15fdc90720ee_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2b96e28c-5d76-4a9e-b051-83f70f1998fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4b0a939a-b228-413e-b500-94528a1cfd3e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_2cfc2045-0aa7-46d6-a6df-bf152382b66f_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a0de3f85-07e3-42f3-b337-d038839e7e21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_181282c7-6e33-4d6e-be6b-48720a11af26_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_9d53b613-e07a-4def-a703-8027c8e26fbc_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_70e65577-cfc0-4ce1-9f26-145ba22097af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ddb5c6b1-47c4-477c-8293-1625bf2b7fa2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2024OfferingWarrantsMember_bcc6fe51-b950-40f7-a328-c566a6fd4c87_terseLabel_en-US" xlink:label="lab_ino_December2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2024 Offering Warrants</link:label>
    <link:label id="lab_ino_December2024OfferingWarrantsMember_label_en-US" xlink:label="lab_ino_December2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2024 Offering Warrants [Member]</link:label>
    <link:label id="lab_ino_December2024OfferingWarrantsMember_documentation_en-US" xlink:label="lab_ino_December2024OfferingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2024 Offering Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember" xlink:href="ino-20241231.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2024OfferingWarrantsMember" xlink:to="lab_ino_December2024OfferingWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_67232cdc-68a0-439f-8829-debf2517dbee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt interest based on the fixed rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6b79c141-bcf4-4fe9-ae53-90437faf3a7b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_bed76116-a449-4b44-a9fa-21c85aa83314_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_091b37ba-f9c1-45d4-8bf3-4447c4ce884e_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series&#160;C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_6b50792e-3136-4ba5-b712-a711185d9392_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_5cf3bf7a-0a84-4f44-b37c-b57383c2ac10_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a612337d-87b4-40b1-a9e5-2dac73a6f4b4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_2607d5dd-5f56-4790-8bcc-44a3aab40dc4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_1f00e96f-b39f-410c-901f-110cf5f417fe_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d6da7387-d2f3-4fbf-bff6-d8fa171614c3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_91b6da99-f309-4f23-b423-95518d79408c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_bd239279-c632-424a-a4ae-49e19c5f9053_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a53b84e5-95b5-4c81-9b52-8832fa38d27e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_d0e546ab-0418-4f8e-9f59-298b47bef2a1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_69398030-cacd-4bdb-89a6-ebb6deac8b43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WarrantsPolicyPolicyTextBlock_46c1ff9b-34bf-4dbb-920c-53207747b72d_terseLabel_en-US" xlink:label="lab_ino_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ino_WarrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ino_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Policy [Policy Text Block]</link:label>
    <link:label id="lab_ino_WarrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ino_WarrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WarrantsPolicyPolicyTextBlock" xlink:href="ino-20241231.xsd#ino_WarrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WarrantsPolicyPolicyTextBlock" xlink:to="lab_ino_WarrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_3fa320bb-870b-4e86-a145-db251c9d4637_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_20f95aae-9fac-421d-8ae9-e1923c91f949_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_85b097bb-c950-4eb7-a127-799086477540_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EngineeringAndDeviceRelatedMember_ecfb3f66-9083-4891-9c3f-feb7e9df13cc_terseLabel_en-US" xlink:label="lab_ino_EngineeringAndDeviceRelatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Engineering And Device-Related</link:label>
    <link:label id="lab_ino_EngineeringAndDeviceRelatedMember_label_en-US" xlink:label="lab_ino_EngineeringAndDeviceRelatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Engineering And Device-Related [Member]</link:label>
    <link:label id="lab_ino_EngineeringAndDeviceRelatedMember_documentation_en-US" xlink:label="lab_ino_EngineeringAndDeviceRelatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Engineering And Device-Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EngineeringAndDeviceRelatedMember" xlink:href="ino-20241231.xsd#ino_EngineeringAndDeviceRelatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EngineeringAndDeviceRelatedMember" xlink:to="lab_ino_EngineeringAndDeviceRelatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_c8024eec-03c9-496b-9c82-93eaa4e18914_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_e1607384-d82f-42a3-b262-d80c5d3d2f0e_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20241231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_1b0f8dad-6932-4e12-88d6-cbf3e6ad4632_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_25f4a800-01c4-4509-af7a-2ab8bc9b6e26_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_bdee3ca1-f955-4e96-ada5-d96e7f4b78cf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment disposed of</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b25deaf7-7300-47c0-b4dd-21f250fa9803_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5dd0227c-bccd-4394-aef6-17732f25081d_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17f44927-d610-4c04-bec6-4854df8752a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2e8b9889-9451-4989-9cde-4202d143dcde_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ResearchAndDevelopmentCostDomain_d11857db-ac2b-4d80-98ff-897c54ec9eba_terseLabel_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Domain]</link:label>
    <link:label id="lab_ino_ResearchAndDevelopmentCostDomain_label_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Domain]</link:label>
    <link:label id="lab_ino_ResearchAndDevelopmentCostDomain_documentation_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostDomain" xlink:href="ino-20241231.xsd#ino_ResearchAndDevelopmentCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain" xlink:to="lab_ino_ResearchAndDevelopmentCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_383406cb-b424-4ec1-9c9c-5b794dcdd10f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ebdc95eb-4725-4db8-a96b-4977a28e9338_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_7ea8f968-cfa1-46ff-baaa-e226e9250531_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_5e3871ba-b77e-447b-a140-3149bdf22cbb_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ef114efe-7798-41da-b3a1-edc47d9ec136_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7ab7675b-200d-41ae-9117-28d1a2a0ba7c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_133bc2c4-268b-495c-a10f-0d68fd4e4c19_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_06dcee67-e287-4c1b-ad5c-0247b486529b_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0e275024-265e-4439-a16f-1ff970d29feb_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_5b89a5ab-954e-4630-97ca-77034e4536a5_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20241231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_ee0fdd00-1a32-4bf4-9d39-15be1aaf3267_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of cash settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_06f734b8-8ced-48aa-a16f-9d866ce15ec3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_42fe9114-7365-4ea9-8def-54c843d5f1c9_terseLabel_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember" xlink:href="ino-20241231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoCaliforniaMember" xlink:to="lab_ino_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_f935d418-697f-49e9-90c0-692f5bbf4e25_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2022InducementPlanMember_d38c3563-322b-404d-81d8-4b20bf159c22_terseLabel_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_label_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan [Member]</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_documentation_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember" xlink:href="ino-20241231.xsd#ino_A2022InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2022InducementPlanMember" xlink:to="lab_ino_A2022InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_da228d02-e6d0-459e-b94e-f8907f697a55_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_ce017594-4c71-4146-80a8-c4d2bf9ae8a4_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability, including from affiliated entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_174b59f2-3d0d-4f09-a333-99f2eec20d44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ResearchAndDevelopmentCostAxis_56b17d1a-6afc-448b-af3d-a7cef2d5a680_terseLabel_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Axis]</link:label>
    <link:label id="lab_ino_ResearchAndDevelopmentCostAxis_label_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost [Axis]</link:label>
    <link:label id="lab_ino_ResearchAndDevelopmentCostAxis_documentation_en-US" xlink:label="lab_ino_ResearchAndDevelopmentCostAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostAxis" xlink:href="ino-20241231.xsd#ino_ResearchAndDevelopmentCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ResearchAndDevelopmentCostAxis" xlink:to="lab_ino_ResearchAndDevelopmentCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_fd574f6d-93ff-476a-a495-4631b395a866_terseLabel_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid clinical expenses</link:label>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_label_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Clinical Expenses, Current</link:label>
    <link:label id="lab_ino_PrepaidClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Clinical Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent" xlink:href="ino-20241231.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidClinicalExpensesCurrent" xlink:to="lab_ino_PrepaidClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_7c084a10-6a01-4825-95a3-694d6efc3b61_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:href="ino-20241231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_8025f7c8-4a27-4bcf-898b-594b8b4c7b61_terseLabel_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrant liability</link:label>
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_label_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Common Stock Warrants</link:label>
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_documentation_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants" xlink:href="ino-20241231.xsd#ino_ChangeInFairValueOfCommonStockWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInFairValueOfCommonStockWarrants" xlink:to="lab_ino_ChangeInFairValueOfCommonStockWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_469fdb10-8cfd-44cb-9c64-0342bed1e9bb_terseLabel_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_label_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_documentation_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:href="ino-20241231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:to="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_b072b480-a41d-44e2-a7d3-bcf027f80f22_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_adde8855-45ee-4aa4-bc48-652394ab08d7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_a21fe321-b17b-4290-b2bd-9870601122a5_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_014fe30e-a339-4d12-8e5e-3f616cd7d124_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2024SalesAgreementMember_78eaab68-59b5-4df8-b750-e6715804edb0_terseLabel_en-US" xlink:label="lab_ino_A2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Sales Agreement</link:label>
    <link:label id="lab_ino_A2024SalesAgreementMember_label_en-US" xlink:label="lab_ino_A2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_A2024SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_A2024SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember" xlink:href="ino-20241231.xsd#ino_A2024SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2024SalesAgreementMember" xlink:to="lab_ino_A2024SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_288ebd7e-13a4-4605-ae57-29b4882e3dfa_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_b52e9c5a-a3a9-4ffb-bfbc-11b766ed9d84_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_ee73b380-0510-4af3-935e-03ac193fa4d7_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, area of land under lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20241231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_374dea18-970d-44d3-9a12-209caf018500_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5145baf8-1641-4422-a32a-f4b14cead0f8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_60750f14-907b-46ce-9266-19f4603a05b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_277d81a3-a093-4350-9658-baaad8e004fe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_3dc63e9a-25ba-4705-81b3-a320f1c9bf01_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="ino-20241231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_59e59df1-10ad-4808-81a4-cad88521ca6c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_00f9957a-5677-443a-9265-b1fddc61c762_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_532e8022-5357-4036-a99c-51967c18212c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock as part of litigation settlement</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_6ca40531-6503-48c7-ad38-7a900b9de648_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_April2024OfferingMember_650d3bbb-7661-4717-87f4-593f9a25b5fb_terseLabel_en-US" xlink:label="lab_ino_April2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2024 Offering</link:label>
    <link:label id="lab_ino_April2024OfferingMember_label_en-US" xlink:label="lab_ino_April2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2024 Offering [Member]</link:label>
    <link:label id="lab_ino_April2024OfferingMember_documentation_en-US" xlink:label="lab_ino_April2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2024 Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_April2024OfferingMember" xlink:href="ino-20241231.xsd#ino_April2024OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_April2024OfferingMember" xlink:to="lab_ino_April2024OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_be0aaabc-dac6-415e-99cf-693adfa24fbd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4250f12d-b936-46f8-a3c4-743efb8ea3ba_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_4ede0df5-9fce-4cda-99bb-82d6ee8eb543_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$1.78-$18.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesOneMember" xlink:to="lab_ino_RangeOfExercisePricesOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c3f7723b-19a8-4fce-9e53-9af09c1e67f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_426e9e16-ee61-4ce2-ab42-d141f44832f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_a6dbe78e-967d-4fa9-a82d-c4785702d5a4_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement, aggregate proceeds from issuance of stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_eb3b7cda-05e8-4b58-9ed1-9e528eccd5ba_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3e35d408-c3a9-4abe-b77c-f6240c9d2950_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_2b85bcac-b038-48fa-90df-295b832cd056_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_2b064f20-15db-4981-a5bb-cd76b33a718e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_34774ac8-758c-4547-9bcc-e5417ff57e8f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_43d43a0d-4f53-46d3-8531-e55468f719d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b64977f7-0b22-47e2-a904-7dedd37813a1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_8a18ab96-781a-4e9d-844a-3e75c3123572_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_27be0de0-3c4e-4f94-811f-92ef8b0fa4e7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_823aa20d-7e8f-4b80-9da4-57eb15649360_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for legal settlement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f958b2c8-746c-4f10-a8cc-d3b31e166550_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ab38a248-5a33-4677-863c-1a61690640a9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_9a69e45b-4997-4921-bc31-3d0842d70903_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ce779b88-55e3-48e3-82cc-9b346f3b0802_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42882e9b-4198-44c2-a9e1-ba397d86e770_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_444b90ee-6a64-436c-ab7f-8abe700d8591_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_59eb6735-cfba-4132-bc6d-017a585d55b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b605581d-3f95-434d-b409-f38901916592_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1e3e4f02-b585-47dc-93f2-2a2edff6c9e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d234e858-88f7-4abd-ab2f-09a7b9208cae_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_8635f420-aa0c-49c2-b051-cf355c40b0d0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual life (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherUnallocatedExpensesMember_ce656232-1755-49fa-b3e4-b83f2cfcb5d9_terseLabel_en-US" xlink:label="lab_ino_OtherUnallocatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Unallocated Expenses</link:label>
    <link:label id="lab_ino_OtherUnallocatedExpensesMember_label_en-US" xlink:label="lab_ino_OtherUnallocatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Unallocated Expenses [Member]</link:label>
    <link:label id="lab_ino_OtherUnallocatedExpensesMember_documentation_en-US" xlink:label="lab_ino_OtherUnallocatedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Unallocated Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherUnallocatedExpensesMember" xlink:href="ino-20241231.xsd#ino_OtherUnallocatedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherUnallocatedExpensesMember" xlink:to="lab_ino_OtherUnallocatedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_af9f1d29-685e-42a3-8d2d-e2d9f57e62b9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6859889d-a840-44e6-9a24-ca162bee3219_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5f64afa6-c5df-4d67-aff2-3fdfb3949712_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_9d3fd987-d15a-416b-ad15-00487a5b4a2e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_10d33a30-a132-4d43-a9cb-2aabc59c66a7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_424d46d0-7c69-48af-a101-608a4109382c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f95855f4-c59e-4e53-be30-d7cad658eefe_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_12176bb9-6b5a-47cc-bfd7-7b6344b0ec8b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_a4fee77a-2ea5-4fba-aa78-b4214359743c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock shares outstanding under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_cb7a3811-9adb-4954-b812-e186968e84a0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_1c4e0db4-3c0e-43c4-bad3-8becadca7563_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20241231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f4d1663b-2fd3-4b13-9545-8ecdf44b5ad4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_70de4bc5-3b09-4785-a07d-6bb79c81bb10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6344bf6f-cdcb-4e24-87f2-64fcef1f0edf_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_cfa004a9-4782-497b-a0a5-1970f751d1c3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0b8c4832-dd5d-4c5e-9bc0-803e9a6c5810_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_15cea680-59b9-4a3d-b757-3c526f131b1d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_47dffeba-e9cd-4da0-9f11-27db989dfffb_terseLabel_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, common stock, maximum (percent)</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_label_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent</link:label>
    <link:label id="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_documentation_en-US" xlink:label="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:to="lab_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ead4f177-195c-41a5-af2b-a4e34ec7ac26_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5d72db45-47b6-4e7c-9304-d41e5ae810f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f5f32d53-b66e-4863-8382-742250dccaa5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_ba5eb6c2-dea2-480e-aa2d-70e0c23a45a1_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1513ef15-da9a-49c1-98e5-6be0ef5e0494_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_5b051b57-a083-46fc-9375-0e42bf465a4b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8aeb6176-141a-4853-9f41-3ffc00e896ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9ea94a7a-6511-4d2a-88fa-b6126ebfe3fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_f084c3ad-d3e8-4fbe-b785-0d996d6cfea4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue From External Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_ed24fea1-cb7e-4e11-98ab-01432725c37e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development and other tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityMethodInvestmentsMinimum_65afc0fe-4250-4c29-9da6-a3593cd156b1_terseLabel_en-US" xlink:label="lab_ino_EquityMethodInvestmentsMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments, minimum</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentsMinimum_label_en-US" xlink:label="lab_ino_EquityMethodInvestmentsMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Minimum</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentsMinimum_documentation_en-US" xlink:label="lab_ino_EquityMethodInvestmentsMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentsMinimum" xlink:href="ino-20241231.xsd#ino_EquityMethodInvestmentsMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityMethodInvestmentsMinimum" xlink:to="lab_ino_EquityMethodInvestmentsMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_8af6ac21-efa8-4c9a-8101-3644ca8e7fa1_terseLabel_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average pre-funded warrants (in shares)</link:label>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_label_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</link:label>
    <link:label id="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_documentation_en-US" xlink:label="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:href="ino-20241231.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:to="lab_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20df7603-a844-4561-9794-289bec052052_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0d692014-852c-4bbe-b4c0-4b54ac3518ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9bc5d4ba-5778-49b1-90de-5d32c0a754ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c62af783-2f4c-4113-ac8d-5b5af8c8dfc2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_67ecde19-a513-4375-8fba-e24a770c526c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_2b748204-3adc-47d6-ab94-ddff2c5de6ad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2023IncentivePlanMember_b2763237-c2bc-4552-903b-d8bb27b35886_terseLabel_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan</link:label>
    <link:label id="lab_ino_A2023IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2023IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2023IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember" xlink:href="ino-20241231.xsd#ino_A2023IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2023IncentivePlanMember" xlink:to="lab_ino_A2023IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_57045ee8-e171-444f-a62a-9f5db422c413_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_45912f45-be98-485e-aaf9-793314be63b8_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement amended amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAmendedAmount" xlink:to="lab_ino_CollaborativeAgreementAmendedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_9b3da667-bbe0-4609-af42-a13044ea096b_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funding received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_78521d77-aae9-42ee-81b1-9ddded609f83_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_e80893ab-2f05-40ff-82c8-013ca72e78ff_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_fb5d8bec-29c3-4f41-ba14-19fd740ebe6c_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5d404767-fa42-4300-b16f-65d0689f2fea_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5f3c6da7-a0a5-4df9-b294-cf156c5807f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_e4b7f575-8503-4ae7-83d7-83b0f4cefbd4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_14866b88-8abe-45af-975c-9218e50f7ed0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0e8d9be5-54e0-4fa6-81af-eac88164e7d5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_81163081-9336-40dc-9800-bb00cfe151c4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_883cb9ce-3d55-4098-946f-009678a06d66_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_9e380f9d-21b3-4927-b92e-51e26fd739d9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f7130a32-510c-4832-ae0a-5bf6ec8fe0c3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2024 and 2023, issued and outstanding: 36,099,991 at December&#160;31, 2024 and 22,793,075 at December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_a92328c0-0e8e-4f53-a32e-1b538f356b40_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_2f89d766-4995-4dd0-be48-09f773e3fa56_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20241231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_62628c5e-5350-4ae8-820e-a186bc83d7ab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AuditInformationAbstract_label_en-US" xlink:label="lab_ino_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ino_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ino_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AuditInformationAbstract" xlink:href="ino-20241231.xsd#ino_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AuditInformationAbstract" xlink:to="lab_ino_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3409932d-fd70-450a-b033-d17cde91b5f9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6bba27a4-df82-4eca-ab3b-6b012e467c31_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_84f8d9f1-f5be-4644-a320-a7fb82f5f1d2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2024 and 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_97ec9c35-2170-47a5-97eb-273ade89c8b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_7b3d3b1d-f555-4c63-a28e-99b93dfaad65_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8c6948b2-e8a6-4861-9485-a2b86a7ccd52_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_75c27e19-2b49-4fd4-b40d-4a9763c14a24_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_35cb0068-aeda-41c9-8623-349f0fbee393_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_71931bf5-c695-44c9-b3e2-f974789e59ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_64fea3f9-e898-42d1-9fc1-26e6efafe712_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_7b4fc51e-22e8-4082-929b-9d28cb55be1b_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_70ad2646-05dc-4f01-b718-a68918e85a06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_640758e5-77d9-489c-ab85-1426e8e652d2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_867d6ca1-05b0-4c5a-b8cd-2f0e0b2a3f05_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d99739c6-5e3f-4969-8d31-fd9b4e10fed4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_6946bf3d-54be-4461-95af-5fae1a95f6e4_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying common stock (in shares)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_2a95ece4-f73f-427f-a896-cf2f56adf63b_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:href="ino-20241231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_633a4730-e045-4c12-8f01-578fe730aae8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea7bb846-b12c-45b4-bf7c-f991a21c4b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4467e7a0-f4d7-4c08-a30c-c3db80366b95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_997d1ef3-7d89-4467-a0a9-8672b8811d55_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_a8303b3a-38c8-49e8-827a-b67c27601044_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9f7d02cc-1a4b-407d-96f5-483524efd0b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ed29b8b0-bf49-4dfd-9a26-03ca178a4d73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, exercises in period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_d635bd91-9168-4bb4-acb7-cb1ff25380c7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expirations of Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_a620db39-afd8-4462-8c8f-b617ca02b215_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20241231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f77565d5-7af4-40ef-8001-bb6b36918cfb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_97156f53-bcc4-4520-ac35-667728cf52fe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_8841caea-3baf-45b6-a041-6be368bc8e4c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4779278e-0148-4e39-ae49-745ab46e6f81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_0d94f11d-747b-4174-aaaa-ac586959b8cd_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Milestone-Based</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Milestone-Based [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Milestone-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:to="lab_ino_RestrictedStockUnitsRSUsMilestoneBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9332ac06-0751-4047-81f5-098907df466f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a3e19df0-7740-4e76-9d18-1821ab108b87_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_faa48eff-f06a-407d-886e-db9cd5338505_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_b3ca5762-8bcf-4398-9e86-9fb8d3284910_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_da7ffe3a-1151-4564-8f93-459c57b4a04c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_110e3be9-adc6-444b-bae7-1cc2b3aa1785_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2c83c282-67c3-4df0-88ed-8ba92832b9e4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_42a2ecfb-eced-4493-a7dc-ad6cc18cbda9_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20241231.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7277169a-fde5-49e8-b52e-6698aa6fab5c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e8b149b5-4d6e-4232-a2fe-1472ccf0f0b4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_e6edae0d-2cce-4e3a-90d8-b17e14abfa8a_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation period to pay royalties</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20241231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ee3941f9-5fa7-40c2-8d75-8a86a0c8fc77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestrictedStockUnitsPerformanceBasedMember_046fcc33-5d16-4b6c-b49f-2b33c25908b7_terseLabel_en-US" xlink:label="lab_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units, Performance-Based</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsPerformanceBasedMember_label_en-US" xlink:label="lab_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units, Performance-Based [Member]</link:label>
    <link:label id="lab_ino_RestrictedStockUnitsPerformanceBasedMember_documentation_en-US" xlink:label="lab_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units, Performance-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:to="lab_ino_RestrictedStockUnitsPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c449e224-1280-45b7-9705-6ecdc46b7028_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e28e3645-d2db-4cc7-859b-2860be128fb2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_8e6fdba3-8694-46c8-820f-7cfe6a7814b0_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20241231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_4817ca52-80d7-445c-8540-22935f89a2e4_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards settled in cash, percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_086e3457-e889-4ccf-b7c0-893129dc1eff_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_342516d1-6d9e-4b26-9935-c69f555ffcd3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41033030-6d5a-41f7-bb87-f26f07f515f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_495023c9-24be-44d4-b1fb-c677aec83e92_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c741f6fe-81bc-4680-a4db-d5470b7499a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, expirations in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8eaf8873-4b80-4ff6-9b39-409abfeb0265_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_15d9d81a-dcff-44ba-b26f-7af983da6251_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase of base rent percentage</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:href="ino-20241231.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:to="lab_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2b6b609e-6811-4684-bffa-2d10001de7e2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_72b2eaa3-3d8c-4a32-abe7-3c935c9d19e3_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets, including with affiliated entity</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6007eaa1-7b80-4337-bb27-6981a1e964a6_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_cf6bda05-f7e9-4076-a42e-193e014b1b74_terseLabel_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Operating Loss And Tax Credit Carryforward Expirations</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:href="ino-20241231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:to="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b2ef9f31-1797-476e-ac35-00449434d8bb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_fc135f16-50e5-499f-81e6-e9f0a8409355_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_ff50da57-da5d-4f84-9ff0-3356287bbf04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits Rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_bbb499d5-6464-40b8-ab79-d0220707654a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2b6e147f-df5d-4caa-ab1f-aaec686057a7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_de2f81ba-00a3-481e-8d39-4dbbdb88d7f6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c036a74f-6546-46fa-8837-463fbf0dae5e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards_59b981a4-f61a-4252-ae1c-299776a105fe_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Awards Granted, Percentage Of Target Awards</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Awards Granted, Percentage Of Target Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_1ce9afcd-3d1d-412e-a05b-ec4e91f4986f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, upper range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ca4a46df-b8fe-486f-8206-380cf07b21e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-and market-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c9f6aa8c-12bc-4f69-bf6a-5ad76d9ba59d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ad18bda1-1689-44d7-b41e-6d17683828fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_3fc54d74-e5b6-4144-b271-73a5910ce132_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_12d0232f-4791-4534-a524-2b0468bc0983_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ino-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:17b32d98-3816-4b9f-8e66-a2aab92f0705,g:04b54f73-b42b-4be7-b731-92d690b75cab-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20241231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_811d7842-596b-44b4-a1c0-6ead1e2362aa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_DocumentType_811d7842-596b-44b4-a1c0-6ead1e2362aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ec6d3026-aebd-457b-b6dd-05721aae3044" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_DocumentAnnualReport_ec6d3026-aebd-457b-b6dd-05721aae3044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8ecea0ea-b702-4867-b782-233bfcdc63db" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_DocumentPeriodEndDate_8ecea0ea-b702-4867-b782-233bfcdc63db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_eeae07f8-3527-4a4d-b38d-b7349cae7ab0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_CurrentFiscalYearEndDate_eeae07f8-3527-4a4d-b38d-b7349cae7ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e3278c76-d4cc-4e3d-a232-72aff9f45dd6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_DocumentTransitionReport_e3278c76-d4cc-4e3d-a232-72aff9f45dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ba7e9f55-0fa0-46ca-a441-a95ea7b3c5ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityFileNumber_ba7e9f55-0fa0-46ca-a441-a95ea7b3c5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d9364c2c-367a-4e79-818c-eeb2a872f93e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityRegistrantName_d9364c2c-367a-4e79-818c-eeb2a872f93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_776d1928-c3cc-4d3b-bcb3-8755254008b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_776d1928-c3cc-4d3b-bcb3-8755254008b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b18f2926-cf0a-4bfc-a075-e94848d1d2eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityTaxIdentificationNumber_b18f2926-cf0a-4bfc-a075-e94848d1d2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6527f0e5-9afd-482d-9c69-f5b7b35c9d65" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityAddressAddressLine1_6527f0e5-9afd-482d-9c69-f5b7b35c9d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_672c4085-7e73-4593-91db-ff4478f2fc1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityAddressAddressLine2_672c4085-7e73-4593-91db-ff4478f2fc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a968d7db-001a-4798-95a6-a8fceab2a9d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityAddressCityOrTown_a968d7db-001a-4798-95a6-a8fceab2a9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c63d61d1-774b-4dda-8ff8-823dcf340403" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityAddressStateOrProvince_c63d61d1-774b-4dda-8ff8-823dcf340403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bf3fb980-b882-43e1-be37-c6d3e82b9c9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityAddressPostalZipCode_bf3fb980-b882-43e1-be37-c6d3e82b9c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_afb4d47d-d28c-45ea-88a8-359e6776f39c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_CityAreaCode_afb4d47d-d28c-45ea-88a8-359e6776f39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_02f68c06-03a3-41d4-99b2-280af0928db0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_LocalPhoneNumber_02f68c06-03a3-41d4-99b2-280af0928db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1a28e7d7-f023-4e2b-8966-048f876a9aa9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_Security12bTitle_1a28e7d7-f023-4e2b-8966-048f876a9aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5bc2b328-2765-4a95-919c-5f9c1cb4697e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_TradingSymbol_5bc2b328-2765-4a95-919c-5f9c1cb4697e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fd123522-75c5-4987-8024-25bafea7eb97" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_SecurityExchangeName_fd123522-75c5-4987-8024-25bafea7eb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_2eee056e-76c4-4aa6-b9fd-154bf82f0a07" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_2eee056e-76c4-4aa6-b9fd-154bf82f0a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c21fa986-c038-4a1e-a7f0-911d17fb42b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityVoluntaryFilers_c21fa986-c038-4a1e-a7f0-911d17fb42b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8c93f73a-64c2-42db-a352-2c9b61745c4e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityCurrentReportingStatus_8c93f73a-64c2-42db-a352-2c9b61745c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5d60999a-c196-466a-80cc-0c0618ae845b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityInteractiveDataCurrent_5d60999a-c196-466a-80cc-0c0618ae845b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1a668d7d-0d4a-41a3-9345-a80b5658f787" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityFilerCategory_1a668d7d-0d4a-41a3-9345-a80b5658f787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2eb4de00-647e-44df-baeb-30696f6ffbb8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntitySmallBusiness_2eb4de00-647e-44df-baeb-30696f6ffbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_61d69688-dcd5-4374-b600-087bff35435a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityEmergingGrowthCompany_61d69688-dcd5-4374-b600-087bff35435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_57ffc203-75c4-468b-9374-fadc01754673" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_57ffc203-75c4-468b-9374-fadc01754673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_e805e2f3-bdb1-44ab-b6ea-e397321eb517" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_e805e2f3-bdb1-44ab-b6ea-e397321eb517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c575b226-25c7-4fda-8fdd-45055a1a3773" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityShellCompany_c575b226-25c7-4fda-8fdd-45055a1a3773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_74b8a853-91ba-4766-b4b6-b2717c6d2076" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityPublicFloat_74b8a853-91ba-4766-b4b6-b2717c6d2076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6749a2b3-b00c-4da2-bd8a-c527af0b2786" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6749a2b3-b00c-4da2-bd8a-c527af0b2786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_80bb111b-9447-42f5-8714-145c57fb9586" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_80bb111b-9447-42f5-8714-145c57fb9586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8dae6c48-6cc3-4ce9-a6ff-a00f62a307af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_AmendmentFlag_8dae6c48-6cc3-4ce9-a6ff-a00f62a307af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_83c36345-c19f-4316-8424-6d2afd47e240" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_DocumentFiscalYearFocus_83c36345-c19f-4316-8424-6d2afd47e240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7626b40c-6083-46c7-897a-0a7f743be637" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7626b40c-6083-46c7-897a-0a7f743be637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5e33a941-69b9-4fc1-bed6-607df3095540" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b62d4fb-7dec-4528-a875-d9b978bea17e" xlink:to="loc_dei_EntityCentralIndexKey_5e33a941-69b9-4fc1-bed6-607df3095540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AuditInformation" xlink:type="simple" xlink:href="ino-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AuditInformationAbstract_508cae9d-139b-4b3c-84a1-1979fb56ffed" xlink:href="ino-20241231.xsd#ino_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_3b251287-ee4b-41b6-8757-00f82ef5c216" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_508cae9d-139b-4b3c-84a1-1979fb56ffed" xlink:to="loc_dei_AuditorLocation_3b251287-ee4b-41b6-8757-00f82ef5c216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_dc975a29-45e9-4502-af62-b6d5f1ca762a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_508cae9d-139b-4b3c-84a1-1979fb56ffed" xlink:to="loc_dei_AuditorName_dc975a29-45e9-4502-af62-b6d5f1ca762a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_8cd69228-a2b4-43cd-8fce-6e3fb98762d8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_508cae9d-139b-4b3c-84a1-1979fb56ffed" xlink:to="loc_dei_AuditorFirmId_8cd69228-a2b4-43cd-8fce-6e3fb98762d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_556df3b6-67fb-46be-8ad5-b32ba13a8850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_467dd741-7083-49b0-b89e-d7b4dbd7c38b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_556df3b6-67fb-46be-8ad5-b32ba13a8850" xlink:to="loc_us-gaap_StatementTable_467dd741-7083-49b0-b89e-d7b4dbd7c38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_467dd741-7083-49b0-b89e-d7b4dbd7c38b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_66db659b-db3e-4bed-a816-783c6a32dffe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ebee69d9-eb1a-4a0c-9436-e4797ed6cc50" xlink:to="loc_us-gaap_RelatedPartyDomain_66db659b-db3e-4bed-a816-783c6a32dffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_721d3b75-ec66-4060-8eff-60664bba02b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_66db659b-db3e-4bed-a816-783c6a32dffe" xlink:to="loc_us-gaap_NonrelatedPartyMember_721d3b75-ec66-4060-8eff-60664bba02b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_e5671939-a64e-40d7-97b4-8233114e1f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_66db659b-db3e-4bed-a816-783c6a32dffe" xlink:to="loc_us-gaap_RelatedPartyMember_e5671939-a64e-40d7-97b4-8233114e1f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_240a87d5-d355-428a-b243-ee616d8d5133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_467dd741-7083-49b0-b89e-d7b4dbd7c38b" xlink:to="loc_us-gaap_StatementLineItems_240a87d5-d355-428a-b243-ee616d8d5133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_240a87d5-d355-428a-b243-ee616d8d5133" xlink:to="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3030cccc-00da-4377-8808-a680e514b15d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3030cccc-00da-4377-8808-a680e514b15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a04d4ef9-9b29-408b-a8f5-7610060f488b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_ShortTermInvestments_a04d4ef9-9b29-408b-a8f5-7610060f488b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_04567f62-b7b3-432b-8a50-ac3db3b57c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_04567f62-b7b3-432b-8a50-ac3db3b57c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5368c6c-46fd-4ee7-a1ef-bb95a4f4b413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f5368c6c-46fd-4ee7-a1ef-bb95a4f4b413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_98ac2eeb-3650-4ae9-9f73-c4088bd8badf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_61d87b6d-360d-4396-bcf1-287795c02ae9" xlink:to="loc_us-gaap_AssetsCurrent_98ac2eeb-3650-4ae9-9f73-c4088bd8badf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7e56cba8-596e-4bca-b236-3d891f39e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7e56cba8-596e-4bca-b236-3d891f39e30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d57c6eec-d019-4c7b-993a-ac7213bf7abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_d57c6eec-d019-4c7b-993a-ac7213bf7abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc4efc44-e793-4175-b1a7-887d8b6d8aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cc4efc44-e793-4175-b1a7-887d8b6d8aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5a10b5dc-a2d6-4e05-8ed5-60faceb5960d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5a10b5dc-a2d6-4e05-8ed5-60faceb5960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b46b2f8b-2ecc-456f-ac7f-0e2058a3dc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_cf71f80c-b04a-4a86-b2a6-950c9447df14" xlink:to="loc_us-gaap_Assets_b46b2f8b-2ecc-456f-ac7f-0e2058a3dc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_240a87d5-d355-428a-b243-ee616d8d5133" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e3baa97c-ea47-49a2-a0d7-fc3160beb419" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_e3baa97c-ea47-49a2-a0d7-fc3160beb419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_2fc338f5-63c7-4e58-8717-487302831a96" xlink:href="ino-20241231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_2fc338f5-63c7-4e58-8717-487302831a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_525f8a46-1154-4437-99b4-65eed52fd567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_525f8a46-1154-4437-99b4-65eed52fd567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c661a5f6-8909-4722-bef0-5d51073f208c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c661a5f6-8909-4722-bef0-5d51073f208c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_92bc2001-6825-4dd5-b7eb-de0ec6c307a7" xlink:href="ino-20241231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_ino_DeferredGrantFundingCurrent_92bc2001-6825-4dd5-b7eb-de0ec6c307a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_7b5f3b8b-69b7-480c-a37e-eb43e14568f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_7b5f3b8b-69b7-480c-a37e-eb43e14568f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e17f9e18-fd91-4f65-b0b2-353f7b2c54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15a607a4-7db0-4ac5-a8e9-7dde023a5cc2" xlink:to="loc_us-gaap_LiabilitiesCurrent_e17f9e18-fd91-4f65-b0b2-353f7b2c54c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c69e8f88-a719-459c-b1d1-8931b5ed1d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c69e8f88-a719-459c-b1d1-8931b5ed1d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bc3bb252-c219-491a-b9a1-abbcd8d3ddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_Liabilities_bc3bb252-c219-491a-b9a1-abbcd8d3ddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4781a13a-5020-44e6-8b72-6e665a154353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4781a13a-5020-44e6-8b72-6e665a154353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_684ae8ee-8fa4-4bf8-9b6e-0cb2e58f6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_PreferredStockValue_684ae8ee-8fa4-4bf8-9b6e-0cb2e58f6a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0d5b7ea3-41f8-4593-8d07-d10cc5684b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_CommonStockValue_0d5b7ea3-41f8-4593-8d07-d10cc5684b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e7ed6259-a17b-4832-ab9c-5a84686a4534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e7ed6259-a17b-4832-ab9c-5a84686a4534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43b2661f-ddf9-4ff9-bc80-194f0e23c30e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_43b2661f-ddf9-4ff9-bc80-194f0e23c30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f9a1a04-b527-4188-90c1-dbdc082f64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f9a1a04-b527-4188-90c1-dbdc082f64ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db6b0b13-e6bb-4f96-9789-fa27f2fe2091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e342c266-e66b-41f0-98a2-f6f468eb5676" xlink:to="loc_us-gaap_StockholdersEquity_db6b0b13-e6bb-4f96-9789-fa27f2fe2091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5221d3d6-a9a3-4764-9f2f-a6c72634b552" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_008a3f64-80bd-4279-ba53-0f924c90a2b2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5221d3d6-a9a3-4764-9f2f-a6c72634b552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_84515386-d18f-4843-a95c-03ad23fe0734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_84515386-d18f-4843-a95c-03ad23fe0734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c2e0024d-3039-4e33-892b-f937965c40d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c2e0024d-3039-4e33-892b-f937965c40d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3f5cc99b-fce3-48ed-bad1-389e3138c4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3f5cc99b-fce3-48ed-bad1-389e3138c4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2a22e83e-4793-4d2d-a83b-5943ba61157b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2a22e83e-4793-4d2d-a83b-5943ba61157b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3cff549c-e3c8-4ef1-ab15-3cec708efbea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3cff549c-e3c8-4ef1-ab15-3cec708efbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_485b5ca1-1b85-45f2-bf3b-3a0a77e0017c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_485b5ca1-1b85-45f2-bf3b-3a0a77e0017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_156467db-e0e4-4ddc-9cc3-898084c666d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:to="loc_us-gaap_CommonStockSharesIssued_156467db-e0e4-4ddc-9cc3-898084c666d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d86e217b-0da8-405d-8a09-7f93b37fa160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8941e33f-f35e-4fde-bbd3-3cf8c53cedc6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d86e217b-0da8-405d-8a09-7f93b37fa160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5b364a61-ee80-49ea-8162-5824c4b4b859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ba415014-f568-4036-bf8e-8c31f87fa8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b364a61-ee80-49ea-8162-5824c4b4b859" xlink:to="loc_us-gaap_RevenuesAbstract_ba415014-f568-4036-bf8e-8c31f87fa8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_736062f5-24fe-4763-a852-909e2a8c8bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ba415014-f568-4036-bf8e-8c31f87fa8cc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_736062f5-24fe-4763-a852-909e2a8c8bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_06ec3762-d44a-467e-b947-82944cb4b26f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b364a61-ee80-49ea-8162-5824c4b4b859" xlink:to="loc_us-gaap_OperatingExpensesAbstract_06ec3762-d44a-467e-b947-82944cb4b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f5ee5a47-95e2-4198-ac46-32c1f0aa6bff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_06ec3762-d44a-467e-b947-82944cb4b26f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f5ee5a47-95e2-4198-ac46-32c1f0aa6bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c7be5002-ad3e-4b1c-a29e-26c8d071333d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_06ec3762-d44a-467e-b947-82944cb4b26f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c7be5002-ad3e-4b1c-a29e-26c8d071333d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_96655b34-8c66-4af5-b524-197b5d4d4db1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_06ec3762-d44a-467e-b947-82944cb4b26f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_96655b34-8c66-4af5-b524-197b5d4d4db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_30fbd013-03b9-4ba0-83df-921937a3ef0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_06ec3762-d44a-467e-b947-82944cb4b26f" xlink:to="loc_us-gaap_OperatingExpenses_30fbd013-03b9-4ba0-83df-921937a3ef0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_11070b94-7f87-4f1b-8544-441a01920f48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b364a61-ee80-49ea-8162-5824c4b4b859" xlink:to="loc_us-gaap_OperatingIncomeLoss_11070b94-7f87-4f1b-8544-441a01920f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a846fe2-8c14-4e4e-9745-46ec68fac3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b364a61-ee80-49ea-8162-5824c4b4b859" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a846fe2-8c14-4e4e-9745-46ec68fac3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c4b496a7-ac1e-4f47-b09b-33f80e74d332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a846fe2-8c14-4e4e-9745-46ec68fac3ce" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c4b496a7-ac1e-4f47-b09b-33f80e74d332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_f86d8cde-3d7b-4e9a-9ed4-1fc2a812408c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a846fe2-8c14-4e4e-9745-46ec68fac3ce" xlink:to="loc_us-gaap_InterestExpenseNonoperating_f86d8cde-3d7b-4e9a-9ed4-1fc2a812408c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_dab941b6-675b-4238-878b-7202afc3563e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a846fe2-8c14-4e4e-9745-46ec68fac3ce" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_dab941b6-675b-4238-878b-7202afc3563e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_9e82fc8f-4475-459a-bc9b-881527df1b2e" xlink:href="ino-20241231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a846fe2-8c14-4e4e-9745-46ec68fac3ce" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_9e82fc8f-4475-459a-bc9b-881527df1b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_78bc6b76-6525-421d-bedc-db23eb4f780c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a846fe2-8c14-4e4e-9745-46ec68fac3ce" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_78bc6b76-6525-421d-bedc-db23eb4f780c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_10596b3c-6a58-456d-93b4-eed2597cf378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a846fe2-8c14-4e4e-9745-46ec68fac3ce" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_10596b3c-6a58-456d-93b4-eed2597cf378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_de5bf6d2-9400-46a1-aea0-72b989ad1aec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b364a61-ee80-49ea-8162-5824c4b4b859" xlink:to="loc_us-gaap_NetIncomeLoss_de5bf6d2-9400-46a1-aea0-72b989ad1aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9b001e04-9c59-45bc-86ae-b51a2ace76f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b364a61-ee80-49ea-8162-5824c4b4b859" xlink:to="loc_us-gaap_EarningsPerShareAbstract_9b001e04-9c59-45bc-86ae-b51a2ace76f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0299844c-7df1-425b-8b11-89c248494c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9b001e04-9c59-45bc-86ae-b51a2ace76f8" xlink:to="loc_us-gaap_EarningsPerShareBasic_0299844c-7df1-425b-8b11-89c248494c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_02e7268f-b8ff-4486-b1c2-1760a49eb771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9b001e04-9c59-45bc-86ae-b51a2ace76f8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_02e7268f-b8ff-4486-b1c2-1760a49eb771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_217f01ae-6a56-470c-8207-f5b9a92cc9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5b364a61-ee80-49ea-8162-5824c4b4b859" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_217f01ae-6a56-470c-8207-f5b9a92cc9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ea312af-10e9-4eb6-a23a-7f2d08104f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_217f01ae-6a56-470c-8207-f5b9a92cc9fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ea312af-10e9-4eb6-a23a-7f2d08104f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7f35b235-28df-459f-bb8d-a00c8ef48796" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_217f01ae-6a56-470c-8207-f5b9a92cc9fa" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7f35b235-28df-459f-bb8d-a00c8ef48796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8366f05c-0070-4adf-8e24-879e0ac6009e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f6997d5d-b097-43c9-ba92-45fc48467f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8366f05c-0070-4adf-8e24-879e0ac6009e" xlink:to="loc_us-gaap_NetIncomeLoss_f6997d5d-b097-43c9-ba92-45fc48467f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c660f981-e21f-4baa-91b7-ec83c9a9d068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8366f05c-0070-4adf-8e24-879e0ac6009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c660f981-e21f-4baa-91b7-ec83c9a9d068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a7792e2a-9d56-4417-8dc3-653de5bba432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c660f981-e21f-4baa-91b7-ec83c9a9d068" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a7792e2a-9d56-4417-8dc3-653de5bba432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_48a1ce64-fe98-488f-8d81-7a51ce9e06d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_c660f981-e21f-4baa-91b7-ec83c9a9d068" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_48a1ce64-fe98-488f-8d81-7a51ce9e06d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d10987c6-6523-4cdd-95bc-b09db0967227" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8366f05c-0070-4adf-8e24-879e0ac6009e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d10987c6-6523-4cdd-95bc-b09db0967227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_959f7c2c-5589-4dca-bd9c-6837c1c1798a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3dc8dca9-ae30-4225-b338-e6bb503e527f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_959f7c2c-5589-4dca-bd9c-6837c1c1798a" xlink:to="loc_us-gaap_StatementTable_3dc8dca9-ae30-4225-b338-e6bb503e527f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_76f3d074-0675-4528-9469-7e0cf7666d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3dc8dca9-ae30-4225-b338-e6bb503e527f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_76f3d074-0675-4528-9469-7e0cf7666d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_76f3d074-0675-4528-9469-7e0cf7666d7a" xlink:to="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_13249820-9329-4e53-b488-a430eb32eac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_PreferredStockMember_13249820-9329-4e53-b488-a430eb32eac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_29fb8304-280d-4f11-b9a1-e03cc29823b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_CommonStockMember_29fb8304-280d-4f11-b9a1-e03cc29823b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1b5c0f85-3c03-4e97-9d00-4824eeaa1a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1b5c0f85-3c03-4e97-9d00-4824eeaa1a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ea5a22cb-9589-4830-9733-13ad13d43a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_RetainedEarningsMember_ea5a22cb-9589-4830-9733-13ad13d43a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_90b293ce-9532-4317-a425-a71dd203b4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86bb99ce-181c-4077-a6d6-1f9ae81c4943" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_90b293ce-9532-4317-a425-a71dd203b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bfdf46ce-8297-4bd3-881e-92a6fd1a86a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3dc8dca9-ae30-4225-b338-e6bb503e527f" xlink:to="loc_us-gaap_StatementLineItems_bfdf46ce-8297-4bd3-881e-92a6fd1a86a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bfdf46ce-8297-4bd3-881e-92a6fd1a86a0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_82a8652a-11c0-4b11-a43d-f90f9af11002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_82a8652a-11c0-4b11-a43d-f90f9af11002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ac88819e-ec0f-4968-83f4-846d155bb8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ac88819e-ec0f-4968-83f4-846d155bb8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7cabb347-9f21-4e55-aad9-1ca83dab27ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockholdersEquity_7cabb347-9f21-4e55-aad9-1ca83dab27ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2861879c-f91b-4745-9628-c5a995ac593d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2861879c-f91b-4745-9628-c5a995ac593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4905057c-6f1d-430c-ac8a-226a01724419" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_4905057c-6f1d-430c-ac8a-226a01724419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93884981-087c-4304-ada7-e4003a532918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93884981-087c-4304-ada7-e4003a532918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bc3f980f-1453-4fc1-bc1a-96fedcb2fc00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bc3f980f-1453-4fc1-bc1a-96fedcb2fc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_57ab51ae-e057-4786-b371-b330a26ea62b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_57ab51ae-e057-4786-b371-b330a26ea62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_49d7f556-e510-434c-9bb6-c025286e3b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_49d7f556-e510-434c-9bb6-c025286e3b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a07e93c2-6723-4375-9f55-e5f21d097970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a07e93c2-6723-4375-9f55-e5f21d097970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_23376a79-188e-4978-b925-1a23de20e7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_23376a79-188e-4978-b925-1a23de20e7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94fd0eac-017c-47f6-aaa5-edf4a0bd1118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_NetIncomeLoss_94fd0eac-017c-47f6-aaa5-edf4a0bd1118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_76b8a5e5-1a79-4255-a202-ad123a4d10d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_76b8a5e5-1a79-4255-a202-ad123a4d10d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_95ccd6a3-dd93-4e39-b8d5-62797a053f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_95ccd6a3-dd93-4e39-b8d5-62797a053f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d48b0262-543f-479d-a3f0-b7791e9f288d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d48b0262-543f-479d-a3f0-b7791e9f288d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9335ce9d-d82c-4381-b5e0-afb100b36645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9335ce9d-d82c-4381-b5e0-afb100b36645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d729a76-eafe-49f7-8278-2d08492f8d32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5dd94e78-bddb-454f-89f9-9de7c73a1f0a" xlink:to="loc_us-gaap_StockholdersEquity_0d729a76-eafe-49f7-8278-2d08492f8d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f70f4c6e-092c-460a-a048-c3a6bcc18f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f70f4c6e-092c-460a-a048-c3a6bcc18f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c12706dd-9110-48ae-ba14-73e8c883197e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f70f4c6e-092c-460a-a048-c3a6bcc18f7c" xlink:to="loc_us-gaap_NetIncomeLoss_c12706dd-9110-48ae-ba14-73e8c883197e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f70f4c6e-092c-460a-a048-c3a6bcc18f7c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e6242bc7-1066-49c5-8299-dfeec086b824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_Depreciation_e6242bc7-1066-49c5-8299-dfeec086b824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4181b3fd-58bd-477d-a3b8-e775b0d4498d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4181b3fd-58bd-477d-a3b8-e775b0d4498d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6b48574a-249a-4b08-a37a-ccb3b2cb7c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6b48574a-249a-4b08-a37a-ccb3b2cb7c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_008b8eeb-0ef7-4452-ae1e-75c576a0fd74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_008b8eeb-0ef7-4452-ae1e-75c576a0fd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6918f81b-023e-45df-8907-2f1615ecdd11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6918f81b-023e-45df-8907-2f1615ecdd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9e866096-b071-43e6-92de-82a2f02f6247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9e866096-b071-43e6-92de-82a2f02f6247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_52ae4963-2e07-4270-8513-c8ce8c534b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_52ae4963-2e07-4270-8513-c8ce8c534b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_43fbed4d-db2a-405c-b1b9-129681be1342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_ShareBasedCompensation_43fbed4d-db2a-405c-b1b9-129681be1342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_6ca7b09d-faed-40dd-a810-f20e7c2eef3c" xlink:href="ino-20241231.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_ino_NonCashInterestIncomeExpense_6ca7b09d-faed-40dd-a810-f20e7c2eef3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_732b7546-735d-4b4f-9a28-6a55b52d927c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_732b7546-735d-4b4f-9a28-6a55b52d927c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_7493bd4a-d2e1-4179-8ea0-c01abb946d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_7493bd4a-d2e1-4179-8ea0-c01abb946d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a4d4d328-dd87-40b4-b76f-8ffc38468e52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a4d4d328-dd87-40b4-b76f-8ffc38468e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_c8957363-c9b9-44a5-a2e9-5c237c9d19e6" xlink:href="ino-20241231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_c8957363-c9b9-44a5-a2e9-5c237c9d19e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dc3f4e1e-5b1e-4b14-aa58-eac5db08a6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1df4d127-bb61-442a-91b6-b2ed58f02f0b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dc3f4e1e-5b1e-4b14-aa58-eac5db08a6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f70f4c6e-092c-460a-a048-c3a6bcc18f7c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bc4cbd0d-2e7c-4b7f-8039-f1ffd1bb95dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bc4cbd0d-2e7c-4b7f-8039-f1ffd1bb95dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2420b3e6-a454-4b4a-8f32-a327ff7c46a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2420b3e6-a454-4b4a-8f32-a327ff7c46a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a74cbe87-5043-4668-97c1-9d0ceb4ed7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a74cbe87-5043-4668-97c1-9d0ceb4ed7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f6a9bdfc-3353-454b-9bcc-4b62243695c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f6a9bdfc-3353-454b-9bcc-4b62243695c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_8546adf5-fce8-4267-924f-735f012ffdc5" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_8546adf5-fce8-4267-924f-735f012ffdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_99352bc1-a3df-4c27-9917-5364806c6ef3" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_99352bc1-a3df-4c27-9917-5364806c6ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_43b5e4ed-2f7f-4a43-b87e-1a492eab2bed" xlink:href="ino-20241231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_557a8f3e-8747-43cf-ae24-a023011fccc5" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_43b5e4ed-2f7f-4a43-b87e-1a492eab2bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ea2a1500-8f7a-46d0-a6c7-3c36d0caf03f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f70f4c6e-092c-460a-a048-c3a6bcc18f7c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ea2a1500-8f7a-46d0-a6c7-3c36d0caf03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_99a547c1-11f5-432a-898e-c8a6eecac1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_99a547c1-11f5-432a-898e-c8a6eecac1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_79ed03e9-7c9c-4a59-bc29-326abb4b650c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_99a547c1-11f5-432a-898e-c8a6eecac1fa" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_79ed03e9-7c9c-4a59-bc29-326abb4b650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_cd012ff2-ade5-4ee3-9311-a6eb5c79e988" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_99a547c1-11f5-432a-898e-c8a6eecac1fa" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_cd012ff2-ade5-4ee3-9311-a6eb5c79e988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b2d85fb-80ae-4975-bc11-5ae88a41ae66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_99a547c1-11f5-432a-898e-c8a6eecac1fa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b2d85fb-80ae-4975-bc11-5ae88a41ae66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2095eac9-b3ca-464c-8a56-422e6551edd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_99a547c1-11f5-432a-898e-c8a6eecac1fa" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2095eac9-b3ca-464c-8a56-422e6551edd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c71a4f1-b4b7-49b1-b0ca-5e649a0e4ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_99a547c1-11f5-432a-898e-c8a6eecac1fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3c71a4f1-b4b7-49b1-b0ca-5e649a0e4ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_a78043a7-d9e1-4dc1-9003-77957bdba282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_a78043a7-d9e1-4dc1-9003-77957bdba282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_e58673cc-e95c-440f-a490-8be3b88f5140" xlink:href="ino-20241231.xsd#ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:to="loc_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts_e58673cc-e95c-440f-a490-8be3b88f5140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f653a551-4280-425b-843a-a54b477a12da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f653a551-4280-425b-843a-a54b477a12da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6cea08d8-4921-447d-bbd7-092fd97356d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_6cea08d8-4921-447d-bbd7-092fd97356d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b91952a7-265f-410c-b081-19750e4a646c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b91952a7-265f-410c-b081-19750e4a646c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_609b496e-0727-4e07-854c-bce385f26056" xlink:href="ino-20241231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_609b496e-0727-4e07-854c-bce385f26056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f21169b-b9e7-4cf1-a591-e1bc505afc98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1d2ce73f-91fd-48d3-bd29-7519bbebab28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f21169b-b9e7-4cf1-a591-e1bc505afc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b144688-d71d-41ba-a9b8-eace028234f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b144688-d71d-41ba-a9b8-eace028234f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_013f77df-0dcc-4894-8cb6-80fa067f62bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_013f77df-0dcc-4894-8cb6-80fa067f62bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f385643-028e-4a6f-b14c-d532fd10348e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f385643-028e-4a6f-b14c-d532fd10348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e690698f-6c60-4cdd-909e-0064988f4a01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e690698f-6c60-4cdd-909e-0064988f4a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9957d49-1ddd-4fcf-8ed6-2db6207bdb91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7d14bf1b-7149-4ac6-b08d-83b0e82b88c5" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9957d49-1ddd-4fcf-8ed6-2db6207bdb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_73fb73c3-81fd-4bcf-afbb-4894f631d5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9957d49-1ddd-4fcf-8ed6-2db6207bdb91" xlink:to="loc_us-gaap_InterestPaidNet_73fb73c3-81fd-4bcf-afbb-4894f631d5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_30dd14b4-6f66-4aca-ba67-120b2db19924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9957d49-1ddd-4fcf-8ed6-2db6207bdb91" xlink:to="loc_us-gaap_StockIssued1_30dd14b4-6f66-4aca-ba67-120b2db19924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/TheCompany" xlink:type="simple" xlink:href="ino-20241231.xsd#TheCompany"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/TheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17946a8d-5563-4a54-8fa4-dce8478098cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_766e8bea-e7c6-4975-971d-2b3041e9fb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17946a8d-5563-4a54-8fa4-dce8478098cd" xlink:to="loc_us-gaap_NatureOfOperations_766e8bea-e7c6-4975-971d-2b3041e9fb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48be4f3d-0cd8-472b-8f5b-945cce9ff0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_371ac0c8-0dc1-4625-8ffc-53dee1fae5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48be4f3d-0cd8-472b-8f5b-945cce9ff0fd" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_371ac0c8-0dc1-4625-8ffc-53dee1fae5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" xlink:type="simple" xlink:href="ino-20241231.xsd#RevenueRecognitionandConcentrationofCreditRisk"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_de6353c7-e63d-4e58-bb8f-2298e2963f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_07b2423b-1e07-4111-8ad7-e34fd86fb7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_de6353c7-e63d-4e58-bb8f-2298e2963f7f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_07b2423b-1e07-4111-8ad7-e34fd86fb7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20241231.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89f091a0-8e25-4425-b9dd-47b86b762d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_22270a1c-fa93-4617-81c0-90ed24de8484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89f091a0-8e25-4425-b9dd-47b86b762d1a" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_22270a1c-fa93-4617-81c0-90ed24de8484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b32c0358-8935-4734-b138-843a5c9a46db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_05fdec87-34e5-42a8-a9ea-841f3ea6243e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b32c0358-8935-4734-b138-843a5c9a46db" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_05fdec87-34e5-42a8-a9ea-841f3ea6243e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ca22783f-8e7e-4666-8107-a6fbaf6045b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b32c0358-8935-4734-b138-843a5c9a46db" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ca22783f-8e7e-4666-8107-a6fbaf6045b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="ino-20241231.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_ed0a2c09-e075-4e87-afa3-a41f4753a236" xlink:href="ino-20241231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_50a35e80-f572-4a54-85ad-56a1e1e4c24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_ed0a2c09-e075-4e87-afa3-a41f4753a236" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_50a35e80-f572-4a54-85ad-56a1e1e4c24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:type="simple" xlink:href="ino-20241231.xsd#FixedAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_698a0dad-feea-4818-8153-b012de229aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_da490983-c708-459f-8e8a-ca2c7fd7b324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_698a0dad-feea-4818-8153-b012de229aa6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_da490983-c708-459f-8e8a-ca2c7fd7b324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20241231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76965e7a-6588-428b-9d6e-ec8719f3de7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0151a675-aabb-4d08-85b1-47acfd944199" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76965e7a-6588-428b-9d6e-ec8719f3de7c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0151a675-aabb-4d08-85b1-47acfd944199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20241231.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f9bc44fe-5f3b-41d5-afd6-0c98e7dbbf43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_15321280-1b90-403c-bf6c-dad936959cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f9bc44fe-5f3b-41d5-afd6-0c98e7dbbf43" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_15321280-1b90-403c-bf6c-dad936959cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a0f6b8b3-5f8d-4e23-8e62-ca71b2c57bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cf66e83c-bd11-43b2-8632-ff912dc4cc36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a0f6b8b3-5f8d-4e23-8e62-ca71b2c57bb9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cf66e83c-bd11-43b2-8632-ff912dc4cc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ino-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c7152d8d-eeff-475d-ad7d-3ebed16682aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9151db33-06b3-4e91-a9ae-d5546f93d577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c7152d8d-eeff-475d-ad7d-3ebed16682aa" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9151db33-06b3-4e91-a9ae-d5546f93d577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_83d017e2-489e-489b-a56c-4842796dfb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_58c4f7c3-ab95-492c-ae32-cc592956c8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83d017e2-489e-489b-a56c-4842796dfb5f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_58c4f7c3-ab95-492c-ae32-cc592956c8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlan" xlink:type="simple" xlink:href="ino-20241231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1c733e19-a943-4cf4-abbd-e421f67be5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_239a8d69-987e-4c5a-8ef5-495d9ed0c980" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1c733e19-a943-4cf4-abbd-e421f67be5ac" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_239a8d69-987e-4c5a-8ef5-495d9ed0c980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20241231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b3578afb-faa6-483d-b9f5-99d9d43cef2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4d2c8c39-ccd1-4d8c-b977-b330af587a06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b3578afb-faa6-483d-b9f5-99d9d43cef2b" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4d2c8c39-ccd1-4d8c-b977-b330af587a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20241231.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_6e8b30b1-7515-4c03-9962-bfef0af72b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6bf52eb9-f89a-4f4f-a83a-221246ea38fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_6e8b30b1-7515-4c03-9962-bfef0af72b6a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6bf52eb9-f89a-4f4f-a83a-221246ea38fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SegmentInformation" xlink:type="simple" xlink:href="ino-20241231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d66fcee3-a48f-454c-8b96-474ed6a8727f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_45f4978c-be2e-414e-a012-2da55b04623e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d66fcee3-a48f-454c-8b96-474ed6a8727f" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_45f4978c-be2e-414e-a012-2da55b04623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20241231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_91140d03-1caa-432b-a316-ef3dbb65decd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_10e9a6a3-8806-4a36-98b1-3421e78bba60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_91140d03-1caa-432b-a316-ef3dbb65decd" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_10e9a6a3-8806-4a36-98b1-3421e78bba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2abd882a-ef0d-4673-830f-a301c5b4f26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2abd882a-ef0d-4673-830f-a301c5b4f26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_dc4b00b4-4cdc-4009-8525-f851b14992a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_dc4b00b4-4cdc-4009-8525-f851b14992a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_161ba89f-5b6c-4133-ba96-aad59ff0a517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_161ba89f-5b6c-4133-ba96-aad59ff0a517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_394701d0-53b2-423a-8495-17d692284f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_UseOfEstimates_394701d0-53b2-423a-8495-17d692284f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_88e23feb-2f1c-4e4a-813f-15c7f677c63b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_88e23feb-2f1c-4e4a-813f-15c7f677c63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2440f2b2-5d2a-4cb2-83ea-91a4e9b821c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2440f2b2-5d2a-4cb2-83ea-91a4e9b821c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0f49eaee-002c-4571-a26c-cabca101a955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0f49eaee-002c-4571-a26c-cabca101a955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_96646350-ef57-4bf0-ab28-dff11de5d25d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_96646350-ef57-4bf0-ab28-dff11de5d25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_32e8e59d-1d20-45a0-b8e6-1e484e58a802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_32e8e59d-1d20-45a0-b8e6-1e484e58a802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f595b9c2-2f42-4ac1-81a2-c6051ec8f33f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f595b9c2-2f42-4ac1-81a2-c6051ec8f33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WarrantsPolicyPolicyTextBlock_608718dd-4932-4d74-b1e4-465e3e5a8de1" xlink:href="ino-20241231.xsd#ino_WarrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_ino_WarrantsPolicyPolicyTextBlock_608718dd-4932-4d74-b1e4-465e3e5a8de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5d3b6725-2a0c-4827-8aaf-3223854564a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5d3b6725-2a0c-4827-8aaf-3223854564a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_bfd97151-0077-4d86-b043-4bef71e932d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_bfd97151-0077-4d86-b043-4bef71e932d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_348068bb-e292-408d-9301-274fd9038480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_348068bb-e292-408d-9301-274fd9038480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock_f4058336-079e-4c38-9bd3-b9f12efc0327" xlink:href="ino-20241231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_ino_GrantRevenuePolicyTextBlock_f4058336-079e-4c38-9bd3-b9f12efc0327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_a7599212-0b60-4269-bc35-d4e69cd7f2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_a7599212-0b60-4269-bc35-d4e69cd7f2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_140ede38-eb1b-4565-b778-d52ff606109d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_140ede38-eb1b-4565-b778-d52ff606109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_94cd9906-a020-4817-a33b-1fa956d2e0be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_94cd9906-a020-4817-a33b-1fa956d2e0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_c813194e-e374-4bf4-972c-7f22f1028593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_c813194e-e374-4bf4-972c-7f22f1028593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_6556a78f-aced-4045-ac82-6feb5c8fc72c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_6556a78f-aced-4045-ac82-6feb5c8fc72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99dde8ad-7da1-4ffb-a430-a2333cce63f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0c53c8fe-bbb8-48f0-ae97-8121bb50e7d3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99dde8ad-7da1-4ffb-a430-a2333cce63f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ae0a259-49bf-461d-a2be-2666f912592d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_7f427760-b0b7-4940-a93d-bba65934685f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ae0a259-49bf-461d-a2be-2666f912592d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_7f427760-b0b7-4940-a93d-bba65934685f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5eca11ae-4ef1-478d-aebf-281898d6a61d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ae0a259-49bf-461d-a2be-2666f912592d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5eca11ae-4ef1-478d-aebf-281898d6a61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5fb9a6c8-b026-4135-b7d1-512820c52610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ae0a259-49bf-461d-a2be-2666f912592d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5fb9a6c8-b026-4135-b7d1-512820c52610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" xlink:type="simple" xlink:href="ino-20241231.xsd#RevenueRecognitionandConcentrationofCreditRiskTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_330fd705-5212-4f4d-9598-20e8f29c35d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_955fb9c2-6002-40b8-a9ff-d9b3e3b1dc33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_330fd705-5212-4f4d-9598-20e8f29c35d1" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_955fb9c2-6002-40b8-a9ff-d9b3e3b1dc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f675ac5e-7cf9-4089-9528-f8cb7746ec11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_700901fa-c18a-4924-8aa7-b2351af22913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f675ac5e-7cf9-4089-9528-f8cb7746ec11" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_700901fa-c18a-4924-8aa7-b2351af22913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cdd3a627-f965-4f6d-8903-1a057c506f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f675ac5e-7cf9-4089-9528-f8cb7746ec11" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cdd3a627-f965-4f6d-8903-1a057c506f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d070a788-1ddb-4b72-884d-0db62b881600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f675ac5e-7cf9-4089-9528-f8cb7746ec11" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d070a788-1ddb-4b72-884d-0db62b881600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_10b90fda-165d-49a0-82dc-47e12212620d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f675ac5e-7cf9-4089-9528-f8cb7746ec11" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_10b90fda-165d-49a0-82dc-47e12212620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="ino-20241231.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_aaf30159-68ce-45dc-b8c8-9ab2050b6337" xlink:href="ino-20241231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_37a9851d-6001-47e0-9cea-b2f456c6606b" xlink:href="ino-20241231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_aaf30159-68ce-45dc-b8c8-9ab2050b6337" xlink:to="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_37a9851d-6001-47e0-9cea-b2f456c6606b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6dbb11c2-ea6b-471d-bb4d-60f21f6c304f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_aaf30159-68ce-45dc-b8c8-9ab2050b6337" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6dbb11c2-ea6b-471d-bb4d-60f21f6c304f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:type="simple" xlink:href="ino-20241231.xsd#FixedAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f546b4fa-c6af-4bce-b021-30f301c6d0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_82da0ee4-5f88-42db-a1c0-005a852f7d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f546b4fa-c6af-4bce-b021-30f301c6d0b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_82da0ee4-5f88-42db-a1c0-005a852f7d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d93c4e2b-e9e6-4594-adef-34c4e07a0a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_4ad291e3-04fa-4797-8bc9-8da06eaad31a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d93c4e2b-e9e6-4594-adef-34c4e07a0a8a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_4ad291e3-04fa-4797-8bc9-8da06eaad31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_fc2f9b4a-7fa2-40ca-a879-2940cbe4a172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d93c4e2b-e9e6-4594-adef-34c4e07a0a8a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_fc2f9b4a-7fa2-40ca-a879-2940cbe4a172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_edf24564-40ad-4fbc-84ba-44c13dcff4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d93c4e2b-e9e6-4594-adef-34c4e07a0a8a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_edf24564-40ad-4fbc-84ba-44c13dcff4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9cd70258-e9a2-4706-8431-ed2ceb5f0a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d93c4e2b-e9e6-4594-adef-34c4e07a0a8a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9cd70258-e9a2-4706-8431-ed2ceb5f0a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_5199a373-ab11-4a8f-b49e-f113dc954b8f" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d93c4e2b-e9e6-4594-adef-34c4e07a0a8a" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_5199a373-ab11-4a8f-b49e-f113dc954b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ino-20241231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef4f7167-af6e-4b1e-9a4f-7bf25a328655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6c0f6156-c89d-4943-a126-a1f3d1484317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef4f7167-af6e-4b1e-9a4f-7bf25a328655" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6c0f6156-c89d-4943-a126-a1f3d1484317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ec9b36be-07ff-4927-847b-b1ea0ac41898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_6e87698a-4650-4938-b29c-d3a340e364f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec9b36be-07ff-4927-847b-b1ea0ac41898" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_6e87698a-4650-4938-b29c-d3a340e364f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_893e5edc-dea5-4ca3-a6ca-f4cea1bfd468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec9b36be-07ff-4927-847b-b1ea0ac41898" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_893e5edc-dea5-4ca3-a6ca-f4cea1bfd468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9a5ba715-c7f9-4e36-af7d-8c0b5af34161" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec9b36be-07ff-4927-847b-b1ea0ac41898" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9a5ba715-c7f9-4e36-af7d-8c0b5af34161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_a491b1f4-bbb0-4cb6-84ca-90cfbd76296d" xlink:href="ino-20241231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec9b36be-07ff-4927-847b-b1ea0ac41898" xlink:to="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_a491b1f4-bbb0-4cb6-84ca-90cfbd76296d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_50922966-33cc-4cbd-b325-4de84b42818b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec9b36be-07ff-4927-847b-b1ea0ac41898" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_50922966-33cc-4cbd-b325-4de84b42818b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ino-20241231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4d23dfe2-db76-488b-a693-c8ecfb0525a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_84472555-465c-4fe1-8f02-4979d4ab4eac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4d23dfe2-db76-488b-a693-c8ecfb0525a3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_84472555-465c-4fe1-8f02-4979d4ab4eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ff7cfcdf-0c85-4dcd-8640-40beb16d930c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ff7cfcdf-0c85-4dcd-8640-40beb16d930c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_46ec630d-82bc-430b-9362-ccf71ae15964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_46ec630d-82bc-430b-9362-ccf71ae15964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_426b033e-ef87-427b-afe2-a606322892c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46ec630d-82bc-430b-9362-ccf71ae15964" xlink:to="loc_us-gaap_EquityComponentDomain_426b033e-ef87-427b-afe2-a606322892c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_30d78974-262d-426a-bbd4-3687b3b2cbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_426b033e-ef87-427b-afe2-a606322892c8" xlink:to="loc_us-gaap_CommonStockMember_30d78974-262d-426a-bbd4-3687b3b2cbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_bb925a3c-9854-40d2-af94-0d2765cfdb43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_426b033e-ef87-427b-afe2-a606322892c8" xlink:to="loc_us-gaap_WarrantMember_bb925a3c-9854-40d2-af94-0d2765cfdb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_64a3ef2b-7ec5-4280-aabd-a492151c7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_64a3ef2b-7ec5-4280-aabd-a492151c7b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_64a3ef2b-7ec5-4280-aabd-a492151c7b10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingMember_5a81a6b9-2a5d-44c5-950b-d678824c2186" xlink:href="ino-20241231.xsd#ino_December2024OfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:to="loc_ino_December2024OfferingMember_5a81a6b9-2a5d-44c5-950b-d678824c2186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_April2024OfferingMember_60c8229a-74e7-4994-834c-9ca57f19ac63" xlink:href="ino-20241231.xsd#ino_April2024OfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:to="loc_ino_April2024OfferingMember_60c8229a-74e7-4994-834c-9ca57f19ac63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_4a7e9050-c3e6-45eb-bbd9-40f3df7f361f" xlink:href="ino-20241231.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73389739-db89-43fd-8070-7f97995e9e4e" xlink:to="loc_ino_SalesAgreementMember_4a7e9050-c3e6-45eb-bbd9-40f3df7f361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_202ada00-4719-4e7f-9cd0-03dd87420f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_202ada00-4719-4e7f-9cd0-03dd87420f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c289eb07-6cc0-4c95-a11d-02a4b93af3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_202ada00-4719-4e7f-9cd0-03dd87420f7c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c289eb07-6cc0-4c95-a11d-02a4b93af3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember_67040baf-312c-4089-bd22-a35516cb42ca" xlink:href="ino-20241231.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c289eb07-6cc0-4c95-a11d-02a4b93af3dc" xlink:to="loc_ino_December2024OfferingWarrantsMember_67040baf-312c-4089-bd22-a35516cb42ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_April2024OfferingWarrantsMember_72fc2892-e029-40ee-bf36-decf6665f1db" xlink:href="ino-20241231.xsd#ino_April2024OfferingWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c289eb07-6cc0-4c95-a11d-02a4b93af3dc" xlink:to="loc_ino_April2024OfferingWarrantsMember_72fc2892-e029-40ee-bf36-decf6665f1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e9247f92-b716-4bb0-9b62-e708f68463c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_srt_RangeAxis_e9247f92-b716-4bb0-9b62-e708f68463c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b83a7e3a-41bc-4a7a-b51c-aa54c31ac5e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e9247f92-b716-4bb0-9b62-e708f68463c2" xlink:to="loc_srt_RangeMember_b83a7e3a-41bc-4a7a-b51c-aa54c31ac5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f03dc90c-3927-4547-abd6-f32761a47aaa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b83a7e3a-41bc-4a7a-b51c-aa54c31ac5e2" xlink:to="loc_srt_MinimumMember_f03dc90c-3927-4547-abd6-f32761a47aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_53a24b7a-ffa3-4f4b-8823-1bdc0e65e5bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b83a7e3a-41bc-4a7a-b51c-aa54c31ac5e2" xlink:to="loc_srt_MaximumMember_53a24b7a-ffa3-4f4b-8823-1bdc0e65e5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_168a13ef-6d74-4844-a916-10256f49d30d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed5257f8-3b9f-440b-a820-5ad04c86f630" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_NetIncomeLoss_ed5257f8-3b9f-440b-a820-5ad04c86f630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_2709627b-01ca-40dd-ba67-14019069cf8f" xlink:href="ino-20241231.xsd#ino_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_ino_WorkingCapital_2709627b-01ca-40dd-ba67-14019069cf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5bfef70-a088-4e10-96fd-2ab7fcc35afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5bfef70-a088-4e10-96fd-2ab7fcc35afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4d240f8a-9e7b-461e-8a7b-9d510e5573d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4d240f8a-9e7b-461e-8a7b-9d510e5573d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17a20d77-074a-4782-aa75-9d18c7f2fa10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_17a20d77-074a-4782-aa75-9d18c7f2fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9ff7f39a-eaa1-4e00-a055-f5b37c367d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9ff7f39a-eaa1-4e00-a055-f5b37c367d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bc166eaf-9fc2-4f25-a2a8-b45c648f06cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bc166eaf-9fc2-4f25-a2a8-b45c648f06cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5442e028-f2bb-4c52-a9f8-9d3a99d0422f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5442e028-f2bb-4c52-a9f8-9d3a99d0422f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97138ce3-9156-46de-bbfa-3e04f265e273" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97138ce3-9156-46de-bbfa-3e04f265e273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e8365e5c-6ea3-44ec-bb70-a7e1238b9ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e8365e5c-6ea3-44ec-bb70-a7e1238b9ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f5714d8-eb32-40d5-86a6-2fccd6dca9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4f5714d8-eb32-40d5-86a6-2fccd6dca9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a8bcc33e-de5e-4803-8b81-ca07553ada24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a8bcc33e-de5e-4803-8b81-ca07553ada24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_83573090-f5a1-425e-8332-a726074ecf59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_NumberOfReportableSegments_83573090-f5a1-425e-8332-a726074ecf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_253a4d38-f0ef-4f36-bf50-43b470638578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_253a4d38-f0ef-4f36-bf50-43b470638578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3e2d8f2a-62e6-4256-8477-4f9f19671543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3e2d8f2a-62e6-4256-8477-4f9f19671543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7dce8e06-c3c8-49c4-a2d9-9b738d0ef18c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33b4f06e-a0e1-4527-a6c1-d5e3ace9b46f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7dce8e06-c3c8-49c4-a2d9-9b738d0ef18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_16a90122-3963-4d04-ad65-e968fa289736" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c84d6153-cbf4-4ebf-b679-0623f4070f81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_16a90122-3963-4d04-ad65-e968fa289736" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c84d6153-cbf4-4ebf-b679-0623f4070f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2d297783-f555-4250-a35c-275599e5567e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_c84d6153-cbf4-4ebf-b679-0623f4070f81" xlink:to="loc_us-gaap_NetIncomeLoss_2d297783-f555-4250-a35c-275599e5567e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7065be6d-2fbc-4efc-8ad2-28efc042200d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_16a90122-3963-4d04-ad65-e968fa289736" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7065be6d-2fbc-4efc-8ad2-28efc042200d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WeightedAverageNumberOfSharesOutstanding_3baf0b36-5a5a-44b0-9b70-cb38f64514e2" xlink:href="ino-20241231.xsd#ino_WeightedAverageNumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7065be6d-2fbc-4efc-8ad2-28efc042200d" xlink:to="loc_ino_WeightedAverageNumberOfSharesOutstanding_3baf0b36-5a5a-44b0-9b70-cb38f64514e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_b5b72349-aac6-435c-8426-41922905085f" xlink:href="ino-20241231.xsd#ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7065be6d-2fbc-4efc-8ad2-28efc042200d" xlink:to="loc_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants_b5b72349-aac6-435c-8426-41922905085f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b42ef907-7d52-4574-8494-30a47c20162f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7065be6d-2fbc-4efc-8ad2-28efc042200d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b42ef907-7d52-4574-8494-30a47c20162f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dbc74b55-a02d-4f91-abfe-c78a2642a2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7065be6d-2fbc-4efc-8ad2-28efc042200d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dbc74b55-a02d-4f91-abfe-c78a2642a2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_f07aaeae-01e7-4bdc-a7c5-813b25db2ee1" xlink:href="ino-20241231.xsd#ino_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7065be6d-2fbc-4efc-8ad2-28efc042200d" xlink:to="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_f07aaeae-01e7-4bdc-a7c5-813b25db2ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c66c1642-1644-41b0-9f04-5f8925fdf623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_f07aaeae-01e7-4bdc-a7c5-813b25db2ee1" xlink:to="loc_us-gaap_EarningsPerShareBasic_c66c1642-1644-41b0-9f04-5f8925fdf623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c1efdc86-b4d1-490e-93f8-b4a81cc2d5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_EarningsPerShareBasicAndDilutedEPSAbstract_f07aaeae-01e7-4bdc-a7c5-813b25db2ee1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c1efdc86-b4d1-490e-93f8-b4a81cc2d5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_79eed36d-60b5-4e97-bc17-5e5082d756b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79eed36d-60b5-4e97-bc17-5e5082d756b5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4898ec6a-ceaa-4c7c-94a6-a3b21d3dbece" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4427bd9c-b6ce-47ce-ae22-bf2350c9eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_WarrantMember_4427bd9c-b6ce-47ce-ae22-bf2350c9eeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_70cab780-ccdc-4886-9763-4bf723a249cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_70cab780-ccdc-4886-9763-4bf723a249cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_8ec77fbe-6b6c-4b5e-a925-204e2b21d3de" xlink:href="ino-20241231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_8ec77fbe-6b6c-4b5e-a925-204e2b21d3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4f68f80f-a63d-4d1e-8976-bd81a82a485f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4f68f80f-a63d-4d1e-8976-bd81a82a485f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_da33a500-d610-42cb-b4ca-4056361b5756" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_da33a500-d610-42cb-b4ca-4056361b5756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_46c33c8d-9669-4823-a6ba-068aa8dcf441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c1f6ad0b-d8d4-4010-888c-cda21af2d75a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_46c33c8d-9669-4823-a6ba-068aa8dcf441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2ceb8990-7aab-48df-9230-7a412f125445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:to="loc_us-gaap_DebtInstrumentAxis_2ceb8990-7aab-48df-9230-7a412f125445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e93fe351-8fad-4b9f-903e-8a54fc46db2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ceb8990-7aab-48df-9230-7a412f125445" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e93fe351-8fad-4b9f-903e-8a54fc46db2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_80d8325c-4b5c-43d5-a455-fa16807c1f6f" xlink:href="ino-20241231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e93fe351-8fad-4b9f-903e-8a54fc46db2a" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_80d8325c-4b5c-43d5-a455-fa16807c1f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57cce3cb-7bd6-4e99-882a-0864b85959ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d6052f20-f9c3-487d-b2ab-a2975ce5c02e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57cce3cb-7bd6-4e99-882a-0864b85959ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_149284f5-9457-4c23-99a8-c952e5e384dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_57cce3cb-7bd6-4e99-882a-0864b85959ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_149284f5-9457-4c23-99a8-c952e5e384dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cc191569-6622-4a5b-a46d-5f6e6b4277a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cc191569-6622-4a5b-a46d-5f6e6b4277a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b9d97096-e7d3-47a1-b9a0-989216ad146d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:to="loc_srt_TitleOfIndividualAxis_b9d97096-e7d3-47a1-b9a0-989216ad146d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bf440637-8a2c-4597-b3fd-3b2ae29833e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b9d97096-e7d3-47a1-b9a0-989216ad146d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bf440637-8a2c-4597-b3fd-3b2ae29833e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_d4886813-0412-4947-bf86-c61da3decbd6" xlink:href="ino-20241231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bf440637-8a2c-4597-b3fd-3b2ae29833e2" xlink:to="loc_ino_EmployeesAndDirectorsMember_d4886813-0412-4947-bf86-c61da3decbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_7522dc0a-52bb-4e91-94d3-3b8124ca6c6a" xlink:href="ino-20241231.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bf440637-8a2c-4597-b3fd-3b2ae29833e2" xlink:to="loc_ino_NonEmployeeMember_7522dc0a-52bb-4e91-94d3-3b8124ca6c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_feffb7b6-1983-448a-a0bc-071471fdd8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:to="loc_us-gaap_AwardTypeAxis_feffb7b6-1983-448a-a0bc-071471fdd8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c98efc87-537b-4f59-859d-6daff653a8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_feffb7b6-1983-448a-a0bc-071471fdd8d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c98efc87-537b-4f59-859d-6daff653a8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d219db34-8eef-4ce0-93f0-fb41d9cbfb12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c98efc87-537b-4f59-859d-6daff653a8ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d219db34-8eef-4ce0-93f0-fb41d9cbfb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599253f5-2f2f-4beb-94a5-eb7bc1a4920a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5eae9c73-e686-4fa8-85c3-329f6c9671bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599253f5-2f2f-4beb-94a5-eb7bc1a4920a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:href="ino-20241231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_599253f5-2f2f-4beb-94a5-eb7bc1a4920a" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32e81ec7-170c-4a24-a809-aff25d221f15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32e81ec7-170c-4a24-a809-aff25d221f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4da3afc6-e07b-431b-a9ae-bf02989784ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4da3afc6-e07b-431b-a9ae-bf02989784ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4512737f-da7e-46ea-95ff-7734ee3d97ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4512737f-da7e-46ea-95ff-7734ee3d97ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cbe9b4f4-4186-4e5e-8306-2c5a48ba26bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_df697948-2da2-4ea4-8ff4-12e29d1b2ec1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cbe9b4f4-4186-4e5e-8306-2c5a48ba26bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_44eba3ad-ceb9-46b5-89b5-fd55f0ed404a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_44eba3ad-ceb9-46b5-89b5-fd55f0ed404a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_14118168-a13a-4181-a75a-e621adf65abc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:to="loc_srt_MajorCustomersAxis_14118168-a13a-4181-a75a-e621adf65abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_323357e5-5f32-45b8-87e1-7da63f5fe204" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_14118168-a13a-4181-a75a-e621adf65abc" xlink:to="loc_srt_NameOfMajorCustomerDomain_323357e5-5f32-45b8-87e1-7da63f5fe204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioCorporationMember_e4325b4e-8bd2-4946-9d31-d08f04a8ce75" xlink:href="ino-20241231.xsd#ino_ApolloBioCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_323357e5-5f32-45b8-87e1-7da63f5fe204" xlink:to="loc_ino_ApolloBioCorporationMember_e4325b4e-8bd2-4946-9d31-d08f04a8ce75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_318335e9-4285-4c26-9758-e06bda6492ab" xlink:href="ino-20241231.xsd#ino_AllOtherCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_323357e5-5f32-45b8-87e1-7da63f5fe204" xlink:to="loc_ino_AllOtherCustomersMember_318335e9-4285-4c26-9758-e06bda6492ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15b98877-ffad-4350-8fd3-b86d78d8705c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15b98877-ffad-4350-8fd3-b86d78d8705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_18ce15e0-451e-4c1c-adeb-b7cbc25b9332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_15b98877-ffad-4350-8fd3-b86d78d8705c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_18ce15e0-451e-4c1c-adeb-b7cbc25b9332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_32ae672b-c2da-4fd5-8783-872cab256a95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_18ce15e0-451e-4c1c-adeb-b7cbc25b9332" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_32ae672b-c2da-4fd5-8783-872cab256a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1b5c8e31-7d4b-4786-b054-4293f577e1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1b5c8e31-7d4b-4786-b054-4293f577e1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bc7bc308-3b5c-4f54-b078-f291631970b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1b5c8e31-7d4b-4786-b054-4293f577e1ca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bc7bc308-3b5c-4f54-b078-f291631970b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5788e4f7-86e9-4dd1-99f6-9f7ac28d1b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bc7bc308-3b5c-4f54-b078-f291631970b9" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5788e4f7-86e9-4dd1-99f6-9f7ac28d1b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e845aa7e-1751-48b1-be9e-43f7829848d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f1a36bdb-bf2b-4991-8e3a-a06b6ea6e693" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e845aa7e-1751-48b1-be9e-43f7829848d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6aaa8e26-6ebe-452b-ad8c-e3a580d7b2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e845aa7e-1751-48b1-be9e-43f7829848d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6aaa8e26-6ebe-452b-ad8c-e3a580d7b2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2fe23874-8c8a-4e2e-9efc-b67c23e394af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e845aa7e-1751-48b1-be9e-43f7829848d5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2fe23874-8c8a-4e2e-9efc-b67c23e394af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7d0dca06-ef42-45e0-9df9-72fc79e37569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7e05ffdc-b3f8-463e-82a8-f3ad64e6e65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7d0dca06-ef42-45e0-9df9-72fc79e37569" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7e05ffdc-b3f8-463e-82a8-f3ad64e6e65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce447b68-887a-4a21-b88e-f09448d0fc49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce447b68-887a-4a21-b88e-f09448d0fc49" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_306666c9-badf-4181-83f7-92cf7e62b2eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:to="loc_srt_CounterpartyNameAxis_306666c9-badf-4181-83f7-92cf7e62b2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_306666c9-badf-4181-83f7-92cf7e62b2eb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_17cc07f8-2df1-4ae1-9d8b-9aaa050056a5" xlink:href="ino-20241231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:to="loc_ino_AdvaccineMember_17cc07f8-2df1-4ae1-9d8b-9aaa050056a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_69f428d0-b602-47d7-ac8d-0cdb96fe0cd2" xlink:href="ino-20241231.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:to="loc_ino_ApolloBioMember_69f428d0-b602-47d7-ac8d-0cdb96fe0cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_9e6b86cc-7c69-46fb-b209-c97e9b781781" xlink:href="ino-20241231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_9e6b86cc-7c69-46fb-b209-c97e9b781781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_525a91d4-5c65-4f87-9330-18efcaf305a8" xlink:href="ino-20241231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0339faaf-4c5a-4fa0-b0aa-fe9ab12d8fa8" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_525a91d4-5c65-4f87-9330-18efcaf305a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_977710db-690c-4f70-9236-97173b5f5098" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:to="loc_us-gaap_TypeOfArrangementAxis_977710db-690c-4f70-9236-97173b5f5098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d008b66e-3048-43d2-a83b-cd6f4243b7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_977710db-690c-4f70-9236-97173b5f5098" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d008b66e-3048-43d2-a83b-cd6f4243b7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_25ef6b59-81d1-448a-908f-116e8b9016b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d008b66e-3048-43d2-a83b-cd6f4243b7f8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_25ef6b59-81d1-448a-908f-116e8b9016b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0663ae23-af36-4c9c-863d-76acf31dc8f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:to="loc_srt_ProductOrServiceAxis_0663ae23-af36-4c9c-863d-76acf31dc8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_851ee33f-8bff-4ca2-9414-84326d41c429" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0663ae23-af36-4c9c-863d-76acf31dc8f7" xlink:to="loc_srt_ProductsAndServicesDomain_851ee33f-8bff-4ca2-9414-84326d41c429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_cd499a17-ba6a-4486-9ca0-1ddf1b023b74" xlink:href="ino-20241231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_851ee33f-8bff-4ca2-9414-84326d41c429" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_cd499a17-ba6a-4486-9ca0-1ddf1b023b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_5160e081-620a-4802-a816-d2ef418bdafb" xlink:href="ino-20241231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_851ee33f-8bff-4ca2-9414-84326d41c429" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_5160e081-620a-4802-a816-d2ef418bdafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b24df4ff-ae5f-4286-8d1f-bbdb0e628762" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_87ae4603-4348-43aa-8ae3-e9d0f5006240" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_87ae4603-4348-43aa-8ae3-e9d0f5006240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_afa507f6-a27e-4891-ad2c-abce343f0734" xlink:href="ino-20241231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_afa507f6-a27e-4891-ad2c-abce343f0734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_3b6120c9-b9ec-4122-891b-2b3e17d407fa" xlink:href="ino-20241231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_3b6120c9-b9ec-4122-891b-2b3e17d407fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_89edbbfb-362f-4297-a059-2cbe670ea46e" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_89edbbfb-362f-4297-a059-2cbe670ea46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_957f8e22-af77-4711-8eb1-5f6b55b914de" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_957f8e22-af77-4711-8eb1-5f6b55b914de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_6bd6e48c-cbc3-4ac0-9133-1629da96307c" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6975bee1-537b-48af-ba01-905c9ca99532" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_6bd6e48c-cbc3-4ac0-9133-1629da96307c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_72add515-4fe8-4cb7-99ca-29bfd590dcef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_72add515-4fe8-4cb7-99ca-29bfd590dcef" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a682e9ee-4e73-4b4e-9bcb-a2ea0a551809" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_0b2ff77e-e35f-4493-8399-f58e604a9236" xlink:href="ino-20241231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:to="loc_ino_MutualFundsMember_0b2ff77e-e35f-4493-8399-f58e604a9236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_4dae95dc-b06d-4088-b32d-ad2ccb919cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_4dae95dc-b06d-4088-b32d-ad2ccb919cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f1dd8b1d-664a-4754-88cd-47b814659378" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f1dd8b1d-664a-4754-88cd-47b814659378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_f4649bf2-58bf-4e57-8e06-727fb9d5d2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71ff4f36-f442-437c-ae31-885d48b9cfa2" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_f4649bf2-58bf-4e57-8e06-727fb9d5d2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:to="loc_srt_RangeAxis_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1fed439-6a3c-4f1a-b2ab-e45534ae99d1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9bcc7648-f02f-474d-a0aa-1e9e56a1bdd1" xlink:to="loc_srt_RangeMember_d1fed439-6a3c-4f1a-b2ab-e45534ae99d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_24f8f8b7-bf63-4d5d-bfa1-10ba02c69f3b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d1fed439-6a3c-4f1a-b2ab-e45534ae99d1" xlink:to="loc_srt_MaximumMember_24f8f8b7-bf63-4d5d-bfa1-10ba02c69f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_79eb4a53-c603-4cb0-b510-6e833272664a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_03bef5e3-1c0e-43af-8e96-28dfebd11cf7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_79eb4a53-c603-4cb0-b510-6e833272664a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_98bb3ce6-dba9-4d68-b8fc-ebee15dc8b75" xlink:href="ino-20241231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_79eb4a53-c603-4cb0-b510-6e833272664a" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_98bb3ce6-dba9-4d68-b8fc-ebee15dc8b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_79eb4a53-c603-4cb0-b510-6e833272664a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ad93061c-4fb1-48ef-82e4-f65bdaad599c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ad93061c-4fb1-48ef-82e4-f65bdaad599c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_543e298a-6cb6-4911-9c58-0d3458f641ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_543e298a-6cb6-4911-9c58-0d3458f641ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_eb3e4ddd-5fb5-4d7d-aa90-630ff8ae19a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_eb3e4ddd-5fb5-4d7d-aa90-630ff8ae19a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e6177957-185f-4271-93d2-522c25ffc334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f332f3e0-30d0-4785-a441-1b412b12b484" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e6177957-185f-4271-93d2-522c25ffc334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6c226329-5642-480c-ad35-a82860ff3659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_98ba8c04-2833-4091-813f-e5fb95766510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6c226329-5642-480c-ad35-a82860ff3659" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_98ba8c04-2833-4091-813f-e5fb95766510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c520b2c8-ab11-4583-9979-3998e34e391c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_98ba8c04-2833-4091-813f-e5fb95766510" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c520b2c8-ab11-4583-9979-3998e34e391c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_132fd930-6941-4cc3-aeca-c2ca33bdae52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c520b2c8-ab11-4583-9979-3998e34e391c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_132fd930-6941-4cc3-aeca-c2ca33bdae52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_53bd5753-9421-452b-b9db-178b8b3463d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_132fd930-6941-4cc3-aeca-c2ca33bdae52" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_53bd5753-9421-452b-b9db-178b8b3463d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_98ba8c04-2833-4091-813f-e5fb95766510" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_dbedbd3a-cc50-4684-a7a4-8a4db7f2483d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_dbedbd3a-cc50-4684-a7a4-8a4db7f2483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_c01a4d82-e971-4222-86ad-5c517a2035ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_c01a4d82-e971-4222-86ad-5c517a2035ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_33701154-0afb-4ea4-b45a-3162f54c952d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_33701154-0afb-4ea4-b45a-3162f54c952d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_82ecbc0f-4010-40ba-8d31-9b164e7aab5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_82ecbc0f-4010-40ba-8d31-9b164e7aab5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_4e75a31f-3dab-4029-b484-6ac5a7f47d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_4e75a31f-3dab-4029-b484-6ac5a7f47d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_ddc4eb02-85c0-4d3c-a337-bec277dcb0da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_ddc4eb02-85c0-4d3c-a337-bec277dcb0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_240ca828-3a1b-4ece-a3f3-9a192982b750" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c5ae5cc-8eca-41f7-be64-473e6636e238" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_240ca828-3a1b-4ece-a3f3-9a192982b750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_72e56f56-ce43-4cf3-9cc1-238210d9f70e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_72e56f56-ce43-4cf3-9cc1-238210d9f70e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2bace38c-0f7d-4c85-88d8-8847bf807588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2bace38c-0f7d-4c85-88d8-8847bf807588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_91a576b0-33dd-4c83-97ea-2b4256d6e717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2bace38c-0f7d-4c85-88d8-8847bf807588" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_91a576b0-33dd-4c83-97ea-2b4256d6e717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_02876c10-d916-4026-8e31-0f06d06c0e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_91a576b0-33dd-4c83-97ea-2b4256d6e717" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_02876c10-d916-4026-8e31-0f06d06c0e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ed667fd2-a3b3-486d-baae-cb9c4a9a84cb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_6cfb7c76-696b-4d2a-81c5-1c22f646d7a7" xlink:href="ino-20241231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:to="loc_ino_MutualFundsMember_6cfb7c76-696b-4d2a-81c5-1c22f646d7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f30cbe19-b266-421e-9c35-e51bc710c517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f30cbe19-b266-421e-9c35-e51bc710c517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_16782278-5e1a-491c-8e42-c220e0027f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:to="loc_us-gaap_CertificatesOfDepositMember_16782278-5e1a-491c-8e42-c220e0027f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3d357a24-62b6-4664-bd73-87bb6c03e403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_581783ae-58cd-44df-ba8c-b1b7ff405dbf" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3d357a24-62b6-4664-bd73-87bb6c03e403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ade004f-000f-46cc-ae9f-262f45f43071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ade004f-000f-46cc-ae9f-262f45f43071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5ade004f-000f-46cc-ae9f-262f45f43071" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5069add9-90ae-4b51-9231-a96dea285df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5069add9-90ae-4b51-9231-a96dea285df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_41f5e07f-e714-4b2e-8bfa-380f9abf0456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_41f5e07f-e714-4b2e-8bfa-380f9abf0456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0d47c157-42ec-4623-aaab-fadfcb11bd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12f8a799-99ee-4e4f-ba72-d5b5f20449ae" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0d47c157-42ec-4623-aaab-fadfcb11bd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c80c60c0-e057-44ec-a59f-196754933dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_cf1c5035-f287-4af8-b625-f656c0301d94" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c80c60c0-e057-44ec-a59f-196754933dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c32cb65a-f534-4c41-92f7-61a967318e66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c80c60c0-e057-44ec-a59f-196754933dde" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c32cb65a-f534-4c41-92f7-61a967318e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c32cb65a-f534-4c41-92f7-61a967318e66" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5ebb3fa-178d-4777-a865-71ce98b9ce06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5ebb3fa-178d-4777-a865-71ce98b9ce06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a3045875-3bab-4f9c-8671-093dceb74f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a3045875-3bab-4f9c-8671-093dceb74f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_abf5a80d-097c-46ac-8fa5-f404d2fa5e87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d614eac0-8ccd-401a-a88d-1ae075230e9f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_abf5a80d-097c-46ac-8fa5-f404d2fa5e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ae638080-c7f9-4175-ba43-3dd0827885d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_c32cb65a-f534-4c41-92f7-61a967318e66" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ae638080-c7f9-4175-ba43-3dd0827885d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockWarrantLiabilityFairValue_cecf3e01-e15b-40f5-b21f-5734bf691bd1" xlink:href="ino-20241231.xsd#ino_CommonStockWarrantLiabilityFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ae638080-c7f9-4175-ba43-3dd0827885d0" xlink:to="loc_ino_CommonStockWarrantLiabilityFairValue_cecf3e01-e15b-40f5-b21f-5734bf691bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_52dbdcf3-e0b0-4b43-9464-728602902cde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_ae638080-c7f9-4175-ba43-3dd0827885d0" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_52dbdcf3-e0b0-4b43-9464-728602902cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5fa43d78-0604-46d0-97e8-271cf08b54a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_068006ad-c19c-4d1c-9c70-bcc6253be38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5fa43d78-0604-46d0-97e8-271cf08b54a6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_068006ad-c19c-4d1c-9c70-bcc6253be38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3cc36366-e909-4d6d-ad5f-ccc3596002dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_068006ad-c19c-4d1c-9c70-bcc6253be38e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3cc36366-e909-4d6d-ad5f-ccc3596002dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3cc36366-e909-4d6d-ad5f-ccc3596002dc" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ac29808d-4cc4-4132-809e-4ad78b2abcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ac29808d-4cc4-4132-809e-4ad78b2abcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_aa919cbd-5d70-4cec-b4dd-22564ba7ba2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_aa919cbd-5d70-4cec-b4dd-22564ba7ba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_26575553-eb4d-4d0f-89d1-067bf6857958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_26575553-eb4d-4d0f-89d1-067bf6857958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_e4d6e461-7652-4f95-b268-ab96259b52b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_afdad4b9-ce05-4c90-bf32-311e5fe0e9e6" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_e4d6e461-7652-4f95-b268-ab96259b52b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6c3a2ea-531b-4178-950c-d23fb5150338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_068006ad-c19c-4d1c-9c70-bcc6253be38e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6c3a2ea-531b-4178-950c-d23fb5150338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WarrantLiabilityMeasurementInput_9d71b588-67e7-40fe-8949-243914fd6eb5" xlink:href="ino-20241231.xsd#ino_WarrantLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a6c3a2ea-531b-4178-950c-d23fb5150338" xlink:to="loc_ino_WarrantLiabilityMeasurementInput_9d71b588-67e7-40fe-8949-243914fd6eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ce0dfa45-7fd0-4c21-ad5e-222c9ef088d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_a7fcd092-5dfd-4d6c-b57b-ca4a62209259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ce0dfa45-7fd0-4c21-ad5e-222c9ef088d9" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_a7fcd092-5dfd-4d6c-b57b-ca4a62209259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_53e7bc11-5237-45a6-a00a-105454732c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ce0dfa45-7fd0-4c21-ad5e-222c9ef088d9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_53e7bc11-5237-45a6-a00a-105454732c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3efca9b9-af7a-43d9-a3f7-9b6c3be32e44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_53e7bc11-5237-45a6-a00a-105454732c7f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3efca9b9-af7a-43d9-a3f7-9b6c3be32e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1b00b48c-6523-436e-a3dd-2f0154da34e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_53e7bc11-5237-45a6-a00a-105454732c7f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1b00b48c-6523-436e-a3dd-2f0154da34e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8041af43-3225-4634-b1c4-cba315215cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_53e7bc11-5237-45a6-a00a-105454732c7f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8041af43-3225-4634-b1c4-cba315215cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_913fb412-3bb1-4f6c-8d91-ffe659a0a354" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_53e7bc11-5237-45a6-a00a-105454732c7f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_913fb412-3bb1-4f6c-8d91-ffe659a0a354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_4765e9e6-61a1-4d8c-aff0-853961f194ab" xlink:href="ino-20241231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidClinicalExpensesCurrent_c38be78d-caa4-4c31-9c3f-7dfdc415abc9" xlink:href="ino-20241231.xsd#ino_PrepaidClinicalExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_4765e9e6-61a1-4d8c-aff0-853961f194ab" xlink:to="loc_ino_PrepaidClinicalExpensesCurrent_c38be78d-caa4-4c31-9c3f-7dfdc415abc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_815dead7-e366-4e18-bfdb-ba38441468cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_4765e9e6-61a1-4d8c-aff0-853961f194ab" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_815dead7-e366-4e18-bfdb-ba38441468cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3d04e125-eb6b-4778-8e84-20ccff245340" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_4765e9e6-61a1-4d8c-aff0-853961f194ab" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3d04e125-eb6b-4778-8e84-20ccff245340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_5272a4e9-d1af-4b0f-bb39-5f9d44f2d96e" xlink:href="ino-20241231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_b4b84d3e-6ab4-42f7-8867-9bd7a4e708cc" xlink:href="ino-20241231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_5272a4e9-d1af-4b0f-bb39-5f9d44f2d96e" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_b4b84d3e-6ab4-42f7-8867-9bd7a4e708cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_b4b84d3e-6ab4-42f7-8867-9bd7a4e708cc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ca78a69e-21a3-4383-8fee-82f85aed2ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_55e8a1c3-95ce-46d4-a286-bd7fe64c83b4" xlink:to="loc_us-gaap_RelatedPartyDomain_ca78a69e-21a3-4383-8fee-82f85aed2ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_3537f4d0-e4e8-4316-8930-1c285a483ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ca78a69e-21a3-4383-8fee-82f85aed2ce8" xlink:to="loc_us-gaap_NonrelatedPartyMember_3537f4d0-e4e8-4316-8930-1c285a483ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:href="ino-20241231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_b4b84d3e-6ab4-42f7-8867-9bd7a4e708cc" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_2cfb4743-833a-4e84-a5cb-0a943d866cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_2cfb4743-833a-4e84-a5cb-0a943d866cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_8b75b2bf-174a-486d-a1e6-b4652809af08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_us-gaap_AccruedSalariesCurrent_8b75b2bf-174a-486d-a1e6-b4652809af08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_9bed5267-dabe-45f7-a27a-518eb7647772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_9bed5267-dabe-45f7-a27a-518eb7647772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ca461efd-38f4-48e6-9cb2-257acb920647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ca461efd-38f4-48e6-9cb2-257acb920647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpenseCurrent_3e84b87e-32cc-4b7f-8376-cc1d0f8380bd" xlink:href="ino-20241231.xsd#ino_PrepaidManufacturingExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_ino_PrepaidManufacturingExpenseCurrent_3e84b87e-32cc-4b7f-8376-cc1d0f8380bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantLiability_54fbbe4e-2fcb-42ab-858f-60e76f8140e6" xlink:href="ino-20241231.xsd#ino_GrantLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_3037c0f2-d105-4d3b-bba4-2ea0a6d6fdb4" xlink:to="loc_ino_GrantLiability_54fbbe4e-2fcb-42ab-858f-60e76f8140e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#FixedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fe55829b-5e29-4ae2-8030-b08e86288e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b508e7ae-dffe-4f66-a001-5b5c1e13ffcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fe55829b-5e29-4ae2-8030-b08e86288e0d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b508e7ae-dffe-4f66-a001-5b5c1e13ffcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b508e7ae-dffe-4f66-a001-5b5c1e13ffcf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1986ebf8-85ee-4e9c-a5a2-a6f888d2877c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_05cbe6e8-060f-4949-8014-7425db1d721a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_05cbe6e8-060f-4949-8014-7425db1d721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_aedb3d23-cfb9-496b-a5a9-30200ede7bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:to="loc_us-gaap_OfficeEquipmentMember_aedb3d23-cfb9-496b-a5a9-30200ede7bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9f3a1168-c4ee-48e5-beca-8c70cfd66945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9f3a1168-c4ee-48e5-beca-8c70cfd66945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_c1cb670c-78bb-4b20-9c43-0f0e3ddcddad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7abc78f7-6231-4f33-bf6e-63e37ea0316b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_c1cb670c-78bb-4b20-9c43-0f0e3ddcddad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b508e7ae-dffe-4f66-a001-5b5c1e13ffcf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d39184a1-d8eb-4e04-afb4-6cec36b0fe04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d39184a1-d8eb-4e04-afb4-6cec36b0fe04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d715eb15-48e2-4674-ad76-eef26ff88175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d715eb15-48e2-4674-ad76-eef26ff88175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_54fa4222-0062-4557-bcfd-3527884148b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_54fa4222-0062-4557-bcfd-3527884148b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_79233d99-861c-4d8a-9fd7-1c6a8205f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_Depreciation_79233d99-861c-4d8a-9fd7-1c6a8205f56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue_c629092d-860f-45ed-b409-80bb6f67b572" xlink:href="ino-20241231.xsd#ino_GainLossOnSaleOfFixedAssetsNoNetBookValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue_c629092d-860f-45ed-b409-80bb6f67b572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_fe9c7a7f-99d7-4396-ac49-3b8018932490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e3b2a2e7-8468-4398-8484-045659b2d4bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_fe9c7a7f-99d7-4396-ac49-3b8018932490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8326c5d2-822e-4732-8b2e-1f2277b4ce15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_4bd7d447-b6fc-4618-9228-5e0c8b6ed97d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8326c5d2-822e-4732-8b2e-1f2277b4ce15" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_4bd7d447-b6fc-4618-9228-5e0c8b6ed97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a83f7db2-9f83-4a84-918a-cc137cd48743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_4bd7d447-b6fc-4618-9228-5e0c8b6ed97d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a83f7db2-9f83-4a84-918a-cc137cd48743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ab29938-920f-4123-b469-7eec821a1476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a83f7db2-9f83-4a84-918a-cc137cd48743" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ab29938-920f-4123-b469-7eec821a1476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_a83023d5-a1fc-41a9-8e47-04b04048c54e" xlink:href="ino-20241231.xsd#ino_BiojectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ab29938-920f-4123-b469-7eec821a1476" xlink:to="loc_ino_BiojectMember_a83023d5-a1fc-41a9-8e47-04b04048c54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_fc8be8a9-50af-444f-8ca0-0dcc5e2cbb39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_4bd7d447-b6fc-4618-9228-5e0c8b6ed97d" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_fc8be8a9-50af-444f-8ca0-0dcc5e2cbb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cdcf3576-8030-425d-96ba-9014f417e0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_fc8be8a9-50af-444f-8ca0-0dcc5e2cbb39" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cdcf3576-8030-425d-96ba-9014f417e0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_87adf84b-ad87-44a6-b85e-e7ddfb367707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_fc8be8a9-50af-444f-8ca0-0dcc5e2cbb39" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_87adf84b-ad87-44a6-b85e-e7ddfb367707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ba569c07-3fd0-42d4-91e4-ea239b892a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ba569c07-3fd0-42d4-91e4-ea239b892a8b" xlink:to="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f64e227b-aea1-4e72-9eb2-97e6d9000913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:to="loc_us-gaap_DebtInstrumentAxis_f64e227b-aea1-4e72-9eb2-97e6d9000913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3b38cd5-5e40-40d1-8bd9-2fc7a212e5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f64e227b-aea1-4e72-9eb2-97e6d9000913" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3b38cd5-5e40-40d1-8bd9-2fc7a212e5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7f0ef9ad-5f2b-41b8-9325-011de466061f" xlink:href="ino-20241231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3b38cd5-5e40-40d1-8bd9-2fc7a212e5ad" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_7f0ef9ad-5f2b-41b8-9325-011de466061f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bab74529-a29e-4938-8ade-6fccbde08a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bab74529-a29e-4938-8ade-6fccbde08a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d175df89-73f0-4386-8114-b1eff4b9ca60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bab74529-a29e-4938-8ade-6fccbde08a7f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d175df89-73f0-4386-8114-b1eff4b9ca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_aec260c4-5fe4-4dc5-a8e7-f80cf769adca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d175df89-73f0-4386-8114-b1eff4b9ca60" xlink:to="loc_us-gaap_ConvertibleDebtMember_aec260c4-5fe4-4dc5-a8e7-f80cf769adca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c1b91b88-c18a-4733-9876-95507ceebdcf" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3bf82052-5dfa-421e-b71a-8eddb3244967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3bf82052-5dfa-421e-b71a-8eddb3244967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c32b281-3ced-495f-a8f1-c8e9ce14b35c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c32b281-3ced-495f-a8f1-c8e9ce14b35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_94919d20-f6dc-4603-8231-e64e135fe9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_94919d20-f6dc-4603-8231-e64e135fe9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_14cc5fce-2f0e-4ea3-9ad2-53b5f1b1002b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_14cc5fce-2f0e-4ea3-9ad2-53b5f1b1002b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_a36500a3-12dc-48d3-b35b-fc80caee0d41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_InterestExpenseNonoperating_a36500a3-12dc-48d3-b35b-fc80caee0d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_c9267435-df8e-4371-9492-ece940341b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9f3e097e-8861-4eec-903a-63160e2fbfb4" xlink:to="loc_us-gaap_InterestExpenseDebt_c9267435-df8e-4371-9492-ece940341b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityScheduleofPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c741aa75-8cbf-461a-8056-bc1fd4f9f040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fdbabc2c-b28b-439c-8280-b5eaa2cab1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c741aa75-8cbf-461a-8056-bc1fd4f9f040" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fdbabc2c-b28b-439c-8280-b5eaa2cab1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b66b927a-9b27-4264-bd85-5bbb17279b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fdbabc2c-b28b-439c-8280-b5eaa2cab1de" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b66b927a-9b27-4264-bd85-5bbb17279b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0291b076-45c6-4df6-b731-f9109e8aa50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b66b927a-9b27-4264-bd85-5bbb17279b26" xlink:to="loc_us-gaap_ClassOfStockDomain_0291b076-45c6-4df6-b731-f9109e8aa50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_a64d6013-43cd-4e23-9cd4-474cad775d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0291b076-45c6-4df6-b731-f9109e8aa50b" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_a64d6013-43cd-4e23-9cd4-474cad775d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2e84e50a-c1e2-491e-9fdf-5b953e31bdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fdbabc2c-b28b-439c-8280-b5eaa2cab1de" xlink:to="loc_us-gaap_ClassOfStockLineItems_2e84e50a-c1e2-491e-9fdf-5b953e31bdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2e84e50a-c1e2-491e-9fdf-5b953e31bdfb" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5b682f8f-bd60-470e-b719-8332f33eed95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5b682f8f-bd60-470e-b719-8332f33eed95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6d178ac9-c129-4e74-94fd-14262ac9913d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6d178ac9-c129-4e74-94fd-14262ac9913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_87eb326f-6430-4b2a-88cd-c24774b6cbba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_87eb326f-6430-4b2a-88cd-c24774b6cbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8eab8df0-d9c6-4db5-9f57-0e83110c9257" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5dac6208-824c-4956-a50f-f6f81fb113f8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8eab8df0-d9c6-4db5-9f57-0e83110c9257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5bac31c7-5002-4d2c-a421-22af4501909f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_42010e26-da1c-4bfa-8886-46c86d0f74c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5bac31c7-5002-4d2c-a421-22af4501909f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_42010e26-da1c-4bfa-8886-46c86d0f74c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7b6cfe4c-738a-4f35-8d46-bf98f21bad62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42010e26-da1c-4bfa-8886-46c86d0f74c1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7b6cfe4c-738a-4f35-8d46-bf98f21bad62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4c6513e1-a050-4e15-b7f6-9225e5fd16ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7b6cfe4c-738a-4f35-8d46-bf98f21bad62" xlink:to="loc_us-gaap_ClassOfStockDomain_4c6513e1-a050-4e15-b7f6-9225e5fd16ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_bff59990-6822-4c5c-a5e8-f186883c6a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4c6513e1-a050-4e15-b7f6-9225e5fd16ca" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_bff59990-6822-4c5c-a5e8-f186883c6a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e8ca9f68-4199-432f-af60-bf98464603a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_42010e26-da1c-4bfa-8886-46c86d0f74c1" xlink:to="loc_us-gaap_ClassOfStockLineItems_e8ca9f68-4199-432f-af60-bf98464603a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_f6796ce0-e985-4113-bf57-2f09ea628dab" xlink:href="ino-20241231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8ca9f68-4199-432f-af60-bf98464603a4" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_f6796ce0-e985-4113-bf57-2f09ea628dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b28d9b46-bef8-4f12-b0ee-0eecf8120d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e8ca9f68-4199-432f-af60-bf98464603a4" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b28d9b46-bef8-4f12-b0ee-0eecf8120d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_eba0aa31-b817-46f9-a476-89bdf3243ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_eba0aa31-b817-46f9-a476-89bdf3243ec4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_badd0a45-4233-416d-9389-13695ba62852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_badd0a45-4233-416d-9389-13695ba62852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0f115e13-ba6d-4e8b-8f6d-3d4645fcb5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_badd0a45-4233-416d-9389-13695ba62852" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0f115e13-ba6d-4e8b-8f6d-3d4645fcb5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024OfferingWarrantsMember_07c271cf-6205-4939-a979-ee8e8da860a4" xlink:href="ino-20241231.xsd#ino_December2024OfferingWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0f115e13-ba6d-4e8b-8f6d-3d4645fcb5fc" xlink:to="loc_ino_December2024OfferingWarrantsMember_07c271cf-6205-4939-a979-ee8e8da860a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b9c02a74-d38c-4799-b67e-d78905c45a13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b9c02a74-d38c-4799-b67e-d78905c45a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_64e3c7f8-6f46-4fca-9c98-778fc44fe979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b9c02a74-d38c-4799-b67e-d78905c45a13" xlink:to="loc_us-gaap_EquityComponentDomain_64e3c7f8-6f46-4fca-9c98-778fc44fe979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_24341b19-d41f-4508-9007-693289420365" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64e3c7f8-6f46-4fca-9c98-778fc44fe979" xlink:to="loc_us-gaap_WarrantMember_24341b19-d41f-4508-9007-693289420365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6f9416dc-89df-46a7-bf5c-1c9f7fe5123b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64e3c7f8-6f46-4fca-9c98-778fc44fe979" xlink:to="loc_us-gaap_CommonStockMember_6f9416dc-89df-46a7-bf5c-1c9f7fe5123b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ddecb612-ff4a-4f1e-bfae-e0a6413bb389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ddecb612-ff4a-4f1e-bfae-e0a6413bb389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e470e830-2e25-4334-ada1-ce79046ac96d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ddecb612-ff4a-4f1e-bfae-e0a6413bb389" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e470e830-2e25-4334-ada1-ce79046ac96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenRegisteredDirectOfferingMember_7875bc66-530b-44bc-9dd7-f953b4c3013c" xlink:href="ino-20241231.xsd#ino_UnderwrittenRegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e470e830-2e25-4334-ada1-ce79046ac96d" xlink:to="loc_ino_UnderwrittenRegisteredDirectOfferingMember_7875bc66-530b-44bc-9dd7-f953b4c3013c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_449ed6fa-9ed0-4ba5-83af-be4dd4c6072f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9fce45b1-4f33-4c81-acb0-469730e40bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9fce45b1-4f33-4c81-acb0-469730e40bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_a571ec2a-47f7-49f0-bc02-ae0d68458cab" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent_a571ec2a-47f7-49f0-bc02-ae0d68458cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_e7e2cb90-8e1b-485c-acb3-e0be7ce198f4" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent_e7e2cb90-8e1b-485c-acb3-e0be7ce198f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_a22114c2-8d73-4f6f-9341-dd664e80d142" xlink:href="ino-20241231.xsd#ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4876aa82-8fab-444d-9d8f-0896a09f872d" xlink:to="loc_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent_a22114c2-8d73-4f6f-9341-dd664e80d142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityAtTheMarketSalesAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_73950239-630d-4c23-a903-ce7f6b59b1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_73950239-630d-4c23-a903-ce7f6b59b1e6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6c7587df-08c9-43a2-aa15-a78e10d461fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6c7587df-08c9-43a2-aa15-a78e10d461fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad32fc49-205d-4fe7-acb1-20fad851f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6c7587df-08c9-43a2-aa15-a78e10d461fe" xlink:to="loc_us-gaap_EquityComponentDomain_ad32fc49-205d-4fe7-acb1-20fad851f60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ba505002-51f7-4479-bb99-cdfb2f90e0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad32fc49-205d-4fe7-acb1-20fad851f60e" xlink:to="loc_us-gaap_CommonStockMember_ba505002-51f7-4479-bb99-cdfb2f90e0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_07ffedef-791a-43b6-87f3-4b1547160bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2eb8b064-ceb4-48dc-8195-7ef91bbd8ed5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_07ffedef-791a-43b6-87f3-4b1547160bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember_ca992c94-8b2b-4b6f-9c00-a3acb990dbcf" xlink:href="ino-20241231.xsd#ino_A2024SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_07ffedef-791a-43b6-87f3-4b1547160bd7" xlink:to="loc_ino_A2024SalesAgreementMember_ca992c94-8b2b-4b6f-9c00-a3acb990dbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_2fa007e2-21fa-4d46-bdbf-c1c21d086843" xlink:href="ino-20241231.xsd#ino_A2021SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_07ffedef-791a-43b6-87f3-4b1547160bd7" xlink:to="loc_ino_A2021SalesAgreementMember_2fa007e2-21fa-4d46-bdbf-c1c21d086843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_899ebcde-7e47-472e-b8fc-ef669dac7099" xlink:to="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_9f122bf3-d3a3-404d-881a-998cff117c9d" xlink:href="ino-20241231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_9f122bf3-d3a3-404d-881a-998cff117c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_f3a8739c-da40-4ac5-a52c-b1dd1011f631" xlink:href="ino-20241231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_f3a8739c-da40-4ac5-a52c-b1dd1011f631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_2816cdaf-c1f6-49ca-b8ed-3e660765952c" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_2816cdaf-c1f6-49ca-b8ed-3e660765952c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_f406a868-230a-4c30-a589-3bc24ad16b65" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_f406a868-230a-4c30-a589-3bc24ad16b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_dac649c0-e90a-439a-8ae0-52ba3a95eb3c" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_dac649c0-e90a-439a-8ae0-52ba3a95eb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementRemainingCapacityAmount_9c5c13c9-b620-4f16-9f4d-500582b1adf2" xlink:href="ino-20241231.xsd#ino_StockSaleAgreementRemainingCapacityAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_53e8823b-c760-4930-b56e-fd6675068a98" xlink:to="loc_ino_StockSaleAgreementRemainingCapacityAmount_9c5c13c9-b620-4f16-9f4d-500582b1adf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityOtherIssuancesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_56afad49-c65d-4a80-a593-2f249914ddca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8a893fc2-3711-4ce2-8807-0f1a4dadd101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_56afad49-c65d-4a80-a593-2f249914ddca" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8a893fc2-3711-4ce2-8807-0f1a4dadd101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8a893fc2-3711-4ce2-8807-0f1a4dadd101" xlink:to="loc_srt_LitigationCaseAxis_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ac456234-074c-4e5e-a49c-664f1e9d7030" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b6c5b541-06ea-42b2-ab3e-c97bf7cdde2d" xlink:to="loc_srt_LitigationCaseTypeDomain_ac456234-074c-4e5e-a49c-664f1e9d7030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_d3a4f092-dd15-4c8a-86cb-413028f2a7c9" xlink:href="ino-20241231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ac456234-074c-4e5e-a49c-664f1e9d7030" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_d3a4f092-dd15-4c8a-86cb-413028f2a7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_97fd48fb-959e-4153-a995-3ad821f7a6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8a893fc2-3711-4ce2-8807-0f1a4dadd101" xlink:to="loc_us-gaap_ClassOfStockLineItems_97fd48fb-959e-4153-a995-3ad821f7a6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_0f33563c-a841-4ad5-b924-cb47f61cf702" xlink:href="ino-20241231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_97fd48fb-959e-4153-a995-3ad821f7a6a3" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_0f33563c-a841-4ad5-b924-cb47f61cf702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_76ee8768-8f3b-403b-86c1-815e2aece599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_76ee8768-8f3b-403b-86c1-815e2aece599" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c4d3dd89-0263-42cd-8727-4a9146e656da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_PlanNameAxis_c4d3dd89-0263-42cd-8727-4a9146e656da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c4d3dd89-0263-42cd-8727-4a9146e656da" xlink:to="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2023IncentivePlanMember_562d2d7b-ae74-4df9-8bdc-86c21571c276" xlink:href="ino-20241231.xsd#ino_A2023IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:to="loc_ino_A2023IncentivePlanMember_562d2d7b-ae74-4df9-8bdc-86c21571c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_7b855453-3e30-4d03-ba67-956db3bf704a" xlink:href="ino-20241231.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:to="loc_ino_A2016IncentivePlanMember_7b855453-3e30-4d03-ba67-956db3bf704a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_11c8e31d-bb30-41ec-9601-a6e92e044fef" xlink:href="ino-20241231.xsd#ino_A2022InducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:to="loc_ino_A2022InducementPlanMember_11c8e31d-bb30-41ec-9601-a6e92e044fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_9003e9d3-b301-441e-a9db-369dc9c2dec2" xlink:href="ino-20241231.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f5be14c8-7d0f-4b50-8755-82ece76b092d" xlink:to="loc_ino_A2007IncentivePlanMember_9003e9d3-b301-441e-a9db-369dc9c2dec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_abbbacb9-777f-421f-a352-9511edf3d40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_abbbacb9-777f-421f-a352-9511edf3d40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_284e43ae-ec72-4398-b70c-93dc3e505ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_abbbacb9-777f-421f-a352-9511edf3d40e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_284e43ae-ec72-4398-b70c-93dc3e505ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9589808c-a08c-41cb-952d-6cb71f6c4d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_284e43ae-ec72-4398-b70c-93dc3e505ad8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9589808c-a08c-41cb-952d-6cb71f6c4d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1664602d-ca4a-4a54-8749-82e8ae02be4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_284e43ae-ec72-4398-b70c-93dc3e505ad8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1664602d-ca4a-4a54-8749-82e8ae02be4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d5fdba06-eb23-46f1-bd05-33708f0ba110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_AwardTypeAxis_d5fdba06-eb23-46f1-bd05-33708f0ba110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc542369-5ee1-4f7f-8929-135c60e95f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d5fdba06-eb23-46f1-bd05-33708f0ba110" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc542369-5ee1-4f7f-8929-135c60e95f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_df4b7161-9d39-46e9-a3d5-b3d41516da8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bc542369-5ee1-4f7f-8929-135c60e95f3c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_df4b7161-9d39-46e9-a3d5-b3d41516da8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_2e820429-27f8-4ddb-9fef-96d2873f45cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_GranteeStatusAxis_2e820429-27f8-4ddb-9fef-96d2873f45cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_decc0077-cfd7-48f6-882c-f611dc3f1555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_2e820429-27f8-4ddb-9fef-96d2873f45cf" xlink:to="loc_us-gaap_GranteeStatusDomain_decc0077-cfd7-48f6-882c-f611dc3f1555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d80f79eb-000d-4025-b060-3cb86c595964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_decc0077-cfd7-48f6-882c-f611dc3f1555" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d80f79eb-000d-4025-b060-3cb86c595964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1c9e19cd-4405-40b5-9004-4c0e09a83574" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_srt_TitleOfIndividualAxis_1c9e19cd-4405-40b5-9004-4c0e09a83574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_caaf07ea-b872-424c-ba1e-76ebd9d43e7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1c9e19cd-4405-40b5-9004-4c0e09a83574" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_caaf07ea-b872-424c-ba1e-76ebd9d43e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_a24cea8c-ef8a-41d8-9a09-d217c7615366" xlink:href="ino-20241231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_caaf07ea-b872-424c-ba1e-76ebd9d43e7c" xlink:to="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_a24cea8c-ef8a-41d8-9a09-d217c7615366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_73007740-76c4-4119-b80f-ca8a912db190" xlink:to="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5e814f1b-7ffd-40f6-b55d-6861fae701b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5e814f1b-7ffd-40f6-b55d-6861fae701b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e34d5402-2c5e-43ad-8787-fecb3aa2b616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e34d5402-2c5e-43ad-8787-fecb3aa2b616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9759e43c-3219-4beb-8b81-f8e4ad6e9c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9759e43c-3219-4beb-8b81-f8e4ad6e9c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_1f38c3a1-c8c1-447e-99c4-9701da417899" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_1f38c3a1-c8c1-447e-99c4-9701da417899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19305917-93d1-44fa-b852-ea7180daf7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19305917-93d1-44fa-b852-ea7180daf7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_6bf488de-cc9a-453e-88ea-3662683274ce" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_6bf488de-cc9a-453e-88ea-3662683274ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_fcf6dd89-89d0-4ab3-a55d-915bcf815382" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_fcf6dd89-89d0-4ab3-a55d-915bcf815382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_c29bc600-098e-4988-ac1e-09e68fe00517" xlink:href="ino-20241231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_c29bc600-098e-4988-ac1e-09e68fe00517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_474f04b3-94d1-412b-b720-53d09eac2dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_474f04b3-94d1-412b-b720-53d09eac2dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_aa461e30-a8e8-499f-9e3f-d9ca2793c67d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_aa461e30-a8e8-499f-9e3f-d9ca2793c67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9911cfb8-7a34-4b0b-b309-98588e2bd55b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9911cfb8-7a34-4b0b-b309-98588e2bd55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c1204a80-24b9-4e5b-a0d7-c8a2b17fd119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c1204a80-24b9-4e5b-a0d7-c8a2b17fd119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_993a1e16-d6e4-4c7e-beac-a56c6c4009a1" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_993a1e16-d6e4-4c7e-beac-a56c6c4009a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ab9ddc33-3f9b-472d-868b-27085429369b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ab9ddc33-3f9b-472d-868b-27085429369b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_b1e33187-7164-4135-8aa8-50db16b44830" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_b1e33187-7164-4135-8aa8-50db16b44830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c1a1b8d0-3f8c-4102-a9ca-727defe55b61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c1a1b8d0-3f8c-4102-a9ca-727defe55b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_8ae90322-dacc-447b-9cc9-89e18f3e8016" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_8ae90322-dacc-447b-9cc9-89e18f3e8016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_f982ef75-bff1-4d23-b503-dbc8f3b7dd43" xlink:href="ino-20241231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_f982ef75-bff1-4d23-b503-dbc8f3b7dd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_cd4df652-f667-4a8a-bf1c-47519f088bba" xlink:href="ino-20241231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_cd4df652-f667-4a8a-bf1c-47519f088bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9a21c5ef-0c5a-41b9-842b-432f5cf7c843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9a21c5ef-0c5a-41b9-842b-432f5cf7c843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_29f95a36-74ef-45ae-9e2a-67b2efe7f3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_29f95a36-74ef-45ae-9e2a-67b2efe7f3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80efbff4-9bb9-412a-943f-6210ab730fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80efbff4-9bb9-412a-943f-6210ab730fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d23564e-4e3f-4a19-a8bb-490b971eb044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0d23564e-4e3f-4a19-a8bb-490b971eb044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5092729d-4085-468b-952b-2647434d73e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5092729d-4085-468b-952b-2647434d73e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_446e8569-142c-42ee-98cc-5a8746d7dd34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_276bddfb-99c0-4b51-b1e9-9d52b9b8db30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_446e8569-142c-42ee-98cc-5a8746d7dd34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityScheduleofStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f858ddfe-2da0-4500-8638-ced1bedb7906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_2ff993c5-9736-4a87-a9ab-67fb1b42e84e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f858ddfe-2da0-4500-8638-ced1bedb7906" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_2ff993c5-9736-4a87-a9ab-67fb1b42e84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ddbf9300-da76-43ab-862d-66a580f69a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_2ff993c5-9736-4a87-a9ab-67fb1b42e84e" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ddbf9300-da76-43ab-862d-66a580f69a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ddbf9300-da76-43ab-862d-66a580f69a87" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_9495474b-8ee2-4db2-83a4-829c167b4fca" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesOneMember_9495474b-8ee2-4db2-83a4-829c167b4fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_2a57b4a5-89a1-42af-b531-9c8be99cee6a" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_2a57b4a5-89a1-42af-b531-9c8be99cee6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_10651bf4-9cd9-4e8a-a4bf-ec14aa4141eb" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_10651bf4-9cd9-4e8a-a4bf-ec14aa4141eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_12a7ad72-5f81-415a-a106-2267f1abfdec" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesFourMember_12a7ad72-5f81-415a-a106-2267f1abfdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_85dfbf36-acda-4f63-942d-873164d294db" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_85dfbf36-acda-4f63-942d-873164d294db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_801becf8-06c9-469e-b9a0-10e9ba4efd32" xlink:href="ino-20241231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_14f680dd-9717-4afd-b150-f893ad427717" xlink:to="loc_ino_RangeOfExercisePricesSixMember_801becf8-06c9-469e-b9a0-10e9ba4efd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_2ff993c5-9736-4a87-a9ab-67fb1b42e84e" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_42997676-b902-4ad0-b37c-d2b4cb5ef09e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_42997676-b902-4ad0-b37c-d2b4cb5ef09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_26600a6d-efab-4cc1-bf10-bc3fd5633dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_26600a6d-efab-4cc1-bf10-bc3fd5633dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_bda3848a-e8d5-4506-841b-477883912148" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_bda3848a-e8d5-4506-841b-477883912148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7514be6f-9c86-40f3-8805-d3b42ff5bc57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_7514be6f-9c86-40f3-8805-d3b42ff5bc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2660228a-0fad-470f-8c75-7dbc4692a32c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2660228a-0fad-470f-8c75-7dbc4692a32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_db36f7d3-868b-4138-a219-aef5a594992d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_db36f7d3-868b-4138-a219-aef5a594992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_298fa958-6561-4ce5-b921-86ac94123752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_8298093b-b40a-4dd0-9848-f9aaae1a74c4" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_298fa958-6561-4ce5-b921-86ac94123752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_43f94af5-0bc3-4e26-87d1-adef0023bf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ab1f1f6-df21-448a-9ca8-b50f15c79978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_43f94af5-0bc3-4e26-87d1-adef0023bf2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ab1f1f6-df21-448a-9ca8-b50f15c79978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f06636ed-3649-490e-85d5-11b3ab024216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ab1f1f6-df21-448a-9ca8-b50f15c79978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f06636ed-3649-490e-85d5-11b3ab024216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85b8c8cb-a7cb-454d-8ba4-300a535e4241" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ab1f1f6-df21-448a-9ca8-b50f15c79978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_85b8c8cb-a7cb-454d-8ba4-300a535e4241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_29d6e585-fb37-4db3-bd78-2ac53d11215b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ab1f1f6-df21-448a-9ca8-b50f15c79978" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_29d6e585-fb37-4db3-bd78-2ac53d11215b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a7cd3d8d-664b-48ad-8d8c-996558620d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ab1f1f6-df21-448a-9ca8-b50f15c79978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a7cd3d8d-664b-48ad-8d8c-996558620d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41e5c6a8-ee83-4668-ba87-1916b31725e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9ab1f1f6-df21-448a-9ca8-b50f15c79978" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_41e5c6a8-ee83-4668-ba87-1916b31725e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_496cf1ea-29f0-47d6-ab6b-b5f05681f557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_43f94af5-0bc3-4e26-87d1-adef0023bf2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_496cf1ea-29f0-47d6-ab6b-b5f05681f557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b376f42-2666-46cc-9c71-82a543e7fed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_496cf1ea-29f0-47d6-ab6b-b5f05681f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b376f42-2666-46cc-9c71-82a543e7fed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48ea5644-8148-44d5-b969-e16d0ed4ca89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_496cf1ea-29f0-47d6-ab6b-b5f05681f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_48ea5644-8148-44d5-b969-e16d0ed4ca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_31951956-e1af-4a79-b6b0-e2ab146c69e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_496cf1ea-29f0-47d6-ab6b-b5f05681f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_31951956-e1af-4a79-b6b0-e2ab146c69e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bd0f9d5f-a16b-4754-8999-92774395f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_496cf1ea-29f0-47d6-ab6b-b5f05681f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bd0f9d5f-a16b-4754-8999-92774395f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fd8eeee0-2773-4e9c-803a-144b5ca9c5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_496cf1ea-29f0-47d6-ab6b-b5f05681f557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fd8eeee0-2773-4e9c-803a-144b5ca9c5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_91d96e04-a97e-4dc1-a7c1-2f6a5ecf86e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab56be9d-c34f-498d-bcb0-f61269ea768a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_91d96e04-a97e-4dc1-a7c1-2f6a5ecf86e4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab56be9d-c34f-498d-bcb0-f61269ea768a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e47a353-85b6-46f6-b8e9-f8764ed014a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab56be9d-c34f-498d-bcb0-f61269ea768a" xlink:to="loc_us-gaap_AwardTypeAxis_7e47a353-85b6-46f6-b8e9-f8764ed014a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81205044-58c9-42cb-b1b7-db63c6312370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7e47a353-85b6-46f6-b8e9-f8764ed014a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81205044-58c9-42cb-b1b7-db63c6312370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0a7f0942-a594-4a77-b8be-78495063bba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81205044-58c9-42cb-b1b7-db63c6312370" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0a7f0942-a594-4a77-b8be-78495063bba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa495bc6-1774-4f40-89a9-53ae2980da84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab56be9d-c34f-498d-bcb0-f61269ea768a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa495bc6-1774-4f40-89a9-53ae2980da84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa495bc6-1774-4f40-89a9-53ae2980da84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0c662923-4a47-4755-bf83-0eeb741c89d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0c662923-4a47-4755-bf83-0eeb741c89d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82d4af3a-c906-4272-9f8b-3ceae4d24a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82d4af3a-c906-4272-9f8b-3ceae4d24a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_524adb5b-79b1-4c97-9091-a4bc5be1adca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_524adb5b-79b1-4c97-9091-a4bc5be1adca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_27a94619-8bce-475b-b7a0-7696538b39f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_27a94619-8bce-475b-b7a0-7696538b39f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a6869cc-62e8-4a40-b477-d86f1ee2ad62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6457f951-22cf-412b-9fb7-ff8682d4ab7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7a6869cc-62e8-4a40-b477-d86f1ee2ad62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a70b9bcb-8a09-476d-b04c-016fee83bab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15575da6-823e-47bd-a644-d12acc4a5edb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a70b9bcb-8a09-476d-b04c-016fee83bab3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15575da6-823e-47bd-a644-d12acc4a5edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_83751d2f-bc5e-4824-9396-a1f260221102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15575da6-823e-47bd-a644-d12acc4a5edb" xlink:to="loc_us-gaap_AwardTypeAxis_83751d2f-bc5e-4824-9396-a1f260221102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d62217b5-8091-4d61-84b5-0498194b4506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_83751d2f-bc5e-4824-9396-a1f260221102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d62217b5-8091-4d61-84b5-0498194b4506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_cab2ac69-6e42-447c-8634-73a7b3ee60ea" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d62217b5-8091-4d61-84b5-0498194b4506" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_cab2ac69-6e42-447c-8634-73a7b3ee60ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15575da6-823e-47bd-a644-d12acc4a5edb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b81c71a0-7939-4fd7-b6a6-0139226a5fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b81c71a0-7939-4fd7-b6a6-0139226a5fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d7ef528c-3f68-4931-a6c0-58b45cd2e87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d7ef528c-3f68-4931-a6c0-58b45cd2e87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8e75b641-516b-4bf7-bb1c-6d6ea2307595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8e75b641-516b-4bf7-bb1c-6d6ea2307595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24de2a34-c644-4cdf-bf20-65fcd9a10633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_931960cd-2e14-4c9a-9494-f124663bae83" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24de2a34-c644-4cdf-bf20-65fcd9a10633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityPerformanceandMarketBasedRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9b691ccd-29e8-41cf-bdce-ce78a6145907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9b691ccd-29e8-41cf-bdce-ce78a6145907" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d696954-eff2-4e49-8c69-be243611f510" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:to="loc_us-gaap_AwardTypeAxis_5d696954-eff2-4e49-8c69-be243611f510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5d696954-eff2-4e49-8c69-be243611f510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8988747b-3610-4c9d-a667-7a9b1b195b99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:to="loc_us-gaap_PerformanceSharesMember_8988747b-3610-4c9d-a667-7a9b1b195b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fa18a5e3-0667-410f-a262-8f77702774c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fa18a5e3-0667-410f-a262-8f77702774c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_3a24ea04-f1b4-488f-831a-bd1bcc131fc7" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsRSUsMarketBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:to="loc_ino_RestrictedStockUnitsRSUsMarketBasedMember_3a24ea04-f1b4-488f-831a-bd1bcc131fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_b18c7b6d-17f1-4cf7-a450-feadd202d62d" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsRSUsMilestoneBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0e78430-bcf9-4a31-acaf-5efda4b3035c" xlink:to="loc_ino_RestrictedStockUnitsRSUsMilestoneBasedMember_b18c7b6d-17f1-4cf7-a450-feadd202d62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_2567123c-b8d1-498c-a6cf-c60c782c3ea5" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_2567123c-b8d1-498c-a6cf-c60c782c3ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis_2567123c-b8d1-498c-a6cf-c60c782c3ea5" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsSpecifiedThresholdPercentileMember_b54aa8bd-d65f-4ce7-87bd-2772dc0a9f5b" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsSpecifiedThresholdPercentileMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:to="loc_ino_PerformanceRSUsSpecifiedThresholdPercentileMember_b54aa8bd-d65f-4ce7-87bd-2772dc0a9f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsTargetPercentileMember_7309a99a-cbd4-409f-b8aa-24df438a5833" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsTargetPercentileMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:to="loc_ino_PerformanceRSUsTargetPercentileMember_7309a99a-cbd4-409f-b8aa-24df438a5833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PerformanceRSUsSpecifiedMaximumPercentileMember_265abd3d-df30-4097-8df7-57dad98911ab" xlink:href="ino-20241231.xsd#ino_PerformanceRSUsSpecifiedMaximumPercentileMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain_f0655903-f357-4c17-9b83-34dab35d72a0" xlink:to="loc_ino_PerformanceRSUsSpecifiedMaximumPercentileMember_265abd3d-df30-4097-8df7-57dad98911ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_71208795-32fa-4346-ba73-ad3e8f6d619d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:to="loc_srt_RangeAxis_71208795-32fa-4346-ba73-ad3e8f6d619d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b00cb8eb-2779-4429-8bd5-2c3042727056" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_71208795-32fa-4346-ba73-ad3e8f6d619d" xlink:to="loc_srt_RangeMember_b00cb8eb-2779-4429-8bd5-2c3042727056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37e20f09-8107-46fe-a15d-7f42efa1b419" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b00cb8eb-2779-4429-8bd5-2c3042727056" xlink:to="loc_srt_MinimumMember_37e20f09-8107-46fe-a15d-7f42efa1b419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_05f12a49-3250-48ff-baee-c2ac35f64829" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b00cb8eb-2779-4429-8bd5-2c3042727056" xlink:to="loc_srt_MaximumMember_05f12a49-3250-48ff-baee-c2ac35f64829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bba5cdb4-9763-4775-a508-d6cc3201b0d4" xlink:to="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d41e588b-5aa3-4121-bef7-f67a08a0cf50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d41e588b-5aa3-4121-bef7-f67a08a0cf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased_af3de1a5-42d4-4a6d-bdac-773b49919687" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased_af3de1a5-42d4-4a6d-bdac-773b49919687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased_1875d179-b217-43ba-85b6-87be69e64d77" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased_1875d179-b217-43ba-85b6-87be69e64d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_6df1edda-29b1-4df6-a641-4b27eec66334" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage_6df1edda-29b1-4df6-a641-4b27eec66334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d8c281c0-7b92-4922-b945-1131820e880b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d8c281c0-7b92-4922-b945-1131820e880b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards_a7d50adf-438a-42af-80dd-6072766f4bc6" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards_a7d50adf-438a-42af-80dd-6072766f4bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_97d36d60-116f-4830-8feb-e5490e288720" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_97d36d60-116f-4830-8feb-e5490e288720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59d806ea-dbf6-4e71-af2c-a5a1fc5cc84e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_59d806ea-dbf6-4e71-af2c-a5a1fc5cc84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e2c74aee-560b-4ef6-a6aa-0212f917dc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_30ee41f0-7eb4-4394-9da3-4b5c7f00e2e1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e2c74aee-560b-4ef6-a6aa-0212f917dc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#StockholdersEquityDecember2024PerformanceBasedAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ceeff3e5-d01d-49be-905c-5e5ef1348923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ceeff3e5-d01d-49be-905c-5e5ef1348923" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:to="loc_us-gaap_AwardTypeAxis_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f34f2880-2cb7-4099-9b60-d8f3ad5ef2b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b595ba49-a153-4361-9424-a2cd91959905" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b595ba49-a153-4361-9424-a2cd91959905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e71ea2f0-9683-47b0-83eb-6ec8bbfc29ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e71ea2f0-9683-47b0-83eb-6ec8bbfc29ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestrictedStockUnitsPerformanceBasedMember_9cb19694-9469-43f8-aa0b-e164d1e2eab0" xlink:href="ino-20241231.xsd#ino_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:to="loc_ino_RestrictedStockUnitsPerformanceBasedMember_9cb19694-9469-43f8-aa0b-e164d1e2eab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockOptionsPerformanceBasedMember_7fc3c4c5-200e-4614-ba1c-49317c1ad87a" xlink:href="ino-20241231.xsd#ino_StockOptionsPerformanceBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67667ac1-a710-4278-9d25-084ac1ca6881" xlink:to="loc_ino_StockOptionsPerformanceBasedMember_7fc3c4c5-200e-4614-ba1c-49317c1ad87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_890f81b2-8473-40d6-8d4d-4c2013a4ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:to="loc_us-gaap_AwardDateAxis_890f81b2-8473-40d6-8d4d-4c2013a4ce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_467266ed-b599-4692-9622-53d79b99dc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_890f81b2-8473-40d6-8d4d-4c2013a4ce26" xlink:to="loc_us-gaap_AwardDateDomain_467266ed-b599-4692-9622-53d79b99dc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2024Member_0c600f6d-1d58-4eb5-905e-dc7c0b8f780c" xlink:href="ino-20241231.xsd#ino_December2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_467266ed-b599-4692-9622-53d79b99dc5b" xlink:to="loc_ino_December2024Member_0c600f6d-1d58-4eb5-905e-dc7c0b8f780c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_685ec89d-c48f-4e2b-91a5-378dd7a2f55d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_c7e7c868-572a-46fd-9ac8-0e864ffa8f29" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock_c7e7c868-572a-46fd-9ac8-0e864ffa8f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_fb71e937-a8e6-4cbf-99ef-857bc8556005" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue_fb71e937-a8e6-4cbf-99ef-857bc8556005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_11429a60-f3e2-4884-b889-c9101558a1e0" xlink:href="ino-20241231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice_11429a60-f3e2-4884-b889-c9101558a1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34bf4c61-dd2f-404e-a3b8-87e1088aeac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_34bf4c61-dd2f-404e-a3b8-87e1088aeac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6bcbc4d6-cc20-4a2a-8cca-e361652bcc97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4df046f3-fd7f-4541-b150-c3752ac2f525" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6bcbc4d6-cc20-4a2a-8cca-e361652bcc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19145f75-2f21-4df1-8798-37f5a20ad6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19145f75-2f21-4df1-8798-37f5a20ad6d8" xlink:to="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ca43fa81-25d1-437e-b844-84a8b9138000" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ca43fa81-25d1-437e-b844-84a8b9138000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_123589f4-c147-4a09-8e12-48f1c546e3a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ca43fa81-25d1-437e-b844-84a8b9138000" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_123589f4-c147-4a09-8e12-48f1c546e3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_ca697f05-7f36-439c-9230-997b33b5568b" xlink:href="ino-20241231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_123589f4-c147-4a09-8e12-48f1c546e3a0" xlink:to="loc_ino_SanDiegoCaliforniaMember_ca697f05-7f36-439c-9230-997b33b5568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_0cf3df32-0261-4237-b952-84c9e919dbc0" xlink:href="ino-20241231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_123589f4-c147-4a09-8e12-48f1c546e3a0" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_0cf3df32-0261-4237-b952-84c9e919dbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7f19be1-794d-4272-9d46-160db75190cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:to="loc_srt_RangeAxis_a7f19be1-794d-4272-9d46-160db75190cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a1591e71-2d23-4125-a2a1-9854832cebb9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a7f19be1-794d-4272-9d46-160db75190cc" xlink:to="loc_srt_RangeMember_a1591e71-2d23-4125-a2a1-9854832cebb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9be195f7-fa32-45a7-b6f2-43f4eac5cb49" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a1591e71-2d23-4125-a2a1-9854832cebb9" xlink:to="loc_srt_MinimumMember_9be195f7-fa32-45a7-b6f2-43f4eac5cb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c8453c3-8521-4c31-ab18-53b8ac10a2a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a1591e71-2d23-4125-a2a1-9854832cebb9" xlink:to="loc_srt_MaximumMember_2c8453c3-8521-4c31-ab18-53b8ac10a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_aba7fd64-6696-4868-aa8d-d477736b5047" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:to="loc_srt_LitigationCaseAxis_aba7fd64-6696-4868-aa8d-d477736b5047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bc3a8ff6-e10e-4d42-8170-d6ba11e76b40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_aba7fd64-6696-4868-aa8d-d477736b5047" xlink:to="loc_srt_LitigationCaseTypeDomain_bc3a8ff6-e10e-4d42-8170-d6ba11e76b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c9c5b4d3-e385-4276-b798-53d6413eb989" xlink:href="ino-20241231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_bc3a8ff6-e10e-4d42-8170-d6ba11e76b40" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c9c5b4d3-e385-4276-b798-53d6413eb989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BehestiVKimEtAlMember_fffe6922-4ad1-4fd7-b657-faed74de2f1d" xlink:href="ino-20241231.xsd#ino_BehestiVKimEtAlMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_bc3a8ff6-e10e-4d42-8170-d6ba11e76b40" xlink:to="loc_ino_BehestiVKimEtAlMember_fffe6922-4ad1-4fd7-b657-faed74de2f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_ff01c0c6-ad75-4a2c-822d-5efdc22aa322" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4802fc66-4c1c-4901-b16f-47afde28043b" xlink:href="ino-20241231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_4802fc66-4c1c-4901-b16f-47afde28043b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_3258c34a-18da-43b7-8a2f-23e8a73d4503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_3258c34a-18da-43b7-8a2f-23e8a73d4503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_fedf6d98-6156-4217-81d8-4c2f9df4dd5e" xlink:href="ino-20241231.xsd#ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease_fedf6d98-6156-4217-81d8-4c2f9df4dd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_9f07eb64-b9a5-4cdd-896e-b3b3e44726dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LeaseCost_9f07eb64-b9a5-4cdd-896e-b3b3e44726dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_da04529f-b833-4aac-885a-4a1570c4f93c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_da04529f-b833-4aac-885a-4a1570c4f93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_fccbe0e9-dc6c-4fce-9092-3e195e0232ed" xlink:href="ino-20241231.xsd#ino_LitigationSettlementAmountAwardedToOtherPartyShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_ino_LitigationSettlementAmountAwardedToOtherPartyShares_fccbe0e9-dc6c-4fce-9092-3e195e0232ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_e32b1532-3a72-40fb-ae87-3f0bb65eafee" xlink:href="ino-20241231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_e32b1532-3a72-40fb-ae87-3f0bb65eafee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_8ad793d4-8fff-40f4-a0d0-c095581b9030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_8ad793d4-8fff-40f4-a0d0-c095581b9030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_474bd446-92c8-40e7-b6cd-b68583ffd91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5a0135d4-ab26-4067-b27f-fab7db569ee0" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_474bd446-92c8-40e7-b6cd-b68583ffd91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e89bced6-e8fd-4c80-a8d1-70ce8635ba8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e89bced6-e8fd-4c80-a8d1-70ce8635ba8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c2c7fa86-9259-404c-bcdd-4eec650f5605" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c2c7fa86-9259-404c-bcdd-4eec650f5605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_32f8d6bc-1240-4ae4-87c9-60165d858794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_32f8d6bc-1240-4ae4-87c9-60165d858794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f070d960-cf9a-4f23-b7b6-b884dba5e851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f070d960-cf9a-4f23-b7b6-b884dba5e851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a6945c5c-fdd2-4e17-b549-a6ed71b01525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a6945c5c-fdd2-4e17-b549-a6ed71b01525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a397b8e-35f1-4e2b-a842-fb5fcd9f3a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a397b8e-35f1-4e2b-a842-fb5fcd9f3a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d0f95ae-d1b7-4c07-b300-241dd7e787e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d0f95ae-d1b7-4c07-b300-241dd7e787e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8081cec5-b984-4342-b53e-6b7d3d0b28f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_OperatingLeaseLiability_8081cec5-b984-4342-b53e-6b7d3d0b28f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1d93d325-4d67-47fe-95a7-ff5f83932a89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1d93d325-4d67-47fe-95a7-ff5f83932a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8608635b-9dc4-4da0-bff8-2d8f6d1833c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8608635b-9dc4-4da0-bff8-2d8f6d1833c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6479d8b4-cc96-42a5-b3b5-9b26f06cb4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6479d8b4-cc96-42a5-b3b5-9b26f06cb4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3a741257-2566-49d0-b021-df1b870c3fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb7873f-e149-4a80-a376-eca0a6f4917b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3a741257-2566-49d0-b021-df1b870c3fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_50815ff1-7fe3-4216-b593-35ce1a0cffd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4bd97785-8c30-4799-acea-e567cb130a16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50815ff1-7fe3-4216-b593-35ce1a0cffd6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4bd97785-8c30-4799-acea-e567cb130a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a6832d47-4c8f-498f-9d63-df3f00413109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50815ff1-7fe3-4216-b593-35ce1a0cffd6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a6832d47-4c8f-498f-9d63-df3f00413109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1aa08a5-e20f-4bcc-981e-cad96b3a87db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50815ff1-7fe3-4216-b593-35ce1a0cffd6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c1aa08a5-e20f-4bcc-981e-cad96b3a87db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2e8533b3-cc20-42fd-964f-052dac3f8478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e8533b3-cc20-42fd-964f-052dac3f8478" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5ae1ae87-ec21-45d1-8d06-45e535919cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5ae1ae87-ec21-45d1-8d06-45e535919cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0c5142d9-251d-498e-b36d-547bfd99b056" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0c5142d9-251d-498e-b36d-547bfd99b056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3e97be57-f303-410e-a814-742619f2d709" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3e97be57-f303-410e-a814-742619f2d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_127024e9-78d9-4677-a0cc-1edee32e750c" xlink:href="ino-20241231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_127024e9-78d9-4677-a0cc-1edee32e750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e5d92cfa-e822-488e-b46a-815e2f9b6e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e5d92cfa-e822-488e-b46a-815e2f9b6e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_32df35eb-c63d-41ee-bfb0-3d1f5e59a757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_32df35eb-c63d-41ee-bfb0-3d1f5e59a757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_eb042161-3843-4456-bfd9-f63029cefc39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_eb042161-3843-4456-bfd9-f63029cefc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_49f8826c-df2a-4c99-9449-f951402a499a" xlink:href="ino-20241231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_49f8826c-df2a-4c99-9449-f951402a499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_0ff5154d-6e99-4099-ab9a-51690309a876" xlink:href="ino-20241231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_0ff5154d-6e99-4099-ab9a-51690309a876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1924cae3-f22a-4121-9606-594fbc462632" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1924cae3-f22a-4121-9606-594fbc462632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4d36a548-6ea0-40b7-bca7-92dbf7a17ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_4d36a548-6ea0-40b7-bca7-92dbf7a17ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_4d7420b6-5b7a-4868-b2be-1dce8791e95d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_4d7420b6-5b7a-4868-b2be-1dce8791e95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f40e8548-bbb5-4308-928c-ff3f2525a875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_dfc9b7f8-1e76-4492-8c9b-efe90511119c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f40e8548-bbb5-4308-928c-ff3f2525a875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e5222347-9979-4e56-8314-097d895c5441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5222347-9979-4e56-8314-097d895c5441" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_84824232-728c-458a-bcd8-d657c4b78525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_84824232-728c-458a-bcd8-d657c4b78525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_84824232-728c-458a-bcd8-d657c4b78525" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_8a4f9074-339e-4209-88d5-6d01e7aaab69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_8a4f9074-339e-4209-88d5-6d01e7aaab69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_7c2bae79-11ca-4a8a-a2b3-ad789528f042" xlink:href="ino-20241231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_7c2bae79-11ca-4a8a-a2b3-ad789528f042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_b2a6ccf8-7467-43a2-944b-5143c1c0d690" xlink:href="ino-20241231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_b2a6ccf8-7467-43a2-944b-5143c1c0d690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_b84553bb-7a05-4f3a-b788-366afe6a689b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_us-gaap_DomesticCountryMember_b84553bb-7a05-4f3a-b788-366afe6a689b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_7be40439-54fd-4c67-9e26-3cd9e7c96d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_us-gaap_ForeignCountryMember_7be40439-54fd-4c67-9e26-3cd9e7c96d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4af53d04-7827-459d-9fac-406869392261" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_c6d5cb34-0dba-4c75-bfa5-a4c1c0196593" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4af53d04-7827-459d-9fac-406869392261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_d73cc8a8-4115-4050-ba58-23ef9fa4c476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_d73cc8a8-4115-4050-ba58-23ef9fa4c476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c4d4014e-9d05-47ba-be14-7c0f418b8aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d73cc8a8-4115-4050-ba58-23ef9fa4c476" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c4d4014e-9d05-47ba-be14-7c0f418b8aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_d4af3cf3-342f-4b35-b3f5-e766567d7803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_c4d4014e-9d05-47ba-be14-7c0f418b8aca" xlink:to="loc_us-gaap_ResearchMember_d4af3cf3-342f-4b35-b3f5-e766567d7803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7b48f296-779e-423d-8daf-cc70a9277d23" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6e28e8b4-5cc8-4fa5-9433-e6ff208092cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6e28e8b4-5cc8-4fa5-9433-e6ff208092cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_6d64ca80-d827-46d6-9af5-d48e4b56edd9" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_6d64ca80-d827-46d6-9af5-d48e4b56edd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_89f5cd71-f18f-42cf-bdbc-ef77ebe7da51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_OperatingLossCarryforwards_89f5cd71-f18f-42cf-bdbc-ef77ebe7da51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d30e3c98-833f-4185-89f0-af1e753d200f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d30e3c98-833f-4185-89f0-af1e753d200f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_6122aaaa-e088-4b5b-bc35-a7e89a7b6601" xlink:href="ino-20241231.xsd#ino_TaxBenefitsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_ino_TaxBenefitsExpired_6122aaaa-e088-4b5b-bc35-a7e89a7b6601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cc7f200a-733f-4a22-8d45-424b4d0403b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_4ef0e476-850e-44a5-bab5-22e62e65a795" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cc7f200a-733f-4a22-8d45-424b4d0403b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_33da5c34-4e8c-4e51-8a10-c2acf4fe1d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33da5c34-4e8c-4e51-8a10-c2acf4fe1d10" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d6de21f7-6d59-4f42-bef3-18ff2ec2038b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d6de21f7-6d59-4f42-bef3-18ff2ec2038b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e02edfeb-9313-444a-996d-b6b8c26864f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e02edfeb-9313-444a-996d-b6b8c26864f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_e5f7fba9-cd01-4f4f-a74b-75c749a8729f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_e5f7fba9-cd01-4f4f-a74b-75c749a8729f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_850ca0d2-499c-4fb4-ae33-e6471065d4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_850ca0d2-499c-4fb4-ae33-e6471065d4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ec24c82e-4729-4004-a486-47e06d247a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ec24c82e-4729-4004-a486-47e06d247a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_72104044-9410-4d6e-b2d4-26ef2d0988d2" xlink:href="ino-20241231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_72104044-9410-4d6e-b2d4-26ef2d0988d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_867b2994-edfa-40f8-9f5e-507ff828c915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_867b2994-edfa-40f8-9f5e-507ff828c915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_e985d26a-2797-49a1-bea8-b666d57e8fd8" xlink:href="ino-20241231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_e985d26a-2797-49a1-bea8-b666d57e8fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_6e79b9ad-74ae-4169-a2d2-b8c7de9dc381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_6e79b9ad-74ae-4169-a2d2-b8c7de9dc381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ddb98465-2bae-43a2-8b0f-15a11442f616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ddb98465-2bae-43a2-8b0f-15a11442f616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_63b031b7-fc26-4321-bf5f-7d199331abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_63b031b7-fc26-4321-bf5f-7d199331abcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_483ebc27-d85c-4613-8553-be4eb766c452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_483ebc27-d85c-4613-8553-be4eb766c452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1a522a2a-87d9-4e6b-b68c-ceee241937ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_22f5bb55-62ec-456a-a747-de4472306fb3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1a522a2a-87d9-4e6b-b68c-ceee241937ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03a55ec5-129b-43a7-b414-c95f3f83f910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33da5c34-4e8c-4e51-8a10-c2acf4fe1d10" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03a55ec5-129b-43a7-b414-c95f3f83f910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_8bb84421-39f6-449d-b829-bcfc3d541563" xlink:href="ino-20241231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03a55ec5-129b-43a7-b414-c95f3f83f910" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_8bb84421-39f6-449d-b829-bcfc3d541563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_aea634f9-d328-4dc1-a819-48a8d32d437e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03a55ec5-129b-43a7-b414-c95f3f83f910" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_aea634f9-d328-4dc1-a819-48a8d32d437e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ca3977b6-4874-41a3-adad-6b22ec132bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_33da5c34-4e8c-4e51-8a10-c2acf4fe1d10" xlink:to="loc_us-gaap_DeferredTaxLiabilities_ca3977b6-4874-41a3-adad-6b22ec132bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1fec2f9d-0afe-489e-9477-b75cf1427023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1fec2f9d-0afe-489e-9477-b75cf1427023" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_3ff9906d-887e-4c9f-993a-632fca2f4452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_3ff9906d-887e-4c9f-993a-632fca2f4452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ded5cf43-e6ff-4c95-a783-748a8348686f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_3ff9906d-887e-4c9f-993a-632fca2f4452" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ded5cf43-e6ff-4c95-a783-748a8348686f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_496bcff3-d11a-48d4-8203-7906a5e97bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ded5cf43-e6ff-4c95-a783-748a8348686f" xlink:to="loc_us-gaap_ResearchMember_496bcff3-d11a-48d4-8203-7906a5e97bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_897074cd-5aaf-4bda-9db6-5ff1a98d10fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_897074cd-5aaf-4bda-9db6-5ff1a98d10fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_897074cd-5aaf-4bda-9db6-5ff1a98d10fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_aa0eace8-b7e8-4278-8770-480083900bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:to="loc_us-gaap_DomesticCountryMember_aa0eace8-b7e8-4278-8770-480083900bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a7147028-2714-4baa-a6f2-1d792f9c3ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a7147028-2714-4baa-a6f2-1d792f9c3ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_83d492be-374c-4105-8c79-3d83a7d296d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ceaa5dbf-95b2-4014-b93e-6c016a7cd994" xlink:to="loc_us-gaap_ForeignCountryMember_83d492be-374c-4105-8c79-3d83a7d296d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_85e3dbc5-0bd3-4d29-8747-93745482d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_09a43eb2-5b1d-4dc3-857f-a7ca1ccd4198" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_85e3dbc5-0bd3-4d29-8747-93745482d3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_85e3dbc5-0bd3-4d29-8747-93745482d3c0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_8f2b9fdd-59fb-434c-a05f-9d7c1611fb00" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringInNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear_8f2b9fdd-59fb-434c-a05f-9d7c1611fb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_7a5d300f-4a5e-44b5-80c3-0d418f2bcb0f" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_7a5d300f-4a5e-44b5-80c3-0d418f2bcb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_8a2754da-27e6-443a-8b91-b0b71424bac7" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_8a2754da-27e6-443a-8b91-b0b71424bac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_0760ee5b-5021-478b-84cd-b7d53f70b7ef" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_0760ee5b-5021-478b-84cd-b7d53f70b7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_4ecfa24f-9067-45b6-9489-3c5c36473c87" xlink:href="ino-20241231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_4ecfa24f-9067-45b6-9489-3c5c36473c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ee9e4cbe-598b-4396-b31e-aad22d3b5b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_82eeeb5b-75a4-4dd5-8574-732a221e04ad" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ee9e4cbe-598b-4396-b31e-aad22d3b5b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_85e3dbc5-0bd3-4d29-8747-93745482d3c0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_1ed2175a-ca6c-4859-9542-23699758df06" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInNextFiscalYear_1ed2175a-ca6c-4859-9542-23699758df06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_f8b85dd7-6d2b-4211-9be6-a81bbd1bbb24" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_f8b85dd7-6d2b-4211-9be6-a81bbd1bbb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_85bcc3e0-e51e-4aad-a552-abdfc0883814" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_85bcc3e0-e51e-4aad-a552-abdfc0883814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_70bae01c-4da8-4387-96e4-83b8fa1cfd48" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_70bae01c-4da8-4387-96e4-83b8fa1cfd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_52414470-baa9-4043-a5c2-67b65d176209" xlink:href="ino-20241231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_52414470-baa9-4043-a5c2-67b65d176209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_789455d3-e364-4655-a239-27815a08cf11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_c3256f60-9ba3-425c-9d86-64e1d9811fe5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_789455d3-e364-4655-a239-27815a08cf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_63635f94-71e9-428a-80e6-16a2f34e04fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_65203f05-2565-4563-8bb0-6533f5bec07d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_63635f94-71e9-428a-80e6-16a2f34e04fa" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_65203f05-2565-4563-8bb0-6533f5bec07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_df7f3073-e8f6-41a3-8073-64556015c367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_65203f05-2565-4563-8bb0-6533f5bec07d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_df7f3073-e8f6-41a3-8073-64556015c367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f9561283-bac6-42c7-9f10-46f813003916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_65203f05-2565-4563-8bb0-6533f5bec07d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f9561283-bac6-42c7-9f10-46f813003916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_12d2b3ad-4af9-4b16-b9ad-7917474fc465" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_65203f05-2565-4563-8bb0-6533f5bec07d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_12d2b3ad-4af9-4b16-b9ad-7917474fc465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a8b1e685-4228-4e89-adb6-c2950ecbb0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_65203f05-2565-4563-8bb0-6533f5bec07d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a8b1e685-4228-4e89-adb6-c2950ecbb0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e2e9e19e-73fd-4a19-ab69-cf6f15c50681" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_65203f05-2565-4563-8bb0-6533f5bec07d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e2e9e19e-73fd-4a19-ab69-cf6f15c50681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2ba6ad57-05bc-409a-8020-63b3ff3163ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_98e2b9fd-39bc-4aa0-bffc-6cc5b34382d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2ba6ad57-05bc-409a-8020-63b3ff3163ae" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_98e2b9fd-39bc-4aa0-bffc-6cc5b34382d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6eb9183b-b3a0-4924-9594-0ad82581db73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2ba6ad57-05bc-409a-8020-63b3ff3163ae" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6eb9183b-b3a0-4924-9594-0ad82581db73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_392374ba-4a9b-4526-bbdb-f63158d2356f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2ba6ad57-05bc-409a-8020-63b3ff3163ae" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_392374ba-4a9b-4526-bbdb-f63158d2356f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7b569f45-4b77-4bd5-8ac4-b4fa8cfcb07f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7b569f45-4b77-4bd5-8ac4-b4fa8cfcb07f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_64b57950-73d6-47e4-966c-735e5b53eba2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:to="loc_srt_OwnershipAxis_64b57950-73d6-47e4-966c-735e5b53eba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ffbdb11b-fb97-4ae3-ba2f-d9cbafcc9658" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_64b57950-73d6-47e4-966c-735e5b53eba2" xlink:to="loc_srt_OwnershipDomain_ffbdb11b-fb97-4ae3-ba2f-d9cbafcc9658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_7fd08598-5e1c-4311-87e8-ddaac2a38eb3" xlink:href="ino-20241231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ffbdb11b-fb97-4ae3-ba2f-d9cbafcc9658" xlink:to="loc_ino_PlumblineLifeSciencesMember_7fd08598-5e1c-4311-87e8-ddaac2a38eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6156eada-1455-4188-9b81-5d4edca6fed0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:to="loc_srt_CounterpartyNameAxis_6156eada-1455-4188-9b81-5d4edca6fed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722af4d1-bafd-4cf0-9693-923c56d358ea" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6156eada-1455-4188-9b81-5d4edca6fed0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722af4d1-bafd-4cf0-9693-923c56d358ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_5348cf63-961d-4d8c-9361-7dedaed69419" xlink:href="ino-20241231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722af4d1-bafd-4cf0-9693-923c56d358ea" xlink:to="loc_ino_PlumblineLifeSciencesMember_5348cf63-961d-4d8c-9361-7dedaed69419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_56ebfc6e-978b-4440-a876-4a034790448a" xlink:href="ino-20241231.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_722af4d1-bafd-4cf0-9693-923c56d358ea" xlink:to="loc_ino_TheWistarInstituteMember_56ebfc6e-978b-4440-a876-4a034790448a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6b4abfe-d907-4aae-9887-11d391927f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6b4abfe-d907-4aae-9887-11d391927f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a5b7726f-2e53-433b-aae1-34037e66f06d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f6b4abfe-d907-4aae-9887-11d391927f1b" xlink:to="loc_us-gaap_RelatedPartyDomain_a5b7726f-2e53-433b-aae1-34037e66f06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_3be7073c-0489-4c12-9ac6-b7f628a01cc7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a5b7726f-2e53-433b-aae1-34037e66f06d" xlink:to="loc_srt_AffiliatedEntityMember_3be7073c-0489-4c12-9ac6-b7f628a01cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_85b7d1d3-ca9b-433a-ae28-9595d9b8b715" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_63569ab8-5715-4d68-95d8-65a39324ede0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_63569ab8-5715-4d68-95d8-65a39324ede0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_756812bd-1be8-40c7-be31-c3154125727f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_756812bd-1be8-40c7-be31-c3154125727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6b4f2486-5188-472d-a2fa-67acacf07601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6b4f2486-5188-472d-a2fa-67acacf07601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_91a29f16-1592-4042-990a-7975eb7b3821" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_91a29f16-1592-4042-990a-7975eb7b3821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_179635c9-c2c5-499c-b7c2-f7813b045f80" xlink:href="ino-20241231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeArrangementTerm_179635c9-c2c5-499c-b7c2-f7813b045f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_143a9a8f-1f89-44ac-895c-29e91f9c1931" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_143a9a8f-1f89-44ac-895c-29e91f9c1931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_60b3a835-9388-44f7-a1a7-bfcfd4d92308" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_60b3a835-9388-44f7-a1a7-bfcfd4d92308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_1d421e61-e969-4b6a-8ede-277908e3be7c" xlink:href="ino-20241231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_1d421e61-e969-4b6a-8ede-277908e3be7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_5a8ff594-8308-40b5-914c-5dd5c17f772c" xlink:href="ino-20241231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_GrantProceedsReceived_5a8ff594-8308-40b5-914c-5dd5c17f772c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d0bcde58-ca12-4329-beba-43e2c9e060e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d0bcde58-ca12-4329-beba-43e2c9e060e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_23dd8d6f-13eb-4f67-8195-e0ee80505bde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_AccountsReceivableNet_23dd8d6f-13eb-4f67-8195-e0ee80505bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2302c4f6-cb16-45fa-919f-9a76947ddd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2302c4f6-cb16-45fa-919f-9a76947ddd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_e71d4633-dc7b-4f20-a163-75abc5be0989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_e71d4633-dc7b-4f20-a163-75abc5be0989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_a6aafbcb-f750-4d67-ba0b-7f53ea6ad02b" xlink:href="ino-20241231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f45e470d-36da-4baa-9eea-e788b92c84d7" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_a6aafbcb-f750-4d67-ba0b-7f53ea6ad02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_ad908e26-e5ca-450c-bb96-de169df6fcda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_b3765188-a177-4b25-b25b-c4a45542d627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_ad908e26-e5ca-450c-bb96-de169df6fcda" xlink:to="loc_us-gaap_MinorityInterestTable_b3765188-a177-4b25-b25b-c4a45542d627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_61104cad-0179-4c14-adea-6e7ac6c78b24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b3765188-a177-4b25-b25b-c4a45542d627" xlink:to="loc_srt_OwnershipAxis_61104cad-0179-4c14-adea-6e7ac6c78b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e807611d-bfda-493c-9b47-f145d0c7b2a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_61104cad-0179-4c14-adea-6e7ac6c78b24" xlink:to="loc_srt_OwnershipDomain_e807611d-bfda-493c-9b47-f145d0c7b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_ddf15cd1-6c0b-4890-97cc-4185631fc162" xlink:href="ino-20241231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e807611d-bfda-493c-9b47-f145d0c7b2a7" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_ddf15cd1-6c0b-4890-97cc-4185631fc162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_b3765188-a177-4b25-b25b-c4a45542d627" xlink:to="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d31978ef-df3c-4ab5-866d-a5a293977585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_d31978ef-df3c-4ab5-866d-a5a293977585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a1d95c03-6682-4653-a865-e35de603d081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:to="loc_us-gaap_EquityMethodInvestments_a1d95c03-6682-4653-a865-e35de603d081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentsMinimum_117b4757-8694-4cd1-9773-afa356a09bd6" xlink:href="ino-20241231.xsd#ino_EquityMethodInvestmentsMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a9347322-6b65-4a22-9096-937b0fa94853" xlink:to="loc_ino_EquityMethodInvestmentsMinimum_117b4757-8694-4cd1-9773-afa356a09bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1c97bf45-490d-465d-b001-7bc4cc23d322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7eece737-6185-4008-b5fc-dde42d0d1a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1c97bf45-490d-465d-b001-7bc4cc23d322" xlink:to="loc_us-gaap_NumberOfReportableSegments_7eece737-6185-4008-b5fc-dde42d0d1a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1c97bf45-490d-465d-b001-7bc4cc23d322" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_40cd6eaa-a26c-4aaf-a221-528a9971529c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_40cd6eaa-a26c-4aaf-a221-528a9971529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2b1867f4-0ecd-46ee-af44-99abdf4a59b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_40cd6eaa-a26c-4aaf-a221-528a9971529c" xlink:to="loc_us-gaap_SegmentDomain_2b1867f4-0ecd-46ee-af44-99abdf4a59b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ReportableSegmentsMember_90bb59df-3eda-40f8-9f6a-6947ba6c25d6" xlink:href="ino-20241231.xsd#ino_ReportableSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2b1867f4-0ecd-46ee-af44-99abdf4a59b2" xlink:to="loc_ino_ReportableSegmentsMember_90bb59df-3eda-40f8-9f6a-6947ba6c25d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostAxis_1f18de6a-a570-43e6-9168-27ca96614e36" xlink:href="ino-20241231.xsd#ino_ResearchAndDevelopmentCostAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:to="loc_ino_ResearchAndDevelopmentCostAxis_1f18de6a-a570-43e6-9168-27ca96614e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:href="ino-20241231.xsd#ino_ResearchAndDevelopmentCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostAxis_1f18de6a-a570-43e6-9168-27ca96614e36" xlink:to="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO3107Member_eb2aac7d-862d-448a-8d95-f2d4b15ea4a5" xlink:href="ino-20241231.xsd#ino_INO3107Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_INO3107Member_eb2aac7d-862d-448a-8d95-f2d4b15ea4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO5401AndOtherImmunoOncologyMember_21dcb4a4-3a39-41c6-a34d-815a9f832e76" xlink:href="ino-20241231.xsd#ino_INO5401AndOtherImmunoOncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_INO5401AndOtherImmunoOncologyMember_21dcb4a4-3a39-41c6-a34d-815a9f832e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherProgramsMember_3f670df8-e061-4eec-bd8d-d4d20d15c46a" xlink:href="ino-20241231.xsd#ino_OtherProgramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_OtherProgramsMember_3f670df8-e061-4eec-bd8d-d4d20d15c46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EngineeringAndDeviceRelatedMember_12ccf775-c586-4e7f-8953-141a461efcd8" xlink:href="ino-20241231.xsd#ino_EngineeringAndDeviceRelatedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_EngineeringAndDeviceRelatedMember_12ccf775-c586-4e7f-8953-141a461efcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockBasedCompensationMember_47842eb7-e99f-45b3-9396-ecc56113e0f0" xlink:href="ino-20241231.xsd#ino_StockBasedCompensationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_StockBasedCompensationMember_47842eb7-e99f-45b3-9396-ecc56113e0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherUnallocatedExpensesMember_507ee646-66f5-4240-9aa3-8ba4cba93a8f" xlink:href="ino-20241231.xsd#ino_OtherUnallocatedExpensesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_ResearchAndDevelopmentCostDomain_9b6cfadf-459c-472f-9e9c-f6b4f473a058" xlink:to="loc_ino_OtherUnallocatedExpensesMember_507ee646-66f5-4240-9aa3-8ba4cba93a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_086f35eb-e924-4b8c-963c-b7194ec19959" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_255cc652-357f-4739-83b3-76d4be7634de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_255cc652-357f-4739-83b3-76d4be7634de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6203e7cb-1b6d-4d16-8723-1b5feece4bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6203e7cb-1b6d-4d16-8723-1b5feece4bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1374ccf0-d214-4d2d-a72a-c97936af81fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1374ccf0-d214-4d2d-a72a-c97936af81fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c489784c-d882-471c-83d0-31190c8c3966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c489784c-d882-471c-83d0-31190c8c3966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_baffeb57-8fcf-4453-85cd-439ee623d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ae8723cb-ab09-4daf-83fa-784b32212d27" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_baffeb57-8fcf-4453-85cd-439ee623d4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9cd8e64f-f787-4877-867d-9d4f4d003b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_OperatingExpenses_9cd8e64f-f787-4877-867d-9d4f4d003b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_028c9c82-84d2-4604-97af-8b4d7b567f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_InvestmentIncomeInterest_028c9c82-84d2-4604-97af-8b4d7b567f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_481205b8-fa16-42d5-a1d2-17dd17c70cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_InterestExpenseNonoperating_481205b8-fa16-42d5-a1d2-17dd17c70cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_f67bdb7c-9a5d-4951-a8fa-0b729ea7ccd0" xlink:href="ino-20241231.xsd#ino_ChangeInFairValueOfCommonStockWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_f67bdb7c-9a5d-4951-a8fa-0b729ea7ccd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cadec33f-7d6a-4a63-984f-7f7657a02e28" xlink:href="ino-20241231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cadec33f-7d6a-4a63-984f-7f7657a02e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ffe6018e-fae1-4bba-99ed-392820f0f4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ffe6018e-fae1-4bba-99ed-392820f0f4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_070c5dc1-7e6b-4136-a746-b5d5a2dd3249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_070c5dc1-7e6b-4136-a746-b5d5a2dd3249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9d730eb-9e16-4468-af77-8aa97ca4d017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_NetIncomeLoss_a9d730eb-9e16-4468-af77-8aa97ca4d017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_70805761-1d4f-44f6-a6cb-eab5935aa92f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4bc81c76-380d-49df-b26c-fa538f885485" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_70805761-1d4f-44f6-a6cb-eab5935aa92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20241231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e31b5a25-80a9-4227-8b2a-79279318eb15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e31b5a25-80a9-4227-8b2a-79279318eb15" xlink:to="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_97ed47c1-4028-49ac-8f97-c56316f5a19b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_DebtInstrumentAxis_97ed47c1-4028-49ac-8f97-c56316f5a19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_12221db3-041f-4853-bf6d-6ce1d79ea659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_97ed47c1-4028-49ac-8f97-c56316f5a19b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_12221db3-041f-4853-bf6d-6ce1d79ea659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_f73187b8-23d8-4395-bd71-74cb74f380ab" xlink:href="ino-20241231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_12221db3-041f-4853-bf6d-6ce1d79ea659" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_f73187b8-23d8-4395-bd71-74cb74f380ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_741adc70-c6fb-4136-96e0-a14e91a5e993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_741adc70-c6fb-4136-96e0-a14e91a5e993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_887948f2-dd56-4849-8eca-6c13790161f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_741adc70-c6fb-4136-96e0-a14e91a5e993" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_887948f2-dd56-4849-8eca-6c13790161f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_77b89954-7000-482a-ad3c-ddfce7112c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_887948f2-dd56-4849-8eca-6c13790161f9" xlink:to="loc_us-gaap_ConvertibleDebtMember_77b89954-7000-482a-ad3c-ddfce7112c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8b2b3be1-eb30-4fba-9c6b-bc7c44327329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8b2b3be1-eb30-4fba-9c6b-bc7c44327329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_abbb47e8-a7cd-4257-b096-f515b8d9fcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8b2b3be1-eb30-4fba-9c6b-bc7c44327329" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_abbb47e8-a7cd-4257-b096-f515b8d9fcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5c2e955d-5d3c-4f1d-b653-aafe006741e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_abbb47e8-a7cd-4257-b096-f515b8d9fcc0" xlink:to="loc_us-gaap_SubsequentEventMember_5c2e955d-5d3c-4f1d-b653-aafe006741e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_811199b7-e54c-4341-a822-f9cc517326f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_811199b7-e54c-4341-a822-f9cc517326f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647988cd-28c3-4c90-92b6-3e11191c3f18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_811199b7-e54c-4341-a822-f9cc517326f9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647988cd-28c3-4c90-92b6-3e11191c3f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2021SalesAgreementMember_6b345d00-8c17-4036-adc2-fa6f75700524" xlink:href="ino-20241231.xsd#ino_A2021SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647988cd-28c3-4c90-92b6-3e11191c3f18" xlink:to="loc_ino_A2021SalesAgreementMember_6b345d00-8c17-4036-adc2-fa6f75700524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2024SalesAgreementMember_ddce2088-1331-4f48-8b78-603ff0487c1e" xlink:href="ino-20241231.xsd#ino_A2024SalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_647988cd-28c3-4c90-92b6-3e11191c3f18" xlink:to="loc_ino_A2024SalesAgreementMember_ddce2088-1331-4f48-8b78-603ff0487c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4e308711-403d-401d-8d7d-b7f08a32cd20" xlink:to="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_273be13a-6c67-41f4-ae71-efade0e59caa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_273be13a-6c67-41f4-ae71-efade0e59caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b75ba5d7-a216-45e6-96b8-27dc4083cf69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b75ba5d7-a216-45e6-96b8-27dc4083cf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0063bb58-919d-4d61-b06b-4a10ebccf1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0063bb58-919d-4d61-b06b-4a10ebccf1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_b9f6ac43-2c10-48ab-a213-743e335ec0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_b9f6ac43-2c10-48ab-a213-743e335ec0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6d037d0f-880a-481d-a626-83e78aa80ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_f94c66e4-0831-4f50-882c-1dba665a5b77" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6d037d0f-880a-481d-a626-83e78aa80ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ino-20241231_g1.jpg
<TEXT>
begin 644 ino-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B^?;RU6OU//9KPL''4\LT<?3SQQU=9-QSRW'/'/+<
M>] ?01<2L:]P<+CXV:Q,75ST^)D:<?5QQSQU3-SQRW/'NY;GWLO0L;IZ8B;J
MDU'@8QYXYDR^/!N7YX;DK#-SY/Y<_(Z YXBZY_FPZ1_33IS_ /#F,_\ 4K]X
M-U]+2N[1:EP$CLW+M'F<<;LWU78;+\,@.?HN'P[AX"0F"/.8>0WYX$,G2(GX
M;E^!&=W?AFY?ZC>?N7V:VH*$S.\-VI*S.S.\5F&1F=_<S]!OP[_(R ^NB\+R
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
M,).>,=N8JTE@"(!$1 $1$ 1$0'\D+$SL[,[.SL[/[G9_>S_6=6P>Z/[Q3YM,
M?!MKK6_U:PQ<#CI[)63?Q-2XBK"Q/7FE/^B9O&1 ;R\NYWZ(-:]J>"X3U0%]
MO3>I,AALA1RV)N6,=D\;:ANT+]20H;-2W7-I(9X)1=G P-F?Y6)N0)B B9P-
MCHO*CD[N3MVX_>;2K!>.M4US@8*\.IL7&0AZRS_.HL]CX'X+X/OF#O+&#&./
MN.520W$JTL\C: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
MY20?0Q61'R>>HY._/U9('=SB^3KCX-1F%-]=>:V1FKRQSP2R031&TD4T,A1R
MQF/F)QR [&!L_FQ"[.WNY7%75^&ZLROE?N6I/R[$NJ?PDOO0;[K=;=TUZPKX
MX^SII/&VG>3?MAZICPE^CM5K@I6T2>\O)OC[OGX<Y/WZ7).+;LIE">[E-J(,
MR\]3+A79=J:OU[H[/:GBPLUREI.W5H9C(4V\1R]:@*P-IZ48O*(5XA$K\D8G
M# ,@3EX<3R-%RYB;W\^7U6\_[RAG6]#R]/G"&7193YT';1.4)*O(J4Y5>;1-
MI*VM60G6Y1WY9PE7+EG&45Q,X[\']:X6U.>F:WB3Q[UO.FU)RQLW'4Y5QRL.
M_90OHG*$H\RVG"<9TW0KNA97'^W)<1UMHRAGJ$N/R$77%*W(2"[#-!*+/X<\
M!NS]$D;OY>3B3.X2"<9&!<H(_J+\G?ZJ_'0>(L[2L[$U/3<N_ U# R*LK#S,
M6R561C9%,E.JVFR+4HSC)?@UNI)Q;1Z.&,;*P<G'S<*VW&RL6V%^/D4RE7;3
M;6U*$ZYQ:<91:_L?1M')^P]WC6J>S]E:^A];O<U%ME*?1CY(Q*;(Z>@>0?S5
MA.H^9:$0GQ>P!._@FPR8R2%G>*]:1U[J_!ZZVLU%EM.92IF,+F](YN6AD:4O
M7!8B+&VF\B<>N*0#%XYH9HPF@E$XIHXY0(1J+:UT;1SU$Z-Z)B!_;BE9A\:M
M,S.P3P$[/T&/+L[>8F+N!L0$0OUOV<>UCKWL_9?(XJ(CS&D,[#8ARFG[$TL6
M,R4-F ZIY+%R/XXXO-0B0^)+$!^-X<<%T)X/ D#OS[-WC_I7C%I=N!D2Q=+\
M1\+#F\[!7)CX7%-%=;5FJ:='W:Z<UKWL_%CM&NR3NC'Z+-V8_>WV5_:NCQ'I
MRTC6W&O5J<=UV+;ECE5J'(\K%CV:VV>3B1]ZAMV4)T?5U]JZ%/KQI?+S #_+
M_2L_N_E_YSA]S1D_^1]?TN?.+/8RVP^UY#8QSPOQ^@9G*J_N?GGGEN.'4#NT
M.I*F3H2R4Y6,6!QDC=V\6$G;EHY1;S$N/<_'2;>T+NSLZFC[FG(].:W)HN_O
MIZ9MQCR7M<3YN&8N/H&Z?S.SOY$74WO$?*K?A)IV5I?&UNGYN/=BY54\JB_'
MOKE5;59'%MDXSA-)Q?N)KIM)---IHFWPZFX:MIR:V;636T^G7Z-=+K^<>A/2
MB(KUEI3$_MU_$YN3]J.7_>Q*J?I__FL_^[_X.K6';J^)S<G[4<O^]B54_3W_
M #6?_=_\'5-/:B_Y5IG^B7^_D5^\6/\ "6+_ *C+_>VD_/<]SF^WF=C<G<(]
M6W>@?+@>NCCR+C_O/YJ6=1)]SQ\7^H/MMM?@['J6Q62\-/\  &E?ZG7_ &DI
M\!O_ -3X'^@7_>D%$]WQN2>':W#PLY<7M=86L[,S.SM'BL_>X)W\V'FFSLX^
M?6PM]"[NTL*AJ[Y^^S:-T53]GF;6+V>'=V+BK@\I$[LWN<6]=9B=_-G<./>Z
M^?$F[DT+5)?_ '64?Z<HP_\ $?7C^SET;/?QIY/Z<X0V_/FV(.<A[.*#_P"^
M_P!5E:7[O_'>K;-;?!QQXF"&UQT]'+7;=JZS\?*SM8YZ_P#K&?K?Z)59,^73
MC8V_[!/_ "_O*SCM=O5I3;+93;C(:KRU;&Q#H32[15O$::]D+98*E--!C:8O
MZQ=E>0S+B('"('ZY2BC9R:KGLWYN/B6ZQG9=]6-C48TG=D7V0JIJ@\B#<IV3
M<8Q7N=VTO3N1+X:95&-E9N5DVUT448"\VZZ<:ZZXRMK;<YS:C%>YW;Z^AG5+
M((B1D0B(LY$1.PB(BW)$1/PS,S,[N[NS,WO4&G;S[T[%8^KE=$[=209C*6X;
M.*RVI79Y,5BXYP>M:BQ3^0Y/(B!R -ENJA5E;JYN&)0C@1VR.\AU5N2UG#8C
MUC2VCR?H+'5K+MD\M&+OYYF[ X,\$OD18NN[U&9F">6YQUO&$(,\L8LW#=3-
M]1O\RUGQ/]JZ6?DUZ/POS5X]^15CY&K60<+KH661KE#!JFE*B$E+;Z3;%7--
M^554U&UZ'Q[[0WTRW]': W&B<U5=J,XN-EL92Y91Q*Y)2J@T]O/L2M>[\N%3
M4;)9,:(B:/'F[-PS1,+,W[3-_>X6*N[,W5=C'^EC-_\ YBX__(\OVUEK@!Z,
M4;^[EA;_ #%[EAIN1,QY$^'YZ(P!^'Y\^9"?]O@FY5?^+;O[UU![_P KDT5K
M_9FK=O\ LS3.(7RXM4?BXK;\]_[#J.W\O[7^E<8M_+^NZY/;^7Z_#<+E^WVT
M&9U1E:.)Q6/N9#(Y&<:]'&4H7ENW)2_0B/+-#&PLYRS2N,<43'+*<<8/(WE\
M+?"?7^+]06FZ!I]N9<MIY%W2K#P:-_>R<[,LY:,6B"3;E;-2GLX4PLM<8/&Z
M31.R<8PBYM[)))O=M]%T3ZOLEW;Z(RPV>M-=TWBY?>\<#U2?Y>JJ90<?6\HV
M;ZG''"['>E];C^7\OD636Z78ER&S&"TE4R=V&Y=S]?(7+\56-O4\9?KG3\3'
M03N[G;:.&S"4EJ1A\>SZR4(-"(\=%/$+_)_>4%^+W!=O#'$NKZ#=D4Y=FG9*
M@\G&5JQKXWTU94+*/.C79*IUWQY)RA%S7O<JWV.%7M)<*Y/#G'?$^DWU.F5.
MIVY,*WM[E&HPAJ6-'IT26/EU;)=NW38XJ]'ZW^;S_P!"X)J:R.*R.!RQM[ W
MWQ-@N/9"OF0&"(G_ +IPXUG=_9$',G\F7<;PCS[EU/OAACL:4S;0L[SUJ1WX
M&%GZO&Q[M<CZ>GSZ^J'@6'DN7;I]KA93P'U&F'&'#U65/R\3/U&O1\NU_P")
MP]=A9HN9?W[T8N?=:GZ.">TMMGY_9ZXUEI/&_#&:VX06K8V-=+?;EQ\^3T_(
M;VVZ*C*LW]-M]U+LY;>ZT[/YZFU=<U_DX7+$:5(JN(8Q^=V]16(FZIFZOH@Q
M5*1S\F_/5RL3$/JY@=BAEB#V!<?I^'9W;Z?37MXS)Z;H9@IRZ/'M9#*Q-=RD
M]MP\FM/?FL!+$[\UGC:HPQA7&,,OUVZX%X(_]'M/KTV<5')JE+Z;MU_OO[-L
M4]EO&IQ54'LMXP4FDVS^KS@K0XX&GTU])66I7WS3W4K;8IO9^L81Y:XOUC%2
M[MGAU7@[\SMB/0Q539C 6^,EJ*&OD]9' []=73K3.='$G(W]#DS5FOXMJ-G\
M1\96>*86KY$6EG(WOW@Q6@]*YG568+BGB:9SC#U"$MVT_L4Z%?J\GL7;)1UX
MFX?ASZR;H G:G#GL:.MM2YK6VIX MYC.79<C>E*29P9SX""K$Q2-TUJ=<(JE
M6-F9@@AC%F;AUL=7C/PWP;J.+G<04Y^8JHRR,;#TZG'NMG?"2C3.U9.3BUQA
M&7-.OWVY6UQW7*I;ZKXI\2RQ\5X&-)++S*Y)MMI58_6,I2:3:=KWA'H]XJSL
MTC!KF/&T?D$R#E^>/(6;ZO\ +_.ZM3]RWV.2T9HZ7<;/5"AU5KVK&5..<7:Q
MB](M*,^.KN!,SP2YHXX<Q:!O:*#X+CG8)ZQ110S]BWL8R[J;P08JW ;Z)TV=
M?4>HY.'*&>@TY/CL!UOPW5EKD!U91Y>3X-KWI0]L&)KHM:M'" 11 $448#'%
M%&(A''& L(  "S"( +,(B+,PBS,S,S<*UGB_XPXFK:1IE&CW^9BZMAXNIW6+
MI)8N17&[&QK$FU"V3:LR*V^:MPA%])21'/@3P).N5VKYD4[7.RO'WZISW<;+
M8M]=HK>N#[-N;[Q1^Z(BK"6<"Z?W[WOP.W&D<YK/4MGU?$X.F=F41=GL6YWX
M"ICJ<;NSS7LA9**I4A;Z.:4.IQ!B(>WW?R\_+Z_U/K_M*FQWK?;?/=S6@Z0T
MS<>70&CKDL,<U:;KJZFU!$1P6\PY1\!8Q]%NJEAWZI8I6]9R,9D-NOX,A>&O
M ENOZC#&7-'%JY;<VY?XNG?[$7V\VYIPJ77;WK-G&N1I_''%M.C8%F58X^8T
MXT0;^W9MW:W3<(?:GMZ;1W3DC!;>7>7/;KZWS>O=3'Q:RDWYEIB3E6P^)KNX
M8[$U!=WX@IU^&(OHK-D[%J5RFL2._,.S?V>LUO#KO$Z'P;20UYB]9SF5 .J+
M!X*N0^NY"1R9X_&)G:O0B-G]8OSP1=+Q^(0='VAF'U;%XZO-;O6YH:E6I4B*
M>U;MV#&&O5KP1"4DT\TT@10Q1B1R2D("SD0JYSW:_8CK[-:(CBR 0S:UU$\6
M1U7>%@-X)G#FK@JLHN?-+$1D\;D!D%J\=RXW 311Q7'\3.-,?AC2(4XD:X9-
ME?T;3J(I<M<:X*+N<>OU>/%Q:3W4['7![J4VJF^'7"U_$^KV9^9SRQ:I^;;*
M6^\^:3:@GZ3N:?;;DK4FMGLGFOM3M?A=%:<PVE=.U!HX7!4(,?0KL_4310 S
M/+-(_M3V;!]4]JP?,D]B26:1W,W==@HBY]773LG.RR4IV62E.<Y-RE.<FY2E
M)OJVVVVWU;ZLN_77&$8PA%1C"*C&,4E&,8K91271))))+HD$1>'=?F?<@V[W
MW:@0ETSK:"/@I6/3F1,6?@G!I[^,(W]S$POD 9_HB;I%WZ8Q952NVSI/YYA<
MU&+>V$^-LOPWFX/ZS4=^/^R]L7=_D:-O)F5@3O/N\2IZJU=2VITA)5O:>P>5
M:356=B>.Q%>SD$-FO%B<9*S$+5\1-*[W[<1<SY ?5(W\&M.\\//:@P;7='WS
MZ>3HS5;8OQR[,,X0R<?6Z)GZO^R+_(WERB]K[PXR^#_$_1=4MH^C8_%VG8VH
MPC]GW[K+M*R(V0Z<MDG1CYTUMU^DPG+ZQS2Y[^.\,5ZUGV8DE.,X5VVN'V5D
MUQY;E%KONZDY2[.<Y]UU>$W8J[5N7V1W+T_N!BFEFAH2O2U!C8W9OAG35TXF
MR^-X(A!Y2CBBMT7,A"/(U*<IDP@2V5^A=:XO4F%Q6H,+;BOXC-8^IE,;<A?F
M.S2NP!8KRC\HN<1BY 3,<9=0&S$+LVJ[MU??_+^^KBGHY?:X/.Z-S^T>8NO+
MDM%SEF=---*SS'I3*2"UBC$QOUR1X;,E,X.SDT%7*5*K###7@8K*^SKQNZLF
MS1[I/RLKFNQ=WTAD0CO9!?!6UK?^?6MEO.3-M]FKCWRLNS1KI[TYN]V+N^E>
M57#>R"W]+Z8;_!3IBDN:R3++:(BN07;"(B (B( B(@"(B (B( B(@"(B (B(
M NN]VMLL9K/3&=TIF <\;G\9;QEOIXZXPM1$ SQ<^RTU>1PL0N3.+2Q@Y,[<
ML_8B(#74;F[<Y72&H<UI;-QM%EL!DK6+O,'5X1S59'C\>!R9B>M:#HLUB)A(
MJ\T9$(N[LW!E/YWZ_9I?%ZDP>Y^-@<:.HJ\>!U T<3M'%F\>$LF.O2F/+=>2
MQKO3/J8!8L3"0O))9DZ8 T 1$0!$1 %;*[CKM)-J'0=[;V_8Z\IH:<I<<)E\
M]ETWE;$L]<6Y\Y QV0.U49_-H*LE"!F$!CYJ:K,;L$=H]]J]T=.ZHFF>'$22
MEA=1^VX1O@,J<(7)9N/(HZ$T57*])<MUT )FY9G8"^4B_.*43$3 A,#%B A=
MB$A)N1(2;EB%V=G9V=V=G9V\E^B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
M+](9CC,)(C.*6,QDCEB,HY8I )B"2.0'8XY -F,#!V("9B%V=F=?FB N+=UA
MWA<>Z>#;2>J;<0;@8"JSF<AB!:GQ,+!&.8@!^GJOUW(8<Q!'U<&\5\>F.V45
M>7I:Z+;K</,Z2SF+U)IZ]+C<UAK87,?=AX<HI@9P(2!_9E@GB.2O9@-GCGKR
MRPR,X2$RO"]A/MFX;>C1T.9J^%3U#C1KT]5809&*3'9(HRZ;$(N_B%B\D\4T
M^-G-FZA":L;O/4GX S81$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B( B(@"O#
M=U/]+]MQ]C\O^,F95'E7ANZG^E^VX^Q^7_&3,H"0I$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!:WW>F:3-=K'=BQ*)$53=?<H/:+Q.(\-G\QB
M8'=^&9A:.O&X#Q\Y;H!B)PZEL@EKDY\=*?:;WN*?@[%?<C=DIS9A9GG+7F6B
MF)ND19F.0BXZ!%O-N&8?)5,]L7*=/"UDUNO=RUOZ;SQIP6_S][I^?YZ!XE7N
M&DYC3VWQLA?G*OD7_?9E=+,%2"2Q(S]$0.3LS<D3^3" _P#:,G81]S<OYKA^
MAMVH<C=DQURJ./L'SZG\_>4+7#$Y1=3Q1=$[,W4P^;2-ST.Q#TK]]UKLE+&5
MYF9_#>_"$S\>3"<4[!U?]ESZ6\_+J<&^HN@\UB([<0VJSN)BXFQ [B<9B[$)
M@0OR+L[,XNWFSLS_ "+Q^P[[ O!WB7X4ZSK&K3OCQ'J>IYV#I&K49%^V@?HZ
M&/Y']XPNAC9GTB^<[,ZO*A.=F%957BV8=VV243NN4)>78N2JZ#A"Z/5UV;_>
M6Z^,=UZKLXO9E_CLVY/UW;W0MOEG]9TAIR9W9F;VI,14(FZ>7Z79W=G'GV7;
MI^1=UJ#;N>^WYC=7:>QVU>HI!HZTTOCGAQDLI $&I\+4)QBEJ.Y?\ZX^$@CO
MTF%GE@ ;U5BB:U'5G(9U<2?!VH:!7C:3JD5'-PL3%HNG!RG3=*NF%;OHLE&#
MLILE&4H3<8RVZ3C":E&/0?@_4H96F8-L+(6/Z-1"QP>Z5T*HQMB]]FG&:?=+
M=;-=&F=/;];&:=W(TIF-':HIM<Q.7KE";MP-FE89N:N2H3.SO6R%"?IL5)P;
MV) X,3C(P*C[VE>SCJ39;6M[1NHPDL4WYL:?SOA>'2U%AS<7BNU^"(8[,!%Z
MKDJ;NTE2[&?2QU):EBQ?D6'G;8[&^GMZ=&V--Y=@J9.H9WM,YX(^JU@\NT1Q
MA,/2XE-1L"7@9&B1>%:@<3Z1M5ZD\$M^$GB=9H.7Y5[E/3,F2^D06\G1-[)9
M54?C%)*V"_E*UV<X5[:OXF>'U.N8;48QCF4Q;HLZ+G2W?DS?P;ZP?W)^JC*>
M](_1NML[H;4F'UMI*Z5#-82T-RE9#J>,_(H[%.W&!!ZQ1NUY):EVJ;L$]:62
M-W;EB&[-V'NV9@=ZM&5M0XWPJ6:IC#4U5I]IFEGP>6<'<P;EADEQ]MPDGQ=P
MHP:U6\C&.Q%8ABI4:RVZU#HK4V3T)J^@5#.XNT-2Q"[D<$S2.WJMZC.X ]K'
MW8W&>I9 &::(FY$38XPRH[-.:U?LOK*EK+3N3A.,O#K9_"]$WJ&?PKFTD]"<
MW(&&8/.7'W/!ZZ=IAE%GB*>&65?:5X@X0Q\'!R-6UK"TS4,JJZW1[;%=;^D*
M:?+G=2OHM5TI4OSZI5VN/+79;%Q?).W>OWA9Q=G:)EWX&;7;+$A/EOW3WIEU
MBK>5[/GCR\MD(K><5V<HPVN^(NK]F]W\'KO3N.U/IZRUG'9&-W9BZ1L5+$;]
M-BC=B$S\"Y5D9XIXG)^'9C CB..0NT%46B^%L(65RC.NR,9PG%J49PDMXRBU
MT:::::]"Y%%\+80LKE&=<XJ<)Q:<91DMXRBUT::>Z84;7>0]B.ONSIREE,7#
M''KC2$OPAI^ST#U9"HQA+D-/6#XZGBO1@\E)RY&ODHZYNS12V&.25%[*,NZE
MRE1=919*NVKS:GM.,;JITV;-IKWJYRBTTTT^J/)JNF4YF/;BWQYJKH.$EZKX
M2B_24))2B_223*4V)LO;ADI6HRAM0')!)%*+A+#/$3QS031FS%')'*)1F!,Q
M 8D),SLZSZ[N;M7%MYJ4M'Y^SX>D-2VQ:O/-(XQ8//3.$4-EG+V8Z62X&K=Y
MZ&CL-6M=0@-CK[8[T3LH'@<G_-1TW58<9D[ AK"K #LU+)RD 5\X("SBU?)&
M[PY(OG?AW_ LOXI7[!PQ696E%DZ;RLS.73Q(WROY<<NS?R9USERZ,_@CB%.+
M?EQLYH/9JJ^BQ^O[%T=XS2WY+$TGS03*O759FB:CLGMD8LN:$MFH96/+XKUA
M;'>,ENW":DD^>&ZNM(HIN[*[7IZPPQ:(U%9<M5::K#ZG8G-GESF!BZ(8;'43
M]<E_&OTU;_+.\D15;?69S66BE9Y5^>'=>Q]3PZ,W&ES570YMG]J$ETG7/;M.
M$MXOT>VZWBTW9O1-8IS\6K*H?N61ZQ?VJYKI.N:])0ENGZ/I);Q:;*+#O1NS
M >K=+!K/#URDU'HNO8GDC@#JFR>G7=I\C4Z6]J:;']!9&F#,1^5V"$2DM])2
MGK^)0$A(2%B$F<2$F8A(7;@A)G\G9VY9V?R=G\U\\0Z'1J6%D861'>J^MP;V
MW<)=X61_:KFHS7S6SZ-GSK>D59^+=BW+W+8[*6V[A->]"R/[4)I27QVV?1LI
M4T9X\I19N6(Q'D7YYY'ZWU>.?+]M_>L,.VGJO561TYI+#7<A/:TUHV;+#C*)
M.3M1/.35I#D,N7:2()(/ JL;?F,;$D,)#%-T#+SVW>SM+M9N#.]&'HTGJ8YL
MKI]P%VBJ$1 62PQ._LL]&U*YUA;W8^Q49^3"1UA9N7I&MDZ4\<D;2U[4)QR"
M_P HGSU-\O#CSR+^]G9G;W,N;6LZ1DZ/FY^D7RG5"YRIERN2A-1G"ZOITYJI
MRA5=%/NDGLF50R*[\'(MJLYHW42\G)@MTK:E*,D_VH3Y86U[_L2(,2G7X%-]
M?R_EYKD6O=*3X+*6L;89W>&1WAD\^)JY.[PS-_W@X8V\^F1C'E^GE^[^S1L\
M^H,BV4OQ,^&QLK<B;>S>NBS%'6;GR>&'D9;+\^?L0\/XA.,9:_J-.EXU^3E/
MDACI[KIS3GOM&N"]9SE[L?3U>R3:R.?KN/C42OD]X1CS+XR;^S&._>4GT7P[
MO9)[9Y]@7LQ9'+WL/BX*Y_#FK[=:-W>/D\;B&YFDFD;CD KU&FR5KJ\^@ CZ
M7,&$KU.A]'T=/8?%X/&Q##0Q-&M0JQB/###6B&(7?W\F?3UR$[N1R$1$[D[N
M\5_=9]F8L+AYMP,O78<AGX&@P,1C[=3!\L4EOS%NF3*RL#QL/+-2@A-B_-)@
M$O2N+['GAGD:=I.3Q-JE;AJW$\J\B-<H[2P])K3^@8\=US1\Z+^DS6_O5O%4
MXJRN1)O@YPY;5BW:OF1VS=6<;(Q:ZTX4/^3UK?JN=/S'UZP\E27/%A$17&)F
M"(B (B( N+ZKT3AL[6>GF\3C<O4=^?5LG1K7H.KCCJ:*S%* DS>XF9B;Y'9<
MH1?CD8]=L)5VUPMKFN6==D8SA)/NI1DG&2^331]+*XSBXSBI1DMG&24HM?!I
M[IK\3 O6_=I;/9QS,M,/BI39_GF$OW,<PD[\];0!*=7GY."@(./T#>3K%+5/
M<K:-G<BQ&L=48]R=WZ;\&)RL8_48&@JXJ7I;S^CFD)_Z;R\YH441ZW[/O!6H
MMRR>&M*YY;\T\?'6%.6^W64\)X\F^B6[>Z71/;H:?G^'FB9+;MTS%W?=U0>.
MW\VZ'4V_FV5\,OW']_S]1W&K2LW/3ZWIN:!^69NEG:',6/>_/+MSPW'#/[FZ
M\R/<9:IE]VMM,R\>YYL7D1?^^)2.S<?4?]I64D6O:5[+W!NGY4,W3<'.TW*K
M>]>1@:UK.+=6_C7;5G1LA\=XS3,!+P:X?WYHXEM;]'7F9::_!N]LK+OW"^HR
M%N==X",^/:\/&9,A8OK=<[<M]?H%_K<>2^_0[@R^[_FG<RK$W /\XTS+._5Y
M=;?/,O6Y9O/H?RY\N696245CM UG6--C&%'$/$5L(J*2SM:S]1V45LO>S[LB
M?X^]U]=S(4>%^CU]J<B2^$\S+E_7=O\ Q*_^G^X1P$9_\K;D9RW%TOP.,P&.
MQ<C%S[WDMW<T#C_V6A9^>7Z_-F;OS2O<D;/4'$KUS6><X\W#(9JI5$GYY\_@
M7%XL^&;V69CYZ?>[ER2F$1;A/Q-U^4>1ZKE)?&,HPG_TD(QG_P!8S%'!&E5_
M9PJGM_E'9;^_S9SW_,Q!VZ[!.S^EBBEQ6@-/E8AX<+>2J-F+3&/F,K2Y1[;A
M*+_0G&P$+LSL[/YK+F&$(P&.,!C !81 !80$6;AA$19F$6;R9F9F9O)E^J+4
ML[4\G*ESY.1=D3_6NMG;+\G.4FC8<;#II7+3575'X5PC!?NBD$1%X3TA$1 $
M1$ 6$W>![1OJW;3+C!%XN0P!AJ/'L(]4CR8Z*8;<8_*_C8V>Y'T_TS@7!$ L
MLV5^4T0R"0&+$!,XF!,SB0$W!"3.SL[.S\.S^3MY.M9XTX6Q]<TC4M(RE]1J
M.'D8ECVW</.KE"-L?VZIN-M;])PBULT:YQ?PUCZSI>H:5E+>C4,2[%L>R;AY
ML'&-D4_OU3Y;(/TG"+3312A:1GX?W\^[CS_6_67ES^3S60':PV4+;[7>:T\$
M91X_Q&R.%=V?@\/?.0ZC [\N0U3":@Y=3OXE0V)^IG6.G6Z_G0XCT3*TG4,W
M3,V'E9>!E78F1#T5N/9*N?*VEO"3CS0EVE!QDNC.'>N>&]^#E9.'DU<F1BWV
MX]T=MTK*INN6W3K%M;QEVE%IKHSHCM'X_P 7"U; MR]7(1=7E[HIX9HG=W^3
MY[X#>?EYLRR'[N79R[NMFL1I%VE'%8JU+;U#;#J9JN!B,;#@TC,[!8ORR?!E
M-O>QF4_!1UY7;K;<O&M=P.3@X<B]6*8&X]YUR&P'DWGPQQL[_K++/N)MXXL'
MNED])V3$(M;8*8*3D[-U97 #+E(H1^J4N,^%)/?Q^9N..HF==R_85T[%XT\#
MM2T/+^LNX.XQLU*BI;-QQ+::,Z2>[WC7<LO6(RVVZQDU[RW+E^S%@U6X-&F9
M+<:J-3FN7;[55RA="M]FE;>[*Y;>DFUUZJW#A\36H5:M&G!'6ITJ\-2I7B%@
MB@K5X@A@AC!O( BB 0 6\F$6;Y%])$5B4DDDELET271)+LDCHVDDDDMDNB2Z
M))=DD%A5VX^UC6VJTB=RN\4^I\R\M#36/-NOJM]',V1L1^_U'& XS3._LRS'
M6JM[4[<91[@Z^Q6E\)E-0YNT%+%8>G+>O63XX"&(>>F,>6>2:4^F&O"/)SSR
M1PQL4ABSU(=\-Z<MNOK._JO*^+#2=WK8/%R$SQX?#1$_J]9F%W#UB;VK-^5G
M)Y;<TC";01P1QQ1XM^(4-"T^7))?3<B,HT+NZX]I7M?L_9K7WK-GLXPF1_X@
M<6/3\=4T2_OW*3C5MLW37VGD->G+]FK?O8]]G&$T=88:">22UE\I8FN7K<\M
MNW;M&\MBY;L$\LT\TA<D<DDAD9N[_K<>3+-+L,]E1]V-52W\U7(]$Z<F@ERH
MR,[09JZ3^)6P(OY>+"8AX^58'=HZ;QUY'![\3OC-HC0&6UQJ7$Z-T['U7LI/
MX0R$)/!2JQ"4MS(6G'Z&O5K@<IN[B\AL%<'>6:,2ME;&[-8C0.E\3I;"Q]-7
M&UQ&6<A%I\A=-F*[DK;C]'9NS]4TGGTQBXP1,$$48#73P*X$OU74OTYF<ZIP
M[HVU2YI*4\F+C;5&,MU).N7+=;)/?[$?O[QBOP_X4^GY'FVQWP\62=C?7Z1D
M=)*IO[RCTG=OW3C!]+-UVO! $0!'& QQQB(1Q@+   #=(  BS"(B+,(B+,PL
MW#,S+]417CW+*A?.R^7JT*MF]>LP4Z5."6U;MV90@KUJT %+-//-(XQQ0Q1B
M1R2&0B "Y.[,W*^ARJI_>_=XD>K\A<V?T)>+YG,=9:'6N9J2\!G,E6DY/3U6
M6-^3Q6.F 'R<K&(WK\;U.AZM60K>Y<"\%9.NY]>'CKE@MIY-[6\,>A-*4W\9
MO[-4-TYS:6ZBI2CKG%7$V/I.'9E7M>ZFJZ]]I6V;=(KX+UE+9\L>NS>R>*/>
M1]O2]OGJH,/@I9ZVV^FKDPX:!G./YH[HEX1ZDR$3]+E&0 XX2M*/-2I*=B0!
MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
M971.)EA:'(9+&AJ3+B[=,GPCJ!AR)1S<MU>)5K2UZ9"3OT>K] \" LU2K0VA
M7W1WNT/H$0\?''F:4&2BXY"2G7YR^><V;S\-L95.L?'F'3*3>3LKLN\>_P!H
MC;G%/E=9ZCQ6F\=$'SM[T[#/.P-TM%1HPM+>O2^3"$%*O/*3](B#N[,OZ)_9
M?\*I\*>%_#&G_1YO6>,+)<8:E7"N4LAT9=4:-!Q>2*=G+#34KG2UO7E7Y#V3
MG(Z0>Q9X;U:!PY9GWQA5?J#^EWVSVCRPNC&5,)3EMRQKQ8T3V>W)9==\6=SK
M@NXFYNGM(XN?-:HS6,P&)K-\^R&6N04JPOP[C&,DY@TLTG2[101=<TI>S'&1
M.S/70[3??TV[7K&*V<TYTL75$.KM65B9V'R;UC&:="4"ZW\S@DR\XL' %9Q4
MCN< P<;FZVUCN%E&SNO=1Y/45\>OP9,G8ZJ],3?DX\?1!HZ="(O)B"E7A8F$
M6/GI'BY/"'L]ZIF\ENHS6FX[ZNMI69<EWV\I-0IW[;VSYXOJZ7V<Z\6^-FE:
M<I0HE]+N6Z7(^6E/^?UE/\*XN,OUT6%.TWW\^"HG9Q&TNGYM3W1\2+YI\Z$N
M.T_&?#@,N/QXNV4RK ?M==AL57)A%X3M1R=8P*[S;\;D;JW2O[@:IR&:A<VD
MAQ9$-' T6%^0"CAZ8PT8'C;AFL%%+=EZ1*S9L2<R/U1);QV.%W'I)Q;S(N&9
MN&]__N_]Y9=]G?L)[O;MO7GTYIX\9IZ=^7U1J%SQ6%:)G9GDJ,<9W\HY,[O$
M..IV(C?I\2>",O%:R>C\%\.<+T?27''H<%M+.S;(2OE)+M"RS90E+_)X\:^=
MI;0DTBO^H<;\1\2VNC$KN54GNJJ82C!1?3=PCUE%?KW2:CZM(Q*>GC\:+<])
MNXL;-R/#,[>7+_+^OY-]9EWSL-V9MS-U['J^A=+W;E 9/"GSMD"QVG:KL[,;
M29>P UII8N6>2K2>U< 7$G@Z3%WLC]FCN4]M-('7RFL3L;@YV+H-H\F/JVFJ
MLHB/)5\'&9^MEXC$77EK5Z-O8>*M 8N1S$8O%5:->&I2K04ZE<!BKU:L,=>O
M!$/D,<,$0A'$ _H0 1%OD91=Q=[2&/4I4Z-CO(GU7TK)4JZ$_C72FKK5\YRI
MV?W9(WWA;V>Y3E&_6,AM[[^16U.?X2L_DZ_PA&S=?>B^T$'9G[BS2N'>#);I
M9D]:9)G:0L'C"M8O3,!,[.P22L<66RS#Y\G(6.AE;@3HLS$QS@Z)T#@]-8ZO
MB-.X?&8/%5 &*MCL11K8^E!&+<",=:K'%$+,WU!Y?S=W?EURU%6+B3C/4]7L
M\S4,RV_9[QK;Y**_]'1!1JATZ;J/,TO>DWU+&:'PS@:;6J\+&JH6VSE%;V3_
M )]DMYR_!RV7HD@B(M8,Z$1$ 7CA?,S.;IXZK-=R%NM1IUP>2Q;N3Q5JT$;>
M\YIYB"*,&_IB)F^NHENT+WU>SNC2L4<!<N;@YJ%B%ZVF8N<1%+Y<#8U#;:+'
M2-SRQ_!99,XB$HY@B/R6;T/AK/U*SRL#$ORIK;F\JMRA#?L[+.E=:^=DHKYF
M-U+6,7#AYF5D541]'9-1<OE&/VIOY13?R/0[W;NGM/\ :.TE+;QL-##[J8*G
MTZ5U--$X1W:\4WK,FF,\<3C)/B;[%8BJ3F\IX._9;(UXYHO7*5WU>Y*[6N7U
M_M=8T/K=KM7=/97(!MYKS'Y;ELQSC6GJ8/*WO$9I9CR%/'V*LM\V)K^1Q61G
M&:QR4QPK;\=[_O?KYYJ>%M4MO<)*W0-338%+F)(^7=WMZAO,=CK=GZ7?&5<2
M#![)#*_)OV7W5<.1TWK,]TH\A=NV;&=Q6@]WANV;-VQD--ZZF:+0&L;%B;QI
MY;FF];4K>(RL]B9H(-/9U[\DE>/%V/7+!ZCX;:MC<*Y%.KVTR6);5DZ95"3N
MMP[;)*NW'G;MR>3E\RJKIKE."S'3-22E/>-]+\4-*S-8IP<.4I6WQM4IO:$;
M/*@[=X0^VW&$)S<I*#Y(RW7;:WHB(JPDM!$1 $1$ 1$0!$1 $1$ 1$0&+O;-
M[/E?=#;;5&CY&!K=ZB5G#6";GU3.T':WB9V?AW$'M1!!8Z>"DJ3V(F=O$=U0
M=R.-L4[%BG;B."U4GFJVH)&XD@L5Y"BGA-OD..0" F^1V=ELA%3B[Y7LU-HG
M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
M$1$ 1$0!$1 $1$ 1$0!?)SV;JXRC=R5Z:.M2Q]2Q>N6)2Z(H*M2$Y[$TA/Y#
M'%%&9F3^3"+NOK*,+O>=ZOF/V4S]>";PK^KYH-(U&9W8SBR82RY5AX^1\/5O
M@?+.SB?1Y.0NP%0;?K=FSKO6FI]8V^MI=19FYD@C/Z*"I+)TT*S_ %/5J(5X
M.&9A;P^!81X9NI41 $1$ 1$0&<O=Q; %N-N_I/#S0O+B,;:^:3/.XN\;8S".
M-H:\CMY<9#(-1QW'+$P6CD'EHBXO5,W#<,W#-Y,S>YF^10#=PSL3\'Z3U/N%
M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0'Y3PA*!QR ,D<@D$D9BQ@8&SB8&),XD)"[
ML0NSL[.[.SMY*@!VN-E9-O-RM9:0<3&MBLY<?%D?T4N%N2/=P\CEPS&?P=8K
MQS$+,/K$<S,S<<-L!%5O[^W9=Z.J-':\K1-X&?QMK3V3,1XZ,CA3&WCCD+]$
M=W'W;,0-^A#$ES]$R K_ *(B (B( L_>["WD;16]>C+DTK14<Y<?2E\G=V'P
MM0.%.HY\>72.4^#RY+@09GD)^!6 2_>K<EKRQ6(#**>O+'/!*#N)QS0F,D4@
M$/F)!((D),[.+LSL[.R V1*+I_L_;H1:UT/I35D3L[9_ XW)2=+,S#8L5HRM
M1LS>0^'9\6/IX9QZ>'$79V;N! $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 5%KO-OC[W-^SE7\!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^F+
MVS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[3W
M1WQ":*_NQ^&;RI+*[3W1WQ":*_NQ^&;R DG1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!8']OWL18G>K2)8XG@HZJQ'BV]+9J1B%JUP@XDQ]XHQ.23$Y%
MF&.U'T2/!(,-V&,IJX@>>"(#7*:ST;E=.Y;(X+.4+&+S&)M2TLCC[(B,]2U"
M_!Q'TD0&WN*.6,SBFB()83.,Q)^-*WEWL7=Z-N/AY-=Z2IL^N\#2Z;-. !$]
M4X>L[F]0N.&DRU",I),;(7)V8V?&D7#U7AJ(21D!$!B0&!$!@8N!@8NXD!@3
M,0F),XD),Q"3.SLSL@/X1$0!$1 $1$!*CW87> 6-HM1-@L_8DDV]U%<#X4!^
MN5]/Y&1AACSU0&=W:#@8XLQ7C%WFJB-J,#LU0CFN9X[(P7*\%NK-%8JVH8K%
M:Q"8R0SP3@,L,T4@.XR12QD)QF+N)"3$SNSLM;VK"W<^=X@V(FI;2:VOB&*L
MFT&B,Q;F=FH7)I/9TU:EDY$:=LS_ .1I"(!K6><=P4=FH-<"STB(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$ 5
MX;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(@
M*WO?VYTGN;;8W]!'6U%>^I[<LF+K/Y]7OXA;RZ?_ +Y_<O7[A'<*FV1W*TH7
M#7I*>FM01/SPYUHY<OCIA9N.2\*0X"X9_9:;EV]OE<-[^Q^-8;>M\GS-9G\*
M5E%KW;^__P#,^[1>C;]FPT.'SS/H[-N<GAQ^IZ@B**C*9/R(M4SP8FT1./+P
M1S1 X/,Y*W^D:"\W@!8]:WL>)D9,$N\K,?-MR>1+U<_*<$O5R1!>5GJCBB5L
MOLJVJIM_=C;C5U;OX*//N_DB^,B(J@$Z!$1 $1$!XX6&._?=\;0[D-))J71F
M-^$9&?IS>'\7!9J.1^7:3U_%G6.SP3]3PWAMUI"9O&@D9N%F>B]^G:IDX=BN
MQ,B[&MCVLHMG5-?[4'%[?%;[/U/+F8-.1!U7TUW5OO"V$;(O_9DFBLUOAW#&
M7I^-<VQUM%<$>HXL)K('KS./+N,4><Q=:2(I&%F$/6,3$$AE[<U<&<E$1O/V
M;MS]MGD^;K166QE*(G$LL$(9+".S<<'\,8X[5*,2Y;I\::%W=V!Q:3D6OM\+
M^)8A,7$Q8Q)G8A)F(29VX=G%^6=G;WL[.ILX;]H;6L/EAF1IU*I=_-2HR-O@
MKZH\C_G64V2?JR(>)/ K1<[FE5">%:^SJ?/6G\77-\R_"%E:^1KKGM8RX .+
MB R#^@\Q<FX9^7XY?GV2]Y?1,_UF]2CIZSC[<63PMZUCLA7=RKW\9;GI78'?
MAW\*U5DBL1L7#=3"8L3-P7+,KI>_7=8;+Z_:>:UI:+3>4FZR^%]'O%@+;3$W
MYXDK00GBK<S%U$[W<?8:0B(Y6,GY:&+>[N+MP<#XUO;W4^/UA4#J*+%Y@0P&
M;\-F(FB&UXDV(N3<,(-(9XN.0R<G" &X4^<.^/&@:@E7DSEI]LERRAF07DRW
M[I7PYJN79[-W>3O\"%-8\$M>TYNW3[_I<(^\E7)\ZV[?5R<;-^G:MS,9]D.]
MUWTT(<5?)Y.GKW#QNPG2U37_ .41C;WM5SU%J]X)'X9F+(AE8Q%G8(1=^MIF
M=A^_2VHU&4%+6-7,;?Y*3H!Y\C 65T^<I<"[#EL8$L]4.KJ(I<GCZ56*/IZ[
M;ERS5EMS-O\ 6>AK3T->:1SFFYV?I8LOCY8:TWM.'55R0-)C[L;FS@,U.W/"
M;L[!(2Z]*OC;C>R0@3M[G9G;E_KM[O\ R;WK(ZWX0\-ZQ#SJJ:J96+>.5ILX
M51E^THP4\6S=]7+RG)_K=F>;3/%OB'2)^3G5VVQ@]I0R83L:VZ;;OEOAVZ+F
MY5\.YL*-";C8#5&/CRNF\SC,[CI6;P[N)O5[]9W=N>'EKR2")<>?23B3?*S+
MFC+7;:.NZDTG?#+Z0S^9T[D0XZ;N!R=K'2F/4Q/'.5.6,;$!.+>)7L-+!(+,
M,D1CRRE/V0[[[=W2CP5=98O$;@8T' 99Y6^9_4#1MRQ&-^A7FQTTC,[FX3XA
MGD<1!K%<7<V@?B3V;]2HYIZ;DTYT.K55NV-D?**<I2HF]N\G;5OZ1)IX;\>-
M*S-HY*EBSZ;R3\VO?UWV2LC^')+\2WTJLOI*6I.B/:?%]1?/9-4Y'H]GIXKQ
MXBJY?TW5^:F8?T/#O\O"D]V&[Y;9/6?@5LEFYM"96;H%Z6L8PQ]-I2?I\,,[
M$<V&]_'!6+E;JZF81<N6:!3TB'<Z#4.ZVA<%B+5?)UL;H."[!+1L!9@DN:CS
MN2$HPDB<H7YJ8?'S>(!D)1SAR[,/G2?VC]!U'3^'LO$RL+*HR,N_#Q:*Y43W
MNLEETRY*6DXW<\82C'RW+F;26^YC?'[7L7)X0SHXM]=_TJ[ HAY4U-\SS*;7
M%Q7O1;KIL]V23W6VWH0Y;%X-[-VSDC'YW4%H(2=FX>Q.SO([?+S'"S,[^[B9
MF;GEV:5_NF<H63[7&C<1"_5'IK0^M]071'AV"6Y0JX>!S\GX<(\I$[<]+MZR
M#L_$G!8&X2G5TU@N;!B$./IRVKTWN9S 'FLR?*[\DQ#&WF3MT"S.3\/GCZ,O
MIFQJ??7=?<:S&;_!>@PP8D3NX1GJ_4F,NPQ!R724E>GHEH&(1(H83<'*,+##
M+=KPN\+H\$>&%NG7I1S'IU^3J<EM[VIZKR5RK;727T964X49)[2CCPG]YIZ7
MX&<)_1'BQE':5+\VQ].N18MY+IT?EU)PZ?JP?J7=T1%6TMR$1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5;SONM$/6U3HS4HQNP9/"W</-+\CS8
MNVUN$&?ZK19*4N/K\JR&HJN^$VH/4.TDN7K1N=O1V9HY[V&9S+'2!/BLG'U/
M]#%'#?BR$O'F_P '@S/YNSP/[3'"\M6X)URB$'.W'QX9]22WEO@VPR;.7YNB
M%T4EU?-LNK(Z\5]+>7H.?&*WG37'*AMU?][3C;/9=VW5&Q;+J]]EWV*ME.[T
MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B ^=E\M7H5+
M5ZY*%>I3KS6K4\C\!#7KQE+-*;_(,<8$9/\ 494$NUYO[9W.W&U3K.8S>OD\
MC)%AX3\O5,#1_,F'K,/DPNU**.>PPLS27)[,[BQ2DS6=^^B[2?S';8%I2C9\
M'-;@2R8D6C-QFBP%;P9<],W2[/X=F*2#$R<^119&46\_-J>R (B( B(@"(N2
MZ-T?D=0Y?&8'#UWM97,WZN,Q]=O^MMW)@@A8GX?HC8S8I9']F.(3D+@1=T!8
MG[AWLV.P:CW4R-?CQ'/2^F2D9^7 /#L9Z]%Y\/&4OJF.BD;GDZ^0C]GI]JR(
MNG>S]LWC]OM&:<T;C."K8'%UJ)3L#1O<M #%=OR"WNDNVRFLFSN_2\G2S\"R
M[B0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %@5WH'Q![F?8.'\*X]9Z
MK KO0/B#W,^P</X5QZ HR(B( B(@"(B M_=QC\2EC[=]0?O3#J9)0V]QC\2E
MC[=]0?O3#J9) $1$ 1$0!$1 $1$ 1$0!$1 8E=NS=[YA=HM?:E$VCLU<!8I8
MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
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MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
MBC"*( CBC$8XXXQ$ CC!F$  !9A  %F$1%F819F9F7[( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"P*[T#X@]S/L'#^%<>L]5@5WH'Q!
M[F?8.'\*X] 49$1$ 1$0!$1 6_NXQ^)2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WI
MAU,D@"(B (B( B(@"(B (B(#I_M"_P#0#7'VGZF_ MU:\J#Z /\ NC_H9;#G
MM 1%)H/6T8"1F>D=2  "SD1$6&NL(B+>;D3NS,S>;N_"UXT#^P'_ '!_T,@/
MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 50N_EW/;(;AZ8TK%(Y!IO3A7K$;.SB%S/VG)F?CZ&5J>/KD
M0OY^'+$7N,5!8LM.W?NFVM-X=PM0@?B5[&HK%"D7R/C\%#!@:+BWFP]=;&QR
MFS.[>+(9<NY.[XEH B(@"(B YSMAH:34^I-/Z;B$B//9K&8C@.6)@R%R&M*;
M./),\<4AR<BSNS#RS.[+8DXS'Q5*U>K  QPUH(J\,8,P@$4,8QQ@(MPPB("S
M"+>3,S,RI8]T+MB6I=]M+RE&\E33%7*ZHN/\@>HU'I4"Y?R8FR^2QYL/O( D
MX]SD-UQ $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE7\
M!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]T
MK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.
MDOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[3W1WQ":*_NQ^&;RI+*[3
MW1WQ":*_NQ^&;R DG1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 7A>40$=_>*=A7';T:4<:H5Z>M<
M%%//IC+2-T-(1#US82_(/#OCL@0 S&;'ZC98+43<>L1S4G-3Z8R.$R5[#Y>E
M8QV4QEJ:ED*%N-XK%2W7-XYH90?W$!-Y$+N!BXR1D0&)/L<U!WWMO=W?-SC9
M]Q]&4>K6>'JC\-8VL+,>IL/5!^9(P;AI,UC(6YK\?/+],'I<G-%1! 5,T3_P
M\GY\GY;WL[/P[/\ 59V9V^HB (B( B(@"ET[K#O!Y-J\Z.D]46S?;[4%OF66
M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
M%>&[J?Z7[;C['Y?\9,RJ/*O#=U/]+]MQ]C\O^,F90$A2(B (B( B(@"(B (B
M( M;-VO=F/YGFZFO-&!%X-7":CR,.-!@<!'$697NX@09_>,>-L58NH?9(HR=
MF;W-LF'5-/TA;9>7#[LZ<UK#$[8_6>E8:<Y\D;_#NF+4U:UU^RPPA-A[^#:O
M'U.4IU+TC-[+\6#]G/6_(U?(PI2VAGXKY5OMS7XK=L/Q:IEDF@>(>#YF)"Y+
MWJ+.K^$+=HR_?.-1PW;[O>MV<1MOH_06CJV$P$.F-/4=.CJ$ZGPOE[,.-@"G
M6GAAO!\%U#B@BC 1DI7A?CF1R=VXPNW$UMK?7=DKFMM5Y[4LI%U_\LY*S9K1
M/RY,U>DYC1J1B1.X15:T,4?+^'&+<KJ;8VMF<J[X7!8;)9S)G,QUZ>+H6<A:
M<)>D.?"K1RD -)PQ2FPQAUMU$*EMV:[G_?'63Q6,U5QF@,5(S$\^H+36LLX/
MSYP8/%E/*!,[.Q1Y*WBS%N"$)!=E9ZV'#6@.>3;^CL"ZV<[IV3\OZ59*<I3F
MX;\^58G)MJ%2<5OM&,5LBL.JOBK5LFW$QEDVXU4E76X\WD*O9>7OMR4Q:@TG
M*QI]/>;]8OXL)CZC<R&+NWZ$>/K?5X][+[&G8[N8NQXO36%R6=R4KNT-##8Z
MYE;TK_*X5:,%B9V;EG(FCZ0;VB<6Y=K3.R7<:;58 X;FK[F<U[?C<3>"]9?$
M8)I&X?RQF+**S9!BZF*._DK5:4.&DJ\L_,M6W>U.F=(T1QNE\!B-/T081:MB
M<?6HQD(<L#R>KQ@\I"SOP4CF3,_'/"C+B'VD]-HWAIN)?FS[>9:UBT;^CCO&
MRZ:7ZLJJM^W,;+HGL[Y=[5FJYJ@GU==;=LOP:BX5Q_*5GX%2C9WN@-\-8^%/
MF:^+T#CI';KEU!9>UDQC\N2BPV+*8BDZ79QAMW,>S\.)RQ&W2I;]D^XXVLP+
M0V-7W<SKZ^'0<@79SPF%*1F]OHQF+G:R\+FS$,-O)V^&]B0I1)V4U**!^(O&
M[B#4.:*R_H53W^JP8^0_^G;GD]NC2N47^J3=H'A+H>GI.&'&^:V]_)VM[?YO
M:-/_ &>Z]&=>[<[2Z6TA1CQNE=.X33E",7$*F%QE/&P^T_43D%2&)I#,_;D.
M3J.0^3,B)W==@\+RBBBZ^=DI3LG*R<FW*<Y.4I-]W*4FVV_5M[DCUUQA%1A&
M,(Q6T8Q2C%)=DDMDDO@@B(OR/N$1>.4!Y11N]IGO5]G=LWGI6M0?--J&,7Z=
M.Z3$<M;$W;V6O7@,,1C&9^'(;M^.UX;]<%6?CI> KM#]]+N[K<I\?HZ&IMU@
MY'D 9*##D=36(B=V%Y\Q:!ZU'V>EV#%T8)XCZO\ E&:-V%I-X4\(M<U;EG5B
MO&QY;-9.9S45N+^]7%Q=MJ?I*NN4&^CDC2.(O$/2M,4O/R8SLCO]32U9-->D
MFFH0?Q4Y1>W9,M*;\=JG;[;*DUW7&JL3@F,'.M3L6&EREUF8OSCB:_C9"VW(
M]#G!7.,3<1,Q<FY@1[1??Z7;;V,;M+I(H(_;CCU1J\6>0GYZ1GHZ=J2DPQ\-
MUQ29+(#(74PS8Z!P?K@*LX"WDKEC+9N]:R.2N&TMS(Y*U-<O6C9F%BGM63EL
M3.(L(AU&3  B \"(LWL29''468 9CD=V$&][D9/TB(BWF1$[\"S>9._#,[JS
M/"GL]:3A\MF?*>I7+9\MB=.+&7RIA)RLV?3ZVR4)+JZUOL5WXD\?\O)<J=+I
M\I;M<T%YEFW;K9)*,/C[D5)>DWW.UM:[UZ_UYDI,UKS5>9U':=R>M!>LN&.I
M^([$;8_$56@Q6/!F9A8:=.%GY,B<C(B+"[>74'K60&G&_,-$.DO/R*S)YR/Y
M?_#'HC;Y6)C^1V61.HL]\'X^:Y(S-($3-&#MY/.?E''PW#\,;^UQP_2+K":T
M9R&<DA.1F1&9/[R,G<B)_P!=W?\ T*7,+&IJ?+157337[M==4(UUQBNGNP@E
M%+;KLEZGET>>18HW94Y69#CS62E)SESRZR7,VV^1/EW]>YQRU#RWN\UG?W3.
M%.SVD]H^AG?U?4D]LVZ7+B.#"Y0B?V6?AFY9^I_9'WNL() 4O/<0:'?+=I#!
M6&#K#3^F=59^;R?@ "K5PD4ON?CIN9RJS._3YDS<\NS/CN.LM5:)J]C]--S5
M^+GCV07[W)+\3?N'GS9>+'XWU?PG%_V?UE\)EY7AEY7,XL6$1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 54OT@K+//KK;[',3.-32^4M$'//!W<
MI%&)./'L^S4=A?E^?/W<>=K15+._S;C<[2Y_TFB&?];C+9!__!3#X%03XBQF
M_NT9<E^+HG'^J3-'\1)M:7;^U92G_P!)%_UI%<*T?B32G[^J0W;];J\O/];C
MCR626*TI1M8^GX91L;U(')BXY<RB%S?GGY2=W_7?W+&^&/W+F6(U'8K"(,[N
M(^3-SYLWU&^3RY\E>VC(C&3YNS6V_H54XEP,C(A7]'M=5E<W)?"2:VV>_3^*
M]22GLL=M_=39&(\=I/(4KFF9;DM^QIC,T8K6-DMSC$%BS6M0M!DZ4\P0Q"7@
MW7K.X]953D=R>>#L\]^WM[GB@Q^X&'R6@<F?A@^1;G-:9E-^!(WNUHX\E0;J
MY,AN8UZ\4;BSWY3Y9JJ&%UM.<,TSPRR5JK1%;F\$S@JC,?A1%9E87C@&63YW
M&4I"QR< #N7#+DL=S'7A;K81<OE;W>?UG_\ !_VEI/%/A1H6LNRV['563-^]
ME8LE5:Y-)\T]MZK9---NVN<MMNJZ'Y:'XH\0:-RU7)Y&/'M&<79#E3:]W=JR
M"WWV5<^7?T[HV$N@-R]/:KQL.7TSF\5G\7/_ $._B+];(5G=F9RC*6M)((2A
MSQ)#)TRQ%[,@"3.S<W9UKQM"9C4FC\A\,Z)U#E=.Y+V>JWAKTU(YA#EP"U%&
M316XP=W<8K44T8OYL'/FI<=A._.W'TX45'<; 8_6N.!^E\MC CP6H@#I9N9H
MPYPU]V=F=NBIC#^B\268G9QKEQ1[.6IXW-9IM]>H5+=JJ>V/DI?!*4G19LO7
MS:Y2]*]WL3OPQX[Z5F\L,E2P[7LFW]95O\]DK(;OT<))>LMEN6R44?\ V<^\
MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
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M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'A4Q.]_[-GS!;L7,M2K^#@]?!8U)2<&
MXA#+/,PZBJCPS,)M=FAR) W(L.4CZ'9OG<=SQ1E][%V:WW#VERT]*MZQG]&M
M)JC#C'%XMF>.E"7POCX.GYXYW,8TQ1P@QO8MUJD;1N?08 4HT7AG9V9V\V?S
M9_K+R@"(B (B( B(@"(B (B("2[NHNS7_-$W;Q$UV#Q<!HUX]49=B%BBFGIR
MM\"T3ZO9<;.3&*::-Q)I:E.S"3,TG4-V)10]SWV:FT'M34S-VOX6>U[)#J.\
M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
M@"(B (B( B(@"(B *A_Z3YW'O!9GM.[28EW.0O6]X-*8VL[N8A $;[A8FK#[
M#'$$ !JVI!"TMMY&U"WB6!RI3WP%Z]NI%8BE@GBCG@GC.&:&8!DBFBD%PDBE
MC-B"2.0"<# V<2%W$F=G=D!HEF)G9G;S9V\G][.WR.WR.S_57E67_2(^Y-L=
MG75Y;D[=8E_YAVLKHB%>L92-MYJJW-*1Z=GA(&>#3649PETM9&:<*\S7<'8&
MF%?#?"%:! 76/1A.^Z^9:[B>S1NQF7;3>3LO5VEU/E+7SO Y&P3%'H"_9F\H
ML3D9GD+2TTLK14;TC8 &"O9Q44&P79:(TP8FX?GY/-G<29V?D2$A=B$A=F(2
M%V(29B%V=F=;+KT;;OO'WPT]%LQN?DP+=W1^,!\)E[)QQR;B:5H1-&UU_H?%
MU/@X8PCU (MU9"N4&: 7*3(#7 L8=K[XI=T?N=ZV_%K)K2#X?\Z5?V/!^Y"M
MWQVOOBEW1^YWK;\6LFM(/A_SI5_8\'[D* ^BML'Z,3](_LM^R-T_X9MPUJ?%
MM@_1B?I']EOV1NG_  S;AH">U$1 %4R]+H[%9:ZV,P.[.+JE+G-F<Q//?*(2
M(Y=$:M/'8_4#2LQ@'1CLE1P&7:>0)BK5Z=^* 8VOV#5LU=?[L;8876VE]1Z.
MU)2BR6G]58/*:=S="<6*&YBLS2GQ]^N;/\DM:Q('+<$+NQ"[$S.P&C/7\F#$
MSB3,0DSB0NS.SL[<.SL_D[.WD[/Y.RR[[>78]SFP6[VN=I=0>-)9TEEGAQN0
MF9O^6].7H8\AIS.1R,$83-D<19JE9., "/(QWJA1PS5IH8\1D!M6O1I>W[#O
M7V;]/X')7WLZXV?@H;?ZHCGL>->L8ZA5*+1^=GZ_G\@9? U8X#MR/*]G)8O*
M,=B6Q#88+"RT_7<M=YA=[+N]F(UC:.>70>H0@TSN5CH6*0I--3V1DBS=:!B%
MILEI>T3Y.H#OU3U"R5$.#NL[;>326K,9GL7CLWA;U;)XC+T:N2QF1IRC/4O4
M+L(6*ENM,#N$D-B"0)8S%^"$F= <A1$0!$1 $1$ 1$0!$1 $1$ 1%ZE^_!5@
MFM6IHJ]:M#)8L6)Y!BA@@A!Y)9II3<0CBBC$CDD,A$ $B)V9G= 1D=\/W@%#
MLV[#:PW .S"&I;-<M-:!HR'&TN2UMF:UH<1'#'(,C3!CHX+><NMX4HACL5;D
MD#PP):=26S/,<D]JQ-;M3R23VK=F0YK-NU.92V+5F:0BDFL69C.:>:0BDEE,
MY#(B)R>?/TA+O77[2^[QXS3%LI-IML[%_#:*<2=HM19.5HH,_K,P=AXBR$\#
MT,$S\E\"UH[I$)Y26O! 2@"^=F/SI:_8\_[D2^BOG9C\Z6OV//\ N1(#? HB
M( B(@"(B (B( B(@"(B QN[9/Q0;J_<WUS^+&46D/P_YTJ_L>#]R%;O#MD_%
M!NK]S?7/XL91:0_#_G2K^QX/W(4!]%;9CT:3Z2;9/]CZX_A(U@M3.MLQZ-)]
M)-LG^Q]<?PD:P0$["(B (B( B(@"(B (B( B(@"(H(>_][U6EV:=G+]?!Y&&
M/=C<*GD<!M[2%XIK6-,X@KY764M8NIFIZ9@MA8K'8!ZUG,R8VF83#++"X%)/
MTFWMYQ[R]I#*:<PEP+6C=GJ\FB,1-7F:6MD=0N4-O664C(/G1A#E6# 02"4O
M4.$EL!*\=MHXZ[*_2>>6622:>::Q//+)/8L6)#FL6+$QE+/8L32.4DUB>4SE
MFFD(I)93*0R(R=W_ #0&97=Y]E.]O?O?MCM;2@.6'5.K<5'G9!C:0:.DL?9C
MR6K<A,),\?16T_5OC"$KC'8O2U*7B =H"6Z4P^(K8^I5H4H8ZU.E6@J5*\3=
M,<%:M$,,$,;>? 11 $8-SY"+,J.WH>O=]V:5/6?:.U)C_"?,1OH7;9YPXE/%
M59WGUCGXF=N6K9'(18["42Y B^!LK(X'7LU)7O-H B(@"U<GI97TX62^YEH#
M]TU MHVM7)Z65].%DON9: _=-0("M4K5GH?7TT.ION.ZC_&?1ZJIJU9Z'U]-
M#J;[CNH_QGT>@-F(B(@"(B (B( B(@"_.2,3%Q(1(29Q(29B$A)G8A<79V=G
M;R=G\G9_/ZC_ *(@-:'Z2/W(?\Q'45G>K:_%..TFKLG))J/"T(":';K5&2M/
M(_@Q!R$&DL_:G?X-"$(X,'?Z\9T1TI\?T52UO--T-L<!K33F<TEJK%4\YIO4
MF+NX;-XC(0C/3R.-R$!UK56>(F=G&2*0F8AZ3C+IDC(9 $FU,7?6=T?J'LI[
MF34((K.2VJU98L7=MM3R2%8-ZP"TMS2F;E<1*+4.!(B$2/Q!R^&>EE(K$EM\
MI5H 0RR1B8N)"Q"3.Q"[<L[/[V=G\G9;%WT97OO'W(P]'L][KYGKW"TWC@BT
M!J/*7.NSKO3N/A)GP]RQ8?Q+.J].TX0=Y9)9K.=Q(/>)SN4<@<FNE7(-(ZLR
MF R^)U!@LA:Q.<P.3HYK"9:C)X5W%Y;&68[>/OU)>'8+%6S%'+&[B0NX])B8
M$0N!O4%#%Z0W])=V@/M/K?C%A%U[W$7?%XSM4;=O6STE+';PZ+KP5M=X.OTP
M0Y.%R\"EK+"U>IR'$9AV%K4 =;8G*O/CR)XO5)9^PO2&_I+NT!]IU;\8L(@-
M18O#^YUY7A_<Z W.7=._2L=FG[@&S?\ !UIQ9_K #NG?I6.S3]P#9O\ @ZTX
ML_T 1$0$)'I O;]?L_\ 9OU9EL3;"#6^MG#0.A@:4 GBRF>CD#)YF,"ZI"'3
MVGX\IEA<(S$KT%"K*< 6O'CU(@#PS-R1<-YD9.1$_P I$1.Y$3OYD1.[D[N[
MN[NK+/I27;T/=KM$3Z$Q%WQM&;+U9-,UHXI'*M>UG>\.UJW*%TN\<I4_S!I^
MJ;.?@_!V0*,A]?F!JU" _B200$C)V81%R)W\F9A;EW?]9F=_VEM9O1JNP.6R
M/9NPN1R]0J^M-V+$6X6I6GA\*U1J7Z-:MIC!%R(GX6,PD,-HP-R_Y3RN4EC=
MHI@ -?!W-/83_GBNT1H7;V[6*QI:K-+K'7@L[B):-TU/3DR%20F9^(\SD+>*
MP,OG&[Q961HY0F\)UN)X( B (H@&..,1".,!8   9A   681$19A$19F%F9F
M9F9 ?JB(@"(B (B( B(@"(B *J'Z6EV$"W"V-QV[6#I#/J;9K(G?R91Q]5FW
MM]F1:KJ.(79N7^![PXG4/!%TM2H9,  [$T+-:\7%M<:*Q>I,-EM/9RG%D<-G
M<;=P^6H3]7@W<=D:TM2[5D<"$V">O-)&Y 0&+%U 0DPNP&BX7YRQB8D!-U"3
M.),_N=B;AV?ZSLZRU[=79%R^PV[NN]I<R\LLNCLW/3QEZ9N#RVF[/%S368+B
M.('ER&%FJ2V_"C&".^UN&%RCB$BQ.0&UL]&T[?DF^/9OP-+.WWN:YVOF^8'5
M$DTKR6K]7'1B>ELW,YG)(1Y+3IT8KDIE\^RM+(R"$41QQ#8$6J5]&L[>O\Q+
MM)X7%Y:]ZKHO=RO#M_J$9'9JM?-6+33Z*S$CN0]$M3,G+AFD]H?5=16V.,C:
M&2#:U( B(@"(B (B( B(@"(B *OYZ4/]))NS]D]K_P"%C1*L!JOYZ4/]))NS
M]D]K_P"%C1* U22^;F?SI:_8\W[F2^DOFYG\Z6OV/-^YD@-XUV;_ (N]!?:7
MI;\!T5W0NE^S?\7>@OM+TM^ Z*[H0!$1 $1$!%WWQ/=_U>TEL+K+;V,*L>J(
MJWS0Z$R%F-W&AK#"B=K% 4H,\T-7*\2X7(21,9#1R$\G@SN PGIX\OA[F.N7
M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0%.STSKXC=H_NQA^(>LEKHEL7?3.OB-VC^[&'XAZR6N
MB0&4?8;^.W9O[JNWGXVXA;LU:3+L-_';LW]U7;S\;<0MV:@"(B (B( B(@"(
MB (B( B(@"UB_I>.)BK=K3'31]77?V8T/;GZGY9I0U+KZBW0W#=(^!2A=V?G
MV^LN>"9FV="UI?IA^'*'M-Z-OO&XC?V:P58)')G:5\;JW61R"(\^R\+9.-R?
MANKQAX=^E^ *H:L;^BGYH*G;'TW&;DWK^@-?4AZ69V(WK8RR+%S[A_,W/+<O
MU,+<<.ZKD*:[T=/5?P3VS=E'<PC'*9+4>%,CX9G:YI'.3Q@SO)&S%+8IP1A]
M&Y&0@T9$3.(&W!9>41 %67]+7^E R?W1MO?PM*K-"K+^EK_2@9/[HVWOX6E0
M&KW7SLQ^=+7['G_<B7T5\[,?G2U^QY_W(D!O>Z_]#C_[@_ZK+]E^-?\ H<?_
M '!_U67[( B(@-?%Z:9\86P7VFZ^_#>F%2L5U/TTSXPM@OM-U]^&],*E8@)L
M/1T/IS]D/LGJC\1]2K;@+4?^CH?3G[(?9/5'XCZE6W 0!$1 $1$ 1$0!$1 $
M1$!U3OCLEI?<C2&H="ZTP]3/:6U1C9\5F<3=B"6"U5G9G8F8Q+PK-:88K=*T
M'$U.Y!!;KF$\,9CJ0.]^[JW5/92W/L:7R!3Y;0VH);N2VWU<8.P9C"QRB1XG
M(GYA'J73X3P5,M%RPW0\#+UA&"X4%;<*K!/O%^[\T-VE=L<SMMKBJS#9$KVG
M,_!$!9726I8(90QNH,3*_#C-6*0HK=4B]7R6/EM8ZV)U[)L@-+VN<;8[FZ@T
M5J3!:OTGE;6#U-IG*T\U@<O2,H[-#)4)6FKS XD/7&3L\5FN;O#;JR3U9Q."
M:0"[B[8G9$UML3N-J/:_<&@-+46G; ,T\#2OC,WBK(O)C-082Q-'&=O$92!G
MD@E<6.">.U0L,%RE8B#&5 ;4_L)][AI[M6=EG<S*2%0Q.Y^EMM=6T-Q](UY"
M;U*\>F<N%3/XJ&9_'ETYJ 8)+5"7F9J5D;>'L3R6J!R2:I_#_G2K^QX/W(5D
MIV9^U'K7:+45K4^ALHV-R&1T_G=*9>":,K&.S.G=1T),?E,5E*;21-:@(3CM
MU7<Q.ID:M2W&3O"\<F.U:!HHXXAY<8P",7?CEV 6%G?AF;GAO/AF;GY$!^RV
MP?HQ/TC^RW[(W3_AFW#6I\6V#]&)^D?V6_9&Z?\ #-N&@)[41$ 1$0%5+TH7
MNF+.\^WE3=_0F+>WN5M;2LED:%.!Y+VK= <36\EBX0B%Y+.4P-E_AG#@3&YP
M/EZ$3#)?C(=9S'()B)"[$),Q"3>YQ=N6=OK.WFRWN:UM?I)/<93;19O*;\;4
M89FVGSUL;.M,#CH2Z=O-0Y&WX<F3AKQCX<&CLY<L0"#1,$>#R\Y5S <?=JE5
M J1JWQZ./W]];:&:CL1O1F8:FUMR:P^B=:Y6VX0;?Y*U-')\ 9>>;F*OHW(S
M26K%:_--%#IN^3PR,^*O=>+J#KP[,[.SMRS^3L_N=G]_+?*R WM-2W%8BBG@
MECF@FC"6&:(QDBFBD%CCEBD!R"2.0'8P,'<2%V(7=G9>PM7YW-?I(>MNSU%C
M]O\ <R'*[B;/PE!6QXQSA8UAH*HS]!!I^6W)&.:P<(.QAIZ_<A.F,;QX>Y!$
M0TBV-/92[8^V>]^EJVL=KM78G5N#G&-ICH3\7<99D#K>AF<9*T=_$9"+@AEI
M9"O!.) 7 D+=3@9-(B( B(@"(B (B( B+%[M9=M#;#8W2\^K]T]8XC26%B"=
MZ[WYNK(96>N F=+!XFNTN3S60+KC$*6-JV;#G+$S@WB"[@9/22" N9$PB+.1
M$3LPB(MR1$[NS,S,W+N_DS>;^2U^'I'W?_4-:5<UV>-C<W'=TO.UK%[I:[QD
MAO7SOAS/!:T5IB[&0QV<.?ARQ:ES$#S5<K#(V)Q\TE5[\LN%??%^DMZVWY@R
M&W^TL69VWVHL.<&2N2S!4USK:K[0>!DYZ,\PZ<P<[.QRXC'7)+UX>F+)WQKO
M8QTE7, 81819A$69A%F9F9F;AF9F\F9F\F9O<@/+,S,S,W#-Y,S>3,WN9F^1
MF_O,I1.[+[KK5W:.O:YO4?7\1H;;?2.=U)JG5$%09V+*T\1:O:?TCB_&"2*?
M,9NS",MGIBL_!F&BL7)H?&L8V.SCEV'.Q1KKM";DX3:_;VD$^:RO-K(9*TTG
MP3IC 02PQ9'4N<EB$SBQM#QXQ&,!*Q?N2UZ%0#L6 9MM-V6^[[T/L#L1;VCT
M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ino-20241231_g2.jpg
<TEXT>
begin 644 ino-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ()!:(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'V4?WC4]% $'V4?WC14]% !1110(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHI,T +1244 +1244 +129HH 6BDS1F@!:*2B@!:*2B@!
M:*2B@!:*3-% "T4E&: %HHI* %HI,BC- "T4F:* %HI,T4 +1124 +129I:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML_PSX/\ C59Z_93:WX]T+4-)20&XMK?2?+>1>X#9X-<Q\"?^3D?C-_UUM?\
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M3=WY49- #J*;DTHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYKR:[,DR@$&1BQ''89KH_%7C+1/ ^DOJ>O:E;Z78H<&:X; SZ#N3]*Y3P?\
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M5L1+E3Y6O>?Q:16J_/?<T/'46H_&SXP:9\.;^^N;'P[IFEQZCK4-G*8VNI6
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M4<(?RT\SE]HW8]<<U)7RQ]:%%%% !1110 4444 %%%% !1110 4444 %%%%
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M23UKPKPCXD_X7=I_Q#^)+Q.ME:: ^D6*RKC:XC)F8#_>XKV_]F7GX$^#L?\
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M'8INY%>(^./A+;Z)I_[/7@GQ%;BY1KJ1;VWW$ LR[BN1Z$U]*^#_ -F_X?>
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M5V\5SX"_9OBFB26)KNV#(Z@J1Y?0@UOZ7X \1Q_!_P"-6GOH]TM[JFHW,EE
M4^:X5AP5]0:I>/O"_B72OAK\$+B#PUJ.IW6@3037UE:1@S1A4P01ZYKJ]I&=
M5OF5W)]?[G^9R>RE"DERNRBNG_3S_(]N^+GPC\+>+? 6LVUQHME#,EL\L%S#
M L<D,BC*LK 9!!%?.WV/Q;\2_@O\,/%,.E-XN7PY>.;_ $AG&^\1"5#@'AB
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MCQL5&G#=/7W6[VVU^?9G;@9.56>TEI[R5K[Z6\NZ-2BBBO(/9"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@""ZL;>]V?:+>*?8VY?,0-M;U&>AJ;%+13
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!6E_DW^-?.E%4\ER[_GRA?VUF/\ S^9]%?\ #<GC/_H%:7^3?XT?\-R>,_\
MH%:7^3?XU\Y44_[%R[_GRA?VWF/_ #^9]%']N?QI_P! K2_R;_&D_P"&Z/&O
M_0)TK\F_QKYQ;[QI&JO[%R[_ )\H/[;S'_G\_P #Z._X;J\:_P#0)TO\F_QI
M#^W5XU_Z!.E?]\M_C7SA32V<XJEDF7?\^43_ &WF/_/YGT>?V[/&O_0)TK_O
MEO\ &D/[=OC;'_()TK\F_P :^;VIK=*?]B9=_P ^4+^V\Q_Y_,^D/^&[O&W_
M $"=*_)O\:/^&[_&W_0)TK\F_P :^;:1J/[$R[_GRA?VYF7_ #^9](_\-X>-
M_P#H$Z3^3_XT?\-X^-O^@3I7Y/\ XUX_X7^'\?BC0&NX[EH+M9"N&&485AZ]
MX1U3P\Q^U6S&+M+'\R_GVK*.5Y3*;I^R5T;RS3-HP4W5=F>]_P##>7C?_H$:
M3^3_ .--_P"&]/&__0(TG\G_ ,:^:]V0::U=']AY;_SY1S_VYF7_ #^9]*_\
M-Z^-_P#H$:3^3_XTW_AO;QQ_T"-)_)_\:^:J;5+(\M_Y\+\1?VYF7_/YGTO_
M ,-[>./^@1I/Y/\ XT?\-[>.?^@1I/\ WR_^-?-%)5_V%EG_ #X0O[<S+_G\
MSZ6_X;Y\<_\ 0(TG_OE_\:3_ (;Z\<?] C2?^^7_ ,:^9F[4E3_8>6_\^%^(
MO[<S+_G^SZ9_X;Z\<_\ 0(TG_OE_\:#^WWXY'_,(TG_OE_\ &OF3=UH/S5?]
M@Y9_SX7XB_MW,O\ G^_P/ID_M^>.?^@1I/\ WR_^-(W[?WCK_H$:1_WR_P#C
M7S*>M-:J_L'+/^?"_$/[=S+_ )_L^G/^&_O'/_0'TC_OE_\ &D_X;^\=?] C
M2?\ OE_\:^9&Z4VG_8.6?\^%^(O[=S/_ )_O\#Z</_!0#QR/^81I/_?+_P"-
M'_#P#QS_ - ?2?\ OE_\:^8FI*/[!RS_ )\+\1?V[F?_ #_9]/?\/ /'7_0'
MTG\G_P ::?\ @H%XZS_R!](_[Y?_ !KYCIK=:?\ 8.6?\^$']NYG_P _V?3G
M_#P3QW_T!](_[Y?_ !I1_P % _'9_P"8/I'_ 'R_^-?+U*M/^P<L_P"?"$\]
MS/\ Y_O\#Z?_ .'@GCO_ * ^D?D_^-#?\%!/'?\ T!](_P"^7_QKY?[BD:G_
M &#E?_/A?B3_ &[F?_/]GT__ ,/!?'?_ $!](_[Y?_&D_P"'@WCO_H#Z1_WR
M_P#C7S!3?\:?]@97_P ^%^(?V]F?_/\ 9]0_\/!O'G_0'TC_ +Y?_&C_ (>#
M>//^@/I'_?+_ .-?+M%/^P,K_P"?"_$7]O9G_P _W^!]0?\ #PCQYVT?1S_P
M%_\ &C_AX1X\_P"@/H__ 'R_^-?+JT-UH_L#*_\ GPOQ%_;V9_\ /]_@?4'_
M  \*\>_] ?1_^^7_ ,:/^'A7CP=='T?_ +Y?_&OEQ>M#?>I_V!E?_/A?B']O
M9G_S_?X?Y'U)_P /"O'G_0&T?_OE_P#&D/\ P4+\>#_F#:/_ -\O_C7RY36I
M_P"K^5_\^%^(O[?S3_G^_P #ZE'_  4*\>?] ?2/^^7_ ,:#_P %"O'@'_('
MTC_OE_\ &OEM>E#4?ZOY7_SX7X_YB_M_-/\ G^_P_P CZC_X>&>/?^@/H_\
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M+_XT?\/$/'O_ $!M'_[Y?_&OEBBC_5[*O^?"_$/]8,T_Y_L^I_\ AX=X\_Z
M^D?]\O\ XT?\/#O'G_0'TC_OE_\ &OEBBC_5[*O^?"_$/]8,T_Y_O\#ZG_X>
M'>//^@/I'_?+_P"-'_#P[QY_T!](_P"^7_QKY8HH_P!7LJ_Y\+\0_P!8,T_Y
M_O\  ^I_^'AWCS_H#Z1_WR_^-+_P\-\>_P#0'T?_ +Y?_&OE>G4?ZO95_P ^
M%^(O]8,T_P"?[_ ^IO\ AX=X\_Z VD?]\O\ XTG_  \.\>?] ?2/^^7_ ,:^
M6&ZT57^KV5?] Z_$/]8,T_Y_L^I_^'AWCS_H#Z1_WR_^-'_#P[QY_P! ?2/^
M^7_QKY8HH_U=RK_H'7XA_K!FG_/]GU3_ ,/#?'G_ $!](_[Y?_&BOEBBC_5W
M*O\ GP@_U@S3_G^S]DFIM.:FU_/Q^]L;3*?3*:)&4QJ?3&JA,8>]-IQ[TVJ)
M(VI*5J2GT)9&U--.:FFK0F,;I4;?>J1NE1MUJB1AZTRGGK3*?0EB=ZCJ3O4=
M4A#6IE/:F51(C4VG-3::$R*FM3J:U4 E1M4E1M5$C&ZU&W2I&ZU&W2J1+&TQ
MN]/IC=ZHAC*1J6D:J B;H*;3FZ"FU2$QK=ZB/:I6[U$>U-"$IM.IM40R-J:W
M2G-36Z4T(C:F-3VIC5?070:U,;K3VIC=:HDC;O3*>W>F50A&ZU'4C=:CJD2Q
M#VJ-N]2'M4;=Z8B%J;3FIM601M3&J0U+%IUU<_ZN"1AZXIW2W%9O8J=Z1^E;
M,/A/4)L;E2,?[35<3P3)C]Y<J/\ =6H=6"ZFJIS?0Y5NM-;I78?\(3#_ !7,
MA^@%*W@JUV_ZZ3]*7MX"]A,XMJC;O7:MX)MNT\@_*H)/ L9SLNF'^\M5]8I]
MQ>PGV.-:F-73W'@>[7_53QR?7(K,N/#&I6_)MBP]4.:WC4@]F<\J<UNC(I'[
M4^6&2%L2QLA_VABHV[5LC+J1TU_NTZFO]VM$)C*8W>GTQN],DC:DI6I*I&3(
MVJ-NM2-4;=:M$2&-WJ-JD;O4;5?0@C;O4;5(W>HVJT9C&IE/:F5:)(YOX?I4
M8[U)-_#]*C'>K1#W&5&W4U)4;=35F3&-3&I[4QJI$,C;H:@?[M3MT-0/]VM8
MF$R.HZDJ.K6YB]B.3[U5Y.]6)/O57D[UL<<B*N$^)%R?.M(,G: 7KNZ\H\8:
MI_:6N3X.8X?W:_AUKYOB*LJ>#Y+ZR:7ZGTG#5%U,;SVTBF_T,3WJ&0BI&-02
M-7Y8?K)6FDJLSU),U5FY-("56JW#S5*.KT(Z4P)V;BJLG6K,E=G\)?AK<>//
M$"/*C+I5LP:>4CAO]@>YI@<%)#)"X61&C) 8!A@D'H:GA-?0_P ?OA>VHZ?!
MK>D6P,UG&(YH(QR8@."![5\[1<'I@T@+RU(M0QU,M4 -6WX3NF2[> _==<@>
MXK$:K&EW9L[Z&7L#@_0UZ66XCZKC*59NR35_3J>9FF'^M8.K22NVG;UZ'?"F
MU:T_3+O5& M+:2?/=%X_.NGT[X5ZM=D-<-'9I_M'<WY"OW*5:G3UE(_"84:E
M1VC$XQJC8]:]<L?A-IL.#<W$UPW?'RBMFU\$Z+9'Y+"-B.\@W5R2S"E':[.V
M.7UI?%9'A,:M*V(T:0^B@G^57H/#^J76/*T^Y8?]<R/YU[[#9V]N,0P11#_9
M0"I\GUK"69/[,?Q.E98OM2_ \&B\"Z],,C3I!_O$"K4?PWU]_P#EU5?JXKVZ
MBLGF-7LBUEM+JV>*?\*MUT\F.(?\#I&^%>N$<+"3_OU[4W>H)XA/"\;%@K@J
M=IP<'WH_M"MY%?V?1\SRKX3?#N'QAXF:WU.:)+>S9OM=LD@\P;3C'T)[U[-X
MB^#_ (0U2V=+6R6QDQA6A8\5DZ'86OAQ EC L"[2K,H^9L]R>IYJ\VO7B6_D
M",'G_69KSL1B,15JJ<9M6['K83#X:E1<)P3;[ZGAFM?"_6M-U">""W^U0QMA
M9%(Y'TK(F\%Z[#G=ID__  $ U]!&1I7:1CRQS2,QYYKU(YE525TF>-/+:3D^
M5M(^;Y]%U&V_UMA<I]8FJDX9"0ZE#_M#%?3>XMUY^M036-M<#$MO#(/]I :Z
M(YF_M0_$YY97VG^!QWP=A>Y\/M'&-S-.V,?A7=:AISVL;+,AF3^(8X%6_!-G
M:Z?K$4,,$<,<F1M08&XUV.L:;*L,J1Q>9NZC'(KY_%8J]=M:)ZGTV#PB^KI/
M5K0\+\0?#'2M80RVP^Q3N,AXA\I^HKS/7_ .KZ#N>2#[1;K_ ,M81N&/4BOH
M*XMQ:XAW NI);';/:HL=?0UZF'QU6FE=W7F>1B<!2G)V5GY'R]NINX;B,\^E
M>\^)/ASI7B!)&6/[%<L.)H1CGU([UROA7]G#6=:UBY$VIVL5@N,7; Y/MM]:
M]J.94.7FF^4\9Y;7<N6"YCS"BO5/B9\ [WP#I2ZG;7ZZI9@[9"J;63WQZ5Y7
MVKT,/B*6*A[2D[HX<1AZN%G[.M&S(V[5WWP7^&\?Q(\2307,OE65I'YTV.K<
MX"BN!:NI^%?Q)E^''B^*\,#R6LZF"=0?O(>_U%98SVGL)^Q?O6T*P?LOK$/;
MKW;ZGT]>?#OPSINGO:PZ/ 8U7#$H"?SKYJ^)_@VW\,:FD]@?] N22B_W".HK
MW2^^(VDZK:O<VVLV\=M(,L';##VQ7A/Q+\96_B6\AM[$$V5KG;(W61CU/TKY
M[*8XF-;W[VZW_K<^FS>6%E1]RU^EOZV.)I&IQIK5]D?%@W2FTYNE-JA,1J2E
M:DIDCH(9+F>.&)2\LC!$5>I). *Z?X@?"WQ-\,;BRB\1Z<;%[V/S8/F#!E^H
M[^U=G^RSX('C+XLV4LL#7%CI*-J%PJKG(3E5Q[G%>N_$JQ\0?&;X(^)=5UO2
M;RRU?P_JLEW:?:H60M:.?NKGJ *\#%9D\/C(4%;ETYNZYM(V_7U/>PN6K$82
M=9WYM>7M[NLK_IZ'R!4MK;S7ES%;V\333RL$CCC&69CT 'K7N^F^$_ 7A'X$
M^&?'&N:)<ZUJE[=2P?9$N#''+@]6/8 >E=1J/@_P1X-\=?"WQ5INAW']E^)
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MZV5M]U]UKWZ'A.A:-=^(M7L]+L(Q->W<HAAC)QN8]!FNJT;X+^+_ !%XRO\
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M"M*VT&23!E;8/1>M;D-K%;(%C0*/:GXK&55O8V5-=2I;Z7;V^-J9/JW)JUM
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M+<[?FF#8Y^E=<XX;"24<3*\GT7ZG-!XK&1<L-&T5U?Z'A6O^.-6\0,1/<&*
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M  B<O_/=?RII\(S'_ENOY5I'Q H_Y9'\Z3_A(5_YY'\Z/;3%[.D9O_"'R_\
M/=?RIO\ PALW_/=?RK3_ .$C7_GB?SI#XD7_ )XG\Z?MIBY*1F?\(9/_ ,_"
M?E3?^$)G_P"?A/R-:9\3J/\ E@?^^J3_ (2A?^>#?]]4>VJ!R43+;P3/_P _
M"?E2?\(//_S\)^5:A\4I_P ^[?\ ?5-/BQ1_R[G_ +ZI^WJ=Q>SHF8? L_\
MS\I^5-_X06X_Y^4_*M0^+D_Y]V_.F_\ "8)_S[M_WU1]8J=Q<E$R_P#A ;C_
M )^8_P C2'P#<?\ /S'^1K4_X3)/^?=O^^J0^-$_Y]F_[ZI_6*G</9T3+_X0
M"X_Y^8_R--/P]N/^?J/\C6K_ ,)JG_/LW_?5-/C>/_GU;_OJCZS5[B]G0,H_
M#NX/_+U'^1I/^%<W'_/U'_WR:U?^$X3_ )]6_P"^J;_PGD?_ #ZM_P!]4?6J
MO<7LZ!E_\*WN/^?N/_ODTP_#6Y_Y^X_^^36L?'D?_/HW_?5-_P"%@1=[1O\
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M?S?@A?4LL_ILYIOV1]5/_,;MO^_9J,_LAZN?^8Y:_P#?LUT__#65G_T )_\
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M:A^S?KAA(L]6LQ(>\J,0/PKB=6_8Y\9:XQ-UXPMMG:-(F51^ -:Q_;LT\?\
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M (4W_AX)IO\ T*5U_P"!*_X4_P#6C,OYU]R%_9V0?TY'+?\ #OW7O^AFLO\
MORU)_P ._=?_ .AFLO\ ORU=0?\ @H1IH./^$2NO_ E?\*3_ (>$:;_T*-U_
MX$K_ (4_]:<S_P"?B^Y$_P!G\/\ ].1RW_#OO7O^AGLO^_+?XTO_  [[U[_H
M9[+_ +\M73'_ (*&:8./^$1NO_ E?\*:?^"ANF*,_P#"(W7_ ($K_A1_K1F?
M\Z^Y"_L_A[O^,CF?^'?.O_\ 0SV/_?EJ3_AWSX@_Z&>Q_P"_+5TW_#P_3/\
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MN_7_ /H:+'_ORU(?^"=OB#_H:;'_ +\M6Y_P\JTO_H3+O_P*7_"C_AY5I?\
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MYEI7_0EWG_@4O_Q-'^M>;?\ /Q?<A_5>&/YOQD8G_#N?Q!_T-5C_ -^6I/\
MAW/XA_Z&JQ_[\M6Y_P /,M*_Z$N\_P# I?\ XF@_\%,]*'_,E7G_ (%K_P#$
MT?ZV9M_S\7_@*%]5X8_F_&1A?\.Y?$/_ $-5C_WY:E_X=S^(?^AIL?\ ORU;
M?_#S32O^A*O/_ M?_B:0_P#!372O^A*O/_ M?_B:/];,V_Y^+_P%?Y!]4X8_
MF_&1B_\ #N;Q!_T-5C_WY;_&C_AW-X@_Z&JQ_P"_+?XUM?\ #S;2O^A*O/\
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M?^AJL?\ ORU'_#N/Q#_T-5C_ -^6K9_X>=:5_P!"3>?^!:__ !-'_#SK2?\
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M0R_.(XV^=2W5,#^5>+^$/CW\2))I=(\(1,)[WY/)M8#*P)[C.=I]Z^@O@?\
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M7]H[PKXICU"6?0K;1$TZYN(X6W1.8]I^4\G!J3MHU,'3K)I17+*%GZKWNO\
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M[G]_<B/9GRXQW] *Q-5_9^\*^,O ^N:UX)@\1Z->Z'MDN+7Q%;E%GA)P9$;
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MS/$)/O&F5[?/^S7%>^&M<OM$\:Z9KFM:'$9M1TBWB93&@X)60G#8^E9G@_X
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MKEC@>IJI%,+:T5V^:20EMO<L3FGQVID8//\ .W9>RU)[L8J,4D*UY$W0,_\
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MGM<^[RG.Z6*?L,QITVXQ?)*45HTM$^C1ROQ.\8:-XNU:WET72CI=M;Q^4J\
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M5U!4@@]".E,;O2]G%*QE#+,-"#@TVFK:MO3LNQ\E6_[)/CCQ1?:3;>./'/\
M:>@:6P,-K#N+%1VYZ<#&>:]&^/O[.<?Q?T;0K?3M2&CW.C_+;LZ%U*8'![@\
M5[8U-;I0J<;-$QRO"QIRI<MU*U[MMZ;:^1\Q^-_V6_%/CGX?^'=#U/Q;#>ZC
MI<\DC7MQ&QWHV-JCGL!74?&;]G"+XF:7H5Q9:E_9/B;1X8XH;Y5.U]H& >XY
M&0:]Q:F-3]G'4?\ 9N&<91<;\R2>KZ;'S)X4_99\1ZMXVL/$?Q'\5#Q"VGX-
MO;1@D-CIDGM5_P".O[-&K?$#QU9>+O"^MQZ+JL2(C>8",%> RD=\5]%'I3&I
M>SC:QF\JPOLG2:=F[MW=[][GR]H_[)?B&T^(VA^+=3\7KK%Y:R)-=O<H2\C#
MLI["MCQ1\ O&NF^/-0\2^!?&(T\7Y8RV6H R1IGJ #D8_"OH>HJ7LXV$LKPL
M8N,4UK>]W>_J>*? ?]GR3X5ZMJFO:MJBZKKVHC$CPILC0$Y.!ZDU[*W2I&ZU
M&W2JC%15D=V'P]/"TU3I*R0VF-WI],;O5'0B-J2E:DH$QC=Z8U/;O3&H$1MW
MJ)JE;O434$L8U=)H2[=/3W)-<VW6NGT7_D'14&D-RXU:^DKBW)]360U;.E_\
M>H^IH.F.Y;II[4ZFGM0:A7D7[3_PQD^)WPMOK6TCWZG9'[5;#NQ4<J/J*]=I
M#[UT8>O/#5HUJ>\7<Y\10ABJ,J-3:2L?G=^S/^T-<_![6GT/73(WARXDVNC#
M+6DF<%@/3U%?H'INJ6>NZ;!>64\=[97"!XY8R&1@>]?(_P"UA^S+;I'>^-_#
MTL-HJ@R7]E(0BD_WT/J?2OFSPS\9O&/A#P[=:%I.MW%KIMP/FB4Y*^NT_P /
MX5^A8C+:'$$%C<'+EF_B3_K?\S\ZP^9XCAZ;P6-BY07PM=O\OR/LO]H+XI?"
MCPC#/8ZGH>F^)->(P+.&)<H?]MQ]W^=?'7@CP#J?QJ\??V?H6FQV,,\GF2K#
MGR;6+/)R?;\ZL_!_X/ZM\;?%#65M>PVZJ?,NKJYDRX7/)"]6-?HG\+_A-H'P
MET%--T2WVL0//NI!F29O4G^E77Q-#AVBZ%&3G6:Z[+SMLO3<SH8;$<25EB*T
M%"BGT6K\K[OS>QH_#_P38?#SPG8:%IR!8+5 I;'+MW8^Y-=#117YK.<JDG.;
MNV?IT(1IQ4(*R6PC4E,FN88<"2:.,GIO<+_.D>>*-0[R(B'HS, /SJ"R2O%?
MVH?A'KWQ=\-:/9^'Y+6.[LKP7)-VY5< <= >]>R&\MU4,;B(*>C&08/XYIOV
MRWD.$GB<]<*X)_G0!\XZ!\"?'_B_XD>'_$OQ$U/3&M="4"TLM-!P2.A.1[5O
M>%?@7J=I\0OB7J>K-:R:1XFB:*!8V)< C^(8XKV]+RV=@JW$+,>BK(I/\Z?)
M-%#CS)$CSP-[ 9_.G<#XW\)_LG^/O!_@_P <:/:76F^;K:I!!)Y[#$0?)W<<
M'%=?K7[&>@3?"%=+L-+LX?&BVZC^TB[;3*.O/I^%?2EUJ%K81B2ZN8;:,]'F
MD"#\S3TNH9;<3)-&\)&1(K KCZT78'*_"G0]6\,_#_1=)UQHGU.S@$,K0L60
MXX!!^E=6WW:C-Y;JJL9X@K=&+C!^AS2R3Q1X#2(I;H&8#/T]:0#J2HFO+=&*
MM<0JPZJTB@_SIZ2),NZ-UD7^\I!'Z5) 5A>-_"-KXX\*ZCHEV/W5W$R!L?<8
MC@_G6[15IV=R91C4BX25TS\Q&T$?!?XG?8/%VB)K%I:2%9+>3(6://#J1[<U
M]Y_"6X^'WB;0(=2\':?IT<./GCCA42Q-W5AU!JM\<?@9I7QDT)HY0MIK4"DV
ME\HY!_NMZJ:^#X[[Q;\ ?'-Q;6UZ;#5+5]LJPR;XI1[CH0:_2+PXEPZY)N%:
M*U5W9^=OUZ'YM:?#.(]^FIT9/1V5UY7_ $ZGZ(_$SXE:3\+?"\^KZK,JJJD0
M6ZGYIG[*HK\ZM5U#7_CO\3C)M:XU+5)PD<8Y$29X'L *C\;?$+Q1\9?$EM)J
MMRU[=R,(K>UC^6-">,*O:OM#]FW]G>'X5Z8-7U8)<>);I/FQRMLI_A7W]35T
MJ-'AG#.K5:E6GM_7;NS.K6K<3XI4J2<:$=W_ %U[+H>J> _"5OX%\(Z7H=MS
M'9PK&6'\38^8_G70445^;3E*I)SD[MGZ7&$:<%"*T0T]Z2E/>DJ"T<SXM3]]
M V.Q%<\U=+XN_P"7?\:YIJDYI_$Q*0,T;[E)5AT(I::W6D9'3Z-XVEMPL5Z#
M*G02#[P_QKL[+4(-0B$EO*LB^W:O)*EL[ZXT^426\C1M['@U5^YU0Q#6DCV6
MWOI83P<CT-5=*UA-)U"\6^RJW,F]+C'R_P"Z3VKD-+\?+M6.^B*M_P ](^0?
MJ*Z./5K*Z4*95&[^&08S^=4=BDI:IA:_![P6WB[4_%(TB"[U;4U47,TSF5'V
M]"$8E0?H*V%4ZTUQ9VP%KID(,1\L ;VQT'H!6/=11V5G//"SP[4+ Q.0*M>&
M]0>PTNW0KNR-['N2>:=W8=E<\&OK7Q1X7\0)IGB#16$5U<B&RU*Q^>&0L3M5
MAU4@=>U8_P 7+2ZL?!NJ0O$\<J@!U88.,\U]71ZK;7&!(H!'(W#.#5+Q1X/T
MCQIITUK?VZ3)*I4L/O8^M75E&IJHV?D<<,*X._-<_.G;$JQSL>%48YXH-T6X
M#"//0=6/X5W?QP^$UW\.]3,=JCW&G*V]67G8O;-:WA'1H++0[%F@C-PT8=I"
MHW9//6N5^Z>DM3B])\$ZCJBB1T^R0GH]QRQ^BUTUI\.;"(?Z1//<GTW;1^E=
M;14E6,:#P=HUOC;81L?5\M_.L[08QX>UR^THXCMYR;BV]!GJOX5U#ML5F)X
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M8]1U"W659%+9"@L,#([^U=O\*=)TB#XX:IX@L_&__"6:U:VT\U['9:?Y<%P
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M/\0Y?B+ID>HV$DQ6V66U,X#Y&2!VXKZY^#_B+PCXD\%PS^"+9;/08Y&CCA6
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MP6,>R")8E[[1R?J>] $]%%% !1110 5EZ[X=M/$%KY5RGS+]R5>&0^H-:E%
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MTKZUA^&Z^%_C-X0L5\':[XWNX1;R-XMU.^?[-$F <HJ_+A>P)K(\90ZAX?\
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M2O# ODE%*44M.UT8OCC]JS1O&'P+U6?3Y18>(9T%K)8LWS(6X++ZBO*/V+?
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M**[W_A07Q(_Z$G6?_ 5J/^%!?$C_ *$G6?\ P%:J#ZK7_P"?;^YG -25WS_
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MIC7$W_/:3_OHT?6O(/K'D>X>:G]]?SH\Q/[R_G7AOVB;'^MD_P"^C3?M$O\
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M_:E]_P _MS_W];_&C^U+['_'[<?]_6_QI?VROY/Q_P" +^T?[OXGZ+?;(/\
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M?_GO'_WV*_,YM7O_ /G^N?\ O\W^-)_:U_\ \_US_P!_F_QH_MQ?\^_Q_P"
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M_P"_S?XTW^V-0_Y_[K_O\W^-']O?]._Q_P" ']K?W/Q_X!^H/VRW_P">\?\
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M[K_O\W^-+^WE_P ^_P ?^ 1_:_\ <_$_4?[9;_\ />/_ +[%'VRW_P">\?\
MWV*_+C^V-0_Y_P"Z_P"_S?XT?VQJ'_/_ '7_ '^;_&G_ &]_T[_'_@!_:_\
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M"TLU;(@CRP'J:XS2YL%:9+.RLVX%:"UD6$G K5C;(J@'T444 %%%% !1110
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M"!C4E*U)04A&Z4M(W2EH9(@[T-0.]#4NA(#[IJ.I!]TU'4B8A[4-TH/:ANE
MQC4?PT-1_#0P&T445("+2TBTM !39/NFG4V3[IH$,IU-IU!(M,I],H ****
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M;R945R%A<%<<UT=G/N IB-6BF1MTI], HHHH **** "BBB@!"N:ADCJ>@C-
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MEJ*OU ^^&-]ZFMUIS?>IK=:3)8UJ8U/:F-4DLCIK=:=36ZU)(QN],I[=Z94
MQK=/PJ-NE2-_2HVH)&TQNE/IC=*D1Q?CKXL>&OAS<VL&NWC6LERI>,+$SY ^
M@K!TW]HWP!JMVEO%KBQ2.<!IXF1?S(KR3]LA0WBCPNI&0T1!_%Q77?$;]GGP
M?)\.;K4-,TT:9J5M9BY2:)V(8A02&!)&#7E2K5W4G&G:T3R95Z[J3C32M'N>
MO^(/%>F>&?#TVMWUR%TR)0[3QC>,'H1CK3?"?BO3?&VB0ZMI,QN+&8D)(5*Y
MP<'@U\U_"[Q]>6W[/OB?[3#!JJZ5*HAAOE+QE6(^4C/(%=+;_'"X\(? W2-=
MMM&L8;R\GDABMK9"EO&0>N,_UJHXN,K2>BM?\2HXR,K2>BM?\3Z!;O3:\$\+
M?%+XD7EUIEW-I^E>(M)O2ID72B/-MU)_B^;@CT-:_P 3/C5J.D^+K?PEX6M+
M>XUJ0 R3WC8CBR,XZCFM?K,.3F=_N-?K5/EYG?[CV%N](P^6O#O"GQJ\0:3X
MYMO"WC6"P,UW@07VGL"F3T!P2*TO&'C+XC3>);BPT#1[/2M+@SC4M5("RX[C
MD8%+ZQ!QND^UK:@L3!QYDGVM;4]=J*O&?A3\<M2\37VN:;KUK;M=Z9"\_GV'
MW)0@.0!D^G45R>D_';QSXVN+^?0(M%@BMF^33[EOW\H]LL,GZ5'UJG9-=2/K
M=*R:Z_H?2+4VO,M8^+UUX5^&\6O>(-'?3]6D?R4T]C]]_4'^[7!77QD^(>A:
M7;^(M2LM(DT69@3:PO\ OD4]/XL_I1/$4X[_ /#>H2Q5..]^^VWJ?0[4VO$_
MB1^T!-H>C^'Y=!MX7EUB(2K/=9*1#.,''<&K_@?QQX[N?$5O9ZSIUCJFESKD
M:EI9!2/(SSR:/K$'+E6H?6:;GR+4]:;I4;=J>>],:NDZ6,;K36IS=::U)B&-
M24K4E(!LG:HZDD[5'02QC4QJ>U,:CH-#:3L*6D["I9(QNM-:G-UIK4@&-24K
M4E3U 93'^]3Z8_WJ?4D8U-IS4VI'T%AFDMY-T;E6'H:V[/Q-T6Y3'^VM8)IK
M52DX[#4G'8[F&YCN4W1NKCV-/K@XYI(9-T;E#[&M*T\37,/$P$R^O0UM&HGN
M:JHNIT\E-!(Z<5FP^([2?&XF(_[0J]#-',-T<BN/]DUHFGL7=/8MQW<\>-LK
M#\:G76KF/KM;ZBJ=-;!:K4FB[NQI+X@D[Q*?H:=_;_K%^M9-)34F"DS5;Q >
MT/ZU&VORG[L2CZFLP]:*.9CYF7)-:NFZ,J?055DNIIOORLWXU&W6FDXJ+MD-
ML1N3254NM7M+3_63KG^Z#DUD77C"-<BWB+G^\W J'.,=V0Y)'0,:S-0U^UL0
M07\R3^XG-<I?:Y>7WWY2J_W4X%9S5A*M_*8RJ]C4U+Q)=:AE%/D1?W5ZGZFL
MG'.:6BN9MRU9E?FU9"W>FTYN]-J2!K=:2E;K24,!K?>%-?[M.;[PIK_=HZ$L
MCHHHJ1H92-2TC4!T$IE/IE)B&M4;5(U1M4B8QJ;3FIM)DC:@O(S-:31C[S(0
M/RJ>DI%%CPU=+=:):LO5%\MQW##@BM.N5CEDT.\>YB0R6DIS/&O53_?']:Z6
MUNHKR!)H9%DC<9#*:^DI5%5CS(^EHU8U8W1+1116QL%%%% !6=K^AVWB'39;
M.Z7*..&[J>Q%:-% 'S7KOA^Y\+ZM)9W X4Y1^S+ZU8T^XZ<U[5XU\)0^*M-,
M9 6ZCYAD[@^GTKPUK>?3+R2VG0QS1MM96IDG26\FY:M*<BLBSF^4=ZTXFS5
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M&8>M>Z_\(/H7_0-A_7_&C_A!]"_Z!L/Z_P"-'U2?</JLNYX.3S4>X>M>^?\
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MU_QH_P"%:^&?^@/;_K_C2^HS[H/JD^Y\OL1N'--<C;7U#_PK3PQ_T!K?]?\
M&C_A6?AC_H#6_P"O^-'U&?="^IS[H^6\BDW#UKZD_P"%9>%_^@-;_D?\:/\
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MW^-']GU.Z%]2GW1\BLP]:8V",'!'>OKS_A4WA'_H!6W_ (]_C1_PJ;PC_P!
M*U_7_&E_9]3N@^I3[H^.8?/TN5GLG4(3EK=_N'Z>AK<TS7K?4OD&8;@?>ADX
M8?3U%?57_"I?"'_0"M?_ ![_ !J&;X-^#)V4OX?MBRG*L-P(_$&N^C1K4])-
M-'?1C5IZ2=T?-N?>C-?3G_"K_"W3^QH?S;_&C_A5WA;_ * \/YM_C77RL[.8
M^8\T9KZ<_P"%6^%O^@/#_P!]-_C1_P *N\+?] >'\V_QHY6',?+US;Q7=O)#
M*H>.12K*W<5X_KFBMX?U9[0\Q-\\+'NOI^%?H%_PJ_PL/^8/#^;?XU5OO@YX
M,U+9]I\/VLVS[N[=Q^M'*Q<Q\!QL/6G[AZU]W_\ "B? 7_0LV?\ X]_C1_PH
MGP%_T+5I^;?XT^5BN?"&X>M&X>M?=W_"A_ /_0M6OYO_ /%4G_"A? /_ $+5
MK_WT_P#\51RL+GPEN'K1N'K7W;_PH3P#_P!"U:_]]/\ _%4G_"@_ '_0MVW_
M 'V__P 53Y6%SX3W#UHW#UK[K_X4#X _Z%JV_P"^W_\ BJ/^% ^ /^A:MO\
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M^"/^A<M/_'O\:3_A2O@C_H7+3_Q[_&E_9-7^9$_4*G='PX6&#S0&'J*^X_\
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M)_T+5G_X]_C7/2R[%4')TYI733]'OT+EE<JEN9K1WZ[H^#<C'6F,1ZU][?\
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M*_\ ,OQ)_LNK_,C\^0PVGD5'N'J*_0K_ (4'\/\ _H5[+_Q[_&D_X4#\/O\
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M^A4L?R;_ !H_X9[^'?\ T*EC^3?XT?V'7_F7X_Y"_LFK_,C\Z]P]117Z*?\
M#/OP[_Z%6Q_\>_QHH_L.O_,OQ_R*_LJK_,CT.BBBOM3Z@**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ino-20241231_g3.jpg
<TEXT>
begin 644 ino-20241231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+X17AI9@  34T *@    @ ! $[  (
M   /   !2H=I  0    !   !6IR=  $    >   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2F5N;FEE(%=I;&QS;VX    %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,U-@  DI(  @    ,U-@  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJG\%3RZ#JUYX-U!V;[*//TZ5_P#EK;L>GN5/'Y^E3%N^IC2G)3?,]&W\C0\
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M !1110 4444 %%%% !1110 4444 %%%% 'CU>D^$_P#D6+3_ ('_ .AM6/\
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M 'T*//A_YZI_WT* )**C\^'_ )ZI_P!]"CSX?^>J?]]"@"2BH_/A_P">J?\
M?0H\^'_GJG_?0H DHJ/SX?\ GJG_ 'T*//A_YZI_WT* )**C\^'_ )ZI_P!]
M"CSX?^>J?]]"@"2BH_/A_P">J?\ ?0H\^'_GJG_?0H DHJ/SX?\ GJG_ 'T*
M//A_YZI_WT* )**C\^'_ )ZI_P!]"CSX?^>J?]]"@"2BFF6,*&+KM/0YX--\
M^'_GJG_?0H DHJ/SX?\ GJG_ 'T*//A_YZI_WT* )**C\^'_ )ZI_P!]"CSX
M?^>J?]]"@"2BH_/A_P">J?\ ?0H\^'_GJG_?0H DHJ/SX?\ GJG_ 'T*//A_
MYZI_WT* )**C\^'_ )ZI_P!]"CSX?^>J?]]"@"2BH_/A_P">J?\ ?0H\^'_G
MJG_?0H DHJ/SX?\ GJG_ 'T*//A_YZI_WT* )**C\^'_ )ZI_P!]"CSX?^>J
M?]]"@"2BH_/A_P">J?\ ?0H\^'_GJG_?0H DHJ/SX?\ GJG_ 'T*<TL:XW.H
MSR,GK0 ZBH_/A_YZI_WT*//A_P">J?\ ?0H DHJ/SX?^>J?]]"CSX?\ GJG_
M 'T* )**C\^'_GJG_?0H\^'_ )ZI_P!]"@"2BH_/A_YZI_WT*//A_P">J?\
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M )ZI_P!]"CSX?^>J?]]"@"2BH_/A_P">J?\ ?0H\^'_GJG_?0H DHJ/SX?\
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MO*L%5(S@+GCOT.?<^%-<;3+BSL-/OX=,6>VEATZ>^C>2-EDS)Y+A_E0+C +
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M"_XT;]/_ .@O8?\ @0O^->844?VI/^4/KLNQZ?OT_P#Z"]A_X$+_ (T;]/\
M^@O8?^!"_P"->844?VI/^4/KLNQZ?OT__H+V'_@0O^- :P9L+JU@3Z"=?\:\
MPHH_M2?\H?79=CUI=,+J&2XB93T(.0:756M(%MQ>7]K:_)M7SI0F[&,XSUKS
M32-9N=)NE>)V,6?GB)X8?X^]7?B#,)IK H<H5=E/L=M>SEU6.-GR;,TEC+49
M5$M4==]JTK_H.:;_ .!*_P"-'VK2O^@YIO\ X$K_ (UX_17T']F0_F9Y_P#:
ML_Y4>P?:M*_Z#FF_^!*_XT?:M*_Z#>F_^!*_XUX_11_9D/Y@_M6?\J/8?M&E
M_P#0:T[_ ,"%_P :/M&E_P#0:T[_ ,"%_P :\>HI?V9#^8/[5G_*CV'[1I?_
M $&M._\  A?\:/M&E_\ 0:T[_P "%_QKQZBC^S(?S!_:L_Y4>P_:-+_Z#6G?
M^!"_XT?:-+_Z#6G?^!"_XUX]11_9D/Y@_M6?\J/8?M&E_P#0:T[_ ,"%_P :
M/M&E_P#0:T[_ ,"%_P :\>HH_LR'\P?VK/\ E1[#]HTO_H-:=_X$+_C1]HTO
M_H-:=_X$+_C7CU%']F0_F#^U9_RH]A^T:7_T&M._\"%_QH^T:7_T&M._\"%_
MQKQZBC^S(?S!_:L_Y4>P_:-+_P"@UIW_ ($+_C1]HTO_ *#6G?\ @0O^->/4
M4?V9#^8/[5G_ "H]C273I&VQZQI[-Z+<*3_.K\>F,&1Q-&1D'@]:\-K?\,>(
MKG2=0BA>5FLY&"O&QR%S_$/2LZN7.,;P=S:EF:E)1G&QZQ=V#7%RTBRH <<$
M^U0?V2__ #VC_.I%.Y01WI:\@]DB_LE_^>T?YT?V2_\ SVC_ #J6B@"+^R7_
M .>T?YT?V2__ #VC_.I:* (O[)?_ )[1_G1_9+_\]H_SJ6B@"+^R7_Y[1_G1
M_9+_ //:/\ZEHH B_LE_^>T?YT?V2_\ SVC_ #J6B@"+^R7_ .>T?YT?V2__
M #VC_.I:* (O[)?_ )[1_G1_9+_\]H_SJ6B@"+^R7_Y[1_G1_9+_ //:/\ZE
MHH B_LE_^>T?YT?V2_\ SVC_ #J6B@!;73V@N4D:5"%SP#[5G7-SIBW4HDUC
M3XW#D,CW"@J<]",]:NRG;$Q'85XQJK%M8O6/4W#D_P#?1KLPN'5>33=K'%C,
M2\/%-*]SU7[5I7_0<TW_ ,"5_P :/M6E?]!S3?\ P)7_ !KQ^BO0_LR'\S/-
M_M6?\J/8/M6E?]!S3?\ P)7_ !I1<Z6>FMZ=_P"!*_XUX]11_9D/Y@_M6?\
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M!O7/^<UH2>(+W[+#;696PAA)*K:LZDD]26+$G\ZQC*ERM27^9G&5.UFCHY=
MT>>\L9+6!DM6M9;EDWMF4+C ))XSGMBLY=.TN6+1KV:W>*.\9XY((')!=7P.
M6)(![\_3UJJ/%^J;K4LZO]G0H0^YA*",'?D\GWXJLVN2--:,;2V\JS!\B !P
MB$G);[V2<^IK:56@]E^'I_P324Z;V7X>G_!$\16D%CX@N[:U3RX8V 5<DXX'
M<UFU<U34FU6\:ZF@ABE?ES%N^8^O)/Z53KCJ.+FW'8YYV<G8****S)"BBB@
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MI/\ ;'PE_P"A<U7_ +^-_P#'J/[8^$O_ $+FJ_\ ?QO_ (]7FU%'/Y!]8?\
M+'[D>E#6?A,.GAS5?QD;_P"/4?VU\)O^A<U3_OL__'J\UHHY_(/K+_EC]R/2
MO[:^$W_0N:I_WV?_ (]1_;7PF_Z%S5/^^S_\>KS6BCG\A_67_+'[D>E?VU\)
MO^A<U3_OL_\ QZC^VOA-_P!"YJG_ 'V?_CU>:T4<_D'UE_RQ^Y'I7]M?";_H
M7-4_[[/_ ,>I?[:^$W_0N:I_WV?_ (]7FE%'/Y!]9?\ +'[D>F?VY\)_^A;U
M/\S_ /':/[<^$_\ T+>I_F?_ ([7F=%'.^P?67_*ON1Z9_;GPG_Z%O4_S/\
M\=I1KOPG'_,MZE^?_P!MKS*BCG?8/K,OY5]R/3X_$'PH$@_XIS4%]V&1_P"C
M37H?A+5O!M];M'X8$$+ 9>!(A')]2.I^O-?-M6-/O[G2]0AO;*0Q3PN&1@?T
M^G;%5&I9[&M+&N$KN*^2L>^>/_$OA?P]_9__  D5C?7?G^9Y/V;'R[=N[.77
MU'KTKCO^%D_#?_H!ZS_X[_\ 'JH?&R\74=+\*WL8PMS#-*H] RQ'^M>2U[%+
M X>M!3G%-L[ZU3WW9+[CVG_A9/PW_P"@'K/_ ([_ /'J/^%D_#?_ * >L_\
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MM'_"ROAO_P! 75O^^5_^.UXG11_9F$_D0>U\E]Q[:/B7\.!_S!-6_P"^%_\
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M_=N?^^1_\56911]67\TOO8?6I?RQ^Y&GNT;^[=?]\C_XJC=HW]VZ_P"^1_\
M%5F44OJR_FE][#ZU+^6/W(T]VC?W;G_OD?\ Q5&[1O[MS_WR/_BJS**/JT?Y
MG][#ZU+^6/W(T]VC?W;K_OD?_%4;M&_NW7_?(_\ BJS**/JT?YG][#ZU+^6/
MW(UX6T(N!(+E1ZE!_C7>^&++0I(?-L)A,5Z@<%?J#R*\KJ[I&HRZ5JD-U$Q
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M^PBG_HN2O2:\V^.?_(CV?_813_T7)653X688O^!(\%HHHKB/EPHHHH ****
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M,CEL] O3G.,U@ZK=Q7VKW5U;Q>3%-*SHF.@)K3&J:BKNZ:E>HTAW.RW+@L<
M9///  _"J%S%)=3--/<22RM]YY6+,?J37K8?/L'*?-.\?E_E<Y*D)."A'4H4
M5.UI(.F#^-1M%(O5#^5>Y2QV%K?PZB?S_0Y'"2W0RBBBNP@**** /;+$YLX_
M]T59JM8?\>4?^Z*LU\<?;A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5+;?\?"_C_*HJEMO^/A?Q_E0!?KS;XY_\B/9_]A%/_1<E>DUYM\<_^1'L
M_P#L(I_Z+DJ*GPLYL7_ D>"T445Q'RX4444 %:_A>\AM=>CCO&"V=XK6ER20
M (Y!M+9/3:2&_P" UD44UH.+Y7<]&M+/P_?I+9ZC=Z<UOIT/V.&03[7W",L\
MB$S*I!E9L$))GC(Q@FDJ^'"MW8AXK*U\BQ\R:"\<M.6>(RDJ6*L4R_ 7C!XR
M*X<*3T!/X4;&_NG\JKF\C?VRM\*.XN-)T*<20^5I-G?/;7!ACM]4\R$,'C\H
MF1I"H8CS1@MC@' S3-<TK0+?2-3.G?8!+#(AAF%Z)FD7$8*HHER#NWG)C8$9
M^9<"N*V-_=/Y4;&_NG\J7,NPG5BT_=.[TVVT34-'T03V^B1%()A<M+.5E=P[
M;05\^/DC!RQ [ ]%J5-+\+?V['86]O;WD4^I3@RK=.QAMTBC=0-KXVEBXW,>
MBGYAC<//]C?W3^52VT]U97*7%G+-;SQG*2Q,59?H1R*?-Y#59:7BNAZ.-%\)
M)--]LL(;<[8C'$+R,>9$5;=+&S76W)<$8WR8"C*\FJD%KX?U$Z4TEGHT,3::
MJ22?; FR?> QEC,Z,< 'D')W$X?  X6\N[W4+EKB_GGNIV #2SN78XX')YJ$
M(YZ*Q_"CF78IUHWTB-(PQ ((!ZCO13_)D_YYM_WR:/)D_P">;?\ ?)J#E&44
M_P F3_GFW_?)H$$QZ1.?^ F@!E%3)9W4K;8K:9V]%C)-=CX4^&>K:Q>13:K;
MR6-@K OYP*R2#T5>HSZG]::BWL:4Z4ZCM%!\5 5\'^!P1@BP8$?]LX:\RKV#
MX\QK%'X=CC4*B"X50.P'E5X_7U.%_@Q_KJ>K65IV]/R"BBBNDQ"BBB@ KU_4
M=3AN?&&M//?07EK<6EZEHE]XAAG@E+2H55=C*8%( ^4L#@=?E)KR"E"D] 3^
M%1.',:1GRGHD.E>$OM=QNCTQ[<3E;MFU-@;2,0(2;<;P9CYIE .'SL7CG)M6
M-EX:UB19-9N],9$TZSA!>YV2QL+4 D$S(O# #&V0YX( Z^8[&_NG\J-C?W3^
M51[-_P P_:+L>D_#;5(;#1)$>^2W8ZK"\B'4XK0&+8P9G5_]:@R,H,$\<U1_
MLOPFFD1F26T>U^SQ$ZA'=G[6TYG59!Y!;A1'O(S'T .XDX/";&_NG\J-C?W3
M^5/V?O-IA[32UCTA-*\,'5X8KBQT>,-+<J!!JXDB6$>7Y4KEKA<MDN-@="1D
M[>,$L[/PQ>+IRWUMHD:164R%[:[(\ZY6>0 .'N$.TQX<,S)G@!L82O-]C?W3
M^5&QO[I_*E[-]P]HNQU?B6/P]9:=/'H]G$\\VHS*DDEUYDEM"J0LH CD9""S
MR ,2W (R2,CDZ<(W)P%8GZ4ODR_\\W_[Y-:15E:Y$G=W&44_R9?^>;_]\FCR
M9?\ GF__ 'R:H0RBI!;S'I#(?HIJ2.PNYF"PVL\C'@!8R31= 5Z]TN 5\+>'
M%88(TV$$?]LTKBO!WPJUC6[Z&?6+:33].5@TGG*5DD']U5/(SZGU[UZ7XRC2
M*XM8XE"HB%54=  !@5\_G=2,L,XK^M4;\DE1E)^7YG-4445\.<85:TIUCUFR
M>1@B+<1EF8X &X<FJM%5%V=QIV=SJ8Y-(NH5A<[(S>RNR2SJVX^6=IXV84G
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M-2]5_E8F.&51VBCTJP_X\H_]T59J*WC\JW1?05+7IGTP4444 %%%% !1110
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MK6%VEI+##+=O*81:VMU%<3!QU4QQLS \8Y'6J=&BMTA>UJOJ=W_PO[Q+_P!
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M/_OAO_BJ47DO_/I9_P#?#?\ Q51T4?6*G</:S[DOVU_^?2T_[Y;_ !H^VO\
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MRDM<3M'YH7>I 3GYBV< <'J:/:UW_P ,/GJ_TBE]M?\ Y\[/_OEO\:/MK_\
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M;P39P:58W-[,NHH[1VT+2,%\N09PH)QDCGWK:AI51E6_AL^;:*V_^$*\4_\
M0M:Q_P" $O\ \31_PA7BG_H6M8_\ )?_ (FO;YX]SR.678Q**V_^$*\4_P#0
MM:Q_X 2__$T?\(5XI_Z%K6/_   E_P#B:.>/<.678Q*UO#&I1:7XAMIKSFSD
M)@NUY(,,@*/P.ORL3]0*E_X0KQ3_ -"UK'_@!+_\31_PA7BG_H6M8_\  "7_
M .)I.46K7&HR3O8Z_3]9\)N;NWU*\AEL[>(6=JDUD,O&L1'F*WDNX+2%GQOC
M(W9R3P*#:WX8GFGAO+6S-C'!8K"(+(1R.0T1N?G"AMQQ(,D_0\U@#P3XJ/\
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M'_"G_'7_ $ C_P"!<'_Q=;^UI_S+[S'V<_Y6<317;?\ "G_'7_0"/_@7!_\
M%T?\*?\ '7_0"/\ X%P?_%T>UI_S+[P]G/\ E9Q-%=M_PI_QU_T C_X%P?\
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M[]_SJN,[<=3[&O#S>HJU!PIZ_P##HW]C-4I76K_S//Z*W/\ A#-?_P"? _\
M?U/_ (JC_A#-?_Y\#_W]3_XJOC_J];^1_<SD]E4_E?W&'16Y_P (9K__ #X'
M_OZG_P 51_PAFO\ _/@?^_J?_%4?5ZW\C^YA[*I_*_N,.BMS_A#-?_Y\#_W]
M3_XJC_A#-?\ ^? _]_4_^*H^KUOY']S#V53^5_<)/JUE<6L[R1,;F:%4*- A
M57&U=RR9W ;5^[CJ>O>K4OB*UEED,375LSM.5GC0%X]\H<8^8=@0>1UJO_PA
M>O\ _/A_Y%3_ !H_X0O7O^?'_P BI_C6]L3_ "/[F:_OOY7]Q9_X22U_?'_2
M45YI9#"J+MN T:K\YSQDJ2>#U_&FQ>(+-8K@,+G][$(]G)5OW*IT#@=03DJW
M&.E0?\(7KW_/C_Y%3_&C_A"]>_Y\?_(J?XU7^U?R/[F/]]_+^!9_X2.(+L%W
M?+NMC"71=H4_+M(3S"!T;)!'7IURJ>);9+B*3-RR+)&X@9%VVX5&4K'\W<D=
MEX'>JO\ PA>O?\^/_D5/\:/^$+U[_GQ_\BI_C1?%?RO[F'[[^5_<*?$;30QQ
M7<MU(@A17^;DR+*&WYSUV#&>M5]?U2WU.2W:W\TF)"K/*#EOF)')=CW[FI_^
M$+U[_GQ_\BI_C1_PA>O?\^/_ )%3_&HE'$RCRN+^YDM5FK.+^XPJ*W?^$*U[
M_GR'_?U/\:/^$*U[_GR'_?U/\:Q^KUOY']QG[*I_*_N,*BMW_A"M>_Y\A_W]
M3_&E_P"$*U[_ )\Q_P!_4_QI_5ZW\C^X/8U/Y68-.BC:65(T&6=@H'J36\G@
M?7&;#6Z(/5I5_I71:'X,.FS+<W9\ZX7[H7[J^_N:UI8*M4E9JR\S2&'J2=FK
M&]14GV>7^X:/L\O]PU]0>T1T5)]GE_N&C[/+_<- $=%2?9Y?[AH^SR_W#0!'
M14GV>7^X:/L\O]PT 1T5)]GE_N&C[/+_ '#0!'14GV>7^X:/L\O]PT 1T5)]
MGE_N&C[/+_<- $=%2?9Y?[AH^SR_W#0!'14GV>7^X:/L\O\ <- $=%2?9Y?[
MAH^SR_W#0!'14GV>7^X:/L\O]PT 1T5)]GE_N&C[/+_<- $=%2?9Y?[AH^SR
M_P!PT 1T5)]GE_N&C[/+_<- $=%2?9Y?[AH^SR_W#0!'14GV>7^X:/L\O]PT
M 1T5)]GE_N&C[/+_ '#0!'14GV>7^X:/L\O]PT 1T5)]GE_N&C[/+_<- $=%
M2?9Y?[AH^SR_W#0!'4MM_P ?"_C_ "I/L\O]PU)!#(DREEP!_A0!<J&Z8K$"
MI(.[M4U5[S_4C_>H J^;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@!W
MFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@
M!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTV
MB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH \K^-NNZOI7]B?V7J
ME[9>;]H\S[-</'OQY>,[2,XR?SKRG_A-?%/_ $,NL?\ @?+_ /%5Z/\ 'W_F
M ?\ ;S_[2KQVO9PT8NDKK^KGE8B355ZFW_PFOBG_ *&76/\ P/E_^*H_X37Q
M3_T,NL?^!\O_ ,56)171R1[&'-+N;?\ PFOBG_H9=8_\#Y?_ (JG?\)OXJ_Z
M&75O_ Z3_&L*BCDCV#FEW-W_ (3?Q5_T,NK?^!TG^-'_  F_BK_H9=6_\#I/
M\:PJ[G0/AO\ V[IWA^Z&J^1_;-S-!M^S[O)\M7.<[ANSLZ<=:F7LX*[14>>3
MLC#_ .$W\5?]#+JW_@=)_C1_PF_BK_H9=6_\#I/\:V;_ .&UQ8'7]U[YHTJ*
M">V:.#(O8Y6PK+\W'_CW((J8?#FT'B=?"\NO[-?:'=Y0LR;<2[-XC,N_.<8Y
MV8Y]>*CFI?TBN6H8'_";^*O^AEU;_P #I/\ &C_A-_%7_0RZM_X'2?XU4T[0
M+_4O$L6A0QA+Z2X^SE7/",#ALD9X&"3C/2MK6/!2:9K%OIWVN[MGFF>,76K6
M/V*V94ZNLA=BPZ?P@\CN<5;]FG8E<[5RA_PF_BK_ *&75O\ P.D_QH_X3?Q5
M_P!#+JW_ ('2?XUN7GPRN(OB%;^%[+45N?-@6X>[: H(X\$D[023P.!W) XJ
M*+P"LVK3V[7&IV-M:64M]=3:EI1@=8DXS&GF'?D^I7O4\U(KEJ&1_P )OXJ_
MZ&75O_ Z3_&C_A-_%7_0RZM_X'2?XT[Q/X7_ .$?ATN[M[LWECJEL+BWE:+R
MW']Y64,V",CH2*P*N*A)72(;FG9LW?\ A-_%7_0RZM_X'2?XT?\ ";^*O^AE
MU;_P.D_QK"HI\D>PN:7<W?\ A-_%7_0RZM_X'2?XTJ^.?%:,&'B35LCUO9"/
MR)K!HHY(]@YI=SU/P9\9M6M;^&S\3W!N[.1@IN2,20Y[DCAAZYY_E7N@F<C(
MD8CZU\<5]7^%97G\&Z++*VYY+"!F8]R8U)->;C*48VE$[\+4E*\6;'FR?WV_
M.CS9/[[?G3:*X#M'>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@!WFR
M?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@!W
MFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTVB@
M!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WYTV
MB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^WY
MTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3^^
MWYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\V3
M^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OSH\
MV3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]OS
MH\V3^^WYTVB@!WFR?WV_.CS9/[[?G3:* '>;)_?;\Z/-D_OM^=-HH =YLG]]
MOSH\V3^^WYTVB@!WFR?WV_.I;>1VG4,[$<\$^U05+;?\?"_C_*@"_5>\_P!2
M/]ZK%5[S_4C_ 'J *=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRG1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?[AH CHJ3[/+_<-'V>7^X: (Z*D^SR_W#1]GE_N&@".BI/L\O]PT?9Y?[AH
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M_OM^='G2?WV_.F44 /\ .D_OM^='G2?WV_.F44 /\Z3^^WYT>=)_?;\Z910
M_P Z3^^WYT>=)_?;\Z910 _SI/[[?G1YTG]]OSIE% #_ #I/[[?G1YTG]]OS
MIE% #_.D_OM^='G2?WV_.F44 /\ .D_OM^='G2?WV_.F44 /\Z3^^WYT>=)_
M?;\Z910 _P Z3^^WYT>=)_?;\Z910 _SI/[[?G1YTG]]OSIE% #_ #I/[[?G
M1YTG]]OSIE% #_.D_OM^='G2?WV_.F44 /\ .D_OM^='G2?WV_.F44 /\Z3^
M^WYT>=)_?;\Z910 _P Z3^^WYT>=)_?;\Z910 _SI/[[?G1YTG]]OSIE% #_
M #I/[[?G1YTG]]OSIE% #_.D_OM^='G2?WV_.F44 /\ .D_OM^='G2?WV_.F
M44 /\Z3^^WYT>=)_?;\Z910 _P Z3^^WYT>=)_?;\Z910 _SI/[[?G1YTG]]
MOSIE% #_ #I/[[?G1YTG]]OSIE% #_.D_OM^='G2?WV_.F44 /\ .D_OM^='
MG2?WV_.F44 /\Z3^^WYT>=)_?;\Z910 _P Z3^^WYT>=)_?;\Z910!\^?$_Q
M!K5G\1]3M[/6-0MX$\K;%%=.JKF)"< ' Y)-<E_PE7B'_H/ZI_X&R?XUN?%C
M_DJ&K?\ ;'_T2E<=7NTHQ]G'3HCQZDI<[UZFK_PE7B'_ *#^J?\ @;)_C1_P
ME7B'_H/ZI_X&R?XUE45IR1[&?-+N:P\5^(ATU_5/_ R3_&E_X2SQ%_T'M3_\
M"W_QK(K8\)Z!_P )1XILM&^T_9?M3,OG>7OVX4M]W(ST]:3C!*[0U*3=DQ/^
M$L\1?]![4_\ P+?_ !H_X2SQ%_T'M3_\"W_QKI+CX8S)X(NM?M=2%Q+;2S!K
M,088QQ2;'D#;NW!(QP#UHOOAH--O-2:]U?9INF6D-Q<70MLNS2CY(TCW8))X
MY8#G-9\U'^D7RU3F_P#A+/$7_0>U/_P+?_&C_A+/$7_0>U/_ ,"W_P :N:[X
M473O#NG:_I=\;_2[YFBWR0^3)#*I.49-S#H,@@GH>G&;O@/P!)XTN'\W4%TV
MV#^3',T7F&6;:7V*NX=$5F)SQQQSQ3=)1YGL)*HY<IC?\)9XB_Z#VI_^!;_X
MT?\ "6>(O^@]J?\ X%O_ (UTGAKX:/K^CZ;>R:A-!_:<DR0F&R,T4/ECK-)N
M7R\D''!XY]<&G_#/[7_9=K<:PD.J:Q!+/8VZ0>9$RH"1OEW#;NP<85N!^%3S
M4EI^@^6JSF_^$L\1?]![4_\ P+?_ !H_X2WQ'_T']3_\"W_QKI++X9_:TL[1
MM6\O6;W33J4%G]FS'Y?\*M)N!#$ \;3C'6N:TOPW?:OI5]J%J]JL%BH:7SKE
M(SR0. 3_ +7!. <$ D\52=)B:J(7_A+?$?\ T']3_P# M_\ &C_A+?$?_0?U
M/_P+?_&IYO!^IPV.EW7F6++JA(MU%[%G(SU)8#MC@G!^4X;BJ.MZ-<Z!K%QI
MM\T+30.58PRAU.#CMR.G0@$=P*:5-NRL)N:W)_\ A+?$?_0?U/\ \"W_ ,:/
M^$M\1_\ 0?U/_P "W_QK(HJN2/8GFEW-?_A+?$?_ $']3_\  M_\:FMO&WB>
MTE$D6O:@6!_Y:3LX_)LBL*BCDCV'SR[GO7PU^*ESXBO1HVN;5O64F">,;1-@
M9(([-CGC@X/3OZ=YTG]]OSKY2\%RO#X[T-HVVDW\*DCT+@$?D37U57DXJG&$
M_=ZGI8:HYQU'^=)_?;\Z/.D_OM^=,HKD.D?YTG]]OSH\Z3^^WYTRB@!_G2?W
MV_.CSI/[[?G3** '^=)_?;\Z/.D_OM^=,HH ?YTG]]OSH\Z3^^WYTRB@!_G2
M?WV_.CSI/[[?G3** '^=)_?;\Z/.D_OM^=,HH ?YTG]]OSH\Z3^^WYTRB@!_
MG2?WV_.CSI/[[?G3** '^=)_?;\ZDMY':=0S$CG@GVJ"I;;_ (^%_'^5 %^J
M]Y_J1_O58JO>?ZD?[U %.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_Z&<?\ @!_]LK3ZU1[_ )D?5ZO8\4HKVO\ X9V;_H9Q_P" '_VRC_AG9O\
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M1/)A<XX(+AVQN&2JD#/)X.)8_$HN+]X;/2=1N;:.9[=KV-(_)\Q<AEP7#G#
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M3Q1::5=SVLEO<3W$2VQ6.+8/-:>1XXU4LRC.8VSN('(P23BCE8<R-JBLB_\
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MW>DV]O:R*ZI9Z3Y/D$/NW0'S28G.2"?F![ <YZ^BBI<F]QI);!1112&%%%%
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M=X_A[ @]-11S,.5'-OX6N4\,Z7IMGJ,:7&FS1S)/-;F1"5S\NP."%YP!NX
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M5H[:WS)#;!0UU"05N"N<$MT9?XA_%D9J"7X<F:U*R2Z*96U(7SPG1_\ 1'Q
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MO^U2:Q#K=M?ZCK-O#A4MYH(PLH+",1;D?9C&?,![YPW3B@#KZ*Y.6'Q)Y#+
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ino-20241231_g4.jpg
<TEXT>
begin 644 ino-20241231_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX*M>*?!UC_P2K_:%\2:YJ5M)I%S\#/$PCG\Q6CG\[2KA(0C="7=T5<=2RXH
MXO\ :X_X*R>'/@M_P3PT_P#X*:_LQ?"RV^,_PWNK>TNKG^RO$S:=>K;W-W%9
MQM%"UI+YCI<2^7-$QCDB*L"K%6"Z'[ 7_!5/X>?\%-/V*+C]J;]D[PC:7GB;
M35>WUWX<^(/$7V2;2]10;C:S7,<$N%=/GBF$160$ A"'"?!?_!OOX$^)/A3_
M ((&>$KGXC6=Q'I_B#]I_P +:CX3ANU(!TMO&7A^'*JW1&N8;MAV.[<,ALGS
M;_@H%^SA\8O^#;K]O1/^"H?[$/A*YU#]G?XD7PT[XM?#JP.VVTEYW),*K]V*
M)G9I;27A892T!Q'(J2 '[4_LJ?&+Q;^T+^SMX.^.WC'X?6GA:X\8^';/6K;0
MK373J)M;:Z@2>)))C!"#*$D =54JK @.XYKQ3]I7_@JGX ^%/[9'A;_@G3\!
MOAQ=?$WXW>)[0W]QX:M=633]-\.:>(S*;O5;YDE-LIC&]8XX9I6!3Y/WD0D]
M2_8%_P"3%/@K_P!DE\.?^FNWK\DO^";>C^)?AI_P=Z_M-:1\<4DBU;Q)X(UJ
MX\(2WN<W-K-=Z/<VGDD_>"V$;K\O01.O\)  /T/\7?\ !5;2OV</VPO!/[&G
M[=/PB@^'.I_%)&7X9>-=%\4'6?#VM7:2)&]A)<2VMI-:W0>6%0KP&-C-&!+E
M@#Q'[>?_  69\:?L1_MY?"W]A#_ADVR\4ZI\8[FU@\%:_'\1&LK='GO/LBB\
M0Z=(T&),$^691M((R<J/C/\ X/,-(UKX@6?[+/P>^%]K->>/_$'Q U2+PG86
M!/VJ25EL(5$>.03/+;@'U ]*I_\ !?;3_&=Q_P %Z?V#-+T#Q'966OM?Z3':
MZM>::UU;PW7]N(!,\"R1&5 _S%!(A(XW+UH _4+P/^U1^U3%^U%X?_9[^/'[
M&=AX9T?Q+HFH7FF^/O#?Q(76;$75JL3M8R1/8VTT<K)(74LH4B-MI;:<=%^W
MC^UL_P"Q1^S;JWQSTKX/^(/B)KD-W:V'AGX?^$X))=3\0W]Q,L:6ULD<<CLP
M0R3-M1B(X9&P<5SO_!/OX6?M/?#/2/B=8_MA>/;+QAXLO/BY>ZCI_BK3]#.G
MVE]ITFFZ>EJ;:W9G\A(XE^SE0[X>"0&20Y=N4_X*R?\ !,"?_@J+\-/"7PW'
M[5/BWX7?\(EXAEUJQO?"<*-)<7QMI+>)W)=''EQRW  1U)$S9- &'_P32_X*
M<_M2?MX?$KQ#X0^,O_!*OXI_ 71M!T1;R/Q%\2([JW34+EYE1+6WBN+&W,IV
M>:[,K'8$4$?.M=-_P5C_ ."B/Q#_ ."87[.C_M3Z9^RS/\2_"6F7L-OXI.F>
M*Q87>D+,_EQ7#1M:RK) 9"D;.'#*TJ?*5+,ORW_P1^LO^"FW[#O_  44\9_\
M$K/VT?C]>_&;P*GPJ_X3KX=_$75))9KJW@748;'[/)).SRQ[R\N;>2641FW4
MQ-L=C7Z4?%[X4> ?CO\ "OQ%\%OBIX>AU;PWXKT6YTK7--G'RW%K/&T<B9Z@
ME6.".0<$8(% 'C'P8_;_ -$^-_\ P3:T_P#X*)^%] \/QZ?J'@:7Q*-'F\62
MFVMEB5FFM)KQ;,LL\1CDB=5MVQ-&4&X8:O%_^"AW_!8OXR?\$TOV+/ _[9'[
M0/[#]OY?BW6+32M3\&V/Q+SJ.AWES;7%S%%*S:<(I"L=LRR;6^20[5\Q1OKX
M,_X-Z?!?Q0\!?MR_'#_@C'X\^(PU_P"%7P+^(EUXPTV&6 ^;J=Y9WR6UM!)D
MX2V\XVM^T2C N;-,$H\@?W3_ (/0/^44?A3_ ++EI'_IKU>@#ZXN_P!OK]K[
MP[I/PR\>>*/V#M%N/"/Q"\1^&=.O]8\+_%T7UUX;MM;NX+6VO;JTFTRW9XUD
MN%#")FY!R0H+#Z>^(_Q"\'_"3X>Z[\5/B%KD.F:!X:T>YU76]1N#A+6TMXFE
MFE;V5$8GZ5\:?\$^?"_Q[^!">.?C[^V/\8-)U[X>R? CX>W_ (1U2U\--IUI
MHEC86^L375JT1EF,T\+21SM,&+/Y\6%3:J#T/_@HCXCT+XE:OX0_8WUOX:^(
M?&'A[Q3<-K7Q0T;PSIANY6\/6; Q6LJJR[$N[_[-$03B6W@O4YYP =_^P#^V
MM\,?^"AO[)'@[]KGX26\MKI7BNQ=Y=+NIE>?3;N*5X;BUD*\%HY8W7.!N7:P
M&&%?-WQ2_P""ROQ0\!?\%6M%_P""2NB_L@:-J7C+Q-HLVK^'O$ES\4)+;3);
M1+*[O/WV-*DEAE,=G*NP(Z[RHW[26'Q9_P &U7Q:\3?L#?\ !0'XY?\ !%/X
MP1:SIMC/J\_BKX4P>)K;[/=31K&K,K1DG$EQIYM;G:IVJ;6?DDFH?VX(_C%+
M_P '?WPN_P"&?M0\.6WC-?@S>OX>;Q=83W.FO<+X?UYA%<);S12!' *>8KYC
M+!]DFWRV /T,_9?_ ."OG@'XT_MX^,O^"9OQG^"^M?#7XQ>$+#^T(]*O=3@U
M'3=:LS%%.);.\AVESY,T<NQXT;86_B1U7ZP\7^+O"_@#PGJ?COQOX@M-)T71
M=/FOM7U2_G6*"SMH4,DLTCM@(BHK,6/  )K\4O\ @W^\5^%_VN/^"N7Q\_:>
M_;]-YH7[8/AR272O^$ $"6FDZ9I$<4%C*]C$6>622$1+ Q>1QY<ZR R&9G3[
MA_X.._#OQ3\4?\$5OCMIGPABNI-330+*YOH[('S&TR'4[2;4,8_A%HDY?U0.
M.] %C]E+_@JI\:/^"B+:S\1/V!_V,[37/A1I.K3Z;9_$OXG_ !#D\,QZ_<0G
M$ITZR@TR_GEB!('F3>0,DJ<.KHNAX\_X*G_$'P1^S?\ '?X[ZI^QAK6D:E^S
MY>^5XN\)^*_%4%I-J$":=%?27-C<6L5U%/$8YXS$6*>8-V[RF&RN3_X-F/$G
M@KQ%_P $2O@FG@F2#9IUCJMGJD$)&Z&]75KPS!P.C,S>9SR5D4]"*]'_ ."S
M&GZ-=_\ !*7]IV70+.UDO_\ A4>M#57M$4S;H]/:0"4KSE8F# -T1@>AH M?
M\$S/^"@OCO\ X*6?L967[8WA'X Z7X5LM?EO8O"VB:IXWDGDN7M;J:UD^TR1
MV %LIDA;:468E>2HZ5SOC'_@I-^T-X/_ ."?R_MT']BJPU&=M8ALHOA[IGQ*
M:349_.U:/2H1%)_9HB>5[B13Y>0-A!WECL'F'_!JI+%)_P $//A,D<@)CU+Q
M(K@'[I_MV^.#^!!_&N\\%NEQ_P $O/A5J,#AX+[XN>!;RTE4Y$L$WQ#TR6*0
M'NK(ZL#W!% '8?\ !(O_ (*G?"[_ (*W_LN3?M%_#WP9<>%[S3/$5SHWB#PK
M>ZDEW-I\\822-O,5$WI)#+&X;8!DNO)0FO%_@]_P7LMOV@/^"IVH_P#!,?X4
M_LJS236+7D\'CS6?&HMK2]T^WB\PWD4$=G*[)*N&A&[$B.C[E5N/AWX/^#?C
MO_P28_X+U?&+_@GG^SSH>H6_A+]K'0?[0^&UQIL8$?AR:>263^TU4_*(]-4Z
MN-@Y9((<]0*ZCX#>!O"WPP_X/(-:^&O@;2(]/T3P]\'+'3-'L(L[;:U@\*Z=
M%%&,]E1%'X4 ?:MO_P %F_'EQ_P5RG_X)$)^R3IP\40:?_:3>+C\2'_LXV7]
MGK?!]G]F^;YGEL$\O&/,R-^WYZ^CO'/[0_QG\,_MA>$_V9="^!FAZCH_BOPK
MJWB"/Q=/XXDMY+2UTV?3+>Z1[,6#YE,NJVPC592KJ'+-'C!_+2TBDL_^#UFZ
M>[0QB[^& :V+C'F@>&D!*^O*./\ @)]*_3_QTR2_\%)?A:D3AFM_@?X],ZJ<
MF,2:QX/V$^F[RY,>NQL=#0!\_?L\_P#!9OQU\?/^"IWCG_@E?%^R3I^E>(_A
MUI\VI>(_%#_$=IK)K*-K,;[=!IJR22,+Z B-A&/O L,9/WC7XG_\$[O^5P?]
MJS_LF-W_ .A^'*_9&Z^)O@VT^)UI\'Y=64Z_>:!<ZTEDHSY=E!-! TCG^ &2
MX4+G[VR3'W&P >0_M1_\%%_@#^R7^TQ\$?V6?B;J?E^(?CCXCN]*T!A.JI9>
M3;DI+*.3B:Z>VM8QQN><G.(V%=9^US\>OB%^SU\,;'Q5\*/@9<_$;Q'JWBC3
M=$TGPK;:W'IWG27<XC,SW$D<BQQQ)OE=BIPD;'M7XT?\%ZO@[XI_;5_99US_
M (*3_#3X5?$*'QOX"\9QZ_\ #KQ=:Z$ZV,'@*R4I%-#<!^$E<-K2R[056XV'
M[HQ^LW_!+;]MKP__ ,%$OV#?AS^U?IKVXU#7]$2/Q-9P8Q9:Q;DP7L07JJB=
M'9,X)C=&Z,* /G7_ (?7?'@?\%,!_P $IC^POH ^)9T'^UOMW_"XG_LGR?L/
MVW;Y_P#8_F;_ "^,>5C=QG'-:7[6?_!:'XL?L:?L-ZA^VA\9/V%9+)_#OQ#N
M/"/BOP4WQ%3[99W"W#10W,$RV+17,$JA) V4.R5" V3CY*?_ )764_[)A_[K
M1KW3_@[I55_X(T>(BJ@9\>:"3@=3]H- 'H/[5_\ P6?^+/[)W_!-OP!_P4R\
M0?L/Q:]X2\:Z=I.H:AI&B?$<F[T&TU2WCFLIKAI--5&!,B0R;3\DLD8!D#%E
M^B?AC^V!??%?]@73/VX_#7A7PR(=7\!)XLM=+F\9R+8Q69MQ<LDU]]BW1.D6
M\/\ Z.0LB%2< L/-?V:_V;/ ?[8?_!"[X6?LO?$N$-HOCG]F/PUI-W+Y89K9
MI-"M1'<(#QYD4@25/1HU-?G3_P &\OQ3^-_BWX=^,O\ @@_\<_#M\FH?!WXI
M7$WC"[>-C;1^%8;J26ZTT.1M<7&IQQPE#CS;/4KADR(C0!]M?MS_ /!9;XQ_
M\$^OV#/ _P"W5\>/V&8H;;Q?J5E97W@F#XDG^U-%EN[>:X@6;=IHC9A'"1(H
M;,;L%&\ L.YF_P""@_[7FC^#_AE\5]=_8+T:[\'_ !#UOPO:WNI>&/B\+V\\
M.6>N7=O;6]]=6DNF0,\:/<KN$3-C:W(56<?+7_!Y7_RB4T?_ ++)HW_I%J5>
MX_\ !-OPM\?/@9HOBG]H3]L'XP:3KGPU?]G#X;WWA*_MO#3:?::#9Z=;:U/>
M6SH99O/FB\V"9I]VY_-C 1 BK0!]A_M!?%2;X%_ 7QO\;;?PI<:])X.\(:EK
MB:':2[)=1-I:R7 MD;:VUI/+V [3@L.#TKX4_:N_X+C?M"?L6_&#X(? CX\_
M\$]-.L/$_P >=2AT_P +Z?9_&-;@:9<R75K;>7?NNE[8]LEW'DPF885R"< '
M]&2JR(5=00PP58=17XH_\'+7_*7'_@GI_P!E/@_]/^BT ?I!X2_;Q\2^"9?B
M_<?MQ_!?3_@_I'PB\/Z9KU[XG7QD-9TW5=,O!>#[1!(MK!("DEE)%Y1C\UG*
MA5.Y-_$_LY_\%*_VC/VS/V<[[]L#]E;]A(ZI\/I7NF\'Q>+OB(NDZ_XIM[:1
MXY)[6QCL+F&,.\;K$L]U$9"O/EJ58^4_\'5_@GXE>-/^",'Q!_X5Q:7,\6F:
MWHNH^)[>T4EY-+AO4,A('+)'(896[*L3,<!2:]N_X(:Z[X7U[_@D!^SMJ/A.
M>%[2+X6:9;3-"PVBYAC\FY!QW$\<H/N#0!C?"O\ X+'_  F_:I_85D_;&_8D
M^%NK_$+68O%>E>&;GX87]_%I.JV&K7NH6MG]GNW82QP",70G,OS1F-&.X8;;
MYSK_ /P6O^//AK_@I?X>_P""4^J?L+: /B7XET%]6L;U/C$YTF.%;&YO2LD_
M]C^8'\NUD&!$PW%1G!)'R1_P:0>'_%&N_M-_MD_&?PI%)_PK;6O'EO;:)<J#
M]FO+I+W4IU\H_=)CMYXBV.@N(_45J?&/_E=9^%'_ &3"Y_\ 4:UF@#]6/V1O
MV@/B7^T#X1\27?QA^ D_PW\2^%?&5WX?U3PY-KZ:FK>5%!-%=17"11AXIHKB
M.1/E!VL,X.0.9^!W_!1?X _'[]M[XN?L'^!]4W^+?@_I^EW6M.9U,=Y]J1FF
M6$#K]F9K>.4YXDN N 5-=U^U1\;9?V=/@'XC^*^D^&WUK6;6V2V\,Z!"#YFL
MZS<R);:?8KCG,UU+!%G^$.2> :_!_P#:Q^W_ /!%_P#X*Z? C_@I3X>\#^/-
M*\%>-[*'PW\=M:\5Z UF=<U.8%=5U JKL&DG0I?B,8S/:.>AX /UD_X+%_\
M!5+4O^"1GP(T7]H[6OV?(_'?AO5?$UOH$\5GXN_L^]MKN:"YG1A&UI*CQ;+9
M@6\P,&91L(RP^B_V=_B5XM^,GP3\,_%GQGX*L?#UWXET2UU2/2+#6VU!;:*X
MA25$:9H(,N ^& 3:".&8<U^8/_!Y=>V>I?\ !)/PIJ.G7<5Q;W'QIT:2">&0
M,DB-IFJE65AP00001US7Z)_ [XB^#_A#^P3X.^+'Q"UF/3M \,_"+3M5UK4)
MC\MM:6^EQRRR'V5$8_A0!ZIKLVN6^CW,_AK3K2[U!(6-G:WUZUO#+)CA7E2.
M1HU)ZL$<C^Z:_/K]A[_@MS\>/V__ !-\:?!WP(_8"L)-5^!>K1:;XHTN_P#B
MZL4^I7,DE]&B6!;3/*DR^GRC,TD ^>/U;;^AMM.+JVCN1$Z>8@;9(N&7(S@C
ML:_FN_X)N?&K_@H#^S;:_P#!2?X^?\$^O#_A'6]>\+_$:TNM?T7Q%H5S>7?V
M#[?XC\R]L3%<QH9K90\IAECD6102.8_+F /VH_X)Q?\ !5WX4?\ !5#]F[7O
MC-^RSX*O+7Q+X8U,Z7KW@;QQ>?V?+8WVT.JR3P1W \IUW%)51B2C*RJ58#Q;
M_@G'_P %POCK_P %1?ASXQ^)7[-_[!^A6EKX)UJ+2M2L_%?QF^QSW-U*FZ-(
M-FDR1MN.%!=T^8@>]<[_ ,&IWP\_8WT'_@FV/BC^S%XQU?6_$_C'7#<?%Z;Q
M!<1M>66O11JK6>R, ) JMYL).6=+C>QRQ1/S[_X-I_A1^U?\2_V>_&%Y\ ?B
M?9:?X;T/]JSP+J7Q \*KX=::]UO3(-3M)9O*O!+_ *-'$J">1?*)=('!=5)5
M@#]B?#'_  4(_:3\??!SX6^*?!/[!-\?'/Q!\8>(-!U[P-K7CR&TC\)'1[N]
MM;FYNKY+6198O,LP 8XSN-Q&%WY!/C_[/'_!;?X__M/_ +8WQ<_89^%7[ VC
M3>.?@U#<OXD%[\8_)L[UH+A;<I:2G2<NS2.NWS5B7')*U]\>$_%O@GQ)J.NZ
M)X1O[::?PWK+:?K<5O'C[->R007C1GC!8QW4,A(SS)SSG'XU_P#!%#_E9;_;
MI_WM4_\ 3U;T ?1W[='_  7Z\5_L(?LZ_!O]HGXB?L-7=U!\71):CP[_ ,)^
MMOJ&@ZG$%\ZSN5:Q*,%8E?,5^2C95>"?K;]J#]HKXZ_LY_ 73_BU8? /P]XD
MU=];TO2]6\.V_CZ6VC@EO]1M]/@:"Y?3CYZB2YC9]\<15%;:'( /Y<_\'HD#
M0?!/]G;4FBV6T'Q0O!--C"(6MHV&3VR%8_\  37Z@?\ !0YT/[-]M:%P)+OX
MH^ [:W4G[\LGB[2$11[EF% '@7_!1#_@LA\0/^">7[27P6_9K\7?LFZ5XCO_
M (Y:K#I7A?5-.^),D-O9WQN+.VE6Y#Z676)9;V/$B!V9 6V*WR5NZA_P6&T?
MX,?M^^#/^"=?[9G[/E]\/?%GQ'L8YO /B?2/$D6M:#J\KN\2V_G^5;SPR-+&
MT2AX!EBF=H=6/P__ ,'0L.M7'_!3#_@GU!X;U"UM-1?XG2K875]9M<00SG6=
M "/)$DD;2H&P2@D0L 0'7.X<K\&_%GB#]JW_ (.7;/X??\%F#9>&/B/\(;*,
M_L]:%X/M6L_#6O/#+-=0W1>X>6>661'6ZB'F -);M$VUHA"X!]F?\%$/^"_&
M@_\ !,']LKPQ^SC^U#^R[?1^"_$Z6EU'\4?#_BG[7#I]E<3SP++<V9M$=)%-
MM,[0K(Y*(QC:0J5KZC^,_P"T_P#$7PAXL^$ME\$/A7X;\=^'OBSKHTS3O$I\
M>M91VN=+OM5%T%CLKA9[=K2PE*NCY9WC7:%8R#RC]K_]A[X&?\%$?C!\:?V6
M?V@="^TZ-KGP7\%-9W\*K]JTB^35/%?D7ULQ'R31L<CLRED8%'93^;G_  2-
M^)W[:7[#/_!23X8_\$'/VS-+GUBT\#>/]6\5?"GQD&;RIM%'A;Q#$4A+\R6L
MAN!)&,[H)$GA;. L8!^G'Q__ ."M_P"SO\(?C7I/P3\%:MHGBR]T[QZ/#_Q?
MF3Q3#8?\*[L_[+N]1;5+U)D_>0+%:.&8%4!#*9!(%C?Z$^"7QM^%7[1WPJT3
MXW_ _P ;6GB/PIXCM/M.B:W8;O*NHMS(67< PPRL"" 00017S-^VO_P2HUO]
ML'XP^(?B[:_M/3^$9I? <&F>!;.P\$6EQ_PCGB&.^BN#X@>1G5K^1H($LO(E
MPHMY;F,-MG<5]7^"_#S^$O!^E>%Y;J&=].TZ&VDN+>QCM8Y61 I=88P$B#$$
M[%^5<X' H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MIEQ<6]I;O=74Z111(7DDD8*J*!DDD\  =Z 'T5R7P)^.?PJ_:7^$.@?'CX(>
M,;;7_"GB>P%YHNKVF=EQ$25/! *E65E92 0RD'D5UM !1110 4444 %%%% !
M17S3\8_^"MO[$WP#_:MT/]B/XH^,/$]A\3_$_DMX;\,0_#_5[AM4CEEEBCE@
MEAMFBDC9X91O#[1Y;9(VFOI.WF%Q DX1U#H&"R*589&<$'H?:@!]%%% !117
MC'QZ_P""@'[+/[-'[1'PQ_98^,7Q ETWQI\7[V:T\#Z;'I5Q.EU+&47$DL:%
M(0SR(BER,LWH"0 >ST444 %%?+GCS_@L7^PW\-_VHI_V+/$_B+QPWQ1@M&NO
M^$-TGX4:_J%Y-;K"TYGA6ULI!/'Y2,^Z,MPI[C%;?A#_ (*M_L$?$;]F/Q?^
MU_\ #7X]0>(O O@!)'\;7FCZ)?2WVB*@RYNM/\D7<&U0S'?"#M1FZ*2 #Z(H
MKA/V9OVE/@Y^V!\"_#W[2/[/_BA]:\'^*;:2?0]4ET^>U:XC29X6)BG1)$P\
M;C#*.F>A!KNZ "BBB@#YJ^,G_!*7]ECXI_M)+^V5X.E\5?#/XM/:&TU'X@?#
M#Q VF7FJV^%'DWL3));7BX2/F:%V/EID_(F/2_@U^RSX!^#WBBZ^(\_B/Q+X
MN\7WMB;&X\8>-M::_ODM"ZN;: 86&SA9T1WBMHXDD:-&<,R*1Z510!\ZZE_P
M3(^ &D?M!>)?VIO@'XF\6_"/QWXVA6/QQJ_PYU*WA@\0E2S++=V5Y;W-G)."
M[D7 A6;,CDN2Q)W_ -E;_@G_ /LV_L<S^+?$GP;\.WY\7>/K]K[QO\0-?U)]
M1US7+HEB))[JXW9"EB5B55A4DXC&3GVNB@#QSPE^P_\ "#PY\)OB!\#==UGQ
M)XH\*_$V;59O%ND>*M7%VD\FI^9]N,;;%:%9?,8^6A$:$Y14YSSG[8'_  3"
M_97_ &W_ ( :!^RK\;=)UI/ASX9-F=)\)>']6-A;QFTA:&VR\2B4B.-BH3?L
MX!*D@$?0U% 'S/\ '#_@E)^S1^T=^R-H'[#'QCU_QIJ_PS\-06,&FZ#_ ,)
ML$AALHTCM(Y;F*)9Y5B5!MWN2QY<N0I'LO[/7P-\*_LT_!KP]\!_ 6KZM=>'
MO"FDV^E>'HM9NUN)K.QMX4A@MA*$5I%1$ #2%G]6/&.SJA/XI\-VWB>V\%7&
MO6B:Q>V$]]::6UPHGFMH7ACFF5,[BB/<0*S 8!E0'[PH X#X)?LK>#?@/\1O
M&_Q/\,>./%FI:C\0]675/%$?B#61=PS7B0Q6\<L:L@-N$@ACB6.(K&$4#9D
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M(J?LP_LS:7K'P_\ @%\7_C'X4^'FO:A->:C\+='^)%Q'HNZ7 E2([?MENK@
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M+VSBM799/D*^:""1QR,@'UE1110 4444 %%%% !1110 4444 %%%% !1110
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M%#X;?%"?P/X;U-M(BLK?59YDL3;W-W!:B.,>4;N9F6(1AU@1?E9B]>M^%_\
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M1Q\'_P#!([5OVX[&&Q\*>+7U=?&8^%QD>2W^TW-REHEL-23:1+=2$RM(Y88
M5<9K[)_:(_9+\:_M ?\ !/OQ+^Q/<_%S3-+U3Q3\.I?"=_XQ3PG)-!''+;?9
MI;B.Q-ZK!C&6*J;@A6()+ ;2 ?DAXA_X*\_\%;/AU^QG^QK^W5?_ +3_ (9U
MI_C9X\N/#OB;P#<_#FQ@T^ZA%]+!'/-<1C[0LN$;)MVA0#RQL8J[2_6W[&?[
M<'[;.B?\%Y_B[_P3"_:)^.]E\1O"&E?"^V\5^&]1/@^STF;2[IETUWMXQ:C+
MP'[;, )GED 2/]X2&+8?CK_@W0^(GC/]BC]G3]C5?VZ](M8/V>/&-SX@TSQ
M?A#*[ZS(]V]S#%+#_;($2H9'5BK,7&TC9@[O;O __!)7X@>%O^"O7B__ (*L
MZE^U3IUQ)XQ\"_\ "*W7@BP^'TELUK:BWM(UEBOFU*3$P>S1\M 5PS+M'#
M^$_VN_\ @LW_ ,%,_P!DGP-X+^+WQ=\>Z7H7Q+C_ &A#X9^(?P&TJWT;6_#M
MEX>FCFEM%DU&SMI+BQOGCA^6*6^\Z1=\X@6/")]<_M&_MV?M*?'3_@K-K_\
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MO_Y7&?V9?^S=;_\ ]$^+*SYO^#6+XFW7['^G_LH:E_P4YU&]M_#_ ,93X_\
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M?_!&/XL^*O\ @I%I?_!4O]B']L.W^$WQ*N]#BT;Q_:ZGX)&LZ9XAMDAC@WM
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MU2_\*>+K*&T\/> [RTTG?HUQ:Q16]_+=3VEK'(T\E[%<LB;PBP21L4#.$B]
M\>_LM?M!_$/X2:%\)/$W[46G:I;7FM17?Q5N=9\"/+_PE5EYBO-I=M%#?PQZ
M;9RHH@:/;<%H=RNTCR2R/\L_LG?\$4_B]_P3R^ 7[0_P>^%O_!20>&/ 'Q2A
MU34_#RZ;X!DL)OAQ>2HZK=V=VVJR%D2 11OE4=A;1LLD3 D@'Z0U^-OPTE_:
MB^)__!V7\6_AA/\ M>>(+&S\$?!6.XT,1Z%83PV^D7%QH-Y+I$<,T;)%&[W
MW7"CSV,2DOV'WK_P2 ^&_P"T[\)?V%O#W@/]K#XN>(O'/B&QUK5TTCQ1XPM)
MH-7U#1?M\XTZ:\BG>2:*62V$<OE2NTL2R)&Y#HRCCKS_ ().>)M _P""OFJ_
M\%6?A#^TW_8$WB_P3;^&O'/@^]\'I?-=V\)L_FM+IKA%M6=;"V4EX9L8D(Y=
M3& ?EY\/O&7[4WPH_;L_X*K_ !T_97^/5KX U;X?V\WB26_;PI;:K<7KV;W\
M\=J@N]T$4;A)5=FB=^4V[<-GZB\8_P#!=+X_1?\ !,S]CGXD1FRTKXG?M/>-
M[+POK'BC3_#[7J:+;1:B++4-3M;!5D\^Z.8VBM]CKNE;"/M6-O4-+_X(,_$K
M2_''[8/C:/\ ;4T5G_:XT.[TW5;<_">7'AM9WF&^(_VQ_I)6&XF3#;,OL?@*
M8VSOB+_P;JV7Q#_X)=?"C]@F^_:RFM/&WP-\13:S\-/BUH_@]K-[6:2YEN/+
MFLS>RE@3*,NDR$-#"X'RLC@'O'_!.GX__MA^._CU\;?@C^T5X*\:ZAX*\)ZU
M8W7PB^*OC'P&^@W'B73;J$M/;30_9;6,RVLR[ Z01ET8$KQN:+_@J;^Q1\$?
M^"A.L?#[]E;X_:,UQH?B&P\2>1>6^!<Z7>)91-!>V['[LL3X8=F&Y&#(S*?8
MOV3?A)^T_P##?PJ]W^UQ^TY;?$KQ7-:P6QN]$\*)H>FV\<>[YTM5EE+SR,V9
M)6<*=J+''$ P9OQ>^!7QO\>?M&?#[XR>"OC7X;T30O!2ZB+[PWJ/@2>^N-4^
MUPK$V+Q-1A6#:%W+^Y?D\Y% 'XC_ +'7[6G[1_\ P2J\<>(?^" W_!0B2ZO;
M*?Q1HLWP(\:+"[V]S!)K5K*D$;')-I.$D:/DF"=98&Z@1_L]_P %#OV@O#WP
M,^!$/AZ_^+6D^"-6^(VN0>$= \3:QJ\-C'I4ETLC7-^)IV5%DM;**[ND#'#R
M01Q]9!6'_P %#_\ @F7\$_\ @H.GP\\5>,D32O&?PK\=:9XE\%^*H;8/-;_9
M[R&>XLI!D%X+A(=K+GY7$<@R4VMUFI?L\?&[6?VVM+_:;U3XZ>'IO!^A>#KS
M0]$\ MX$F^TVLEW/;37-[_:']H[6F?[+%&,VV$C!4<N[. ?DQ_P;-?M!Z!^Q
MO^W_ /'K_@C1>?%S2_%7AAO$%WXD^$7B+3-8AO+;45C1#*(Y869'DFL#:SLB
MG"-:7 /S9KTO_@JE^S?_ ,%7_P!D+_@HSXG_ ."M_P#P2=FL?B1;:WX?T[1/
MBY\+/*%]<1FSMH?+C-FKK+*C0_9YE%NRW*-,S!3'*2?H7]OO_@BA\0/VNO\
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MI;^'?B,OB;P-'K%AXKMHX8H?/FAAGM0DA2"#=&FU"UO"R&(H=WV[\,/".O\
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M_F\!Z=K<FE1I:?:EDNY/[1DM4VQ[Q:VKC8 (_.*MMV9CJ']I_P"''QT^%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#E/'?P)^"'Q1U2WUSXF_!OPIXBO;-0+2\UWP];7DL !R CRHQ7GG@UT
M]I:6EA:Q6-C;1P00QA(884"I&H& J@<  < "I** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH X_5/VAO@!HGQ*@^#&M?'+P?9^,;K;]F\)W7B:UCU.7<,KMM6D
M$K9'(PO(KJM.U'3]8T^#5M)OH;JUNH5FMKFVE#QS1L RNK+D,I!!!'!!K^?+
M]ES_ (*86?\ P2OUKXB?\$J_^"\7['][J.A>.?&^K:KJGQ6.C&]C\3+>SY>_
MN48;KZ')#)<V[M-"H2/R@\?R_?O[0G_!3+PU_P $J/@%^QU\)O@)X*TCXO?#
MSXD0:#X%\/>-(_%K6<@MHK>RMH+]42VF2=7A<.5WH0R[>^0 ?HM17Q9\!_\
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M^/O@KPE?7Z[K&R\3>*K.PEN!G&8TGD4N,\< U\"?&S_@LU^V]X2_8_\ B?\
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MA/QKX-\?:2-?\"^+=,UJQ9BJWNDW\=S"6'4;XV*YY'?O7XD_\%8=1\'>$/\
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M?$KC*>'FUB 7S?N_,X@W>8?W8W_=^[STYKX1^-G_  6P^++7WQ[U_P#8J_9
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M3F:6Q\/:/#90O(0 7*0JJEL #.,\"MZB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I) 2C!>N#BEHH _.O7/@5^V=^T9_P2T@_8F_X*!?\
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MZ?Y\+P2O#!=3/#'*T$LL)F5!+Y<CIOVNP,/[&W[!_P"R_P#L"?#V;X6_LM>
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M_@I]X7N[7X3?"/4/#?B/X17UAJ7P,\0CQ!I,3ZMJDMXG]HW$\OV@S6<$=O!
MT"KAGDR\BY2-4^\OV1O$?[1?B?\ 9U\*WW[6WPZM_#'Q'BTJ*W\86%AJ5O=6
MLU[&@62YMW@9E$4K NJ'#)N*D':&;TBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\P/^"@/_!8;QQX(_X*(:[_
M ,$Y/!?Q@L/A->Z-I/A2YT#7+W1(;N]\7ZAJ>K6$<]M:O=!K:**&SN)25,;2
MRR))M=!$0WUAI(_X*9ZO\$_%GPUO=>^'=A\0K;QS-I'AKXEGP]/_ &8V@&TA
MN(M9;3#<LTUV&D>V-N)DB\]"^?*7:_R9_P %S/V??^">7_!1;PMXX^"OQ';2
M=&^./PJU3PM9Z/XC6XCBU:RTW6+^QC%RJ!U-W9J+NX!BDRJ2Q,P\LN&;D/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3X;E;B*Q\0:1#>PI,N=L@2964,,G#8R,UM6]O!:0):VL"111($CCC4*J*!@
M = !VI]% !1110 5X7X!_P"4@GC_ /[$32O_ $8U>Z5X7X!_Y2">/_\ L1-*
M_P#1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5X7X!_Y2">/_P#L1-*_]&-7NE>%^ ?^4@GC_P#[$32O
M_1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5X7X!_P"4@GC_ /[$32O_ $8U>Z5X7X!_Y2">/_\ L1-*
M_P#1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EW[0
M_P"VE^S'^RM+:V/QQ^*]GI6H7T<4MGHEM;S7NHRP27,=JMPMI:I).81/-%&9
M=FQ6=06!(%*_[;'[(J_L^ZK^U8O[1_@Z3X<Z&)/[8\80Z["]E921L$>&5U8[
M)@[*GDD>9O94V[B ?RC_ ."\OP0_X*"?L2?M=>(_^"KO[/%C:^/_ (2^*M)\
M*Z;\5?!UQ*%N])BTG4[2XMA"2"R12SP1D2Q!RDES-YD14AC]R_\ !-3]HG]A
M'_@HY^S)JG[7W[,'PE6Z;5/']QXD\2^#M6MH5N=-\81Z;!;2@JS>0)G@$+K,
M#L<S^:2KL^T ]2_8J_X*7_L,?\%$K#6K_P#8U_:&TOQJ?#DJ)K=I!975G=6F
M\L$=K>\BBE\MBC!9 I1BI 8XJTW_  46_8N3XJ+\'&^.MC_:[>,CX0%W_9UW
M_97_  D7E>;_ &+_ &GY/V$:ALY^Q^?Y^?EV9XK\H?\ @FA\<-%^$'_!8K]M
MN;XF_L@ZW\'OCCX@\"7VO^#?"D=U;3Z2FEV5M%*R@6Z[);FYE6&[:=&>*0F4
M+L*GS?C.ZUW6Q_P:66_CUM:NCK;_ +6IU+^U?/;[1]L\ICY_F9W>9D9W9SGG
M- '])7QX_; _9X_9JUG1_"_Q=\>R6NM:_;W=SHOA[1]$O=6U.\M[6/S;FX2S
ML(9IS#$G+R[-B9 + D ]7\*?BO\ #7XY_#G1_B[\'O'&F^)/#'B"R6[T77-'
MNEFM[N%NC(Z\=001U4@@@$$5^0?[*7Q>^(7QU_X.H[F^^*8=GTG]DO2TL+:4
M?)"MU8:5?3A5Z &XOKG./>NG_P"#,/Q[XN\4_P#!+KQ;X3UZZEGTWPQ\8M1L
M]!:1B5@@EL-/N9(5] )II9/K.: /UUHHHH *\+\ _P#*03Q__P!B)I7_ *,:
MI]4_:E^,MAJ=S86W[%OC>ZC@G>..YBN;;;,H8@.,MT(&1]:X_P#9M\>^)?B!
M^W!XZUOQ/\,M4\+W$G@C3U?3M5=&EC"2X4DH<8;<2/\ =- 'T[1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?'O[:7[.'[?OBC6O&LWP&\3^
M"_%_@[QCK_A+5+;P9XGN;C3KS0+O3=0T][F6WNE\V*:"6*T61X62,J58H7=B
MK^:?"G_@E'^VU^Q%\%;B+_@GM^U/X"\/>/?%OQHU+X@?$^P\1^!B?#>MI>#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY/63]7_2"BBBOK#T@HHHH **** &7-M;WEN]I=VZ2Q2*5DBD0,KJ>H(/!%>
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MDR2Y;+OR1\HQZ<^M?3M>%^ ?^4@GC_\ [$32O_1C4 >Z4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%^ ?^4@
MGC__ +$32O\ T8U>Z5X7X!_Y2">/_P#L1-*_]&-0![I1110 4444 %%%% !1
M110 4444 %%%% !116)\1/B'X2^%7@V^\>>-]52STW3X2\TK<ECT5%'\3L<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !15+7?$?A_PO8-JGB36[2PMEZSWEPL:?3+$<UP%W^TUH6M7
M#Z9\)/!NL^+[I6VF33[4Q6B-Z//( %^N"/>O%S/B+),FFH8NO&,WM!7E.7^&
MG&\Y?]NQ9WX3*\PQT7*C3;BMY;17K)VBOFT>F5F^)O&7A/P78_VEXL\1V6G0
M]GO+A8]WL 3EC[#FN!_X1O\ :7^(/S>)?&.F^#;%^MEH<7VF[*_W6F?Y4/\
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MA/&0XBR"T<?15FOLUZ?6E/N_Y'T=E=>ZX^#FN75W56.P>E:'3I./\K_1_P#
M:];!# ,I!!'!%%?(?[$'[5/B'PCXA/[*/[0AEL=6TV?['H=W?MA@R\"TD8]>
MWEMG# A0?N9^O*^EX3XJR[B[*8XW"WC)/EG!_%3FOBA)=&G]ZU._+<QH9GAE
M5IZ/9I[Q?5,****^F.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOUUSQ<M]XIU,<F^\27;7/X!#\@'H"#BO0+6TM;&W2SLK:.&&-=L<42!54>@
MX%245[669'D^2P<<#0C3ONTE>3[RE\4GYR;9P8O,,=CY)XBHY6VN]%Z+9+R2
M04445ZIQA1110 4444 %%%% 'XI_\%Y?@A_P4$_8D_:Z\1_\%7?V>+&U\?\
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MU HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7SM<****^@/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_N66UI+^:?)1C\U.:J+_P %FO\ 96%I?Q\737E'FF_OC'D_\G/1[[4=/TR
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVBBOI<+@\)@:*HX:G&$%LHI12^2LCRJU>MB)\]63D^[;;^]A111709!1110
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MM<>-?$/[7O[26D_LL?#.])TG2+XC5+N/YH_M"@^?,WJL*;D XRY8<[EKWO\
M;<_:*C_9[^#T]UI%XJ>(=;W6>A(#\T;$?O+C'I&IR/\ :9 >#7)?\$Y?V=)/
MA?\ #9OBIXLLV'B#Q7$LJ^</GM[(G=&ASR&D/[QO;8#RIK\AXWK5>,.(*/!^
M%DU3TJXN2Z4DTXT[])5';S2L]5<^9S:4LSQL<LIOW=)5'VCTCZR_+R/>O O@
MKP]\./!VF^!?"ED+?3M+M$M[6(==JC[Q/=B<L3W))[UK445^M4:-+#T8TJ45
M&,4DDM$DM$DNR1])",8148JR6P4445H4%%%% !1110 4444 %%%% !116'XN
M^)?P_P# <1D\8>,-/T\@9$5Q<J)&'^RGWF_ &N?%8O"8&@ZV)J1A!;RDU%+U
M;LC6C0K8BHJ=*+E)]$FW]R-RBO,3^TF/$Q,/PB^%WB#Q,2<)>BV^QV;?]MI<
M8_[YI/['_:D\;?\ (5\4:#X.M7_Y9:9;&]N@.X9I/D!]UKYG_7++<3IEM*IB
MGWI0O!_]Q9N%'[JC/6_L+%4M<7.%'_'+WO\ P"/-/_R4]*O;ZRTZV>]U"\B@
MAC&7EFD"JH]R>!7":_\ M._![1KO^R]-\12:W?'[ECX?MFNW?Z%/D_\ 'JJV
M7[+?@&[N5U+X@ZOK7BR[4[A)KNINZ*?]F-2J@>QR*[O0/"_AKPK:?8/#/A^R
MT^'_ )Y65JD2GZA0,T<_&N8?#"CA8]Y.5>?_ (#'V4(O_M^HO78.7(,-NYUG
MY6IQ^]\\FO\ MV+//_\ A9?Q^\8_+X#^"D>D0-]S4/%U]Y9'UMX_W@_.E_X4
M]\8/%OS?$?X\W\$+?>T_PK;+9JH]/..78?45Z=11_JE#%:YEBZV(\G/V</3D
MHJFI+RGS^;8?VU*C_NE&G3\^7FE_X%/F:?\ AY3A/#?[-7P7\-W'V]?!<.H7
M9.Y[S6)&NY';^\?-) /T KN+>VM[.!;:T@2*-!A(XU"JH] !TI]%>YEN391D
M]-PP.'A23WY(J-_6R5WYL\_%8[&XZ7-B*DIO^\V_NOL%%%%>D<@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=XL\)>&?'7
MAZZ\*>,-#MM1TZ\CV7-I=1AD<?T(/((Y! (((KXO^+7[+OQI_8P\6R_'+]E[
M6KR\T*/+ZCIC RR6\(.2DT?_ "\0?[7WDZG!&^ON&CKUKX[BS@K*N+*4)U&Z
M6)IZTJT-*E-]+-6O&^\7IVL]3R\RRK#YE%.7NSC\,U\2?^7D>-_LL_MF_#W]
MI+34TK<FD^)X8LWFB3R_ZW YD@8_ZQ.Y'WE[C&&/LE?+/[4W_!/^'Q!J3_%[
M]F^4:'XFMI?M,FF6LOD17,@.[S(6!'D2Y^BL?[IR3!^RY^W[-=ZLOP9_:>A.
MB^(K67[-'J]Y#Y"32#CR[A2 (9/]KA&[[3C=\OD_&N:\/YA#).+TH5):4L2M
M*5;R?2G4[IV3>UKQYO/PN:XC!5EA,STD_AFOAGZ]I>7_  +_ %;10"",@Y!Z
M$45^LGT@4444 %%%% !1110 CHDB&.1 RL,,K#((]*\SU_X%:MX3U>;QI\ -
M<CT*_E;?>:).I;3;\^C1C_5-_M+T[8R37IM%>1FV1Y=G5.*Q,?>@[PG%N,X/
MO":LXOO9V:TDFM#MP688K 2;I/26DHM7C)=I1>C_ #6ZLSS[P1\>]-U+6E\"
M_$G19?"WB3HMC?N/)NNVZ";[L@)Z#KV&<9KT&N6^+.G?"35_#3Z?\7[K2(=/
M.2LVJWB0>4?[R2,04/N"*^<O%'[<OP,_9<G^S6_[7G@7QGX?B;#:++XNM9M6
ML5]$:)V\P#^ZP!Z  =:\JA5XGR67)BZ4\70Z5:4&ZL?^OM*"][_'16O6E%79
MZT,!A,YUP:]G4_D=^1_X)O;_  S?_;[V/K:BOE&'_@M/^P+JD4</A/Q]X@UZ
M_=,MI.A^"]0N)T/]TD0B,G_=<CWI_P#P]#O_ !'\GPK_ & /V@M?W?ZN\G\!
MBQM'^DTLO_LM?=T\KS&I34_922>OO+E_]*M;YGFRRC,H2M.DX^NGYV/JNBOE
M3_AKW_@HSXI^7P%_P2WN[2)ONWWBKXIZ=:;/3,"H7/X'BC_A)_\ @LYXJYTC
MX7_ 'PI&W4:]K6JWTJ#V^S *3^E:?V76C\<X+_N)!_A%MB_LZJOCG!?]OQ?Y
M-GU717RI_P *4_X*X^*/^0[^VU\.?"V[K_PC7PW^W;/I]L<9_&C_ (86_;1\
M0<_$#_@JKXYN2W+_ /".>#=.TD$^WE[MH]J/J&&C\6)A\E-_^V6_$/J>'7Q8
MB'R4W_[;;\3ZKHKY4_X=7V.L?/X]_;Q_:-UW/W[>?XF&&W([@1QPC&?K2_\
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M^) .:^JJ*/[6QO\ =_\ !=/_ .1%_:>*_N_^ 0_^1/E8_P#!/3]H2X0'4/\
M@I]\8F<$X-LUG",>X$9S]:=+_P $XOBQ=*AN_P#@IA\>2ZC!,'B"VB!_!8?Y
MYKZGHH_M?'=U_P" 0_\ D0_M/&=U_P" Q_R/EJ?_ ()H>++IU:?_ (*1_M(
M+VB\>PQY_P"^;84L_P#P2_DN9$>?_@HK^U(=A^ZGQ86,'V.RU&:^I**/[7S#
MI/\ "/\ D']IXW^;\%_D?+5U_P $L]$OBIO?V[_VF9BOW3+\796Q],PT7/\
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M0?\ ;&G\5ZI;R-X&\+%3'#(I"O;(Y\J(C^].X9V'78&&?E%?=BJJ*$10 !@
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M);U*;2YO^OD&G"IZSBY)?#)'9A\XQ%.DJ%=*K36T9ZV_PR5I1_[=:3ZIG(^
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M_P %$?'$>/N_;]"LKK\]P&>/UYH_X9K_ &]['_D%_P#!1]I5[17_ ,)]-?\
M'>'!Z=J^BZ*/];\X?Q1HR_Q8;#R_.DP_U.R5?!*M'_#B<3'\JJ/G0_"+_@I1
M8?\ 'I^U[X+O_P#K^^'ZQ?\ HM_\YH_X1G_@JA8\VOQ-^#%][7NBZC%_Z+-?
M1=%'^M6)?QX;#O\ [@4U_P"DQB'^J>%C\&*Q"_[F*K_]*E(^=/MO_!6"Q_X^
M-%^ 5\!S_HMSK,3$>GS\9_2@>.?^"H5EQ=? KX57N.";/Q/=1Y]QYB].U?1=
M%'^LM)_%@,._^W)+_P!)F@_U8JQ^#,,0O^WX/_TJFSYT_P"%Q_\ !22U_P!?
M^QIX1NNW^C?$2-/Q^=.E'_#0_P#P4*M?]?\ \$ZK.Z[?Z-\7=.3GU^>/I[=:
M^BZ*/]8,N?Q97AW\\0ORQ"#_ %=S)?#FN(7RPS_/#L^=/^&H/VZ8?DO?^";%
MZKC[P@^*FF2#'L0G-9/B+X\?M#>+%/\ PEO_  2UU+4%Q\S77BC3)G ]LKG/
MT-?4-%8XC-.'\92=/$9/AY1>Z<L0U]SKLNEDN?4)\]+.,0GWY<-?[UAT?%MY
MJ?C*6<WFE_\ !,;QYI=P?^6^E^-H86'T ?:/RJ,^//V@;$[='_9D_:#LRO'E
M)XOM)8AZX!'/US7VM17S4LA\-7+FAP_AZ;_Z=SKT_P#TBJCU55XX2L\\KR_Q
MPP\__2J3/BG_ (6U^UY'_P >WP$^.(]?-O=/?^='_"U_VM7_ -?\ OCH<_>\
MO4;!?R]*^UJ*7]A< _\ 0I_\NL;_ /- _:\9?]#:7_A/A/\ Y0?%/_"P/VA+
MGG5?V;/VA[CU1?%MI&A_!12?VSXTU'Y=5_X)Z_%O6GZO_;7C*)01]5<9/M7V
MO11_J_X:R_B9!0J?]?*F(J+YJ=5W#VW'"^'.ZT?\-/#Q_P#2:2/D#1?&_B_0
M"&T__@DYKS%>AN]:LK@C_OZ6KK-,_:D_:6TRW-IX:_X)J^);91C]TOB33[=,
M?@,5])T5[6!GP=E:M@LCPU+_  .M'_TFJC@Q&!XIQC_VC.J\_6-!_G29\Z?\
M-9_M@?\ 2./Q'_X7&G_X4?\ #4?[</\ TC:U'_PY^F?_ !%?1=%>E_;N3K;*
MJ/\ X'B?_EZ.3^P,Z>^;5_\ P##?_,[/G3_AI;]OQ_G@_P"":3E#]TR?&'2E
M;'N/+XH_X:$_X*&/\Z_\$\;! >0C_%K3R5]B1'@GZ5]%T4?V_E:VRK#_ /@6
M*_\ FD/]7LU>^;8C_P !POZ88^=/^%V_\%'9?E3]B#PW$6Z-+\2[=@GUPG./
M:C_A:W_!2V?]W%^R?X%@/7S)_'>Y?IA4S7T711_K#@5MEF'7_@]_G78_]7,>
M]\TQ#_\ !"_*@CYT_P"$^_X*?7'SP_L__"^W X*3^*[AR??*KC%'_"2?\%49
M^(OAK\%H-_W3/K.I-L_WMHYQ[5]%T4?ZR4%ME^'7_;LW^=1A_JSB'\68XA_]
MO4U^5-'SI]J_X*R7'$.E?L^VY'4SSZVX/TVT?8?^"L4_SRZY\ 8">L<-MK+*
M/H6YKZ+HH_UGMM@L.O\ N'?\VP_U6O\ %CL0_P#N+;\HH^=/^$4_X*FS_NY?
MBO\ !R ?\](="OV;\F.*!\/?^"G=Q\TW[0_PRMR. MOX2G<'W.YJ^BZ*/]:<
M0ML+AU_W IO\TP_U3P[WQ6(?_<>HOR:/G3_A4O\ P4KF^>3]KCP1"6ZI%X"#
M!?H6?)_&C_A1G_!1F;]W)^W7H$*GK)%\,;5F7Z!GP:^BZ*/];,>MJ&'7_<M0
M?YTV'^J.7O>OB'_W,XA?E41\Z?\ #.__  4)G^27_@HM:0#KO@^$6G,WTPTF
M*/\ AF7]O2?Y;[_@I5.RCH(/A'I<1S[D2<U]%T4?ZW9JMJ>'7_<KA?\ Y2+_
M %.RGK5Q#_[F\5_\NL?.G_#*W[:L_P E]_P4BUAD'(%O\.=-B.?J&.1[4?\
M#)/[74GR7'_!1KQ.4/WA%X+L$;\&!XKZ+HH_UOSGI&BO3#89?^XA_P"IN2]9
M5GZXG$O_ -S'SI_PQ[^U#_TD4\:?^$[94?\ #&'[0TGSW'_!0SXA%S]XQZ?:
M(N?8!>*^BZ*/]<,\Z.G_ ."*'_RL/]3<BZJK_P"%&(_^6GSJ/V+OC_D;O^"A
M/Q&([XM+3_XFI+C]BKXS7*A)/V__ (I  Y_=O:(?S6,5]#44O];\]O?FI_\
M@FC_ /*QK@W(;6Y:G_@^O_\ +#YT_P"&'?C!_P!) OBO_P"!=O\ _$5+!^Q!
M\4U4BZ_;Z^+CG/!CU"V7^<1KZ&HH?&&?/[</_!5+_P"0$N#>'T_@G_X.K?\
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M:\5ZQA%GW?X4_9Q^$/A2Z_M1/"RZE?D[GU'6I#=S,W][,F0#[J!7<*JHH1%
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MY[2MGI_G-=AHG[ W[#_A[#:5^R)\-E9?NR2^#+*5Q]&>,GOZUR\N3Q^U4?\
MV[%?^W2.FV5K[4W\HK]6<WKG_!4[_@GIX?W&_P#VL?"DFWK]AN7NO_1*-GI7
M,7?_  6A_P""<R3-::-\=+O5YUZP:3X.U68_G]F"GOW[5[UHGP&^!OADJ?#?
MP8\)Z?M^[]A\.VT6/IM0>E=1:6=I80"VL;6.&-?NQQ(%4?@*/:9/'_EW4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5X7X!_Y2">/_ /L1-*_]&-7NE>%^ ?\ E()X_P#^Q$TK_P!&-0![I111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO+^9+M^6Y]MT5\^_LP?M_P#P[^-YM_"/C@0^'/%#806LTF+:]?I^Y=NC$_\
M+-N>< OS7T%7Z=D/$63<3Y?'&Y;652F^VZ?:2>L7Y-)_(]_!X["X^BJM"2DO
MR\FNC"BBBO:.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH[RRN(YH94#Q2Q.&5U(R""."".]/K]2335T?0[A1113 **** "BBB@ HHHH
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MCX7?#_QA\2]7\ 2:JFHVGPT\6>/;B_T"RG2594$=JP&Z,2*',4K21LP#.K,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5X7X!_Y2">/_ /L1-*_]&-7NE>%^ ?\ E()X_P#^Q$TK
M_P!&-0![I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/Z5]2W-K;7D)M[NW26-OO)(@8'\#7+:[\!_@CXGR?$'P@\,WC-UDN-"MV?\
M!BF1^='^K/BC@O\ =L\A5715</!??*#NP^H<0TO@Q:E_B@OS1YMH?_!1_P#9
M.UC:+OQS>:<S=%OM%N/U,:.!^==?HO[7?[,>O8^P_''PZF[H+S4%MO\ T;MK
M'UW]@W]DWQ 2UU\'[2!CT:QO;BWQ^$<@'Z5R.M?\$N_V8]4R;%_$>G9Z?8]6
M5L?]_8WI^U\:,'\5/!5U_==6$G]_NAS<54MXTI^CDG^.A[EHWQ(^'?B+;_PC
M_CW1;[=]W['JD,N?IM8UM=>E?(^L_P#!)#X>3EO^$>^+NM6O]W[;80SX^NTQ
MYK$_X=??%_PMS\/_ -I(1%?N?Z-<6?\ Z+E?%'^M?B9A?]XX?4UWIXFF_P#R
M5JX?VCGU/X\%?SC4C^3U/M.BOBS_ (95_P""D/@_GPY^T/\ V@B_<C'BNZ?'
MMMN(]H^F<4?:?^"M?@K_ %D!U:!.GR:7<;O^^<24?\1,S##?[[D6-AYPIJHE
M\XR0?V]6I_Q<'57I'F_)GVG17Q9_PU__ ,%"_!?'C#]G#[9$O^LG/A:]'_D2
M)]@_*I+3_@JYXHT*<67C_P#9Z>"3^(Q:J\##_@$D)S_WU0O&7@FD[8V57#O_
M *>4:B_*,@_UHRF/\5RA_BA)?DF?9]%?+GA__@J]\"K[;'XA\$^)M/<]6B@@
MGC'XB56_\=KNO#W_  4(_9-\0[4/Q--C(W_++4=+N(\?5O+*?^/5[^"\2. L
MPM[',J.O\TU!_=/E9V4L]R>M\->/S=OSL>TT5Q_A[]H+X%>*]H\/?&+PS=.W
M2*/6X/,_[X+;A^5=;;7-M>0K<VEPDL;#*R1N&4_0BOK,+CL#CH\V&JQFN\9*
M7Y-GI4ZU*LKPDGZ.X^BBBNHT"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;YL7F^1YB[RN[9GG'K
MCTH =1110 4444 %>%^ ?^4@GC__ +$32O\ T8U>Z5X7X!_Y2">/_P#L1-*_
M]&-0![I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P  [O\ ^,UZG_PS)^S;_P!&]^!__"3L_P#XW1_PS)^S;_T;WX'_ /"3L_\
MXW0!Y9_P]J_X)T_]'2:)_P" =W_\9H_X>U?\$Z?^CI-$_P# .[_^,UZG_P ,
MR?LV_P#1O?@?_P ).S_^-T?\,R?LV_\ 1O?@?_PD[/\ ^-T >6?\/:O^"=/_
M $=)HG_@'=__ !FC_A[5_P $Z?\ HZ31/_ .[_\ C->I_P##,G[-O_1O?@?_
M ,).S_\ C='_  S)^S;_ -&]^!__  D[/_XW0!Y9_P /:O\ @G3_ -'2:)_X
M!W?_ ,9H_P"'M7_!.G_HZ31/_ .[_P#C->I_\,R?LV_]&]^!_P#PD[/_ .-T
M?\,R?LV_]&]^!_\ PD[/_P"-T >6?\/:O^"=/_1TFB?^ =W_ /&:/^'M7_!.
MG_HZ31/_  #N_P#XS7J?_#,G[-O_ $;WX'_\).S_ /C='_#,G[-O_1O?@?\
M\).S_P#C= 'EG_#VK_@G3_T=)HG_ (!W?_QFC_A[5_P3I_Z.DT3_ , [O_XS
M7J?_  S)^S;_ -&]^!__  D[/_XW1_PS)^S;_P!&]^!__"3L_P#XW0!Y9_P]
MJ_X)T_\ 1TFB?^ =W_\ &:/^'M7_  3I_P"CI-$_\ [O_P",UZG_ ,,R?LV_
M]&]^!_\ PD[/_P"-T?\ #,G[-O\ T;WX'_\ "3L__C= 'EG_  ]J_P""=/\
MT=)HG_@'=_\ QFC_ (>U?\$Z?^CI-$_\ [O_ .,UZG_PS)^S;_T;WX'_ /"3
ML_\ XW1_PS)^S;_T;WX'_P#"3L__ (W0!Y9_P]J_X)T_]'2:)_X!W?\ \9H_
MX>U?\$Z?^CI-$_\  .[_ /C->I_\,R?LV_\ 1O?@?_PD[/\ ^-T?\,R?LV_]
M&]^!_P#PD[/_ .-T >6?\/:O^"=/_1TFB?\ @'=__&:/^'M7_!.G_HZ31/\
MP#N__C->I_\ #,G[-O\ T;WX'_\ "3L__C='_#,G[-O_ $;WX'_\).S_ /C=
M 'EG_#VK_@G3_P!'2:)_X!W?_P 9H_X>U?\ !.G_ *.DT3_P#N__ (S7J?\
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M]J_X)T_]'2:)_P" =W_\9KU/_AF3]FW_ *-[\#_^$G9__&Z/^&9/V;?^C>_
M_P#X2=G_ /&Z /+/^'M7_!.G_HZ31/\ P#N__C-'_#VK_@G3_P!'2:)_X!W?
M_P 9KU/_ (9D_9M_Z-[\#_\ A)V?_P ;H_X9D_9M_P"C>_ __A)V?_QN@#RS
M_A[5_P $Z?\ HZ31/_ .[_\ C-'_  ]J_P""=/\ T=)HG_@'=_\ QFO4_P#A
MF3]FW_HWOP/_ .$G9_\ QNC_ (9D_9M_Z-[\#_\ A)V?_P ;H \L_P"'M7_!
M.G_HZ31/_ .[_P#C-'_#VK_@G3_T=)HG_@'=_P#QFO4_^&9/V;?^C>_ _P#X
M2=G_ /&Z/^&9/V;?^C>_ _\ X2=G_P#&Z /+/^'M7_!.G_HZ31/_  #N_P#X
MS37_ ."M_P#P3GC95;]J/1LL<#%A>'\\0\?C7JO_  S)^S;_ -&]^!__  D[
M/_XW7BO[4'P"^!.D?&+X,V.E?!7PE:P7WC66*^AM_#=JB7$?V=CL<",!USS@
MY% &O_P]J_X)T_\ 1TFB?^ =W_\ &:/^'M7_  3I_P"CI-$_\ [O_P",UZG_
M ,,R?LV_]&]^!_\ PD[/_P"-T?\ #,G[-O\ T;WX'_\ "3L__C= 'EG_  ]J
M_P""=/\ T=)HG_@'=_\ QFC_ (>U?\$Z?^CI-$_\ [O_ .,UZG_PS)^S;_T;
MWX'_ /"3L_\ XW1_PS)^S;_T;WX'_P#"3L__ (W0!Y9_P]J_X)T_]'2:)_X!
MW?\ \9H_X>U?\$Z?^CI-$_\  .[_ /C->I_\,R?LV_\ 1O?@?_PD[/\ ^-T?
M\,R?LV_]&]^!_P#PD[/_ .-T >6?\/:O^"=/_1TFB?\ @'=__&:/^'M7_!.G
M_HZ31/\ P#N__C->I_\ #,G[-O\ T;WX'_\ "3L__C='_#,G[-O_ $;WX'_\
M).S_ /C= 'EG_#VK_@G3_P!'2:)_X!W?_P 9H_X>U?\ !.G_ *.DT3_P#N__
M (S7J?\ PS)^S;_T;WX'_P#"3L__ (W1_P ,R?LV_P#1O?@?_P ).S_^-T >
M6?\ #VK_ ()T_P#1TFB?^ =W_P#&:/\ A[5_P3I_Z.DT3_P#N_\ XS7J?_#,
MG[-O_1O?@?\ \).S_P#C='_#,G[-O_1O?@?_ ,).S_\ C= 'EG_#VK_@G3_T
M=)HG_@'=_P#QFC_A[5_P3I_Z.DT3_P  [O\ ^,UZG_PS)^S;_P!&]^!__"3L
M_P#XW1_PS)^S;_T;WX'_ /"3L_\ XW0!Y9_P]J_X)T_]'2:)_P" =W_\9H_X
M>U?\$Z?^CI-$_P# .[_^,UZG_P ,R?LV_P#1O?@?_P ).S_^-T?\,R?LV_\
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MM7_!.G_HZ31/_ .[_P#C-'_#VK_@G3_T=)HG_@'=_P#QFO4_^&9/V;?^C>_
M_P#X2=G_ /&Z/^&9/V;?^C>_ _\ X2=G_P#&Z /+/^'M7_!.G_HZ31/_  #N
M_P#XS1_P]J_X)T_]'2:)_P" =W_\9KU/_AF3]FW_ *-[\#_^$G9__&Z/^&9/
MV;?^C>_ _P#X2=G_ /&Z /+/^'M7_!.G_HZ31/\ P#N__C-'_#VK_@G3_P!'
M2:)_X!W?_P 9KU/_ (9D_9M_Z-[\#_\ A)V?_P ;H_X9D_9M_P"C>_ __A)V
M?_QN@#RS_A[5_P $Z?\ HZ31/_ .[_\ C-'_  ]J_P""=/\ T=)HG_@'=_\
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M]J_X)T_]'2:)_P" =W_\9KU/_AF3]FW_ *-[\#_^$G9__&Z/^&9/V;?^C>_
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MM7_!.G_HZ31/_ .[_P#C-'_#VK_@G3_T=)HG_@'=_P#QFO4_^&9/V;?^C>_
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M\8?CG\(?V=?V?V^(\_[-G@>/Q-\7+N;Q6-*6",QF=K/3U%K<?;;I+=)9&5S
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M9/=7EEX,T!KV98U*@N[L4A@0%URTLB#&2,[3CF?V:/\ @HKX*^/W_!.G0?\
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M*?C&U^R>+?$%WXA$T>K6A-N3;R6S1^0D>+6W $:(4$8V%:[?XJ_L/_ WX_\
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M3V\4^+_%?[-%YXML)?'VHC4/&-MJ_B)M0BU.[!E*SMYZLT;AII#F-DW9&[<
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M_@HY\9E^.W[6.A^,=?UN#38M/L(H/&MW;6EA;1Y(B@@C8)&"Q9VP,LSL23V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **_*[]I70M=MO^#F;X(? G3OBY\1+/P)XJ^#6I^(O$7@JR^).L0Z5?:E"
M=56.9K9+H( /+A)10$)B4E3\V?N;Q5_P47_8.^'_ ,3-=^"GBO\ :R\#6/B7
MPEX?N-8\4:3+X@B9]%LK>2**5[Q@2MLPDFB41RLLC&0;5- 'M=%>5?LG_MO_
M +*'[<OA+4_''[)_QOT?QIIVBZD;#6'T[S(Y;*X SLEAF1)(\C)4LH#8.TG!
MQB_$_P#X*0?L3?!O5]4TKXB_'JPL(=!U1=-\2:U'IUW<:5H=Z2H%M?ZC#"]I
M839=,QW$L;#>N0,B@#V^BO)/VCOV[?V1?V1_!^C?$/\ :.^.FC^%?#WB$@:)
MX@OEE>QNRR!U"7$2-'ED.Y06RR@E<@$C9^*'[5'P*^"OPIL?C?\ %;QC/H7A
M;4)K:*#5K_0[U51[AUC@65!"7@,CNB*)%7<[HHRS*" >A45\K_$/4?\ @F_\
M2_\ @I9\(O$?BCXX6DO[0/A7P]K$'@3P79^)YUN8[.\L6ENFO-.0_NC]F5V4
MW"QY]&9$V^Q_&;]K'X _ +7+3PG\2O';1ZY?6$E_:>&]%TB[U;5);.-@LET+
M*QBFN/LZL0K3>7Y:D@%@3B@#T6BN.^!'[0GP1_:>^'-K\6_V??BAHWB[PY=R
MO%%JNB7BS1K*AQ)"X'S12H>&C<*ZG@@5Y_\ \%*O#T>L_L%_%_58->UO2=1T
M3X9Z]J>C:MX>U^ZTV[LKR#3IY(9HYK62-PR.JL!DJ<<@CB@#W&BOQA_9H^!'
MCKXA_P#!NMIW_!070/VS_CAX9^-.A_#/7O%X\=/\;O$%U;WMQIT][(MO=6%W
M>2V4D$D=JD17R1C.X<YW<A^UA^TU\3/V^?\ @B1^R!^W+\9Y]5TWQSK'[07A
MO2-=72]7NK33M52#5[^U>X>PCD%LYF:TCGR8LHV50J@ (!^YM%>&_#/_ (*6
M?L&_&7]HV]_9)^%O[4?A77/B)8QSO+X:L;QF>7R-WGK#+M\JX:/:^](G=D\M
M]P&QL:_QH_;I_99^ 'BJ_P# OQ*^)SKK6D:)_;.N:3H6@7^KW.D:;\V+V]CT
M^"9K.W.UL33A$.UL$X- 'K=%>1^-?V^/V*OAS^SYIG[5GCG]J/P1IGPZUNU%
MQHGBVZ\00K::DI!(6W.[,\G##RHPSY4C;D$5R(_X*X?\$SD\<:S\.;[]MOX?
M6.L>'O#<.O:W;:IKJ6B6=C*L3([RS;8P^)X<P[O-7S%!0$T ?15%?,WB[_@L
MC_P3 \!:)X0\2>,?VS_!^G6/CJUANO#5U<S3*DUO*[)%/+^[_P!$B=D<+)/Y
M:-L8@D*2.A\>_P#!3W_@G_\ "_\ : TG]EKQY^U;X2T[QYK5[!96&@R7K,3=
M3*K0V\DR*88)I Z%(I'5V$B8!WKD ]XHK@/C5^U#\"_V>]1T/0/BIXY^RZQX
MGFFB\->'=,TRZU+5=6:%-\QMK&SBEN9UC4AG9(V5 06(R*?^SS^T]\ _VKO!
M=S\0/V>OB=I_B?3+#59]+U-[,/'-I]]"0);2Y@E59;:=-R[HI45P&!(P10!W
ME%>%^(_^"EW[#/A'Q=:>$/$O[0^E69OO$/\ 8%IKDUG=#19-6#,AT\:KY7V'
M[2'1T,)G\P.I4J&!%>@_&3]H3X/? &QL+OXJ>,5L)M6F>'1M+M+&>]U#4I$3
M?(MM9VJ27%R43YF$4;;5^9L#F@#LZ*\5\)?\%$OV+_'OP+UK]I3P5\>-.U7P
M7X9O)K7Q3J]A974K:%-""TR7\"Q>=9&-1N?ST3:""< C-KQ7^WU^R#X(_9TT
MK]KGQ-\;].M_AEK4"3Z?XX2UN)=.:)VV([RQQL(59OE4R;0S$ 9/% 'L%%?'
M'_!0_P#X+!_ ?]BJ?X,^&+#6QJ>J_&'QUX<M=.NH=-GGM++P_=WL)N]1E=%P
M";03"&,$R.[!@C+&^+7[7'Q'_P""6O[1OB7X /\ M#_M$V%KK<?Q0TGQ#\&-
M$M_$MSI^H:MK0N6M;0_8DVSRP&=BA9XP@(P752V0#Z]HKBOC-^T1\&OV?K/3
MKGXL>-HM.GUFY>WT/2[>TFO-0U69$+O':6=LDEQ=,J NRQ1N54%C@#-9?P3_
M &P?V9/VBOA]K7Q3^#WQHT75=#\,W=S:>*+J2=K5]#N+<%IX;Z*X$<EE)&H+
M,DZH57DC'- 'I-%>'> ?^"DG[%'Q,\=^%_AOX4^.$']I^.8I9? C:IHE_86G
MBA(UW.VF7=U!';ZB I#9MI),@Y&1S7R5^VWX6MO#W_!QO^Q)XBT_6];8^(O#
M_P 0&U&PNO$%W/9![7P],D3PVLDK0VS;9I QB1-Y;+9/- 'Z345Y5\6OVV?V
M9O@?XDU+PG\1OB)-!>:%IT=_XD_LWP_?ZC#H-K(&:.?49K2"6/3HV5697N6C
M#*I8$@9KO?AYX_\ !WQ7\ :'\4OAWKT.J^'_ !+H]MJNA:I;AA'>6=Q$LT,R
M[@#M>-U89 .#TH V**_+G_@XA3Q;X.^+G[)>H_#GXO\ C_PG)X__ &B]%\*>
M,$\(_$#5=+BU/2KF2)9()(K6X1,[5P'"AQEL'DU]U>.OVN?V./V8O''A/]G#
MXB?M!>&]!\4^))X[/POX4U/7S/J=V7+;7,;,\WEDALS2808Y>@#URBO$?V<?
M^"D?["O[7?Q/U[X,_LU?M.^%_&/B?PU;?:=6TG2+IF<6^]4-Q$S*%N80S(#+
M"70%TRWS+G6^.G[</[+G[-^JWF@_%OXHBTO],TH:IK-AI6C7NJ3Z58'=B\O(
M[&&9K.W/ER8FG"1GRWPQVG !ZQ16'\-/B9\//C+X"TGXI_";QMI?B/PWKMFM
MWH^N:+>I<6MY"W1XY$)5AU'!X((/(-;E !1110 4444 %%%% !1110 4444
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M'&<']$OAM\-_ ?P>\ :-\*_A=X2L=!\.>'M-AL-$T;3(!%!9VT2A(XD4= %
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M5B"8BC]MV"00#\X?^"-G_!.GX/?MH_\ !#KX*>#/C]\2_B1J/@S6=&NI=:\
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MUP<*,3_\%A/!_A/PK_P:V>";[PUX:L;";3?#OP\U>QEM+5(VAU":>P,UVI4
MB:0SS%Y/O,97))+'/W'!_P $G?V?K;]A<_\ !.*'XC_$)?A.UF;$Z)_;UO\
M:/L!D,ILOM?V;S_),A+8W[L?)NV?)2?&W_@DW^S]^T1^QWH/[!WQ;^)'Q"U/
MX:>'X+.WM='&O6\,T\%F(A9PS7,=LLTJ0>4I7+98\N7*H5 .'_:3\7_"34O^
M"NO@/X?? SX:6VN?M)V/P9U&\_X2/Q'K5S#H7A+PA+?I%)=3VT39OKF2Z/EQ
M6\?ELP9C)-"H1J^+?@IXC^.OP>^"7_!6K7?!7BM;KQQHOB;4KQ-9\/Z:UBJ7
M3:1.UQ>6\'FRM RKOD7]X[ H"78C)_0;XX_\$COV</V@?C-X%_:0\:?$;XH:
M?\1? F@-H,'CSPEX\GT75=7THO(_V*]GL5B,D>99/FC\N0[R2Y/-:G[./_!)
M_P#8Q_95^-_COX[?!_P7JUM>_$,HVNZ#?>(+BYT99! 8))H[)V,1FE1I \\@
MDE(FF =5ED5@#RK]F#X+_P#!/S]NG_@A3\)? 7QB\/:-JWP:C^$^AW>MPMJ\
MMC#I\^FV\;73RW-O)&\,D-S!/YK!P2RR;B0S9\Q3XC2>//\ @X&U?X+:C^T7
MXL^&CW_[,>B3?!]=,T_2UEU&Q-[-/?P(FL6%T5F9U1G1%25EL#OW" !?3OA+
M_P &\7_!.GX*?%NX^(7@2Q\?P^&I]<76?^%12^/;IO!XOE=9$F;3<@3!75&$
M<SR1C8HV;0%KU'_@H9_P2<_8]_X*8V?AZ[_:&\.ZS8^(_",YE\*^./!^L-IV
MLZ5N8,R1SJK!D+*&"NKA6&Y=I)) /%?%W[ 7P"_9&MOVO/BQX,_:$\?>+/B/
M\8/@IJ>K^/=%\1S:9]DV0V-W!;7PM].TZUC@DD;[0BEC^]*SE5)20CYTUVXM
MO^(,Y)'F39_PHNV3<6&-W]I(H'UW<8]:_2#]DG]@+]G7]C3X5ZO\*_AMI>KZ
MTOB:0R>,/$/C?6I=7U7Q"YB\D?;+F<EI56+Y%C 6-5+;5&YB? M%_P"#>_\
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M#CZ!M+:*RM8K. OLAC5$\R0NV ,#+,26/N22: )**** "BBB@ HHHH ****
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MI.4^#.K_ !AUOP1'?_'+PAI.AZ\;F19+#1=0-S (@?D8.0#DC.1VKQC_ (*
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M\+6?C?QY-?:?87%Q;2VLERMIM6(S^3-*BRD%E$C8(S0!]!U\0+=?M6_M)?\
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M0OB/PGX0\8Z7\??$T-WHEA:VE@]L(XA?_9I2CW$K'SHI-^[#9 4#WK_@VO\
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M?1_$_P 2-6O=.T."\34)KG;#<W+1[<P1@%P=BK@8!- 'ZH45\WZ]_P %??\
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M<7OB;]I^.\F2P^&7AN2!96$+OK3!F3/!(QP<5Z/17E9IEM;,8Q5/$U*/+?\
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MOW<LLTS3SV[1;!())Y75X]C+O8 A6*FK\,?^"27P@_9Y\-2^$/V4OVCOC/\
M"W3;Z:2YUFP\,>-8KRVU"[DYGN_(U6VO(K2:5B6=K1( 6.0!@8 /'_\ @@;^
MU+^VK\0[3XW_ +$W[>GB6#Q7XZ_9T\<V_AT_$"WY_MZTGCE:$R/@>;*BP;C(
MP61DGB\P>8'9N+_X-0/^3"/BC_V<GXH_]$:?7V[\#_V(?@_^S1\%M5^#/P"U
M3Q!X9/B#5KC5O$GB^+4UO==UC4[A@;F_NKR]29IKB7&#(PRHP(]@5=OCW[.7
M_!%/]G+]DCP;J'P[_9S^/OQQ\*:%JVJ2ZEJ6E:5\3YTBGNY5599\[-RR.J("
MZE6.T<Y - 'R7_P<'11?MJ?\% OV0?\ @FS\&'&K>,K/XC+XT\;+8G>WAS1(
M6A!N;@C_ %>Z);EU!()\I!UDCS]>?\%-Y?B9\??%7P\_8&^!ECH-_JWBC5$\
M9>/+7Q)=S0V \,:-=VTK6UR\$;R*MY?O96^T+^\B6[7HK$>L_LM_L"_LG_L;
MZCKGB7X#_"M++Q%XIF\WQ5XRUG5+K5M<UJ3.<W6HWTLMS,-WS;&DV \A15+P
M9^PGX#\$?M:ZY^VCI_Q<^(-WXP\2:7%I6KP:EKT4^GR:;#))+!9);-!M@AC>
M61E\K8^YV)9B[E@#\X_^"TFC?MP?LF_&_P"!W_!:[X@>!_AY$GP/\40:'X[_
M .%=ZKJ%Q=:AX8U*;R)HYUNK>-=B--+'&021)?AL'&1V7_!UQ\-/$O[0_P#P
M2A\*?M&_ M/^$CTGX?\ Q T?QO=OI^9([G17M+F'[4H )9%-W!(6QA8C(QP%
M)'Z!_MF_L??#/]NOX$:I^S;\:=>\0V_A'7MBZ]I_A[4$M7U"-'618I)3&SJ@
M=%;"%22H!)'%,_96_8W^&7[)'P!M?V8?!/B+Q'XA\$Z?8?V?I>C>-]334Q9V
M.PH;-7>,,\&T[1'(755PJX4;: .W^$7Q3\%_''X5^&_C-\.-8BU#0/%>AVNK
M:->PN&6:VN(EEC8$>JL/H>*_,+QWX(U/]JC_ (.V?!GQ!^&B-<Z-^S?\"/L_
MQ!U.'F*VO[^+5UM[)G' E:/5HI!'U*Q2G^$X] _;@_X)A_M]? +X+W4'_!"7
M]JC4/AK9I+/<7_P0U26UN-'N1(YDD&CW-]%*^C.SESY,<D=N3)E3!@E_<?\
M@EOJ?[./@;X.6WPX\*? ?7OA!\0]9NI-1\?>#/B&+EM?U36V7=>7CZA=DMKH
M8JS"]BDE0I@'RRIC0 ]&_P""C?P2\6_M)_L!_&CX!> %W:]XO^&.MZ7HD6_:
M);R:RE6&,GL'D*J3V#&OEW_@U\^,?A3XC?\ !'WX?_#G3YA;^(OAKJ&K>&O&
M6B3+LN-,ODU&XG5)8SAD+0S1/R!RS#JIK]"J^6_B9_P2._9K\4_M!ZK^U;\&
M?&_Q"^#'Q#\18_X2SQ'\(/% TQ?$)!)#7UG-%/9W+Y+,7>#>68L6)YH ^C_$
MGC;PKX0N]*T_Q%K,5M<ZYJ2Z?H]L06DO+DH\GEQHH+,1'')(Q PB1N[$*K$?
MGI_P;K?$K5?B?;?M:ZY\6&/_  L__AK#Q"OC.&[YNK>W2"U@L8#GYA!$L,\,
M2=%$3@5]I?!;]E7P;\(-?;QYJWCGQ;XZ\6O9M9_\)=X]UO[;>0VS,K/#;QQI
M';6:.R(SK;0Q>:8XS)O\M-O!>,_^"9OP4U+]I36_VN?@_P#$3QU\*O'GBRPA
ML_&^J?#G6+>W@\31Q#$37MK=V]Q;R3(N56=8TF 8_/S0!^='[,W@74_AU^SA
M_P %<?@9X=L0GPG\/:CXO;P1IJ)FST^_GT+4)M1MH%Z1K&#8C8N O'<UL?M
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MCOX*^*F^*UEI$2P1W]I:6\HM+FZ"  E[MK.+S&ZFWB'5171?\&POC>/XV?\
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M<S6!_P!?L=594G>1/D4%2 !7W;0 4444 %%%% !1110 4444 %%%% !1110
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MXP^ _C[\2KGQAH_C#X=K=P:#X@\#^,KS1+M[.Z4+<64TUHZ2-!( 00K*P#.
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M$G[>6@?%+Q\OQ%\6Z.FD:_>S:Q;26ESIT90Q6HM6MC%&D9C0J44/E22Q+.6
M/DS_ ()=Z1I5E^V#_P %)_!5KIT":2?BG!<G3UB A,MSI=P\[[.F7;EO4]:\
M4_8,^&WP_/\ P9N^+M1'@S3!<:Q\&_'NHZM<"S027EW;:AJWV>:5L9=XO(AV
M,<E?*7&,"OT(^%O_  2Q^#GP9\7?%GQ[\//C/\3++6OC=*)OB/J+Z]:ROJ$X
M#J)HP]H5M7"2RQ@P",*K\ %$*5/ 7_!)#]G?X9?L-ZE_P3F\%?$;XA6?PFU2
MVNK2?0/[>MWFCL[IYY+NTCN6MC,D,TD[NX#YSPK*K.K@'P-\1OBQXATGPO\
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MO%Q\):<VJ)\?6M(]0:S0S);RP-++$KD95'D 9U'#E5+9VC'P9>?$OQ]\$?\
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MF*W59)<=-S 9;\:M44 1R6=I-<QWDMK&TT(80RL@+(&QN /49P,XZXJ2BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,667,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2025 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2024.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,813,297<span></span>
</td>
<td class="nump">$ 14,310,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">28,300,232<span></span>
</td>
<td class="nump">130,982,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,199,056<span></span>
</td>
<td class="nump">2,405,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets, including with affiliated entity</a></td>
<td class="nump">2,517,465<span></span>
</td>
<td class="nump">5,414,097<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">97,830,050<span></span>
</td>
<td class="nump">153,113,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">3,659,818<span></span>
</td>
<td class="nump">4,960,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investments in affiliated entity</a></td>
<td class="nump">1,613,844<span></span>
</td>
<td class="nump">2,780,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">8,113,840<span></span>
</td>
<td class="nump">9,491,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,979,654<span></span>
</td>
<td class="nump">605,315<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">113,197,206<span></span>
</td>
<td class="nump">170,951,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">2,021,860<span></span>
</td>
<td class="nump">2,365,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="nump">13,255,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,497,360<span></span>
</td>
<td class="nump">2,406,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability, including from affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,770,654<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">35,325,584<span></span>
</td>
<td class="nump">42,570,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">9,367,827<span></span>
</td>
<td class="nump">11,032,066<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">44,693,411<span></span>
</td>
<td class="nump">53,602,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2024 and 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2024 and 2023, issued and outstanding: 36,099,991 at December&#160;31, 2024 and 22,793,075 at December&#160;31, 2023</a></td>
<td class="nump">36,099<span></span>
</td>
<td class="nump">22,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,799,362,625<span></span>
</td>
<td class="nump">1,740,954,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,730,219,262)<span></span>
</td>
<td class="num">(1,622,965,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(675,667)<span></span>
</td>
<td class="num">(662,601)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">68,503,795<span></span>
</td>
<td class="nump">117,349,129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">113,197,206<span></span>
</td>
<td class="nump">170,951,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">16,200,013<span></span>
</td>
<td class="nump">19,847,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 1,351,163<span></span>
</td>
<td class="nump">$ 1,070,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">36,099,991<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">36,099,991<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 217,756<span></span>
</td>
<td class="nump">$ 832,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">75,620,340<span></span>
</td>
<td class="nump">86,676,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">36,996,338<span></span>
</td>
<td class="nump">47,582,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">112,616,678<span></span>
</td>
<td class="nump">144,772,038<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(112,398,922)<span></span>
</td>
<td class="num">(143,940,028)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,766,993<span></span>
</td>
<td class="nump">8,133,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(177,833)<span></span>
</td>
<td class="num">(1,222,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrant liability</a></td>
<td class="nump">2,808,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Loss) gain on investment in affiliated entity</a></td>
<td class="num">(1,166,443)<span></span>
</td>
<td class="nump">773,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">2,077,182<span></span>
</td>
<td class="nump">5,850,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(3,163,711)<span></span>
</td>
<td class="num">(4,711,596)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,254,126)<span></span>
</td>
<td class="num">$ (135,117,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (3.95)<span></span>
</td>
<td class="num">$ (6.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (3.95)<span></span>
</td>
<td class="num">$ (6.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">27,160,863<span></span>
</td>
<td class="nump">22,173,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">27,160,863<span></span>
</td>
<td class="nump">22,173,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,254,126)<span></span>
</td>
<td class="num">$ (135,117,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">32,403<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on short-term investments, net of tax</a></td>
<td class="num">(45,469)<span></span>
</td>
<td class="nump">40,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (107,267,192)<span></span>
</td>
<td class="num">$ (135,081,212)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,090,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 222,362,756<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,090<span></span>
</td>
<td class="nump">$ 1,710,888,191<span></span>
</td>
<td class="num">$ (1,487,847,784)<span></span>
</td>
<td class="num">$ (698,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for legal settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for legal settlement</a></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">13,999,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">5,461,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875<span></span>
</td>
<td class="nump">5,460,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(466,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="num">(466,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">11,072,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,072,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(135,117,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135,117,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">40,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">$ (3,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">22,793,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,793,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 117,349,129<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,792<span></span>
</td>
<td class="nump">1,740,954,074<span></span>
</td>
<td class="num">(1,622,965,136)<span></span>
</td>
<td class="num">(662,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,213,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">36,033,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,214<span></span>
</td>
<td class="nump">36,020,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants for cash, net of financing costs</a></td>
<td class="nump">16,146,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,146,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(353,120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="num">(353,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,595,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,595,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(107,254,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,254,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(45,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,469)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">$ 32,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,403<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">36,099,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,099,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 68,503,795<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,099<span></span>
</td>
<td class="nump">$ 1,799,362,625<span></span>
</td>
<td class="num">$ (1,730,219,262)<span></span>
</td>
<td class="num">$ (675,667)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,254,126)<span></span>
</td>
<td class="num">$ (135,117,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,752,147<span></span>
</td>
<td class="nump">2,621,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">145,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">1,377,895<span></span>
</td>
<td class="nump">736,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrant liability</a></td>
<td class="num">(2,808,608)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,984,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(32,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">6,595,108<span></span>
</td>
<td class="nump">11,072,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NonCashInterestIncomeExpense', window );">Non-cash interest on senior convertible notes</a></td>
<td class="num">(355,654)<span></span>
</td>
<td class="nump">155,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of discounts on investments</a></td>
<td class="num">(1,690,527)<span></span>
</td>
<td class="num">(4,686,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Realized loss on sales of short-term investments</a></td>
<td class="nump">1,905,369<span></span>
</td>
<td class="nump">4,805,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net (gain) loss on disposal of fixed assets</a></td>
<td class="num">(22,466)<span></span>
</td>
<td class="nump">317,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss (gain) on equity investment in affiliated entity</a></td>
<td class="nump">1,166,443<span></span>
</td>
<td class="num">(773,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="num">(2,077,182)<span></span>
</td>
<td class="num">(5,850,626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, including from affiliated entities</a></td>
<td class="nump">1,206,172<span></span>
</td>
<td class="nump">9,332,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, including from affiliated entities</a></td>
<td class="nump">1,483,393<span></span>
</td>
<td class="nump">39,020,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">38,900<span></span>
</td>
<td class="nump">78,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses, including due to affiliated entities</a></td>
<td class="num">(3,367,087)<span></span>
</td>
<td class="num">(45,989,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="num">(343,522)<span></span>
</td>
<td class="num">(8,228,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(1,573,401)<span></span>
</td>
<td class="num">(2,020,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability, including from affiliated entity</a></td>
<td class="num">(109,407)<span></span>
</td>
<td class="num">(2,453,297)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(104,076,553)<span></span>
</td>
<td class="num">(124,365,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(54,138,026)<span></span>
</td>
<td class="num">(203,475,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="nump">158,637,578<span></span>
</td>
<td class="nump">284,932,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(487,832)<span></span>
</td>
<td class="num">(320,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of capital assets</a></td>
<td class="nump">59,319<span></span>
</td>
<td class="nump">6,219,263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">104,071,039<span></span>
</td>
<td class="nump">87,355,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible senior notes</a></td>
<td class="num">(16,415,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of pre-funded warrants, net of issuance costs</a></td>
<td class="nump">16,146,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">36,033,473<span></span>
</td>
<td class="nump">5,461,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">16,063,796<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">67,675<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(420,795)<span></span>
</td>
<td class="num">(466,646)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">51,475,546<span></span>
</td>
<td class="nump">4,995,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">32,403<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">51,502,435<span></span>
</td>
<td class="num">(32,018,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">14,310,862<span></span>
</td>
<td class="nump">46,329,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">65,813,297<span></span>
</td>
<td class="nump">14,310,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">533,487<span></span>
</td>
<td class="nump">1,066,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock as part of litigation settlement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Warrants, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text">The Company<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#8217;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body's cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA),  HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $107.3 million for the year ended December&#160;31, 2024. The Company had working capital of $62.5 million and an accumulated deficit of $1.7 billion as of December&#160;31, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $94.1 million as of December 31, 2024 are not sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements.  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of 10,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 10,000,000 shares of common stock (the &#8220;Warrants&#8221;), at an offering price of $3.00 per share and accompanying Warrant. The exercise price of the Warrants is $3.76 per share. The net proceeds from the December 2024 Offering were $27.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;April 2024 Offering&#8221;), relating to the issuance and sale of 2,536,258 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $94.1 million as of December&#160;31, 2024 are expected to be sufficient to support the Company's planned operations through the fourth quarter of 2025. The Company's current </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $60.8&#160;million from equity offerings during the year ending December 31, 2024, and $6.1&#160;million and $5.5&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2024 and 2023, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the fourth quarter of 2025. The Company's consolidated financial statements as of and for the year ended December&#160;31, 2024 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, and from time to time in the future may be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of its common stock (the &#8220;Reverse Stock Split&#8221;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#8217; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM"), the President and Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States, as further described in Note 16.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses and common stock warrant liability. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The estimated fair value of the common stock warrant liability is determined by using the Black-Scholes pricing model, as discussed in Note 5.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2024 and 2023.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2024 and 2023. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Affiliated Entities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable from affiliated entities are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. There was no allowance for doubtful accounts for potential credit losses as of December&#160;31, 2024 or 2023.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:f-355">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. No impairment losses have been recognized related to long-lived assets for the years ended December 31, 2024 or 2023.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting period while the warrants are outstanding. The Pre-Funded Warrants issued in April 2024 met all the criteria for equity classification and were recorded as a component of additional paid-in capital on issuance. However, the Warrants issued in December 2024 did not meet all the criteria for equity classification and were recorded as a liability at fair value upon issuance. The Warrants met the definition of a derivative and did not meet any scope exceptions under ASC 815. As a result, the fair value of the liability associated with the Warrants will be remeasured at the end of each reporting period while the Warrants are outstanding, and any change in fair value between reporting periods will be recognized as gain or loss on the consolidated statement of operations for that reporting period. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs associated with the issuance of the Warrants classified as a liability were expensed at the time of issuance and have been included as part of other expense, net, on the consolidated statement of operations for the year ended December 31, 2024. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carryforwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $349.2 million and $327.5 million at December&#160;31, 2024 and 2023, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. The outstanding Pre-Funded Warrants (see Note 10) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the year ended December 31, 2024 given their nominal exercise price.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 9) was considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, basic and diluted net loss per share are the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the year ended December 31, 2024 and 2023 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,655,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,173,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,160,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,173,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.95)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804,214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-and market-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-07. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company has adopted ASU 2023-07 and included the segment disclosures in Note 16 below.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance its consolidated financial statements. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2024-03. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024-03 requires public business entities to disaggregate operating expenses into specific categories such as employee compensation, depreciation, and intangible asset amortization, by relevant expense caption on the statement of operations. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition and Concentration of Credit Risk</a></td>
<td class="text">Revenue Recognition and Concentration of Credit Risk<div style="margin-bottom:3pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the years ended December&#160;31, 2024 and 2023, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.407%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No revenue recognized during the years ended December&#160;31, 2024 and 2023 was in deferred revenue as of December 31, 2023 and 2022, respectively. </span></div>As of December&#160;31, 2024 and 2023, the Company had no accounts receivable balance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements  <div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated in 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. The 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounts for the 2021 amendment under ASC Topic 808. Reimbursements from Advaccine are recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility is assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $0 and $3.6&#160;million respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), which was amended in June 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, the Company received $218,000 and $245,000, respectively, from the ApolloBio Agreement that was recorded as revenue. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations (CEPI)</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56&#160;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, the Company received funding of $1.6 million in connection with the final close-out of these grants, which was recorded as contra-research and development expense. During the year ended December 31, 2023, the Company received funding of $1.8 million in connection with these grants.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Gates awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2024 and 2023, the Company recorded $39,000 and $70,000, respectively, as contra-research and development expense related to the Gates dMAb grant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2024 and 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,167,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,876,951)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and 2023, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $900 and $1,000, respectively, and gross realized loss on investments of $1.9 million and $4.8 million, respectively. During the years ended December&#160;31, 2024 and 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $2.1&#160;million and $5.9&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2024 and&#160;2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2024, the Company had&#160;19&#160;available-for-sale securities with an aggregate total unrealized loss of $1.9 million. All of the securities had been in a loss position for longer than 12 months as of December&#160;31, 2024. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2024&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2024, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,914,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,094,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2024 consisted of mutual funds and the Company&#8217;s investment in its affiliated entity, PLS. Level 1 assets at December 31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2024 and 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of December&#160;31, 2024 or 2023. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 liabilities held as of December 31, 2024 consisted of liabilities associated with the Warrants to purchase  common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 10 for additional information about the liability-classified warrants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. The following assumptions were used to estimate the fair value of the warrant liability:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">On Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#8217;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $2.8&#160;million on the consolidated statement of operations for the year ended December 31, 2024. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s total Level 3 financial liabilities for the year ended December 31, 2024:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock warrants in December 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,063,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-574">Decrease in fair value of liability</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,808,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2024 and 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,167,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,876,951)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and 2023, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $900 and $1,000, respectively, and gross realized loss on investments of $1.9 million and $4.8 million, respectively. During the years ended December&#160;31, 2024 and 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $2.1&#160;million and $5.9&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2024 and&#160;2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2024, the Company had&#160;19&#160;available-for-sale securities with an aggregate total unrealized loss of $1.9 million. All of the securities had been in a loss position for longer than 12 months as of December&#160;31, 2024. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2024&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2024, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,914,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,094,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2024 consisted of mutual funds and the Company&#8217;s investment in its affiliated entity, PLS. Level 1 assets at December 31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2024 and 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of December&#160;31, 2024 or 2023. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 liabilities held as of December 31, 2024 consisted of liabilities associated with the Warrants to purchase  common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 10 for additional information about the liability-classified warrants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. The following assumptions were used to estimate the fair value of the warrant liability:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">On Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#8217;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $2.8&#160;million on the consolidated statement of operations for the year ended December 31, 2024. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s total Level 3 financial liabilities for the year ended December 31, 2024:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock warrants in December 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,063,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-574">Decrease in fair value of liability</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,808,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,091,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,432,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,200,013&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,847,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt">As of December 31, 2024 and 2023, balance included $0 and $1.5&#160;million, respectively, of prepaid manufacturing expenses.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As of December 31, 2024 and 2023, balance included $0 and $4.3&#160;million, respectively, of liability for unused grant funding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text">Fixed Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,761,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,390,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,370,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,571,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,431,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,416,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,093,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,083,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,122,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,462,447)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,659,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,917,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,753,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,164,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,078,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,816,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,204,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,812,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,851,913)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,960,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Depreciation expense for the years ended December&#160;31, 2024 and 2023 was $1.8 million and $2.6 million, respectively. The Company determined that the carrying value of its fixed assets was not impaired during the periods presented. During the year ended December 31, 2024, the Company sold fixed assets with no net book value for a gain of $59,000 and disposed of fixed assets with a net book value of $37,000. During the year ended December 31, 2023, the Company sold fixed assets with no net book value for a gain of $148,000 and disposed of fixed assets with a net book value of $466,000.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets <div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, and a general decline in equity values in the biotechnology industry, the Company performed a quantitative impairment assessment of </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">its goodwill and long-lived assets. The goodwill was determined to be fully impaired as of September 30, 2023, and the Company recorded an impairment charge of $10.5&#160;million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2023, the Company also recorded an impairment charge of $2.0&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $16.9&#160;million obligation in full, including accrued interest.</span></div>For the years ended December&#160;31, 2024 and 2023, &#160;the Company recognized $178,000 and $1.2&#160;million, respectively, of interest expense related to the Notes, of which $178,000 and $1.1 million, respectively, related to the contractual interest coupon.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:47.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2024, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $326.40 per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of 275 shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Offerings of Common Stock and Warrants</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed the December 2024 Offering (see &#8220;Basis of Presentation and Liquidity&#8221; in Note 2 above). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Warrant issued in the December 2024 Offering has an initial exercise price per share of $3.76, subject to certain adjustments. The Warrants may be exercised at any time, in whole or in part, until expiration on December 16, 2029. In the event there is no effective registration statement covering the shares of common stock underlying a Warrant exercise, the Warrants may be exercised via cashless exercise. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 4.99% (or, for certain holders who so elected prior to the issuance of the Warrants, 9.99%) of the Company&#8217;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#8217; notice to the Company subject to the terms of the Warrants. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Warrants are not indexed to the Company&#8217;s common stock, the Company recorded a liability for the Warrants at fair value upon issuance on the Company's consolidated balance sheet. The common stock warrant liability is remeasured to fair value at the end of each reporting period. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, no Warrants issued in the December 2024 Offering had been exercised.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed the April 2024 Offering (see &#8220;Basis of Presentation and Liquidity&#8221; in Note 2 above). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Pre-Funded Warrant issued in the April 2024 Offering has an initial exercise price per share of $0.001, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the Company&#8217;s outstanding Common </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#8217; notice to the Company subject to the terms of the Pre-Funded Warrants. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Pre-Funded Warrants issued in the April 2024 Offering are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of December 31, 2024.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, no Pre-Funded Warrants had been exercised.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market Sales Agreements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2024, the Company entered into an Equity Distribution Agreement (the "2024 Sales Agreement") with an outside sales agent (the "Sales Agent") for the offer and sale of its common stock for an aggregate offering price of up to $60.0&#160;million. The 2024 Sales Agreement provides that the Sales Agent is entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agent under the 2024 Sales Agreement, and the Company has provided the Sales Agent with certain indemnification rights. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company sold 133,900 shares of its common stock under the 2024 Sales Agreement. The sales were made at a weighted average price of $7.02 per share, resulting in aggregate net proceeds of $925,000. As of December 31, 2024, there was $59.1&#160;million of remaining capacity under the 2024 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the sales agents were entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold 543,620 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2&#160;million. During the year ended December 31, 2023, the Company sold 875,305 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $6.33 per share, resulting in aggregate net proceeds of $5.5&#160;million. The 2021 Sales Agreement was terminated in August 2024 in connection with the entry into the 2024 Sales Agreement described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to a securities class action litigation settlement, as described in Note 11.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#8220;2023 Plan&#8221;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2023 Plan will not exceed the sum of 1,166,666 shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#8220;2016 Plan&#8221;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At December&#160;31, 2024, the Company had 800,526 shares of common stock available for future grant under the 2023 Plan, 188,082 shares underlying outstanding but unvested RSUs and 282,579 shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over three years and have a maximum contractual term of ten years. The 2023 Plan terminates by its terms on March&#160;24, 2033.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. At December&#160;31, 2024, the Company had 129,000 shares underlying outstanding but unvested RSU and options outstanding to purchase 904,669 shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over three years and have a maximum contractual term of ten years. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed 166,666 shares. At December&#160;31, 2024 the Company had 84,328 shares of common stock available for future grant under the 2022 Inducement Plan, 20,829 shares underlying outstanding but unvested RSUs and options outstanding to purchase 53,684 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2024, the Company had options outstanding to purchase 96,296 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vested over three years and have a maximum contractual term of ten years. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2024 and 2023 was $6.4 million and $10.4 million, respectively, of which $2.8 million and $4.5 million was included in research and development expenses and $3.6 million and $5.9 million was included in general and administrative expenses, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024 and 2023, there was $2.1 million and $4.3 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.5 years and 1.3 years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024 and 2023, there was $2.0 million and $3.5 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.6 years and 1.5 years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2024 and 2023 was $226,000 and $669,000, respectively. As of December&#160;31, 2024, options to purchase 66,056 shares of common stock granted to non-employees remained outstanding.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2024:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:26.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.78-$18.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.01-$39.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39.01-$52.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$52.01-$90.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90.01-$130.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.01-$233.28</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the aggregate intrinsic value of options outstanding was $1,000, the aggregate intrinsic value of options exercisable was $0, and the weighted average remaining contractual term of options exercisable was 5.5 years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, the aggregate intrinsic value of unvested RSUs was $618,000 and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2024 was $1.3 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, options to purchase 1,337,228 shares of common stock and 337,911 RSUs were expected to vest.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2024 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2024 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $139.02 for the 38,503 options which expired during the year ended December&#160;31, 2024 and $38.86 for the 9,357 options which expired during the year ended December&#160;31, 2023. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $6.69 and $11.19 for options granted during the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $8.30 and $10.34 per share for RSUs granted during the years ended December&#160;31, 2024 and 2023, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $68,000 in proceeds from the exercise of stock options during the years ended December&#160;31, 2024. No stock options were exercised during the year ended December 31, 2023. The aggregate intrinsic value of options exercised was $39,000 during the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance- and Market-Based RSUs </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, the Company granted performance- and-market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. As of December 31, 2024, 83,800 performance- and market-based RSUs were outstanding.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the target number of RSUs underlying each PSU Award, up to 70% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#8217;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining 30% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#8217;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#8220;Relative TSR&#8221;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#8220;Performance Period&#8221;), expressed as a percentile ranking.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Market-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from 50% of the target number of RSUs for performance at a specified threshold percentile, to 100% of the target number of RSUs for performance at the target percentile, and up to 150% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#8217;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#8217;s total stockholder return is negative for the Performance Period.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company valued the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value was affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the three-year period ranging from zero to 150% of the target number of awards granted. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Milestone-based RSUs was $643,000 based on the grant date closing price per share of $10.96. As of December 31, 2024, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the year then ended.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the Market-based RSUs was $269,000 based on the fair value of $10.69 per share as determined using the Monte Carlo simulation method. For the year ended December 31, 2024, the Company recognized $44,000 in stock-based compensation for the Market-based RSUs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2024 Performance-Based Awards</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company granted performance-based stock options and RSUs (such performance-based grants, the "December 2024 Awards") to key employees under the 2023 Plan. Each award was expressed as a target number of stock options and RSUs. With respect to the December 2024 Awards, the Company's Board of Directors established specified performance goals and a corresponding performance period over which the goals must be attained, the satisfaction of which are conditions to earning the December 2024 Awards and vesting of the underlying stock options and RSUs. As of December 31, 2024, December 2024 Awards were outstanding covering 25,686 shares of common stock underlying stock options and 19,314 shares of common stock underlying RSUs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of the performance-based RSUs was $34,000 based on the grant date closing price per share of $1.78. The grant date fair value of the performance-based stock options was $38,000 based on the Black-Scholes per share value of $1.46. As of December 31, 2024, the underlying performance milestones of the December 2024 Awards were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the year then ended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 56,600 square feet of office, laboratory, and manufacturing space in San Diego, California and approximately 57,400 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2024 of 2.4 to 5.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the leases. Rent payments under the leases include base rent with annual increases of approximately two to three percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,435,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,570,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,865,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,497,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,368,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2024 and 2023 were $2.6 million and $3.5 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Company entered into agreements to sublease a total of approximately 11,400 square feet in its Plymouth Meeting headquarters with sublease terms through December 31, 2026.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, the Company amended the sublease agreements for its Plymouth Meeting headquarters to extend one sublease term through December 31, 2027 and the other through December 31, 2029.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a purported shareholder class action complaint was filed naming the Company and its former President and Chief Executive Officer as defendants and alleging that the Company made materially false and misleading statements in violation of certain federal securities laws. In 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $30.0&#160;million in cash and issued 760,083 shares of its common stock, with a value of $14.0&#160;million at the time, to settle all outstanding claims. The Company's insurance carriers paid the $30.0&#160;million cash component of the settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, a purported shareholder derivative complaint was filed naming eight current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff sought unspecified monetary damages on behalf of the Company as well as governance reforms. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 2020 and 2022, additional shareholder derivative complaints were filed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the court entered an order preliminarily approving a proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $1.2&#160;million to plaintiffs&#8217; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI, but VGXI later discontinued its third-party claims. The Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#8217;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,979,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,351)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no provision for or benefit from income taxes for the years ended December 31, 2024 and 2023. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2024 and 2023, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,523,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,375,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,543,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,922,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,749,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,394,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,846,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,056,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2024 and 2023 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,204,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,143,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,336,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,734,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,720,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,808,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,928,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,486,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,224,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,493,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,704,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,993,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,704,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,993,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2024, the Company had federal, California and other state tax net operating loss (NOL) carryforwards of $1.1 billion, $259.9 million and $88.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $801.9 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2025, and the California and other state NOL carryforwards will begin and have begun to expire in 2028 and 2025, respectively, unless previously utilized. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also had Korean NOL carryforward of $1.0&#160;million as of December 31, 2024.  The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2035, unless previously utilized.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2024, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $46.1 million and $7.9 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2024. As a result of the analysis, the Company estimates that approximately $5.3 million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes, could further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2024 and 2023, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,114,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,608,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,114,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $22.9 million and $20.5 million as of December&#160;31, 2024 and 2023, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2021 and state and local income tax examinations before 2020. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#8220;IRS&#8221;), state, local or foreign tax examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) Plan<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#8217; contributions, up to 6% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $961,000 and $1.4 million for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned 597,808 shares of common stock in PLS as of December 31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a 17.3% and 17.8% ownership interest, respectively. The Company's investment in PLS is recorded as investment in affiliated entity on the consolidated balance sheet as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and was valued at $1.6&#160;million and $2.8&#160;million, respectively, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the closing price of the shares on the Korea New Exchange Market at the applicable balance sheet date</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon expiration of the 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the exclusive right to in-license new intellectual property developed under this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $13.6&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19. In August 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the sub-grant was amended to a total of $12.5&#160;million in funding through September 2025. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company received a $1.2&#160;million sub-grant through Wistar, which was amended in 2024 to $2.4&#160;million with funding through November 2024, with an option for an additional $4.2&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2024 and 2023, the Company recorded $482,000 and $1.0 million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements. Research and development expenses recorded from Wistar for the years ended December&#160;31, 2024 and 2023 were $1.5 million and $1.8 million, respectively. At December&#160;31, 2024 and 2023, the Company had an accounts receivable balance of $1.2 million and $2.4 million, respectively, and an accounts payable and accrued liability balance of $1.4 million and $1.1 million, respectively, related to Wistar. As of December&#160;31, 2024 and 2023, the Company had a prepaid expense balance of $0 and $20,000, respectively, and recorded $0 and $22,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos Therapeutics ("Geneos") to develop and commercialize neoantigen-based personalized cancer therapies. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company held 23% of the outstanding equity of Geneos, on an as-converted to common stock basis. The Company accounts for its common stock investment in Geneos as an equity method investment under ASC 323. Due to continuing net losses of Geneos, the Company&#8217;s investment had been reduced to $0 as of each of December 31, 2024 and 2023. The Company has not made any further investment in Geneos. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos, as the Company has no obligation to fund Geneos.</span></div>The Company continues to exclusively license its immunotherapy platform and CELLECTRA&#160;technology to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information<div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:69.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.187%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,  </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity<br/></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1019">Research and development:</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3107</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,930,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,840,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-5401 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other programs (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,701,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Engineering and device-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,393,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,863,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,606,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other unallocated expenses (b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,259,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,905,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,996,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,582,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,616,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,772,038&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,222,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,808,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,166,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,163,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,711,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,352)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          (b) Includes impairment of intangible assets of $2.0&#160;million recorded in 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2025 through the date of these financial statements, the Company sold 512,518 shares of common stock under the 2024 Sales Agreement at a weighted average price of $2.16 per share, for net proceeds of $1.1&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,254,126)<span></span>
</td>
<td class="num">$ (135,117,352)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data (including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data) (collectively, &#8220;Information Systems and Data&#8221;).  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Information Technology department (&#8220;IT Department&#8221;) (including its Senior Director), with support from service providers, helps identify, assess and manage our cybersecurity threats and risks. The IT Department identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment and our risk profile using various methods. For example, the methods include manual and automated tools; subscriptions to reports and services that identify cybersecurity threats; analysis of threat and threat actor reports; threat environment scans; law enforcement coordination; audits; threat assessments; and vulnerability assessments.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: security incident response strategies; tools designed to detect and respond to security incidents; data encryption strategies; access controls; physical security controls; asset management strategies; systems monitoring; personnel training; penetration testing; and cybersecurity insurance.    </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes.  For example, the IT Department works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business and our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example: professional services firms (including legal counsel); cybersecurity consultants; cybersecurity software providers; managed cybersecurity service providers; and penetration testing firms.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use service providers to perform a variety of functions throughout our business, such as application providers; hosting providers; and contract research organizations. Depending on the nature of the services provided, in order to analyze the cybersecurity processes of certain vendors we review their internal security assessment reports and certifications, if available.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including in particular under the caption &#8220;if our information technology systems or those of third parties upon which we rely or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to, regulatory investigations and actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse consequences.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data (including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data) (collectively, &#8220;Information Systems and Data&#8221;).  </span></div>Our Information Technology department (&#8220;IT Department&#8221;) (including its Senior Director), with support from service providers, helps identify, assess and manage our cybersecurity threats and risks. The IT Department identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment and our risk profile using various methods. For example, the methods include manual and automated tools; subscriptions to reports and services that identify cybersecurity threats; analysis of threat and threat actor reports; threat environment scans; law enforcement coordination; audits; threat assessments; and vulnerability assessments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">As indicated above, the audit committee receives reports from the Senior Director of IT or other designee concerning significant cybersecurity threats and risk and the processes we have implemented to address them.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including the Senior Director of the IT Department. This individual has previously held roles as a head of cybersecurity, cybersecurity consultant and information security specialist for other organizations. This individual holds several certifications related to cybersecurity including Certified Information Systems Security Professional (CISSP).  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IT Department reports to our Chief Financial Officer (CFO) who is responsible for helping the IT Department hire appropriate personnel, integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The Senior Director of the IT Department is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CFO.   The Senior Director of IT and the CFO work with our incident response team to help mitigate and remediate cybersecurity incidents of which they </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are notified.  In addition, our incident response and vulnerability management processes include reporting to the audit committee of the board of directors for certain cybersecurity incidents. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated above, the audit committee receives reports from the Senior Director of IT or other designee concerning significant cybersecurity threats and risk and the processes we have implemented to address them. The audit committee also receives various written reports, summaries or presentations related to cybersecurity threats, risk and mitigation. In turn, the audit committee routinely provides reports to the board on cybersecurity matters.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">The IT Department reports to our Chief Financial Officer (CFO) who is responsible for helping the IT Department hire appropriate personnel, integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The Senior Director of the IT Department is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">This individual has previously held roles as a head of cybersecurity, cybersecurity consultant and information security specialist for other organizations. This individual holds several certifications related to cybersecurity including Certified Information Systems Security Professional (CISSP).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including the Senior Director of the IT Department. This individual has previously held roles as a head of cybersecurity, cybersecurity consultant and information security specialist for other organizations. This individual holds several certifications related to cybersecurity including Certified Information Systems Security Professional (CISSP).  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IT Department reports to our Chief Financial Officer (CFO) who is responsible for helping the IT Department hire appropriate personnel, integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The Senior Director of the IT Department is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CFO.   The Senior Director of IT and the CFO work with our incident response team to help mitigate and remediate cybersecurity incidents of which they </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are notified.  In addition, our incident response and vulnerability management processes include reporting to the audit committee of the board of directors for certain cybersecurity incidents. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated above, the audit committee receives reports from the Senior Director of IT or other designee concerning significant cybersecurity threats and risk and the processes we have implemented to address them. The audit committee also receives various written reports, summaries or presentations related to cybersecurity threats, risk and mitigation. In turn, the audit committee routinely provides reports to the board on cybersecurity matters.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Liquidity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss of $107.3 million for the year ended December&#160;31, 2024. The Company had working capital of $62.5 million and an accumulated deficit of $1.7 billion as of December&#160;31, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $94.1 million as of December 31, 2024 are not sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements.  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of 10,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 10,000,000 shares of common stock (the &#8220;Warrants&#8221;), at an offering price of $3.00 per share and accompanying Warrant. The exercise price of the Warrants is $3.76 per share. The net proceeds from the December 2024 Offering were $27.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2024, the Company closed an underwritten registered direct offering (the &#8220;April 2024 Offering&#8221;), relating to the issuance and sale of 2,536,258 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#8220;Pre-Funded Warrants&#8221;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and short-term investments of $94.1 million as of December&#160;31, 2024 are expected to be sufficient to support the Company's planned operations through the fourth quarter of 2025. The Company's current </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $60.8&#160;million from equity offerings during the year ending December 31, 2024, and $6.1&#160;million and $5.5&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2024 and 2023, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the fourth quarter of 2025. The Company's consolidated financial statements as of and for the year ended December&#160;31, 2024 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div>The Company is, and from time to time in the future may be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div>The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM"), the President and Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States, as further described in Note 16.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div>Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses and common stock warrant liability. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The estimated fair value of the common stock warrant liability is determined by using the Black-Scholes pricing model, as discussed in Note 5.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short Term Investments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2024 and 2023. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable from Affiliated Entities</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Affiliated Entities</span></div>Accounts receivable from affiliated entities are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:f-355">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div>The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantsPolicyPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent </span></div>reporting period while the warrants are outstanding. The Pre-Funded Warrants issued in April 2024 met all the criteria for equity classification and were recorded as a component of additional paid-in capital on issuance. However, the Warrants issued in December 2024 did not meet all the criteria for equity classification and were recorded as a liability at fair value upon issuance. The Warrants met the definition of a derivative and did not meet any scope exceptions under ASC 815. As a result, the fair value of the liability associated with the Warrants will be remeasured at the end of each reporting period while the Warrants are outstanding, and any change in fair value between reporting periods will be recognized as gain or loss on the consolidated statement of operations for that reporting period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carryforwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $349.2 million and $327.5 million at December&#160;31, 2024 and 2023, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div>The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div>The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantRevenuePolicyTextBlock', window );">Grants</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses - Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. The outstanding Pre-Funded Warrants (see Note 10) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the year ended December 31, 2024 given their nominal exercise price.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 9) was considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, basic and diluted net loss per share are the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to service-based RSUs, performance-and market-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span>The Company recognizes forfeitures as they occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-07. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company has adopted ASU 2023-07 and included the segment disclosures in Note 16 below.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2023-09. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance its consolidated financial statements. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASU No. 2024-03. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024-03 requires public business entities to disaggregate operating expenses into specific categories such as employee compensation, depreciation, and intangible asset amortization, by relevant expense caption on the statement of operations. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share for the year ended December 31, 2024 and 2023 are calculated as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,655,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,173,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,160,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,173,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.95)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because of Their Anti-Dilutive Effect</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-and market-based restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804,214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used To Estimate The Fair Value Of Stock Options</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue From External Customers</a></td>
<td class="text">The following table indicates the percentage of total revenues in excess of 10% with any single customer:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.407%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloBio Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2024 and 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,926,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445,706)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,980,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,167,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,876,951)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,389,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,522,888)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,164,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,978,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,973)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,873,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927,161)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,989,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,300,232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,480,709&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,914,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,094,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,819,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,866,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,189,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,982,913&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,056,121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,763,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,836,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The following assumptions were used to estimate the fair value of the warrant liability:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">On Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.3%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.4%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">111%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s total Level 3 financial liabilities for the year ended December 31, 2024:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock warrants in December 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,063,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-574">Decrease in fair value of liability</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,808,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,255,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical expenses (a)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,410,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,414,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable And Accrued Expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,091,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,007,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses (b) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,432,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,200,013&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,847,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt">As of December 31, 2024 and 2023, balance included $0 and $1.5&#160;million, respectively, of prepaid manufacturing expenses.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As of December 31, 2024 and 2023, balance included $0 and $4.3&#160;million, respectively, of liability for unused grant funding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule Of Fixed Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2024 and 2023 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,761,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,390,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,370,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,835,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,571,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,431,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,416,232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,093,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,083,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,122,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,462,447)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,659,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,917,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,753,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,164,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,538,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,078,165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,816,577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,204,090)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,812,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,851,913)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,960,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock Authorized, Issued And Outstanding</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:47.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2024:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:26.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.78-$18.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$18.01-$39.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39.01-$52.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$52.01-$90.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90.01-$130.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.01-$233.28</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Stock Options, Activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2024 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule Of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2024 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used To Estimate The Fair Value Of Warrants</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Monte Carlo simulation method were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Maturities Of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,483,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,435,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,570,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,865,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,497,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,368,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule Of Components Of Pretax Loss From Operations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134,979,579)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,351)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2024 and 2023, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,523,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,375,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,543,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,922,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,749,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,394,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,846,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,099,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,056,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Of Deferred Tax Assets And Liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2024 and 2023 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,204,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,143,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,336,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,624,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,734,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,822,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,720,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,808,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,928,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,486,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,224,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(327,493,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,993,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,704,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,993,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,704,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,993,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock', window );">Schedule Of Operating Loss And Tax Credit Carryforward Expirations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule Of Unrecognized Tax Benefits Rollforward</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,114,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(841,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,608,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,114,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:69.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.187%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,  </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity<br/></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1019">Research and development:</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-3107</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,930,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,840,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INO-5401 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,293,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,758,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other programs (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,701,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Engineering and device-related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,393,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,863,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,821,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,606,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other unallocated expenses (b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,259,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,905,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,996,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,582,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,616,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,772,038&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,222,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,808,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,166,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,850,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,163,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,711,596)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,254,126)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,117,352)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          (b) Includes impairment of intangible assets of $2.0&#160;million recorded in 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 18, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,254,126<span></span>
</td>
<td class="nump">$ 135,117,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,219,262<span></span>
</td>
<td class="nump">$ 1,622,965,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,033,473<span></span>
</td>
<td class="nump">$ 5,461,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,224,000<span></span>
</td>
<td class="nump">327,493,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember', window );">December 2024 Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in USD per share) | $ / shares</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_December2024OfferingMember', window );">December 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="nump">$ 27,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_December2024OfferingMember', window );">December 2024 Offering | December 2024 Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in USD per share) | $ / shares</a></td>
<td class="nump">3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_April2024OfferingMember', window );">April 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_April2024OfferingMember', window );">April 2024 Offering | April 2024 Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | December 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | December 2024 Offering | December 2024 Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares) | shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | April 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,536,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | April 2024 Offering | April 2024 Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,135,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of current assets and current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_December2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_December2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_April2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_April2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ino_April2024OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ino_April2024OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (107,254,126)<span></span>
</td>
<td class="num">$ (135,117,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WeightedAverageNumberOfSharesOutstanding', window );">Weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">25,655,527<span></span>
</td>
<td class="nump">22,173,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants', window );">Weighted-average pre-funded warrants (in shares)</a></td>
<td class="nump">1,505,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)</a></td>
<td class="nump">27,160,863<span></span>
</td>
<td class="nump">22,173,662<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)</a></td>
<td class="nump">27,160,863<span></span>
</td>
<td class="nump">22,173,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (3.95)<span></span>
</td>
<td class="num">$ (6.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (3.95)<span></span>
</td>
<td class="num">$ (6.09)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WeightedAverageNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WeightedAverageNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">11,804,214<span></span>
</td>
<td class="nump">1,658,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">1,337,228<span></span>
</td>
<td class="nump">1,128,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">337,911<span></span>
</td>
<td class="nump">274,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-and market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">128,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">254,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in estimation of fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 217,756<span></span>
</td>
<td class="nump">$ 832,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_ApolloBioCorporationMember', window );">ApolloBio Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 217,756<span></span>
</td>
<td class="nump">$ 245,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_ApolloBioCorporationMember', window );">ApolloBio Corporation | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 586,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entity | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_ApolloBioCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_ApolloBioCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AllOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - Collaborative Arrangement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">ApolloBio Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Lassa Fever And MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | D N A Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 30,167,433<span></span>
</td>
<td class="nump">$ 134,873,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">9,750<span></span>
</td>
<td class="nump">36,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,876,951)<span></span>
</td>
<td class="num">(3,927,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">28,300,232<span></span>
</td>
<td class="nump">130,982,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">25,926,415<span></span>
</td>
<td class="nump">55,389,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(1,445,706)<span></span>
</td>
<td class="num">(3,522,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">24,480,709<span></span>
</td>
<td class="nump">51,866,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,164,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,189,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">2,980,273<span></span>
</td>
<td class="nump">2,978,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">9,750<span></span>
</td>
<td class="nump">11,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(281)<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 2,989,742<span></span>
</td>
<td class="nump">$ 2,990,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 1,260,745<span></span>
</td>
<td class="nump">$ 1,340,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(430,964)<span></span>
</td>
<td class="num">(403,973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 829,781<span></span>
</td>
<td class="nump">$ 936,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">$ 2,077,182<span></span>
</td>
<td class="nump">$ 5,850,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | position</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Decrease in fair value of liability</a></td>
<td class="nump">$ 2,808,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares) | shares</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 28,300,232<span></span>
</td>
<td class="nump">$ 130,982,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">24,480,709<span></span>
</td>
<td class="nump">51,866,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,989,742<span></span>
</td>
<td class="nump">2,990,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">829,781<span></span>
</td>
<td class="nump">936,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">28,300,232<span></span>
</td>
<td class="nump">130,982,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">1,613,844<span></span>
</td>
<td class="nump">2,780,287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">29,914,076<span></span>
</td>
<td class="nump">133,763,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockWarrantLiabilityFairValue', window );">Common stock warrant liability</a></td>
<td class="nump">13,255,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">13,255,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">24,480,709<span></span>
</td>
<td class="nump">127,056,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">1,613,844<span></span>
</td>
<td class="nump">2,780,287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">26,094,553<span></span>
</td>
<td class="nump">129,836,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockWarrantLiabilityFairValue', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">3,819,523<span></span>
</td>
<td class="nump">3,926,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">3,819,523<span></span>
</td>
<td class="nump">3,926,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockWarrantLiabilityFairValue', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockWarrantLiabilityFairValue', window );">Common stock warrant liability</a></td>
<td class="nump">13,255,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">13,255,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">24,480,709<span></span>
</td>
<td class="nump">51,866,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">24,480,709<span></span>
</td>
<td class="nump">51,866,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,189,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,189,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,989,742<span></span>
</td>
<td class="nump">2,990,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,989,742<span></span>
</td>
<td class="nump">2,990,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">829,781<span></span>
</td>
<td class="nump">936,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">829,781<span></span>
</td>
<td class="nump">936,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CommonStockWarrantLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CommonStockWarrantLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 16, 2024 </div>
<div>yr</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantLiabilityMeasurementInput', window );">Warrant liability, measurement input</a></td>
<td class="nump">0.044<span></span>
</td>
<td class="nump">0.043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantLiabilityMeasurementInput', window );">Warrant liability, measurement input</a></td>
<td class="nump">1.11<span></span>
</td>
<td class="nump">1.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantLiabilityMeasurementInput', window );">Warrant liability, measurement input</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WarrantLiabilityMeasurementInput', window );">Warrant liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WarrantLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WarrantLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company&#8217;s Total Level 3 Financial Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change in fair value of common stock warrant liability<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of common stock warrants in December 2024</a></td>
<td class="nump">16,063,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Decrease in fair value of liability</a></td>
<td class="num">(2,808,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 13,255,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidClinicalExpensesCurrent', window );">Prepaid clinical expenses</a></td>
<td class="nump">$ 627,962<span></span>
</td>
<td class="nump">$ 3,410,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">1,889,503<span></span>
</td>
<td class="nump">2,003,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,517,465<span></span>
</td>
<td class="nump">$ 5,414,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidManufacturingExpenseCurrent', window );">Prepaid manufacturing expense, current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantLiability', window );">Unused grant funding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade accounts payable</a></td>
<td class="nump">5,091,503<span></span>
</td>
<td class="nump">3,577,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">10,007,180<span></span>
</td>
<td class="nump">9,837,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,101,330<span></span>
</td>
<td class="nump">6,432,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 16,200,013<span></span>
</td>
<td class="nump">$ 19,847,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccountsPayableAndAccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccountsPayableAndAccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 20,122,265<span></span>
</td>
<td class="nump">$ 25,812,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(16,462,447)<span></span>
</td>
<td class="num">(20,851,913)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">3,659,818<span></span>
</td>
<td class="nump">4,960,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,752,147<span></span>
</td>
<td class="nump">2,621,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue', window );">Gain (loss) on sale of fixed assets, no net book value</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposed of</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">466,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">11,761,522<span></span>
</td>
<td class="nump">15,917,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(8,390,612)<span></span>
</td>
<td class="num">(11,753,081)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">3,370,910<span></span>
</td>
<td class="nump">4,164,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Research and development equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,835,298<span></span>
</td>
<td class="nump">3,538,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(2,571,747)<span></span>
</td>
<td class="num">(3,078,165)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">263,551<span></span>
</td>
<td class="nump">460,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,431,633<span></span>
</td>
<td class="nump">2,827,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(2,416,232)<span></span>
</td>
<td class="num">(2,816,577)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">15,401<span></span>
</td>
<td class="nump">10,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,093,812<span></span>
</td>
<td class="nump">3,529,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(3,083,856)<span></span>
</td>
<td class="num">(3,204,090)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">$ 9,956<span></span>
</td>
<td class="nump">$ 325,039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GainLossOnSaleOfFixedAssetsNoNetBookValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Sale Of Fixed Assets, No Net Book Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GainLossOnSaleOfFixedAssetsNoNetBookValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,984,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,415,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,833<span></span>
</td>
<td class="nump">1,222,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series&#160;C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare', window );">Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 326.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares) | shares</a></td>
<td class="nump">275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 16, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember', window );">Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent', window );">Class of warrant or right, common stock ownership (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock | Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent', window );">Class of warrant or right, common stock ownership (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember', window );">December 2024 Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in USD per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent', window );">Class of warrant or right, common stock ownership (percent)</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent', window );">Class of warrant or right, common stock, prior to issuance (percent)</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent', window );">Class of warrant or right, common stock, maximum (percent)</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Common Stock Ownership, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ClassOfWarrantOrRightCommonStockOwnershipPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenRegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ino_December2024OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - At-The-Market Sales Agreements (Details) - Common stock - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2024</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">2024 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Common stock aggregate offering price</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sales Agents will be entitled to compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Sales made at a weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementRemainingCapacityAmount', window );">Stock sale agreement, remaining capacity, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">2021 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sales Agents will be entitled to compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Sales made at a weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementRemainingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Remaining Capacity, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementRemainingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2021SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Other Issuances of Common Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares', window );">Shares issued in settlement (in shares)</a></td>
<td class="nump">760,083<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Awarded to Other Party, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LitigationSettlementAmountAwardedToOtherPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Restricted Stock Units (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="nump">1,337,228<span></span>
</td>
<td class="nump">1,128,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value for options exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm', window );">Options exercisable, remaining contractual term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber', window );">Number of options expected to vest (in shares)</a></td>
<td class="nump">1,337,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, expirations in period, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 139.02<span></span>
</td>
<td class="nump">$ 38.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, expirations in period (in shares)</a></td>
<td class="nump">38,503<span></span>
</td>
<td class="nump">9,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 6.69<span></span>
</td>
<td class="nump">$ 11.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">$ 67,675<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercises in period, aggregate intrinsic value</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 226,000<span></span>
</td>
<td class="nump">$ 669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="nump">66,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-and market-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="nump">337,911<span></span>
</td>
<td class="nump">274,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value of unvested</a></td>
<td class="nump">$ 618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value of vested</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber', window );">RSU's expected to vest (in shares)</a></td>
<td class="nump">337,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in USD per share)</a></td>
<td class="nump">$ 8.30<span></span>
</td>
<td class="nump">$ 10.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-and market-based restricted stock units | Former President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash', window );">Awards settled in cash, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember', window );">2023 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (in shares)</a></td>
<td class="nump">800,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="nump">188,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="nump">282,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="nump">904,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan', window );">Number of shares of vested restricted stock outstanding under the plan (in shares)</a></td>
<td class="nump">129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (in shares)</a></td>
<td class="nump">84,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="nump">20,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="nump">53,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="nump">96,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of vested restricted stock outstanding under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_FormerPresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_FormerPresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2023IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2022InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">1,337,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 45.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">913,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 59.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember', window );">$1.78-$18.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">1.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">568,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 10.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">205,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 12.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember', window );">$18.01-$39.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">18.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 39.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">249,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 35.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">191,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 35.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember', window );">$39.01-$52.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">39.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 52.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">152,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 44.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">151,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 44.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember', window );">$52.01-$90.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">52.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 90.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">126,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 76.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">123,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 77.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember', window );">$90.01-$130.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">90.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 130.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">112,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 98.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">112,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 98.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember', window );">$130.01-$233.28</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">130.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 233.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">128,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 137.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">128,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 137.48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">1,128,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">328,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(8,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(111,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,337,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 58.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">8.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">8.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">76.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 45.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details) - Performance-and market-based restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">274,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">214,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(126,133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(24,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">337,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Significant Assumption Used in Monte Carlo Simulation Method (Details) - Market-Based RSUs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">3 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Performance-and Market-Based RSUs (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares) | shares</a></td>
<td class="nump">83,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased', window );">Milestone-based RSUs (in percent)</a></td>
<td class="nump">0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased', window );">Market-based RSUs (in percent)</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares) | shares</a></td>
<td class="nump">337,911<span></span>
</td>
<td class="nump">274,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 8.30<span></span>
</td>
<td class="nump">$ 10.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Performance RSUs, Specified Threshold Percentile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Performance RSUs, Target Percentile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Performance RSUs, Specified Maximum Percentile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage', window );">Threshold percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 269,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 10.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards', window );">Vesting percentage</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember', window );">Market-Based RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards', window );">Vesting percentage</a></td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember', window );">Restricted Stock Units (RSUs), Milestone-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 10.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Market-Based</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Milestone-Based</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Awards Granted, Percentage Of Target Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis=ino_PerformanceRSUsSpecifiedThresholdPercentileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis=ino_PerformanceRSUsSpecifiedThresholdPercentileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis=ino_PerformanceRSUsTargetPercentileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis=ino_PerformanceRSUsTargetPercentileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis=ino_PerformanceRSUsSpecifiedMaximumPercentileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis=ino_PerformanceRSUsSpecifiedMaximumPercentileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsRSUsMilestoneBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - December 2024 Performance-Based Awards (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 6.69<span></span>
</td>
<td class="nump">$ 11.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="nump">$ 10,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | December 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock', window );">Underlying common stock (in shares)</a></td>
<td class="nump">25,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | December 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock', window );">Underlying common stock (in shares)</a></td>
<td class="nump">19,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsPerformanceBasedMember', window );">Restricted Stock Units, Performance-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice', window );">Share price</a></td>
<td class="nump">$ 1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ino_StockOptionsPerformanceBasedMember', window );">Stock Options, Performance-Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=ino_December2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=ino_December2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_RestrictedStockUnitsPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ino_StockOptionsPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ino_StockOptionsPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>defendent</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares', window );">Shares issued in settlement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
<td class="nump">760,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares', window );">Estimate of shares settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember', window );">Behesti v. Kim, et al.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease', window );">Annual increase of base rent percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease', window );">Annual increase of base rent percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,400<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LitigationSettlementAmountAwardedToOtherPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Awarded to Other Party, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LitigationSettlementAmountAwardedToOtherPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss, Value of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LossContingencyEstimateOfPossibleLossValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_BehestiVKimEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 3,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">3,555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">2,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">14,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">11,865,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,497,360)<span></span>
</td>
<td class="num">$ (2,406,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 9,367,827<span></span>
</td>
<td class="nump">$ 11,032,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Pretax Loss from Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. Domestic</a></td>
<td class="num">$ (107,254,126)<span></span>
</td>
<td class="num">$ (134,979,579)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(137,772)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">$ (107,254,126)<span></span>
</td>
<td class="num">$ (135,117,351)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Benefit from income taxes at statutory rates</a></td>
<td class="num">$ (22,523,000)<span></span>
</td>
<td class="num">$ (28,375,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(1,543,000)<span></span>
</td>
<td class="num">(3,922,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">21,749,000<span></span>
</td>
<td class="nump">28,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncomeTaxReconciliationStatuteLimitations', window );">Research and development tax credits</a></td>
<td class="num">(5,846,000)<span></span>
</td>
<td class="num">(2,139,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,579,000<span></span>
</td>
<td class="nump">2,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">2,344,000<span></span>
</td>
<td class="nump">861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits', window );">Expired NOLs and credits</a></td>
<td class="nump">4,687,000<span></span>
</td>
<td class="nump">1,352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits', window );">Limited NOLs and credits</a></td>
<td class="num">(2,056,000)<span></span>
</td>
<td class="num">(997,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="nump">403,000<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1,206,000<span></span>
</td>
<td class="nump">404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeTaxReconciliationStatuteLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Statute Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeTaxReconciliationStatuteLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxBenefitsExpired', window );">Tax benefits expired</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">22,900,000<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">46,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">259,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">88,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,087,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 801,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">46,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">348,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxBenefitsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Benefits Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxBenefitsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expense</a></td>
<td class="nump">$ 54,204<span></span>
</td>
<td class="nump">$ 50,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">250,336<span></span>
</td>
<td class="nump">235,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Research and development and other tax credits</a></td>
<td class="nump">31,250<span></span>
</td>
<td class="nump">27,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,060<span></span>
</td>
<td class="nump">3,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment in affiliated entity</a></td>
<td class="nump">1,651<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">2,492<span></span>
</td>
<td class="nump">2,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,720<span></span>
</td>
<td class="nump">6,808<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">350,928<span></span>
</td>
<td class="nump">329,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(349,224)<span></span>
</td>
<td class="num">(327,493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(1,704)<span></span>
</td>
<td class="num">(1,993)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,704)<span></span>
</td>
<td class="num">(1,993)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear', window );">2025</a></td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2026</a></td>
<td class="nump">17.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2027</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2028 and thereafter</a></td>
<td class="nump">245.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">801.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">1,087.0<span></span>
</td>
<td class="nump">$ 801.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear', window );">2025</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2026</a></td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2027</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2028 and thereafter</a></td>
<td class="nump">333.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">348.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2027</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2028 and thereafter</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInNextFiscalYear', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInThreeYears', window );">2027</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInFourYears', window );">2028 and thereafter</a></td>
<td class="nump">46.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">46.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInNextFiscalYear', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInThreeYears', window );">2027</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInFourYears', window );">2028 and thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringInNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Next Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringInNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Indefinitely Carryforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsIndefinitelyCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Carryforward Indefinitely</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardCarryforwardIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Next Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 22,114<span></span>
</td>
<td class="nump">$ 21,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">2,297<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 24,608<span></span>
</td>
<td class="nump">$ 22,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum annual contribution per employee, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution to 401(k) plan</a></td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,199,056<span></span>
</td>
<td class="nump">$ 2,405,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,620,340<span></span>
</td>
<td class="nump">86,676,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Agreement amended amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Agreement amended amount</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.30%<span></span>
</td>
<td class="nump">17.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAmendedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Amended Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAmendedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - Geneos Therapeutics, Inc. - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EquityMethodInvestmentsMinimum', window );">Equity method investments, minimum</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityMethodInvestmentsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityMethodInvestmentsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 217,756<span></span>
</td>
<td class="nump">$ 832,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 75,620,340<span></span>
</td>
<td class="nump">86,676,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 36,996,338<span></span>
</td>
<td class="nump">47,582,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">112,616,678<span></span>
</td>
<td class="nump">144,772,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,766,993<span></span>
</td>
<td class="nump">8,133,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(177,833)<span></span>
</td>
<td class="num">(1,222,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="num">(1,166,443)<span></span>
</td>
<td class="nump">773,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">2,077,182<span></span>
</td>
<td class="nump">5,850,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(3,163,711)<span></span>
</td>
<td class="num">(4,711,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(107,254,126)<span></span>
</td>
<td class="num">(135,117,352)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember', window );">Reportable Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">217,756<span></span>
</td>
<td class="nump">832,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">36,996,338<span></span>
</td>
<td class="nump">47,582,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">112,616,678<span></span>
</td>
<td class="nump">144,772,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,766,993<span></span>
</td>
<td class="nump">8,133,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(177,833)<span></span>
</td>
<td class="num">(1,222,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInFairValueOfCommonStockWarrants', window );">Change in fair value of common stock warrant liability</a></td>
<td class="nump">2,808,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="num">(1,166,443)<span></span>
</td>
<td class="nump">773,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gain on available-for-sale equity securities</a></td>
<td class="nump">2,077,182<span></span>
</td>
<td class="nump">5,850,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(3,163,711)<span></span>
</td>
<td class="num">(4,711,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(107,254,126)<span></span>
</td>
<td class="num">(135,117,352)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember', window );">Reportable Segments | INO-3107</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,930,344<span></span>
</td>
<td class="nump">17,840,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember', window );">Reportable Segments | INO-5401 And Other Immuno-oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,293,401<span></span>
</td>
<td class="nump">11,758,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember', window );">Reportable Segments | Other Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(77,955)<span></span>
</td>
<td class="nump">18,701,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember', window );">Reportable Segments | Engineering And Device-Related</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">19,393,929<span></span>
</td>
<td class="nump">8,863,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember', window );">Reportable Segments | Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,821,226<span></span>
</td>
<td class="nump">4,606,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember', window );">Reportable Segments | Other Unallocated Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 17,259,395<span></span>
</td>
<td class="nump">24,905,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInFairValueOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInFairValueOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ino_ReportableSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_INO3107Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_INO3107Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_INO5401AndOtherImmunoOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_INO5401AndOtherImmunoOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_OtherProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_OtherProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_EngineeringAndDeviceRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_EngineeringAndDeviceRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ResearchAndDevelopmentCostAxis=ino_OtherUnallocatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ResearchAndDevelopmentCostAxis=ino_OtherUnallocatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th">
<div>Mar. 12, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,415,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2024 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_A2024SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  Z <EI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  Z <EI]IS8&\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL].PS ,AU\%Y=XZ3<6_J.L%Q DD)":!N$6)
MMT4T3908M7M[VK!U('B '6/_\OFSY$8'J7W$Y^@#1K*8+D;7]4GJL&([HB !
MDMZA4ZF<$OW4W/CH%$W/N(6@](?:(@C.K\ A*:-(P0PLPD)D;6.TU!$5^7C
M&[W@PV?L,LQHP X=]I2@*BM@[3PQ[,>N@1-@AA%&E[X+:!9BKOZ+S1U@A^28
M[)(:AJ$<ZIR;=JC@[>GQ):];V#Z1ZC5.OY*5M ^X8L?)K_7=_?J!M8*+RX+7
M176S%EQR+L7U^^SZR^\D[+RQ&WMFQK<_C(^";0-_[J+] E!+ P04    "  .
M@'):F5R<(Q &  "<)P  $P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4
M?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-
MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    (  Z <EK+2&!G@0@  ,8R   8
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M *T2H-4$X!*_HK$/'5VP#KR,HJ(!'Y&T[:YQ.;@\N[2D])3!K>EI4JO2*WV
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MJ='@H[DRZ<>&-[2H7:ONA#:-[Y:5F;0@;8#9WPNACX8]H)O=V5]02P,$%
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MWLGO[9%R5Z_R..N'AONCW],)AP(KCLZYCQ%Z+$4:)4DTT[+9H&Q86-E\>;%
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MXPSH^T)K?)VX#?J?G?)?4$L#!!0    (  Z <EK#(2YB,0@   5    8
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M#$M9--%.EENEP63U>@VP@)VR']&C;!I9P4$JY'U1%MVS"T=J^3<G"4H$2B9
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M(6_:0G^KV4Y7850&]%SO .3:OHMWW+ 9>CC>O@UUR0#!,$>6XG28>MJD=!0
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M2Q^NZ2'8.GXL+FR @,>?)?2:'&_ ^\*"INT#'[#]WX/SOP%02P,$%     @
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M$NKJ#BK^_*>+Q?S\>4W?U]N8_Q\9NO^;)*=%!/QZ6U;-I#'5CJ"[,76SXZ^
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M]0Z'M+LL /79"*$3=OBJ>%O9A'T7XFR2VAS9D(B&+A^&R9G2MN2#VYFP98)
MHYX^:UJ-M7C[ T90>&AVQ6M$9S*R,])HTY*(0/5 R/1IQGJ2K6/%N63 /4A*
M%5D%GZ>MA+Y$WD%2$A>2SR/A+]02<12)\$C [C57O4N^$';^02Z<+3,8!@U
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MW++<Q$>5V2);?Z/Q=)2(PC(2.!&]/00Q?FSO/]&0?NS5]4[C"(GNL2"?UKN
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MUAV26GDN'$.7B$2YA+D%P99^@B SIWR\PH,ETS%@DH-IMHCCZ7+JH/8,>X]
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M&D^B:3QF<4SZ?09R(EU-^U&:C)ZBJW30!R5, UWU4U@^?<ZF*? V&@&C<3H
MO:31(!FCYD;1:#!VTI@F8^")M!6CCB= 0YRRKW]4S("C@1]!$L/MMBP'CGKL
M#=R  UIPQZW@VC"!X?F,<T4T]K5:K7FYA92<*8T3%J361JD+SF3)(./*(!Z
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M*[I<"@[Y& ? ^[F"[.IO<(/F!Z-N_@-02P,$%     @ #H!R6II$,5E% P
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MXQ7HO-;:G1?>P3B<UW\#4$L#!!0    (  Z <EJS$VDM:@,  'L'   9
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M+?%HC\N:WU)T08#O2\M%?-@$ \/KO/X.4$L#!!0    (  Z <EKL==/S;0,
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M6 <S&="161VIHJ?&Q5)J*-*J=42$1"_U<Q51'0A:F-"+4%M.EJVSW<,F!:G
MLY<876NI[;<$(=;LH9VD9BF3@2&*",@"$>8KL0' 1J#MJ*%M0&SY=8G6!\9]
MDD&T6Y@\]442/YH=#,9BE"DM:+RP @P? _=YO:L9PMB>%V*0\MH)R)KL$#5R
MV%[>AZE*+LLJ004(\,0%N"-LKFC)_C*-6,5II:";A.JL5]@$?\#%BKK,TB1&
MBR_BC$91FL<PT0NY!^6VW>(0SQ6$;%RW%0MDK:RL)#%85D(B[E62P@!\ <R1
MELF1?0A@PDAT)DR" %(6792[B/PWX,:9\.<G8)^'_9F8#Q.O?D302@[ _Q +
M3\%^RGG. _]]7H[O P;Q]3L@BGG'7X>8 ]K[B\&3,>+_84YI8,"%#.(-N==I
M7T<_'H9&P"FTQ8%$X)EQK@<T8XXM!LK4)01F10E%C011LQFDQNDJ948D52>7
M!S!6)<)U"LKG:(=7$I*61*RJ,A_<%8<$QPA. !^  D0PYNE7L/8RWJ8-?!X"
MY$06&&.'H5E52WNH>1Q.AY@; LV;Y@HPXNJGN/H"2]W%&59DD)$K32*FMFO
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MG.N_5.;9A^UP%C3*2@1(:0.0[\3,FJ5 0+<L"N3">=#FS)!,[E+\2TGK75G
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M 1OIS/_D855HS.%6:B2,7$OX,Z<G::S= 'X7C:-]>-M4*!K0'JC"F?[2"J?
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M,S9!V@*SOQ-"'P-[P#"(D]]02P,$%     @ #H!R6BQU:+Y# @  B@8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULG95;;YLP%(#_BL6D/;7AELN6
M 5+2;EH>.D5IMST[< "KQF:V">V_KVT(RZ:$2GD!VYSS^3M&'**6BV=9 BCT
M4E$F8Z=4JEZZKDQ+J+"<\!J8?I)S46&EIZ)P92T 9S:IHF[@>7.WPH0Y2637
MMB*)>*,H8; 52#95A<7K&BAO8\=WC@L[4I3*++A)5.,"'D']K+="S]R!DI$*
MF"2<(0%Y[*S\Y7IAXFW +P*M/!DC4\F>\V<SV62QXQDAH) J0\#Z=H [H-2
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MG#;^_0$3$OS^06MW#$*!Z44K?P%02P,$%     @ #H!R6N31^C_6"P  63<
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M+VXG\\>I;1AHG7]H6^<?_I36^:I+V;^]+?1L9SL\C"JXF@8H?M)2_.1/I_A
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MCG7-LSOA1E+-D[M\4>;S/%5ED]RD:=6635XNDO=5D:>Y-LDC]]?CGTX;;$T
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MI: YB#$!22NC6>A:2'&]J?.FT66R;F<P%\!F#K2PR2-:<^)A\7%_M3^>/!Z
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M)XS\)E8N)^L HTJI"V<$L!,N>D,N@S]U#6]-MI7U0$)IHY$ML -'\%GK)L[
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MV1M@/*'B7;#K:!%*%@VY>,M#2,A9!]$P@Y1UZ8K8VM5.[-L]Y':L+;>Y^H2
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M5LI2D_VVH.<<M0N@\UPINS=<@?8/8OH74$L#!!0    (  Z <EJ9G74UF08
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M (TWH/V=UNXT\0'&SXO57U!+ P04    "  .@'):X+/(JWL#  "#!P  &0
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MBOQ]2?N$'%U&=F5S9WJ9P\K#NC"@G\!;__A#& <_7>$=S;RC:^CK1RS#8FB
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M5Q*T"\#OI5+V9>(VF-_=]3]02P,$%     @ #H!R6C3H+_TR!0  E T  !D
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M9:G%^>&2OBFHG0.MSY6R6\,EZ+Y2TS]02P,$%     @ #H!R6ES7MRX:!P
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M.*AE.J$P0/(1, :)6]7:E"W56O)-J[%XB180SUKSNN7U[?B6,,JMADA1332
M*DUUJX5\0!0"4H $A_?(9,-J5G#MD%8A%B6^]]/$,4@'.1%^6N<F!1S"U0\F
MS;E5; /]Q-61 =9FB+;O.RM0Y+JN";Z?.$&\LML;C1;N,1Q20Z>#&RQ8#E=3
M]DY"RCBKL,,X"IP4,,WZ8DOK6T0@=[1L;0 H>D+KC,&-.'&8HB1!K6EHEM<0
M/"JSK;F#G-U!ZVN@D6ES99ED.8=2.UHY21AU"GW'"]+>8I%]^04[36YB!@W0
M:O6P1JPJQTWMZA,8(37T7@/=",5ML'TG"*TM2>29SU^%R'>\+ FO&LJE,:<O
M,\])(^,N>7/?<+"/_/'^2AGK>VM#)TIB(^)!45GA*UYQ/24,[KBKWK4TC9_>
MY#[A0M=<.0DB$Z^! (;<RCF4FP1C.<1JH(70(KZ'/)9@D.\:98!F?7XY2.Y7
M!U@@&E@@^FX6N&1@%MX45O^94@S</H,KN.)T X6J.9LDXX,*I@G@!NZ#%SRC
M$+#'3(U5C*V!U@_&R_BUPH'$VH4W2*U=&)IR;Q<6HR@.5*RA>;45NQJJ S)]
M#0Y.GS#2E_]7N287M.&:EOQ?>"[[<F#WF,T,H@)4[0_!6KF.9TL/4XED5,H'
MX)0=E3ED,GP;!#:^/K!ZY'^CQG O3&*,JPU,1B2# BTEL""#Z1( ZI8-V6*K
M__E:!&LCBQ9 85C;S[*OK2D>7FO(=(ZC%(ECJREU;?6\J^^@%1I#H1!H41A6
MAT.8XOH!DCE:>5V=A5U:7S$P8(C@ Q1WF/H=$22=I6_Y/5*[#7@86H@@L$IM
MG41.[%N;(R=Q$RL!=Y+ZW=I/G3"Q*C]/<-U1 $SG^V'/D7"/8=HQYD<!P9Y,
M/B#(+M# ,E;\<<:,,G--S(\"S+56,8N Q-PAS'&='E Y3O+GCOT!D,\>^D'B
MB ?BB+^;.+IA#?JI&>"0,Y!"+DR>0MGL<]^2\?.#W4&=TUQR;C*Y!0[IVBAS
MAD:(=:-,M\0ABSUF=&0$K-X,4Q6F!&;ZQ*BMDR-(YPKZ"UH[7X]L)_"[A*W)
MVTZ-:1:V*YMES_AVTPE=OZ)5\_JRD^MWP#8K"(P7+0QK+/S)>.U7(!\1+UYX
M!/_ZIT\_02HF$0AXB_204&(N!"N)T4)#/?GA"DX$0;  +6!2&(VTO(/YIN U
M]$>2N(CL+N+_H<;P'/QQW"0V+@5ALC >FIW!>VF$#N1@,N1@\MTY^*G&B1+:
MRK]= ^L&+D6N(9I=^DVEW$$5S\^O-D<PY^V,:M\ @'9E>ICY98[$)EE)NP0;
M];:?%6G'!H]&TWZ:9 >G25H:_H+9<<-N>5V;P=BVSP<\_1+IWO/Z=@0S73>,
MX80OD7S5V+2LE3B0V+-/QRX_[:>DQ(N>8!SEK%O.QWB-Y#! 3Z!Y'=918OE\
M/G:%89M[[ 3,:!VM/_)H*GF6HS<&%9.WYKT(_D9H:VU?'@Q/AU<O9_:-PU[<
MOK?YG4JX5$5*5L!12'/XD2/MNQ"[T:(Q[Q\V0FM1F>6642AT%(#O"R%TOT$%
MPPNIT_\ 4$L#!!0    (  Z <EJJ%N:LZ00  ,,)   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;(56VVX;-Q#]E8$2I!9 64ON58XM('9Z,9 ;[+1%
M4?2!THY61'9)A>1*<;^^0ZZD*(CCODA+<GCFS)D9DI<[8S^Y-:*'+UVKW=5H
M[?WF8CIURS5VTIV;#6I:61G;24]#VTS=QJ*LXZ:NG8HD*::=5'HTOXQS'^S\
MTO2^51H_6'!]UTG[<(VMV5V-^.@P<:>:M0\3T_GE1C9XC_[WS0=+H^D1I58=
M:J>,!HNKJ]$K?G&=!?MH\(?"G3OYAA#)PIA/87!;7XV20 A;7/J (.EOBS?8
MM@&(:'S>8XZ.+L/&T^\#^B\Q=HIE(1W>F/9/5?OUU:@:08TKV;?^SNQ^PWT\
M><!;FM;%7]@-MGDV@F7OO.GVFXE!I_3P+[_L=3C94"4_V"#V&T3D/3B*+%]+
M+^>7UNS !FM""Q\QU+B;R"D=DG+O+:TJVN?G]]B0Q!YN]9#@H-391[EHT8TO
MIYX\!+OI<H]V/:")'Z!Q 6^-]FL'/^L:ZV\!ID3MR$\<^%V+)Q%?X_(<4LY
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MAK.R9+,\'P.O6)EP5I0YZ=10\M#&> 9J:HD3BVV,B\]82M@S,8.*547*>)G
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M1SUTHOI%1 YO> ;O<U8(>0",,\L3LN(*\URJSDCU MES?Z\+%L/,PX.M0>W
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M)[+A-4I:A7*F6E4<.VR"P>0<Q5/;0#_H&RXN:Q\ C2^H:Q] T*!K][:P4V]
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M#TRL4[U RV"ED>[;"^V2J'=UU2>*E]4NI"57BN?580(L!F$:Z/LKSM7SB7E
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MIFN90Q#U]T 7-(YS),7CKPIT4C\S=SP\?D'_4 2O@ED101<L_B,*Y>YBXD]
M2#<DB^47]O@[K0)R<KPUBT7Q"QXK6VL"UIF0+*F<%8,D2LM_\E0EXL !NCT.
MJ') 70>[QP%7#K@(M&16A'5-))F?<_8(>&ZMT/*#(C>%MXHF2O/7N)1<W8V4
MGYPO=XS+J:0\ 3?I Q52O2(I $E#\(%$''PE<4;!+24BX[2\-P5+-9C"+*:
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MP@1;;[.(/*IJ&0NMG91&M6#S4DA?@Z[<6@O$R+4\N[M,HS/$MF7CGIZ'&^V
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MP8[+-&A%O(/HBG3\"Q)X09<\S>[(V9_G)!.*V1NC8BI!-3AZ^^.PG1*V">W
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M70WPO<JB!2\F6F2VBYT+C3VQ'<;XV0+2".#^4@B]FQ@#Y8?0Y']02P,$%
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MD.8#@A0?J+3IS@) !#A!W%3KM;H<5E?XBT?O):OKK&R]8C<#YO :(T+ 6:1
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MNA-0WZ\J126[-]WS.O?/9[W^/U!+ P04    "  .@'):^.FYE&$#  #R#@
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M&)S0O[PN!ZQR855>S"AS96GB*2Y7-)2B=@'T/%'*/BS<V%./N=.?4$L#!!0
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MRX^$!Z:I<PP(7)%K^W) X74Y>,N%51L_[&)E:73ZQXR^55 [ WJ_4LH>%BY
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M"'RRD:JD!H=JZ^I* 2T:4,G=P/-BMZ1,.-FLF5NJ;"9KPYF I2*Z+DNJ'F^
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MPVX2E W YQLIS6%@^Y6^/\W^ 5!+ P04    "  .@'):[XXI,#\%   T&0
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M2NW\D6?]BKIK^Q.4&:'H$^' 4+B#:O%#_Z'C]7](965?EZJL$Q;JA$6:8+V
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M[32.?$Q^[7SCOV*[+,'W26RE<*S$IX.+W_K*/T6#+2NT==C6$,O<K9U#]4?
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M0*J?R<=O.=??R3OR>QB"Y.F.B)!L1)*@X&7/$?G*I&2I5B/"TH!<27@7YFD
M0?. O-F"9CQ6;Q'G1V(3%3$):FEKG*X9U/;KJ7VHIN8>F=H6_#&AWHBXCCOM
M*-_TE[_/));/N\IM%*E1RFV4<DN\Z1&\6V0I"\FUAI1<PXXK#1)Y;[G$)=DH
MUL6S%]@8]5)ES(>5A4Y4(!_ 6O_T _6<7[I8#P36TF#2:# IT2='--C$3"FS
M)NH?FPA)2N>3/S]C5_))0Z+^ZI)@,J0$ X&U))@V$DQ[ET$C0;&70!H)1L2O
MC**,48@H4K14Q#/R)@/I0ZK?=NG2.]BINE1@M'*$>8$_K)TQ72P62_NA@_)%
M0_FBEW+C;"U(EDL_PM=FF^S?Y'^XHW?P4R48"*RED]?HY)W)'=Z0$@P$UI)@
MUD@P^Z_N@$>T <>5DTGNPT$?U73"O8.GY/9F2] RU;[1:9K>.9PJ5P4V:WG&
M<6BW9>:-#O-^'09S1^\XIW(="*PER:*19'$F=RR&E& @L)8$U-FG+><U=X_^
MT4Z5ID;[U_[A'-T_Z$'(I+VT,<I!<H>>-EEL'RZ?-I9.:KV()U,;"*W-?Q\=
MJ7NFM4\'S8Y#H;5EV*='VIO,7FEWJ"<Q/UC%D_',:]9P+<4Y0B3=ITCZJC&2
M=D8_9WI@W9KV0(&S37N?)&E_E'PA[9%9!O@( R=7*F<I+HE^_A?/OKIJ_N<(
MB'2?$&EO^GHY?_R+SY,\>8:U]VS@KUD/F@GM@^,&<];SA<D=3Q6)(41X9SQ#
MC65U?%(UM,C*$X@[H;5(RLL(&$8BTP&?AT+HIX8YU&@.L=;_ %!+ P04
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MZ[T\$'2CMXJ?J! TUR_71 YLIBZ0[R\I%2\'*D']#Q"+?P%02P,$%     @
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MB[D3% 7X[\NBJ/=?1 .'UY/<_A=02P,$%     @ #H!R6GKT%%_&!@  LBL
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M4!:Q9A*>O^9J]$L #6N@8?MD:TS-5ZX.-+\<6T.%:##A?F Z2?/]AN;[3GN
M1$.)V*%TTK*^T[SSD8NQ0?.)!A&Q@V@\S3_B"/=_WB>:7*0;N4;2?N6M+F)S
M=^H;J$\THDBWU;XAVD^:JWT080Q-%5![V31PKM1;^TESFC2?3TT39:+I1.QT
M*D5?:#_$)O&W&QCZND[#B;BO*/[D)<A&--F(?;8UIO@K5P?B7PZNH_\,("":
M5J0?K4X!@7)UL.B/3230J")V5)U$ K^I Q A'QM>\&H\43N>1GS%:W>$^[_C
MI9IGM!O/1B*!\E:7--^;NM[Q>J4:7K3;.N 0*M#F.J"U&C2JZ,#95&\JT.9$
MJFL*-<.HG6$5&@0B!!'+!::6,*P6!JHHK>V?H*^("/H2_*.:?]0^.1L3$<K5
MX?N <G0-1:)!1ON![!0NT.9KK5WIM0:IX47M\#H%#<KTX2.B1TU;0*CF%;7S
M:D0TV!U1A0;<_86PJP'G=@/<6!N G.:;33R?$D,)N!IA;K>UP2$\<%O6!BTE
MX&I(N0-G6+UYX#8G5ZUYF]6V428L?R@WBQ:BX+8IKW94[K_=;TA]5VW#U)=7
MNUD_!?E#)#(:LWO1U)G*[9]YM4&T.N'9IMR4>9=QGB7EX9H%(<OE!>+W^RSC
MNQ/I8+]-=_D_4$L#!!0    (  Z <EIDQ(Y^1@,  -4*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8T+GAM;+667V_;. S OXK@.]QMP#6VY,1Q>HF!INW^
M/'07K-CVK-I,;%26/$E)6F ??I+L.+G&,=8 RT,LR2+Y(R72G&Z%?%0Y@$9/
M)>-JYN5:5Y>^K](<2JH&H@)NWBR%+*DV4[GR526!9DZH9#X)@L@O:<&]9.K6
M%C*9BK5F!8>%1&I=EE0^SX&)[<S#WF[A<['*M5WPDVE%5W /^DNUD&;FMUJR
MH@2N"L&1A.7,N\*7<SRT F['UP*VZF",K"L/0CS:R<=LY@66"!BDVJJ@YK&!
M:V#,:C(<WQNE7FO3"AZ.=]K?.>>-,P]4P;5@WXI,YS,O]E &2[IF^K/8?H#&
MH9'5EPJFW#_:-GL##Z5KI479"!N"LN#UDSXU@3@0",D) =(($,==&W*4-U33
M9"K%%DF[VVBS ^>JDS9P!;>G<J^E>5L8.9W<:Y$^YH)E(-7?Z/;[NM#/Z +=
MF]//U@R06"*W!?U7N2A>V2C:/5^X$=D)?.0I<!M>M&"4HS<WH&G!U-NIKPVC
MM>2G#<^\YB$G>#!!=X+K7*%;8R#[OP+?.-=Z2'8>SDFOQAM(!RC$_R 2D"'Z
M$_E(Y52":AX]%L(VAJ&S$)ZP\&E=/IA8V%!UJ*P9:PW#;@TV]2Y515.8>2:W
M%,@->,E??^ H^+>';]CR#?NT)W-8%9P7?&7NKSF>%-";@C?NOT4_.@-14]=Z
M(Z?7YO<FP9C$<32<^IL.H%$+-.H%>B\IUY#],L;H"",D<3B.NBFBEB+JI;A]
M ID6ZA4<T1''18Q'DVZ,<8LQ[L6XMB?"V"LPQL<8&.-X%':#Q"U(W!\/GIUS
M1^+C.Q*&8T+B;II)2S/I3:IOKIY"=G&U 6F^#VAW7&@ABQ2Z2":_(<=PL"^D
MP1E9E@G&J%2H,@7"Q= &<U^$.@MD;2<^B.@H'IRZ[?B@TN-?SKISL)H/27#
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MWHJPD&2B<6K()0._Y,L_&^RYLI9[I*O1SM7([BJ?ZMY@:=1D">U9LA9ZI*7
M-[.\;S5U9V(T[[KW.D9/E+_F&=RJ]]:^ZTJMZK[$.('+8:M0<^7=D5K5.S3>
MX?]NZ"JJ5!Z[$!J,@F"O3S2D@X/N8-1MGI0#PU*!%5DF?VMZ)]$IWA FWT;
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M:**;/"LJ!(WTT <BE8Q:(-^O*15O#VJ#O$\X_0]02P,$%     @ #H!R6MZ
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M"J7Y4%H I84HFBZSQMAPS&7YV_@QR;9R36:<%^65,W++TU0\QO?L6*49ZFA
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M263J;<'7 K;J8$R,DX40#V9RLQPYGA$$):3:,%!\;& "96F(4,;/AM-ICS3
MP_&>_;WUCEX65,%$E-^*I<Y'SAN'+"&CZU+?B>T':/P,#%\J2F5_R;:NC6.'
MI&NE!6O J( 5O'[27=.' X ?/0$(&D!P#.@_ 0@;0&B-ULJLK2G5-!E*L272
M5".;&=C>6#2Z*;CY%^=:XFZ!.)W<\%0P(%_H#A2Y(!/!*L&!:T5$1F82--V1
MCT(IDDG!R.<*)#7M5^1LBGM%J<X1=3^?DK.7YT-7HR+#ZZ;-Z>/Z].")T_V
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ML\,</TP@30'N9T+H_<0<T'[JDM]02P,$%     @ #H!R6B2FSU*#!   I!(
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M_BX%1Y^.YZZ0::A@;M9^\K+Y9/#&)_T ?*5$;#CX3'*4OPS@ROP[$,$SB,O
M&C%%V1D(_1,0>$%D2&CU<??0X)Y^W#VPH F[DH0Z7OAN2<#G)]G?'(&C2T10
M@<7Q"5A)ZC#98K(&US5BND[\I%>FUS7\^^*!"R;[ZQ]3J9I4(G,J:M(YYS7,
MT,*1LPI';(><Y<\_^8GWBXGF'QDL_4'!7I0@ZDH0V:(O6[I!P6@%<$.MT!T
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M#.3[@E+Q?*,^T!U,+?\#4$L#!!0    (  Z <EHFY9[<#P8   (U   9
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M\HP*@^:RV$C!A-%(+M$56S*EV,*:HDNM&3RF8H%N.'WD.3<<_-]?,4-YKC]
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MB\>%H6+%'W/FG-]Q9^PD:7\\79LT2-QX:8.7#N)=BQW3IER*T*[I<@DMG1K
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MU8V1F_)P]B@-'/7*RS6<QIFR!O!^*:5YN;'GO>9\/_L?4$L#!!0    (  Z
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M@#8RP"E^9+)4.#T\GE6$!VM;C,4""F,![$FT&0[@_&WU[[U@@.&@UI.H8\K
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M@K0!YOE2"+V=V W:,S;[#5!+ P04    "  /@'):YXKQOU '   32   &0
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M@G1L3)U00QU%T_726.JNW5/_O.#D:U)()LB'K)")7$NS8*"N.I3F06D^E!9
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MES([7 !RD=DC6NU#W%POV.'!$3M@0E&%+BQ7B9WZ2$K=>7[<J#JK587/J%H
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M\?@K;QP*M;Z9R&7]+WIL9(,1FFVD$D6S&"PHLG+W,_W6!.)@ >U;0)H%I+.
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M'$CMY(=.01\_) ;2B1_2KU:Z)6HRN(""1=LTA]X))0NA+0 ZI!*SK^BQ[IR
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M5E6[2ZV[+TJLZWNA#T(I4=0?5SR=\TH+P.\70JBG+_H%^ZO%T[\!4$L#!!0
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MNM%N-CI7<YO7E3+AV(].E0V@\3N]]R-A9*4N1]?VH)Q8RJUJOA1\RJ(X?L$
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MS7?J/8R?AS+<>K[6>/WOI'J\G%MNE[\NOW9.;L(5Y_J^8GC^"U!+ P04
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #H!R6GVG-@;R    *P(  !$
M             ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M#H!R6IE<G",0!@  G"<  !,              ( !Y $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    "  .@'):RTA@9X$(  #&,@  &
M    @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M#H!R6D(Y*L4] @  QP4  !@              ("!W!   'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    (  Z <EH40UT*&P<  $H?   8
M          " @4\3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    "  .@'):)8<^;_D"  !3"@  &               @(&@&@  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ #H!R6OJ]ZNE_!0  W10
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M965T.2YX;6Q02P$"% ,4    "  .@'):Y!" 1?PB  #0;0  &0
M    @('30   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M  Z <EK(BXR7* ,  (0'   9              " @09D  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ #H!R6N%YY.R="0  61D  !D
M             ("!96<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    "  .@'):4]&#160-   \2@  &0              @($Y<0  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (  Z <EJ:1#%910,
M *@'   9              " @=1^  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ #H!R6K,3:2UJ P  >P<  !D              ("!
M4((  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  .@'):
M!5]Y5&8#  "I!P  &0              @('QA0  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    (  Z <EKL==/S;0,  &8'   9
M      " @8Z)  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ #H!R6C[+I]$E%0  B4P  !D              ("!,HT  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  .@'):/$_[GQT0  "#+@
M&0              @(&.H@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    (  Z <EJN)QL'Z0P  *\B   9              " @>*R  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ #H!R6I%9I98$
M P  IP8  !D              ("! L   'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    "  .@'):V;.$I[ &  "Q$0  &0
M@($]PP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  Z
M<EKK)O1KIP,  %X(   9              " @23*  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ #H!R6E)L$2ND!@  L T  !D
M         ("! LX  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    "  .@'):O[ZAJH "  "$!0  &0              @('=U   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  Z <EJ0&'KN/@(  )0%
M   9              " @937  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ #H!R6BQU:+Y# @  B@8  !D              ("!"=H
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  .@'):/*4S
M.!$"  #=!   &0              @(&#W   >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    (  Z <EKDT?H_U@L  %DW   9
M  " @<O>  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M#H!R6H8L+63G&@  &U<  !D              ("!V.H  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    "  .@'):&E&I6C4%  !,#0  &0
M            @('V!0$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    (  Z <EH=DS@>V0(  "P&   9              " @6(+ 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ #H!R6IF==369!@
MH!,  !D              ("!<@X! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    "  .@'):_C/5OGT#  !J"   &0              @(%"
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  Z <EK@
ML\BK>P,  (,'   9              " @?88 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ #H!R6C3H+_TR!0  E T  !D
M     ("!J!P! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z <EKEYM!GDP,  * ,   9              "
M@3@\ 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ #H!R
M6@>&[GQI!   WQ<  !D              ("! D ! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    "  .@'):TG2#3(X#  #S#0  &0
M        @(&B1 $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   (  Z <EJ^U^9<" 0  ,\4   9              " @6=( 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ #H!R6CL$S0M- @  ] 0
M !D              ("!IDP! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    "  .@'):!0JI GL%  !G)P  &0              @($J3P$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  Z <EHZ'HF;
MJ@4  $$>   9              " @=Q4 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ #H!R6IY23]VT P  % T  !D
M ("!O5H! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  .
M@'):O&Q'$6$)  "K50  &0              @(&H7@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  Z <EKXZ;F480,  /(.   9
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M970U-"YX;6Q02P$"% ,4    "  .@'):L6:2K\X"   ]"0  &0
M    @($_>P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M  Z <EH?&Z>1^0,  )D4   9              " @41^ 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ #H!R6C1UA[4/ P  Z0P  !D
M             ("!=((! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    "  .@'):ABGC&)X"   9!P  &0              @(&ZA0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (  Z <EHDD$ #P@,
M - 2   9              " @8^( 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ #H!R6C!Z(F8-!0  #"$  !D              ("!
MB(P! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    "  .@'):
MX7UUAG$"   ]!@  &0              @(',D0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    (  Z <EH,WKKU3PL  *ID   9
M      " @724 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ #H!R6GKT%%_&!@  LBL  !D              ("!^I\! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  .@'):9,2.?D8#  #5"@
M&0              @('WI@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    (  Z <EIZ-&+="@,  (0'   9              " @72J 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ #H!R6CK8T G+
M @  JP8  !D              ("!M:T! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    "  .@'):N*S#A0H&   B)P  &0
M@(&WL $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (  Z
M<EJ>V N90 0  #,4   9              " @?BV 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ #H!R6MZ N+F;!P  P4T  !D
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M=#<S+GAM;%!+ 0(4 Q0    (  Z <EK6^+&G3@0  .L/   9
M  " @?W4 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
M#H!R6B1I'L=:!0  ,B0  !D              ("!@MD! 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    "  .@'):TMU&U?X"   :"0  &0
M            @($3WP$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4
M Q0    (  Z <EKC9F6PN0(  &\'   9              " @4CB 0!X;"]W
M;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ #X!R6N>*\;]0!P
M$T@  !D              ("!..4! 'AL+W=O<FMS:&5E=',O<VAE970W."YX
M;6Q02P$"% ,4    "  /@'):2QIG_8@"  #N!@  &0              @(&_
M[ $ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (  ^ <EKJ
M:CMF#P@  &8L   9              " @7[O 0!X;"]W;W)K<VAE971S+W-H
M965T.# N>&UL4$L! A0#%     @ #X!R6C):#UU>!   T!D  !D
M     ("!Q/<! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4
M"  /@'):*K>T65T#  "0%@  #0              @ %9_ $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    (  ^ <EJ7BKL<P    !,"   +              "
M >'_ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (  ^ <EJ-EF94$P8  &,U   /
M              "  <H  @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  /
M@'):JYPQ2VX"  #:+P  &@              @ $*!P( >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  /@'):1.3?6!X"  "7+@  $P
M            @ &P"0( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     60!9
+ &88  #_"P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>273</ContextCount>
  <ElementCount>428</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>107</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/TheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Revenue Recognition and Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Short-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</Role>
      <ShortName>Short-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Short-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SegmentInformation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company???s Total Level 3 Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company???s Total Level 3 Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssetsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Stockholders' Equity - Schedule of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Stockholders' Equity - At-The-Market Sales Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails</Role>
      <ShortName>Stockholders' Equity - At-The-Market Sales Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stockholders' Equity - Other Issuances of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Other Issuances of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Stockholders' Equity - Schedule of Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Stockholders' Equity - Significant Assumption Used in Monte Carlo Simulation Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails</Role>
      <ShortName>Stockholders' Equity - Significant Assumption Used in Monte Carlo Simulation Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Stockholders' Equity - Performance-and Market-Based RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails</Role>
      <ShortName>Stockholders' Equity - Performance-and Market-Based RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Stockholders' Equity - December 2024 Performance-Based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails</Role>
      <ShortName>Stockholders' Equity - December 2024 Performance-Based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails</Role>
      <ShortName>Income Taxes - Components of Pretax Loss from Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails</Role>
      <ShortName>Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/A401kPlan</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SegmentInformationTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ino-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ino-20241231.htm">ino-20241231.htm</File>
    <File>ino-20241231.xsd</File>
    <File>ino-20241231_cal.xml</File>
    <File>ino-20241231_def.xml</File>
    <File>ino-20241231_lab.xml</File>
    <File>ino-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20241231_g1.jpg</File>
    <File>ino-20241231_g2.jpg</File>
    <File>ino-20241231_g3.jpg</File>
    <File>ino-20241231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="821">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ino-20241231.htm": {
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ino-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "ino-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ino-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 343,
   "keyCustom": 85,
   "axisStandard": 35,
   "axisCustom": 2,
   "memberStandard": 46,
   "memberCustom": 57,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2024": 5,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://www.inovio.com/20241231": 1
   },
   "contextCount": 273,
   "entityCount": 1,
   "segmentCount": 107,
   "elementCount": 809,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 821,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.inovio.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inovio.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorLocation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorLocation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "longName": "9952154 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952155 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inovio.com/role/TheCompany",
     "longName": "9952157 - Disclosure - The Company",
     "shortName": "The Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk",
     "longName": "9952159 - Disclosure - Revenue Recognition and Concentration of Credit Risk",
     "shortName": "Revenue Recognition and Concentration of Credit Risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "longName": "9952160 - Disclosure - Collaborative Agreements",
     "shortName": "Collaborative Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements",
     "longName": "9952161 - Disclosure - Short-term Investments and Fair Value Measurements",
     "shortName": "Short-term Investments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItems",
     "longName": "9952162 - Disclosure - Certain Balance Sheet Items",
     "shortName": "Certain Balance Sheet Items",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inovio.com/role/FixedAssets",
     "longName": "9952163 - Disclosure - Fixed Assets",
     "shortName": "Fixed Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "longName": "9952164 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "longName": "9952165 - Disclosure - Convertible Debt",
     "shortName": "Convertible Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "longName": "9952166 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inovio.com/role/CommitmentsandContingencies",
     "longName": "9952167 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "longName": "9952168 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inovio.com/role/A401kPlan",
     "longName": "9952169 - Disclosure - 401(k) Plan",
     "shortName": "401(k) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "longName": "9952170 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "longName": "9952171 - Disclosure - Geneos Therapeutics, Inc.",
     "shortName": "Geneos Therapeutics, Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inovio.com/role/SegmentInformation",
     "longName": "9952172 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.inovio.com/role/SubsequentEvents",
     "longName": "9952173 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables",
     "longName": "9955513 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)",
     "shortName": "Revenue Recognition and Concentration of Credit Risk (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)",
     "shortName": "Short-term Investments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsTables",
     "longName": "9955515 - Disclosure - Certain Balance Sheet Items (Tables)",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inovio.com/role/FixedAssetsTables",
     "longName": "9955516 - Disclosure - Fixed Assets (Tables)",
     "shortName": "Fixed Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "longName": "9955517 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables",
     "longName": "9955518 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inovio.com/role/IncomeTaxesTables",
     "longName": "9955519 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inovio.com/role/SegmentInformationTables",
     "longName": "9955520 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955521 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ino:WorkingCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955522 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ino:WeightedAverageNumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
     "longName": "9955523 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails",
     "longName": "9955525 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)",
     "shortName": "Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
     "longName": "9955526 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)",
     "shortName": "Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "longName": "9955527 - Disclosure - Collaborative Agreements (Details)",
     "shortName": "Collaborative Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-78",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails",
     "longName": "9955528 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Schedule of Available-for-sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
     "longName": "9955529 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955530 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-111",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails",
     "longName": "9955531 - Disclosure - Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Schedule of Assumptions Used To Estimate The Fair Value Of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-138",
      "name": "ino:WarrantLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "ino:WarrantLiabilityMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails",
     "longName": "9955532 - Disclosure - Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company\u2019s Total Level 3 Financial Liabilities (Details)",
     "shortName": "Short-term Investments and Fair Value Measurements - Changes In Fair Value Of The Company\u2019s Total Level 3 Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails",
     "longName": "9955533 - Disclosure - Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)",
     "shortName": "Certain Balance Sheet Items - Schedule of Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ino:PrepaidClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ino:PrepaidClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
     "longName": "9955534 - Disclosure - Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Certain Balance Sheet Items - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ino:PrepaidManufacturingExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ino:PrepaidManufacturingExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inovio.com/role/FixedAssetsDetails",
     "longName": "9955535 - Disclosure - Fixed Assets (Details)",
     "shortName": "Fixed Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "longName": "9955536 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "longName": "9955537 - Disclosure - Convertible Debt - Narrative (Details)",
     "shortName": "Convertible Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails",
     "longName": "9955538 - Disclosure - Stockholders' Equity - Schedule of Preferred Stock (Details)",
     "shortName": "Stockholders' Equity - Schedule of Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.inovio.com/role/StockholdersEquityPreferredStockDetails",
     "longName": "9955539 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-161",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
     "longName": "9955540 - Disclosure - Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)",
     "shortName": "Stockholders' Equity - Offering of Common Stock, Warrants, and Pre-funded Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-166",
      "name": "ino:ClassOfWarrantOrRightCommonStockOwnershipPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "ino:ClassOfWarrantOrRightCommonStockOwnershipPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
     "longName": "9955541 - Disclosure - Stockholders' Equity - At-The-Market Sales Agreements (Details)",
     "shortName": "Stockholders' Equity - At-The-Market Sales Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-167",
      "name": "ino:StockSalesAgreementMaximumAuthorizedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-167",
      "name": "ino:StockSalesAgreementMaximumAuthorizedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails",
     "longName": "9955542 - Disclosure - Stockholders' Equity - Other Issuances of Common Stock (Details)",
     "shortName": "Stockholders' Equity - Other Issuances of Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-173",
      "name": "ino:LitigationSettlementAmountAwardedToOtherPartyShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
     "longName": "9955543 - Disclosure - Stockholders' Equity - Stock Options and Restricted Stock Units (Details)",
     "shortName": "Stockholders' Equity - Stock Options and Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails",
     "longName": "9955544 - Disclosure - Stockholders' Equity - Schedule of Stock Options Outstanding (Details)",
     "shortName": "Stockholders' Equity - Schedule of Stock Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails",
     "longName": "9955545 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)",
     "shortName": "Stockholders' Equity - Schedule of Stock Option Activity Under Equity Incentive Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
     "longName": "9955546 - Disclosure - Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)",
     "shortName": "Stockholders' Equity - Schedule of RSU Activity Under Equity Incentive Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-188",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
     "longName": "9955547 - Disclosure - Stockholders' Equity - Significant Assumption Used in Monte Carlo Simulation Method (Details)",
     "shortName": "Stockholders' Equity - Significant Assumption Used in Monte Carlo Simulation Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-211",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-211",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
     "longName": "9955548 - Disclosure - Stockholders' Equity - Performance-and Market-Based RSUs (Details)",
     "shortName": "Stockholders' Equity - Performance-and Market-Based RSUs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-206",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
     "longName": "9955549 - Disclosure - Stockholders' Equity - December 2024 Performance-Based Awards (Details)",
     "shortName": "Stockholders' Equity - December 2024 Performance-Based Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-217",
      "name": "ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "longName": "9955550 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
     "longName": "9955551 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails",
     "longName": "9955552 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)",
     "shortName": "Income Taxes - Components of Pretax Loss from Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails",
     "longName": "9955553 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)",
     "shortName": "Income Taxes - Reconciliation of Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.inovio.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955554 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ino:TaxBenefitsExpired",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955555 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
     "longName": "9955556 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)",
     "shortName": "Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-238",
      "name": "ino:OperatingLossCarryforwardsExpiringInNextFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-238",
      "name": "ino:OperatingLossCarryforwardsExpiringInNextFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails",
     "longName": "9955557 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)",
     "shortName": "Income Taxes - Unrecognized Tax Benefits Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-17",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.inovio.com/role/A401kPlanDetails",
     "longName": "9955558 - Disclosure - 401(k) Plan (Details)",
     "shortName": "401(k) Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955559 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-245",
      "name": "ino:CollaborativeAgreementExpensesToReimburse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "longName": "9955560 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-256",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-256",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.inovio.com/role/SegmentInformationDetails",
     "longName": "9955561 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-258",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.inovio.com/role/SubsequentEventsDetails",
     "longName": "9955562 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-272",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ino-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ino_A2007IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "A2007IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2007 Incentive Plan",
        "label": "2007 Incentive Plan [Member]",
        "documentation": "2007 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2016IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "A2016IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Incentive Plan",
        "label": "2016 Incentive Plan [Member]",
        "documentation": "2016 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2021SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "A2021SalesAgreementMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Sales Agreement",
        "label": "2021 Sales Agreement [Member]",
        "documentation": "2021 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2022InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "A2022InducementPlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Inducement Plan",
        "label": "2022 Inducement Plan [Member]",
        "documentation": "2022 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2023IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "A2023IncentivePlanMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Incentive Plan",
        "label": "2023 Incentive Plan [Member]",
        "documentation": "2023 Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A2024SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "A2024SalesAgreementMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Sales Agreement",
        "label": "2024 Sales Agreement [Member]",
        "documentation": "2024 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.50% Convertible Senior Notes Due 2024",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AccountsPayableAndAccruedExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "AccountsPayableAndAccruedExpensesLineItems",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Line Items]",
        "label": "Accounts Payable and Accrued Expenses [Line Items]",
        "documentation": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AccountsPayableAndAccruedExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "AccountsPayableAndAccruedExpensesTable",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses [Table]",
        "label": "Accounts Payable and Accrued Expenses [Table]",
        "documentation": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Accounts payable and accrued liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r134"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable",
        "label": "Accounts Payable, Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r842",
      "r931",
      "r1193",
      "r1194"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued clinical trial expenses",
        "label": "Accrued Clinical Trial Expense, Current",
        "documentation": "Accrued Clinical Trial Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r855"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Depreciation and Amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r178",
      "r691"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r92",
      "r185",
      "r686",
      "r729",
      "r730"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r19",
      "r569",
      "r572",
      "r626",
      "r725",
      "r726",
      "r1068",
      "r1069",
      "r1070",
      "r1081",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r357",
      "r850"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r916",
      "r1226"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1163",
      "r1227"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r481"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants for cash, net of financing costs",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r43",
      "r119"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AdvaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "AdvaccineMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ApolloBio Corporation",
        "label": "Advaccine [Member]",
        "documentation": "Advaccine"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated Entity",
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r846",
      "r931",
      "r1130",
      "r1177",
      "r1178",
      "r1180"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r981",
      "r1014"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r974",
      "r984",
      "r1017"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1009",
      "r1018",
      "r1022",
      "r1030"
     ]
    },
    "ino_AllOtherCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "AllOtherCustomersMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All other, including affiliated entity",
        "label": "All Other Customers [Member]",
        "documentation": "All Other Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r511"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r290",
      "r330"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r352",
      "r358",
      "r878"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ino_ApolloBioCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ApolloBioCorporationMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ApolloBio Corporation",
        "label": "ApolloBio Corporation [Member]",
        "documentation": "ApolloBio Corporation"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ApolloBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ApolloBioMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ApolloBio",
        "label": "ApolloBio [Member]",
        "documentation": "ApolloBio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_April2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "April2024OfferingMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2024 Offering",
        "label": "April 2024 Offering [Member]",
        "documentation": "April 2024 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ino_April2024OfferingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "April2024OfferingWarrantsMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2024 Offering Warrants",
        "label": "April 2024 Offering Warrants [Member]",
        "documentation": "April 2024 Offering Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r146",
      "r180",
      "r211",
      "r244",
      "r252",
      "r277",
      "r281",
      "r327",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r564",
      "r566",
      "r604",
      "r681",
      "r787",
      "r869",
      "r870",
      "r916",
      "r938",
      "r1124",
      "r1125",
      "r1181"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r188",
      "r211",
      "r327",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r564",
      "r566",
      "r604",
      "r916",
      "r1124",
      "r1125",
      "r1181"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r903"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assumptions used to estimate the fair value of stock options",
        "label": "Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]",
        "documentation": "Assumptions used in estimation of fair value of stock options."
       }
      }
     },
     "auth_ref": []
    },
    "ino_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944",
      "r967"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944",
      "r967"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944",
      "r967"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross\u00a0Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross\u00a0Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r336",
      "r680"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Sale [Abstract]",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r336",
      "r580",
      "r673",
      "r903",
      "r907",
      "r1098",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Axis]",
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Date [Domain]",
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Liquidity",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ino_BehestiVKimEtAlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "BehestiVKimEtAlMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Behesti v. Kim, et al.",
        "label": "Behesti v. Kim, et al. [Member]",
        "documentation": "Behesti v. Kim, et al."
       }
      }
     },
     "auth_ref": []
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "BillAndMelindaGatesFoundationMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bill And Melinda Gates Foundation",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "documentation": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "auth_ref": []
    },
    "ino_BiojectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "BiojectMember",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bioject",
        "label": "Bioject [Member]",
        "documentation": "Bioject [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r560",
      "r896",
      "r897"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r560",
      "r896",
      "r897"
     ]
    },
    "ino_CaliforniaIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CaliforniaIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "California Income Tax Authority [Member]",
        "documentation": "California Income Tax Authority [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r176",
      "r853"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r103",
      "r207"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r103"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CertainBalanceSheetItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CertainBalanceSheetItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Balance Sheet Items [Abstract]",
        "documentation": "Certain Balance Sheet Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "ino_ChangeInFairValueOfCommonStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ChangeInFairValueOfCommonStockWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of common stock warrant liability",
        "label": "Change in Fair Value of Common Stock Warrants",
        "documentation": "The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Loss) gain on investment in affiliated entity",
        "negatedLabel": "Loss (gain) on equity investment in affiliated entity",
        "terseLabel": "Gain (loss) on investment in affiliated entities",
        "label": "Change in Value of Investments in Affiliated Company",
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r182",
      "r183",
      "r184",
      "r211",
      "r235",
      "r236",
      "r238",
      "r240",
      "r246",
      "r247",
      "r327",
      "r384",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r422",
      "r423",
      "r426",
      "r429",
      "r437",
      "r604",
      "r740",
      "r741",
      "r742",
      "r743",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r773",
      "r796",
      "r818",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r1052",
      "r1075",
      "r1086"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r246",
      "r422",
      "r423",
      "r424",
      "r426",
      "r429",
      "r435",
      "r437",
      "r740",
      "r741",
      "r742",
      "r743",
      "r885",
      "r1052",
      "r1075"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ino_ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, common stock, maximum (percent)",
        "label": "Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent",
        "documentation": "Class Of Warrant Or Right, Common Stock Ownership, Maximum Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ClassOfWarrantOrRightCommonStockOwnershipPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ClassOfWarrantOrRightCommonStockOwnershipPercent",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, common stock ownership (percent)",
        "label": "Class Of Warrant Or Right, Common Stock Ownership, Percent",
        "documentation": "Class Of Warrant Or Right, Common Stock Ownership, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, common stock, prior to issuance (percent)",
        "label": "Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent",
        "documentation": "Class Of Warrant Or Right, Common Stock Ownership, Prior To Issuance, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in USD per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities called by warrants or rights (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Table]",
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coalition for Epidemic Preparedness Innovations",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional revenue to be achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obligation period to pay royalties",
        "label": "Collaboration Agreement, Royalty Period",
        "documentation": "Collaboration Agreement, Royalty Period"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAmendedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeAgreementAmendedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement amended amount",
        "label": "Collaborative Agreement, Amended Amount",
        "documentation": "Collaborative Agreement, Amended Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeAgreementAwardedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "documentation": "Collaborative Agreement, Awarded Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awarded option amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "documentation": "Collaborative Agreement, Awarded Option Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses to reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "documentation": "Collaborative Agreement, Expenses To Reimburse"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeAgreementFundingReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding received",
        "label": "Collaborative Agreement, Funding Received",
        "documentation": "Collaborative Agreement, Funding Received"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, funding to be received",
        "label": "Collaborative Agreement, Funding To Be Received",
        "documentation": "Collaborative Agreement, Funding Received for Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, period to receive funding for research and development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "documentation": "Collaborative Agreements, Upfront Payment Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r168"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ino_CollaborativeArrangementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CollaborativeArrangementTerm",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "label": "Collaborative Arrangement, Term",
        "documentation": "Collaborative Arrangement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r136",
      "r683",
      "r772"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r374",
      "r375",
      "r844",
      "r1113",
      "r1118"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929",
      "r930",
      "r932",
      "r933",
      "r934",
      "r935",
      "r1081",
      "r1082",
      "r1084",
      "r1163",
      "r1225",
      "r1227"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of common stock shares outstanding under the Incentive Plan (in shares)",
        "label": "Common Stock, Other Shares, Outstanding",
        "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r773"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r86",
      "r773",
      "r793",
      "r1227",
      "r1228"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock\u2014par value $0.001; Authorized shares: 600,000,000 at December 31, 2024 and 2023, issued and outstanding: 36,099,991 at December\u00a031, 2024 and 22,793,075 at December\u00a031, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r685",
      "r916"
     ]
    },
    "ino_CommonStockWarrantLiabilityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "CommonStockWarrantLiabilityFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrant liability",
        "label": "Common Stock Warrant Liability, Fair Value",
        "documentation": "Common Stock Warrant Liability, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r125"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r193",
      "r195",
      "r200",
      "r674",
      "r697",
      "r698"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r67",
      "r68",
      "r288",
      "r843"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r67",
      "r68",
      "r288",
      "r732",
      "r843"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r67",
      "r68",
      "r288",
      "r843",
      "r1054"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r158"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "%\u00a0of\u00a0Total Revenue",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r67",
      "r68",
      "r288"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r67",
      "r68",
      "r288",
      "r843"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r859"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from deferred revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Debt, Current",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r394",
      "r395",
      "r405",
      "r406",
      "r407",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible preferred stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423",
      "r426",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r47",
      "r85",
      "r117",
      "r432"
     ]
    },
    "ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share",
        "documentation": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r397",
      "r424",
      "r633",
      "r654",
      "r678",
      "r856",
      "r858"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r288"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r956",
      "r1045"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1043"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r1036"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r1037"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r1035"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r1038"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r1040"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r1040"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1041"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r955",
      "r1044"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1042"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r1039"
     ]
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "D N A Encoded Monoclonal Antibody Technology",
        "label": "D N A Encoded Monoclonal Antibody Technology [Member]",
        "documentation": "D N A Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r209",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r382",
      "r383",
      "r393",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r409",
      "r416",
      "r417",
      "r419",
      "r613"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r75",
      "r76",
      "r131",
      "r135",
      "r218",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r914",
      "r1076",
      "r1114",
      "r1115",
      "r1116",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r613",
      "r614",
      "r881",
      "r882",
      "r914"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt interest based on the fixed rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r395"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r914",
      "r1076",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r218",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r914",
      "r1076",
      "r1114",
      "r1115",
      "r1116",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r47",
      "r50",
      "r72",
      "r116",
      "r118",
      "r218",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r418",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r914",
      "r1076",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, realized gain",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities, available-for-sale, realized gain",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities in a gross unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r338"
     ]
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual maturity",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "documentation": "Debt Securities, Available-for-sale contractual maturity."
       }
      }
     },
     "auth_ref": []
    },
    "ino_December2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "December2024Member",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2024",
        "label": "December 2024 [Member]",
        "documentation": "December 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ino_December2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "December2024OfferingMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2024 Offering",
        "label": "December 2024 Offering [Member]",
        "documentation": "December 2024 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ino_December2024OfferingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "December2024OfferingWarrantsMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2024 Offering Warrants",
        "label": "December 2024 Offering Warrants [Member]",
        "documentation": "December 2024 Offering Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ino_DeferredGrantFundingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "DeferredGrantFundingCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability, including from affiliated entity",
        "label": "Deferred Grant Funding, Current",
        "documentation": "Deferred Grant Funding, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "DeferredGrantFundingFromAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred grant funding from affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "documentation": "Deferred Grant Funding, From Affiliate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r164",
      "r1078"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r133",
      "r540"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, gross",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research expense",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "ino_DeferredTaxAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired intangibles",
        "label": "Deferred Tax Assets, Intangible Assets",
        "documentation": "Deferred Tax Assets, Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in affiliated entity",
        "label": "Deferred Tax Assets, Investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "documentation": "Deferred Tax Assets, Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expirations of Operating Loss Carryforwards, Components [Abstract]",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOtherTaxCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development and other tax credits",
        "label": "Deferred Tax Assets, Other Tax Carryforwards",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expirations of Tax Credit Carryforwards [Abstract]",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's contribution to 401(k) plan",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum annual contribution per employee, percent",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer matching contribution, percent",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation",
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrant liability",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944",
      "r967"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944",
      "r967",
      "r1010"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share",
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r233",
      "r235",
      "r238",
      "r239",
      "r240",
      "r243",
      "r558",
      "r562",
      "r577",
      "r578",
      "r675",
      "r699",
      "r861"
     ]
    },
    "ino_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "documentation": "Earnings Per Share, Basic and Diluted EPS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in dollars per share)",
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r235",
      "r238",
      "r239",
      "r240",
      "r243",
      "r558",
      "r562",
      "r577",
      "r578",
      "r675",
      "r699",
      "r861"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r242"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired NOLs and credits",
        "label": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits",
        "documentation": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits"
       }
      }
     },
     "auth_ref": []
    },
    "ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Limited NOLs and credits",
        "label": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits",
        "documentation": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options to purchase common stock",
        "terseLabel": "Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "ino_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors",
        "label": "Employees and Directors [Member]",
        "documentation": "Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_EngineeringAndDeviceRelatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "EngineeringAndDeviceRelatedMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Engineering And Device-Related",
        "label": "Engineering And Device-Related [Member]",
        "documentation": "Engineering And Device-Related"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r171",
      "r197",
      "r198",
      "r199",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r230",
      "r232",
      "r245",
      "r328",
      "r329",
      "r362",
      "r439",
      "r548",
      "r549",
      "r555",
      "r556",
      "r557",
      "r559",
      "r561",
      "r562",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r615",
      "r616",
      "r626",
      "r695",
      "r725",
      "r726",
      "r727",
      "r749",
      "r818"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Geneos",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r262",
      "r281",
      "r325",
      "r1062",
      "r1107"
     ]
    },
    "ino_EquityMethodInvestmentsMinimum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "EquityMethodInvestmentsMinimum",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments, minimum",
        "label": "Equity Method Investments, Minimum",
        "documentation": "Equity Method Investments, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r69",
      "r326"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in affiliated entity",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r603",
      "r854"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in affiliated entity",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r580",
      "r603",
      "r678",
      "r679",
      "r903",
      "r925",
      "r927",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain on available-for-sale equity securities",
        "negatedTerseLabel": "Net unrealized gain on available-for-sale equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r1106"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r971",
      "r981",
      "r1014"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r978",
      "r1011"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of common stock warrant liability",
        "terseLabel": "Change in fair value of common stock warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583",
      "r907"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r592",
      "r593",
      "r595",
      "r641",
      "r642",
      "r643",
      "r881",
      "r882",
      "r893",
      "r894",
      "r895",
      "r903",
      "r907"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r584",
      "r903",
      "r1168",
      "r1171"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Investments and Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r590",
      "r591",
      "r592",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r672",
      "r903",
      "r908"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r463",
      "r468",
      "r581",
      "r593",
      "r641",
      "r893",
      "r894",
      "r895",
      "r903"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r463",
      "r468",
      "r581",
      "r582",
      "r593",
      "r642",
      "r881",
      "r882",
      "r893",
      "r894",
      "r895",
      "r903"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r581",
      "r582",
      "r583",
      "r584",
      "r593",
      "r643",
      "r881",
      "r882",
      "r893",
      "r894",
      "r895",
      "r903",
      "r907"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r589",
      "r594"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r584",
      "r903",
      "r1168",
      "r1171"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in fair value of liability",
        "negatedTerseLabel": "Decrease in fair value of liability",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r594"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock warrants in December 2024",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r594"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r594"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r592",
      "r593",
      "r595",
      "r641",
      "r642",
      "r643",
      "r881",
      "r882",
      "r893",
      "r894",
      "r895",
      "r903",
      "r907"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1171"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsChangesInFairValueOfTheCompanysTotalLevel3FinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r594"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r339",
      "r340",
      "r418",
      "r435",
      "r574",
      "r600",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r696",
      "r876",
      "r903",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r917",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1164",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis",
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166",
      "r1170"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Jurisdiction",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1018"
     ]
    },
    "ino_FormerPresidentAndChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "FormerPresidentAndChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former President and Chief Executive Officer",
        "label": "Former President and Chief Executive Officer [Member]",
        "documentation": "Former President and Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "ino_GainLossOnSaleOfFixedAssetsNoNetBookValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "GainLossOnSaleOfFixedAssetsNoNetBookValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on sale of fixed assets, no net book value",
        "label": "Gain (Loss) On Sale Of Fixed Assets, No Net Book Value",
        "documentation": "Gain (Loss) On Sale Of Fixed Assets, No Net Book Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized loss on sales of short-term investments",
        "label": "Gain (Loss) on Sale of Other Investments",
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net (gain) loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "GeneosTherapeuticsInc.Member",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geneos Therapeutics, Inc.",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "documentation": "Geneos Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r798"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill",
        "verboseLabel": "Impairment of goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r341",
      "r347",
      "r351",
      "r877",
      "r904"
     ]
    },
    "ino_GrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "GrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused grant funding",
        "label": "Grant Liability",
        "documentation": "Grant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ino_GrantProceedsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "GrantProceedsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant proceeds received",
        "label": "Grant Proceeds Received",
        "documentation": "Grant Proceeds Received"
       }
      }
     },
     "auth_ref": []
    },
    "ino_GrantRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "GrantRevenuePolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants",
        "label": "Grant Revenue [Policy Text Block]",
        "documentation": "Grant Revenue [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Axis]",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Domain]",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "ino_INO3107Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "INO3107Member",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INO-3107",
        "label": "INO-3107 [Member]",
        "documentation": "INO-3107"
       }
      }
     },
     "auth_ref": []
    },
    "ino_INO5401AndOtherImmunoOncologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "INO5401AndOtherImmunoOncologyMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INO-5401 And Other Immuno-oncology",
        "label": "INO-5401 And Other Immuno-oncology [Member]",
        "documentation": "INO-5401 And Other Immuno-oncology"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r944",
      "r967"
     ]
    },
    "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r352",
      "r359"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r1074",
      "r1112"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r521"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r140",
      "r145",
      "r676",
      "r693",
      "r863",
      "r869",
      "r1087",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r521"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r370",
      "r371",
      "r586",
      "r589",
      "r594",
      "r722",
      "r724",
      "r803",
      "r850",
      "r906",
      "r1196"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r586",
      "r589",
      "r594",
      "r722",
      "r724",
      "r803",
      "r850",
      "r906",
      "r1196"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r522",
      "r523",
      "r533",
      "r545",
      "r902",
      "r1161"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r522",
      "r523",
      "r533",
      "r545",
      "r902",
      "r1161"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r515",
      "r522",
      "r530",
      "r531",
      "r532",
      "r538",
      "r544",
      "r550",
      "r552",
      "r553",
      "r554",
      "r745",
      "r902"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails",
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense (benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r165",
      "r231",
      "r232",
      "r244",
      "r260",
      "r281",
      "r520",
      "r522",
      "r551",
      "r702",
      "r902"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r518",
      "r519",
      "r538",
      "r539",
      "r543",
      "r547",
      "r739"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r902",
      "r1157"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r522",
      "r527",
      "r902"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r526",
      "r902",
      "r1157"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefit from income taxes at statutory rates",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r902"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1157",
      "r1159"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1157",
      "r1159"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r1157",
      "r1158"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r902",
      "r1157"
     ]
    },
    "ino_IncomeTaxReconciliationStatuteLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "IncomeTaxReconciliationStatuteLimitations",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Income Tax Reconciliation, Statute Limitations",
        "documentation": "Income Tax Reconciliation, Statute Limitations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r902",
      "r1157"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued expenses, including due to affiliated entities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, including from affiliated entities",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial expenses",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets and liabilities, net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets, including from affiliated entities",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant funding liability, including from affiliated entity",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ino_IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants",
     "calculation": {
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average pre-funded warrants (in shares)",
        "label": "Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants",
        "documentation": "Incremental Common Shares Attributable To Basic And Dilutive Effect Of PreFunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1009",
      "r1018",
      "r1022",
      "r1030"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1034"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1034"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1034"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, debt",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r413",
      "r420",
      "r883",
      "r884"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r1072"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r204",
      "r205"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income",
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r255",
      "r281",
      "r869",
      "r1071"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of discounts on investments",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares owned (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762",
      "r827",
      "r833",
      "r835",
      "r930"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r735",
      "r736",
      "r737",
      "r738",
      "r828",
      "r829"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term Investments and Fair Value Measurements",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r170",
      "r291",
      "r292",
      "r601",
      "r602",
      "r1190"
     ]
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "LassaFeverAndMERSVaccineMember",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lassa Fever And MERS Vaccine",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "documentation": "Lassa Fever And MERS Vaccine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r915"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r624"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, area of land under lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase of base rent percentage",
        "label": "Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)",
        "documentation": "Lessee, Operating Lease, Base Rate Percentage, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Maturities Of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total remaining lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: present value adjustment",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, remaining lease term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r1175"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r75",
      "r76",
      "r77",
      "r79",
      "r80",
      "r81",
      "r84",
      "r211",
      "r327",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r565",
      "r566",
      "r567",
      "r604",
      "r771",
      "r862",
      "r938",
      "r1124",
      "r1181",
      "r1182"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r137",
      "r688",
      "r916",
      "r1077",
      "r1108",
      "r1172"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r175",
      "r211",
      "r327",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r565",
      "r566",
      "r567",
      "r604",
      "r916",
      "r1124",
      "r1181",
      "r1182"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_LitigationSettlementAmountAwardedToOtherPartyShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "LitigationSettlementAmountAwardedToOtherPartyShares",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in settlement (in shares)",
        "label": "Litigation Settlement, Amount Awarded to Other Party, Shares",
        "documentation": "Litigation Settlement, Amount Awarded to Other Party, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r1114",
      "r1115",
      "r1116"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r42",
      "r1114",
      "r1115",
      "r1116"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Damages paid",
        "label": "Loss Contingency, Damages Paid, Value",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of cash settlement",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r380",
      "r381",
      "r512",
      "r879"
     ]
    },
    "ino_LossContingencyEstimateOfPossibleLossValueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "LossContingencyEstimateOfPossibleLossValueOfShares",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of shares settlement",
        "label": "Loss Contingency, Estimate of Possible Loss, Value of Shares",
        "documentation": "Loss Contingency, Estimate of Possible Loss, Value of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNumberOfDefendants",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of defendants",
        "label": "Loss Contingency, Number of Defendants",
        "documentation": "Number of defendants named in a legal action."
       }
      }
     },
     "auth_ref": [
      "r1120",
      "r1121"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major Customers [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r888",
      "r919",
      "r923",
      "r1128",
      "r1195",
      "r1197",
      "r1198",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r479",
      "r512",
      "r584",
      "r670",
      "r721",
      "r723",
      "r731",
      "r763",
      "r764",
      "r826",
      "r830",
      "r831",
      "r832",
      "r834",
      "r848",
      "r849",
      "r875",
      "r885",
      "r898",
      "r907",
      "r908",
      "r912",
      "r913",
      "r920",
      "r1126",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188"
     ]
    },
    "ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "McDermidVInovioPharmaceuticalsIncAndJJosephKimMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim",
        "label": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]",
        "documentation": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life in years",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583",
      "r584",
      "r907"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583",
      "r584",
      "r907"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r479",
      "r512",
      "r584",
      "r670",
      "r721",
      "r723",
      "r731",
      "r763",
      "r764",
      "r826",
      "r830",
      "r831",
      "r832",
      "r834",
      "r848",
      "r849",
      "r875",
      "r885",
      "r898",
      "r907",
      "r908",
      "r912",
      "r920",
      "r1126",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Line Items]",
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest, ownership percentage by parent",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestTable",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest [Table]",
        "label": "Noncontrolling Interest [Table]",
        "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64",
      "r90",
      "r94"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. agency mortgage-backed securities",
        "label": "Mortgage-Backed Security, Issued by US Government-Sponsored Enterprise [Member]",
        "documentation": "Debt security collateralized by real estate mortgage loan issued by U.S. government-sponsored enterprise (GSE), including, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and Federal Home Loan Bank (FHLBank)."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1129"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ino_MutualFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "MutualFundsMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds",
        "label": "Mutual Funds [Member]",
        "documentation": "Mutual funds."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Major Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r888",
      "r919",
      "r923",
      "r1128",
      "r1195",
      "r1197",
      "r1198",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.inovio.com/role/TheCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/SegmentInformationDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "negatedLabel": "Net loss from operations",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r105",
      "r141",
      "r173",
      "r192",
      "r194",
      "r199",
      "r211",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r237",
      "r327",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r558",
      "r562",
      "r578",
      "r604",
      "r694",
      "r795",
      "r816",
      "r817",
      "r936",
      "r1124"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ino_NonCashInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "NonCashInterestIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash interest on senior convertible notes",
        "label": "Non-Cash Interest Income (Expense)",
        "documentation": "Non-Cash Interest Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ino_NonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "NonEmployeeMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Employee",
        "label": "Non Employee [Member]",
        "documentation": "Non employee."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r975",
      "r985",
      "r1009",
      "r1018"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r874",
      "r1088"
     ]
    },
    "ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares of vested restricted stock outstanding under the plan (in shares)",
        "label": "Number of Shares of Vested Restricted Stock Outstanding Under Plan",
        "documentation": "Number of shares of vested restricted stock outstanding under the plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expenses:",
        "terseLabel": "Less:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r863",
      "r1087",
      "r1089",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability",
        "negatedTerseLabel": "Less: current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability, net of current portion",
        "netLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r915"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r915"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Total",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards that will expire due to IRC Section 382 limitations",
        "label": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net",
        "documentation": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsExpiringInNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "OperatingLossCarryforwardsExpiringInNextFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Operating Loss Carryforwards, Expiring in Next Fiscal Year",
        "documentation": "Operating Loss Carryforwards, Expiring in Next Fiscal Year"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsExpiringinFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "OperatingLossCarryforwardsExpiringinFourYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 and thereafter",
        "label": "Operating Loss Carryforwards, Expiring in Four Years",
        "documentation": "Operating Loss Carryforwards, Expiring in Four Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsExpiringinThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "OperatingLossCarryforwardsExpiringinThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Operating Loss Carryforwards, Expiring in Three Years",
        "documentation": "Operating Loss Carryforwards, Expiring in Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsExpiringinTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "OperatingLossCarryforwardsExpiringinTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Operating Loss Carryforwards, Expiring in Two Years",
        "documentation": "Operating Loss Carryforwards, Expiring in Two Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OperatingLossCarryforwardsIndefinitelyCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "OperatingLossCarryforwardsIndefinitelyCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite",
        "label": "Operating Loss Carryforwards, Indefinitely Carryforward",
        "documentation": "Operating Loss Carryforwards, Indefinitely Carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geneos Therapeutics, Inc.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r128",
      "r733",
      "r734"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "verboseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r695"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on short-term investments, net of tax",
        "verboseLabel": "Unrealized gain (loss) on short-term investments, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r324"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItems"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain Balance Sheet Items",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other expense, net",
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1109"
     ]
    },
    "ino_OtherProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "OtherProgramsMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Programs",
        "label": "Other Programs [Member]",
        "documentation": "Other Programs"
       }
      }
     },
     "auth_ref": []
    },
    "ino_OtherUnallocatedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "OtherUnallocatedExpensesMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Unallocated Expenses",
        "label": "Other Unallocated Expenses [Member]",
        "documentation": "Other Unallocated Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r973",
      "r983",
      "r1016"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r976",
      "r986",
      "r1019"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r976",
      "r986",
      "r1019"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of capital assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ino_PennsylvaniaStateIncomeTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "PennsylvaniaStateIncomeTaxAuthorityMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pennsylvania",
        "label": "Pennsylvania State Income Tax Authority [Member]",
        "documentation": "Pennsylvania State Income Tax Authority [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/A401kPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r895"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ino_PerformanceRSUsSpecifiedMaximumPercentileMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "PerformanceRSUsSpecifiedMaximumPercentileMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance RSUs, Specified Maximum Percentile",
        "label": "Performance RSUs, Specified Maximum Percentile [Member]",
        "documentation": "Performance RSUs, Specified Maximum Percentile"
       }
      }
     },
     "auth_ref": []
    },
    "ino_PerformanceRSUsSpecifiedThresholdPercentileMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "PerformanceRSUsSpecifiedThresholdPercentileMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance RSUs, Specified Threshold Percentile",
        "label": "Performance RSUs, Specified Threshold Percentile [Member]",
        "documentation": "Performance RSUs, Specified Threshold Percentile"
       }
      }
     },
     "auth_ref": []
    },
    "ino_PerformanceRSUsTargetPercentileMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "PerformanceRSUsTargetPercentileMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance RSUs, Target Percentile",
        "label": "Performance RSUs, Target Percentile [Member]",
        "documentation": "Performance RSUs, Target Percentile"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156"
     ]
    },
    "ino_PlumblineLifeSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "PlumblineLifeSciencesMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plumbline Life Sciences",
        "label": "Plumbline Life Sciences [Member]",
        "documentation": "Plumbline Life Sciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plymouth Meeting, Pennsylvania",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "documentation": "Plymouth Meeting, Pennsylvania [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929",
      "r932",
      "r933",
      "r934",
      "r935",
      "r1225",
      "r1227"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r422"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r773"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r422"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r773",
      "r793",
      "r1227",
      "r1228"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock\u2014par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December\u00a031, 2024 and 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r684",
      "r916"
     ]
    },
    "ino_PrepaidClinicalExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "PrepaidClinicalExpensesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical expenses",
        "label": "Prepaid Clinical Expenses, Current",
        "documentation": "Prepaid Clinical Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets, including with affiliated entity",
        "totalLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense",
        "label": "Prepaid Expense",
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r187",
      "r786",
      "r1192"
     ]
    },
    "ino_PrepaidManufacturingExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "PrepaidManufacturingExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid manufacturing expense, current",
        "label": "Prepaid Manufacturing Expense, Current",
        "documentation": "Prepaid Manufacturing Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of debt",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ino_ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of pre-funded warrants, net of issuance costs",
        "label": "Proceeds From Issuance of Warrants, Net Of Issuance Costs",
        "documentation": "Proceeds From Issuance of Warrants, Net Of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "documentation": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of capital assets",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale or maturity of investments",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock option exercises",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r671",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r852",
      "r886",
      "r918",
      "r920",
      "r921",
      "r924",
      "r926",
      "r1122",
      "r1123",
      "r1128",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r671",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r852",
      "r886",
      "r918",
      "r920",
      "r921",
      "r924",
      "r926",
      "r1122",
      "r1123",
      "r1128",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r624"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/FixedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r159",
      "r162",
      "r163"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment disposed of",
        "label": "Property, Plant and Equipment, Disposals",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r177",
      "r692"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed assets, net",
        "totalLabel": "Net Book Value",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r624",
      "r677",
      "r692",
      "r916"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and other",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r159",
      "r162",
      "r690"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Fixed Assets",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r624"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant, and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r461",
      "r479",
      "r505",
      "r506",
      "r507",
      "r512",
      "r584",
      "r644",
      "r653",
      "r670",
      "r721",
      "r723",
      "r731",
      "r763",
      "r764",
      "r826",
      "r830",
      "r831",
      "r832",
      "r834",
      "r848",
      "r849",
      "r875",
      "r885",
      "r898",
      "r907",
      "r908",
      "r912",
      "r913",
      "r920",
      "r930",
      "r1117",
      "r1126",
      "r1168",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r461",
      "r479",
      "r505",
      "r506",
      "r507",
      "r512",
      "r584",
      "r644",
      "r653",
      "r670",
      "r721",
      "r723",
      "r731",
      "r763",
      "r764",
      "r826",
      "r830",
      "r831",
      "r832",
      "r834",
      "r848",
      "r849",
      "r875",
      "r885",
      "r898",
      "r907",
      "r908",
      "r912",
      "r913",
      "r920",
      "r930",
      "r1117",
      "r1126",
      "r1168",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188"
     ]
    },
    "ino_RangeOfExercisePricesFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RangeOfExercisePricesFiveMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$90.01-$130.00",
        "label": "Range of Exercise Prices Five [Member]",
        "documentation": "Range of Exercise Prices Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RangeOfExercisePricesFourMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$52.01-$90.00",
        "label": "Range of Exercise Prices Four [Member]",
        "documentation": "Range of Exercise Prices Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RangeOfExercisePricesOneMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1.78-$18.00",
        "label": "Range of Exercise Prices One [Member]",
        "documentation": "Range of Exercise Prices One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RangeOfExercisePricesSixMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$130.01-$233.28",
        "label": "Range of Exercise Prices Six [Member]",
        "documentation": "Range of Exercise Prices Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RangeOfExercisePricesThreeMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$39.01-$52.00",
        "label": "Range of Exercise Prices Three [Member]",
        "documentation": "Range of Exercise Prices Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RangeOfExercisePricesTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RangeOfExercisePricesTwoMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$18.01-$39.00",
        "label": "Range of Exercise Prices Two [Member]",
        "documentation": "Range of Exercise Prices Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r847",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r847",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r957",
      "r968",
      "r978",
      "r1011"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r470",
      "r630",
      "r631",
      "r682",
      "r689",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r792",
      "r794",
      "r825"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r630",
      "r631",
      "r632",
      "r633",
      "r682",
      "r689",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r792",
      "r794",
      "r825"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r799",
      "r800",
      "r803"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r470",
      "r630",
      "r631",
      "r682",
      "r689",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r792",
      "r794",
      "r825",
      "r1180"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r629",
      "r631",
      "r634",
      "r746",
      "r747",
      "r748",
      "r801",
      "r802",
      "r803",
      "r822",
      "r824"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of convertible senior notes",
        "terseLabel": "Repayments of convertible debt",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ino_ReportableSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ReportableSegmentsMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segments",
        "label": "Reportable Segments [Member]",
        "documentation": "Reportable Segments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r397",
      "r424",
      "r633",
      "r654",
      "r678",
      "r857",
      "r858"
     ]
    },
    "ino_ResearchAndDevelopmentCostAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ResearchAndDevelopmentCostAxis",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research And Development Cost [Axis]",
        "label": "Research And Development Cost [Axis]",
        "documentation": "Research And Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ResearchAndDevelopmentCostDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ResearchAndDevelopmentCostDomain",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research And Development Cost [Domain]",
        "label": "Research And Development Cost [Domain]",
        "documentation": "Research And Development Cost [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r850",
      "r869",
      "r1189"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses - Clinical Trial Accruals",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r969",
      "r979",
      "r1012"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r970",
      "r980",
      "r1013"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r977",
      "r987",
      "r1020"
     ]
    },
    "ino_RestrictedStockUnitsPerformanceBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RestrictedStockUnitsPerformanceBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units, Performance-Based",
        "label": "Restricted Stock Units, Performance-Based [Member]",
        "documentation": "Restricted Stock Units, Performance-Based"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-and market-based restricted stock units",
        "verboseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "ino_RestrictedStockUnitsRSUsMarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RestrictedStockUnitsRSUsMarketBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-Based RSUs",
        "label": "Restricted Stock Units (RSUs), Market-Based [Member]",
        "documentation": "Restricted Stock Units (RSUs), Market-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_RestrictedStockUnitsRSUsMilestoneBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "RestrictedStockUnitsRSUsMilestoneBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs), Milestone-Based",
        "label": "Restricted Stock Units (RSUs), Milestone-Based [Member]",
        "documentation": "Restricted Stock Units (RSUs), Milestone-Based"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r119",
      "r687",
      "r728",
      "r730",
      "r744",
      "r774",
      "r916"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r230",
      "r232",
      "r328",
      "r329",
      "r362",
      "r548",
      "r549",
      "r555",
      "r556",
      "r557",
      "r559",
      "r561",
      "r562",
      "r568",
      "r570",
      "r571",
      "r573",
      "r576",
      "r615",
      "r616",
      "r725",
      "r727",
      "r749",
      "r1227"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails",
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative arrangements and other contracts, including affiliated entity",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r244",
      "r253",
      "r254",
      "r275",
      "r281",
      "r285",
      "r287",
      "r288",
      "r456",
      "r457",
      "r671"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r1053"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r851"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition and Concentration of Credit Risk",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r459"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues [Abstract]",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agents will be entitled to compensation",
        "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "documentation": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SanDiegoCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "SanDiegoCaliforniaMember",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego, California",
        "label": "San Diego, California [Member]",
        "documentation": "San Diego, California [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable And Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r357",
      "r850"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because of Their Anti-Dilutive Effect",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Available-for-sale Securities",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Deferred Tax Assets And Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r30",
      "r1085"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r902",
      "r1157"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue From External Customers",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1165",
      "r1166"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Components Of Pretax Loss From Operations",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r624"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r799",
      "r800",
      "r803"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock Options, Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r122"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Assumptions Used To Estimate The Fair Value Of Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOtherIssuancesofCommonStockDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r114",
      "r116",
      "r118",
      "r119",
      "r182",
      "r183",
      "r184",
      "r246",
      "r422",
      "r423",
      "r424",
      "r426",
      "r429",
      "r435",
      "r437",
      "r740",
      "r741",
      "r742",
      "r743",
      "r885",
      "r1052",
      "r1075"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Preferred Stock Authorized, Issued And Outstanding",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r85",
      "r86",
      "r116",
      "r118",
      "r119"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Unrecognized Tax Benefits Rollforward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r901"
     ]
    },
    "ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Operating Loss And Tax Credit Carryforward Expirations",
        "label": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]",
        "documentation": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r244",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r288",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r361",
      "r372",
      "r373",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r866",
      "r869",
      "r870",
      "r877",
      "r922",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r244",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r264",
      "r266",
      "r267",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r288",
      "r864",
      "r867",
      "r868",
      "r869",
      "r871",
      "r873",
      "r874"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r284",
      "r287",
      "r865",
      "r866",
      "r872"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series\u00a0C Preferred Stock",
        "terseLabel": "Series C Preferred Stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1063",
      "r1064",
      "r1127"
     ]
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service-based restricted stock units",
        "label": "Service Based Restricted Stock Units [Member]",
        "documentation": "Service Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-based RSUs (in percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Market-Based",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Market-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone-based RSUs (in percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Milestone-Based",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Maximum Percentage, Milestone-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments, Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Awards Granted, Percentage Of Target Awards",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Awards Granted, Percentage Of Target Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grant Date Closing Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant date fair value (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r495"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used To Estimate The Fair Value Of Warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Valuation Assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards settled in cash, percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividend yield",
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contractual year term of incentive plan (in years)",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reserved number of shares under the Incentive Plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares available for grants under the Incentive Plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, remaining contractual term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term",
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, exercises in period, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, expirations in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, grants in period, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of options outstanding to purchase common stock (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Axis]",
        "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Axis]",
        "documentation": "Share-Based Compensation Arrangement by Share-based Payment Award, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Domain]",
        "label": "Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Domain]",
        "documentation": "Share-Based Compensation Arrangement by Share-based Payment Award, Threshold [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percentage",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Threshold, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying common stock (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Underlying Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails",
      "http://www.inovio.com/role/StockholdersEquityPerformanceandMarketBasedRSUsDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "verboseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, expirations in period, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range [Axis]",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range [Domain]",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, lower range limit (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, upper range limit (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonemployee",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of unvested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySignificantAssumptionUsedinMonteCarloSimulationMethodDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected life in years",
        "terseLabel": "Expected life in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value for options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options expected to vest (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number"
       }
      }
     },
     "auth_ref": []
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU's expected to vest (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise\u00a0price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual life (in Years)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r1066"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r208"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r172",
      "r244",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r288",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r361",
      "r364",
      "r372",
      "r373",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r866",
      "r869",
      "r870",
      "r877",
      "r922",
      "r1195",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityPreferredStockDetails",
      "http://www.inovio.com/role/StockholdersEquityScheduleofPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r182",
      "r183",
      "r184",
      "r211",
      "r235",
      "r236",
      "r238",
      "r240",
      "r246",
      "r247",
      "r327",
      "r384",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r422",
      "r423",
      "r426",
      "r429",
      "r437",
      "r604",
      "r740",
      "r741",
      "r742",
      "r743",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r773",
      "r796",
      "r818",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r1052",
      "r1075",
      "r1086"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r86",
      "r89",
      "r90",
      "r171",
      "r197",
      "r198",
      "r199",
      "r219",
      "r220",
      "r221",
      "r223",
      "r228",
      "r230",
      "r232",
      "r245",
      "r328",
      "r329",
      "r362",
      "r439",
      "r548",
      "r549",
      "r555",
      "r556",
      "r557",
      "r559",
      "r561",
      "r562",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r615",
      "r616",
      "r626",
      "r695",
      "r725",
      "r726",
      "r727",
      "r749",
      "r818"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r245",
      "r616",
      "r671",
      "r735",
      "r760",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r773",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r794",
      "r797",
      "r798",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r818",
      "r931"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r245",
      "r289",
      "r616",
      "r671",
      "r735",
      "r760",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r773",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r794",
      "r797",
      "r798",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r818",
      "r931"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r972",
      "r982",
      "r1015"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://www.inovio.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Stock-Based Compensation [Member]",
        "documentation": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock as part of litigation settlement",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for legal settlement (in shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r85",
      "r86",
      "r119",
      "r740",
      "r818",
      "r837"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r85",
      "r86",
      "r119"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityScheduleofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r85",
      "r86",
      "r119",
      "r491"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for legal settlement",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash, net of financing costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r85",
      "r86",
      "r119",
      "r749",
      "r818",
      "r837",
      "r937"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r85",
      "r86",
      "r119"
     ]
    },
    "ino_StockOptionsPerformanceBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "StockOptionsPerformanceBasedMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityDecember2024PerformanceBasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Performance-Based",
        "label": "Stock Options, Performance-Based [Member]",
        "documentation": "Stock Options, Performance-Based"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sale agreement, aggregate number of shares issued (in shares)",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sale agreement, aggregate proceeds from issuance of stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementRemainingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "StockSaleAgreementRemainingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sale agreement, remaining capacity, amount",
        "label": "Stock Sale Agreement, Remaining Capacity, Amount",
        "documentation": "Stock Sale Agreement, Remaining Capacity, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales made at a weighted average price (in dollars per share)",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock aggregate offering price",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r90",
      "r108",
      "r775",
      "r793",
      "r819",
      "r820",
      "r916",
      "r938",
      "r1077",
      "r1108",
      "r1172",
      "r1227"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inovio Pharmaceuticals, Inc. stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r210",
      "r421",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r436",
      "r439",
      "r575",
      "r821",
      "r823",
      "r841"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r636"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r636"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r636"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r636"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r636"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r637"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityAtTheMarketSalesAgreementsDetails",
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ino_TaxBenefitsExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "TaxBenefitsExpired",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefits expired",
        "label": "Tax Benefits Expired",
        "documentation": "Tax Benefits Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward amount",
        "totalLabel": "Total",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "ino_TaxCreditCarryforwardCarryforwardIndefinitely": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "TaxCreditCarryforwardCarryforwardIndefinitely",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite",
        "label": "Tax Credit Carryforward, Carryforward Indefinitely",
        "documentation": "Tax Credit Carryforward, Carryforward Indefinitely"
       }
      }
     },
     "auth_ref": []
    },
    "ino_TaxCreditCarryforwardExpiringInFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "TaxCreditCarryforwardExpiringInFourYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 and thereafter",
        "label": "Tax Credit Carryforward, Expiring in Four Years",
        "documentation": "Tax Credit Carryforward, Expiring in Four Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_TaxCreditCarryforwardExpiringInNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "TaxCreditCarryforwardExpiringInNextFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Tax Credit Carryforward, Expiring in Next Fiscal Year",
        "documentation": "Tax Credit Carryforward, Expiring in Next Fiscal Year"
       }
      }
     },
     "auth_ref": []
    },
    "ino_TaxCreditCarryforwardExpiringInThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "TaxCreditCarryforwardExpiringInThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Tax Credit Carryforward, Expiring in Three Years",
        "documentation": "Tax Credit Carryforward, Expiring in Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "ino_TaxCreditCarryforwardExpiringinTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "TaxCreditCarryforwardExpiringinTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Tax Credit Carryforward, Expiring in Two Years",
        "documentation": "Tax Credit Carryforward, Expiring in Two Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "ino_TheWistarInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "TheWistarInstituteMember",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Wistar Institute",
        "label": "The Wistar Institute [Member]",
        "documentation": "The Wistar Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1179"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityStockOptionsandRestrictedStockUnitsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Title of Individual with Relationship to Entity [Domain]",
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable from Affiliated Entities",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "verboseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r418",
      "r435",
      "r574",
      "r600",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r696",
      "r903",
      "r905",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r917",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1164",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r1191"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r893",
      "r895",
      "r903",
      "r1191"
     ]
    },
    "ino_UnderwrittenRegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "UnderwrittenRegisteredDirectOfferingMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Registered Direct Offering",
        "label": "Underwritten Registered Direct Offering [Member]",
        "documentation": "Underwritten Registered Direct Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized loss on investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of the year",
        "periodEndLabel": "Balance at end of the year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r534",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increases (decreases) related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases (decreases) related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r901"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r154",
      "r156",
      "r160",
      "r161"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "ino_WarrantLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "WarrantLiabilityMeasurementInput",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsScheduleofAssumptionsUsedToEstimateTheFairValueOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability, measurement input",
        "label": "Warrant Liability, Measurement Input",
        "documentation": "Warrant Liability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityOfferingofCommonStockWarrantsandPrefundedWarrantsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common stock",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "ino_WarrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "WarrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants, Policy [Policy Text Block]",
        "documentation": "Warrants, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding used to compute basic and diluted net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r240"
     ]
    },
    "ino_WeightedAverageNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "WeightedAverageNumberOfSharesOutstanding",
     "calculation": {
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding (in shares)",
        "label": "Weighted Average Number Of Shares Outstanding",
        "documentation": "Weighted Average Number Of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "totalLabel": "Weighted-average common shares outstanding used to compute basic and diluted net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r240"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesScheduleofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ino_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inovio.com/20241231",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "label": "Working Capital",
        "documentation": "Net amount of current assets and current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001055726-25-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-25-000012-xbrl.zip
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MK;/%>[#C#)56(Y\.U[[PBY^K&ZUNL6H58:DH<&ZCC5T1/%N2/%#4!#'8-^[
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MGT<2MXYNVEI1<URW%AV#$,:Z7FXN%N&NSVB?%NYZC0U"S!3SG"A3,E:8X!2
MY-3&::3SJ!H7'@^QG7 9FVI0VFQ+@EC,P_Z!GH[P4VN9S&KF##J^5RVN190
M6Q]2SP[;\@VI@/0;#T@XP^44 M7(J$1H(6.3. G^!\9B$CO\*K4VC0N_TQQ
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MXYFI=<B6?;WZ+S\=&L4GRR]02P,$%     @ #X!R6D8F^\FG P  PQ(  !D
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M2VMNJ]SQ<M-__2/2:?=X]0]02P,$%     @ #X!R6D::Q<P6"   :BH  !D
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M$75U7!WRR#71YC-=6MWGR[+_!5!+ P04    "  /@'):!0A[W2H%   $'@
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M0:FQD#+5QN=1AVR9)9L;(]]W)WLB+RA?V#MOLDU0ZALA\SIC7><]282T.A9
M)0$>FP:^#Q'D(<BZOWAMT[E[A"J2L P39VD8!J643#/T .4QF9]'*>4G@"T_
MSYE2!@3^FYDQ[@\D!0EH_64#*TR-?6T"-$J;T)88$JDP\R!N$U;)B6A!HPN-
MEZ5C!$T_0?M"R,19VZH+%R2J6@V@?XI+&?_=,D:HM*Z2RVONGX1M'*=V;<H4
M^<K%&3KP!#8W^J/)G1.TH+&)BY-!HH-!]UK*.MW!HR7LEK?=@/CYZJ_Z!2NW
MVS...,: U*62E%F&"8!%D)F,6>:MA&\EDV XAS*1NI8!6Q0K11*OOQ5O+T-\
MD>K+-*_C[(V[/0SH>&)2\A>(J?\T8\HX]JJ\(@S8)37%I7'3%YJ 4R8QXH4$
M96)KVP;-,H++T!KLH3A08+!5VZY*&*<\,L]18,RL:--6<%:95:DA"I!6IVHR
MH>ZIG95(_V!_]>X4K2IG[Y)U_37T3],P@V9^*"0V70>-SVBA(&A^3&*FBHPN
M L:M#7;1I)8>"JU%;A6<FF:+FU&MQ.JKAFO6/1YW_,'8$&^-;%O'C>*:DW<L
M)]_1\>J8R87QVE&WXZT=^Z[40<<;]A]&[.!.8G>L(RIGH+L5)M?K5K?5+*@+
M(O"+<^)=#:$]@EQW>>7MG]\[[&EJ'^O,[FW+A*S1WP^8*?XGA>LO*I&7>"/+
MA/H/".Y1F??-V#<W>L.)LE?R;K;W]^?YGP<?YF2.Q.GM?';MP'R/A':-8UJ_
M3(I<:\3K0=4MUK1DQ$24R%A,&ON>0]Z,;SNP67^\H]&W$LQSFRHIT,<[8RXM
MM@(#IE%9= <,AT@$F"%D;;*7,DB0^B$-U.P4R,<D87BRL'1A'[EDI(6\;1>N
M]TFW>@OU9%%O'4J&K*A 6K2"=WM]O3=V-[*J8_0/ZP'_=^K+]OKT>^?+]FJO
MU1:R>CU\D//8\$[FS8_GGQ[I.&CUD_>/"/Y@?K0N)NNN+WSHA0_=S"4 59/W
M#-3SXT$5^7FS?%M2DX%?C^]<0#2\;A9%HN3:O!*_C?[LV!<B*R^#;OBF>,O8
M-1;5?+(LA+*OIP()&36$;.4CYD4Y54Z_6$)#K*E2KRZYY;MG?:V^PN[8K[__
M 5!+ P04    "  /@'):M\IF%9<L P @UAT $    &EN;RTR,#(T,3(S,2YH
M=&WLO?ESXDBV,/K[_2OT/+=G[/B 8O-:W?4%QKB*&=OX JZ:GA<O;@@I 74)
MB=9BF_[KWSDG%Z587+@*"H&Y<6.Z#"*5F6???_V_SR/7>&1!Z/C>;_\H%8K_
M,)AG^;;C#7[[1ZU3;S;_\7\__->O_T\^_^_+]HUQY5OQB'F140^8&3';>'*B
MH1$-F?'%#[XZCZ9Q[YI1WP]&^3S_6=T?3P)G,(R,<K%\+!^3WP87I=->I6R?
MG^4K9Z63?+5WWL^?L9.3O%DVS=YYN5\\+1[G!A?%:N^XVC^MY'O5<@\>8Z?Y
MWFFEE#\OVR?GQ=[IL67V<O:%9;*3X_/JV<E9J5@MVSWSK'I:+9_#*YC5LT\M
M>N\P@C/#N;WPPGF.?CL81M'XXMV[IZ>GPG,O< M^,'CG>*[C,3SSNR@PO1"/
M9$9P2>_@&,5\L9POE0_$(G$4S%^D7"R>OX-OU8-A?F":8_5PWPQ[]*#X M>N
MRH=Q%6?ANA7881B9GL7D\[#?KR\\CE_WS% ]_CSS_%.%GBZ=GY^_HV_EHT[H
M5\NETY?VPI^0/PB#:/:,\.',^>SD@/J")^_XE_)19MGIYT)F%0;^XSOX(K6F
MX_FI7<+?CXY?L/P1/58J5TH'">3SL$SJ<;GL2\ O'>>+@*QJ'6NR8&_P1?J\
MH3/ONN&XI7?_OKWI6$,V,O-34%T,($3BY"R+8%.J:(>1C]O,F;]E^"+9\H5K
M @\X8%[^H7/PX=<A,^T/OXY89!KXTSS[,W8>?SNH^UX$_"#?G8QASQ;_Z[>#
MB#U'[VB+[S[\UW_]UZ^1$[GL X C+^'PZSO^V:_O^,H]WYY\^-5V'HTPFKCL
MMP/;"<>N.;GP?(_!^YWG"WR0!?R?CFTSC_X)W]\!3PH<B[_^.6JS_F\'5AY
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MF9KPNY:9QG.0\R?- )X_;+>TBL'*.-%R/UE9NU4YQW4*T3(U3GE)T%8.UG>
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M IXJ*<=16VZ4^V#GVDZ:=H,F4SQC4L&ON.,2/EWX;MKM8H:RI)]KC^2OE8F
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M4D$>+!1'XQ>4,SP,\]H.+_&5<=ZY6S1LH3X'>BVL3\$GV"NH: 7C7EZ\?EV
MK'@EJ%&;=(2J!JK# -@72?1R_NPH=0OJ$/PEQ."0(0'JFU36"_>"N\2@IU:Y
M(MYC,PJ-B6AWP!:<*M3O41+&%! 2T2K4EH5WW%5/$CP4K"2%V;1S(.K!#"](
M(QB1,B$ <@[Z9?VJ:G2%DB1*Y-4W9^H;>J\[B5 OEKRA((A:O2SD7-UT0TR:
MQ@)4W%ED?$$R/B[3ZTG 468SX'6(N9]P*ER%-/H1&Z$HE N"-(9_1Z+@#%F=
M*=N<")(N$TF7S])4I8KV]^EFFE"I;$&ZV49%+HH(P5O"(1C_-G!?T:,%F)26
M7JRHBPS"." '5HHW*Z;0BP,;4^.1&RCY063"'DTW)D*+QYP#(#>A&CK!"8%%
MDPSFC$JO$CTN_F(<EJKORF>$_VKA$>,)_)3K&CCDN">-JD[E!R"+VW+K@NW^
MCCRG;#R"Z"R?P:+G[RI 4_J7)4T_>)+]'WC"M6AS\8)$X]%+'M:0&C6PO_R
M0JR''^D_()<5L\NS$0NXCSL5;DA: CG>'Z(_$A @:N2.)QH0@-4=,U(!>&$A
M L;X,X;=<1%9+I8K.9Z"*QVQC-G8M3#A&*377F/K$\IC#>*!44L)2\K4N[ZJ
MY90VRUW?:@5+7+4]HX984L,FBX>Z>HRIU!Y_%L:]D</[.5&JQ*4H43%NP !&
M@-7&RCR@/5S>U*A#BNS^D+3S@-TIZ]>T@+E*(2'+5N _ ( 1L->0@,?U!WA_
M%,G28EA=6U%?1?Q8*P=BXC0H.OL3S%^F"I2^0RJAD/ZB;0OYX1"M(_(<^E[?
M"4;" )(9 ORVE"#$K22W0]T[4-]"1QY@$Z\VY3O0 JG\..HHPFADGBT0H?K>
M0!)_Q,IYJ8&H0@ C0IN%]#J?RAWAJ**UDD/"-EVEP_557M8CJ0\IUF7YF+=(
M 6%!&YO2NQ!5P [CQC7^*JFA.+[OW*O=B,QQNNTX$>JIV^.71I%E$0X4$!41
MQE3-4N)RQ?7H2C&+E*J2<.7YY^-DY01@"Z:IZIAK#JF$,>RE$B!I$5P&2*1&
M +H/9?2E<!U711@AAW#LO%J/0AY_QIAU0;B S)?C.G?=P((#GY>S<8*F_E2.
MR]%US-NM", C/L[@P/'V&8;"YZYYT#EO+I4Q<65^VKVPV_!A,)J,THGQKG0F
MBLFDBF_J/E>X(LNW10\QT7NB>9,OE9']PK^%CBDT13_(S?<6#6'?>:SFSW%C
M[02Y%KR9:T[8(B3PQT,SF("FCB(7<&J$SGG2*2T3T-.#"R->U[KOU.N4FC,9
MD^J-'8L(23P&*":<_(C5U 6(MY0B6S;PS4A\SUT9($21E"U:!O>E8ICZLV0)
MBS0X^"X >\[FO0ST6O>Y=8X2.3W-\5'FCHG$79'X)E!<(3]Z82^@3(Q-<M]8
MU-2%"G9Y6(.;Z^2>X:=/+2//W9R[38"3Z(86$Y_M4T8>82NU;T 7&D^ Z2$3
M,P>>'TI\F8JWI"')7TNV/N82P'NVDM!F,]^24%<Z"8['NV.>EB_SN$5BG ^Z
M(2 UB/..17:\:#I#>"V^S5'JC] 'I1*A2CV5=8X$""^Z:?U/M]7^3],XQ)YV
M8[ L1F8O'XW_<LC0-:<%*>7S*]63##G?\K&3#V_U)[.J[=P4R99.WNGD2D2(
M*7A2*\#4<]4):OKX.75TDD>RR%1MGF02<AS/4ZI296KK))AX&@K:E .3&!:9
M4LD-2_;NR]HE"B')9/2I]?F-S"-;X8\5BJ%4O=,*8B/&=!PS7;JG%=2*+6 X
MB$@EO1?U;K[,=L;OYDB?XVJQE%-R@:+YYGC".Y%Q-4KY2O3 7EK*\.^C>(1H
MD3 6;%4 UD"X0,0,7,?OP7H1NMI&:&E@')<1;7V\O*5=F8,!]>1$YB:D1R]
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M,8GV6?S */_"C1-2P_&$,XZ9!?WD 0ZV2LP-)Z,Q,/Y0P@ 7$?WF,#W3-W$
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MG:;P6#-J%B\=6= "7W\P*57_=C,>+2UCVOF M2L.+Y8.8D>Y07C 41(A[X+
MO:]<F1&ZN3R^=.8ET^A35$"ZDE U,4],I F(LR>K!(S[JL78R"G4$ .BB:-K
M7@6\ SO%#T5<1EP#6,6 J)J.W'-]WWYQ, <?Q9'B3F(Q!QBG*\71[+6HIA-H
ME8DA?ICKE;@T>/61S)A.^,V\ W/MSI/,2N6\J)]S/I$JP9LA';DE<7OH)M"O
M/YBU(5+C.A/@B&^E$SX-<-5Z2IV!-H@C-,.0SR;$;^?=HK[[*1Q#IVOZJFQ,
MBGOB^7FVC\<0!7@CD*3"\6;*UVC)2C;#;")*WJ+T)E'FL-#<V;X\\6LQ$YTP
M)V#(<-2 K6J*=I2NQIXI0X8M'+H^@Z>OG+ZN&:M/OF"A+T]<YV$'6!JT"PK5
MT Q!W4G)]<WR65H$*[&1N#:GJ&!HNGW58D7> ,E@294)#\:P":D0:K)X<@.'
M*$AXV"FM5*+Y-CVI05AC?/PQ*7SR(HAW\$_H2L88-I!WH52#G*SZ)?>Q/*-\
MK-XVJ$2'[N.7J;=1QC_9VMROWR5W@7ZMRH>D(X?B_8FC=NAS+=?37@PF +P1
M<P\C/B&4F^RPH]Y$WX'P7DYD7O$)F VJ= AL[\ 6VVM-04:Y4E58<M[6<P:J
ML]HV4+I0AQ>U)=7BJ264<3GZQFCCW1UBA\!R\7VKW<[1/TOOJ<TX-2 *Y]V%
MP@Z1N&SBJ?GX+L1(C5J.I#'QQ$$=RA3ELY-?4D;3BP> G4UCR_9Q)\0^G!@+
M2C I<(K66L$8PVY76$#+^VD*GWWKZHI,I7_&+KGOBH0_EVB-R_8$7:&;Z;]+
M.3+5\%CT#(KIYYBVRD?;+KD5-2Y:CQWQFE;^#!.TP0M0'YE6Y!L23DAB>"C\
MJ_"/I%05GKS!B$PH8YHU2A!&0Y,Z/1PV;VKW1]KK(_U(23I=;8#!ZW^$_)11
MQ'B4LB9&#(MK(H.T7NL>4=,UGN2%"_X9FRIZX_E>7O%\KHZGRH!%&(#[H@2[
ML89LA")TDIMJJ",ZO0+94BG\;?V(+RE>I,L6'KW4TZNIM)B8[T3+]4T\OR1+
M,*.&EI#1"YD/1^XW62[)B^55(,O4KI!RX/##&I\H+'N(C54.09:;WLQFVQRK
M;)M2684WNXLF>;92$\0[,G9/\\'JL[/@M]#(E%=!.3.8B/GBN.0G7^OD02T(
M9*(SG\IMR8"AB-SIO>!2,5X>O:5H+75 5#-PA(O#!WG73H5J$[7%3 :-)A/(
ML7L'<;8R 5"-!Q\RD^?Z>\SZNBC[PCC\= ?@.]*,LU1,I2X)<=IH)E9:.L\E
MLI@\X*2N*X5YUM8DY4;7[_OZ8#6M_W1Z]W*H<Y,WH9#A;9ES*+D$=P0LM?_T
MU?;FWZWCI0:_$VAK:!'\A\&V3-4_^/XJ?U-Z*<L\A[HSLIF1V:.(YQ-G@B2_
M44,[+8#4I_6KLVHEO[?JC JAG$O2E0@&,F]#6SX77(W*,J0FP6]?-HKA#A-A
MR $-C1'Q7<*A*6>!"+&(49<ZO J&L"QRZ<A"$N[M:;:\NE<Z:'(CJ8J6Q%\J
M#@7J\R,0ALN932='\QB2&KUSS+:,AJ%L8"-(BL+(G+%AE!>^ C"D11>'5UZ#
M%QC_UE?TP"G'#A)7CC<9FD4%7C60E(/P+LU)21#UK*:4'S%-G?@787>RG>EC
M$BQ\T0O 3_B1=ET\D"N:E<HJH<2>!7VY]X?0A>>V>)U%,#BB19EDE'E&+5=X
M?1/.>2'D3KHJ2I\!B6\SE-D:\VXXV?-V>B'_"3J+"!!7<[SMGQQ.;2;V;S)'
M6B8=HD\/_0C88B_QE-=] "4.Y,:J36$&OD@FN-1-ZW^ZK?9_FL!KJF?E]R0R
M]+1]);_[?C"5/P/(#&0R(&<D[D:H?#G>YA#+OW*B'O(=%D(JP4$"O6 \J($2
M8*:,5 +&]-ER\ER\X%54.ZA]R^'%(E=DP>1LWH%'#-CF3O18ZQ40QCW27>W9
M'C>RXXH0&VA&X+4I-4Z-V>;T.."&% 49$\C@KT1[(4PJH;P9??5D)V0<J#BS
M-'G[C-D]$^042979=\-U<1V2NJ!.OTE.8M827+9*LR1J^?SQWV@'%+^M6=;U
M[D/;R!6X[I'B!A01=$(Q+MX44A61E?([]8(_F6B&.2W3=S:3;"CO+-6Q24@Z
M&P<S\)@&9FJ@,>/PB@/AN1$(E41.<#_"YY*F(6TOPE>;9&AHD47-CRZ2J;"N
M3[D\E(?X$3-5!S(,TG-\JB<*\JHQON9[E4?7TRYXU?4^)T''N[/MR$G8T.U@
M;$CT?$XFG5/# I/B;9^ /AY12WT1FZ<Q&<1F/N5(7@YOO[69K>-Y-4Q[-X:^
M10D! QYZ5+K^-+]1>8"2J8GI02Y-49AJ4*=S0>%I7@@B&:&;Y2=<TUX(++Z7
M785.JI+>$5FSZ6O.S0EFJ6L7A4!3'9BTC-FI! <1[):U!YZ6WZ?D%1X%G0TJ
M9^&1^Q9(VQJ)07G:-]S;8C.1O@.Z(%P4_1,[007;F9';5:H]*GD4I&9:5T.D
MBREJ2+5AQ(1#GAN 2CG]GC([)D8_IHQ63;VD1!W3DBE3C[[[B(9>(M2QSCJQ
M4] !/$:MX=+Q07T/5)ZT$THEG'M#%ZCKT[I+NJ$DNEV&H(KP+ #7Y .+0DRW
MT35BRO06S22G>YC.]O9*>DH2&S CXX\83!C;L;C)VP'[6D1KZKH]QM7^FLL;
M:(0RBL/KDG=+R:ZAM@5?W&.??$]"8_OH9K9'3U((F.J\([KS2,&#'6^,0W7R
MHX)QP_J832P"N3DCN17L:"%+W*@GCVC%TQG#]DR/X?*:I,#$ ?5;)]W7>*H.
MKIB*WA40&C)'(VF)P=U'VGPK99*GVY7P2C)RTE"'%6Y,\[[<Q!FTO<DC-.?V
M;>&U7L?'OU#[?[[)Y$B\]HO:2DUEHR0. EXS]N0'KDW#T?B*KU^J=+9HC^2I
M.]<6Y$<BGU[$IP_($!"LI=>PG9W^D@2G^4 OO7$2;F9V >GXD-Y.Y#S;*69$
M6R(0Q4FOQ] *&*^,Q4X/?!BWR-%TM7%7B%')H]@5$3BO:'\K>@IZB=VIV(TL
ME]2;6ZN21[ACDZLC).IQ2<JKP0DL?C_@HW4FZC'CL'U=.Z*L,&VLMPMX),??
M330-7I:\8O4K;VHJR ?# 0C9ZODO1%I:RK"6,H%JOGRO[3-NPO+69M$+36RF
M<M:P49 W8CR[%@4?5D9M(>Y\T9UN4MR7I\7](1)+N5@Y2GDNE3#"L46ZXHUY
M$*0:?FI^SGMLP*/9B9-8Y']Q[,&0,2F57':-==F5,R3Z48M8-L:<"M>AZ_9Y
MSS7CL-:\.\HMX#6I&O0SX3=)ZAYEU8P7^-2HNUR=/8CR]7$7OBHJ4:=/6MKV
M)E,#6#5%^J4:$Z:5F"07E-@D\BF2$3Q16$H^8<$L^H7BN*(O(&&NZ;Y3MRR+
M3Z@U7RBS"8I3WBV)%E,57M)'!-HEXI660E4NIR\RE4DU;>]A+QLWEJ),;3D]
M.TXU*X_ )GP6(1^M1DF4*8ITBJ3>J/:BW9,"5W[:[B%?[Y3QHV=S;R&]UY+6
MS1*HLQH]&@&JP1WOOT4:B!\D;2-JS:N.<2O:&P(OK]/WD1./4B6OH9Y<L9AA
MO)XU+$7P/"-+,"(9WICE IABX[*\B3.+1=E&F#"%M'IW7IS#ZQR*<1.?$#(H
M78 VGU>D^<0R#,()4[<TI:!J[(&N2?((V$Y288!7!_?C^=1M6ZZVO-J3&5,(
M@V3'U6)IOBGTT75\D/)PNI%IW*+<IL(YX_#CY>W1]I%MZC@C=1R2CW"BG.Q5
MHJE;ACE0_3MDA]D>CM;\AIW RQ H (_-\TR<M&$./#_DL?638YFL*&L>DH3P
M@%OG/+\@Y#XBTK]H[&&R!MQJP$9(36,?4R-X*3OFG>-&DHHP;$H1J?2T9)Z(
MK!'G]@+N :_&*!7YUMX;)H;4!RP)J2..4"!&JT03_2E5,C1W.\''V+,-_G,F
MA8Q(Z.G#3>9)IU3+ROS:DP*HG*0J8X,&;.\IW3Z<JF6(/Y4[#W"C8:E8GZ1L
M*JSX)"H?#!FE_!IWL+NAK&7)&37JVPTZ$-T:?<D"[LG\ K_ ?_/PXTOPE?>#
MT0+3_@.6),F6@J/8(6RF4BB=SVD.@H52KQG2GAUJ0E_85*Z7<BXIMI*:VD.J
M7VIF4BJE2V1W+)IX>R%ROKK,]0&.*';;C'L_NZ"N8>>\<82?'@Z[C787M-DO
MCCL*1?$1FFSYDG'XI5OBJ>5 2^@B9_F.S-*Y%9.GC)J8$7QXW[FM'6TA:&28
M?=8HP:1]#K2\[UF\#B:5L$50P_O!/\Z+V!+EA2P\WBT%">RX/$<9 =:#LR\X
MYX-=<"8[)P7(8B-G#*S+[!F'-TXO,B<^G\2'-@FFSKR8%J9-O@&%H,W(/(>E
MX<@@GRW*)Y*CE69U@Q=*TA/V+/IQH"J;E!Y,-6+1>LNHJ$Z/<L1@+ZT.M[.W
M$YN2JD"\##@+SS+FV<E@ZI23,D&MV83*&FQ)5#NL=>HMH*A;+AIA(5)B]70;
MZ1,83G@,Y/;C;5=-_C4.Z[Q'2^V(X%8Z+<C$M22?2M0O]\U''P#ITL19/:TJ
MEB[M'HN>4'B5J@7N)P7-5V;!O;Q#VI2VR9G]7?+]50!N4_LC'/J.398K!9[*
M5#Y6FQ3E%I@TGI]?9T7DK"IOB)[YR!OX1! :?=#NONO>_L<X1-]2DH 5L9'_
M%T .Z)X=S0EBI:J8I:FGG+I<%="()(=E<4 J<^L!98XD!25&-(11)+@R$J$R
M=[6F'-6B!(9GE>$C6F&+1K2\?3>GPGTNA$;7Y_M<B!=NA\;-:2X0T0%-1E@1
MAU'OQ B';+1-,3R>NT3YH9+]I5)Y%@O:&48#.+W)WME;%]>;,6;O12-\D2'/
MPR!]BNU19W^ZY<MVO89JT6TLAF%OI83FN*DBMM13 PX7B$1]BM]$TI*A2:Q<
M1M\SSPLG[J/I@3$DYGY@#Z\DIU]#7U#,$Q>62CE-)>$NV:V.8[\K8G?S5$))
M%J0P4N]$-)XTWP\/_LT9'YH3,YRP)9((?:G"*_YGFLP( 7 ;^(^R,1)X(%/A
ME=/(]P8^E<]N'7[4DG$Z9!?P$U.M'QT9%>:0-TJB63K:?!Q )R]I?A<$Z&G
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ME_R%LUD]I:64BN\"'=+QF7Q/$"A("+^N%!,KPM@O0'84NW6SB)SBC ':7DA
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M<,.=#EKB]2__6@^/W%E;FBP#AYO,CB)X;5'"$JPY8NI@![\<,>._[EOD9/0
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MW(B3&#O7*!QK])[96ZB7(Y!@WWLXO#UW>J,# 22^=!8].(DP5";/<_@GB]I
M70*>&*K11NN91K/Q=9B"LVJIC*QJVD^@Z&[K=ZHF$*Y8+UMX46%3  ;+QY'0
M6>&>L;Q$W@X2 )/K/64$9T72*0HQO_8GG#=]@ %YYPUSSUU2*PIH>.*C,G)D
MXYF<Y4\^"VY-X'$&YB39Q*^+<C/OFY:CU8/;8J_80;NAGZ18MP4GD6/;"]5-
MK6QZ1&73'3%RUHWH7,N4H*"*'$O4JF$ACF"TZ@7'(@X[L1U",W@$5V%A$VG:
MH!86'.++O-GD"W1?H*^9-%9W,9D1L[Z)K( H(BEO3+^@="\K\2T+*J"QI"C&
MSK,"";N.9099*+&\HE4N_D^)!4XI'4O"#J:%;4K,6U!1(V+&?.+B)Y3&I>[)
M_RB#[QP;3-/CTZW$)EF):\HKM": :<!<13&W\AV1.1JR?! -3DOI9RE4[KM/
M-K4&_$+9 YY(0+ QP^G & >1#+D]&]F,D@E(&E!JE5\1<#K".%M1G$0#0<Q]
M@0*FOBY8+0>QM[4V1488+A@93(U!,U(S87S:7*'?MFQ2H7ET"#3@T"3(3A'6
M#H3K]9C6B]$1.5> BS<9R0H\'IA@6?@4U.9*4T%19KW5R"6"!L@)XY&@UN7
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M;.'HOFJ3E1ZA8III](DOJXO=BG(/5</YO!X+1UB51*N5EHT1-9?!T)3T9?)
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M\./9"Y$;HQ1^9Z_J(7;'WG>>5.^0<J3B>X:5TD:JB:C1!^5Z)(]1H)VUSU(
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MYG\TX8;% ;I]_+P8O3*E.X2D22A/&-;D+_=X=LEW]<3OILQ:+[WZ0K+*06I
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M,8+%I9O]?%U1U\*\#L<3\A9V(NM/-^_")6,D2]@7[8>B9\2_JT7-#3=YOI7
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M%"FK O.:6 %Y1W3+17I$I-W0H\J]R28O&0.?$!3M4'?TKH8MD8(RYTQ/(H-
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M;<DE9&,0@SAVY++)>TP]]545UUJD9Q(^U\^>@/ZX-L57PC*$%WZCG9AAY_W
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MT.CXTY>K:_6V%,W7HQ(!9&<H);.DC=@B-O*P;4&&8'E*VHP'K&I8GZGM >I
MN-?N=R@"L8J/+H;P^-<5%2JV*^)9QR@ECSB6YN\B1JT*+@3UNL\XW@87FGM$
MZHQ9)S3H%&XFW E*'UC%/)J(7DM\!7KQ'BFYB*L<",U8B4 ,X&!Y9!%<Q Z,
MT(8+8WF8&E2V(UQDU?9;\@H2<OO;LN.JZH(%[++Z# UT%^9F[9M7]\V@%\(-
M.LC^NS H_&-V1Y-OD/NZZ,K;2-RIFARDGD1_Y0LH\L$GC#0+(X<!]\=K)E1V
MEUGP$2DJA2:335#!.!O!9!$7,>-CG+JI5N\X^%9"B+C"X<KV?<UI%?"4!.>>
M_6\6/4D<</!(@B^?][?ZGM6 P3\!8^A(:Y7<M@P2=6Q5>,^D4I3W5D#P>@?D
M*F%9<')SEY*IW;;=!RSV_0FZP[]@XU<QL&F,;+Z6"$?#(EBY7;7M(9'<1%5T
MTV9(5"=KJH"JLA= ?N%\+9(,4&0T ^XN7&=13<F'BK$Y0JAUAAQDD(/__-(@
M!U]\KN5U0O#C5[8N0\?U0XZ-\,4 *LDT,NB7HN,O1>E=53L6WRN;!+"9]1GH
MIJF.;)8IUE$YBKD%*V-5')5)&SY#X3GN>"PR>KZ(1TPE*U3=?3AR:<[6?\*X
MC9AD#\-T35C72+*9O$9">@E4B 8QA4M/Y5F>U3ZL"F_>:0; %QJ3/BKB,YCD
M< P&QS]X*I*0)%HM;0C(\)D $5!G\@(].-WP8J;,S%T!"K+B)V*U8D9(^Y=F
ML4ZCCH0 ,KD<OVTU^68+8\@,"K=VPQ!YD[!Y'CRCVPH0G$B>G_%P7@G9J;;<
MF0YXO)GA?/-EW))]I&78,FNINW41JQWL+6DS#=8G,@5 AM=\YA+WXPF6QM_<
M>P-P7$,5#)+&S&@_(\DG& ZASW!=,DV]]OY\4U.#9<M])(?)^8QRT'\+[]6'
ML_MM<J]^]K7"V__V_P;O_?G?'A6S]V43+-G%)>4NZF 9_KHN?VO?;X+9^V]Z
M9Y)N[N8?BMG;91B;L)C>M?-5^.OEU=7/=?C?'\,>Z?##;[O@"[;KBQ\.M*#>
M_Y]]?77%AN:2\M?_.T1 \S+AY%=Q%O<*P:\A#,X4#VIP9;DD5BM*FI:QC!);
MUF2D_#J.H_,B+,&?RV!"7AZ:\J;\+;QT>+C?\+;?M>V'X- 7L]?M#?-+_EA]
MV)7AQ7\\?&A)V^%M\%GKZRHXWO_[L-B++?TY>*#?^H?6VF1\=C:#R6FA9C"F
M::+SG3:[ZC=C>ASFA#WO(^L!P("402]*X?"%-;Q1W/.DM9 NX$&ZW3OQJ?->
M]<Q_'/,X(QU7&0L'L*QLD$!W'&)U<E)CM\6&[1VE-Q=L8\-2FW^@?B49DEV+
M' \9&P*:(.# NU&3,E9";M\D'4YU+*?+N[,9U)W,V0K9R046\@4I.U>+Z6&S
M"(,S4>DB<-EW[>GC!&"B?'AZQA%& V^<V1,>@8&W@=0IG9+6[:A%[^_>_BRH
M_1T%>_KG.>)1G(14#1>_).XV=%0K=W7+9Q#.^0.N6(O&/1<70WQ^$>8HF&B[
M[.+0;]=AW96/9]^WX7A_1=F0CK(W? "_^DTZ;-YJ"PR76<":_J$AD&JP--^_
M>O6V !YQ9K^,K3VP5QQ%J<HF^4@+2EY04H 1W!,=RI(;"&-.YPN__#[L;.TH
MP1O3V]-7CKS=ZV;V[MU;S>]>\? $;XWU[/\=]WKZ-)H]EHW XH3OY<Z\V,%$
M#T!7O8(L.3@RK]LN>#8E=3\T[4W=A7UZ _24P#>:=H]L<'AAD),_>_+LC^Q+
MU:0[02[#55A%J"K,OOW^TE];76*54W_ZS3.D$_+$L[V#INB9?7B,895V8=B5
M]!(#YT>E,EF/\2X].J673S$%V_U."^K>:Z-0H%R$DP?'H,)API86_9/P0N'3
MWW!0VYF%;5837FSV?HZDNIPVOO$TVS!C+MW +153F.XJE.@Y4:4',-Z7,$72
M8%-=\$TDF2/_+970'=E.MO0G:-@(7(IZB/"YXP"BUAD8]+6IYMJ0.2/$C6ZT
M[W>T"B^H-H!T-Z4W2"J7Q6<XY&1[LQ4,A-.UY.^EOHVY-F%CA2F^$5@BF;8Z
MA"KV!U9JV2,1%+Y[T[IN67DJI[$4':K*ZHDZPS?2J,B&U3PYSEV>) #C/80N
MICQ/ P;BE!9Y3G^0)]JEL6$';@DK%#M0R\V8C,,=X0&\'[X2I <X3^5"4$T"
M'%&N"A-#8<MXF(+7TUAE%.A09&0/8;D84CZI$$L5Y8:[W$;3S*H0)]3VVG>-
MR%>TN.3,UY48B1^.C*0+UE-G-)&"31W.=_>+CS4HOSM.'D3'SL*?7NZ85HQ3
MB4V )B*"423Y6V74CH"@L?S!*+,VJZ"&)5]W SV$KKT]P32!@HIUH,)#BC1?
M,FC?Q"AD.&Y:ELP'D2OV#C66H+L%*,8][6&N  S+*ZL+Y-.HTQ\G#CMCHFS"
M<L'<[32:QHQL#:<W+S^EC<=D)UO6MFRJZY;*S9I:3)K*2A56- D8M</+R*'K
M7,6194X>-/5A[E8'5UO]+9CFG>AD*]HL%L3!PX!38CR1ZG*D8T(FEDS@NG0B
M1K/OK>@[_6H3"V"P@Y'"A.\I^AIIQ4V7FVN8J(3K.SG1;),@=D]IYF('E^)<
MM+KOC;%DV:OK3@"M&ZZ$(VTMP1;I0);]KMO/N6,A-BU*YET*B<DKQ+/3/7,_
M?&B?<(@Y828LLW@%F5*Y&9E8/EXX=8]A:;B^#*":8T^#NR?YF*G6OZA/5*G>
M9]K;-&:4&Z" HXX*"&,BH3Z>EUYE?7^>M2]HSR=E<^L1<+-(PTB^39@)ZS1J
M74=<4HZ@!H(/9ZF'WX6JTI S8,?C_(H*QY[Y>A]RY",D;]C9!,3>1_9=^%K_
M7$BJHMN<NM3G:7VP:0U&"Z>@:*/X%JCJ"I'](GC\B*_JGC2KI7W M1H*1>PR
M]1;.D_9PDR8P5-0Y#.+H72?O]7#;5W\F_7_87400*IJ%#3';"2Q1&O*.C?S_
M1*32'Y^< %+IO \^R4D03+M&M$S'$N*<*Z[[ KL91;Z1/+"&)Y,*$G? Q74L
METI=(!,_/ANWAS-N2,-I5ID-4QC_5;V5>:&V-6F:Z 3;TP?;A'],3ZD@N1T'
M1'09.9-\2^+"X39G^O\'/KQ<(M!U(E;"!W-L%D\Q^K=^!*__'#-UFO+0O(EG
MH7=9DQ%$#'<EI"3<2+SY#!YHLZ%0G>-C7"8M_#&2..O?U^'+E--1=JQQG4\B
M_1C-Z4A?2H-=AY0%"U5*0O^PQ;.X'%]&?>LE^8+/T=>Z:)#3&AE(QQ@B=%U2
M+3,\/C6)48<*LH &D%Q:KI2'8>H]3ZU^\B):.L(*H3]$$JXZRUP\\Q2.6EH3
MM( 47!/J:28OJ%"*YREC]% &KH&X&_J@T/C=(+_ID CC0M0?2W7PY?2D_02%
M$A-"TV&&C;NIPSU<XCH=4&GH\ZW!)4K;%5]J*.[JI^QJO[BN^ 33:6;F^<(7
M7)@BX6CK-[*M"0%QN/>^IRQ_9=AM8CJCK5&X;5((!A7LKW*^!K,@O&;R]CN,
MM4@F89E)G]IR37GP4NC,"!L3[GRHRBZAM\EZC]S[ZTM3'FAR.<-HT#>G\7*1
M+X<*)8YNB T0)?P,1M7[)K:Z657"^!7>I5[@ROM&*%-!C7QRB_FE;['=C=@,
M&UD#*/3K]I8)I2GYEG;VT7)GB0DVR;PF /Y !3**V1S<+T<FLDC:D$<;/<V"
MI Q>V=H:)8ADO-<*@CK$]DA%$SHO>>E2@"$MN_Z(L"?SW4EAL IIP^0>X.6^
M6S,:HY.%1.,971[>7.TV?I[P-TF1;]TVA-!V3TQ/BX?E7D[P-K!]32&_8F)W
MDT9*++6S55:EW"<:W\##]?T87<U]Z(I.ELM&I)KJAKKR.-_B$#O]H=]5TLZ'
M7@NM'AHC ,K@I@;!G9,,-J"VU@+^$JIR'>-)400'T7TE QR;UVULB?XH^(J,
MO6-+:7V@6(_Q2O[X(%IZ\I2T6+IKO3UWG9L6^$IM_[EC9'I.)2FMR%?!1^6*
MB.^ESS/W,9I^GNKJ$?@H7+OEHKA**L@JI.KC<V][1E[^]$SL+[((P*?#&"R1
MN,%*Z=OMBFBIYG(R'EUU5& 6B+@?;U@EZ9OBE8?^((2]86&%=;KC*@@+*(@Q
M!B"7/46M?AL.C#I>A<, ]5]IUR9FW58<#% N$LDMOQ/S2_?2;;SD2CSA!;Q,
MD*(,T:W;4[S"%0#WUE_GU#WH,(Z?8ZWTU7[1-H>-.*#VZ2,3(EM49'%Y,<F(
M$0%:UY5L$!-6(H5,,X\%&'>)-"X85N:=HMXGX;FMDK>K2:8CD<:-&7(QO=B=
MR0OT7EB(U!0\S ^)23+TM(UORAY>T+SMC+]C43&B0 3-@PWVU![[)A?JM7/F
M;H.6XA4*[<REQN3P4^I5$;0:LC,2,_VC8I>RMY9G=\7P./%;/)W]=%C@F$*^
M*[O%;0G=DW:YX_]B_V%=*W_+K;4G8ET)UQ>+TWF#S(@4GD!BA!/.89Y@[LXP
M]L.(@TV82,)T!?=N8ZA">H%]HR62]<&9W\'A02NBJ79H[Y;JUN$3TQN?.^PA
M/^G"M77OI=.[NJ$"@>KNN [3N)?GP2M:7#"FG@9KSYT[<^"+^@S.$DDBXJ@N
MDT&%&5HHF8.<KQF*AWD$OM+U6$ <")D.:O4NT6P;+L-23$(V_^)P%5Z1V)WG
M'P!F(J[F=L^,75V81GD%<=JH1;-9:V]8NUSBO\,NVB_<.:;,+"[R(+TO J&.
MKI8[=BIS%=S3]W@\>T\&B.^GR9KJIEQ'VG!F<9/L354,B?T3A0A2T%#L*QTY
MV'!)&*M@)O.3N]*R6SSU84Q$RGT5QIGH3%3)G9]SIH&P^Q8-'7&DZS<%[4O+
MJ:N)5W"=_SB&O5]'EYT!SL%HMAUO_?4RO">5GQ\5V5G<J-/2QZX8_ML%\\MK
M1QO?</;U,HM#PM#^NF^\[!!993H'Z0P)*VO7/WH\>\D==!Q\T %>=F[M;,I?
MD7*1[QMT+ 17-_LU8>L5CN6)8"@-Y_":O)QQD"O1Q9T^:R89F<PP[?<;SMEA
M61UW.?\K^H7I>:5NH%OO"->6NWR[H]_7N9%,H\IK3T0U*!*I^BU]?FVOC!U\
M6WJ[/O<[W'L;Y,ZT&_HR5@+EMRZ@9E%53#4R_(DNIT55;6?+\H,ZR6$1K=Q/
M'GE#,F\755R0:%22GX438D/?#;:>[MTN+Y04Q=XF;$KQ/*C_*.S*>)/DP^!F
MWVAS9-P&P9 :N5''>Z"0<^Z"SSF[EIZZ8>JNZ9_A02K>+;*@_7?"Q59R7FO>
M%SV0ZTJ46_7$CA\VI,I $UGWP>, H='07MKJ2IC)%&#JCENVC)G_@NZ4BJ-R
M$ K%'R')%'LH"LX 5&X)V&QC#.@]F.O(6<7,C(836>\V4(](.,>28F/<!!P<
M#H*E(0B*LEM$Z_O;3K3N$FT^8F2^ 9>5!@2TV]79,E>+\@R#M\7>C?;%"(O$
MDQ-#@ZY9K%^],74X; C("A^'<BN>XAH=3-RZZ&EAQ$J9UWB/0X^&B&B?=';!
M_&ZVQ5/ QPTV!-$:>J5_%.-ML";D %:8"G79Y&GI.=3P&HE$G_B]1FDQX-3D
MQ%?^<\I48J7$0IA[4*+U$H42.OJ>_OD,^DA!'T]/ /3Q^=SVQ&ETT$>C3]M
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M5FH $WHT;E#SC!%\K U8FC!XGADD.$1A,<E_:AW,,O-IS89;X-B">R84V8]
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M 7L\!:]R&M&<</=KZR=CFQN/B^>NS$V4>+I9M$UIMLI.(6_ QH2Z90Z-EH:
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MHTNY$27RO2Q]ZS "RIA3GIG*X&V#F-=G29U&: G%Q=@,ZZI!"X5XJV>-Z67
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MNB)S7Y#)"G8ZOK0%'2+9+7.[&_N"%+AS2VX9*-3]-JQ11W#E8FFDMTX0<['
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MT]A@*HQA >.QVQ\@BXJAAM,E,U^'OO+@,RH$1#(6Y(KN2PI.=K]^G'1ZF^=
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MY@IDJ"N%ZG1<;4X?7HII'*(+=A-SX1WUC$NCC_9HC0@N$2L=TY* ^1JW1XF
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M*;-.\%ZM*6_'>2.L6N1T.8HPY%PXK%X"OTX$$4!N=\/:ULX1E:W_ME?]*D[
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M(%DJB@=_90VIX.#]U7N[&HG88NT.U0X41G5";0-YWVS4GHC3-TI9Y/(L=TS
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M"?$=V97]ON<%7NC"?4]BWT9U]K^[])-N,1]-\7+9S7M>K^)WUZ,[&W3RQ&@
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MJO9\UW@6 SA_:\ZJ *W%*D!F2_$K%[XH?DF!;9K3V[Q9='(\V44^_I;= 1]
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MA'>5;U,KW6H<ZR>B2BBC6V7X,7<-@<"=U0QUH.GZKNMB'L!0YN(DU[? L_-
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MI/CGZ>J^G'5P1S(K;4D%"H^I>-QGSB^4"5TBL#$TGSUEP7 S#TT<ZCQYCZ^
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M.K_PU'_^S^ON5Y#/9TKOYO+TMU\OOYYUKP'DY@; #UM2&X?$$F3(_5FY?/2
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M/-XS^"@ QN/@Z<!B.0?A*6P<V$&>@AD$_D#%7]J!,V0AWPD^^8YY8),.,XO
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MIL38-@;#PKCB@7.;%:;$-GS%.CJQ6FK;U,!XT':D\JUW314P*]XJOJTP.+;
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M5)NMIMIH;IU#0_+^]3'K%^8Q3(!!;FT[(]=SPTB8Z(=2<?CJ#%L>*1!89^I
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M)?04GP$"C6V'4>M':@\)G^+O8U32(IRI:+OE:VC'5L).0<_BC'=8863ZS.:
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MCJ)D:TFB-2YT7>WT]LF6J/U&YZ.:E(16F(2C]=7A\ WV%3B^X*G-[1VH"ZE
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M._VNVN[NDTYROA[BZC)MWX,%6T(5H+Y2GJ_ Z6/CFD49G/QD/78E,G(!Y*\
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M"R-JQIHHG%88A=-D%&YCCG.DHTE<MZ!0  U@HN_,7) K>25ED3\^3T\CMO"
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M%^J)B'WB:M0K7+BK,A'9.,D3_=X\DXQ_DTQS?>=QPSRI77TOVNBG$"S=_O=
MJ)-;80$J$0KS?2ZU\<"=I..V& %4>?4N#;^(<^$"59D[$;GD88'PBZ3$I1[<
MJ?83?,QMBF)IJ!P& Y*0(]>:90T0GWT#$+8!%<P,:X@+?\R9Z'3N%^@8_ #V
M4#3NA&9TZ5J?$[WH"U>+EM6-[@DJ%G=IU2^U1>6+[,;05*[D5*<'&DYQR4>
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M4%-+([S@9AHR-=&)*![2(C@9[6:] ?51F<I,(Q/[="3>UR3&$GI !SR;9PF
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M29^CEJ+<O?0RZ@V <6O7PU9EP*?LN6PMPE_O*C:\A+\3^VS!M9&;:D"R:AV
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M:;B[%KB"@R2R4@BA$;9 !64_D4:AEY&C10VN02WV%%1ET3I44.]_]'R\-XC
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MHN%*(5AU!4SEC<7C+["^JJXUS5K_CL-C<NFYJ>9D0MF$&.^G*-M*XELG'@I
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M< Z7&8AL5%XX-2W%]607P(!:$-I/5)LV,ATL V[E095O]U%*26ZOW<@]\G
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M^S#XME?:VZ#3N.BT#758,'2D;M=?.7P[(+J5IJ!CURFCIW9Z>ZOGKQ-7V<T
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MZ<H,MC,-$#57HDW"!K92Q_56!;7QAQ0! -78GH4&FH-2[<EFSX%BAP@O/YP
MK7G$3O)X90%^IT$>>O 1$.T,7J?8< L\/&$!B@U/A3?:/B"9%2'F*6/XW0X%
MROD*YU!S+X3+D=,]F4Y$!(W8-F8^$O97P:R67_X,MS+Z9@*OH%N91(OL(IRX
MB B_,V74#-X!S&:$<;-E!H%X$<!=R+M"\41B=-C(4ZQA <\%84&X]60"1*-
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MAXCT;H".>IE90S4ZG@TZ'B>L!:^],-2!-E2[^MY=UFML/!ML?/50F%9Z*.S
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M97!RCN,] R@4VHPR]UF '7F4$+Z\\F:PK 5QWO['0%8AA%,S5)Z9SU;4(RB
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M+BO228;1S;/+K$^F8[IC=B^>MJ59/%RCY*]:8.\5%]AK-RZZP[XZ*'# Y3Z
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MAW#)/%]:A)Z/E@O>^CV$U2BZ?@V0G#(N$^_9!'2) "28=#TA9% ,3=AM<_)
M]22< +SPW EC4Y]+0GPR7@0MLB;R#ZI5BCOQM2_PL1L?-S!AMS,\OB+LUP#[
M![U\JKITHMK=ZOES_ E!E8&S0H?7 UAR)$C\R*:.]3^T@2<3$%&(#QR_I86Y
MQ/ *XM#$])_@A7/KTG1 &)$A )CE>11C@&/[C30IA5Z4V 0*?H>9\ MY)LT
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M7I^"X:BX3P'*+AYPQ 7'>Q1.LB3?-6J<5:_+!'SU:MA?UX&06RM%H,:>2<\
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M9Z!(&K($# -;GUG/S%Z>8 O &G2R/75DC>SF<*6F<WHK+-*Q!DXK::6Y'3A
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M=@JOY*VTA&*?Y4$ @Y[K N6P/F12-Z?!@92\G>ZD%+LN#P(5'(W6"+Z@6O
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M0BIH(+#BV/"D6![G#J)F2C7THN1V\XK0XBX$F8YSEVMK*)MH0Z ;Y 1<VX8
ML JKD59;#TA/S)SB;0'6\5'E7@P57H,MZG%S?7Z&IX<?GW@OBGP#2S@E)ZK$
M3Y BP17DF^NAART4L8P?R9)EP5@*Q5$\'Y(7+9;=9YP>M,4X: ?1V092P8)Y
MI+ ';+$+U) ] HN&VYM4;PMT2F6>+* 6 ZF#6,!+0BRTAWMX";T5T+CB!WCU
M ^@L)/_@1P3 W+%FRQ1LZ>T]Z88&V%(OJ6C&*#RP !YA30)1_B6&6[L!M@.
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MHU %%BYV5.&MFW ?$_R39":Z@!QN6 2>:POP\AU:LYGDH\T= '8E@QE "+$
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M- T!;5WIYOM'Z9[1NP4AC%50M./E]:0?\$KS\=%CCXCI@AJ*/_+('+Q"/8F
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M/+NS##L!D!?"*%%*2J8^&RAJMYOO?%1"I)Z6P*!<AR@*U"RY@,R$JH(7HE-
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MB2,)>M@6'O6[Q/5&\^;-!8-3GDB?OEU?<FYNS>>AX_+?EA%#3CRC"\_%5H3
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M62;;;:1N[L.O@3_\-XB7I4)E0J#D$$S>=-H74L[U,RGI(Q!TC&Z&0TT=6=A
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M92*X7E5?DGOM60#5%B^E>H8&WIG\_-?ITO_&OCVL'A?C_P-02P,$%     @
M#X!R6CC1B7T6&@  @# ! !    !I;F\M,C R-#$R,S$N>'-D[3W;<MLXEN_]
M%5QOU6Y/52N^Q7&2[61*D>V49GPK6>G,/DU!)"AA0P%J$+2M^?H%0%(DQ0L
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M+DPW#1MBB.V1V*7*%@D5M=+DQ;-//+YC$(_@%(7BC$6R!Z57OF."P8)]@D$
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M)E47L_G%OYR$B)/NMZ/S!;P/X>/HCW&(X\EX.<;%B"6#(DL&&((&I9V#B,Y
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M:K($X,@4LX[>R6#O<7&[C310XW:(KB\8W8.(^[9WES8X*R\X87*<4<C)9(&
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MXU)/C:%V/%$ZT'Y-Z-OX.U'C!UE)/EK^[;J?GLWFR_%_=PAN[GV,,E/":%-
M!F6 @N\$46)W#:I/V2(KS=<)[T:T$TM^L/7DACKJNV&.D,;*>K(LZ3K-J!T$
M%C)$6[AF]4(GW7R9Y^"&.?P'6T]NH)/>E@6[\&FSCD_98@2%2>!C+*!*)-8R
MPP"E1"<X=ZQYB_W[,.W$&?.#!2=-%77J]@,"K;/>9>"\7A>6M*[=$RVY3!>R
MS#X&WYI$[=H/\!]M6;D'I9WF5MQ-!WNQ=:]Y"-RF (%> % "B?:1"XC<YF *
M6F%;W_NV+\:=2.9^+!_7JQY[ZX7Q\BJV5^79>-%E@$^F^?4<S\;G9R/.A"Y*
M%6 VU!M]L@?'&8/B47$*XV+QK?NQ'0!S)\[]*"O0IU+G"9:&7H>O=9FA-F1=
MU2MM7CB6,-+LC0?#BZ[]&RGS9)$#\U%;:9A)K'66=QC2G4H3?["U[!/H]%3]
MY91PP5L)H;L+#8L AQDA<<.DE$R@:7UZX>C^<N('*:ANKZ$F.ZXO9],ZZXN.
M15=[8\:<$G$50?NN$["+X,EC0Y*UVZQ(GN5K'G'K!NM=8^Q$@1]E/;JIP-M=
M/$EPKET=_X:0S<>I[NRNKI:_^HN-3ZX.P-\TD>L[%G[_DKH-Y#=AB;^7@FDY
M0IXP*:M :QM!Z2S!6Z<A"HN4X8K,4NOSPZ>=84\GAIZ/IV&:KI*PD(50@7LH
MY%,HMO8<@D\.9$8EDW*1PI[VM<4[HAO2:9D!<WQ+\7(?ZN_[0-NV@WTUT'9"
M40B4:UORK QXLF<053)2.A_Y]0+5!VN7\,#->[Y[>AZK_H<X;^F4S<R0]_:!
MU_)N[B Z:0!1.%0Y60K33T//>\];/G ?GN^>GL>JO]VZ>C?%5V5SVJ^F1PEX
MA-%FUUU2+B5%C5K0=[8H0%MRSL+)PEKSN(=I#.F<TG=$^(<F5-^&>UO<(U51
MI0@&/!!(I0NG-(G>81Y]%CQK99J7ZAT:]NZ7C6]V,WBQ6)S3L_';ZD#79NSB
MUT]G"]*43U@8N5-0)CI0+GERL3: 3R6SJ (K[EK[G*T9^K[C#BFT[XDWFSE[
MKVKII8_)-Y0;=[V/$BO!N10)1ZZW'&JR,SI)D%$PU-YS)5H?>;\7U)#"\)ZI
MU(^BFBP#;D*ZZ-?S?#;OT+SZV-T=^_L7G*<Q"21,\\7WUUZ"=^%+O6GSPZIY
M8KV6BM4;Q2,PSFH"H 4XY;!61V6TRM*(;$_KU S<D.+K$YNPAU%P/_V:MN$?
M!6:*28%">5E2W7I1$*-18()4CH)]+IO?F'(OJ"&%MP]@YXY75,]^\G(+IC!4
MO%X#Z["N6LC((087@9>L8C#6>-VZI.EN1-_!P?S3>,B#5-3P\M*/:[M9??7T
M$\Z7M0;X&<;E2#MN0Q .DO$(2@@!4<4,#"7SWFG&6.O Z@XX>Y[1?Y MM=:,
M::6='KLROZT2FW^=E;?C]]-Q&:?:GVY525 [2<\FXT12>)L^8#Z?X*S\%A;U
M,_G9>').23H)LE;OO<9Y=[CN&2[#>')()^=^<!S?_?D$\FG4,?J?W9N#^0G1
M++S'E^=G$>>U]RZ-NWAUOEPL0]<7HD-(3BZK8$6"VI*\MC=4X(SB(**(+!B7
MA6C=XG8O@,?D#;L.--*&<\%2IB 1*:,IDD-(RH*B=T\R[8(U9H=48-?QAK1
MT1];-@/\7C31KJE--<UALLYQ.TQ/ELOY.)XO:P75NUDW^2?KE[G>4[Y>UGP]
MQ]ID!?.E\T^)++:7C/Q^K:N2AK)D(6K+4*;1RZAUV26I;(MJ2*L8I^'; VJU
M64AWBZ36#N7FJ^.DX584"CEYXI2NU$:UAEX=+3$%;VR0KG5JL"?$D]AR53EA
ME 0=>3W/Y"U$YPKH'%ADSO LTO\L6]Z$,0=9\WUT,41K[K50GA)_LC=1U(X0
M-95CY(VR1R.*E"[LW#'S?Y(U;\ZX!]1KGSE7O<%@>?4& Q+491'N/S LSE?S
MWL@LGGRBU*'.N,SFBS#!;R>JCLBZ>D+2(.\ZA8P:95Z7H]:UZ[#*[S>N9EJ=
M":E-9Q;+RM7%2&G&F:&00F:3**X('CP+K!Y]XY8E%V+SN^;VQ7AT!X&[QTOI
M_*RRHK8LI/SXZGG WZKZ:N?+4=8D%HP(S*ONZ@6$((T 85-$--Z:YFUJFP#?
M,SKH=[&K5WK>Z$IP<KVW:WIQ(/2ZP/,->G'&$3P/F*2D_#63CW&Z@)$A%YZ-
M*JGU<98FP(<47GP7C#U<[;TQ=M/=;4YB9%707& -R%5=Q':1\NEZL654V6BI
MDVF^?;0KMB%M>3\H[YHH;WA1:]>-ACZW<0IQ_<D<EI?_>#8-;^J,Y^LEH-/'
MM$?B?+"(MZ5\&\7#ZVVT,-G =(FD'HJ>S"J^$4\Q)E(<"*$<>7D;P&EA(45C
MF3/:B.8K5SM".ZI=[+>2J77B>7G]S.5((V$T,I$D1($15&WM%2*/D)61K+#B
MR_5[7K9WB=UAK"&M5/7!C"N-85O+OIVK7MT:LV6N@7P'X]P (SR@:F?_4%O\
MY>BMC\5FG9HG@[>!.5E XE5.QE@#0CM2L FEKJP[8,I:KCG2I)MWD&L8D)SJ
M?6G#FH,CCWVTU&N3IQ%*K72IMRM)5JLE2G<S>X3$D&<OM5:I=0>Y;3@&E23U
MPHVCI=_G#>(X7]9E@C"II5=O/R N7Y"(-J*A=0/YL.X8O[X"8R6IPR/*-N,V
MN(F\_?P;17SK<;<V[+^XAX1CC(61LV4F4J[$B4[>6@&<91V0L61S^UM*[X5U
M= >Q^L2KXUQ,6#+N,Q,1N*P=S801$&PVX()%SS++HKF/NQW-D+Q::[;<Z ;6
M1B>-SC!T,"[N@5O#N9RF1\%%P PN:KUNHUB[M+K:OC45+86ZSSK=/\J0O%9?
MNF\LZP?U8M<Z.87+3DX7,^K3E>T\^"G\V6&2:+6MMT-#K0MNH8@VU9O\N(ZU
M7*B>K1/((!3ZO0W*<=VZY\D>\)HXN5N?3B._G$W36A+:VF0<O67)U.#3EPP!
MK8=$6;47.6)J?H/M'O"&Y ;[XM=6=]B#]MJMC5P5Q+MYR+@5'66=D?ED(/IZ
M5[KP$IP+'K(H))8@?,[-MS%VQ#8D'WLJ8O6BMY:LJG-^2]YEOC%AFI*2GA?0
MZ#A-6"4(V@;2O$_9Z9"3;[[<MA7)H#:^3L>88W728V3V?/P%\[&+!5L><GRD
M=!^R9FG\QHV/1(++2Q]?XG+$I!;2\0"2*UYO.4_@#:O]:TTT(4D5^CBG?RN>
M!@<NMS^[V^8?9>F$(W,%D:5 LZ7O@D.$3$F($#E04M*Z2]C=B(84N33CR98C
MEJV4TM*/7%2 ;%[,0]]/L),_&<N-ML^W3F$4ZM6HO/"Z+&M!U2Z\!-Z#M2XA
M%L\Q]9 C-,&^9W33;SU;;^Q[$$WWN=(P.SL;7Q82/)UU1Q9QVAU8O#C6^(^P
M7*_TS\K5+OH7#1F.6&QH.GZ#]8;^Y-'( 5\=\7+O>B2R(^IX!2G)NJ,C(GB9
M-.5FH;;:U((WW_ZZ!4K;&S<N'WL1"5HIHQ(AUXX=9.%YO>C,9PM"!\]<3,XT
MWR2X&]&0W&X+=MQ]<\91^NCI5I9+3!L)9=)<\U0;)*KB05E&@4#,"C2+EO.8
M9+3V-#09Y@K "9ERH%::D>4/I+0(;P%W:;//<92+S%;RVL4P\GJP6()C4@ R
M(Y,1R>?8NO_.KMAZE<&?T[R^AZ0NFR?Z* 4Q]--(>*&,%0P*EE)/9B&X2*%2
MTH%+QHU-S3O-'@1T2":X%[9=?]/Z5V??IGJ46-"UG ZRY@*48!9\8K6)BA29
M*R4$:YWK[!2P/*Q9/@E[6JCD>TE*1ORATQ)",+#$Y+I,&J4F.W.WL&)*H@"@
M4.@(2E*,$75F@$:(4 S3QK>.S0;A9S?&^7\8YN\^ST8Q^%@\O<&)UZ@H9J17
M3E$<[6QF/FGZ6VLKN"?$[]*W[L.PO7SKD2H\>4S;@23BX$B6D*,/$K+/!A1)
M &))"1RW6*(Q2F!\2*95D-^E)SX9U_96XX.P[?GL?#Y*/CE1(\U4^^(I5APX
M&RU%FB44QI%9TWHG:%^,0]I<'1S7]E;BPU!M_(E>B,0CA:<2F&<4"&LF(! W
MP&A%,F+1!FQ=0[LOQB'UT!T>U?95XLFI]I+BXW>?<?()_T%Q]X?%J*"VK$@$
M67N=*X<6@A$:M-3U JL4LV[=&?%0K$-JPCLHZAVEU!Z3W]7%BN_"%UQ0SO=Q
M-JUXNV,;R_"E-A2H<EU/;S8]8NOMP(&.3V5;S+!1QKJ"4L>L'9M76?4YL>;;
MZ*OV#1N0?_^RG =Z<<93RKF[6N2ZO$W_DN9&P[R_N"!S9+GAW#@.:"4%:M'6
M[KU)@0PQ1"^U"*QUDMOC=!I<,+TOM&?TS6(Y3J,<4Y:11!=2O8F=TTOI4PS@
MF9).%V>3;WUMSA%PAY0O#X7?6ZZF/@D;6MZ/OB_@Y_3C^/UTQ*7/GGL+7!-H
ME5B&&$H&'5()W O"W7H/Y7"T0TK ?R#R'L*%T\08;Y#$DR@XZAXY*YMO7(O0
M8H?G-XTH]IU/TT""AEF?.OH-IUC&RQ$:DUV0$B1C%%1:FTCAEM>KM4*0$45H
M?M3E%BA']DY=/?*J=-\NP_)\2='UV7BY(OY(.I9R4!9DO0=0V13JZE3M<14S
M9X47+W>YUVWG 8?G;(_CP+7.ICU(O;%+O 'O:7>;XXOI,RPXGV.F#ZRJTFL+
M@I5J)I/9YWJ<;X2B.,4HY7+9"%"%>W"!!4!B@_<N"2GZ"9&/03T\%]F&<@^D
MU[[YN#K:EO_S?-TO:\2D--YKK %CK&=\-<0D+8B*V.C V?7.S7V1[CJT(:U(
MGY!91VFH;_I4:UL/._U!#YAL!!,CE,9HQP5PQ6T]XV3 ZZB B!]2UC9$W;I6
M;$^(0UIU/B&=FFBL;UK=(H\GR^=(>@F3E9.?41)S^>]I5J.4.<]1U95)G^C-
M" R"M!F"Y]I$@<[TM*;4: )#6HT^(25/H.TFG4A6;?''G_"6>1#\\;R[L>K;
M^CJEP=B5)-$?QF2\K519UF.?J78A53H$\$Y;<%;+X*138:=K;AI V?,ZN>^&
M; ^AJ;[MX7J!Y K_GXUIDK5J?!PFHZA,3(*R&^&,!&6*IYC )6#T6M2WQ*-L
M?=CR0*B[T,Y^A[0[I0;[IMO+65WS.4_=78MKV;PX^QC&\QJ!KMZ448DRV>@\
M8''UB)ZG]\/J E*A%$8:3,VO8#@"[BZT<S\>[9IK\E3K([]/0UIV:73GZYDV
M*)U!*#R0:+BU$+$8P&@2"FUE8/WL<>T(<!=Z^1^/7@VTU3>AZ!=7RL%K/:I)
MFA?@K)ZQ"B4 18H2M$!O$TM%NM:%GCM"VVFUEOUX+#I*12>)[+O5Y'OBQ:!B
MSLP*R/56+!58 I]UA)1XS@E+]M>WX0^*['> LA./OM=E_U.KZB%BK>Z.MM_"
MHEZ4<59_LS*VL\5R5)B3Q=7.8C&4>@^<@Q H_14^%RZ+%DJV/M[=!/A.G/P!
M]P5Z5.]I=L W;NW>+$>[L<]Q]0*-)IOCQPW==-^\H10:;:E?#'T)<F/<40I9
M,HD>A/;$):8HHL^20T[9VZ#112<;6XF[\!SCFC=$O/'$JP6L;ZK->%7^7&"G
MA9&,QMA:_I2%HUS:8J:$1@A ZV56BM[NG6XE/V#H(6VX-V/(IOOM6QW-W.V-
M5[/V-A+.ZB XI2.EG@KFM:V1+A*R,X(0<6M4Z]A_&X[F<ULU]U)6)0IH2),8
M'<T..03%#6D7LS+!"U2M5V2V(QGB6W P#ZX[^@;"[X_D6ZH-N,K"(H_ =*2W
M+Z8(000)9.FB=EP7C:V73MJ7B?3;#ZU_CARIESX(<]4;T)C<*!"I5DA)9. 3
MY4=>AY"98CJ+UFV!MR/IQ>KSZ%)DS$(N];R,+QX"KW=G<Z=RK9:PN?5YI/NM
M_@-?:=N "/>2?E_9-V?YULA'NR!\*8FR.D%3S$9"Y#E22*(*3_12*M-7#'!_
M;/RP]7(]DN)H5?3G,U?^6PBCK7$"M*HE[X8\>? *(9B4-,:@7/]&8DOPU&!^
M+VJ?S=KFZ TND 3XX<DT/\-/.)FM>FT6>A$S=PP"FNKH; 9G609K.&G6%!-D
MZ]:(^V(<=$"Y/W_NM9PM5=;?BW-E@?5IF,^_EMG\<YCGQ2CJ@J%>.JXSJ]>/
M6P51IPQ8O-+)HU"^]:F>/> -U.;V1J=&BNJ12;7&M6X#7<'FE"=/0&#(33!0
M2-F4Y\I#=+PD;UT6H?5:]V[(AE2)?!+^'*V>_JAS-< 8)2R<2T:Y%&>UC$;P
M6@](WVE*JA2/Z)NW9+P'TI#JC$]!EB,4TA]+Z)N+WUW<9[>Q]4+>=;T%M+AC
M;\9I$6PT&J3*-62U#AS3'#(KV6B/NO26.+2<QY"*C$_!QU.KODE!PI:(<!FF
M[^LFXNKGD3.VV, T6"Y"/07BP<6@24:89%9:.;_+O8?W#C2D,N&&=&DOY/Z,
MUXOI)[PX_)-$M%C;YR$3&92O;5AXK+>-92ETT%JQWHW0!IXA5?.>)C$[3!7]
M&(7;&M7:G'@IM8K HJ;(S#OP*G!@!GE227IVO;G[;K;AB ;!IZJM[=M$M!!Y
MSWG42!A)857DX)RB0(O5HX*I]JD+Q83BD^+7M[][RIN&5!5[LCQI+_'W1X7;
M[]9!%XK04H*U-%&*PP.XXA!($%*Y&)UVO6\3'W5/TLEJ8$_!F39Z.DTM6(V?
M4]<U_^-XW<ME5M:'],(T=T=+KQ=;-JD$.V;@IG5@S230J JL+LITHVPNS:RO
M,PC,,QD" R&8(K^D*7A-2'1RY)-\\I+SUB?Y[X!S3."S];&="L@1CZ?O/L]J
MI\S%2 EOE;0(N?I?5>BU\=9X0$3EB%E6^;A#W+/C<$/:E&C%@\W8IP^I-XF#
M[P3V8MHU@EY!R]S[HIP!DVH-AXB4MTLO*)U+=0O%\^S"L838''!(&PLGI\3!
MDC\%*6K'YA6R6*(5L3BPIM2Z&_*H09K:Z@Q=-"HP2NN/Y\3E>$/:*W@ 2APF
M]_X8L?G]"W+ 93PEF4TH@6,E.&$8: S=M9<"(F("[[UP25%HQPZFQ6V##FEK
MX&3<:**!4YB,V@+Y^7A!:JD$'F%ABEP9>3C71?VU.:&0'GR,L99X^GA]Y>T0
MNW%UT"&MU3^ \3A" SW<SW5C[US+Y%D]J*\<JU^*A1@3@Q)T<8&59$SK'D>[
MUC3L]R+<_M0MX5XQ&(I)%ABY<K+C+) 63(3BE&)")*O=+AL/^XPYI$B[$1\V
MWX+>Q-_$2NZ$[EO@%\G'A\@X%,]K5QXE(6AK20C!:?I;9'J7D'N_48<4=S\4
M00Y3P<DH\BT0%,7$F$NLWH%LN4KD+$S2(*R3@J,E/^\:,6204?@#$>0P!?3,
MC\T </,/(QU*H<S UH/9-:+(#$@0%!%:GTN2)9BT2Z?<_4<>4DQ^4J8T4<6)
MS,F-T)!1XL"CS,!RJ!OU4E-4F!&*RE&KC/56Y28V9<@1^H,8EJ-4L>.VQ?KW
M]4L,"_S;7_X_4$L#!!0    (  ^ <EJ'R]%W=X(  +;(!0 4    :6YO+3(P
M,C0Q,C,Q7V1E9BYX;6SLO5EW6SF6)OI>OR)N].M%!N8A5V7U\ACM[@C;RW9D
M]GWBPK!ALX+B49&4(U2__FYPT$B*AR) RG3DRG3*DLSS8>_O 'O&O__//\]&
M/WR%R738C?_Q(_L;_?$'&,<N#<>?__'C;Y]>$_OC__R/?_NW?_]_"/F_SS_\
M\L/++EZ<P7CVPXL)^!FD'_X8SK[\,/L"/_RKF_P^_.I_>#_RL]Q-S@CYC_D_
M>]&=7TZ&G[_,?N"4J]6OK7XZ^3LS0?#D+!&6:2*#R\2"UL1S[X/CF1JJ_M_/
M?Z<R*)F-($'R@+\&A@0C&'$\:4>#4=&'^8>.AN/?_U[^"'X*/^#RQM/Y7__Q
MXY?9[/SO/_WTQQ]__.W/,!G]K9M\_HE3*GY:_?:/RU__\][O_R'FO\V<<S_-
M?WKUJ]/ANE_$CV4__=]??_D8O\"9)\/Q=.;'\?H!^/@TN_J'-]&HGQ8_Q%^=
M#O\^G?_[7[KH9W,%;5W"#QM_H_R-K'Z-E&\1QHE@?_MSFG[\CW_[X8>%Y/PD
M3KH1?(#\P_++WSZ\N8]T.)[]E(9G/RU_YR<_&B'B^2?,+L_A'S].AV?G(UA]
M[\L$\D;TJR474*K ^1_ETW[:&],7!#*)%P$(?A?&A>(5,:[[]/TQ7WT629#]
MQ6A6$?']SZZ*MSOSPYH"OO?1%=#./XB<P5F 24VHMS[W!LX5R+L(RT<.Q]W7
M8?>WV)W]- ?WHAM/N]$PE6WUN1^5_>+C%X#9=#M0_"@$PR7CB_?Y?VS^K!O@
MD 7#\;!L++_@7Y<?6*#4@ E_SF"<8+&UK)XXZN*M7QJ5C:V[TL3(!QC-OSNX
MF)+/WI\//L[P.>7 08CP!K^<#KBDWIJD2!)*$<FM)X%+00 TT\DFQ82XK\?I
MBA?93\-<D\M'_%0$]Q.,9M/5=^:BG(MQ,XJ%'"NLZY,/(QA(;5(RDA%#K2#2
M!4J"=;BUF"!32"8*&UJM:8[@]GJNF?%LLEK9\AW:Z2C(D^ZLJCYG734Q+C2%
MH'_\H9LDF*#U@S^:O]A_CZ-N"ND?/\XF%W#]S6X\0U:_&LT?B"\B?"Y?[,N$
M#S JK])[/YE=?IKX\=3'(OCI\\N;/WGVYW Z@( R<<D1",P3Z6DD3@I-0!IG
M(.D8%:W,DO[H*C+H@8/[ 48]@@+=052QCFD52?-R?OCT0C2X8U0T(,G+&V=U
M%3)LM(CN4Z&5_AZ@R1["/PPMM$Y!*Q=("@**WY2(+XZ6L2)JCYY7SFNLGF^"
M#K<,SJ?$AEUDWH %;[OQY :H7^=6Z<!PE@3ZR00B>M>2:HI^=LY$4ZUE")[R
MH"L382V0FEQ89\X_3(3':*BK+=[[.J<UW_PE(E#:,"<<\5KB&FDRQ.$A2"P7
M@C$)+"O6\,T_$6WO*=@&K_>SZ12]K6=A.IO@CC:(V;!L<<<*5):]RVHTG[TF
M3M'HI#0I,UE9S;<1'%[%E9V(/03:X$U>H'EQ,9G@ J] :9:L"3H1H6DB4C@$
M%3,CW!KC5*3<@VNBY3M #J_L?;2S5M'[B+;!Z_S"3[\\&Z?R?Z_^ZV+XU8\0
MW/39[(6?3"Z'X\__]*,+& @J:,3_$$H3+EL80ZRE%K<@2T$Q&9A*E?7?"]BQ
M^+"7$KO6&FA DX]?NLGL$TS.WHR_PG16=K_IP%.9)&1'7. .3R(;\&#+BAC-
M*%H@6=KZ8:,U.$Z!!'O+][[.^=Y'08S=!>+X !&0EF$$;V&V7/2 2C1#LN8D
MF"!PL3P0ZQ4E/@HT<X(R4=8.@SZ$YQ0X4$W>][D@]N7"^PF<^V%Z]><YNK^
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MS=82;TH*0[E( DL,SQ[!@H+$DJX=1-P*ZD3C"'65T<!#N"&%08@B!*XXB;Q
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MW:K:#]EW9IHT4%?%/:84J[SHSLZZ\<=9%W__5QD"/)Y=-;I>(1Y$B&56-"/
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MG:8WH^TA'<>RKN..=+7$8W[O>N%#1>?M O R>!Y49%%SJ+R+G/"E/2L! %"
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M&ZNU-2GZQ??+Z=7BRQ^(*S*,R63^_>(;W K'4U&Y*,FXM 1\J<C-#*8^S*:
M080<4Y<;V&<'.G/CMU7T$"2YRVT.7!$AHF NU-=VZ20+65LF+,_1&1%XZI0!
M>^K$U8T=W+WT-P3[^!I+7<0X/\KJG92_A?)X'\T-2%D-P@11Z_-EEDM23,-
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M)VOSX,7WNS\8:4P%I*9SL_(M:A,M"]I3%)!,4E8[E7R_S6;;R*_@:6*3 :J
MG\CQ1@RH$\6,)OCJ= 7+HA+( +*D:('48P^75O0C(*BQ30:@1'ZDDXW/G;=:
M2$H:6RQG(0+%G-(D<MF]95:CR,&3XXZM^0=W%/$'B-4;VJAQ;+51LJU!H, L
M!2TGEJ"2Q7L36#!:,JEL",[X7+CM<'KM-.@);#LMS3<]A.X/"9([,5_QT9N<
M';-9QMIN1I!*R(\'+V+,]%^4NB\\3BKL/@8P]M1WXQC[&>S>#>E,3$DA9VCH
ME-1T3#(P1C*(N23NO?*B-RC>GE9D?9S]8D^=MR\">TK(V[B-(C- 7MO=Y4K
MH#R=K18U\RKZ B*5K'U_7)Q2\'P<6.RG\<:1\D89[_[];G V,F1CK5TEXX#
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M^!E9N+_R'EO3MZ)M?S/)O^ WO)A^O>-3CG+E"D7C60)!?J22@0+-2)-6*%-
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M*^N,PI4:-&8E@O-86"XT=0V5EM_:2@\',JC@G/&MJ4UV$._PP=QA?+-6%AD
M/+_^U]4RJW;Q99IO4RMI^B('D[ABUGI929X4 T^*0&4R6JXR]ZWSQ[:(<BZ@
M:*'IQF?!%I%H_N/+J\N1$([V1N,(D$'3:4<['.&1Q"N@C 4>8NY"]_OT*"_=
MO(WUN#4AL.&MS<=5W/9V4J:S2ZB?M?]-S?;/ZGT[TU',1C<RZ]$^X-?I;+%D
MSKP9]A8@.B8ODK-,>9[)?<B%PC.;6 &C?/'>Z.;'9Q>YVM&D/3':3]_7/UPW
M4?:V*(.189"UC6&MW+6J9K^)H#&)$$SK5X ]Q#S4'4]S]&RG21O&1,>^#+J9
M9^V>63_HIZLY*6X^7\]HOHR_-$_98NV86?6F:Y_>VLN!&>DA!">,#*DUZ)X2
MZ/BUN0.A85-/TR96&: .8BW+.L+K(LQ =;CW!#E."6Y#0SV$0&\M#VYZ&86W
MKFC&,='^:A')Q=*:A5")SS68$#O1*IZ6R9\ILSV4Q7=1;N,P9;6YU4WL>F[K
MBY? 8S3U&%58;W-X\2P4"ZQF2D2P29I. <JVSS]\:-)#Y=/&^FK,MK(YQ^[G
MZ7RQQ*DHPE.T2S@UM46Z0@JZA*T]LA,$:X5&U<V23XUR[J=U8STWKDW;+MD:
M[EUDVWQR[XB%8QS0K6W3R>0]%-M\"W]&QA!M*D!;DS8AU:+)P@+2WRHU1-%.
M 7](HWI"1M]R1!_3YKOHL[&MW_[Y3@GNUF<.1@F07&;>2CK$M ?F<S"LR*RC
M, ATCG4P[+T//=S!W%[7TQ:*:GPXDR!&<T$3?+?X@K.WEY=7D^F[29I>3#]?
M,VY(D5/4H)D"%9@6R3)0FJ05!D+Q2J+K<D)W&.I\K-M4J:V[JE>AWL^FGV=P
M>>T?JF(=S^05(K>":43R-[+/+.LL>18F:=N%^6[#1Y^)3?LJK;%+]6MM!X=8
M&SVMICI.N$Y/70LG9$K%.<.2\9:$<Z66J2HFM !M!9:4NQRKSPYT)O9MJ]#&
M)?T?%]/TGS_!''/M=DN^QS)N6,NEG=<2HZ-X(=1I1\5"[4V+*1DKA$)>NI3T
M/S7&F=BXF1I;=Q.O>\M?$[A8_AI>Y_[?,*5RAVBU9=86P[34G 4 Q7P$G2($
M!;Y3Q_DG1SD3$S=4Y0 ]SC[07"=76%/[?ZZ<0I 6_QPOOOQ\-5],+W'VZ[_3
MQ57-_:]-ONA_M=_72!J3DC62*4,[#DT]U+9]BCE+SB$Y">0TM*[WVT/,HUV8
M#??N-K2Q!DCIN6EO?0W[FXYP@-Y)E2*#R$-M TF'ERK :-.+2DHA<_/,^ZW"
MG"%6VBA^$%[2IPJ<K>0*'0DGHJT<W,*R*BU]:0IYLZAC:9W4<&+5Y8T,MU-9
M^2Y:'P 2;R^_PGBVRJ]9 +F]M4JU=I6\>4]Z5]Y2L'J)[V;53YKAEWK;]0U7
MW_RU)MW,ZS_Z=7)UN=3>=#(2RNE4B<.S%)KF5)G/G 26@@O*0O&BM#ZEAIC'
MN0#PZ#9N&.Y>SZDF8L_@HA94YTNR2U53+=:[7E9)^T"Z22S[FDWI1")]9<Z4
M$($GG\B9MXTA^(Q(YX*FEIH?@)+];]-I_M?XXN(6]+]/Y_-1A%(PUMS+DL@7
MTQ2J>U-?4U6@&$ J\LA:4R!LEN1L8-!?SPT#YZUS'864/05YI3+Q.::]J^FW
M+K.0*73,G*OXD .KO:_[(_BX.REZ@ /A-M]Z=6I=9W6/N/0I)-J*/!U23%NN
M67 5Z5%G%XUU1;4&P#99SA '3=0^P#%P+<<:GG].)]-KQ(ZT%Y*;Z&F"E5M%
M9L- D)#"Y2Q<<CPU/PN>$.<L0=%&^:V)4K]4RM:WD]_HP/H'7%SANT+N[N5T
MLKP*_F?E>ZB%.,6ZF&FS8@%,G;D1##R=BCPZ&1!<2@\[1FYF3>PTVAE9?R 5
MMV9-74NXENY.F<[;R6V3B1H&P>3[*$'&I%1A+EM@&FJ',D]GG"O.&@=<HNS$
MG[K+H&<*B?8*;\BK>K\X[R.FJ]F2F^NW;W^._YK,$"[&_XWY;Z3,I9=+/J[E
MPB--'@73,0(+ 3-307K)"R\4&C<^0;I)=D;8&= D#6E8;_SA^M1T]Z"[OCM9
M!<6<SC63DV .;61:*,O :<NBR09DSDKJUE523TMTAD!I:((!F%W_Q+6'O$0K
MA.P4Q\@"5B](6\^@U(@)(+@$%"^)UB\P]P0X0_/OK^ !V%IO;T7JB7?OTG5^
M\U9X?84R<MQSXZQ@@F+E2B9.T+0I,H1H@C(DLFP>D.PBX!FB93@#;6=^;5FZ
M?17G^%]7]1WI6W6E>A1N;_FD_F7;741L5;1]?ZQ;B)2@D[6H&?>*O()B./->
M)K)C!&O-LAM=XY6U39;>-6[W/W=5'J)1<>\$38TK6@)<9.:SR[7_'?>@9,JR
M=8^Y37(<K+RZA9T?U;?U5>RIU$S_@G%1FR_/KI:]"FI=07"8M4MU&M+3%EG;
MDY3@6*J$1+88$*%U1^/'4ARMWJJW8:=-%3S \_U]B>YT\>XBUT#ES]MD.DXE
M=%^;/0F!G@H_)""$E))V0\6X%N3">*-8+#8SFU!D%Q!L<YZ.PP+AF?KH0^%@
M%STW+N5X8__#\)^GDV](/O.RZG<RGE)$O,#Y+U=8S;-.?"U.">^B9U)E7Y]F
M#8O9462L4W2ZD#L-74BYNXYW^/"AC76F ZMV@)S/WZ>3SPN<758%?*)_L\2Y
MTP)R<IPE6]8W'\%BI8G7& 08#*$UE?0F.<[&#>BMY &>OQ_*M,9[%ZD&<@,V
M2W0<)Z"_Q9Z!0 ]U#^ $;)'.>Q>T+Y+E;"QM?CHPCPEH\Q/*!2ZL**U=@$."
MX!D'X% 8V$7+ ]C^SB%5!5L?2XZ.I!",9HYS3D))8)!5(AE+0MH&9>*M,W(W
M"G)X5Z"%E::M53S R?_PE+M&N(\RJHB"850D5JGO8LE&%I-+6BOIE&S.S[=9
ME+,Y_UNH>H"4IPUB78.]@V!#<:%M$^I(O&@M3/<\''KH?0AVM*T"0HQ1._0,
M7,W1E<:Q6(ENBQ$F^AQ*2D-?'Q_7*3@L'G91]_ XN*Z"31*#,9F9>EKI4DGQ
ME^334)!S2QX2MF;XWBC($1X9VQCJ:?/OH>6!O(-Q'L/L^T=8$I#5=+P5TH40
M(=1*=Z-),*5K*IZ4K(24C""<V^9!P59ASLI#Z*_N >HC[HA3;\7>E3N=ZZX/
MK0X2#N4L/"O=\;R&!N9\"))A;#'$P?&\I%:[X#UMEM(GQ72JO4]DM$QAG8)(
MJ@A_)FCIX%(<!2R[F*#URP,91U01YV\^SW#YJKT^]VQ4M:,.9SX)5[=22U%Q
MHCF#+<Y0J&P>MG+;_-2P;8 C> V-+3%MK<;&I'!5*+U1J)P32NX]$VJ9=*$]
M\]%Y9KDJA6OODG@N^^C) <[.MOW5./#F?E4%HB^^P SG;^?S*\QO)W=T,*+
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MW-%&G32UR49/-Q!=?[O^$6&._^=__0]02P,$%     @ #X!R6L$@5?$>*08
MAP4' !,   !I;F\M,C R-#$R,S%?9S$N:G!G[+L%5-S-ENC;C;L$=PV$8,$=
M$MS=-="X-*&1QDF"N[LEN!/<(;A#<'=W)SB/[WQSYYRY=][<F7//O6_>NK-9
MJ]>/VE7UW[7WKO[OJ@7/L\^K "Q921E) ! (  !??@#/ZVC:,F)B1LJJ2I(R
M\A)_4:!)RUN![6&P   [L!-$54J44EM'EQ)Q!  #0 8@ -@  &.0XR<%-4EU
MP(O(2(A1.KYT OP+N9[^8W8 8()96IF2$O ?$VS0)XC3BX'*+\QA:N8(>F&_
M%[:%.GWZH_WTA7%-;/Y@&+@_&/)BX L3_L$6?S+37_K\R>__8%,[L.D+_V'S
M)U,[TS^XZX6#7)S-7AA6_H4#7*S,H"\\^<*TMLYV5B]\\\=8.S-C1P  #NV/
M=B<SD.4+OWMA-(BZJM@+"P( 2&@6?\,F?\-.9JY.?RQ*S/Z3&\3*PM*)\@V(
M@9*-CX^74MH,:FOFY,2L; RR,8:84HK9VWTR!KL! '^N^2_RZ@_?4KXXF9N-
MCYN;F9V%[6\<]6\J_YWR1VS_I N5O\0,B#_TU[9_K9]]%@# >_7BFZB_MIDD
M P!U_@  X?Q?VVB_ 0"8+W&K'?V;]>#_D2^63DZ?^%E9H5 HBY49B.4/A_ZS
M_$\[_#OD;Y['\L=T_^P>2G$S<V-G6R?*/_P&LK>U=X90.GXR!IE1,O_W2?QW
M#_S7[6!2-3,W@YB!7T9HOF29%=CB)=Q@4RLG*WLPI17X_RV(?^>P_T[^S.L7
MP<EY N :L0"P1G$!L$=# #@<5 "L?L:+!OC/<9-'U@3\L?.T*';^S/N_"/!_
MG!4F\H\/1RN+OXP34U6G!#E#7/[4_;$M ?  %  F != !" 'T #> )@![  >
M@ #@/4 "( M0 J@#= "& !# $F '@ "@ $_ %T  (!00!8@'I  R 3F 0D 9
MH!)0!V@&M -Z (. 7X IP )@%; %. "< JX!]T @$!&(#L0!$@$I@*^!C$!V
M("]0&"@!E >J G6 'X$60##0&>@)] 6& F. *<#OP$)@!; !V [L!XX!YX!K
MP#W@.? .!A8&#087A@R&#H85AA?F XP<C#J, 8P%C .,.XP?3 1,$DP63 E,
M+4P[S"#,%,PJS ',%2P %A46'Y8*EAF6%U8,5@E6%]8<%@+K#1L"FP";!5L&
MVPC;"SL!NPI["'L+AP"' T<)QPPG "<-IP$'@G. \X8+@TN!*X"KA>N"FX!;
M@SN%>X)'AR>%9X3GAY>!UX:W@(?"!\ GP.?!U\!WPT_!;\%?(R @X"/0(_ @
M2"/H(%@C>""$(:0CE"/\1!A#V$"X0D1$)$)D1!1"5$(T1G1"#$!,1BQ!;$,<
M1]Q"O$%"1:) 8D>21-)% B-]14I *D)J11I'VD&Z1\9"?HW,CZR$;(KLAAR)
MG(/<B#R*O(5\CX*-0H\BA**.8HWR!24)I0RE&V41Y0(5%94:E0]5!=4*]3-J
M$NH/U#[4-=1;M%=H;]'$T/31G-$BT/+1?J+-H5V@HZ/3H;]'UT5W0H] +T3O
M1%]&O\' P6#!D,$PQ?#!2,6HQ1C'.,9$QGR-^0'3$-,=,P&S"G,4\Q +&8L.
M2PS+&,L;*Q6K 6L&ZPH;!YL-6PG;#CL,NPB['WOW%>(KNE<2KTQ?^;W*?M7Y
M:@,'%H<&1PP'A..+DX/3C;.%BX!+CRN#:XT;BEN*.X)[BO<*CQ-/$\\5+Q6O
M!6\5'Q:?#E\&WQ8_$K\2?QK_CH",X .!&4$P01G!.,%O0A+"]X1FA"&$Y813
MA'=$E$021#9$T41U1$O$<,1OB56(H<09Q-W$AR2X) (D()(0DDJ2>5(8TK>D
MJJ0>I-FD0Z179.1D4F2?R)+).LD.R?')WY-;D\>1MY+O4>!0"%-84<11M%'L
M4^)1?J"TI4RB[*(\I2*EDJ9RIOI.-4)U3TU/K4']E;J<>HD&A8:7QIPFCJ:#
MYI26@E:!UI.VF';^-?)KWM>6KQ-?][[^34=/IT472%='MTM/2"]#[TY?3+_X
M!OV-R!N'-UEO)AD0&'@9;!C2&7Z]A7G+]=;R;>K;44881FY&*\9TQC$F>"8^
M)C!3%M,,,QKS!V87YF+F-19\%GF6KRQU+,>LM*RZK-&LO:Q/[[C>V;[+>;?
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MH01WN\1;^*Y%GL@R![ DAA)[.0W[0'I\=4FI$K6*8VG-ZZ&L.EF5.",KB;+
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MUVM<8OOZ0T>,2]"N+! A(2I@06LMJJVO4ZC1%_ #E9!7'>++_3^2EI\!/XS
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M0@B!DX7ZQS[W]U[?#U/C<"R+*(]'QKKS9,$D$?SN)9MF4 L?8=>MYN:;G<P
MLKNE[ Q[DNU )0[GJQOTW )7YIU'S(@Z$<S-I^"IWMV&"]W2C'%2/@KY6^?+
MGL"3 \@S8&C"_CIW+<EK2=; 9<ED,G'CQ+3WKNZ6H%E"ZE#*)]"2-TS6[=+N
MY];21J*"(-/38!V9\SDV#@=.Q:.A7H2[P9RI8L1E* \=#,+P+CI)?'AKZ.I]
M0QKGN=O%([X5!U;H0X:&ZV\W@?.3.]"]U&G7\D0;2^9\U:N>MD.#\ALT'^LR
M[-CYP8N*Z6> ]2();=L-U&/OQGZBSN[H-*2Y";2'N2OHVTU>_"LE4Z'/HBL6
MQ/)K,LX$D]5JT_5T)OSQJ0]D-+BL<"[]- []9JM9]<:XYYB<@ ("!40$9$==
M+L5$K>3Q?KF 5:V^D%;LP)JIX/0[[N@<K!*^RG;-[VPX8C( (:@ESI4M:'*5
MUTDHRN9-WUUO+D9=4A#5:ZDY1) WY<LZWG,90+H:C5Y+ZF9M/\F2G$PT9%JV
MR/*L5A$.&UJ6B-KUR<%]89)<43<-"Y)ITYFIK=N<T"LKO+:IH*-+67)6JC)(
M$I<X]_2_X.!+2=IW.5FIP)/EM%&";!4CL+7KYEJ&V.#31:4'\!K[8<B@I?N]
MUT^_L3!2T%H8QSSRL) \2D>OF;C V?<:KW8]H-(/G3ZP>IOF^58%SO8<=\ZC
M4J6C0WA0QG!$^G.*-!PF?-?\%;\A@J;7D9OKE.QPJER*P7>X%?$='L+R@/O6
MP+7X:.+B^)@CO+;.4[T[\+6$F8?-=>202\[R8H!+\FRHW+A)YYYT/A&,H&1T
MMF >3VZ9IZL.VN0V]!"90]%1NUA6ZK10_-WF=>2OZA_U=[-#G@IXUA5!L!XC
MHAL+*29KC=M)#7SH#T%+-^;XQF"""@\I+0FK:Q(E$J,4$?TAW6M76,!6,?(S
MX)3!EQ<3<QSB&O,4.3@Y11(+L1[EYGQ4I7.T#/[*]YK-'!PK@H7TH;\E#YO"
M(A&<M1$_V(IXJA7^X+%.IDK*>V8YSMG$=U&3KGA0<3F[:32Z)>'&N6EJ:F1K
MS!4>*8'_EBVKI%%=<O=BG *[?N4R0M?/HI6)>;/8OLJNW.LX<=!NRNHQY2XG
M;5Y@@,GGW&>K]T[K]42CX;3BE2!8N#GA9*4*GE_#^*6NTJF@[$9[OU@%,1==
M;(,1/G<QAQIXU#4&Z&<0^\\M95B!HLP=S,T9/J;HGA/(?1K:5.$3X.#@:$MD
M&LIO:HRLHI%6.S8WKXNS$!:1E>*T?6@3:X\>ZND^M@?+.\OP:Z^$]@C"=DGI
MWLC-76A/UF_0?RVW+DEGU)SD/+*@CK":"C:,3C2GRXY&5L3:-C1C+R;(P+I@
MJ0WJ%TL_*CW-B!72TBB6^V['XN9%/;(?\M;'P$;/;B+G8\: Y@B6G>,KD=F+
M*GCT'^-1('%0HD 4(=B:Z?,GPPJ?[(%J^DZ1@HW9 92L9X#4Q2#<,.WVL);A
M31I/P77$B/S&^)P!3\ZY_(/#=/O[,R'#W_L77?5N[^HJ>DFKHO5W-:0$KD\S
MREOFC:B9.N;0&WHTO0F)(N1=LB<W)0V8IU4%H6OA?;>;,%04E"Y&XQ:5 ?[^
MW_>U=173Y1U^5%PV_3C;B\QA=-9KSG2;X]$OJ>VW9V1RK+0;4$CP[2XE3O,F
M<IV]*E +?ZM.W4(=M];D71F;<1Y[P,!#WV0.<+$>:$'?F?<(>V02B,[:X+E^
M^%Y3X'#%) (\:ANAC[[3R2Q]C+$@H-/:,"L7 ,9<H>ODL),;)=5PI]4OZS^Y
M#*IF#C> O7WWZPXJ9TUSRJWF78;&2QYM/9-\QN;TVQX+R^YYC89SM\2N6 J?
M ;*OC&Y@J-\V:U?!-/UJ37R<N-?._#UL)F-K]##M\UOL$:-L8MG_LNTX<[[K
M&=!J\U;N;VXWG862?=IUG@%/E,^ 1RYXF>NH9T"\5=ONQM.3695'J#>-T=&$
MFD]>2#(>^E)W&W;Y]5YAVX2$?$A)*[W/$<;+).M$(B=$(%>:!\P\GT*03V.0
MN"%^B-UKV"8)T_GK"W!I@H/+DZ5N*\9[:8F,!/ 1/1@U<=.P#N%IG9N:''XN
ME;<IH:*UHNU(!.TI._L*=^010W&9*6F_57Q9Y6+#8?"60$CXW(Q$-Y;N%MVF
M]%SQ>"MJFKCR/C:6)'9Q9-.V*;HNSN^$L:EO:,C^B./3OHY'4('@0F]Q27U3
MN$%;K9#^65>M,P:<6/0C#NZGX9UC G/HA8/!JXVI2V^LX4BP @ONB_?P)AZ;
M<#U\6]O"02)/YSOWN6:9LWI"T\@NK8>Q1MI3B4)^?E13&I3>[_6I(WG0Y$>F
M\B&K"+M(]>.5XFB*1X;]-X:X\1<-KFN0SJXV=*<(YK'S2R$;(E-C,['&>9X-
M_=CSRC-F:\6T%-K;X@JZS!:#Z'2UR@:]#+;50W0/I3:%22O-C17R<-O2O*[,
M1"\<JUNH^O)IC(+PCS0S_7QD-:B/"Q.7 K+E,$&1^5F,_&1NDB'-UTGP!RX2
M^8W)=P,F:V]P''&_L==A8'2CWY*B7=&GE!9@H')M\EH$J.S%,("\8V'LBT96
M:)IPW$+KFP06?%IPZ',OR\K&Z%3023/J2+LT#]&BI;0/39[04-AG _M2;,(A
MNELVT3@Q*&=1R:E)HO8V"HDVRJV%WPFV4RK\W"Q!%+M3?DDT3>/+]LS@LE"X
MX<%I<X[SLN/Z\-)3EH8U*':OO^M7;B7I*<^A5J*I+412VT-HM!F*ALP)H:S6
MA['$\*&MX)2X1"XBKA5[P@>3TPO& "[]$M2<TG.*9(U3/3%Z?"O9)I>5Q4HV
M*P,]^QAK%=4TSX:1=R&)%-1]Q_U+N5?DHP?R+A43@=/*3V:#Z[GTQ,E#G'GP
M]B16J0D$PE\2<@,(^!,V ARV_#[?>>UQ/(0_M"4^#9Z[&^G$9>8=0-=6%#6Y
M*K.I0VGLN-O/1_ _G."G&$8V>N35A<4J9#&.\Y;3(]*%#0GD1\:'VK)D[6]N
M\!^6R:K$>'EP584NL^OUR'17V[Z?7=K["29/Z#Q Y[ J7>?0@.EBD>\4LM*;
MJY+<M#U97<P5D-$=TH]%JXC]0@IFI[![ZP05=9D6JIVF8&LX,"0/G4[\%KR9
M=E/^=5(552L_ACS?.*!68A[-6_PQ"LPP'SW+2%(<RE%6=".QKB"HD#.3T&"<
M+*=NC2OUH"D:\7"J4+>Y0E%:6'N]K,$GZRQ_%/A%F!5T%A&HZ>G&.-IK0Z+>
M'?HD]99-:<A/#Z)]RW:W3V)ONB,75Y+7.4#-()T"PXI*P1-8X[U@"=C1/K 3
M^)K<W?=FOJ_#3<<_]%M(*WG5:'PEI:'DU5[?SV> ^&&SVWR ,#.DZ:4NW0N<
MK[VGTG!X<CJ, U$,9Y^U43=F[9BNZ1.X*:KX:6TP<":>L&/CTAQ#O7NFUY>E
MJZ<I5*WG DN_JGPE)1<,,[A[J0!)2ZLE%WG[R?E5UQXVSK5Y2IING*_.N2?N
M>.0_?F?=M7>?EA*Q)8GT"4/W+]%OR\24&ES:V3Y!.2.HSD38*U.IT@K0B'X&
M$'Q1F/,XK-MS_G3'_93J=E ^Z%*#+M8E1$]6?=X\Q]HD3F]O[[=!P?C48-6J
M%:_ ++6\TG)+3W];FAUL8;'JX.HICR9XT8L))C$]7MZFAD#-;UV=)^?(S^SF
MJ@TTZ[1XX1X5CQ!4<X'7MU"7B#CGSSZ'EZ%./%%.=2AO)X5JZ\%U;S;V4I85
MEW(*NHM>/27HY[7QCQ69N@[G=Q\9TCEG"LN:M*WP/ /4FUD9!K*YP(LD(8J=
M#]-<Q@)UL9YSF^DK 5O/@'NOI8=D%TW$NH3#F=.!VFUK!G=Q +EGF@Z" T9&
M(ET]MZXH%'^?CS!"428L.*AAAN9H+5M2;O075\C&W:\,YL@[CG2&9X "8;_K
M7B!%7?YV[KE3W7W:QJ/9Q-Q,O&HX\[)/\\UO@EBU#['V+'KT@3T#78L.)Z6&
MV;?WMQ;V(B+0F(%T]!6!XH,X4.8X+VFS0B?11NERQYS+SM!M$OM57W+S+ )2
M4OU:GQO$KD[R>FW5,R%!(B4OM0V:^/DPS/UH:G4AF353NC53.$ ,IU<(HR>^
MG)5D!RPBJ/4,2$P??P84:3?@&MEE>K#,F3?S5J$GC->B!K#Z60O-VQJQ$K"U
M_I!'/R>M6=MJ[I,*5"7+@A( "]^B'XFD=&_O$SP#;$W*IUMP!-QXD[5BE-"Z
M'R+X^.51YZ@LSC4I_ 05UHZ\!>>Y*_+W,<$6&D18;EB1/4-6O)N:;>,:K\3'
MZHL5)@E^)X"%Q1:@2#H47*QAA0G3O8\%-,E9U,MA-__V_8Q&9YM-E7U[2B!L
MP\W=HOKD>V(?91D2-P0+"H-1/'-S\W./^GJZHG&W9\"PPY<FOJYNHRV?UIDF
MH)YC[8':[EP*547,-XA)?IP;<7*13TJ%IL'C.A7D38 JN<PW/FV=I2FX2M<F
M==NY;/?F&I;Q"BZY>'/RY**%4BHQD^;L.R*J) P.BBC_A='E5?<__V6E"O6'
MO64#=Y.34T\>GSX;O=V/NPAA/J)/?*K$,[0.6PW\"*>;:VO=R[H?2&*E:,-N
MW)L%.*JJZIB>%%>H84TU;-B&22%=(%K5S_VDGP\_T)HSO3=1V%P7/90_VCP\
M/&QSQF\9,\A9,;+C%J#P'AS-'(,CMJ%5E9DQ<=?8V&\W2"Q.1M[NN7%6!#FZ
M'8Y545'H$,+E_I_[@].V&#I\*-3<W (*=7GQ_=;2RXY);CDY9]V3W'%/M+)8
M\,H=PF-X8/Y0E+D-@NL LW=I9;/ZG<.L/\I/LMF92P^G!C2\?L>"8*B-T@P-
MO8Y]LB8I+7#4R'/[X=H0JFC5NW6'B1.<83F_*?^TVJ_/J /X3>!K3L?VR@*_
M/7XM-6#-[9\R0['7(=,\;^1 L&S3E/*@=W=6B20  @;%JFS9\"HQ0A:)0!4X
M,H>WEW(QY3P5M"H"[:9XFPG2:P$<*5;RU &$W2,R9E%)-"'O\"$<47WOX706
M@^>2TU?\O0P[O=+6YH<K)W25.H%]W5IKI ]9G5,@H9CU$?$A_\'RGSPH[Q)5
MWDT5PID8  2!"7W_S4$_RRXQ@X2&[A$QU_3=1S6^&.Q28'DD7V-0=-1?PA/]
MMW3&?SIFNXFKN#XI$'$WGNQ_8_<O?OU[0M.*D3O%.\3,2"38(QE!3Z+*GC M
M]AK<0JR1A0]EH*\QE_[F1Y2\-""&_1(R)\3E_X>[MPR*(UK;14D(1$@@!/?@
M$"RX0P+!+;A#L"'HH(-#"![<99#@#H'!!@8(P3TX S/X0)#!!Y>3_=W]W=K[
MW'.JOG/N/7_NJNJNM;JJU^I^NU<_SROK;7,.X9SBF'++.WFD/;%]G[8AU,U[
M5Z_VY2UQL@;O(]<0_R+KT7V@7YD 6FTYNNB0RXJLR>!L5E3>%G=LZ>C/=D7I
M<!TUKX="PH@(Q ^;H$Q7JO8ED#PB@MG+[SVH 4'S&[IK-*ZU--A%'<%LHNHF
MJ4I#EG@9I-,SYU+&,OK3=R1?L#XV%+\KA/\MJ36:>=F\:4&URJK!44CPS)*5
M;<E>7<=CXU4SYYJAS[I[VZ2J1 =?=<7&V(VQU2O<+X$3-)M4;5 "2?^T0@E:
M4N=\1_QT.U=B_U<HF+B0C!V?5VM(</IL+34KVN/]2ZJ^'R0OZ0:BA9/Y^7VN
M8>UW0:S#PR?C,R?FD_\#24;W:,PZ40<BXO=C) N#I$0L:)4NO0#.%#?W6+ O
MQ]%Y*TUYNJ@G"A1_J<Z'V O2PJ]#QFY!95PXAJ+GTFT[TM.F4U_W!&%P5D!Y
M8RL:?C./MH.EB?'9VK*XIC/C*$;E@ ?GD=!5* J>_5Q?CMX@=\?YMS!%)&@3
MY0+RLH)F3\Y 02#GO"<GN3^X;X['/D:V\1^:[?L)4R&Z.H5$=G]]8C]6E<["
M,/.P@+:J;W6XI&7]\L+=47G!H'=R,NR1Y0CW]O"QX\%">E @>2!M,RM7?V=B
M#T0X+YT6,_!]GQ7YZP'CR.>!T<4%@E ^UK\PH%U>%]-[M3?P1%=.B"Y!H<U\
MKIWB3C+I'@M42X!0^D>3_![+>*[>+.@>Z\4[F:_LL74(8+L,_JI43,(B@@[?
M&+]66MKNB'L4M;5OHLV,J.[ S&?S9@&V%.N$*^P5?82WXH(Q%8T!)>>=^HI'
M^ZSO/NRP4XV<*Y\%E\ZN?\?_$Z$-U9P6,[DDQ&]^_?1$L$3*O^<=([OB8I%5
MH$)N_C@(:PD!E&IL;/U]%7"7'Y'.<QSMX__RO!6<!/R^<[P3E/_*%?ME(BCW
M^WP[,/(>*\<#4-5W-"[567(B2 7?WLJC37#M?GDRWI:V%:=O@/BJO#DQ'Z>\
M>7-(%"P#[$^^YGN;GGQ]8?UX(W+L_SFCQ#F_S]/"%S.;6*D^HW4#8U]RF^/9
M]3-_381=A1WI&QG]KL.0:4[;3T&2,Y1?N3A%__G28 ZXNQT53_*]N!W_.5R"
MIHJQS?VI8,4<XK::B8+$NH%YY5D#_2MON%<'ZJ1EJ4-$KMU;?8'ZZY8C=OY+
M_)(QF9F_-KD10JO./BO6AU%#%!)Y&24O$[P#\VUJ&D'JLT#2B@F*MR-V+]ZG
M3L%?KW[KXT.D]OWDY?46=H"T&V.R,[,K3<-[W4"V;$AXSI?YV*'C2EVX7Z?]
MQS?SU7-=3_N'Y:\@ZMA1\<DN/A(/CGO[P8.V%#:P[ ^NN0H<\W3V7GG*#MDZ
MAM7T>;T[U-:P0+N^A:=+1"!;;ZZN88/BSQ1W?EH;'PVC;HHCZ08?P ?^7X+(
MOUGG:Y7+&I><CLZAG;9O[K![OK_5_ ^T)_[WZ%$%K42S;?,2'L=[K.:=@Y5S
M_=?<9__#_A^^$?_3\=J3%9[#?#$8I].G+_KOUOM_919F--![+)GC2#P^+TFO
MR-25X@:CI7LLW?F(KM^7T6[\)*U'V![;8'>J9M/6%7R#J*>(/?W-$(P*#B"K
M-]JX73Q9/XN#!)6$1X**\V8-'1+-SR*B8,ABQYG_JEA$*#)B&ODB-//2QDUJ
M-_=04=A*HPD\#;*,=VE O\-L@KSO/M<EMG23@B#2/_0R;T0@;S]HK!KS-O'*
M&FWP?GA47_!_&,49_#HJUXA$S_R4 ZDKRK_7F"_K'CW-OI8LEL;7U?G]3W U
MHVK-VPY<C*^[#.I3'2H<@@E[2D_>-M-9'=]CQ62F/ K[KX\,<\OG:(X(X$Y8
M-.2C- 9N][>T!>OD-F!V%2V*WY)FT]QCH6#SQ!]-<J$>#?/9:IE<#TYPVD2V
MC8>Q>TPT@HO657@TATI?109< PI'N< ;H>;MHNVM\NR=9H,0@NK=^2Q/[INV
MU(_&9=79>_5*P$&UCUKUBY3&9?H4*LYMCF 6.M/=&]KT7I.Q'8D.<9SP_MXU
MY"#*^;U\[.=+@&U:;TB<$"/KITBQ5E1"N$A/3*A9*[(Z@+&:L'2C,6+!$2?'
M/3&R* Q#JKO1O6VP0>:R6TP%V>1_R-1SQUJQ7J$L13';;,_O_FSO+ IQ.[D$
M^[G9+&TPF'"HM!1.F9!BP"G2!CY=.WIM(0^KFLR@Z78@0^$_=$A^$BUL:M%$
MA4-&*UQC')3>FU.(;[R#X[W* N1Q50S23M>!Q+?7EJE[_+F>,4(&, [I6VMT
M&K"CXXV"QII,\P3,91I=@3%BL_J"1O("'CNTVS8V8EOI@G!!O=FY^,Z=(3(-
MB%8(DAK28.O3=+E?/O]"L]:M\4B[$U(JL-Z4_;.;#F;AVS+^;&;"=@>4S.7%
M:!ORVN>&.V,1IU+K@3-.:* Y-]7XSEUG.O@:J0C@=_2XD904J8CO_U/T.*%#
MPP^<+KUU&R0X6K[-J>HX(K+P','O,QU\ [X[E,ZJH#R//1FNU]M0$.8."+B)
MG@H((#V&I/JG#7(E&9-LZ4\(4B_2P*$'#$N=AA[['4K2<AQ,6?%[U4FFZ?F4
M";/ JCO4V:>R)3,4,^9TG^<JA.:.77_G'LO!_'V#,ZUY0=]'H2"_1@/C\3AI
M&:[CP,GIZB-0K8EXTJ4Q[CW6/O.-F@KKUQH_=*K9K:^(4I!.\>T'QR[M'>'C
M._-AE+D999ZAH@18K12P54EB('IIL1NV'%]+$7W=<EN;ON,O'I#GHN5V2+,3
M?^P-POUT6U='W(>^FB38K2V2T)_:FO3<F#EQ"2V\Q]+JY[DJ*2QSD?J>[))#
MZK4]SJ9TI_TU_B#K;<FS/,. 2/9K6&<Z'O,!")3MX^OSI&@=06K)EG-7Z-EW
MS.]ZW"E[:V'"2M_HTVH":\!_1W>UT$.*'5_98WT<';0<0W,G?\Y9(TRQ?2GY
M9K@T\RPVZ;CD3EFH3/ANR-J]ZD]6FM0^0N52WV>.3NBIOTF%NY(_:LBS@81L
M]ENR='(SYST6*_4]%L\I3S$)*YDKO2M]X!.EG$CS'7%I_/&K&Y<.&/%=/68Q
M^28H_B:HF]%Q5*5UN5;G'HM[]\BT0W6?*Q--W^*+:[ QT=HO6=K'9TG9R$.=
M,7FVH&#GJK<PQN?""&",LT^28[PE)V*OV+M>[BK_XTU\SJ@Z,RV8.6\SLCV.
M1Y;V:9OTB(#LTR*%O9G!8!^5R,#@8(:\D#,QCJQF@/>; . )5V$X3'^NP5#A
M%%2:K.;J<+WD?G)D9)8GWS92[-SJ+D.895H4FQP*\UPSH\DV2ZZRF= QNCO-
MODL,G0S(99&IC]QO===_HL8#$3GG"8,O-]4L.L>\OE+1G,V][IM4"VG_*X,M
MAVON33XK1W$5UO U1[=I/\&\_#'1,6$BSBJ40VW_\P2U%Y%,27@OE:A_&X2.
ML:^D,5(PI%&\[U,LCNF-$V6D?RMD268)T":"N[=ON0CXZ/;MTMV-"9PZ3J0T
M115,8]X9AC[KT!S-A[U&8+J3OBH5GQD 9;LNTOJ_2/YPV7?I7^,TSU=#TY6N
MEB]^6[;EJ,N3DGOJ.U1N73K3,IOHY<]U]P<_)_'-D0B$X-0S/DVZ^"U)NH70
ME:BUI91_]N>:?9UQ+LE%EPH.M_F=N(#*9GRU)?2+&D]4,B:6O] Y+?SW[TX>
MO/ '0S4*S'3@I[Y]AL=>C,FEU0LH;^O5/]@<//OFWD*Q(WO[K3-71,(X54O2
M&H:5LH0@_LK4_#+(@T.S1V[D<!-6W^HTJ.%6L^%FB>YJO:L1;[@"9<OV"T%\
M*@H-B@?$P5JD#[,4=M)Z-C28P=I4E]EG5=1-+,(G[$RL7IZ5?C87U7*MW#E%
MVZ*IU@H&VD/-C*1_C(U_50]E%(NAF&X6)186 F#0LVPQ=5HQ[_Y@&BI\2GF0
MD*.G]]C0\8^#FJM<:JI0%)5]2F%[\F:AT[FZ4.FPV)5_P,)3 G6;!6$0?<5D
M<K.4:S>GNZK$/=9B.#_9597Z^,8NM2OKVMI@AR9AD/1U[4W[,*<[QJB7*G5Y
MM*120GU9-XZ/5GKLQU]0!^>P,[*>'%ZL[T;[--\%;>IK7,?Z-C#^0E@5%I-(
MF 81:060\8>7ELQ%T]R=:*8E2C;_R<Y%+F$4/LP$IH:Y7\_#/>:7:V9[F>^V
M3R\SP^:3'0]VJ])X%*RRPT?W$(W?0+0EI8JASJ8M[T9/!1U\1_;&?R9&8B?4
M8037!  )_2N\(GLL;UIT^];*N^13L$9[/'?[)B)XNCT559%: V;32:**ZAOJ
M!X9Y"M=DL<FZ^]:37]+TPCEPIQ4S.]Q5F.T/-Y[])?DU2JX-,MK [[A8QW:Q
M<1/1_+7>@K'=_E[]6?4QM/J$N^9%.I.[>MSJDJ))E2@._GJ^@\;>6TL/]^L9
MKIKS+S=T9BS<@&I6B@W[.:A<34V5?4"O_I#VP$EU'L>"YK&V<7>^[O(D;H^(
M/;)B$,]E<K51DD)EX>00:,GYCFOOM)E6,B)0H_P*'+R:,U- XA'P&B%\D]@(
M%R+;Y-P'!9,1_(R-\?1[.&9RB)0SO' 6RXMG7<U)F5L)5TCON0*B;]]T;J\N
MM=[Y!?I1+7_S\,G"_]Y!,L?S!VE\5]R\HB^L8W@HJ3QUZ0M+W4)=!>U8QVFD
MPF&MTA]N LRH4G^<*RQCJM2YYSIG7:=MMX;'^ZJ)LZ^YUZ]X$I$=A6U<7I0+
MTD342R8G)A&82S+@:=!&[3T6'/+1GZ,YBXREIW?W2D%]8<?VE>51G2!!>;9A
MV.56KEQF1T&F9!G;4C4MLLTPTSAH+$XB_0"5OD]_ *B\*]4L[QA+2S^Q]3??
M7V+;;_B@^[)!'L<K/X#GNO2L3OH@:RCI(N^RZB_"1%S1F!:VXVT'(:4;?>ZQ
M_&=UTGONL48C_B.M@08<?$-2%G01<H]U.DW"NB![IUMRCU48?WV9UK1/_\,&
M0M8UB&"<H]B,,8_#B>L0&([G]A]$WMSI:ZOG*[1XK3FPGAUEW^[&:)M4:GR3
MOI:M"JHUN<?R0]3YO[A[/!4TO7V/U?+UQE&=5]X-?-I/3AQN(GZ(Q?WA!D]4
M^CGB<&3_;M/6\YH;AARI+;-3T_#)*][>WIMIXNXD*)TY:@)L]0"_KQ?F=OZ^
M)1MH\'78RG[=-J89?YIEON!$JI+&%_1H>=\XZP1T-S%.?5:T?<0I,<OTQ_EQ
M3\Z0[+:M%XBV,# -=>%,E>XI8?I39)S,Q#EU7UK,;E18.X\@'1C*EVG88N=S
M1M[Q'+6^OM7.:8Z1<A%MEIV*]_HK-*X[5QO+/(4VHBF6PXV_$UI (__/R2PB
MT#)>UV"]<(E[^<DQ:AQG&,]E9?_VR5'],D]8HT KD-IH\@X$$C"ZB^=5O&&.
MR.RM,+TT'>WL)MWLW!6\QWI2;\_ [4/F7]$<M._>CWC1W%OG-B,P9K87/#.N
M9#*D'\ZW;8EJ_9K?S,UPT%\OU_UCO>_7?JC/@D+H8+)*4J7Q5SOOH-#/(C^(
M0\<WM>3&PVSR<O/94%M)0K1*RSXYF/;;8D7S,E=?L@<4?K=1^];NH")26V?I
M[R3:J/9;?Q^1RY6T@35.ZV;Q=VL5HUP^;KZE>-%'KU>+R8$+<3GYI"Y"@:U3
MJOA,CWJ8]M#=;>7B"[)P1I4C[:XK#\=4/>[F$@MK!PG^2G5V%8T9H69Z79MR
M<<;2G;<;O=/TM-:5Q_7KIIGDWC>PDZ.MB$[UW?-5V51K41_OJ8!"#RM=S9@.
M$CC;L4;'X(DCPC(^OEW<Q @H:OD=[RHLKM)@*C!(;$#C)"+(/4=K\]4Y!D^!
ML9.UVY-J\LXD",->A:Z$+Z (PG[,6C ,VET"VF(S,SN%?K.X6X5=G'U%OZ>0
M$$+UC<@^%8XF^A;)HW,9J)%\*<ZSF1<B"(-.!.*7FF9<=20F.X,KK!:@3K4<
ME.I09=?][,N K3/3;[UTGHP9$K8EUG:4X?*T<NX%0^CZ5Q6]#17UT!9CU?2B
MBCJ1JVM8K1?TUUB\E$G0%J83B('=%4#I/ D<"A'5G?$$F0TG.TA2DCI#)6;Z
MHV.#R5?44J;PT8T$U-=7I2 M &.;GF'TV,^3C\V%F,[T\UEED J:(QU^:X'_
MHU?[0J.4SH\NH3NU5CN>1WG$BDT[:3R"_WWOSFG5(]3S)4+9F=6D^B7<BZ(+
M!Y.2ZY+9G/0F[D*24:;RE/:1.,42Q)&C?>\PF;!^CHG8O"KMR))(T)]T(LOE
M1(?PU#*13_83;OZ)_?4.0R,.M9UA#GH'D/2$8XZX)0<>N<1!_5(S/]">K%[U
MYZ+<43!?*,ENUTOHL,")XGMJ3?F'"DSA,EB<&^HC8SM$XCI>NVBS*''R'')2
M+SJI%P*!W&\,=K9]]; 3"*'9X H5X)I/C+>OU]K;N/=I*!DV9>4N4 OZJ/5Z
M$?!N%I[8OX(+$&OE>#BE-87Q9S=3I$4\%IA$.;\SY3X[UC:BSZ!4GI@F?!+R
M'/>'O 2>"R*P[3(@"(5)33_"7L@=%.=M"2PV\:TMW9!3[[_6^7U>@X>Q 68M
M!#B$*%ABQHE>-X>_TECU4@*>A%]WV_ZY@WANDRJS?C8[C]U&8-<]7RA08P]-
MB0IY7(2]\OTP.M&B,14?-M/O&ICYZ)A01]BYKI30M<<%.9LTS-G$=.0(S\C>
MA#A;I=G%WF,I<(8K,/W]$K)3M'4.#ZW9[)M$JUI(.KML^$;DN5_G8>ZQTN?.
M#]&O+AQ6YP@O<GHR%K@,O0 V2U4#;:Q2U\71P5'J8WM@'>*;UOQ1RMV:,K]S
M0]VW2J-.Q#L+J+3RY53KDH+L]DM1I^.X ^N\@F^:EXR_\PR702M,Y/[M$WU_
M^? )%=7=HCA/"% 4I'>)JL3!Y&JOQU>-W/ '-M-5U<^QFU53OB#J)F"B!DN\
M^\L>DWWBCX]O/2-]W&)*4]< Y(C;-#IZP/K&5>PXM*,4JD8[N=2G=3B.K3(.
M,9W"Z)>A- BM]$,X.5N46TVG6EN&;FJE:=L+36=%=7;K]SP'>821<Q>V9N%!
MF6SK/IJA3:&+,:E1DLW7O(N!VY[&GH@+B*+"^%].L^05='K<C@T,2I_^RV'0
M[95P4_.:8[7(B2P'_O)Z[C5F8P)YAT"\9/'HA0R<RJG8>468L?M[HB=040A_
MFUJS+5 AVET02];+!=*2@Z.EGB1AJA^A9?_@\7E,K?+ *@?=$!>M\K5_.&^R
M^)NC7XC'E3MH+NF'UZL=8R@Z'EHN+ZT!2%I&XQ7L9GR2,[$!S<C*C);CSUI&
MLZ%Q()AZX_?2R6GW6 RPHUF?%U\4DAA6_&'0>ZSAG5N;U#;3@H(O1@JXM@#+
MA(MMUO5T+Z_S.XA[MWNW#^<F^A(N:P]*UUD[VWT_FCTM%D]EPF<TKKU5_W8,
M4[44?8*?G2]+IT$34W.D#PSC'L)4&\5P3Y3O'BL*,T13\*B2+ZC2%;ZVY99
MPF"9+2>HNT*W_3;S/=&]+EJ**> <9L_1N#%'X_.J_,?876Q5334QE/6KL,M9
M476XK.>I[U&*+2:MM]>,90>D;3FYD^4EZF:,&LZ4-_<12M=_<9:V6"P%AISV
MH@'06;AE-SJ-0SQ]6E-/O#>^2[E[E)PY'(_4*39JM9B:<-#RI<^6"!R5)M(:
M4_32_]?OG"6:FN'BO<^4)WU+SA39)3F%PHKI-%Q<XK^0<@>V;Q-R8,B9Z.L"
M/ZI<./IBZR35B,:V)OQYC<Z+,%3OFF',888MBRTH26SR"GUHZ4HUBPK.#O^A
MZ#96V=E0^@5&V.NOG5ZF7[R^-O-L/<KKSPXO;\780 E(W'UC-6ZCIFY4>W-&
MY+)QPK1^R<V-A?;5H3FIKS/_M(U[AV?Y$-ZP>LMPU6N4V):M6!QBUZ-@F7MI
M?__[//<!S26;:GV;ATYQ#/7R-(84FY$XCFN3-]+L6[>B^??85?J[+#U3;2:Q
M*6?W6L(;Z4((YD(JC<.@38Z.B?'URY<XK3VJCJ^PQXT4K"Q85U*GYAXAN.JF
MKB"TWM4*D849WP,#<>8?FC^_Q[KXH7BC8@98;4G#CI,_YW7=*,\CO\:UX_LV
MN!IK_G$"0VF<(ZU8MV$%+4)H-16KFPED-UW],0QB0'_(/)V5S#LRT<T".,MS
MJ]()2)Q550^"%CSE*^W];B_:1 ,X'+\&C@>@*?:,N^(1E.8" IF_A$?7+:NU
M>9_X\ ]:9C3Z4N"G7;%&3S.#;%F/BH/LW80JO066&GO[,Z9$C>#*"MU4OTSY
M9Q,7\QZBK"QRB]:W1K3['MV($C!VPSC/P/MYC3+B%+&-=5+R6$> 9%5KVYA:
M>6K,A7?TL8"LHY6SD5CS\.R(85B-4<Z\.E?3N:LG +DU=$:+W,-UCHG0VW@E
MKPEMT/(_BU./6>N24'M][;G7=\LR(CO!R-M@5^A]V]]!9:M=='2&+U];-%JF
M6<[.44_CT)Z1E:Q9^]$U[CA7R",_K3E>LH$KI=%?FE D))R//J*'V#@S<IF3
MCSH%[6JZ):^ON+'7.E057F/<J^SIH;ZE6+A83P=$2[?DXS)R8WY0]@<3A"C+
M4!JZ?;Z*\^><(A1/UZ;3$_*)VY-!]('6K3*+Z',\@%\OEE76:*1BM15&*H6?
M8?;AQN?Y NF"PGIG]>!=) =[$V^VKW.371M7OL-%5IH WX^:L-/Q P68==NO
M <EBT\3EI=#)I#]G\)*; H:%D9__TW#Z")W]@YR]A2M^#SJ=C\&%7;L[!RED
M6-MQ'=\KIW#M(4?#_/.VY2D/;9TAT,^/*"JA)#TIOEZY9_9W=F"5G&)U C+I
MTLQ&H5S73[OB&3_YFN6RP;G9<6]K= A?D6*2*]D]O3D?X= FBMYI;-QC-2VS
MTG'\T^#(=(_5*MN0?B*-A'ER--%RDK8\\>A0BFS]A'<R_^JG:2(48!7R6N.#
M-0@41UV<QV+EAE=6[?Q<'2&2',4/B<)K>YGL4X?7C-_#TQT-.1Y#5*Z=X:"9
MJ,H;%[RT!]\.IL>]ZK9_"V2(D(XF7VW=E.A404166J\!6=Z<YPN]M-S^Q/__
MR<+P_TJ51-!O[5J9M 5I3/Y,&[KB0<P<4L6@>F0PJJ@F!-KU:(.TC/RV8D0-
M%[EN6DWMXG)]EEH(R,]?0#=.7\'B6#JUHJ:[>CG$PV(P9[XM&9&/(T1^3<1&
M=46*5;[G%_AR0_01-#-8I<(5_6I0\N]FV7.<G V9SQ@R+$U9'D%E:8LR"9\P
MLK*>>#Q>^:<+K8N(7[PSF=_M $/QX URO!UL;.;<:]*X@Q8B>"^'6]2VAI?"
M9P.SC=?0#;+IW?!+5$MZP$W13<)X,JZ8.C9M>_[QS(&K=<'D0WHEB?]=[?8,
M14*"8?$7X ?I1Q.)X!'E&O9*X@FZYA=0M+R9Y7Y1U_\M!])_71\TZUOU[.#=
M10AB_(?+'4G_=[:!_S1(-Y^[QO<4QS<'O+^>PB]1D@7^6_-_]0D$:BMC,0%D
ML!YN M1_/61 ?OB@\3,R$M*6W,;/+\T].M1-.QO0WG1N6WZ/=2:7A!G9FR!<
M/^W@*)D%+)YB'HR2=X;%E)DT;R)B4E=9-ARN>F ?=-70P4OZ+>!6O;I9=%/.
MY"LZ0CM'B:1^G$BYY<+5MK%U*QYV80(FA16KC Q_L8>R:^1$<PL''5:RGRT;
MPR8TP]NFZR[J2+Y!8GS-J43$(TCK71.5$E,T[K$:CS2'G^+110?6O7V>FH<F
M6SAW:=8Z,I[U#9_9Z>88U, S_F; Z>>^AZ-J$YBAN [D,6[>U2\Z'[;7X.;-
M!\<SH_Z[6R>;_VFW>VGL^KM7$YK<SG/ZQN *@FQDG7N&*4S2!UR:EX8#A4$
M3X9K421-!R5T/<V4GS2Y7VGRK]IFW_;[HS#9ZG!WSZQ?9DT3F24I1*;HE?ND
M$,7\U;M8G-5!\"@RLZ/M\*^VW2CY\\H-]YL3L,;=4-0P<Z.XI&*J1]?=UG:;
M(Y/<;;8H;#&1Y1MELE\VR^-C+6!C **-HQ#&V//Y.>>LY0D5]'NZM'NN"&IK
M9-AS<7P!@$OX*O"=0CC@8:)?0$-KI9[*BEV 8.ZT%N];NI_S8#CY&NOZD,].
M%Q,)>!3*\4J>:]AM#[(%],MK7I3ZJ667)>;+>#Y<=D+R1L2]G\:SK$EYW>_R
MS(&,VD6U=Z]]RFXJ'*;99<;V_>OKSVOAY'UL!0^<'S'&D+_#,AX,E<L$#V:F
MUW^I<EZZDKZ$2H@* M;6V6\?1VNK6Z"MI6K-PY*&-.( JS?!X\2W9N<6Z\4G
M"A_.R="X$G+'YXV [PG>6_U#W7&A-WFY976-GQ*A@32MC@34KEO#Y?D?<!]_
M7MIS"N\Z;5>#_#2B7YV' (,T.[4#HV-N1Q+P3K9^XN%)TS",,(RFM#H !,))
M>:,)BSWV^=YN;S\C-_'4I(T3$_G,\9B&VD_"KT.=#," ??*-_L&G!R\)CRU(
M+4B!92,C(\L-PZ?_W?O_8'4QC_6<FRI[,4<R&3N>^6OWQD-YT-NVF.+/:GFC
M\UE_]^DG)Y?Z_!]PR7>Y]V\3QGEOZ)O$5-4U"L$4\8XTR8$&4 X#V7ZX&ZIE
MU\>WU8?6UQ1^)&ODQ>B8IA1[U-C(DL.WE5]W>2W\*3XW[PHV95TL)1(H6G?%
MNN-U#$B??J>W97XE_0E-OVTZD$ #SMC9X7RIWG=S^]2\S[CJ$!*D/K^+?\/O
MX0,5PM\G<&NZL"#?*%51V_$.2=K"SG9-[=\ ZHUJ=0]MWJF^)_OVZ^;0FFOZ
MG.T#;CMR;&^JQ8BGATNWH)$;GSPO!.I.!%Q9#2H_+.(=CO.Z]*92O_&/+NSI
MZ0B#WV,9_MU^-REQFB.Y>\':50OF65R/2[E'.<A,!^HF/@YXDG7(=\;;-RV8
MWVVO>QZA9GX]#/Y3[==ZVPUV3_*QG12+U[*S&ZY>+W56O@IY17 0]Y9*<VXX
MQ'TO<32MZ5;"A4;UUM4)UCZT.%QRH_1#MTYL,T&\4\3XT.I8E@HO>9"%7Y"+
M7DIDF[P,V6XI<_R$+N617,$6Y;EC(TMJ\XX8^$'&U-E5-N7S/K%9B9&(/^$\
MAM]X4_M/S0CIZ-ZL_/E7%]W>:.F2DWZ^6SYXDN(F+6\P)$(WQN..?/[)<)E%
MF\&"<OKNR;BNPP\-D]!(93Y+4"#D TZ.../YQCJP794%O=Y/Y-@2Z1E(^U#B
M0\3,SUQCTG[F*B###4F669MQ=7;1UVSN#:+K8HRZL+!,C3Y!8*XV!8@EJ_B*
ME*%9:T1]'^DR_C0;,**Z=LNTS\2-TX4'<8@SE(:G-[%T+$C$U_Q!=,]5"G1+
MR6)[JR]ALZERXI^[HCDEE#4A\F?;HWJ[3_JZK8W> A[>L15TU\7[;GY%LI2'
M#ZO0QLW61\;_A%/DK>QEPUR (</D_69=HB[K\4V8>G7FD;=&3TI2F,53'J?\
M[X,O:=MHA]2Y\![*_*=WJJ^N7,T),+Y]]%I4_Y"6^<'7R/^0;I%^J_YV]*(T
M^JKM0G)F2"SEOY@72?/?DQI!QP/(>O"+KOF+.BEXAS(&_MW!BI?K%+>Y)0 *
M(BMO0%W60;/ERM!3C4^)_/YJLQ)?76PM<HLSKBH7JUEY#6J9$L BX!K<2+R-
M,T9T=,A2 (WY1ZN%-X99<<08;IP2.Y:>C7F*P:Z\*.M^$UK;?N/7@"SN%K6%
M40?>_HR=X/;$-IV=%]]G!1K5GX_9W\2:[--L_*G.[J& C"L[^[S,$KZ9D!FG
M\73Z0M?X5(VX.1O.M?73&3^C9P?)[U1CZ8;YZIUS0;$SVBWXC<S2EK76-P6I
MBWZW?_LJV".Q;\7ZL</_;Q:BM6H'^LG^04-^CI9A2MQ*R*CHZ GB O2.2;UW
M*+V'WL_8TKO H9\Y%.B?>*KQ1#QR4Y1\L-C<7)(R7\T'-QF^8<X;]/ZQ7<UK
MI(D'=^"-;Y;HN34KCBK99_9[_6F-YKT95A;B]T\//S3)0K*1\U(A6'O7)-^L
MZ593LQA/@KQ*4)@[OS"JJ,?"Z,'Q$1-#TDPA:1KB9!C-1M1'1UTG8D] 1OEV
M9&:+>%TV2/M;47)LIC.7BA?9Z+/7TULTQ>SZ3V6TIKW3O^UVJ;=.0IAK$H,L
M&^:4#)O-L[["&V=:2L I9@B:8[%F=_JV$@\3H5/UV!_:^A !/60C]_<"4\T+
M??3L)VHU<<VVJS%^.H%2-L+9QD2( :K&E2@FY(_,VRO8$X*90/\,8U104#KX
MUO/@3P"..SN72YRH2!WG1_TXMB$5H9*,/A&+ZB?1*1'L":'^_-#,R"_)K:.!
M4Z9AC4NCEJ<EI=.ZZ_%$%3Y?"D*'[!K.C N45GILBC^19R&'>)7<6&/B>)/$
M4Q C.PU)NN./_$6F;VS7+K>S:E\:ANB23PVT"1FD64_H385:E*QJFY3UE+ZY
M$'>J(6HJ9K-:%MXR@K(:-]X".011RT_@8&=FDSEE]DL!N5%YDB'7Z#"_P:;*
MKT['8UIF>T6>>0"U^(#>V9:<EZ(W>EGM63Z_4D<6#>PA\'#6C,^R*]B8#<XO
MBM.52DPO )_L5SG4.-^!>!;NU@)(XLF+9HPZ/]JS]T<D4=O89_D&^[0E_!!%
M 7U\\,@W&%%0GA?9+<]^(GQ\JE/Z-;B,&S;#9XQU8]?K]) ^N)\YW[^^UAPD
M_LXG;WD3%2T&M069.XL()W^(1#&'2WH6KU?&SZ2^#^<QYGOXS.?J!_^U(!_Z
M4>EK;&]/H(+]CR/R#Z@);OZ[K5+<PUPAH4!N%KUF$V*'D4[]SO%4+V4S5*="
M7[@0W<2>G_ZP&,MN'J=I\HFOC3_MZ*2GG:$\2(#6PZ38Q%9< BK/[CY;L?4Q
M9162UTXA*@MJVO [=F)%NM?-)Q#2$!HS?+II@/I=2@1+IU.3J[A^%[KT%C&%
MGG,?]IP)+RAS<AD[-KQ\*8S-OLU)? +Q^-'FVW-JG7,).-E40"&B+AE8_9/D
MJE>]_;Y;R<G2?9BT^V;L9)83A9^'GU(RMV9(Z>VE40OD>?R*"H3J*Y9>RH=.
MIYP]?C^'^ZTC:O*M_-C^1'?)X02VJ#33W@-%N9SET1O8\NBTX_EWT-,^>R2L
M/?.W-V<@G9&=@@2*_N?OZNB\CQ]##>M;'%AEQ+8L[=BB%GHOEG@HGOV>I7LF
M[JY,]! F!C^-Y<<F8*5BH'3.L9VH#DNL0' ZL"?%*^F_01G',Z="]9G2YY-5
MK';+#\]HS21;9C7UF1N'FM9-B M;X<H$Z44%9ZY!Q.UBE/NG=^7-]J5U (OL
MQVGNK(PH\&B,C:47RU4XHADL[E84U$9%];T96]>Z:=>M$N[8H8P]\/D&I1JU
M_LR!Y$&[WP-.WK>S:3VIEP/K P4,"0[FH<CXF7!SA7:O>H43%D1M%B>7.;;\
M/DDE5(R>B&BNUYXLL6J+]P5JRHQ]XX>AJ@T %..@Y-S(2WDQ]^W)>C)[0L]2
MO[T$SJ KW%&W]9+3YNI6BDL<PV3W/>/#?*%4%$[V6H(Z>_ 0^[MU_H?0JP/(
M>03,+E\\_:E+OY03]2DJ\.L48W)\(MF98VN5KM>,*9GIA+;_H(;SCG)<P%.7
M.]A1XW/?^KI41'W-SKHUZ],:6*ZE/PS3*):[7>[4"8C6W97:5!/GI[!#VV7T
M@B]C?!P].7N>WYS\YM$SD5CA1A!HJO#B'?M3^>$1>BY[E* LYS=Z%G[NB 3G
MS#L8I=,X9N9< /4[R7]-2B>?QO["/;Y<OVQ3B["LF?9&KBSN"=473'0[:_H'
M!M%1B-^0E=DI$%F7M8D2"IAJ]3N#P=!!F1G#G.4>U'&[6U!L0)0WY74]+WIB
M?])MI]YCD4N:GZ74-,&_UMXY5YX!7A,GX,1TOMMJDS=X&!2.>98?0'Y2("S#
M'];2O$B\SCQ*6MFXJ/SG^DWR:4"K5H1G&Z^]ZM,4WS8YE"L2?VV.VW(3H[\^
M>FO,@T4C:MA^L'.V 3C> 0H9-*?"6_*2^^$NET9/+]\&E77Q^UGUW]8EY_%\
M]M:_AAB)%HJ4Q#!_DW<5V7@@,F*^Q/)HC&G\& *IKXSW3[>]"5^VEY!?M_,]
MDBUJY&WB_VA54$NEU6O_%^"KR]:QR*IQW6HCQU<&",.N^$3C37_;!B^?2WC"
M8FH+78)(K,0=M;T7@E[V>6-,V5BE"_N%*:NR4L_>*^ELA<6;["F_:JVQGG$]
M,H<[//Z3#GC?ST>"9C_1W0#,X2-V66EJA9.1FS&[,4)+ZN(L,C9H?OO$4\,O
MZU<1_;QD>3 FVO>7=^EI+$&LI(%D&!SIZIO.<].I>$0%J4/T4MAZG/S*8,0L
MO>TZPG+D&$]Z8._1R-(Y #5W;J4P :4R[)F/[%T>>*B71A;$2H]MR_ 0  K\
MB@*G :U-<RIYODF1N-8^-*MK60QW/]45EZCP%,1)+4!I5*K0:?>F7KAE%Q[X
MJ##H]0(W^YJR]<5:EKLX;[P-$XO5#:?[P6#:GOST%QU[0LJP\ Z\H;K3CS5]
M$S,?=:^&=[LU=H-X4,>U/RX@D5?,C[&!WFW^L1L(_[CQ8W%IO&U9[5VV,1^[
MHNED->>BW.U2>$E;;:8NAAH^(SIG;8-'STKQRZ[/)<5L,F;MS#4I@-).$%[X
MN]P@-+0+H=2R$C&X&(&"+>Y($_2WY26Z9T&C3'RM 5X YQ<PZ/I.\X#YIM?6
M,&(8U:49X,U^G<9]G;R?KA%_XR$M2=9#C7R# @AV;/[5-^(!Q_V-P!EEJNJ\
M7P,B!NW,$+NK*93D3>?N]5]-I,Y8H3D$A &Z*S@C7HP/=$E\'ULVA&<N[D#J
MAVY*'I5$PO#3?G2?=)2Z/EP?_XX,0V;>CI@0A1S>B$"B#]5*?C>,BX-&SQBR
M;>/T^P9&I/ R\+PA\=Q3H?4/LA6H4MU/SHI<0<ZI]UCN?OVFPL''+7/2VH:D
MGY %EJ:GCB(<Q\#1GV.Q!HWR'9_[,@Q?:-!S5D5IQY)1Z*%/;$S=_^A_D0@H
M=962<A;B7(_/WJDP)-<;]4EMW2S<TA]J;J-IR]+K8^\S0R6&%N.P8^_+S-QC
MX1QT*)#:](A%RVQN1[KWF^X%JCQ-K?'WBUHO-F9!2FGTQ*G>8-<9'^FPUJ51
M496>S[T'<,A,HY)YI 3&&%Y'%@RO.Z^//"/SBC2XM<A$/%(;[/]ZQ<+A6]])
MN16S($UC3N.N4,I/6VXU):]&,3-CBK'1*]KH*-C=J>]\H\MF2$64-JK\TJ[7
MD['+B\V.@-))V1LNI'>V[%3\;#-KV1;BEHQ>=A_Z&G>/E<VAU-BJPMCMKF"N
M%1Q=9!)6:^%N A&_=IK&&*?1,:RVMO\J-953\$^+BA:NGS5R<XVFJFCH>-=J
M&CKX[<C*5PZA$E<;ZNUE2V:QP\+#G81Q*25>_YP5SET-9N\FTLBN=[,QH4F.
M)9D3=@ASW15U<W<B:3HHV86V'(V:7$D5T]UM>W3FDTFO#FEO25.E\3&Z<J>_
M(N6F*T880DD#1=P KCL +Q *ZDP#A9E["?FM<D4N^'&;6HM182O+NKFY@:E4
M>:<(19](:ZI\1&1F]D8A0V,,8RK:;-4GP1IA#)5/=0E=/_M2%;>'G]A>_;T^
M?_G #G_DI9[S?MV3]?G8%T9\PL_,!3S"8B('&*LK^>NZJ#*%F;I,"RS.#R4(
MN/=V#X?/FB9A<@4CSP1@HSS"ZF.M5U8!C=:ZR:5RRI%(#HZ/'C:BAK+-9$D+
MJR,W594IUM,D*^I9AY#Z,A#[Y7Q2NQ,933:PTAL##( MQ1<Z>-4S41"2$C?@
M$IRGZCQM(@#)RWM93!A&@2/6MU)7,)%YF"S%+F2'GBTP50N/Z!Y+B&[W\16-
M&1DL[&+>=/'ZP_C=<:*VAH(3\["1F]\'M1<16$G55LZT[];3CW)NUMBIKEY>
M+RZS/K]YD7*8WH-^'-8@$5,=I-T_Q7N,R?:GMMM0-C=.3M1]^RW&@D(EZ6DE
M'[>KSKHVF=-)3>.(+O"S*IX;W^F?J<>B\NG627"G)\8LRZ:=S,B.*"%#XW\+
M\,@W;\F")>S=&;&_*TR2],S!?FAK^8IRO@\$"DKM'$-(SVE_+# G<HRY"-%+
MH4RQR;0N9&MD&^*#]VDF_9E2$YB3;ZT)O?W9N1(@?*N5=UW&Z8GVR\"\J$ X
M!!X\_O 76&AKQ [/UH&VJ"O!1)6G?@-NU2H6YWK]G-P+_#SDQ^HT"A)26-A$
M/A@*Q5^<2^<@8*H#3%(C,R_$_%)UY'.0\A^%:]7]4EL6H0_W6%K1-K>4&_=8
M/PH!W_!C+/RS/W#=6=R9FQKF35ST_OB#'(#M(>9G4W;X80'<[S6PE0$@\/)K
MSZ7$+"F1F)[E=':E\ 8Q%U_>I" D*?" X^/Y,TL85\DT:<OZ7..8:N;5Y0[&
M,9"O[5KZ^WIA'-V?]IW#ZW?(X6XOA9L2=29IFFJ]H&OAQ17M3FR.K36)S/.-
ML(.@RT:"&^O5 H;OO9/L%$LY.?[Q=K$]M#[1E%?:9$^#X-'RV]?:PK\)--2&
MFT(B=MVV=ZS^N+Y<H_GZ8_GI6?A"5@S25"R[]@AUC[7I**_-/TYW)D6P<X5P
M/[#I%;>VN7NUW#X/G9E>%KJT+S ;S_:>BJ>@HV'@ZH]0I<B+JZ'(CHP=6*;W
M*WHK_024."E$T]J!VV>/J!0_VL-L(\+)RF']XS']&M1$AQI[ATC9"96FGA4H
M]U@NU=_ALHW,W]R>>=WX$KO7Z%,KS 0FJ]UC"6^WM7<^X4JT&4,L<L(1V/9O
M7-V3IB94_C+70:,><<^%F)83KQ+TKFLRYJW<KFS_*\P+Q7,O62$Z:5"5Q921
MC$.J".WCF;UC4X:ES<_%=A:KX/B<2V%J/ICZEC,IMO)*O2%:,[$\NNMC-5,S
M&BE$+D]&1A85\94=!<Y[1CGQ*-D@(9RMD)^7Y*/:U;2O@^&,I&[AK_G5UZ,;
MKAC+SB==OL^8/]WJ./YZI3P!@<@R,6@1A^!D&)EE^FL"-PD6K8+?GJIS3UZD
MXP_9^ZNI3'E6B0QRT(*X_+9;"\LESP9*H"N&DH5T?*T+6TW;C0^"/(2[E=F]
M;Y0B4'V[28:G<K7\N65E"NR]SM/<^6Z&+"G^(\K+AHM"%E03)^=!/"<\J]O<
M )U[K/1CFTL2GJI[K.'KH<:JVLPA1?L[<,<RXXMF8:S3@XL""5E'__<@X-_S
M2^CF3B@DEP*<E_S%=K8#EI<-P:T+-FA+EH3'F79'UE*57]RFXB]8^0 G&U^,
M=ZOX$N^QCHPWH]*WM/*6XJ$\PTZ=(:8!(%N3@,R6>ZS3<SS+-M;Q]!*U[4QN
M#1\ES2<JE',[ET>V.C;"9^B:I>H2WVZJY!_-[?=8)S:)Q@'!Y%9'&\#7SJ5>
MSJ+'Q\"#P^6JUF0EBZ6>M7T$)  X>RD"E*X\]FLQQ$MAJ#6CU"T4=537[*7F
MQ<N&:/ ^=^DF%\X<I$_H>[AD_6%DR>&*[&XK*#CO2O17_9KJE8^@.FNL(<E)
M=6E\09?H)SUH.O2T7]368.VL/G/U!%/LQ'@4E\_>^L/>:6PSI6F_<"IH]?;S
MIK@3O,W%RX^7&^_=]K5/5+XWF#GA9C>L6\YBQ#*=*Q5<4BU-4IBZ.[>;A,X/
M=ZO4 WVUC0MH8_.5HI1]O&+C92[D.\[X4^E$/,J!/$=4!QSA[8B@Z" 9Z>2\
M&>*)K.V2 *KKQU91?S]W VF]*%Q\SOT*P1M7//1EJ]%Q(MV8U.U&,R6E3X'0
M/8+(]'O?!W]^94Q<]Q-O)%>NRONC.0*UM3%6WQ)'J;S8DKE3&E;:K=$(-1=P
MZB5OOA.>TW";SY 7^ZTJ[RY*O1I9?GB/U:UJ*HU'LS&WN2$B#Y()&IQCY[JD
M%F-OX4J!C=F,@)4\1/ 13F:9$Q<#;UNU-58;EEC:7/'%G\:6QY117R;"B-<B
M\;6YU0W5OAE:NR7),C*P;N,O2);5@:6;,]OM@KK29CXOQ#VFX<S!29\FPWW?
MM[X."(38ODZ::8I/CJ;30T9L/U'MY]#E%5\0-T[;V;?8CI$XX(Y=W-5S;8C$
MR^!KC0B/$$P#V()$=I7Y+-GHP,2":(/8&W$85^4OYX=&8Z7R#-6RCRGD]XI-
M=.@I.>SD(]GV"O;39N04;,G=QSCLX?6NR\3ZA79-2U KJ^A*RJ=,T 4_E?1F
M+M<EC9+%LOY2/L:X&@W&C %K#'?@!I2ZPPB5G:N%B?!*0^ZZ$4\-F%SB282B
MJ=_WN/1T/9?A[6.8Y$7:PEDOJ_<-4"<DN4Y4WTN+,X:??]?0YTCW439A(40N
M=F?Q94'-![H&X\MGG\V^+QB0GU1H[M*O%SI:\,/34X&:% ^U[ 6(&,)4O/:'
M2'9_T6G7:!/N!%D_3N;&R5DXEHR\YII8H&GKVGYV1PQ_'0K<48U1W8-+RKF)
MC+-:F[1WZL7)VZ>\NRW[,U>#,UB7: RD;%D3XTZJX[6N'!D-Z2]XN\ =XUU,
M5?--!8D*T=5NYI[*2A$^+OK6NW+P=-QPAG/&;2I7DNA$\JYBL+G]H]/Y9A+(
M<-F[/\F4):9IU>>##GFK!:$KEU>-JY$M7LHTQ7"BU1&YO1"?*!4D^;GGCFY,
M<9K,I>F5PI<'&QO"+W'=6&ROYTQ*V7X1NJ5DQ5@1(XK9)5,LT_46[9A:FR?H
M#)7D1(62E)H6X4RM3<L%*FUOMV#B3;G2-AXDL)\II)YZ%E66IP 6+5HGU!#I
MYLV1SX#W"(<*#2(D$J)RF1L1_:@Y/\4NK\@+3PA43Q&S*;]DY-_8)LJ9/0=@
M9X7X;A1+@M\!#E8'.<,_K$C(]F/]XF18ATM67VO8G/>[U-HOH@7]F67 =$5U
M?&U!@V+^K(PAO:1>N ,;(GA0V<<LF*^4ZTP)NL%S.(NQ-6.[MYIAOUO56\;3
M1N#VA\0Y:D9%KZ688;%3N QQJ>2/]@R%;+F_?.[*E7W@%Q^RA^G.]&?-*3H*
M!$>46]E[B#<:G;QRZ8]U2:D\YHF.;6FVD!L:L%DW-,68C]OH%9,[*=WHK7-X
MHN7;A7&4AQSJ9,IZG;>$IOU'LZY!*LBO^_GU<*7AP.M?@!7H<]"V 0-^AU46
M!3Z[11:KK>53AM=I>"_SE(+[WG.R_/PD8_JHA*>NTW=BU8U\] 5,N,?U?.-;
M7"8"7/]#81<@\_(3IJJ(D<2!C_](5CL[V&CWJ5P:Y=FZWSDD1/O<]G/7 LPL
MN$N61K4DNUK@(E:6TY(4O>G(KY0(266#+]E?1O6?J')OSBC\]$7X5EGJ5B,E
MZT3&!8LP7 ^_?6:JBQF<2$\4 <1D4W]IWY-1Y9_Y02LO17Q$^ "O\R2D[TJH
M;@5(/LXA,S T+<*C,U1G6=6>75]'+[0>72;SC$2_8FWZ<F>@0K!R=^GC\70]
M6^EPF=W",C9@?4/;OCXF0S:3:XG[0R$QNJ=#$E3?M)SJ 0*'G' $#4W7W#SJ
M&=G[6\;^4<8WQ\80$$@S6-P_^DJ78K_O0&,0#2@HK:?J3>8P4HUQ^-/NGIB^
MU:+(&33:@AA-.@$_98^:J?;58J\CC:HPD/[ZBS_?601%1/J:A9[%\A69[:M7
MS@9ABX/_^ /%?^P]3KH/7GKL,TV53WOLZNPVO4S9!2Y7:']+BDE76YLST+ N
M:MZFD'>)K5L)%.F>^S&KQ^&:;12N+K!PXEJ]Z/44?59PU8K^AJKG\&Q(*:1#
M$Y(>.EO\SQP>Q X'7'MS-R/-5M)QY7C=P>.*OF"-MWVKSW7<DD>98_P)NO'Z
M8P8$*UR?7/;K./"Z:4P;X-;@+&O JQO#X4(UQ>8]HTX;:7QQG\:.:;.;WH8'
M,EA<L>V^\,U4<'.V>$;T,N'!R*0VYI_Y>D5,^W.* VT%4;<= ^H3:Y@>'"N*
M->4N8K%T$A/4DQZ->:(AJX<]-*HR6O!B&<CS>A6B1[0U2H6>X;(:-D<^"-4#
M8_;P3FW6^!SHY4RK=ECD4WC+SN.W%@G2\O@R=^I?YN?'HHNOQ8&2+WY-4-H:
MKK>0\U]DI5N'E$=NF[+-\Q$S@XY]/IOBD3"YGJGFNS]F&U"ZSO\_'LOQCZJI
M:3NX-O;W@LK'G1OH#ZO3NS>SR@"OE1(VJR#]2BHWI#:B_N-TS0NTDL1$'^>&
MZL"S&:_ML^0+6]U5T!R=;45<<BR$8F M\9LH_Z78K^E/V89(F*HSBW8"SH7K
MA9EZ29!%'XX^/\+)+V'&*$2XO'X2!I>XTSHS.VH[N2S A&3_E!R9D.G[_>OA
M+]Y><OF'KQFXNO]Y989UR&UXS[FT9\,L[F>3PP9'?\FRT9Y<H>XU14XE R0L
MHQZ45?-6% 1R4.#GC7G$$[JS:#H0D)6GZG2+]$H,*>2JV7NJN4MF%:*ZKKA6
M,#H./2931JV!CL7N\L<;J>H?.A9$OON ]0$+)Q3+,/2#7 LAH3/Y!\/,?Q1P
M^+'YORR(Y/S7V(XJC ')4O#18VC>I]4;COAWFHG_Z9\&[J_31:G0.5^%G)?0
MJ":%+_U;\W_!<<2I@K9=E/VPMTFVRJ7I43Q@&*?0O;W#0PV-Z<G?.YW[$B/S
M[+OSJ.5MTK>J%^.-3,B7&13\91AN<0+Y60TNWUQ^*F6B.K?;Z[?3I7I/%LM0
M=9;N3PIB#*%N_*3 BLK@1;^./J7<S4SX+)N%JPCG;INK*V\;]$%33M]\V#Q.
MQ-=XC@3G9K<@;%K.!Y_72IND@>WN,#BVXVCMU],>(5Q'LZ3^ ;78RE5(C/92
M<G Z1\()(X<0-(Z1U=ZS$MOE0NK+%1QQ>U.]*,I9O)O)&0N/ZQV^Q.,W;7/V
MP:M0JEJH=].0*%'?UU*T5C\X,&?^EW>1S,K)^?=.+#"96BCIYP8&5['%K3:V
MRKT!R^2("WIA?YH?F 3(0OSHVT=RJIOP8=?HHXT:DA5?=E,GJS&>]C_GS:X?
MT-CX1=C7 U"_4_TU=H]E:, /"7+%=3X(3D#2R.)2ML'<I'*GM'#VP!&<6R_V
M8(=24MDP_GBU)VZ)S9Q.#FG>T_N.!%8TD$5R+(' E/[?#?13+&;=2DFC<*_
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M_HCER=*2*73DB?J #R^X!F6F#T!H'J;%K^^^LO)->"O(U_ P)36VLD:6V.E
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M2)K5QR]\*)+A\&#MD*\R*%TY-E+GBA-6D@WQ8UG^+5DZ=W+52,[=Y)SNBF9
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M\876$4LNFF6TB<^%?OOHQ:D1<NM\,TLP"D!AE6EH';LB]<64NC/S:/JKX?[
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M:6M^N7[QAY@ _=U9_HA.XP,%5I:)8:%O+_F56("J<@]&%-YN2,_?1NU@IZ/
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MQ<UU44\8:+(AUWR9GONIBA4T*PZ%,2,F2]\DXY/.6>1[U?#J6'H8AQ*Z<EZ
MIF5*=&F!E.N20C6_*#@'93E:^ZS0CX8\TC[2\A-"'=N;#99ONKMJWFQBSEJD
M]N)&=QFL=I!)8YX0.PVA<>B0O^Z;5XTQ_/S=IHDK4%;!4&CR>X,W.I5$?#/?
M8@:O)0[;*]F&&;9D.3DSL6;+'VSD).<>'^A/-]\%.=EVH(>;YRKC ZO:A9Q*
M.\7;4;'M6^9Z[DL([EO>$MJ;EULQ:ID# DC[J)KWWCW_>W_Z3N?\ A< .D&-
M>I/^1,HUA-J-VJT4W-(SJ?!0RO2:6]B/CDL./<+-]1D]L@@]8WHE/.GJNHCY
M$I$_[."\Z$)A@IO4&-OQ>VJ%;LK&]\:7+B-ZQY@X5C@J_4/E,/7SV':HNZUL
MSM5MI@5E.5] 7MPW&+B@EN')1R$/264*-P;2 7#GFWCNF218^X1,":Y57X_<
MD0I ,_WAOP>)3#A;=AJ2'>F?!+BYS>X,VCL,FKIG!)Z9B:;6<9WVMQXG\,\]
M;-3.&_Y1R8I/'88GX^@(I?VI;'\^WSDVT5;@D$NGD 2AU+YV?='U\*U[^ !@
M#5&8+Z0'[&1%>OUY ,!DS!)BF&Y64]05?H7]ZH_"-XOZH-+Z;]0F_R(V0>7D
MY'2D;?[?27S]OS[OU&>-$#GI1CDHU 4 <.SC$\(&<!/U.0*\DR<)2G,0'0]P
MPP/!-?G7A4\+BFW#+R!=F07#,L;:*Y>D[9+C,)*/7U(##*+4;</$R_Q'1@[O
MQC"M[8WE J?8CEDN]>I2H=GH4SFQ(=T47>/XTJ^\84=: :]7!;VD*#A[-EX9
M1$\3_/CO0VG5#Q_+>*:2U;N%56>U9L\9&.NS7J'8J%E2&O+ZO''UD2P5K!N,
M)]:'%GU.RK9:X=4.NA;I"C#"G%.^-JFD+<QW#F92L5X7/Z70I\;S>\U^Y-EO
M=>D7HL">6K%ZCZ/\B\)BUB4?;D]/6RKDS6%4[G!CYH^C/C0JM3K*C;1#+R*]
MT1#N(4V4,A=,<4"R;;?A/\4*/QOX/^EC6 \*C3RHD;:K^$\(C >@J']?2L(0
M'ZH;5<-KGTG&3KYMFQ21\_]83/@_"7=2,DX95]*&PLV0Z[SZL-7#1DQS\.V
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M3ROIK#%\5VM=Q&,<8<[19RSY8(D\ ?<[&OA0R1WUT-+G'D?-U3R[M$((_$&
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M-1SPZ>BX;#O:YX9K[BB6\4IXHXJ*%RH*SU;;PU=3?E_'*5K\-NV^_MAAJ'=
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M1IX=;^US7(NF+DU*S(5^<3B9'12[AJ64JK"R(9"'U22!C0FPVTJ?.4"-C&'
MI5_W>Q>=,2,NZQ2]+6OV:'20M?+'WZ)*5SELWZ,7\Y,%F1#C#KS]5E*)UK"Y
MQP)A#6?ZTEGOE^^>FU >S.3^C"V5F?(\'5^HH[S;0"9\5U!9C6[)*>DQ+5M
M9V19+N5UO(3>!"2\;8;5E2^91!4];ZFDJIDX Y?5.N762-&4ZS\6X)+"5<A(
M3-><!R\6+J52Z_'V77)I485751E+6D<"OMSFF5,I/RW*ZEO;D )^C?=RR'J_
MI1^7-D/N&VK\XG@W@A][97#?Q79Z42.T,1+UV;(K]23#O_%N_$B[2_][KZ+:
MO\>_[.T86ZELBE%,('D%]R$!RLZBLSK&2O@_EQN')L4FZ2X,.96U,(R4.JJ=
M^3G_YNDH(7#/(3(.3XA,46]HI-YSJZI<?M2-CM.Z,HW0,4]?HC'X-9<69AZF
MDM8[?PL"N1K_H_B"&LYJ.^@H^-J& LZSKQZX+CB:&J@NJYH+Q/39EU-YJHDZ
MX9!8G7F,_,%@G3G4B5]K;&ZS:KJ+SE0K];7W%ZHI'JBJ\"&=]@?*0N<4P8>3
M 06S6YY_,%2FRH9Z^Y!EM[RE7/U5L&O^2E&E@$;3 K;VY9]$%'7]_WT^CQ*!
M8H"A7<90 =IY]J^<)*@%9)@A9[YI0S[1!PK)LLQ$--4*9"'$#-29#4X9-[HT
MTB\@WBC2\OD"5^8JUZSP/9-/J*]?AATT<=9$@T0Y"YX]=8OKG>EGT\R^;1]V
MR6U\6R^-+<4KNM9K(RR--TSJ^Z5$GOQ'>!/1+E!(2Y>/0UJ+]9:&V#/A$N_]
M6^Y_95E88$#WP\W?6I?S1$\^+N\23*P,XSK47!S-^7C<L2M?M.OG0WT*RBRP
M-[LLH=>)4/ (6:N2_7ZCW.IMJZL"IV,*W7A 0?M[,1NZZ#:@_*=99FHWUBW-
M<<-^907V%[N!P2T0?O%;_#M%<2$A=7O!'K,ENO^[@C#/:;-VL_)S7$5C)?B
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M^2,;C%#*L/Z"P7>A?1SQ:#\.7AGHPX%*PES >WS=&=<=? 7[SEWG_-9!3^Q
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MH6XZ=1>O_43&)U?63["\U\C/)= 40LP $6CVSF$LGFABO^/N^P^;H_V40[I
M]U,K]S,5'"FS2'=R@;I<5X&>:%4*J.OG[8W/-P&G%)0?)*GO%OW];"H<,RHV
MZ,34ZTTU1!$!S9!S_PB3E<+=N@V^6*3*1'M&Z>Z"M0IBV"0F<$D'T1N?:<6V
M3W-&IG^)*AR%L:VE)"K,K*.>3P+'JTU,+3<8J$K WQ=?6?NF_*7(&R,C=XU4
M7(U$/NM("<,[QAL: B@PPH2.;(T.+95ZI@0KNT?ZB@1(F G@I[4\P5,HK&5
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MT((-[7R;/EV'8?-B>U262TT.MQ:RB,!407Q0(",@5F>51B2J]&"P 2G!O&'
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MC_.FNH3L2YB"B03P_X;I*'6X5A[S<;6)=V6_"<6JX)H].:4N?-GE(8Z8 =O
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MS=48&<)#(YK!9I]:UY@$]9,922.Z)U;,ABDY-D/Y0-JU,5B<U.R3-7)L^\(
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MU#AP69 ]2F"*, N=.VJLU:C8;G49@8P6X@OR^H-^,-H=!06EG?]%6;OSFR.
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M!JRU/0ZI7 I4LEI;A^_^1?$X2^J:Z]"U\]JRM9_'B_SXK+N;ZAKDG9Z$]1V
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M7^02)6)@*@N+7,"I91'U3[NQKPUC?Q'$ZQ( [%J:Z9VJ'2S]9<[2R6-[R5G
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MA-S^S2G>(@:#N' >;S\"\G#@#AA\XIYF-.J%7H&Y-0#034M2&K?Z21  !+H
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M1, 7PJ]FP2?RCP\@3L/B7>B'8_$>R2U5QC]BV"[-U[3^KYR6?V6UC&P/K^X
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MRQL%$O(*JM)R[S0VT.DF"!D9&E4$TDV43)0K\)A-'EJG9W$#866BIS0 UQ;
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MJC4SKD ,JW/.+J]FBQ:2.P5\19.O6ZX>T X2NUL2 ;7S)U\:#7!<;&4<M,J
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ME2&L(QV>P4"4'1H@\J":NN?O*04X=OJY/,('Y5?Y6@V*#BUW^"[LEY:]QBE
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M]D@?@G3Z-Z#JPZ9))=8LY]IQ%E7>/26+O[A&/[+2(-H3-O-PX:XN?T>#-G\
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M=YP#!UN#),EI04+_;:"=;+7WLJWL@G+AF%&Q]?3930C?I+!73W#1W_Z:14T
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MLER/PVJ75N-G>M2=_/FAM\<-@?8^")'T*G=O@^JTQR=& ,RW_J(%G97:QSS
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M<MEEI<61(12!II>C*$*>$/7MOC_5%P_?SINB,M&.K%<VWF\?> T=J'XP";E
M!/9V<AQIQ63T;0[,Z**GP%+]\O<2*0DQ7U\\*ZK>-ILZ$D7H=39F=U1.\";<
MM][DP%,Y>)O<*5PNA" ^IXOY>=T?46W61U0?'1-AJQ7TAKLRK*0ZP\U1;UK5
M]$0VI8%&[FEB$9F-3E17<@8F%G?QDI53*SX23W,9%(N[)-1?2SKY\_]SBC#X
MRCM#=8%9 HD&:Z:)+54T1!U/^)RW=_PX%L)^SN^TA4?PE[/V+@N0:^)L6U3:
MEPC*O=LPC1@HGNG3F 4M!76:TL&YHTVAI[J1:;BF(&X&X;O,R^$RV_?FDDN>
M1&(V^DC4A<C\=+1$<=JWAW^U+?$)9-\%'3)3A=?DZR="B,(- WN#J>AV^::C
M&TKY5?)B!>B:K=</3B+0"7BZ*-/#YZB;^Q':M"_=?,B#7W^>[287\&JKO0V=
MO]'6,-I!HJ[S+_,HT,24!\M=J2OG@LA\O -SB;32^86SDAQM,5]EU.YM/&_H
MM9I5S1(AX=]R.!,RT$*2;@W(X6??K%)O@:"ER3$(E;?YHDW)Q(T41$0Q_4H6
MCV_"%/)'(,)(@_B8ADGKJ2P717G4[61K9M R]^11LJ5N57"[8PQR<#NNS5BK
M&&^M84Q54DZ.J69"\G9+K/DRI?YAROR'5E\,#W9?_+K@2S^=W308CZRQVZ4H
M^B;P?01KO]I//+@ VN05;=(E4S^FYZ![\%XW(\EWMF2'\V1Z.,7ZN'RS_K6A
MQ7YG3#R"\/QMMYMN^P$9N+#2?MS\?*,@.*D* 3E"Z;T*#JJ'3E3>ZDR[\C_1
M5E'JJM5%;B^_;5WC3JNH\C;M0H?44P_Q/V ^:(PPNSJ_DG$X*E#0W#D,^'3[
M],5&&% G)[9X\U"KBM!5^?Z0O%$[RYYC"JZT><AT]XPY(1=U?4/O<$/V*P/R
M=??^C(Q/27X-;1<BC>GG$,EI<70$6M>JG@R$?A?@\2Z7U,5M.M&7'91_V:B.
ML^F;&<)9R2<J&$85L?RCT-O+?UWA<&9:W-Z2@(6/8KY*T[E[J1][$<EVD:+Z
M3"KD$9P0DY,,!%/7"UIN9M0X3+'(]:X$N4&MQQLCU549:/V4BPLD3+&7 R&R
M$A48@;>>:XC;O) 54&)<Q4ND3:,#5W]3LMGRQI5 ]0W#A"EYM5QU^I&]>YNQ
MHBU'S&+AA<S7 <FVF@\$M_BDW&*Q&L%S(S02';R/Z'E,!+<T<,O%?^/$=V?F
MU[U@-O"N+^M-'1JF[GFTLD8W?ZC1L)DUF!C\3(-9I7^\$VOXE/AJ>M+?XW0L
M)U'=JBAB6TG",G5D*/U'^WUOT?,$BQ]4U4X'93<DM4^J3(B8'\8,=IN*Z8JY
M#4BWOYGNJEG"^,6'&/>G-1HG;G$VJ<V#*1;9TJ6MVQL&2T=X[ (A1Y*ZF,C3
MU,N3B .$Y>RK+*.VI0&67\SY/4%RC"(>VE(:P6PW.OI[LI(BJ;ZJ2UX-P3LY
M5=.)SQ/"QY/LJH)-MCI2\R+[I>26VP3(6:C%LKT3Z1^>> M39[0"R3:],RU*
MC Q?$KS4S6-'B\E,X/\"R(C)'5*IW\&/@?DIW6^?TP0-H,]@>R4S[A\^CB6X
M2=!S/2B;:C<?:,49D.CWCCM\9E/X.$I:[:%T03M5F>9:L)7J-Y\4KN#7QT7K
MTS0'Z'Z#!/M]75*95N=S%XV/OGPG3+N4IP$M77]8D2OYU"6O"'I>5V3CI#AA
M/7F+M^!^K'DS:?0;AYHNCM4*S 7KM:8,7/!?<5S5"WM$)QG3^YJ!U*!1S+.^
MDZXP+E)H,E*Q:*FM;V 0$OHKY;9P>B@%\2"?_HYI$F_RDZ/I@G85C@G6DZHI
M%97!88'"UI4],@@$^KDF^,N)_:NJ-'\?7N,E#\TXR:")T37%N87!_O5A'UR$
MW*(W_GG>MWC-XN(+DEH[XPB7E91K#\A%VG 8FKUG#'_=F$7T<U9<GAEM;(X&
MG=2,S-,"[<(.<$Z2XGIFN9ZC$"CB'"SUALY7O'>+_B(\Q3IW1/GU"":W+C=E
M>R)+XH6RW?C&L?6I[;R4G[7O,F?-F(S9JQ\[T],S"R?=FZ.!I=:V?-$H9%1P
M<J>G6(8J,A2EA4,>,Q#O[_2RE-P&W*/_K?QL8W1\=$,^O$=13,?NE&];FS=9
MO823\0"?4<W<&A-$C\L4=,+Z=C)CS+*2CB[B2-.Z@6'#TW5UTL=[%WK2M#JU
M=YM@4;=VI6Q;SY*]O#; ,^ZTOZ1XR6P?&Q%;HCUFD&5D]W&GQ !F0U0M3-IF
M<:+,&;JQ5/K86J>.QK<<GX(C55/IPB81AN?=%VJ=$O?1@J)1GXF)598[C87+
MHM[0&OE.8S0EE5>J;T2>^QL#\E>X6A37WB$BIF9_CIWW1E;7=G+Z38*^^LXX
M7AN#=VYV"W_(^7(Z'L#*?H;<@1D:6=@S:X^^LS:8$G%)NMSDF\.[G-X?8N(G
MR&W272\%/3M&4P(2:7\0N0G[3(T6RC=Z.6BI.T*[YV(+\8"UBE$C%[:M7(.7
M!,]^E!-[9>3-[/:5^0Z*><$ZKQ71C4QS@<=/K'X='%.S4_9!ZZP+2G/G#$H_
MY.LZ)(=%Q=AE&0@;F06H?STK./M:!]UX:MHWR/4A$-;9FDN4F+2@F2#5JP%7
MA)(^EM^.-;BIGO;Z6<K>QLW^Q+7R?VJ$O;^99H@R99ONKU$COFCT6#T3]1*P
M&JF@45U;)@;R>H5%YAY"M,DTZ?>4FM,%O?F5VK%T23EYSF6"M?62GW\NAL.[
MDR^+38L():NZ:[V,?]B([^SD*>P2C93(5\FBH@8K-BCT_3-HK#V9!BG>78R$
MGKQLHBUPD&\OY[S@?S':J)8NH&V\P5K:U^:IY3/KUWOAQZRC-A7VH?*B+IZB
M%M_G871RHSPG//GH-XYM6Q"7;J,*F;X:8E?MJ&0[P4S'_+Y.]DEXO?MZ@ <+
M;ZA.^=!C/$'NQ7.IOVE\REX#4<6*5]'U=_#WB/F?VJR_>A?L[B!RR3Q\68]5
MV/81J6Y\IB-HPXOU!#<H7+2<WX(4T[$V)<K>.>+?F[P-PH;/["#B0]-^2!%V
M;E5EL\(M_.K$#N,!R]4 .XLU9&P>=>%;ZNYT:YLQEK1V&TVA[Q1U;YN3/L)*
M@W-Y8I9X:[;M#-QU+OE9T6A46[Z1T+U(=U\1,X>8Q!E#A@E^6T3%7D]C][1H
M<>I%45SNJ $\7 -F+_MJA^(T5)XQQG.?9PN=6U<88$(APZ73(>-0@:TB@<%\
MS*^08P$R2_&AXL%QAH9UT]/9KP7$#^O:U!=<L0]-US.XHTM5T2]!SJ'9ZG!5
M9U_JFE(MX3PN_5Q!J,63AN]>5ZY@UMP?U9>V#,5<834"QLR6GT>&$JG<H[^U
M21@SM'BXVVO0WHE"4J\M!%2G4\^G:6O%1CXDG4#[I-47U#$<K#:BGYA.M S"
MY^$\GFBB3_,RO=QL!9"MGI6&J/T2T?Y;-E%O74G;!U[OSJ*W3S%B56X/2_(=
M@)3.(EZJWRQ=N R<Z<1(Q-[S_A%L$%G8#86<0W ?3^=LQC?Z-"$+7=-U@)X5
MN\1/N74:[RF*U7 HQ8C6ND/-"QG,*^BWFQD!>.,%M??>D\Y#!3G>^"L-92\?
M/8\Y(<Z@$HU!'4JOWH*E#5")#=@+/\^R&>[MT3G.E$X'MMV#LD3C5EV!-H>X
MK"<65P(ER\3MM[\F1VLU<Y=0V]M%50)-;(5>M\^TY-;NVIP=-5D:KBGHB=KF
MLFZ(W!]XFCS(LXI8G7LUG@= !Z,E&QI]A8.9(9 3%_#'-[NR^6,I>_28-+=\
MOJG(\]IS#1 7=<@F?N0@HRN;:(0"(7%9;8="/6&&HC"N*+!$4(,+PB$3U:Z&
M\#SY2K&E@1Y+V=GB@^\33A1J"5NFO/.E, OEX_-CMG1CO"+ DC;HG7Q')N<;
M.S@>N1)C1I=>K8K= W'55*Z8XMFSX]U"NC'M<&*A]P>BKQ"T2@OI9#FZU62/
MZB;2[&HKBO6]>H!P!!OVQD2;[US./H8(6W"@3:S<6C/'-FVT3,[Y80X19]8K
M+7 <-_L;AVQV.T+V7 3FX0CNO^S_C=-$Y6,Q=26'T ^L.7V1_G48$"&UZPO0
MR\,9[WAS78.:ZIN+S64NQ$.<B(>57^SC#YC?/0W=OII!5HJ(?Z_Z6: SHU1O
MU^ZRZ43P)5WE!Y?I2#1LJ8=YPY&"3P9F&=Z=\RK,7QT=T*+6J16:())FX,,V
MS]NB'N]N,_:5AXPP\L7^?2?9N_2M]#A]__+J85OTLU;2JRT<YEF!2>2;6S@H
M4XL*C9"O8<CW4\N7&^_[MS4.5, CZJHUYK+</H[!C$G6F%;>YEV65TE&J51E
M3H(74@?>?D?5Z;7-UWS[*N\H(MF*</< &^$BDME&-+Y-=UF<&%B47_(&M7D1
MYW=N7TW"[02:&7QHL\M''7"$R&RZR.1$V8E%*=.-C@9=]61]\>EB65-U@W\$
M2,NQ$VI+L!RPZXU=9"7#+6'<-U,9/]'30R);TWW30S/;B3O$MU^:+XV2$H=X
MV<.'%0=2CK@V-O/$9Z G'Y:-N4(.6@]#*C7L'H>M@BIBU/+ VYV$;2J5ISG"
MN%]Y0NOE.(+,5?I>TC];5MEN[=O=[>M=98?$[L[V'CUX?_7S["@/F6@M+G&(
M_+E5,79&OV'Z"<:=Y29S)^MY,-/0 #O[3T8@]#2]# ^%\N='C2-+UK%[L6B[
M!M(">'Z&OBVU:3MZ>8>L+"NM8@A.KDW]U!SG[5P,'9FI)9E;!:FRKZA5D]08
M3U8O(CWF:]Y1^FO+D+-KNB@#/P;<[]C!C[-7-W93%Z_L);=@?DG2,KC)9?_V
MB4*7V(A"F&UB*Z-TEK;.:]/N?"KM:6X][,_C)M$\>CEKJ#)J8+,B7]>1TL#N
MP\!82E$04!RE.\-DD,:>M/7K08KVEJH"UH,R::T01!_DKMQPPR=MSMV&V+]5
MZ?E"75#]8A6S^^SG$&1**HPP%CZ/XKOG/]NJRX((KNO;07\<90S,6W?&05*'
MO(G(VG3D/?B7))V<_5?*OQ:4A8\=)HG%<Y1(& L2(J4<R_'>TTNMX<;Y4@V=
M !5QNRF;Y.L60SY/NI2CD!$3*>]4;:[E@4.#2^SF# ^Y\DHYOG2D!%WCG5=Q
MA(_E6!(RQ](ORUS#J\9<O()1\I6C)\_&ENV..(&)'ZW+$F371K>I>$#KVN1'
MZU\7WL98H?LC;[K=(9L;Y?]1]=+_D6;=&03*39GE.@#5!#'N']3@&_;E(,$B
M R)E<?[W.50X-# Q7QL<G1V(/,R>Z>=#B$KS?.>LM=&?'"E-PLO:;#\H87;D
M%M[W.2T<'+J:674QK+;%=KOI2>21[Q\H4X;'8+BBV9WJO.)AXR(PX0+$_0[8
M*$#40S&<:X]*72^^S[9];VU^+"RS4NS*B.3M6+?S7K/:G]BHUL"NV/;TD?#W
MTJVKDQF^E$T(OL=[A@FRU [EU_P* D<\5!%K5=;8<]OG<K):Y!&9T5N\F&D0
M-YBF9N0%-TW'DN5AV<<$-2*_C]^IM?B@43EI4R(ZZ_9Z+$NW^0&Z70'&G[@B
MAUUYA,)!!.0&;$N.QVQFK%KA.F9?TR@8BO5>$H) GT)Y: #PF<_+(?_)]/V%
M#HT8^PM,?$=6^D_ ]T$3*MR7B<,'M4DPF^3&IT#I]8^'_QX/9<L_.]HC:/6<
M4["J85I]RAU4'E]+T938*O)5)T@@!MX5^8)B,I3+YV?G\JP2W^%I?NS;._3T
M)H26]/000D+02C?V' 1R$(0>@LX*<""-V'S^@77;8G59N6>J:LL/@S6.1K[]
MX&Y)<@2M!2T!5+(R5"L.:V&"C+N?T21_KT8\QN$#=VE13WT$6JG-+%2O5!KD
MA&LQ4MAJ?TO#I,OG\H0 L,E=R;46F_D4N[F8W'$X-N='"NV+R%1*O::7 _B?
M>$V,[F2N#B[WZ88E-5NNI(4DP=?=WQB((M)_:?\2(5=8O\0^$Z+B9 -V4SH"
ML8^3]C .S+X<AL*KX!+Y $P:=CIQ-_M_GU+'7VGI%ZJ/%1Y1?>:3>QDM#PBC
MH* 42J* "45'H\KQ$ @$2E34@PT'4H/1%3ARKDJ(=N(M#ATP\-:E'5(,K&7
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M]$6F1?<?P:2%6,U(5&$PW0\0>]+%?:J4>MXALW7;YV%?^+O^VTNU$A!C3J-
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MV+P%XPOH+$KC4PQ.@G\M85)X]VJS,H$^YL^D;5F^8S)PYKUAR'O#]H!D3'L
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M_9W"UW^[>SO,4DU9F'ODHN"TP <Q&ZF+UJDA^,IWU'''(";MW*E#[\0NV7'
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MI?.ZI;,]N<)F%%Q>X_%!*3U3CFZUM4D1<YQC#_)B5'CIZMY$+5"P41*O;2=
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M+V%QH45K/M>8PVG/81U+?2P-'HX%E_9E2R$,366YU">9[':#&V;G&<Y4VA7
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M'12RRN$O V%6*,C6 G(7.IH=6'\7MU4K%AKE\IN#_DI*ARQ7?P)1JO:EL\^
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MXP+CV0Y1HH>W%R94D4MNLNO&$*&G&<D,KJIYO=[67C<IQIM\BN5[&RON+?V
ML4.PL <)E4G8J0,U=%,C"@+Y1O%*RQP$#><":E=>%D*[AUL-V;B[LA87?\3R
MWH9<RR.H5+I..%)F-+9$>MFG/'6/>XEBMN?JS1]GVXN4'SP]6&JJ].HTEW5N
MQF(OL1CZQ8Q;_:/?/(;ZYQJ+2ZPNSX>Z>W:M]-O'[_N#CFD;C%K[WNICHW$(
M]<@V:Q-P!P>[N_F$< >'4']K2XR\Z^ BCVT&7P96#P9?],+"E:]OJ-"?9L+[
M@/&'^PTUVSF[1$/BXH].KTD%ALULDCU2=YL#F8=L4EPTK9N!>K\3S RJ%N^S
MFTQR6GL'L\7[BQ%C;PA5.W_';*8_8-"@KCT%W6*7N'>@]^P,-S@^)I!V"*1
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MD<>1M&-%&]T9_H7^N&&8\2;7,%BG.7?Y T;E_M\"!JHK)RACZI.>"(=X/F#
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MILX].I,;G=MJ^\>^/-DX3SV^<+L80?&S:XU254D,]L8#%9K9=8">9L/VM1Z
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MLS1,9!VZ\;6NB*'2\ES3$,EC_H^MX4_H%'!3F]>^JMO:WG!2D9'M9K0_,B]
MCO[<(1:UZ<KG6HRC3TI_NQ*.S??[\N3C<_XCC&L(L0$$ BU/"M#^-C[;_LGG
M<,5KX:Y&+Z HZ'MQ)#]GS6+Y7M*5\*+Y>7GZC8U@S0*/6IB:VH%C16RZ>V:\
M>8U3PPW#H_;Y2C9X@)^:D8E.2[K3)@SESS76C([S"=^&7=(@+TE,A'L&NJ7E
M0T(#WCSJ[P^=^ZWU9H2$9 ;(I"Z%SJ=F+@?63=YAT#3>O+Q=WA-7_D2_C4_
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M@B9;5R("MPB;<@Z%AR-!&DJFU8WL&]1'<BM14C1Q>>K"-Z:-)!D<8F&S ?J
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M7HMORB004_A)E=SE28>D\*Y\N]=,P1?=HB\*=%E/&-*>Y/"&Z0)#%N0+P]Z
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MU1@:I"'_7WM&=8<Q;^7+X5#X<]O!06\=U&D1<-A%\^RLFG@M+LJX[&MM1+2
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ML4K@G:8$CRP<3X[64E)2&8D\.,A_FABP9?0=B(27G9XFS#?D\3Z;4BFI24]
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M16$4"'R4ZV?<96="(,@[(W*9GMV[OZ=XQ8N=X+K5:1_B9A&A@,J4;5F'W&9
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M7Y_F$E;3>W@D1=>T>'DINV[1W$SD&$;008D-+GGG)IH%Y']4;[>.-<S-5R0
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MS503?47OX9@M)/OCH[?G^4/-]L.VQ<IFQYB^G);C:WTVDZ*?^HFI!B:[]"\
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MQ1,'E*_R^S?*![T8?'.$LEBWV:"S9F7Z7&9N7H)(,E=T3A"T!=\' !O8SS^
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M5<N;[A$&O<](*FWIJWW]8"=1V]CGD_F)?B2#0%I^^:=2B4CND&U&6O<(J@S
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M/!<J$)@#*.R"3'6A6E-;O?$$*'OLEOO Z-CIT!LW_;S8M(]5OV^.$8C* ?_
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MPU6">,I*6K]58U&2IIRK&"EFJV5@(WYDS*DZ;':XQ3HX[YH@8W[CEPV9D&I
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M(FY_.7S,7\6[FK?*W917<YE?A':>G5\_NU%TPXI]^K&(PW@M(6F_XRIV%S5
MU9(-ZF&V8F54?0QU-UA?># 5SE$_T[+Y!.6D"++*[4\95MI):807%?>9)H:&
MN'Y;:(I3-\B<#WJ*=5A@KGOWY5\OBBT)11KWSY4EPJ=S4R\I/T*5,;;TG!2.
MN@F@K[VD\0])^]AQOP!;,M*'91]-7#7 _#XL2/!M4=N^J*EQ/_D4+*7ZQI(V
M!^3RE4Y:AM[GQ(_Y('0C--O63 IOD'H+BBB?_%)_A2@5O@-H6S2"TZ%;!MFR
MMX*/+=8->^6P4X6^)"(+?7AU'M+@QTG\(I$+HHS?+%-XQ:;)&D&Y"P1T&CH?
M8_,S(LO6^1X'Z-9F>*\\J),/E <F268\MO,,><[I817WZ=SK-8 _\K]''>3O
MIME0O.0=P.O/A\!#ZQO&^R0PCS.QWT((XW$:MZTW>KJ#&(L%]I"_T!D7.0/%
M_''W>+_4"[BAJG1"-J=2#*IT'V0:=>GFK$Y5GB8/3:-G>O"\<#)+]XXJ7,2M
MF0-,7H**=H:?E2EC]RBB#M5,U>F^3?6&>+)5IR_RH S%7%^O!T_HO\G(-%;:
M6F=/\?JDPEZ;&N-Q;LS]JPX;W):*P6&+$9<7IJ00V6>(]<ET#>/YJR0GE*Z0
MVHVW6),>(>/J9_*D.@IF:.N0[\!$@4/G @QOL#XRB5F)3SAS=#P1EIJ),IID
MO1K!+1D?)'5R,P[45M,O08AYUT+N '*/O4!.5Y9[.)=[ ]<QZAV*S5 #J48I
MU\ R])XE1Y,N2L_"8'CQ4:!AHP>W?HNKYU>+YRW8'\% 0J8M/:)I*KN9A!SI
M,.B,F#YL@@^J&C!':5KF/IWO6]EH$P/UO#@QZ!=]E-/;:O7XHZ3H,^$C>Y5\
M%_6\\O&UW]9ZGD,^DYW<X_Z5WXT,"&NLYGRL;H>+6A/ =7]AS-5Z6#/T.N5X
M3E 7:=PK/#F>&AF^Q5/; 5)%ZALQV= 'G=#V8>RUF!0#9T#0M9XM&IVRB2?>
MR[5S2;FT>'I;<GAH8D/AW_02N>RZK[$Q*)4KXX"$:^+YO;WVFY]BB'<1XY%(
M'J.TP0R?WP%@J NHEU'5\]#W7]5Y^$V>JQ0&49Q?WP'B75^/"V9CH[--9<WC
MT=8$8Z?G2I[SG@MBNTV.U4.-1V\NVS5?? F1V,'NK]X!FO=N#S>-=UL;S1&?
MLXU0,T' VS/8U>X=H++C49*7E]=14'D'U^)%C<1,]OJHY-8BNG/O^+K3)WM4
MQ/(9 ^BO$BD#5$60)"R/=76=Z82:)/EJ+F?^#G#9T0QUHWLD?0<0-& ]#'Q!
M5+,^R70[20().INK)K&<O[D#'//LHL_W] I-)478'B?< ?:&NCK/H.8WQ9'(
MYD_7JZ?7L$ZL64;6^*%XJZB>@J7F)GK>Q'2Q*Q#_%/_9=\>;=3.MMY=#:#[]
M*15+X^J@@T-)\_#;(2H@4& ;&$4<:%XJ209LSS7U2>GL_ $<,U_'>!K@5;AQ
MR\2@+[RS1610AX-J/WS\*WEWQ'Q<D?#!VL-?8B=B,*@4S^XM>'=O;>_$+-<G
M*-7&?>OL;/%W9^.M2:> WY*QVEQ-TB:#*X/P+?HZ7>W6Z;>_&,%U9T<'5PT\
MRX\7U9XS>[VSUC$?[W5XN9VSLS"CDI51E%'T%+ [\A'+)@II'EGQLOEMA*J6
M/W,9E40?B@[^ZIC/,*$8G+7*?\(]&S36P7W)5!I(!27*UJV2W]G=QZHR5,&5
MFL><]O@O&YLU-,>"LD&']Y&[U&Q^@,7;N!YEAD;T^@V&9<;,HF%.Z'+'@D.)
M!IB%8HBRP>RZ EW9@BK&:GL:.B+14Q445CWR8\7UK@W',C))E#%R.97RCU??
M7ZG_:N$3M!D2^=S"(%G#P3+.^S>1X?%C>HD?8Q!3"N\FQ-6LT:NM'+$^42%>
MGT&Q8O0G!$]6XV;O@42ID)P-*%/9*[1E'5Y.,F!V<Z,78G1:> >0V:63F'T*
M:8G3)A!7&_)0BZ\E$PCP_ K_; QL_S,AQ YVGP4%/F5H]\8$NL*#]R@NW.\
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MYTW>9%"XVB60M%-BJKW[.<1#A:;*2U<\+'JVS+!]1O\K-<<6TL1XONAQ%"[
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M@WS6KV^[2<$/8L(J(1&UE_.C:PZAH^!'E]6F:7WI6^#O!R)L7C9>N[W_/+F
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M&;6!!)CK"//(GX+%7M<_./[O)H<_!IZV[#S0L#\]TMI6"<#AX8E\S%-&#%E
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MNE[,STE2A#YQ(3YX3RBJ%2/)NUDCL2G2TIIF:LP+H9"/XKN&&GS(YLK+ )F
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MHQ!JR, 2I+&%+_&YR8=6%JZ[PRGI0JA>%RP&U*?I"B0EK;$@"]*/TH\;HJN
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MX6\,93'YI#9.R;DEV%]TNR<G8:MMB,=#K@/EB*W) J-2!3.G3S;TNCL:7]N
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M"7!"M@F*)2QES6$\#-+WSSAQT!PIZ^,/-I:V&;VH'3WH*X='3V2E/2-#'?W
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MTW?J&V5"*<\XY5/$) $N!S>_T:Y9+X-2_M@](5,I_'K]\?.7JGMB)>PWXLT
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MGMPVH>[<[TT*@#GW0F;Z "]=>6QODZW>5O?!?%1]Z(^%++.8&2'WWO*IO:J
MX$(3=:Z(S&^'IH?NWE?J]29TW,=2>DM\2$!"=_>:/8'41%;VY:F*HV42; _-
M8S?#-<_4X8U]/%,S:V9IYS4\SG.WC1 T[DD.".[/LPY? S/CM/S^W\Z@<X=8
M^]_]<LA.&-Y_(R?<'P?K/GKCE2GJ1 ]2L<SF#K:4F%AJ!2JJXK0^-IL5@;WQ
M*H@75E>U91&().5.$_ZLVF^VK^2*'&88[]*K\!K2+4P>'I 0@ VNKB)Z>#IQ
M2SZN""XV;I_9-KY^(NJ ]Q7LY3Z-3;8N'*R\SA](C2U."SI^'^-E3N)#Y//N
M#\ZK1<$/L(X)T5R>V]QR[H5^546$$RU02=[44=.%;""K+Y8E_IB-;T^RY^59
MS4*UND'6$"Q"Z8;]7[+.XC^Y'&WL[C%G>4K<ID219Z\Q8"']V3.,'8S8@9F(
M].?IM&S8S0M<!S#W$WM+A5&3,^TM+->.V(E*A4\L^.0OP[</9>2CJ>QQK0;E
M1'9ZKC1MN[EU&UCKKC0WDJ\\2:PZ9"R,1LG\2WY?.5"$7:^-1_4/&KN80%A3
MJ]_I4B;#X4L^O3V3CYVFCC5BVP/RCW4&<,/_D4WIO]IZ6L82?)46.#!\\S\V
M-?\14=3<U?SW=(?)3Y__U])-,-HU+N2TOP= ]X[6+K69]OZSZ-?6DY7_<R:F
ME,Q_)#0<VA']CXCC/_?B?X\ILBC\>[K# 6S&_[?E4'NSXU%KZ_K"+-#LT^\=
M/HEFI7+GL[)3#LL89T>WAKR0EH+!S34LN[5WKD9YCY@PUD63EK_VNW"$_Y'.
M\&^#LOU%&:.KK.)# W@.!_< S@$, J'4Z6OEF?2',G,Q)G_W).\4$HB(]@=Y
MON%*:SQ4H7.IOCO"3LXH_A%0%!NR2P4AF,V.MGWUW__HR8_;G-;>5> 3T<*9
MRZ4ZWK(V'V&^@'Z-M$CG5O?=6QYYM)H%4_<] &63E@PI[O[\DK@T[\+^=4.'
MF:N6C6Z5:U;$GD$)KY;M0@5SEVE#.*YYJ!=#3.]&.O-C9<$'<U]#LG+ VL*'
M \A[@+$7[[JI6V*/L?'N' UNVUOA<#?WM""!AB=DW[Y^LDBXHTRQAJ5GC3[[
MP*I7/H M^_]5V:U_J4 L4;0>;I6#-.GGKR@]*^W/S!$AR]V5MNW1)B\IQ*OQ
M[7?[NWAJY.C\?!5%IDGQXR^][P$YUX&</ATJ3GB9UQWSZ*Z)/#SZC!N?D4Q?
M4C9V<$^F;IN@.)5C5W*_!M#R%$3Z-L4.W6/^]ALBTWBXV'@0AE%E"!  _6V!
M_!Z>_ID-'J"H -H #)4]>C5$D""F.C"K9@"]FJ C8C<>V%DVH+ \T!][M&G!
MH0HY_%X\<, A"?<&@5"(#B@J$($ZW[&,D3I^@?C#5M>ITB6TJ63@B;)TTAQ5
M!WJ>KC?M!D)BQ8Q(Z\(&T/@Y4QACSJE+CJ).N@970B6L.CY?*U.LS64VUZO?
MG3E)9TDX:!5Z@3V=H87RDHO&5E;?BP5G%U\,BF5-\\PO,P9B6%SC@+%U0Z+Y
M[O"2]*#:9N\%6J_+1_;FX,H<Y;.UY#BNT7RV&I7X=),CS+XT@(='YPH#4IE9
M:;L?5T@7^]D[A7[:F1FM"#L>:SUSQS!(,(TQ?Q':%)4"AS210K_(]86HFU[Q
M)[A[+V0/0KY<1EPF;'E&BAB%3^PXAH;T:>4R?(E))S_7 I&]\W[1@]\X9V\(
M3K;6]HQVG#,=T M/97KBA6#\_E)S<.D?57+N 1)+OG\%#_WB1]63-AHT);BD
M1*LCBQ<3IPB^!WPJ.=M)/!MH"'#O0K47,1</8-Y[%?Z5TVD?^\SD'/:Z[Q@M
MX]+T>P QUC+ZFGWF1-5I\9DR5E5L_RQX1?K@]V296KD47P9_>6J/484UC6FB
M'>&0"9&J-(<5];-G*.1(HV^5;\N[A7+9/:2N$8Y^0E;QIJ P;E>!"YB2[NI5
M<-6PZ&"H@#E\Z>G;5R[G3,]*9T\<W('NLZ!=F^)2Q\JUWZ;3VKD4KU5PK.56
M%3_7$-X#AH#OXC_)B/L07L]E$&Z40CZ<+64'/O2]4KV,66'WY]:ROG'(64D9
MAO#0X!<J;MR,&R3MQSUMO^: *+E6[$6"'+)?7.G5WVR6['2I""'&-!A:QLDY
MDA+]*Q(##@)A4N<+#L7DD&0IW>&'I%33+5440; M'MVHAIJF3"5604JPQ%8^
MGIZ&33>(7:^&N177Y2.N%752)RY-\\/20+\=)[-I71N0D_2*ZZ]UY$EEU2S(
M>=BR5)'^17:DJN=>?FBZ."E33X_.$*Z'\==^.#]0[-%:6XSGY[+G69O&J#0@
MLLTZC]UM;&V'?8HE;J565<7Z5,[.3[.WWD8'A%B:;6DLI3@XJ*D"L6ZUCMQ(
MB1V9;VY"C>TI*V_WKU'=%ZS6!\QC<>-S$91SIOE3M!RF4RH3J\\MY;EJQ*FG
MU:I*-WMCRC(GS[)3)W1%,,8X/^MG!%&"\.DFERD;V/1(QBL>E.O9Z7J7'D'B
M2"O^KX]ZY.7R!R^3*HD))2.+-@BK<R0[.7O>1P''A>^RC:_+5#TE+IXG2:YW
MIDM7YU%7\+$;<?&Q/6J[L5/6)8/3<"5D= TA,B*.SL*S?+(KI)9C*FI6.-@V
M*%^\'*=^;1=LZ(&F4(&M5C2B.GU\'9BEV:_G^3V3G+R]P3(^#CTMRE9D=JZ-
MNPI_JNM&!UJ=/*04\N+<,Q:'"T7!B\A!;'+D7%PMPUO+,U%V/JD?=9#:\2T^
M94LF/V[XCGGP4WC/]/3[W^4'YRX>A8D2%?("O=';S#]%NCX97$V=LYYR<PP-
MUFJM^B?6+M*OJ"4MGQTD(LE^)ILFFR;*D<9A/2^WM<L+9]DK?%G9)%-O1EQ[
M#=U;7(:V.C3.&0^*OU7M-/3VP/,_03<J./)^L%X6M<Z;24=1\*Z#"7<AV$5D
M1I25NG"Y2 HMOX]]FP)418EV6E]3BX5)6T//<&/4A2D>O19>3# -<CJ8?7*D
M^U>5FS8Q*QNULH.1/[W/8[3**>UJJWRU%2ES^E3JOW3:NMJR;M^<49.VFS5^
M/+S8%,-ZXM3WNX7*^^2J/TA&:+Y\41B6,GK+<3)(D"0F3*(T)5;R>.97)Y#(
M9<U"A'Y_IB;=$T=+83YZ9"&US9_IR9"=]I$B<>GL4Q+/K>UXW=78!\TT:U++
M32NI,%ALX413>/4C7-,E'B!>C_/*MHFC -I2Z]6A[(&KUH'>2I:<:B;Y@1DO
M$4_87Z2BK\]7K(/=9,EY747..<[S0EG+DIPUS7A97QPK6,#?V\;5=*JDK^*@
M*"5%=,F[\8C5?KMENP-.G!BYP$R4A$7!&G45MN(T$!,[7 AUKFSB&_<KBV/W
M*%IQ?&Y4'A&[8 AV1&J9]D6V.ZV3RRB8<"MYY!]WPR].7#KDUJ@43D4$A^:%
MS@5I^<N(J*B)VAU/I$].4:R@RSUD=4,,=FF?N&FOMQ+0><Y_^PTYBX0%*D'Z
M&A^[XV.L]C6Y1K9M%3F1Q9EJPB-,4U(4!IK!^3;,3TI41;8'WE!B:.$(E*.#
MMI2,EM'7RG%XOO '#S*[_Y'UDRKL?_1YL*_"=1J[3U,&=%'I'+U)M*H]5##<
MNC_9Z;9!9'=1 )IF)3X<SY:'VNB$(EA5A:,;*C7CK<HL:2ZCXU7(%,B!35U9
M64U&\Y\Z&</^ZDL$&M%6XC39XO_:/V?8:KPJ(CKF'B#:*=IX)WY#P>3+ZX1+
M\0VZ(*PW:_)RJL67/!G\3JRFRM6G:_]<YZX%K74\5X[H<3T1;N6Y!GHQ49\%
M K-.6R53)I(&$&Z2MG9\>0]!GO;\/@Q#FS&K96"2MNOT'R) 1??^, [CB!6#
MY<TWI&>@DJR0QO%\AH%93*A*=MCU)),XO.$U5>Y9N8A?[.%0'N+N_'"ND[GD
M77C^,)316WK5WH$TC.M+G5[CB">$./]$35J7^=HI2W=PZ/#$I*;R</0"R3/,
MY'$3HY^(TU?3HIR0E.7'Y?RGCN:6ZG=ETR'&U:G>A'A&/>EST#X#1'T1 M$D
M'EHL>KT?YRUWT"'GTWA+!W4XDZL3XQ%L\=H#<VZQS^1*_Y01+8-:15;(5TN/
MJBF9]FX1]!#@>% FDGV%9B0!T[^-SHJB7[^53XF6GO^,%YA*5;S*1X=2F^ =
M:<O<K'V9 M^/0C_[_'JJP%'1-6:BB][#]XMGL*/EQ7+&-H1)!\W-4Y^*?A-!
M4_&]$'"T3IS@R&;) 1Q/:<M,<A]&:H1F*E%RK5-(]>/UMR*<RNX!84A_39LF
MX"\1/2+.F8H;I>6WOXLS\^/TCX8]QA&U\YPZ,_L5O+-\-;X)+SHW-#)2O!02
M0*<_D\L#!6!'9)R9R05UAN_@,"3%XH['I9JW@M8^9=(&/&9S,C6#T)1W2T)E
MBSZRB,W%6& Q(;9/]4@O)KQ/\"O=>S]ANW%I>#?'P9)SMRC[K<$)QA)S<V<D
MCKCK3.*0+*J/B4Z.?BGB$M>\E90M9IS[THHFL&)K57->QQ#X(MIG4YI!5$.3
M*J$R<M. = S\G-5SN1WJT#A/M*>W*K>:Y/8G(PL\I.8;P G"8'-VT:Z#W3/^
MF)+< ]J4C;<MW\Y>8A;NC%5UG7*M%^\![8&!TZ<>EPT<26SN6?COAW?Z:5Y0
M!99O&4 ATR@#N0U=;#D8DKY.G%+QYC#8H>*T6\%KV!)J')QH=TEU.2+:=RD2
MN/;W-7QG-3?I=[71']X+$F+"#70S$#MA._O7;N>0S0)>D+9H@(@6#FG"B 7#
M:=2;\ (K6I^/B+0!V\E(FS8N3\<2$;%O.XD,3GQ@G_UJK7UK4:"Q@=T;1C/E
M+U8#&K!?NL+)9@/#CL<*["Y7'*S<*[' 9W2TB=9Y@/7@=NBND;"'HEY%:495
M7IE38@B?KH-SX[Q";25>B5*G4I)H;>F@ND?#-'-?L;Q:IEUR[@N-%52BOLRI
M]=Y:CWE0407%[X0,3/GS7O._<&.<0!9^#Z@4X7CSHJ.<X60^5 ?7L+?%L/ I
MZ&9S0GGDW$=DWE.C\U3EKQEUS?++,+HUZ2+0 #D3-W,#GJF&)DVE>G%#631'
MM')C(VW@-WE! EQ5-OF63TGVFJ2. KQ!NSTG4%*;&V)B<\NRMM9RU(_BL#1&
M,3F5NF13")NQUL72KRLG94>HHR'[+*.DJQ)2+9HH6>U2?;7,V*,SS:#<4J^B
M<+L]O&!SI%>NI1]SYM05MQ]_? ^@;=G2'"X*6\_9%P[D/&4%C1\R':SBX MI
MB_(&'2(%]_T-*3N<MI8TX=H1+?J#F:96H!M&QE-#WW9TWZ)O?!^APX4D\\]3
M@GZ8\^"6TQZN5)V5ITF++K8]XHN;U>YYY S<S/+5N9QA1"P7[.3T0U9-D/<9
MLV@6U$RK-&Y4.3.J?/&X!+G72-=V#WA^FN6Z;&;4N#JDI9!UES^F0=UYJWI-
M'-8;K-XI>\N(ICT>Q1CG8C+B4C+&]NHX3(SQ[@%6_]@UCXQIW1L7F?,:E-UD
MM]N>G?HXWFZB:-4\LY^FY47V\FAG==,FMD=.2EHV9WX>7)>G8OL\ ",+N'+X
M8LI.'/MF\0_]>MK5]6ME,>-;Q=7+MFMZ@0U;Y\8F)3EE$@F>R@'130%E%M5$
MNWRU*&5V=YNCN4I*]6YOWE;&J!%Z+*;%3YTIE:H.<C(!=0B;$JG;D\4CC\7T
M3>9A+9V#+K:4\D^*JBJ/0QZ/$SH?J(Y0!']%(GHB>.JN_\)59KHYCC/V_M](
M/,6"HPQ[$<-'>SY!\*+$6&K0EMW.C54;;'(@8A4W/NKDET"<1%24[E'E<)SN
MJ._=/6#LKEG',%!QLN%UEN!</4+[3T4H*A:]#&(O+U4Y+TNF/^5C?Z0][<RA
MO6YI'&%55JHD;?S$PD&^U>R67\+E3PNI\L'(WS7G!!3-+8H9#*55E>6<+JSC
M[M&GL62?IC4;J_HU]#5*$&/*DVIF)?@C)'C.S<.N]3H/S$R;3FX>:AU-'VK]
MDPD1J3,83A?YP45@ZZ'EN_<@+H9_U)[1& 6]/\H:V74M*X**SYQS9)M&/K^)
M).M6D@P+ \>TNS_9M$<PR7RG#;PV>/#3)8DF  ]4FNFREE240RN365GAQ&RB
M3W<8N7HGE45<XB/AJUL[KSPO&N7R*T# >REU88I6*<ZZG[\8J9AS?=/2DG%>
MV[ZW?!["I0\NENH&7;HX^]2]5! O1"6?"O@%*_&)A&"'VJ+"_F2 +_(3N2_H
M@[2P<Q,B!3_@&D+X-0^'$-@"HQS<42[)YID6Y(QU2J+I-F<V%9-L2B!IE^AU
M>J9!9FE56]5DO66!AA:;RI+*F">3_C\N(6^A+8P:=@;Y826[;7SP-&FK\7U"
M2<(&>5.C>\ K9&UHN3V;M Q3-79&=:<KR\:-9%9NQXL)/77[7>5-*_6M#NLZ
M5:RVZCD:DUPCH[=#PH)I)HULBKUJIM]^94I_U%=YY+P_W6#/1M4&,<@:\8P5
MM9GW-<9"2,B+UX_'S/(11T3X8ZJ_;ZW.#/I6&T_8!8(1.N>.U8-[!C/&G[?M
MY9S8,P>6A[>0LLI2? <Q:>QS'/[=5'0_N:1QN6"$CU7#I1^RHZ3?_M42-Y"3
M1[A?V##W .^ 5BB&ZNBTTNYI2FHQWDX & ()IQB;LP*9<MXNN;*C&9^,U0_G
M+L4.>KO#F+2I=&#L^63]YHV&C7\2%VOGB6ZUIDW(2W3%- 51'P?1S>TKMS?0
MNJ3 )].9*KD9J_> V5MY]]O06Z!4*? M<^71C(U+J[_\V\^"9J:A2G*9L=,^
M!2])'[J9G52OU/J+6N@@5>.#GUOC?<@J4WZA:#0<)W**<CD*/&+=\90!!3AT
MSB'I*8^]!/VU=3RR3<*],OK'>O BWX^.]40W<.'%5M!]HOD\2-ZKN/U8"M]K
MN!?_D71CTV#?P2[Z%86[2Z7<,#5RU8E9ON@8!,LX"A-BG&AX?9"NW*9Y%L$I
M(W!6$"!FIL4961$/6U6:&S_3*@D#N2.UXY3W<4ZFIAK*NI%/&34HZ4ZVWN1;
M/6/9(UOC29<DB*C[2)L<8L;Z3$1PZR-R-G;9FRYTZO&K?A$&517<&H),]1XV
M1VXI-FD:DW<$J601475U0G,4;1ERP;,^QGP_/=X8&_18%0]+'RCUR.+Z$6G9
M9=1=:94J<^F5 >6\M*BC;XR+PG(+#P^VW6S/.]P^VDJ;-8?7;N+E8CWC;FK%
M19G5-O2V]5%,^YA[S0]/[]CL"Z;]4L;D//"Z!YS%XDR@BCJ,GKAH-HLN7_E3
M8YV"Q5L5[P$FDYP^R@YVV8+.(C7<)N4F_6!^I2$8T2S]JJT-<M=UQ07=P%<K
MY^18N5^Y\*AU,?"917F?SZH<GH%8:03<SS=XG&#S'"MD:Y/$EHPN48WD.(SV
MR949B"SUM4(*KB\3*&7@H&-CPZ. )-U/Y*< 4C4VI+^,L<A!Z:5!['M&ZR$D
M-Z ]SI7:2:_R?7*-%._/V8J)]+(WF;#-4YT,YU48PF9FP.SPE^'GA2)'ZNRV
MD]9C-/<G4\51N-*8'(^P,%_@2<Y7<8D]QP7JQJ=N64VWG* ,(>&:#OD7\IH<
M44/)ILV9=(/0[DI@;%WA+/.@2+E77^L,VKRE6/]JD*$(X\KM2\^4&>*RK/^S
M)NW \([#,L4/S,JLYB/XFB3?QFZQQ!(8Z44?@][XHKP$?<S9]2B"1]B5[O,=
MP\94WI(%20&Y5/W&Y#+OK,;D7OI>&J,\<V&Z$N^DDF.Z_VN[:7$-5<+&(G-X
M=N_AXP57B3HW10L 2D^&1X P9DE7_B.#6.^=B%5*3XZ2W?KT!J6:>H=JL':>
MQ<1K<?UMWM#<'CM#=A]%D!66O2M1N>28'*6$"CW%AR7>*=>7@N.M#U"$&C5,
MA.(L!_[-OM0;T P)HTF2E==ID;#C; @\T]XB?%2;])B.?_U.'OAQ-%:Y-2*Z
M?D<0\'J*N" R'GR2I@1,'=D5E9&9XM'QO7 1M*VMX9J!ZLG$JD:%D<5B"Y"7
MCE$ZDK ,$_TF[&$2Z@P@=$'[21:.D?* O>NUMRRU^4AJ63*]261H#2I)^KT,
MB=*UW)S(NH<F"P)8G95:2'*-2KZ-/&<4YZ;,J.)0A?"4>4S+X]MHK"SV3#<-
MEHV#Q)$*WY?1>)$S9%9D%IGRA79$**ZY;LM]9V!-H_Y QL^LHA+F9PVE/%KU
M5+W=M=]4=ZK%[15\R:N"T,WV([D-.#V26IOKI"EYWTO2"W^4X?BJ>!)\DC9[
MRVCWAKUEA#))5";RT,L>9A B!/TS%[G,VK &59YZROW1LB*US_:".MZP3[8P
MO%L6;M@;G)JQ4IH3N?)6Y<.4Q3-F$5R(\/MRW_:\])W^S!Q?IFT%_\4LU\K^
M&375VA7*DW:]E<<<:G$3K*JABB3#*XL%"4;Q=9:S>X/RHHE.NWDT43%WWQPO
M#P_SII/M'1M#?OPU8IOD715*:HA8VI+VVJ1D>].7O;XXD?AA&)[%=<4R;=>D
M%%V'/U3XK/JPW(CC3%!HA+RI^>R6 Q,0X ?<%[\$PZ 8XUNTA8;19>R1VCBY
ML'Y#[I_X7?N&,4)M4^9O(CZ>S#:+93Q&+ZV\JIN%*=N[2(]KKBEP58,URL.G
M&S"/O4J@D%Q;$O> PRR_A=WCGLR<_GL R.$L\'.+MZIF3U\.+EB1OG1=$GR#
MO@O_Z.$;&!=I#,ELY3N/.X+VMQ;>=IDOVL,IS"HX9&]HA?W['R1#A:_T%+B<
MFVS[U,4)OG W"IB]I(YZDY2&/.,EY1@F;OR5-I_5! (ALMKFY]&C8X<@T"6[
M^\R[[^RJ=R$CW^;G[P&?5EE=4->^F#+7\H2EZQ5Z!E.61?$JS@0KE^D%=L*T
M9D95RY.&C_UK%&YI7%3Z%(!O9EMBM0.?8V6WXATT\/71;9['58$\AI-E>U!P
M_B=2]]9M"=;IP",6UMK35;N?=YCG5QD[TD)BN1SZ^Y=<1<!5QRG^VR(,?>=9
M8'$4=JFRCZ[X6:LI9N:2XC@[0ML4H1HW43N&VUK2D-H7(!^Z:N&4Y&K 8W%.
M/DNZ"]IU+.J&<'!._;6>>Q[[P58>='4P=@?$%PFI''MISW1&CW_Q@**1XGUO
MNUT"YS3S81P0*L.0NR7=Y9#E]M'-,PXD2IP2.M#,']$+EN2)^$D[=5'+N[YK
MB5A2_L55%WB9I1!9'G]05+B"J<WEPG^_L=X0#P$'"/6]JM)M=G+ARWBIR(:Y
M",;D=?*K@+D#GW7N[=[)[HO= UBBRI&#!HCKX@[-*VBM<8+'RCH<J.7I6O4>
MJL0FEO)SK,=U]9G!*+Q[;'KLQ5R'7*I<5J_A@!>),'TQQR'+!+ZQ]+[?+OX3
M\%1]S0EDR.-X;CS9.*=XAGOF6\:6"^.UQI]*3Z^NY(H-]H^5I?A4!5>S48H,
MG;M$(_D]>V]\I&G\MRKJ4%D7\N+GE!(T3/"E[O]%.F)+AC\H[DV5>T#>^+S)
MJ_QB+A"3["?<@"JN.$.%KYR'Z3$#:\T/<&H>_W[P[4%X$FCH'=_(_@AQ_*0N
M?#1K6$(3Y<56<"=U%6U Z6!6/JAE11+HIT9D1,>-3\W&2%F3(&VJTCN%]-P!
M.5SAZ)I *=[H%[TI_\+F:+[I9/I&*C*4OX*N M%EP:6X0@C59HRHW9E O#5X
M]<]H<4]9R"4G".QOT<A94,M/=IK^=&##2U!GIZ'H "LNI'$#LTK\=X6;J@RD
M9;S%+?37TGF:7?KQMD98%KQPN/(048;_XI'J6WA?+BGH>*%1-I7K$CL'3-IO
MD9[R/2&CHN1FZR.:?/Y7FSPG[CU ??D<DOS?8RN$Z./E GT)!Z5R=E8J$D_C
MK!A!V0\W#''$:S5[%$%PM!&1NT44E30;FL>"M:[IO(:/)^-N2$%X5EB^<>-P
MQHA%_6H.[S5JUUXX*D)*9*J(8<0XIB?A?4,R>6Z0%JW-[F39^Z3'T8]>_W,2
M.#[^/&L_V%:G"(']TG+5]3WGJF?]+D@TRZE,7-8'9]M"JPVPW?&T CG@=QQB
MA9/-^'4Z>_Z_6JNXB1<4C;Z'A(:%B\ X?@YU\?)%I*&3V$"B!PN;85YL*M*!
MYGTT'W3+ZHP&?B]FX13R&HF&;'29ELW4"$0]6AY(O;H6"0X:-9#SI6;/^+3\
MJ6OCZ@OZ(5OKX/]TO/ _*,NZ>]6L[8\V\-W$NGJNM*F^YM/\J]+AZG*?^"NP
MV/(YUI&B4!H]7ON_=^G^[[[Q1<8KS$S(=S"7W>S+,^KI5!,([4\4=Q10:OVE
M]XG;P!+!.%R*0B/MVJ5*O'3%"^$30Y3L,[)V:,:QU+=E.R9#'==@FK*G9<94
MK@'54@\:L=GD-XW5L7P8#5L$4X/TWQ*["N_</KDZ&6L3DH^_.@YO;,TW,,RV
M/?D*,U:3(JN+&M3Y8(>X,F%FO2*56]Z?HWU8/_#/U80-.+Q$CB7/.VA-RE]P
M6B]-57>5'/\R1U,/RU#9O2'L#)Z7!]R=_+I!J[*H#>"O*3V9KQ>#]NXIB@'%
M@]J-&<.&)T,OA-#J-N_JM)S-8C\PG%J=NB1RFR0R/]Y(EOA [>#&HB=<<]M7
MX<"@X=Y7E.VK[P&I@^=UG\H5H ASH)"?#SF9Q[.6<]BEQ8I ).UJ_+6$,'><
M9)KK.;]V@Q#YV>*Y4 1KO)1E02GJ\?3!;.936:M0G>5NV8+HX%^P)5G#K)R0
ML\__&\\TD)[0!3W<4NZF&?WTZ:";9F0X0?B:AP?(<;0ULKU_JUEU9'7$O7^E
M8 LZ?:?(=KIYWIA7ZL<%Q"7<79)*'8-<#KZP7?/&J3'[ >34?_?H;>O<;?];
M(Z,:J!##?D<4;(%DQ*)49YM=-Z'R &GT*BXTZ4EL5C-^-J6N<$U,99QVF9I<
M[@,O2TN4DYLW<&IS'SC0]D^&=^R=+WJ@8*PEL-KW,+3XNFS*_>:,(1F*FR0%
M5)<J=DL0&--^1;/D-67K3%)[!PG]<EY,-D1RP/M!'N+F9&(Z/L>YG5;*U*97
MI*[N=:R![)HT>U+$Z,R5UB>]'X1Q^<J8D"JAPS5B])"!E3^7?-AXX!'.^ZCW
MX77OHX"X\)$>'A[O?]S )& B)OY_<#S__W;ZX"7!VT>:-O8@)PI??$C14TGR
MQ#(^UK,*Z8G9!JU?(FZ23.))$=^$79<(.A]S],*1<E3'HSWD[.#IN"<N#9Y2
MVY$*K\VX.,<HR<,C[=]<ZX?9@WE]WOSD(FE77&\@S^QQ%;J,,:1>8*R[R%I"
MTB>/WZ27J4C24HCP/PBIV.3L1KNCW.E!VQ0>#&LPV)QE#*),6$[/.^\]WQ'-
MP(M)_TR^%].V=^#X*><344EFE]E-TG/%418Y7!L+YJ1[P/3HH][JUJL4-MR&
M@HN-K1KT/T_#S M_;-5=QBYQ$:I3,F 1S&0'UVEI[7D5D+Z*A0F[8..7J[4^
M&-1;=@79Y,:'@3D2J1H_/;GT);]H_'5$%5-4XL+YQCY8Z8V25/")G]QQ&B@F
MTK;OL%M-,V/4S[_H 86FK,+79(9(MCH-Z@.;A57ANO2AR@*8%[AFLDV3CXH0
M=IP[8NJGG/\=0OBL<F9/L&8F$WM_;DLN$KLH^HBU7K_AVZR0&W%I_?0?%)D]
MS.3O7N2RCX7H]FDT,^5\B) +E9_93SKO,F6FY<Q%_#I(_B]5N7QN3) V5K>@
M?HS05'KBBKFI"E?<F4<R7[F6%@;]L]#O\?+4/4#A8LD_;AC#;:E)I;G>6H*!
M()MNWT+NS.$_Z)C_GR0!*\P2]->L_6\YUN<Q,A954="._N%&W^'*^O[@$[-5
M/BO@-T16\+'@-3YS[+-F3]?7[*:*JA3'.^S8^+'8X"Z$WCU 5J&.#5*=K@_B
M<N89*2H0Y2L5>>^9J*BL_ 6"XR-#<H/K*%>NGC"8-<#SDK"I7U=9#' BU#4S
MPYZ(*%*K^H/V90L'6O+<67#XT+1;N*YNY*^^<C<NV#T<J-B)XN2SASHV-CL8
M!QDTBJ=8V%=?XWOF0#"!:+MMJV_MUF/W@/!N/TQ3G?CUO$NFF.3RSETGY'J6
MN<6!,310-=/P'J![[736T@Y$Y_24:%<SH5PO#XJP)6\*.P\/W):Y/?9^G^?O
MG@ARK6,D2'=*[@$V,)5+=Z@G7=JB#GIUB>6IP!ZJH1V_J.J3J"#YD]0?T^2O
M43Q)4\'+PUAZTO@Z8/[!0?(96RS^)Y[R(.7)C)HF4,E>*]=8Z$33GP:B%N?4
MZZFP_1KU9XR@]0[L(I'X;#6Q0E9.TRSEQ"!?.E*3OW/X4."K62P70>Q[$D T
M0.<#X$GJI\>ZJ9]T@W7_4;);*X>R3:WN%?ZG+K?*6Y:HD8'Y_N'"N;-"R*3W
M(E8[F"/^^U:46W);LW //BX+V.)FU')69BRCIZ2!+M.B4V0VK]20&FMZT&W0
MM?@T8""\9-Y"@J8O>Z:]^+VP9!YWRY@(AFD*7[MW\^''V!DG/H&W75?IE8IH
MQB^_8KU;Z&SK-^KLOW9CO3K_LJZ?Y*%SILWJV.)26;H&3=[ASR>K@G4<Y1TN
MR&PF)3VWRVH<E&C9V!$<SHLVA3I@<.X!N4'^R#=K> U"AO6%D.:WIY^F4V*%
M5%ZZ<61V#^S@57RDQ:GKMUXR+PMY1;W7O&&P(5LL1Y1"/JGC4O%2MWI+:MO<
ME3!!CEHXX>5+WT^?E+?,[YH)41C'YMBV)<./30M57!7GAIWZ\.WR]@Q&)"_Q
MEP?6>V:[WX2O>*VUR/8U0SI"F>:BTG '6D]KG2QQ^\[L2E^+$\FHXVOWM)?R
M/.18C^CJ9XKNI72ECV_OF>KK-<">YWRE_"[(C.K[,1![_3@[QB*-)]A>$\VH
M.N2?N4EZ^!$YPK*W//M);;M6:5!*>292LK]-!=)[T^!%III1E3-8VH2>$_1(
M;CDHLER:$?L=J=^AXVCUUGW6Y/N2OQS5YEZ+OQZCXK)5CT8-!='KI,]3R;)"
M^0F9]+WK6V]?S=*HSG=P:5SD!_TNL^/A(&Q<= N=$*!43IN<,NU;=Z[/S8TK
MP'$FZ,+Q'<1$RA4 !<N5'5$ZV7*,R9%RSW(R6=0W&"E7J_;X+>9'GE.W>[D#
M[V*PSY8YLAUR'.<Y4'XE*&EL?66LM1M>Q><US')C%FQ1:OL.K1YV=5MQ\Q4^
M,F67!0P#X?62SD*KGI?Z.+EG?6[:MJQF"CA%)Y-;5<I&%NO=8KT$CUS5]: \
M_5H%SJ;@D9+<(&IFNI<^)$Z69Y90.V.KAD/O :MAW8T8(".3"YGMZ,G&B>:U
MITED@2.5]ML_EW0-UAW>(K&H_E6[1?9SK;PP:][ERC:&M!J\93-3;*&\ 5L2
MD$]3V)\M>5P" IV&*:,9M5_=JM\V4PM"AA\+[-D#.$YEX32 T>U#@_> **#J
MR]:Z]U .Y0/XZ%%WZ\H#9ZS?[[/+DO!J3W^T%=#/9 +K?W2H#=CH<Y[:IAQV
MN.^IQ&:ZL1Z%)D5P6&"C1OJ/C*<5 J-ME6 !BSD>0^9Q%K$CUV\VE]C$0ONO
MCDWGT8%J6VM8()C-3?"8JZ>8D,1(W;O^WU:GK(T;'#G/!<,YY?)Y X JIBZI
M;'RRQ:;.9[:;+E-K)&1EZD7//AH1D%P_?$?B&FB=D\CHZND9.[HO!CNJ;P&P
M;=N%[SOH'2/.*8-Q)\URO:[[=D]HMH)=XBE2&E$GW"#VI+N#=V1;B \KO"?W
M@-T*N<E/EY/'!J7]\[=0_8Y9\[NIA<\E%ZB\GXD@%>^X;L>GL5&%/?#8>6\6
M?G/^]C\,T!#].[-.WGO J%QE*1>M3'N5/<;ZPAAH*G"G(&1,'3UU?@\XX!.D
MR_?"5(%9Z0,'FT\WA^/X\SK*"M;-'</N 6VRQI5]:+][P-6P>>6!C;SN,E>Q
M<S.S25"H.DY2OB,L"!!:3\(\0@0NX $!GL.-A--:GWGY*Q^,#,V25YHX&9+K
M%_3!]";KXE(AG]W/>>[*#U\<W -87?K;Y3!C+679.1F1-^7VQ;IO;ID06K,L
M@<R;H_I^5ITEI5<-X67#?0/Z_O[<WS$>KPR--RE,H>B<A%EZ?!3&R.[8"S+K
MU6D3(/6Z6K4^<M-&2"RN<L_O9<M"F/P@Z^/7K0J#O.^D)ACC)V>DIR0>'0JV
MRQ]^"&G'D,DC#]</^:7AHX<'</CAX3]8K1FMK;=I3:<W,4=Z1ZW/'>%Z^%Z-
M^YKSM41_-CWX!%P;+<1?D+V__@+!2\TV#<#JKHH9T,MLN6N.R$D F=I0'DD>
MI;16_>S\ 6I$M"F'QTI6I$[%DT\/[FV;.">V<SMFD"%%/AV-X1,?5'UH&S.*
M>*//!^W-P7,]#Z N]*K9*F)\58*P4!)G25-G5KM$^])KV&C.DHX 6_VJHP^B
M)[O\C*494DP[]$<S=EZ7Q"W6\DOI-%Y)*<V/,!["'):;8#M ;U+_%#]<R!D#
M7*\D>?1[EF)?LQ6.5R9=T"<2EB]2\VM#"%H7KZT.#(=01#.NB>- 9]ET%'L\
M-+G3DQW<;L<.'M0%;\O0)V3K:W/H9V8B:DR]H[?2=;&OW>('[](R0BTMU^+U
M7EK^X[(T^4>VK<N_, +O/*WI)D<7I R>($&I)L/-C !45:^D7=TVMV+YUP?;
MVK<^B*NN+A5V$*RU&=+$Y=N<.P@6[&S),28DT.];9!%]R9DOI6R0#!A55DNV
M@2V9@%3XKK59F*(6")10/9ZU<O0CS.*&2<GM_LN)U_BD,\89_7_5-T;A9N#[
M=&:NV_XNFA"HPGX/\(1L+OT5)DS+G<2F>&?<XCU@7Y\HGZE#JZ4RKNHN4+="
M0JF [C(ZT>;@IFB_#K.<MI9W,]S,/RJ>B[D'8%CGYMJ#IF]3TO'$\ZJUW=)(
M21+[R["4%/T="TF;D]H9E0S\/WI:GI0/45$+2ST;9@:(QU12"P1]/GT85ZX0
MYOCI>TE.V/I?X^AN/JLC;]"Z^7U6XTP1J85JI9;6S\QU"N\[J$!1F\9=,\J-
M?F20'8JP[.QC<9DL8B1G4E:+IIM4S0BZG-+75TC*%ED$;>M?RC@C\<W1=FWI
MQ?4SX?VS4,=ZL=9$* CI(W"G);K]_,CGH#8)[G(U\=CAR>M9]@'E9>(E,C@;
MZWS^^-WO)NGOM,VZPS>3=#2].O8N5*1*'SG5Q<>>,_KUR<'2TC(/54LE7''K
M&38$*7*%@UPZ&)J6]LO'8/["W\JFUU$C^]["ISQ>'6N(XLZ7]X 9'L' Z3*I
MTKI-IPBA2OZ*A$)3<W^2R++\='<._6UD'DG[H<,0MAOR+>/P[D5F%/8ZZ3,3
MW9\FB%7M+/OI#.G^=M7/M9_UM1+55B&>VV[G2*AD!:C3\JPPHK^1579WB3^S
MOZXNQ4!,K($@.:U%3^')8U.0A<F%G\VHG&%:VG"HI2K[ZO0)9\RMSZ^ BR'F
MNL]I_]9EBNM1*+)Z9<-3ZYJ)R%)/WF%DEFN\=$W.<+A;7$H4&'T9&U<LS:4:
MV=O !*-+1!PD_H&L:2K> [;C%@//A%KO :#.7K$9=,GX/4!/4_;1/2!=W.$>
M\'OO"+UP#R"XU;\HDD';:,9?I-T#GNRN[J_>M<- %Z[W /!>#CSPZ(?50QH6
M WVU>,-= 7#1@HRS0JQH@)*H-R9J87_2*[WM^MJWE,=7; PRO:?CIDYLNB+?
MP1&BK^VX1//:@^4C>QD_KIE@I,"/8'.P!%E^HO)CG+F'@;];$I1OV*Q*+T*A
M/,!'OG*[$?> 3W>9#CXUG?5+P.1W\.ZM%>5#^.'!5?.\)^<Q".5@L1V0'6-7
ME+^WEG4-M17R<^88V]E$&W/ZWHK4_MEY;A&(J?B6F%=D\9J/)\C)T<9L@T.'
MOYTB2"5_+O].@7D:UKC)2LD\!,]DC_-".HROV'+F)6MDJ.TN6DWFQDV<-W7*
MM#>OYPR?+^Z+S]RT 1,W0-S*HP=W=74G_:UA3@D838?15<.IN7;[63['E2X5
M[++5WKI @F6^FM=@&4]!.D?P\4ESFF! !@V>VD$6K;M)_.CQM)LQ$B-)'G#(
MPR@]RL,3G:T'*38,WY\/ZE7I^@MNR,/I'$6_@W:Y7*AIHK^"6WLHK<(J-X6K
M=P;];?QI7SEX3P/W:V^=G0X6B8?%QA)[UVH-K-;1<Z2"RC@VC>OVI-/&>PMH
M?="^@%A5V66+O*$5_4Y@BH^4<.=0NT0 Q 4$8D"! AFMG'R%Q5M#KHERT J<
M=?Z7O+*;!;NW\+Z#B$4W??M1ZUHAVTD]F+[ *D^ATS#K.NK7"_CV&L>1S#LN
M%('Y/GX,A4#TR>)7?X-*FWG21L?H%0.LGM=&.V&@,ADJ.Y6E=[@=KP;#6Y^D
MZL=1_8P]VFM^?>".=$]]_%V$_UWH5TY&%$:Y%6@%K%)WP.3FEKJ#M?RDK:C\
M595PSB5-7Z'2L_9@<*#U_ NS[/J-#XIHLW$FF7<RE&[KE6)5V/K&'&(^1HA!
M7ZA]8S3WJUN%/-4&)P'VCB5M:D9GX-NM76Z-^9$ G(!S]MMIQTNW?@<D::NC
M)G00V#F7Y,;/C2K&7H%V'%5=[NB;FU5/;KXGH9X@<TS:CV:V66=BNW+JX8F)
MGFJVBQMVY33K\03%9.GJ6]VN\7:4+Q@ZE#@TV#-TC.L),T/:"W=R"G$+]J8*
MGFM5NPY.TF?Z+^642;)1+9?KZD6R<KX3T2KZB7?0=CK,=E$HB-0!*Y"4RZ+5
M5"S=F.V5:.^*V K5*.Y^*N\;'W-^1[UW/3?('+)0FCL)Q9.W.S*8GM7%FI9C
MV2\#N_C*\Y_Y\BM0>O>Z6ZQOE"MH-JPL+XV?J1I$<AMNTB'$K.48R3\RUHG5
M0P-:RW/'FY\AU5[W(B?&H[#$MM>\',7',1XAJ)6;_?J+1<TFN;4$\<_N3=<G
M Z?W@*W;G'UA5N%"/G)>#,JX9_(4T]U^8A3&%BV]V9*E H]=B?'!B,^9%_;;
MX^I-NI]Q)-:ZP&0^VT8;B=.@FJ(M/A[4S]($%)&X9M=SSP*L]GF2/Y"/P'),
M/?36<5UZ"*IE"!Z[?*U['_R%#< VL@6G88.OTO*P@[0M:F &E4*]]2BB_X.V
MMXR*J]NV12$&"18\!'<([E)(@CO!I9"$PJ7PPB'!W0K7! TNA;M[X0Z%N[O+
M^[Y]]F[O[OON:_>>=NZ9ZT^M/ZO6:F.L-<><??3>S7P10.>PS@K538LWEM/?
M>3<[M$V1HM%&_ A<S&QI75B/P=-3UV%@#EU?\6 > GYQM**"GC61LLS\5P85
M1OQ)P6L%<>'9?1.XVUE,6"AZ <C$TR,6-BBTQ1AB6*F8+>[,OLI[X.H"J9E[
M/BGL,I=:YJ)01"-5B&$;)EW>G8,]\[4CU3I]X[[@OA(KT[9>SN9Y^/5]27+/
M[Z 6^0J!([((4L=\"[R[&3&-%/O .D<SOCQ/Z8K8'BZL:J&;)]-!D!%8(8>X
MVBILT*LKS\V'COE?$FV+,%@MYC\()\MJ_9J1']=((I@ Q*)$AV#A4+VR@SF4
MHSGUJ_N$]@&<A4)5A/6XI>=T5:CC*;BK!3#C1&)HLW;?8[]\+ :4$^69R=N9
M$0]H))-+E3CJ4B#QN[_=;%[R?O*9N-MK%^[SJES*J3S(R*ENN]3OWV'BI;VN
MI75DR?L)1R#:!WJ '\D4.#PI]?@_%/:4JS4S56QXB-;Y8*Q9*I*%SFB6;-A3
MZ_DS?3\[6!<!OGIH WUPC4T0)\"TF5*2+>H@Y=^5S;X\USJ=X6B *B^DDB9T
M+I3%]"#\D[<+W(LCN+EJ*]OI:]![B8*"F/4Z&4B,%:Z/M=LZUC')#8!ZR1I,
MIR6).B 3S9QL>,VA7)' ;@/3X9>Y#\TYR;(70\496&LH:'QGI!GZY8:F UL3
MGHT'-95"-9K+%G]J]R*"K9N*10\$YCM)FSR\0J;B=3_>LMOZ\;!R<NUY&OPJ
M(/%N1)&_!^EVDKC\B:E5&8>];*QW!IB^V,[+S=</B8&P2I"ZK,\)EO@W]MAY
M\)SK\RDZQ<[E32@TN;K%;VCH7_0K%7TGIJ2=5XE%B#[,.-V)_/YLYH7R;6+R
M)A_13*T0IKJ;(C&?%Z&=E#.\V]"YYDG11BX$I<Y?)\)(^A YS"F[#J'*5U>_
M+1N6\>_R[Y*135.03?+W3PW",=M,T\\,,MM,;TI/,/2_R::7'LD6Q;^_&%SV
M\Q#;RQT?,%M&I+G;PNQB(V+F[<*T'WW$LU6Z&G&I !VS!YG%="U=Z^=A^[46
M+&N/TV.EJ<26S+F\$8LR#6XH9][ *$?O5A%#^LP93>0CW<-)]:THXTNOZ>_4
M*?K-K99B9MZOMFMSY<2],Y!]@;.:+H2KAZ.$(BD<O-@N^5=D4+/J;,L(@%KG
M N([1#R;!!LJGL]5^7:VWE=$(%(P05>@;+6I]URT1.6]:2\ZM)<GQ&RO(*%'
M.R%#RO]$OP!<%8 ?FOBI#W>Z^E5V9R\WKA2GE,T6#II@RWS>F_0>070WFG0W
MGMNZJZKTI.2OBJPFNX+Y<(U1Y66_-!!+/E%<D?+ T,JA6X?%+>:P/.64EHF:
MQWW9I77D1$DKC(=T>K=K-FMP()+U4&01OS91O,?M+640</=72>14U>M9,HLT
MU$]F5I*#4-4A?T[%3CY%J]_@5( _1S]-9*GGOJZ(5&:B-X'Z7P&?W:\422TM
M5/%QQPU3\T^4%5.)W1ELS]OCWAS35,15R]MA[)!?>23O4/'HD6^(M;C\XAE^
M]29!-;X)+%5,^,>PC$>^ZE""2[-:LPU/[8N05!>.)+/Q9R.%@S6EX<']K!XI
M1>X)B[P4BX,)_10KF$'X557*7,G$SL3!3%N.F:O/][3 KKV5BM#(J>;&2:Y!
MUO1^V:&RL,H-!^6\2BZWQ&+UB!0%YY &0TIQ>"10@\WIVV5TW$"-%K%0-2>>
M]1=(;F&E$*^E7A&%LNZ4Q9?9M92WZV^_1Y.&"KR2,4PP\5&\FX4+U']48\NN
M5J1L#!YL7^V#'\P6F'):6!HS#"U->4Q:HVJ7L'NA_QRWMB>)22>^EX4X37JP
ME++MP"5HN=$WK5XF?^ACW$.GB7T_W?PRD8K+C^M+[)\N$[D=64+U&"%<N/O#
MAU,QP6&^G8?=_#_KG::;M=>';VFW2NX7\"M; !X(%F"!HECZ3?MJ=PI$;*IJ
MIVZ"T9:ATWD#WHRP!1?6.SN+-CSVUHQM52U#L%Q9;%8G?%Y8OOU64C?O@$PR
M]64WV-'I<PH##X$(FTD#_1;_67RVV27QQ@.79H5ZZ&^R6+)UZ;1#KKC?>"7,
M[D"9W7!BF,,2?C)U?3(,%P;SPNJ((609%#5L=M#'J",ZQ/IS^G%9>DD(8H5A
M4CR=),"PB0).Y6;M&NXT"M@AV=<K!G=ROWEP2D4._WJUM1B^5(/PLB^%3?F6
MP$$9M:FA'\+S?)MQS/?6_XAS_,!K?0/:5_\EM?)*&25XA86:Z[[.K,/](H.F
M;_*T7O/UK,NG@N6EWOZ:^?K]T&<DRLTB6C5E5[K]V'F.N!SOUZ=T@L.9Z!X9
M<Y-U17P[1_Y4,X!G)/Z,@>[]JQDWAC7;=]+W!+N$9:']IKF8T#X=R_CTA9W"
M<;!Q3.M!>@%-V,9YJ8$>0# *78K58[IHHHAXT&CR5,N7]Q$/1HS$U=J'4.['
MO46%05O1]SP]1*PGDXGOY,6,DI>L(Q9-,7&1S]U81DAX62YN'0ZV6;+VSE<S
M"Q[WU*<<0!JJ<1O9KW(%^J_"*>ISZ<]D;6_H/$\A:NHS$9@UQL.,DB[VX8F*
M+9R95 912Y*#]Z6\AQ='?3L5T60"L'AK2QV=N>0^K@3,3:[M)44Z_H(^UB=K
M&O@(^L"7F;;Q%' I,6%$ETKX]]S0W\K$2N_!T:$E'T^GRCY@[4A0!B,!-TQ-
M#;T<B?4F,TS!!L!ES[34LKEKN4%:[M8Y1;:^U(LAGJ@(2;0'19ZIALL-WS"?
M5*"_A';VXG\=JC'2 K,.CQT%SNZE,U!@05/\$T]PB/G>;Y]V:%9X)F*NXJ<B
M318GP:*G8%QA NR%^/,%/&XF94;4OJZTL6]7XMQI UT5LE.())\"97)P7I)'
M!RQL *DT. $KC3PB_HBP^D)V5VT,U]=_&*J^3V#H_;FQV][EJH7U(]897@P+
M4T)//G_D)UI$S?L/?&4E-0%RUSK8O_#74MQPPT %V?7I8'C<!\YF4?5X#_$"
M"?\,YA[.HA(IV.A;^Q7*4*8\DAD2EW5IVZ?<B3<QU(:@&AI_47"X6#\O6P79
M)HMK!75T'N'QG'[KT9,DR,HY'_2/25[.H:F;6.AQLSN'F^88=YUV==K]LW.
MX+U+T%6L3>E\B6QF&<4;\ :&WT0,M%7%U&%Q)K0-YA8-LFH.+R[IXPB@#\AY
M2XNBTU((6':95ZCF79T8K6)V_E[%8@O_]?I >_*6P@),5"LDVCY[G:]$IA,I
ML-W/=8G<<_"*,3D&-SF&"%I/E%I/E"RJ0H1[&X,-B,&];6QL>%+Y9V3.;XGZ
MG[X0.%#Y1$M(IO>E/R0GIR,>4N$&^XW;,) ->-H"(<!-AFDZJ9PQF59^$Y4Q
MT(N>D!7?G1R\\X543[M5!28IQ8%+@>VL9;![!,^$XT).51=+UK]QF[\I&(SS
MW40>4;5#IWWA+6@ U.%#$R?BKYCJU:=S<6UX=X#Z7_#W_&\T!_Z/GY=L8X&3
MN)HP=$TF[5 9YB_L?QN(_E(91*_XVT#TEP2.E-':-R6:X>'FJL^JL*;U<IN(
M7U.&;U>M!NE^3CKVLQ)XDRQ@N29M5N27D).-^ \YKFVP&G03N"YF6$(%I'!F
M;5J ]/G7N/*;3I%Y>7P< N9" L3]^45&?!:?EO.98$V$%DJ4PA9!0\9OC(S"
MP]^%/19[L.YA9$WS566XDGTE9-+6*Y?ZHL47)*# 9,Q4X=#F/1( @1$U [XS
M8SJ\E&;^ 9+[5PN%^7T98"A_(2R>FZZN0?7P<6[(?., KW(PAT5QBY7M,.8;
M?>KY)/HB2$FL'N6]>Y<R^!/A2O4K7BM%_-!IHTCW*XIHDT!7.N18QM]Q)+Y_
MMP&L1[]MZTH*0*2G6[FK"2,RE_P<;8JGQG3W$$V!/ROMOT0V4Y*F"@J*N1"X
M!LTGZ"'7<\WFD4I&0CSPUEV7S%'1W*AN71400O&"]>A>?UC'&E]I%BP6,2CK
MPBW:_L&P'A P2N#$??G"GA("<;[\;Q)-<-UTTU@^%CK6LP9N0+:MSEZX*6'F
M94WCY>%&$4\.<ZV5JW5MT,>8^F!NR7'M]B:JXS>4<O2K8SDVRS?C"$GH"%<L
MA*W3&9D/)Q1,7N1YL[>!UT$8(1GTILQ5,;!N]PWC+Y&A:KXX-]+%NYI8MX#&
MLZ-G)/TG T,XXF$FT>7_'?3T&VGIMP[T_SKWUG?]U[TZ'+[\!?N8S1,Q,?L.
M=^-<P$-EO'>\5*B?^ZPUD>V"H_-#A;S0UB')>W^HC!B24IN+H7'&8/TA8CKI
MD#[@+56@F)7 4&O0C"%*4,C"M*W"\8%0[J9!.-;@7#VS"HS;ACMF*=_T*NCU
MKXMA<MG=!C]Y[( "4MVQVK1**!_70C5]C++#QC#$1LE[$M9G^N P-+LY*U[A
M36Y2Y:1M>?SZ4#+6M70O;47J0 <]3**#IP@O?.(-/<GP5]!^HKBH^K72AT-]
MV+#-?T(=/VO&K;9W:>LQK>@&"Z=,[D_UDLWI=7VKV:>GEUV_V%7^$3F\T&NY
M1PX/L\=6+1^4AGIIU?^I?8&"]>I_>?T7GP [+13.]'/IM#?]D>H]6@+'63<_
M)S--G1+7Z034B/Z)MT,R=HZ#%?$?9Q^XW%1U]/,; &NXDCX04?2ES[*"_QWR
M_B]? [P@=%VV2M&))#;XPAK!D?!F^F01Z2G;--"4V"XJ40(]W:DXQLIWSI >
MIN@PN/:K7;12)Q&@PI:#KH^PE#78# NL*_"1@"A%=]H(LJ'?&\W.;I= !*(*
M=:6)- _.CI:]XOQC=0P\.K49[$RH&>?VV[I_#3R7U*8B@&JL,?T$C-*3^4+9
M9+R:U'NV5+LX022&/87./_Y\9-MI^Q&,+H..^J-MKNOOKA_TOQ9/7<E=_LG!
MLNGIR7-S/O_T\664^8?\ <CLDKSM=A]'OK8AL.V!C1"%>J7R33N>KF\2%MLH
M%3*F+A*AVQ[[[!NWW1Z<[@8*WB\@!YXCK3)PSJE.D>6'XND*Y/!R[3)^]&@X
M^J^COVMZ>B*_NB0HKBCFX)*&YY'/,8XU2ZB'8BDGR5]K>?:=8OC<#;I)?\BL
MTV:!B?>;B%T9(*:$$0^8>'1UK5JG2!?K[SD66_C?M-6UV/[-;/B?L?AW-V&5
MS7^77G\A%O._[5;2L169-'*>AD[J @2(9$,F9SUFK>#$Y7 2K5_\NMV.$+K(
M*34*F*8!Z6H%GBJ7 W,CCZOSW9CG7AISJ1*!%L,P;MC\U[2/<2:$.VOC%G?<
M7F:O&>KZZ8G^.J:XI^$\)U;9/$6VX)$MWAF@I3!&!@IZ1FK_H)2:O1VQ\Z)8
MCRCE^]N'==JHE.H=5P=;S+8P;*>S%BF1A0\G3\](#ZU6MW8ELLN-LTKZ6OG?
M$ @VB?S)%*E?4Y.7EEW=(*:<MHWXTN >A./\!$R>-H@,-8I0>"G3LIA#5K68
M5QJQ_=!26^_DTCG,4:8_OCN@].FFMW^HQ.GL[#O^\*V6Y<&NC7<:5&4YA7.^
M^#014_XE2TXF56*R0JMNS;6\CQ9I&NTY\+ JX<P1D=XB7GL/SZZLH3OA2 9&
MY'%N*7=]EQ=2F8C4,4S #FT1G[3NIP2@JW0Y$$8[S-29E#@T7J)]:"6! 7 ]
MYA;@Z9E[L/O,3'JMN0.4>4[AT?EFCH*<)..!7N"*C1BIEX-X>C>[5OUZXXF"
M"_6E9YJ7PK#&<3L]>L] Z[WDR;IJQ]1W0I@R&F7N7#Z3_<8S$MZ1GVU^XVM$
MENQ)K::B81#]25^!IYH<0>Z-EU[L8X%(WU"5DE:0AE/B"#1S1*U[K#ZV;RXP
M091<TZ.V5)LW\ETUDX2:=@5'8K0TWF=5(M$Z283*=M/+&E-QK\M=W6(U\=\7
M&],%Y@=N%5)G;:;(9L(.K*Y6MS[ON)#I]O(EBZ;.H-/O9#&/LP_W=!8FK$LC
M&WK#\FFDRQR<Z5RL$E?C<X/DI51N\=VE231A9 OATQGO7C%/E?A'6Z&*AQ5,
M/[RM<^.ZY8?Q-3_EB]X_2CHVO3X9V8F7UATNLTY=>0K0F]'EV&I8G#@$2QB,
M[:0Q>%W7J$1HGS9VF2[OI#&>BX"!BX8+U:(;=UX#F3JB.J5+:[8QWZNFE=FB
M>RR\ ')Z"8Y<8'1OD0B(+0&\?S"/?S9]%A3N.6QA# G]X"N;2QF.FG*@[P\@
M,:HQE-!LFW$MV3X3P936-/WL>>;F&^+?@4-)A$(<9?:I;E8VN8= 8$BW.Q53
MY7;Q=);YHI293TM[E*$:\KL0E,]Q3;GF!<@O#N,KB9;M;T\8%GM4!: [:G3W
MX<O.EB!"\O7C'-?+0C)S',B@ :8W_% ?F33RQG@HRAS/N/IZ=17OM9DM3\8%
M2#UBI-T'4S,Q%':6W0)1=TODO"XHM/(QJ*CLGI9O^CZ(&0$G4\'6<G!Z)W+?
M#S!MK[QWL6517X=JFJ&?-(C%H/9/Q:50,SJH=1UWCG=.@^HY/L2I:EO&]:>5
M^(FX;L%X."8/-]AF ]/?X><W0C:3WWR\M-0(SH>9NBG.4@6B?MY($(>\#Y<)
MF4M&_,E<"*I61)PN#MZ%TZ0YM;"586?_(?^*_L'5^.HX3;)7<FAR[?J@'DT&
M6U@W8/.K6\(#V0IAJ:6]RY<F='KBRE2#PS*?PIYGI(PX8&9'DLZ4;*_K=5<&
M9V!4_G W326K:@":<Y.[Q]7ADXVH2VO+ZEC)$'!"P\2A(K:9N\9&)\$#<JC-
ME]!=I*FP!3-RPUC,R>@:EV6NQ/VK[B?ZJ_C(8ZN_KQ1*#2BA7<3X(H$E:^YA
ME\%@ZLN'WE/RDAA?PCU@0'?VPRR;-CTXL9%5D&'Q 4"-9V0S/&O*L_1GX@Y-
MH>MLTW$F.Q>['"]F*B!@LSFVDK*S6LB&/[_1."T@Y</;AJ1@MV8?L_3P#IN:
MR';S9E%"*=&W,A1NP9+YK=;UL5=R"U%C"ZW6N3 !42&2=.2N;R]X ;U@85V#
MC*I%B[.M[?;NNHOX#^D@DS!;&)/[F-8@/$XWWLK]<B4315E]&*8S%!:/I[P7
M=U?$>O\U<J0A2-[L_&P"(9L^'-E4^K;^/B9X[,Z%K]!QNB.!6'F=U<2!5_$9
MZ?=4[MLAFP^UU<QG%]P:OR)"@028#%0O$SZ_R%:?8J+_N$HH,*SB3XFWF,O(
MG?TA=ZJ>-U:^R-9H;=B2PP&J$JX6E[/43U-K4SM&TU"[$VQRW'KH1P<=F^(=
M>6GAI[(_*AHPS.=#3)R=[1BYBA96&P3BL0;UB$]VC4@XY WA^+^9$IKF1K4"
M*2[L4'X:?D;2YF=8N$QNN-&_;B;N3T!XM4\"?Z984*<*N)3F<D7GH&M2_<'0
MT^1\XV*'NJ<:RH:?M4)7!RF!XDV;1M\-:DC2[B7*O3N7?<,V99SANAHK8\5]
M%N^:XO:9A,*M+ZSS5$9(.GQ6,$T^,N!$^I6XQ.A>;VS4N,E@3+)(QI5D :-X
MZC1>J>YWV+Q>6C\]KVH+^[K;7LIF=)$;:$H_NH3E*L#Y?BP5R)(+"L]EN6>T
M7E!1V-F.NK5KQ0F[]3EH2?5[5-Z\&SRS>\Q-B CRY<UD7MO>?XAZ:$U$R[-6
M.I6GL=U8I40A.^)W,5DJ(Y]^.MMA 2^]D3/=#HP&Q:=N7/U,:GVPHW^L/NKV
MA)<E*B_77B4??M0[CQ/AV#*$RC\C$9Z(;)%)I72IB++2&=B,-">G95ZE)T];
M6OSXUBMSN-EE/02_6U+LO4U W]'QU NGOOPP>-G4X/:,=-IJ86:#E;X6,?>X
MQO*,M-9ZMFHMZ&7!*&IXL/",M&210>/1*E5TF8^9&3YS18U_&?@E\&(1RH4*
M:VR$<7D@$(A'>&]JXWW<B(O[->\^QH2E>S;P[BA\5%5(;68OW&@R);8>"RCR
MJ?@T%?1'!L%RDGOC%JU<& &@'AKK(W<R= :'#WQG;YPH!6'(1P_)@J=3)[3V
MT%;9QT .FO:CQJ4SJ<4.MVCT7XXFW+(_\E"DH*#2ER]53H.P_R4GUCP$/^.;
M-+TETO#!\S1U,C;>O5.=WRNI"0_O[[T%,$']5R/>LJ1ETZP=I=@C1#^Q(:HJ
M/+%7-YA[>_KA^V_5U/=[P^Y5XO"RF7(:#B84Q5A$9ZR*T?7;K5NBYA5KX6M5
M!C@9:+C!$W,>_N_KN:]R"\(K&/7[C6D96?5JZ0,W>1;4Y/E8CR>'AEC$6$J"
MLN(4EE:+68[N8KB8;B%= \(LN8OW8D?T;Y:M<,.3M-.,;S/ZN)7'GY3@U&&M
M(GH>"P%?#E^22W+Z%&!A/&Z9I%R9IR=H%&\ !>9LYOB;KI24'--^ZY\YQ.4L
M.( 1"[;>>3&')+\-1%[S]+#[?[?TIXH#X3-.X<6ISK&Y9,F?,(ONW*XC#H])
MQ\G-TM^J4AG=2E8[380%38.*#Y06W:+#6E\59Q5M[CP8S575;&VXZV3TE/5\
MW3NY<;'\(%-<WK2<_?U&I3_K&:G0D?H9J4P3XZMAA);CJ<B?)]R>H$<R F[R
MTS Z'S2+C5'NV6>DE$K#\98Y'_-_ ^C_)[R>62M@^5X\^QFI=.K1>M"^]89:
MY1E)H_9I5X/K_P=[I\!Z,G^L?482+VJ]MGH0/[2=3R>_S-54FS=[(,SW*?,Y
MN\8?F1M\ A;Z<#PCM?Q,0PTNL+>1BW(Y7=-M.=T%6"]G7K"8T5\AT@I-SRH
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MFJCFFVPP,_W0543\.4VNX#8^6_LP*8@>K[[>K1XT16ITYN7\(%#6%C)W X%
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M;OZ EM]Y 3J2%CK"KRBU_]P?[B9(RM;^H;<W,Y/J<&OI&/KXUS2INQ119/$
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MF* QQ."\1*I$C$/?1/7:LM_"Q=FC:O;^%EP[SB.;8OACT6D^(2R9I;BD?UU
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M+OE:V*%V;\RQ2//E1F*7.OVCK"@CVO(1:$'"5*@)<;V$,8.NU/F0+>E';-;
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M%4R9\_+Z5J@NIYV/&%>%Z]L<,6L].U+0E,&K![XWO<]EC=AG\'HNI&N9/*=
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M9WL2)4.O!A=W=R/G E]J(2I9[V!F+'7^,3!:T>G=NKLQU7,Q N4_1)W3+C!
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M)9_JHZE+WPH;VM89B[7-(X/!^APN11H5*&!CM.F9 ZWI;<-'_Y9G&NBHZX1
M1<<JDD550O!F%O6>3><U^U,VN(W.>E/U5 ?'!*?G_I^G[V;WSREE3Q,1G9!
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M_UUS)E#P!C##R'P%J=IR((FY ?RBBSNOZ#C1+,F]'+UPOXXP"?FGZ'()(.1
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M?"V[+%8(DN\NP6]%F6QS#>U^_BA]NC-'@:FYK@=92W&OY3+A^M-ARN]OT3X
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M_L?/9\,Y'SZY,NTY/543=20@F)R#/_+-S^FN42)07N,?>RFL2D.2F95 'PF
M!?1GI[>;O-J?@;6[NXOI5=K4N3QN'_=H[II0#KFO/5X]!VO+^OWQ0]"/8)F\
M[KO?OK:#C[=R(SV-;P!UC:#A8;2?':-AL0.Q2KROC LI,N:G,LG*,(?4YY7^
M_K\\ 6!2SO:/%1V*+C)?MXCM?N)2G/"LEJ>D\UI,V4'M@+(TP\;&MM> NMX?
M: AK' ,Y*2J-MHD(NM+HJEX2[FDCP6^$_:<U]B3R^.G.XJ3%L#/?HH@3CO+)
MB*2/3A/AS)@JUXNC9Y1114M\/[;UDT8PRNF??0\8?D[8W:&$,,..R^<J5"QT
MWEUJGVE'[_2)12,9B>V-KS\'\'E'_,S3Y70\6\GODZND=.Z3;WX;IA5Q3+:#
M^0,7?NY.T9,[><+WP%Z<82_JD77#JF7P/0I'&:E]Z+JTU17XXHZ&W4\&WJ[$
MH*P+D7>XLI_J17407EY*=*_%%/NR:X[Y+-$MRP$TIY.;[O+04T',78]ENE&5
M!Y&2(?]GUO$_-SCVE\B;"VTZ@2A$=3AZ>5M1,;(DU7(4[]>_?R$V;SZ'O@-^
M8$OV;J]9>@6P0;;Q_6MB%[9LYOW3AH>G&:DZM@=2%TU9%3(H!@?-\L.JT692
M/6.TEG"2X50.#\W?N=@CB36RL[-O5?(\B3J).2;K@-&5C'R=;OQ^=#=*U*D\
M_A9U"85BC&!NOS9:>>I=:$>I%ENH77'OL>W]%*+O!-[_KW'R_3L4Z&L_D_"=
MHG-@ V8[&+B?*/+^:_Y_9NO"?,*2,NB9OI/C_%YZZ#4=#7+(/ IV&!BM\*<"
M@Q)8B,CZGX(4M-]TZN 5$_F)YA0VT%_''X,?IV;>LCM;[LT:0/=62_O!8R@2
M1@06<B6VO@4&9 Z@<UZ2V1^./!WI#%AVL,/XU^M,FE!?KO=JBIR5<*;'#?_Q
M!!NC: [1![5-.E6_ZF8N,Y["]4^>K#>_;'\P15?XM>-WN'(E,S?N!N!;-ME]
M<'[UZ'S!I,SMA)29:_,B%BT7P"21<]R,.0RB%93:O$Y%QE66JT6!\WKF62M<
MZVD'@M$T8R'MKQLO4%6HGS(OX$L][N<-5LR+Y1K!+RL+%);YY.['-?T^0/CF
M/,[E J4(*<2VI@I>*>Q4"5:5P[GNSND4*O7@_6\ BG8A+YYX^LX(]0FMB.CZ
M/99K.O!=B,">AG#(R0GQX:!1EZKBC1NTZF=IIS4A;?H=.XZ3'22'D<?=>F>3
M"T*+V]-?ADGF,+6G"11P/7UGC5OGZ0=^*-NX'/J!Q5^_PL.>@YC?9TB;G1VW
M-#%E+<X&#\&#\N5$QLQE]6PX/J,P,!-:BRF"]/:8RI?DYELA?LQ1XWJKNKNK
M\&&JLI)]AZ+TED$DHD5H1_>",2396;/^[,7(VW=2IA<RPN\JJMKHOB//D"#H
M&:R/:)!U*KKZ[_P>2WXO"!BAS1!=V7$+[VK*K(IEEY@@"W,6QP":8G1&@WUH
M>C:V%_QJGG,3_$U?>_N6FK+,GGBD_5)VZP+ZL@._!'2X>B"@).[RK,^F+3(_
MK)L",/#DMS8)0XT6+>QSWU.R6Z&BGXF:X+*RI8'0:(A48YUY<26&)4'G4?'V
ML."]GZ&^OF6"2+%S__$<&Q$3AP1M)XJHF;X[AS4(791XQQY)]\N%U]YRJ"J9
MM(&-@\QKX^36@NC971EC?(G_6"NYM<%JT;S\J17"NWZ(V\UJF/]4R0T[=S6]
MLMV.1;Z;W8,[M:%K/3NE]Y^Z;<-#EA&51PUAKI^D61W>YBC8588\'1Q>&;GT
MNW46JM@_TCT']VA^Y+HP=0.062%UH&G-C7#?O0$4'26GI+ #C4:3\^BVR[58
MW,"!$P.:0JL='_1@UF7> 59SZ.9:.$EED/.8>4T^>/6)>"PI[4KBK^AS&\1H
M1$GFDJ6^-.F##FIGRB^J QK6INX?\GQ2A%XMUYP-<6R>R:F9YU/OHQY&+)LT
M&OP4^SI,YJ=(P#[W^5D:A=1+5AOE&3S4_<6G^,"VIV>GHN+3H:W8:(OP:O[Y
M@TBS<#5,0ES8P?IQ?F(+L'50IWR@Y[M/P8#][-#$%._4MJZ#C"B+;3C?&\Z^
ML=!F/F$[E\[]/LWN!'L X4KKGZD%NE8!_QCP^![?@D):4- S*R^>L/7E]F-5
M?>O-+;[_Q=Y;1\6U;/O"'2&$X,&#>PCN#@E!0G (;L&:X#32."2XNVMPAT#C
M&IRFD> T-.[0N/O;Y[UWQ]O[C'.^<^\[Y]P_OK=KC![]FVO5ZE%=LVK6K+EF
MS6EEH+, *F';<E5?X=54>['G6:NH5ZVP?^1 .1OFLV;M?6H&MRTX7_!L=-E^
M829TTBSW/FN+Q]EF.+/>6Q38^XS"4_S7R4ZZ<WT*:/SZF3)I^4KTD0(&ZR3+
MCV1ID> S65H!:41<<#T=$A'#42_2#'&KF70YMWQQ<8%NHY,?;#WE161[BO?S
M/<]O(IY]$.^],?_KC< O1GCAJS2/44V(P+PXM55[CLP%6\+HM8-3A+DAJ,%T
M4]7.V>#7=QO#8VY!+7,Q%^WH7H<V;F2LA;+EC9;]587M%1J2"_=Y2BLG+B!)
M*R6OO0)1\<F=J$/$C$S!%Q1YL%B9EP&Y)2]SD&X5J3^'#/$9'C=WTH=ZML'!
M@\TNCR2$883]-H#2Y</SHSZ*9>"%9Q9LAQWNV.LP7W>GZ].:Y,ULFM1AC<_@
M<N8IM^J]\(.RM3K4>N+W9)C'8?,#X(N3S]EL>WEJ.^D#P)>7\DS79S]!3?PJ
M]WSQ#JOB 3!?>81=VV[IY#.5H KX.Q%7S40+?#K<7:XO'@#L(+V[]/;UIL(3
MRILMDI_!H4F$$[NBVS_;-*5W$+K8NFLUP^Y^3P#]:Q><&J6G-68_H9,KH%^*
MG7JG[7'E[AX6XB&2E(O3VEDW2\.+E3?>/ENZ)"<XEPFL,G>B%EV(@U,5G)NT
MH;O[C1.=[=- P6+MQO>1KQ+2G*[=]=QURH[?C8\9_#H:[4(3CC[JNCHN;Z^^
MN]^':'9J<<L=1>J9W:DP,]9DD*Y\AA]>2_@DQ;Q^ *RPO-NZ6==2 H/V[\W$
M8IL>3=S+<VY^CDX66)W=8*!=SX+C+E_:IM&5-+@\6_<4=6[\I-=@<;I!^,NO
M?VA*_1B<XT)\'XQXUN5@?-^%QUU?-S"Z0W<T'*G(."%N*Q!W=^G$?DM7N$R.
MN!4M;)^,&+V;GB7P;*7F[ZD+FH-DKKMR/REGN2517@/6.\0MLT9J[W8/KRE/
M\??"@ :9R2&[3^+PEQB%A2,:7!7HO\%VO&1CBX-^+H'.JU.L\[=]7\07C0<7
M9+KE\^,"<8B,*-SS^(D[@ONESJK.)PYP!L^_+;Z;//>U?&7@GW2Z'] IQYG5
MD6JS'I_=:$IF\ASRRO?#FS4( &#PM%*7<(JU*ZS24K[PZRU37%K99!;F;L^X
M;O4N^ :LK;=L("+&E1H7O_CE4^;]Z:XJ[&@NO*9EX-6"QJ@YBT]RXU76TDK=
M96N;N9LN,(V0_6 U:W8]*P!#-SOR3/]=8E@4NWZB])6@14-:IEASVF\CQ'-H
M"=;3VR^NK/T &%NL/+Z94+53?*476%OUGA1MMOYSR5N<MVQ L &N,2'0CNT;
MD,D0@<$@B:39GQ[PCAJW?0 \+G'ECEG?L.01BU%)B'(98U+$!M_0UV1IV&/6
MS.W.IK%K$DBZNLE&#NXC^E2_XUR>FUZW/M:3ICR+C0<=SWO6G@I'>.!\&F^(
M1N@Z&1 _*P_G"PLT M*4J8JX94CLK0].%Z)9:*8'!.=<2KS=(%4AD0ARMG.1
MOVY65O_Y!&<RHL3T;,.=.&.V3H2.$4-!-J,!K4)808YT2B_F>DIAB:.2!=-C
M3[#P]<IKU9[5-UURE)&EF$+JS'XRF):3J\39@1QV##B/C.P2+M?G%X?4#RA%
M)-15KBD)?71C"%@*B:9:7";?W=+''#X J/*'R"O"6&0PC$7?,P%E?=Q69,L^
MW1C&-GV\:S7Y.*_9=&/#,Y'[NK(N.#3KY???]J.11$K[B^9#F)66UXDU8T(>
MGS0.;ZDQ%MYDG$2*5;0% S-I,Q_MN#!^,<72GU]<V&U0\9XPU?ZT:J:6X1BV
MP%VAB!=VV:MB47@B?SW\0K:8;GP_54&\1\R?\$ \%PK?_$0VQ3%Q)NU7SZA]
MDG^2SR:ZQIZ]T[/S"C[PXR=VWS#G(BIW5!QQ\]GK&426U-B%2F+,_-8'@37J
MB2;3%@FP^3E%+S/=8T0[YLIUE3VBN7N__#CT_=BMP8J(9*Y!L5=,E&2UNIN^
M&!D<I]J##;:PU4P<UN"#Y7$@2?@ *&[UZ<1BOL1_,V40X?,EE<XL#&I3 <8U
MM_]22V%([B!CQ+@Z>6!15R1RV,FF32$$;6IZERF]Y1F4>S%;PJ0H<,I'V!^E
MA#<]=:V>'1=C[!U8&ULN[-3<0!3RU/M7DHRR4XJU_+*;;@#%J.<[E)KL0IW?
M9-J@E9J/>$E_A7@C_;%(UC5KV/8&>VSJ_4S]K8(3]=;=>3DWCM>3X)#@9 -9
MWM[HK6<NU]R'U6/0,;&+P]7H2SM3M$OS/7VFK0EP0C^Q^^V-S;> ^1:9UI)C
M359T06'/_39F10-?":!MX<M6=*=DI[0DK<"?\896K;F\5ZRY&FFZ=U],$(NK
M9RE\,I<VQ^(?[*>X'@"_22L2=F0H4U#=0F@D6"W\+/'0I%3RWF%Z7 C8$^(7
MZ15=G] O119Y;S ^_HS"^VO#29QH]*F5L."V&U5]D<GD39 ##8D0+Y_'1!7M
MZWKL\9!Q GO03(7"B+I>:WB-XO[^[2$&(9I4D:4WQQ&#:KQYB?XGTSHK0E[C
MTTNFU<YF/JO<B^N*F_T19QUI'K[9HM9V7;<'P(*-SY.".D=(G=_<K$+DKUEQ
MQ6TA:TS2+M_NL3Z1KST373RURVB%0':^H[RXH.4Y!*R1*%ZEYPJOSJ$:/@R%
M'C -*SK&70ZHVM2?6/?GQ<+I8I%)DKBXWC+]_Y8 0ZZ?N@]\D/ 3E&8BKHG2
M2P%13T)>>L9G*S@PD4&AT*+#P4X;\!<'.LS^'^NT6V"[C#[''A(OI'[JHOUY
M$JOHFX6JK-%RAJ*N<)!KG7ED//UAFQA65J8@HI>GAXRJ]YQUJIA4>O/79Y37
MHZY_":E\8GYB?@T;^.,>#HUM/P<Y?3O*;X?+.R.B]RS"]4Q:/U@K)]7=H?YG
MC5(I' 2)(RY(Y7]I8:D&0>/FR7@/IL<7'?%*37NWIR _-'M/Z&$ Q<IM4949
MY=$J#,I5&O/VJL024B4_,K]0B/MQRZ^:L/;/=M<?4M!I[_Q@;GVR@NTHUM%U
MJ4GQ-9?F/S;*B_.]XB\3Q>;/4 _DA5+H,5M_3_X7/.L-! Q4'F&0-PMG.RTL
M$PPI91L4Q$\YG"D ZY4""AU/[/</'%IP8TSL!O0<8PI)9)B/+]XHFH[WJ4?
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M2:53"N^N&PJ%L;9\Z\7I>T-8P$4.#,/WK2=.FD!T,W<(>CW6\((U<N_ KJC
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M!KS-@ AKP"7$VDRQ$L^9YU,&%LM]86IY]&9II)#HV[++<,2-(KD\A9>MB#@
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MNP$&5:5@^O$M..FM 8OF43S? ^ B8;4#+#@>+9 PER(2XB:(JO=IR5OT]BE
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M1,;:XX2%C;%O41<Q>=42IKM68<MA]\6WRC!F,Y<0R5KN&8UP#";"3FCF(P#
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M,C9[W"AA>Q*/_L8LP49TXTV"S%)_=)S#O;X:X&,O\ 0F% .RH=5BE_7P &5
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MY^%+X^1(Y%A+>RW+)/)]8-NR>6?'2\NJ(GSA_';H%+\@5#)(*G5:=]/[H :
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MC>Q6"KUH9MU>R_$R!E)4MFX(&@0RNHO0OB\9FB$9YN9;J991NZ&#O7MJW@A
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M?=:^#_]<!C&O2QLR"3M-:5IL,!K(XZI44ET4=//E=1.U57N_1"1L*Y-;47X
MN+JOYU?F7\IM-9Z4U\X=:1G@YG>O19J1, JR8Q\C<Q.GDL?_QB')9,Y %I=2
M\R(NI27L<T0-*EIC; L0"(%4K?XQ0+8O3T_O71Y$?)K4'[4[F3OD/[#Z^4W'
M+"'"AHLV^^'A<=Z?^0;Q/-'"J*^);/S\'.7R_@>E3O )ZQ/%^%/PL.]YIMN;
M'G>BYQ@KWQX+88]Q_TF3?RAK&/=,_AZ%:P^'BP!^6G?OK^\YI@^$$7TPXOK&
MY>ND8M/:^[58@6,_<HZ(E9Z5DL(1E.6<3EDB0")/GD!L*VIXQOW^^WU?&H=N
M%]W+$A]2I0?DA3%%/0MW6BKQ.O TQ^F7D:78<,&VV2:=%\1CH\TF4\W!6_[;
MO:1Y1,F9M2?,AKNJUM=F?6]3PCZC?H[ )F[!CDUP_;U'CL44CC>/3_Y0S27"
MOF#_&Z3Y$W5Y+#/6RD-=]P:G%;)"I(YWQA5EPPNOKHLT+!PY$VP5%-EI''!\
M/6_C%=9>I4!^T,7+;@^;V,E_"+7?[)F':Q'[*_B:SSO(][8\%EYB@3X*?U%O
MTQ*[G!("@"AA1+K/E%VEAM_H!R:'[D$@HN/*QN=7T,UE7R@5F$]8:;S[*7&>
MLDNS5<_I3P$*P@HLN:.#@1E*M['V)]A7/?FY?QT0T;Q37'=V!YU\@4FV@K\X
MW6!1E[HTZANNFU]IV%Q&2Y-&#A'*)7DI;=&$VUQX>*\@*Q[MV,?U$I@E[A#+
M%N(@( 9*VDV(=QQDS F[1/Z"V_(-%U&>^#^44/Y_8HX<RISI1>?4OBO+6^?C
MXT=;&,V:\L[IL]7AB& 62!BG/HU4%O:,8!\421_=959WS>)=_EU[2%&>1)]1
M*_[RJDRUBCD^DF0G_G7B%NU.-[;CRY:X/W%J<3^?*O X8VWEE,X,05JTM,N5
M5L6/ZVEE_7-,4L_ZRCXA-X87+_ ($17ZF'30\]"A;:YB!2'AJW8Z_!?!!163
MJQB2%5?T;MJVQVUCHJ5<+%+]>L"T09FIE<'U6OTASOS1;CB$+@P/&NR "NN<
M"D/>'\&\_1K &V G PQMB5';ZMTBWT?+\"8O$6M>72?<FHW+9[$^_6!08Q@V
MUIB0(2/?!^H?(^1G^FZA(_!P/2%O$79TB<2LN)2LR(LXQTG?%4.1##MG^DS8
MOMJ;US:AT1\S$\AIB,D6@%RM8E.\><53Z7FW<+EW5[.O234<DQJF23_EG(>D
MS#9WO*-@0(O!]>C<]2B 6LXVI=!=V8.X@[QTF#)K$5ZGW"?9QR9(?]<S:,EM
M2:I?KJU/"9#C>G>H.#5B=B1=SH.[H\DXQ[!_6!,V;0(<]L#@PN\W(W\?0G9'
MB.)@^:;!E-='_U4^".%2C =12Z,H>_U)BW[1K/RC C] -HF1IX*BZ6,+DAK
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M=K(48;-S]ML%Y0A;J@J:JIV29<YG=;XCBJ%0 1UO;Z85L8$HS/C/XQQ0)"*
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M'XI2'0I!"86PA48X=X^N*8R.]0 \ 4PXQP0+:D0U*>CU'.U&NS',Z4/WU^)
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M;H87?*2NS);HCP])5YGB_D6).5Y$<14$H[YRF6E$A]J1%@&SP%AR+XVBT(4
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M?EO^<15 ]A;,/^AW(QS V%64_MD(R6QKJ0'&.1.PEVH7^2EJ%T&P-%VY+EO
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M6^\J:S]2?D[*F7:"#\>ZW'^RT(NQKJE$TNU3%@ECT':G*79P'@]=!O'!]$
M,'*_3Y$#&:"35"N=JIT/[/1"-2\?N]7/6B"W0\+6">%I9K6LL4]2E;,D^6H7
M/KH>91 C.2SPH=?\0S-337ZMF*N[==HD]8)LY73]K-# I)=^ ]%E86:[AE&%
M(Z5O@ O.\\'8=1XZ MM<XLI4K:%Q=/<@(4QQ*T)WHS;)H=>H;RTRY>,Z32JO
M,UC%MNDY0F#:M&'?-\K(M:_@D8S^/;(U\&ZX_6P%.TILN@A9/4HWCMBM&C
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M/>,TG*11_;4E%&.ATR+(KB,+9M0.X6Q!,T3$3QNO-Y8FDJS?/6U/CM?,Q<H
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MFN;)0&B4GG2^/YRO4AL7W6W+"X4+'7;!L/&"X"_>X&KXPT\Q9N$&4JB"YD!
M@.?X+E281R-_8X$@B32*XUP$LFG:Y9[1,OCC7QOX4]ULF7#9H(>>A0#K)L]O
MGLG6I['G+DXSK*M[BTQ7WL*Z>J]TEF;OLZ+:QLZ8\!D(S]+I H'/CYA&F,6D
MZF,#^#E.C'3'QARF62D6UPR^4HK<U(-YU_H24 N=W[^S@9R9.A7&P-6JQS^,
M\NCK&'4E$:PS*ZSN9YA0+0F?F)<$8+;5K _M((#%^VJ79[K"<3;%MRQ-%)T%
MU2#TWY/ 4B)R?54.<^T(R4OCDEAA0GI?VUK!,<G#D[&1;LU(/L<.%)]N]LW*
M5#*K48$SSQ%M"CWA^,3 7=YZYLN:"X4'FY9,/GW;U5+RLE9M&7U8P09_LPJY
M<@#!T-ZZGV<'I,.481I"3);>*:"E*)Q%D+J?1**1FY@.B6/GM4ML"@H/WMBR
M=7=&>S-VTT=9R,5O(Q7*%\Y2Z'C5(AH6\Z%C8\"0;>:[$AVOJ\/ZDK1NO\Z'
M].'0[&";.:&XRT< <1/,.,>-&I=!/FIZ7A&M:-5]J2&BROV*6:/,:.3HQ11S
MPI3UNT^R>NXF_LH8QAPV5.&F%%]QYTO(U>8N@;47-H*I-OE3R;U_C,O0,GN:
M:6O!BDX<I0C)'2:M&_???(N-KQS4<M\P1-?0P 3_%LP(P15GC(?*U(;7TX=!
M96+D+:=2AXS\6RQ/$JI'N2%PO)X7[U2D3>"OGVPJ#(W40"_N$&K&7O6YCFXJ
MQ@FE^_?*/H<D DW=!WM->;/W?+H;?(Z?^S!4$N(ZMM8TDUS7LI-LTO5B5ZPN
MYW&^IQU:JK\J^+I(H;X@Q'\RN#;GI?6523PI"P<E\UY*;G)X.39# ]W 7*>]
MX(E6JG'$N_=/&_ (\,"77%SV0RN:Z0.M5<BWZFUGW# *=HDFX,^X(CW:PF!K
MY\Q0I%DAF>::ZODFSYWI53LS2H(G"1F]G&(:Q2CRG4/^D^\,8A;%B*(\\BBC
MB*@(&<W2Q P@Z$&IBUMI8D0;2&94G'A@-U?31MDF8!6*]LNY"2O7E1QM^HB)
MRBT>FB%!<JAJL;5B4>V+WD,DZA!31U?+*6+BD1:2J3=<5RX=*1BO_LU-_MG"
M,=+7$3ASZ]1*M-_R\KR.4Q>CN#",%?!SWI:X2LNG>QO0=<![K&)BB3%(*<OR
MB9E#<O@EWWH*IAV:KZ\Q>/EP$!9=:#EM11(L/X[=/J[03L_M&2 M)702A<:J
M@TD;RESWW"PR3*4PH?H%RWH_ZSPD)\4$$/.I5Q2?<"/:)#6TN561_O*UP/2\
MK;"JY+X-3YF]XPN!%LJB;UH5V Q CKZD"0^MU#*'ST!\#.SO2C 1V9.CM6F$
MPHC73/AB)'(NSP.!QG:/%0M7T&2"2>C2QC'GV>NFUZQZ,R/+ZJ$W+>6B<W?3
MT:95?6//$:8_#><.6.K4$<USNKE3?'LJ89KO"VP82PJRE8W>(O47G&NE,@D,
M>3L*4T>]&9OP$R-IQWI:\;?5/FBY\0/JA5H]@TX]6E!ITVIP]S:'N%XS7D*U
M_+^U-*-_M+1%Z)O[5B_5X1;81&-Z*77_5&U2V8!^E\3K!#-]>1!OGT4*#C67
M.Y@,6]!C(3)#:L:DRH;,VQNY!G.<$.&WP#>G[L"9:-,B+UJV%FSC7/V9?<@C
M4_]EVH7)Y]#?JST]Z]S8'6! \D_60P^R*BC*Z.A^]4^>=+*<HVA#[.;!)F@7
M%<2[YA=2I,214RN"069T?2!HW5LC"Z0;5.T@*>5]V#,\S,_?3[H*&<\# FL_
ME_4,2+F*6O+)L[W#.XMUQDR6YJ/1X1.B6F$D;-#><@-K0[QB;RE0^RY,YA'$
M/.ZK(UJ=O- I"#DKB$>X//9G*MNS6=%-2VK;UE?%1%BYXJ0JC,11?.]DUO^6
MLOEOJ5K-E!I%<,($O_511\<+^*7_&B/2B[.#$&P@KV_=\/'A%[:(0>XX +!^
M"DQOJWT>\ZJM?4JDV.H1\#GZ/N&*I/"<Q?>8XQ%0U7S'H7I3TG;EWC:O"'GC
MJZ;^", EO)7&I4#^^)!?\8 J<J&Z:ID]6?L(:.][^/[SN$=QO^01L/8KJK<0
M)BJ^5]._$]1'O!;\A*UZD]1V1?0(F%/\7.*K\BMN1Z:X91KM>BE24OH(" Z_
MS[LR*CQ7\ST^\:WQ.SGF4=S7>@2L&C\"3(51B^]E]>^P?.$5(E@?'THJ'EZQ
M7<2OA65/J3T"NGH>QI'[_@_ZZ7,\N_9B>!?N,\A$Z)BV2;*?\0SMKN.Q3[FX
MF)Q*(CS)\ ,SLW@&)(V,[R:K]'[@X_L.I9A=AL.\&GRG74$[_RVLTM)2JLL#
M\,,A:-FRK&N$/Y*CO";IR_>7&C+#L;UK3I.<?#(M!JY _$C+TV8ES$I9:G3,
MZGB6>/VD:?CG>^=%NU.OI$? 'JC"^9T-^EU=FPGN0=:&;_QB_2- )CMIYM<S
M3O^?/8/F*ZM?A78^ZM V</BKMO)UA4I;V!^&G=</NO=L)D=END8_XV3W;F ,
M)H-1DUE2BG'3N8!M^EBC7==0*P8_F)VYOMPM2 =C'Z'P?>U;A*XAJIW^/E
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M#HD;II7R%G7R./:7;"%V](CER?;/-_HF:<<EO[58=I*$)4V6U9-:$<9=9[O
MUF;_1)R2N(EOM_95!DY,L'<%GW4D9W[E6<%JYUN.BNWO9D^M."Q)78_F3K^;
M_I5G)6S=_;?JNH)APO%(Q!LKMO\R:EZ>0#!Z:+':$^Q\R45S<EX'.NBD':X3
MC!<;<B/J23&[*4#2RNDVB42M#^"P,]G.KISV4E H@$!+;>X%]2-T,QD89&>
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M9#2R_HG@,G]-,K#K?TD_?\DR^C[_R#ZT?TDRB%'_&RW=(4OTMM3!SO8T7"7
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MZM/FE$X2#=B<+ZW7<MY,P705.=E#MX6F.@UIX#; 2Q3=(UTB&0UL'C9;#Y3
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M-ZI8"2PNV>CI&[PN*%AL=4W/90F91%ZOXBMD,",<!R!Q0-#Y]^'9*\-D7GX
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MB2F4E97S]4N_.\<OUQ _87'9%M)LA2<8Z3MI[\!Y@Y6%V*+KWT34/K/,_TS
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M>=FQ0<V*'+/Y,6=:"ZVZQ_M'7%JWFN%%)MMJ<)" 6@%9?=')XID-D9TG@8&
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M?>&09#9E((U-J7H:FP(-\XNH0D-OB($*"M94+/QEXM$\FPRYE>4%[F?-_41
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M[;;B!4_FFP-2'!UZI..,$1@L:BCI$W/D7V,6G\'JP2R*YJ?3-*N/1B=- <J
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MPE-3TT?@][^^+(J/; [T>2Y ,7"XYWK"=0EQ&T/A>1L] /%K;688UR7"F@G
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M(Z>0H'#KHZS,D![[B4U9"?*%X#B$Z:W,FA,2T?,(<G"AJ\REWP%Z:%5ZR9X
MBB4Z2?E%I!1I5VSCLV)YZ9T;^2+ISD'@ZY:E6*CL'E\ICU2J](1Y08BU: WG
M;U/Y9<7#U=9"5*S_@C$Q2>\>3OP:*.R:YDZRWS1E@GI_(GS^9(NR= BY!PZ6
M%XI:)YYS>R=%]=ZU[2JOC%DDULW("F$:YN<YM![=QE]S+IK9U/Z6GVM;\ES3
M=6W=O/V)<*+&7!O]CQ)@O?WE\G42_*C1N^W^XQ +S?P_Z\^);\\\T$+)[K!T
M?R*@I8U8&NB:>Q&W?4TV:3/:\UGEU/["(/2?2@'_1^4*=.9;6$:7$R\>3U8N
M39 <2E<N'=&L=W']I=^<6<&EY4JG9C8D\](41?SBRK3#P$85/@RQN4?/OB4;
M:ZH>^1PQ=H ,%YJW&NKI= 7JZ4BOA:#M"C9S&3-U)=G%S3%A7/GAW37WC&E)
M/#<SSS=)L$>,D5E$%L>T-R_(35B*:F[03A=@ETJ70.Z$ZOU+#GZ]S-2WAHVL
MY&)J"VFR DBAZP3FZSB13[5>\$ -C2X-61J)?T@='"(S H;W,M7\)E-._#)'
M&6L:WUR?U1UV&I#R7=,G/90@CV#J0( U_-)/566$/I1+;P>Y^HP47V&I7?I-
M$W9>(]GMX:>.UY4BN?%>) '0UJ=YBVHN^%LS.EY]-*L>(;4Q42%SHTW3F5LK
M??83 :1LX4",+FUA@^-7@:?W-G;J.HH_PI\P&#4O+R3OV?-][( &B3'2)P:$
MT%#H\>C^4.W?GNK_(0,F=$/7 M9Y;P5 ^;C^EQ,\LJK;> ID^)Y:,.YV!'^8
M9R,F8R+DM1\2N3P>]SUM"%?L3X3A>3=*M!>RH2#44IHCHGWU@ /T&H%UB[/,
M7\E/+YHQQ[L4V>#I!BCVIO.6,2,-,,9+G%WI:QT-/F6]_&S1?+A'7:'_!RY(
MX4?_-0=Y6EPI<5H>*@ZPY5FO@OU\\'L0WY:_"II1#!F8'T%!/U1[C@<V ADU
M;Y$OJK4M_*H%E_]ZEJK(F_U%[TR--1C*C7Z"GOSBP_7QJ\1-$""KJHOO]"5Z
M^4M?&!6L?IE$K;:@<T??CB5%67/-K[9@514%,2FKLDNSG->:E*HOQ)!71R=U
MD;:#%*A)_00!BZB'M))%5K\K<[=.\.T1!L\9".!5,A>DC-(PW6T@U1=HQK;J
MXJ6U<$TBX#$2?_&8M#7Z?%1,Q-*<\=PF:^KFEE_G577*D,O1NJ,ZDRG[U3<Y
MW!FHU 85(+]IJG>3=&:_@]9)G-GT/2V _NW:_C96^;^@%Q$OH8Z7@Y."SR"W
M)<X792'1. 4[+AURU!3Z(UO,\9I=*PZQ\?41,4.&?):=S*,3B+*6MFD76VQ/
M,EM3"NW8$\Y9@>\PESU0>5$<GC"2!)L/[)EG, _3C3%PFIY=^O8T"6D^%Y7@
M5,"4-(,_Y'M*6-HLP3 -&ST&A[2GF^;XG?CCW. /!H5@A5=5SD&/ 10A?7V:
M>-%8GA\+T=,3P !]2M\?=\J0A4RG;\[+X5.5B9&7Y:-KYUODV)&;KOUF!SUR
M:,_YNC=>6[VKL.R3P8UR,Q-.-G)INJIYT6T,@MIRO85]ZLK#S:G-0I)7<34R
M26.FYX"@U M&<,I:KK:##H8/YH12\U/@HV*N<SO;,5<>^(WP=W6/0(OK)BN+
MT5E<^7>E1\]:NH>-1:W')@\[F'9:.),]GR!S1&J>-2SEK2SD:TA6_:VN^?\-
MB_$;2U,\@,[W21Q=+NX*5<W5ZLP2"*DOHL<^]4%=J1[GS.(4"<GHSBI7(P 6
M>)Q&8U+6)A::E!F;CWT(L5ON%%BO"=[:NNS2[YS4Z\-=[/BQU\',5Z9?"."P
M!N5V7V?JL\\C'U=,NM,EX\6!1X6=XCO![O4?B@*/$@XSI_1+0(/Z0NSJ78?(
MF1>E!7#+!8FEE=*.SG5ZUM?V?<RS7,LVP0(+'GFD?;A!GQ/Y'CRB@**6S[4Q
M%^0A;VL7]-NG/)/K;V39==(5]<'#+WIME!DE(H5QV@%4*&M;!)Q:Y%E2Q37W
M^\$CKN$'EG54>V7SBS:*7RYX7"7W%%A:!+^=CTI9*WFB>79Y$MX'>0NLN5/Q
M4U9A^*J,:< MS,H<2RL7*IAC!I\^?/:%C<&3EUES[Y1L;!D<G!.J9AJ.CFW+
MIEYJ@?6R8J?'I>A<<3Y+^[M%A;XU/G3&T&8VO2CK.0?@],M-1<,%E]V_W;TY
M3-1W"$0GLF%-!&-(K>P@Q.@(R1<& Q._%DUA=QA^6-V@J0]LEJ2HTV"?I;,D
M0E>HVP/Y?&]A;"+F5-I[P$H*X,]W4>)HU<2*JQCZ%;+(#?ASW]*6V=9&NI1_
M3)'RJ,M-:N[DD%)H_S#V?TMQ _(CY_OYJ!5%0Z_/29ODFYP2 P^RGP@*6U5W
MD<"?""3GJDAFN?^^^#[%O3P#8<@55#KJ3:>D(KY++>;XT(@8$O$BKWHQB?_]
M5U<?U$<"'\P%&*GN_ [^#MEPB79R_M1"KA?#HAIN [;H02A<'RNBTJGFCJ6X
MUJ(5B04I !W#6(MC<I::@8$)EVQMA^)9?_NWM2;7G*A%<@$2O^9T-4LG_.DT
M0_2*RDJB$Y0RB\CHX<<OQPO?_2'&!3E3O1/1R.HG=;3X5,'&S[6*GQ\6'GR!
M9]?_1+"MEQH8)'RGI+M2IC<>)DME?G]=Q_M!!@<KHU"LUB\1C&/;N-$7B;"F
M6L5&DAKKX78?B+_B/Z.=6Z,SS#Y?9HSVQ)SY/1M&S A&5:,TLVJOF$/_4]%/
M8F*'HZ,MW7^N<9[=#&&GQ!"&^46$^7%BQ\3;BXGM[XLI_/KEK[:_=Z[/OL@+
M>KTMU#:[.,=@SFARGI4PMLL$V@!A5R#3$%B>#"H=#@]CHKP]W!\YA5)R9=M)
M:E'.+BX^[^[3P;0JR2D7$Z)67YMVYUMU("?Y:L!.'@L X*^FI@?-[L$'M@H&
M=!OC*]_B<R3;FNXC0>.#(J-2;4>%E(:/IIBW8%!>$966D1W*MZ[;>MW*38([
M#,J5 B@RB 3)&,"BZFZ:"\/8)SZNR>3>ES^,ON4EYP A',C9WZ-<6(P)RW8Q
MZ?**=%=O:9F5Z&==F?2SM_56K2^IQ0!GR"GZWP, 5KW_:NC[Y^4DZQ+2NH^K
M\"XT]GHG0[?I+U ($MEL7YNXX1J2H_!>?=NKVNHYU+] (3'X%_\1,S&ZLE/J
M25.NQ9^Q'/DVRXYKPDU&SKCQB7#Y$8G_0UHOP0<3.5%V]/F25;P88P)PMR(W
M?_>>5AKG\"M1"^H#KP41;6OO]=VHBKF$YTDY4P1@E-0\MOS4GL$C>H8/:PHW
M)R?:W_3Q=U,RHM%>35MCPXHM7Y]4V60>]1Z:M8-*QG. >+MNBLN3>#8C.1"N
MTI,N#\XG238T11C\)VSNND@XTI_\98^O)-Y^I ++5R[."#4)ZA8["^>-F#^8
M!?1;E*D7V@Z 1S\Y5EX35,U1G[EMXCNB&<?H 4IL&X=4#TS"9V0+*I@=L<G\
M%@)J#^L76EQ\85[0$7G_&1W0D*)2?Y7\KQ_97\"$C=-)C>(Z-ZFQ-/O7M^B)
M\AR2:/QA>*4=$-<FBM8 6ZCZCI:05(\0=Q/?-YJW54LEO$\KU/@BC=+9"P?M
MGELOIU112=AO? K;^*)AG),(ALSNQ*MP_(#J-J6EB^^2:I1--.Z7)T]?"V):
MX69VZL6!Y0(/-HY>G8A 7@7L:Y6Q#6E,*QTO!&N%^K4O \(36F9:DT 9T]CK
MSIH6#4:3:2&ANW/P=_H?,,F2Z E]S68(!W\BB$S6%XA@;S9*M60*W%^0K/KY
MTS0FA<_.V\B&]?VHO=2DR.@TLY)V(DKJAE7$]!D6,SF1A;M:#K!X8J=[8<3*
M_!I]L-/1_A<?_M[/&%X_81VTZ&1CI&4'\W6#Q3F,$!" U)S4(!P<@"NU*P
M= 79<6N6G[/*D9B#[!V)E2V76X\.V:1MH4.AC6CF+)R@E^;2JP^2&%]O!(69
M4OO"IV(-&8A/[VD\7W%,,ODJ^M@)'WM5[:_G'%B5#8_V11>-JE<VZ+3@N[PH
M&KPVH]7*%(DP(:K0X2'@S[]\\Z&<P?8A?":/GT2MPMW'W7;E,A^FS7W82-6G
MDO=T'DZ2NPW+FL65,C)+[XLKXX@Q0F_TW& C]Q&^>#,_+*N188?I07CO(M!"
MM?BC3F/SJ*ZZL?Q*_B-\^N9.R$&=B-#*F,T9=3X I]#^V'FR:YUZ!_G8*F#,
MO*/,M'2YV7$QGG#\6;\S.'9P%Z..$\FO%S[\@]-U=^UX/M(:Q?)1F0ZD$IS_
MQF4=R _,4C7" 1CA;PP'LW%2!&%PR--^Z"*-5WQ7U?$46\I)^=T980\&MCAV
M0HTRUU<<<0Q157DJ#(<P(D[AON_23 T*=1[Y9&?+[S[4[6U:]-]*R\/P1;;L
M0J#H?70E7[J/DVJ&9F/\ETY8VPEO2,@,5!J!K[?1% YY#XMS%H#F5L8<B*JS
MFU98:F.V4L;0VKSC$HV=XD)S+1#PG7!:N';Q](X1>*31D8B!XN4)=(3X'R'E
M448KM3LU\W=K_)OAC _#[_WEJS+!E@MX@CS \\/A5E1P\6R7[C1K:6U7 W:7
M</9L)7).T!YNJ%^/-(,=4Y (JMCK ^/2+D(,AQ#!,+Q7#YP&@XB[GK*MKZP^
MGY)<@;I4Q@AYZ3!OZR%O4^(Z>&E5NH1Y131>TJ/F)MU);3@NA6H])RL!>%#"
MOSV:NAYIV"0N*>*SNIR'*DL1T6Y'7BB%),%O%5&3A32L5TX7)EYW^.:#OV0$
MKVOPS2C,^5RJ'* D+MJ,+3V,=E8-Q(Y[0-&*<[]Q"H'Z9_OT(D_=+ #XKN Z
MIY>:E;,1(0YE'IKXNP#0DRZ#I'JKK3FOW),[AZ@Z3B,>3T6-/ABJF5/@15(Q
MJI-[5FN8'&X\6;"7D*A[)+#$O!HRW)*+4,)Q^';\;BH1%N55YHK$ W#7M_C&
MJ1.W3AK-*'8C/SE?H9@/ L:P7SQO08U:R%@M(Q+DA)9GBFI9303MQ]Y/"ZI;
MP%H6HX!(M=<1T)!81F,B*QZ#YDICKC)W@9[UBY!!4]K!CRAK&N^XDG+NMS_;
M:*B+G$O<40='[=\EPTD@Q,RCQ[OR^'OS,6XIM4DQ59Y( :'RQ=]G /UU/@P(
M#1')G<\X^?N8E6;;_R &"RED&:IITQ47H;I#&CF:4^FI!N"-G84G!."*L.0G
M><5%W2:$[6=3TREWEP7^'(Q&Q0E]BI\D#WI5#\#J..?M4*K[&>O@9/BPBV@\
M(T0@MT6O>Y]UO2YJ5AJ??.XI[ Q/4?:,W_C#CA'ABY'X&*EZ6;^R"\6C/,@B
MC"<$ EJ&M=A\^^1R5'H0[#PJ#D;&U!1B]=VLFMHP(B_,"PK]K$03MN_1D1)(
M-TS%>LB$V^DPIN%48ML<.U\,H';X[1P(* -0$_QZ4*,X(T3H56B^,5!!CB>7
MPJG15N]_(MRJ5"4P<_9[0QIOLQ!BLG-KS5R5=F2 $=L4LS;!.?4X@K65K6SZ
MJ9U= KDZ(X<G2DL+HQ,D56EPH?>&T^5F[#IV.,\HL.DL7=@(=1I.<5[G!5.,
MN./T;\!S@]E1FD^@.'XR;F*^\8=;!@-(+2T%/"7BBZ6SE;'  (W=T$AD&64E
M\\<,^#PS1N0)GM7EE[R(*E+P,C/OZ.N;A(YLA[A<S9R\!<1V7F5O#N[/^[4D
M1E_W"9,3M>@*LV?.VO6:36?M) LM*.+ET8SSR3\+OAV\_,?QDO\54Q]=M!9T
MPPC,D[NO*S\17A6S>#(9\>98G1BUBCAG4*PETCZ;C/U/6DM*8W]P('15KE,"
MUU&+(E!";ZH]NO(PQ 2OX$=!D-UA27UV5$,0E-N"8Y_W9*G&QT6_^=ZFFV7A
M7P_"L!@_)H/IW\#+V*>D9^9\ %Q"C;?921;BJGN[+.,P7IGK5SFNP!]+>V_=
MZ $+XY#\6Z-KQY#:Y:C6DX:HA[0.#332U$7-WEVXJ2-JM/!0YP(?+#MX]R0D
MQ#MYY7E."<DMX\V7XB4*Q5Y;Q;U;)$-5\B2@,6]99#6SWEW(&>^[>M;I3IC]
M84E, 71B:L;GZ>7(@K03:A]CW+2;&LUJZN)6[*@R(6=S;,VK.L8.0B^2V)@
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M]Q0.$I_:*@#HNR4S?T=<(W.'FMZ>9>NX&Q'_]AC;SC#I_K[C&OL<;8N;A_'
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M9KI_1H<<K%J)'>\2-DA@\ONXMN/<'!Q,BAZFADN<M3S%M.NACR$ R(HG-#L
M G._9KN0?"DV.!.AT>@B.2F%XDW6R\$9#"9UW[SK(IU$B%%U<JL^??0E!94K
MHI%5U^?7C.J!&0P1%TTM688'NYA +/1HH((&+#6\UUP?:1-.\HP'2N_0,RWS
MA3B2F(CYPM\=\'8#(%8C"0_JGRWZ1H_D/'[^LP5@<E[+,FKW\=CC+86N8:JJ
M70O$PM<7=:C?E[(GFV6 0UZ94NJ1CH%&'$!(ZW.W@KH80:@%:'DNT8\!> [P
MD40[T_.5;JZC@FAXV$Z"7[I,@PW>IV+@*&#1JHEQVZL,8%;&ICM+2Z(]@K(A
M$+MPG8KKS&;JYB[$#+>K$CB4KEY7@.A$+(#Y?6+QZ*CL0(KE3;2TY3=P](.E
M- 5S>\T>F<&8J.8(3UHBWK=G',C+ZHQOW#/6=D536D/R'VB"JK2VUJTO;S#'
M W$F1HPV'7M72B).9;J2=9AHHZ4#K)))8XFB_QHBLN]1:A<]AX=!-N/YF?-8
M:H\Q7#29*AK4R);7>$)R>#DCJ3J, MY7OB'M4"$7[U/O4M^*DT\JEL+,HS2_
MV]FK2?LYZ\)3?.IK0Y'O.IS9,]-O =;61=6)%HYZ[Y+JN<Y>,L@A14(ZWJ_2
M_LA9D=8IL<C@YN[2MM9ZWA-+@7"^$W$6">&R3*=+C&L>G!R+W(5-Z00TQE=[
M8E2F5ZQ4[K$>2+\6B[9@"8ZP@ .;IUNQ7;PUS%NPJL>VA@J[%@#\6,W?G=9M
MG+L_J@_:D/R,5$P?"#)!-\B.6'DS]K4\.EP7G6[;6 Q%_QSF#N:M6%#TR^,=
M%UO-HBD\-9!^S0U-3LT3KF71QES0, :>VDH3YW_VHQ)YKHAI\.@A:WUQ.[N2
MU;Q0["^0J+.5(O'4ZP92*>.%=9DN ?B.4A2BPG9^]JB4D@@FLL+!+([M.'RT
M%@L;:VE6Z-E(>)H:F"U&R*KL]6AC\^PT*>ZFG>0=Y'EDFR(+:&G4(T*&U$^0
M)CRW6<49![?7?+=+0\!VM9)_._)I ()]9E7>%G_*BK5H]+!QI;J;WSCSYHO,
MJZ8%@W:A]&[0M33\%;Q&7!8YU-=[6/WIX3MCG(8!LS\)8 %!:^MV#Q+U;%WM
MT!2EYI95M/GV'D5)Q!*[]G56!.&C1Y+%[5<O%T]BJD-G]'-O;^M?QX3_@U#J
MP6U!F#\;25WKB3?@C(3INMMM, D+;G@EE'&-]?5V]>U#J9"_5ZC=*L_X#XD4
M(U:!0?CTF,T/8=CI/<JJ@916O:;,J,Z5HJO,G'#KC4UO,<$_@%-Q:(X#/);D
M.G=]/@K2U74#.[%G$;?U,0ZIMR=/R9%B299';XML""1 '1%.@PAP**T>D(*[
M=* OU*=D_E:Y_&6%(F;<?UZYG-2"V@0Q-SN)=LO0LOJSB]RT>F%TV32&@F.N
M;U\XI4=:=#(_-D#;G8! Z8U'*I,L0K8T._('*&%E O5EE7Q*BG]V:A5#]M"B
M"A ,@F"U3KO#:V3TUD6KXK7CU+!:)C3$BKN*MA]R5'M$;/ 46S>L=* ^<MSH
MW*Q&!O?/@^]1/#U FWVWO1BI5Q;U;\_=\8S8U#))U%F19^5@C4G/!]9G-B-I
M[?*/#A1)OCIW<DN^D*+$1?WT%*.N\6V>SG[S))*G!-*2.)=!57CD]VP%5(R=
M.#[+N/F )40$-;'9X-)XLT8U?C8W.K'ZO0D-8UN!"FX>O6,/'K8X)7W/:-\5
M"$2 **N[>P99F?.%4'H)B"@-=]PF3%.T:S3I.OQA;HM?BBVWN]TS0>$RU'*+
M_*HK/_7[#E&-2YWCG_M70)X8N*G(Q>*/A/>3Y4+/[U'R7+1NN[GN4:*NF%"K
M1O^U\$,3;RP0P0=T;^19@SQ_EI[$8_%S3<+0E%F,J,_B[@4AW??BRI\R) (#
M?&T@^O[I(,EP;ZUDYD".8>@4P"!3@N)QP_$D!%/#&A:B\VN0" <>'2C\(BM#
MN)6/OL@3X<@217S^Q!\/ %0]E.PEP:G$J'S*Q1_;2HU #@  GK]^P#>E>Q+X
M]'_Z#ID0V&O#;C(RLA:&%Y065>85%GU#061E@R33L1VKQ;US#F6T?3M1U75[
M,J2$575T7\="N<!NNF,:]IH%U$I'Y.13U- @YP&F)BY*7G$O5I\]'G<&<4W$
M/4K94?O-*.@LHB<;H9]Q"]2R)':2V6E[H6#FSN6ETK!E&$F:&X]).!CX&<\@
MEG6Z?S2F)BVEP-7B>Z?U$%UJK]6\8KXSCOD;S\$/^[I44:WZBYV939%06N@C
MQYGR-_(Z\]K 0GNBG1%NAJJ!^O@QJ9]IN\IXM=?E-A3?W*-?GQ3T\/05CXYY
M!SO!EDY+N>RUDYTNBU6EN73'"9IHB$IER)\/:^!_M?YDZ?K;M7DEU,Q:=C@(
MBIO=N<UT),(1,J[OBNJS[K76>@,.G+LQ4 4@>!<(7D1L@%DC,-]IQ(F=P@6)
MZG)#K.-(7L:ZMY^?(,O-$>J1^,)RJ?L>;-TJ)M7TG*?NF+CR!K)&@[L1*KU2
M0=!N)$'HNP>V"PH;_E:CQ.9 .GF-:4NL>Y3)Z_R24[0E&_ADY%W)Q+G<F2X=
MX U&$A;IRVU-[ R5[I]E'),]HY]2B2'93WH*KM;>O'7S>_&.DM;LY@G&%Y$)
M7'O]>Q2K%#]K4T 4 ((X2UW4X\WL516H.9=N%M*MYWV'520;7&Z51I:7DZR;
M/P4QWWH6H6%"9 :=&M)Z'J/.1(@5?!?#;N99XUV5"3=QYNY/]-/4K*QKB"82
M%6\S@X0&@DKPO9XDYWX/B,&. KJ;$!9*H@V*(O(F?9TD*7]Q?Y0';2B8';_H
M2@<URZ_WX"#+'TOQ7$X=M__32FZ_-JT(D)\.6QNSW/1[;UR'6><QWK7:8D?=
MPJ^+]F16\YQ0HW=-%[^7'Z+64[C-+8;K:-L$Z9+?8OF%8?5>ERW<J([U8GC]
M^)_HMX*B+S+7[%J0^OX88%GRN'D],KY N=U92( J(TK.5T?BS(**3$-E198J
MPFY.*6\BH]D-X3:P5J&]W2AJSCU*C:8Q\N>ON[F$X>=U<2YB&][X*K!;#X\D
MF4Q>O"GR5\012/;C,F=\QX"92W)!).@Q$X#9+4+BF%FQXC5?/MM:.36[[QM?
M^Z-60M8$8O!L@$B,[&KEO)+O&5\DIX=@[)N%3G,CX.70S<<#+?P-3JZ@M<@M
MF@7#K8P]@X46374$V2Z@,.>!!(0\'$RJ7HN'I390!A$(=^RQX2CO(Y72XQ#X
MS S6)/55.K$36GK- N:KK/4P. ;Y]0[X6?%L&,I)6;?I]BX_;.^UBFSV-\)/
M8LIWZ!'FA.;@2I'69(=@C$D0BFLT4:+8JDSJJ+%^ZIWM!%8**.!;?&ER=R)J
M<H-+:Z2 Z^ITN]>,2ITKW9YR<?\,;(PXW#-$1?44[O5- :FBE$<OVA47.W9!
M:2=U34WD(HVG>R(<9*V9I_H%'K!;6S%:,W4,#INC"4?ZX$ "0=AC4@B7\E3^
M'_.S;P&41D?D(DZ5VE%X2Q%\/Q.!'$JL'"R99P=%0-M>.%<L%XZ M:$DVH$0
MUJRF_:F0AYW5O'OV<0+"\4 ^?"+9NY.==<#5J[F/M-Z!=[EIVE7JS3MJI]AD
M/&?Z1U#:1?4P?=C<+KCTQ8>'DW16.X")C.;Q2892+I>-O7'1P]Z1D2P6^4JG
MQO:2PD8A(6!)$0 CT*NL9(+GX@'('?7 6:RM$0R(<!Q&C/3$/?0$,I="A(\M
M;RAEZ8'J5H/O)(6<$V7X(G-& S$H5+R&DB_L0TT<BMA^!<\!6=9;Q#1^LLY4
M_=29EE>RCH]Q(;WQKH7IMA6GV=#$X*">#QZ7RPAFPRZKO>TGCC46K=XT[Q@J
M$YMN.!>&(RC:Q/YQLNY(KW9P4TH*:FV6[_7--15R@!#(URIGMO_PW5#X:-:3
MW::L* I-GHWR'"8+&0HF_I-*<[IL#(&'Z=_H'QVPSI:/LXY.F("5S7D;>0KM
MZV*G1FPN.Y6,:?C(T8 =JQ:-:754#&K-IEEXJS)C2.<7#,;3!RC4@W^L,@QV
M_)JP0WL6%LLI+6!/]FU41I\&P+JW).AS=+>($\_:P;;-"X[,D+'WY"EC:-3F
MM._A/=-@DS,+PHRY/)8SY=>/5#I9 EPZ2;,)1!^P=%#_$0%^Q8+!A0T+!WJ+
M2Z+F@2L#TQ<"5"%O!("5+(Z: 92_?@OFM+]\M1PII[WY=3Z T00O40*$\X#!
MPE&0;0"&3)U,"RZLU.&3L$*4%4UJ]]T:$@1V:GCSV5$D:;>RX:@7/\0C*SZG
M+Y?.\1.$F##>Y@+FYQ:BR&\=R@N!I_KR)!RU4Q30"QLMX]+HTGX-4_S=MJTT
M\ZBF-UKH-/D)PXI1^=QV9/T)1Q_6@S9FM.=WYS7!9"D5,A%S0AR8 C857>3>
M.N8W+-&5$U)XSHM/-Z()UY\%TJ3'FA0\%E14Y?0ZR69@<*0:J5L=[6Y#,*W4
M*KM+AQ0MJ 0 "-/-S%_-<]6,];-)7OS8VAJPCGUH?>;VM'XJ9Y56"R>(-O5T
M0(WSZ+<0%95Y7M9;VB*47JOL0!4XQ7E^,A]9EHK_O![]@]4XYEZ6AU106$X\
MG?@S)&&=1R>'J/,CY[1">DFTL/ :8JWLA!183B2MA9\W1P0>U_7-7%91JQOC
M[4ESG"E,>-R[^(>5QC,/9J*>R2N#)A5N'+%\MT!\ZU*YT9CA@#+>-1BFOM8*
M-6&Q2CC7]E>S2.IE%+U?,'+6RES&HY$\JD78K[!0/L&OS_$9)VJ#/8BKGOBB
M?XQ; 7'$S:EM%4G4U4O#1M:\Z\_,Z\4D%!/H!) /J>^=/#Q(XPG(4L/^C">K
MHZB>$;Z!KOBYOMM)\.N/>/8D?ZT J*;E>PC&(6HC:I4+.+'7A'=<U+*YN4W\
MI[&K1E*'5:2MCS+-51D!F4$0D#:'VD612VQE2#!R3)DIO>KC0=]BP^^ZY5&A
M_#."5PVZ;J4UF[S46J4V>2[$SJOQ MS&\;FL1EDAR_.[<DXSY$DF.U$-^EFA
M]F>2:!$9GM^<9]6$,L92KC8U ;G'VG9\::4T&+*&[ &]6EUFW^D?4&X $NC)
M1</(4M+?!<,6PXM?>WVXC9VSNU;6F9Q@$OJ(?VADLW-A_@1NDYG7):@EI/D$
M#T5R2M@]N$\[6E@^O4(KI5^7WERG&M6/;K)G>#5.FR(DFC%X6-N,88DZC"1.
M@);/*/)Q1F^O5%J2^2V3[)XF(M9[>M;=JMJV0O!"AS@ZKW;25D7PY\W@5MJK
MXVD;+7PGIT .YQ: \LL,/>AER%?M*S)4\&+]8A4CPMUBOG .9HHS,#;^/76B
M>X'HY6S^!UB6*G!^+5*F*[I&AHGGF9E>LNG.AT^+82FI"G^%WM^%3L5NU/_@
MD?.>T*($'3ZR6 ^LPD^>NG+& H<:U( GOKIAP)/4\3,_NA>:&'=Y98OSL[26
M7&3B*8U[Q+JZ"?H2.4T57X1A#-WI:])<913=HWRM%_EL=>FF%[,#*KY37;NC
M*^*D?G#LEZ3>>Y=OW;K.IKRBX_O7MM:18?Y-B^N3SB*%L^67\O$7B5E_;9M-
M3<G.]]?N\O_:M*#WO_+0Q8'G7J"J>!]>4X=S:SU"JT*>;DPNNL 8RDO1'K<1
M058]Y\>JGW2,+;V:- L-DQ@NYQRKRTJ;A&-:Q^PJ#*U>W:/XSHLJ>%%3,L&V
M,SY*(RGF(T5P3N.F)6O8KH"&N(TRYZ;84"$SR"@E9\SO?D&E]/J_"\?^*<5Z
M7$XR+C9FBK9M&V(KUE!%C*=A:L[[G&R1*!,Z$_;DJKD<2,/L?S O2'*D=S#W
M7)U1B-NGTK/F'L6,IT#REG_>,W4LL<3QAJ]SUGK#Y.OSNXU=5AZ0M(.GAZ^!
M^!:6SP"_=Q4?R89,=4B'-5]*<6?T_&UK]!ITK1.?C[F0T=@Y[Y9M&,$_F-"Q
MO1D LF"3FD_$9K<.L;"U"X>]OK4#$EG7R(&[]^BG.(Y[G-$?4'#P)N(XT1^;
M6(#.*?G U#N*@?,Z7KL2VUA <4M@?E'U%)[((TA?] /,LK?-"]2\1Y0O4MHS
M6G/U:_Z;. S]N?F$:W]TSPL**IH+91&=[+;?B P8FF\=D3ML?S5-[\FZ=8,,
MB.P[T![.I(DOP'B52)SR1N0! %*Z$S3]EH(GC\O3AZ>0P_U-:BCJE]JPH>4C
M7 ^^RI2W+[[B;\,BDBSBF![#PIZL))/2!\A2Q0E@>+TMD,EIAX<!<C^UMC9J
MAM# YYG"X_3-\RO5!>5)@O.<1@5;P!JECIXE.XC'1LD%D52LD7LBY2\.!^Q9
M=+O1ZLP,B.Y1#!<0?[[VAJ$C&U"V82C;X!]_#L/9&1_,H6]!;VFN6:]I7.]1
M0NPZ=;+P9T2D&;8I8 XPDOP;+GOB!]Y_JT'YD54YCP-6XG8C;!"ED,G,I-0M
M0A?=_ A4:)!M3Q,P*>^V@1?N=489NY+(],B_K5<V(ROX7 6UM+&5:[1FY!?/
M[]Y!L-%0%?)6696N@:_8LOBXYER(&D=8ZHK@/$T;4?Z98F&4-IXEF.28(.K6
MF&C;*+F81P'B4#8H[>"*^*_3O;-%(-<0R#V0+ASS#P5VNGY&1D8*#/:GW^X?
MQK]^#.;J!F<B4JOV[JG=$GJVR$B#<7NAE-S&N)[.*(=D(4,+S439$:J(;^H#
MRAMVRC3*;.YX+T=A7Y67217K2X1FEVP ^HV5NK]H+V^G2GMQS:X&T%4CKP0;
MQX+[=#770F=-'*B*L.W1I'G7BS(<+=U<%$PIP]RYTD44XP3J1& W7J-GI*$V
M7.'QY>;8O.B4X*&S8K-2V))A#^)U?)M904Y#\W(!^LEPBJJO[064[_!D4^1Q
M)2JJTT)W2S)H<[N]/&(!^30$+N@J3GF5)'.R;:<]-G@W"=>O1U@UE93IBP@6
M>#D%$<%_5#)4GXDC+K=%02+3B@8M$H:+<_ <)$XSF5_>L9;7)R:PQX^K\%*%
MD.1H?C/?&/P%D^Q^MK$>DL!WASO?)-&0MV!D3'7J<([[2>+&%JNLDJ9%^#")
MQE(53M_$X.IRALT8QRD7&!S#@D!V].H($)]E6]DH8X5E1=,&O$_E6Y.<"XP,
M,XREHE^^@08U#P]7R\EHO$G(?](AT'45XM$58,S&OT,DE@RM.UK_G!4\<CCW
MO:CPQ"NS>/+#+"=>5.&.[;I*9'NPO[]1*^$G#)2*6#!_1007^ D8M6GYH^!P
M7O=J:#E5;+8H/W"GWOY9=N>IXZU:+U;G"07V2):8G]R-%4J6+^3DF\I .03^
M)<W1F+YZ8N/1XON@JC+:!<5?]\9:78BR[J8#5Q3BS.NBT7'5CR^A@6UP>'"8
MM_37)U1AJ <3JK HJ?>I@09TW<'++":I9L.Z-.?#^^#11W.WZ&?506WPNIZG
M^IZY"3=!5&'/M;&@- \X\3T\%O?E6JMX8Z(]3LYR)QJ3XL+,C(JSJQ/MB1GX
M7<9)-MUX%)[3OUNS.+-[GT5E&&?ALAZ3K?'QP_?(] Y"_\4%"<+/(@,#\7QL
M-Y='^_O'!OT/YN>KA-B1&Y.E-@3@61%E.Q"Y1AS5\$;K-?M4G+028DSCQ>M4
MFV<.)'4XK[#$F$D>G>YK\![,EJ1-MKP=<.;!:M:M(\X6*(&P3K-3<!6P#\76
MM*F2MI3K=OFA!5/%23 6F*X42Z-3']A(#R,:*GV=^RG9+,0?"-M+(JB'3N=O
M4E"O6, (S9D(IVO1W2;[1;O,9[8M.FL):WUK6)F";$F=??R=P/?6S&NKKP3=
MWAS2$6J%G\F]RTQD:RX.X6"2WJL^\7#/KK8+%[@9 LQI0T)9@+P5$QXIJP.;
MUI5<_<1\2O#7(&<LRM,><N=CL:!PC9W@HYB7DVGF?,:^;23ZL&EIS5& 8;[-
M"I-(L+ I*_/C#+'"*A7H*+ZFBGDOVK#<,@8_M'M5)UUYY\1FJHP&#_4GV;C/
MA!=!5?0B;^)XT&6I>JH'NTVI@WW3^S4W-@V.^,YH_E5[QJ5#.VY(15V[ 'FS
MNV>IHO7-6:DB4YPD/2W:GS9@"L.TM'"<QC]LP'[=W!O#R#W#'P?^H^TM6M1=
M-J7N$1R.+/9U4_Q'Z!8$Z+F%S@GII))A,OD=V]LOJ.SY@2 +M_&_5ZIB6=RG
M',\.0Q+,HN.C+G=)?'2W;GK020C6(/,I>%9< 1TBY-!@5/1_I$78\%8B/[<B
MD.//,B7W*,ZT:!<O_U%<'C5?Y<O(I[GG4.:'SQGQSO?OZ\[NH;99X5B3UVF[
M65V1/\8H_KX(_7"K6/?<[NJ]IK>@;4T$; MDTE(<(].3%NFR6:;\7/..:,+3
M1W3O8F.<"+_L=)'EU,,F[B+JH3S"(^/AAR!1 X>CG7J*":3F36[?C;SR0-&:
MGQK$\"B)X9!5Y0L.0=I-0YG,*4#]'H7)V>_%^%_;?C"3?+QQC\)6_.56:=*O
M7R\+6OU;XTDB7%3/UK]V*/*7MA!I25%]3<TKJ[1/W&S\6 &C,[ND67@6/'LV
M7!C@N@O[4RNK=%QP1>4I6(_>G6J;RLCOA5"MWU@3TK/(- [37MG^A);S,^K'
MGJV^X9^?L.7Y]2<]D2HL+MBC%S\QA1?9VBB1)!I#.$0/9YDA(9OVR*TCP/?R
M4X,F,&8PC]%$BC>!I=K7GF_K/<O0'YVK.6^6GLN]9$X)K3+3:^6_Z6U&2+]>
MD%[_"'J;VQ0M#:MVXYC9J6$WK*4"O.G12'BW 3&1<;<P"J%A<#\R0__1Z&["
MBZ%C'U+<9>G3/*XMI%MTK'KA<</[FDH@C-#?O-;>4^YU,L+.H((Y13#HM.##
M X),1V=4IGN4O;T3_?-C#[/L-+C<,2(D-#G -$UM5<['_4L!E$TL>K1*6;6;
M7+:GC+_$.H7C6,/)FR&X$?O3J]( LL7;&5T!6+Y2(K8M-\2:KZS30$BLN H5
M"VE<N%8VO.39M"V);U%.&DP+<4JX-<23W$C95OFTGC#X9'2/?P][7#^Y,M;&
MQY1.2*T9%NGP*;Z_:UP83_H#9)PN2B1'1\LT.>KB">=5@ 6)MDG$CVINCAMU
M9J)_SW@@SE[:ADKX\GOFWT1<)S L9W^O$4;)_*%4>\O'A_MMVAZ@X!Z%Z,2K
M*/7W(F%;6,EA_[BJ5P3>ICJGND?A\^'5[:S1VG./D#+)P0RA+M;\7$LB-V&1
M?AAWVMW#EM_>0SIN]5D'JFC/5+9LBQ58&1$77)@4C4-,NQ;9-BR LA)'PY\;
M_IX_-T0K:C61Z$>L]+N\<#'&]7 Q(IK8=YB27;#68/<LV>/Z)XXNZXV*=FS$
M,EWSE611\+'D7_AM6JJPBFK_G#/7R3WD:]=22%DYI@&6)\5&9!/A(A?7V*M?
M"<;<4-80ZA_ZLW+FSNL,U/J!!O=M+<3X.0JL=6E7B>4>10MU'G!2 K*Z]K==
M/'#+Q_?[QA%3XV[-@M^/-&B8%Y*E><XL9;4+"XS([9<_%]7!5'I=QX&N7]*B
MXZ75_V.3L#G"Z70 Q^T=L>ZYMYN+SK[&3I13P>9IAEB)VW-#M8W\'1?3/HMR
M1=_>3P35!QTN7LT@OV_E+\76.@:GG4Z@C1]KB9G!H&>+[&]^Y0H=!^9 _/*7
M9\R6@Z\^&?O9>R?L6Y/@-GVBI9+!H)*AY0M*_?SN08O[]\D98;D3R*)E$Y*>
MH%_ [FPQ_=L"S>K6("\DVH0 M&/)9M9#%O0)UE-P4$] Q=A?'1X])U:=<NM3
MS#T5.@8AW\N9O&P"979H;,<&'1$!4'68Z \"9*5+-3AKG44C%X@=E?EDN>T'
M7&M-RP:U6)-GD1B064?=I5*\O$,/1H2@*6D]B3HSRN* #LYZLP.S)\*,%0"H
MC3&;\<#'%S7[5V;KD)HKO=L0&8E]\O0%6YX'$8\;JVF_%P!#A%^WEYTTR\5R
M*" 'I(!"^4(Z4!\E5LL#3R))\G<(6?H^NE<^)QG!/=4,0/VVGPFO)8 ?IKK[
MBKBIY"B[R*O&*^7]L T$!@)*#\!!,[(;>+C$,*8FBSCL%T0HX]WU2B'31'8<
MZ1T[MEA5V>GC*1\MO+%<25-VUAW/C7O?9\U0,1 B-3^OX5*YQ!0(V.=V/Q=
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M%'SRA[D9%U\\%Q_FT"E1B]2ZG]N*0%Y(-4>?4!K:Z'2Q 5?F9 I%-$VY 95
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MNPZ;=M8H&C.A&)SQT308U$:X0,F,5<IE4[]KQV0OP8RC";,A/18."AC@LYR
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MJP*@EOU+H1)1@S]TTED+E.G>K4.Y\/_6AO_/HD (_3.<3F9J=YA[91!NWGF
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MWL2EGQ*[5]+,8])/%%=\YO'V-"LO'[^ H,05R:M2TDK*-U5NW5;5OJ^CJ_=
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MGI)#?#M.7" JF*]=[4BVB-XW;:RO@N7:-9W3++%YI%"/ZI& WBY*LD^AL33
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M9+"@_H77W$QV0XUEG:%FZ$XH(HG@VV14]XTG&-4;[@WM#=)*P5M4V1V*!)#
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MG0IL0XQGO23>^ZKN"ION1L/ZSJ#=I\/NIO*.]][KEA9$<$1YZEE*E4'?AF!
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MU>33V#L&9[Y[UMCD6%!,P(,KY>W3EQ\T/_2'+ILK(5B=IT2N>?5(=P-?'/9
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MY #N[W@NR>Y2W 6QJEQY=I_B8FPM='9BHYB0/MIV!-9#"[UC@B$>\SQ[8:@
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M@VRA2J3^C*+F,D7E\S+6DG<O4E<6*B)I+$A25V'2&&";*5%;8N\"461*HD7
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MQ6SN+I0%[N>Z8G0_5Z/8+V3MMNT]3H\?(=]D,"#IZ<OBGOJ6@BD)B+W4[*!
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M#5-'8Y?U7<!>A>_5T5U%",F2 Z8OV$(YRT C'CA]7IM. [EN_\RY,.6BF-"
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MY#K/Z[SHRH8R5P:(."Y8SHP6/#UCK-9BWP>A6+6EQ\?(/*D<R=D25&[,8N=
MIT^3!UIC?5M]8*[V?$<?CADL;K=X M !@8.,-5"14393DD/V'Y<$8Z%%.,D?
MLXTFD+:F![LP#,]J0'*.@DG""X,=3N#/YMJI:KO<OT04T3>%FN/[);=->)_,
MUM8[Y+HUN5A&MI K=+<Z\AV8L"FURG)YL>K.0LF>S-;,VV+:AD^M?S6\]A;,
MC;&3#/QL5&K6@:79Y.GP"$.4Q44N#46KL^J^<7I?CVF#2SBLZDXM?US8,,&]
MYOCC#6K:OM/%'KRJIU438&2J-S;P>#"DM6CPGI-,J9D&:;4A'R(=\QQI-]LM
MMEU65+ZBAR&TD%:UKIJOBXWT^D6VRB^UU:_T/XV:5_Q60S!T^_S;.U.1#\AO
M'=.2T<#=;]KO0FOV%\_M81)*B0IVN/55PD,)6U/16RR#-FY&7_H5PZ6/9?PC
M+K=LQ58*^WQ(G.RKG/'\E2@,2OY^OF3(4K[+[EK]N\^YZ=&5?7YFM&NWWTVZ
MK$'<V3HX?[V/-&GFY"^:;A V_.Z8KO<=F]KX0/N'B)TZ:MR?]SQ(6(8AQE1-
M\ONK%[S%A(\S6,]PQ<IFX<]QBY!9K3\PRG)!SJ^?)/P(?6!WG]ZKJ184A*>T
MAE+Y?.($[=J; U^E&O9<Z["Z6O$G38;)3/T\7)=]WS:FG4\_2Z;\)=)H_C!"
M$/FA6TK:\'))^_DO+TQ?/I<RRZG(VQE@7D[?9D;N#B$!*QH_>S?2R4!.)T6'
M<-_YY8/$Z1CJT-QMU:*"(%, %[-&(_C![TIY!<+1RA3O^I#F:TG].-ETM5@.
MSTK<=5^9E6  1<F>I<EPQ;-'=%TN*(OM#<K(1H8L3?JYPQ4&8#*[ABNL57X;
M+XU=LUTNA;(->UMQV6EL0<2'/+ZN:B/1W*0I2ZZ:C(7J+!7DW7DNT"O?XO:Y
MN[-LKP.])*Z^@X>",]W0)U>8;\QFV+[]WG%RT:90:P7/HGI_&<]$8Z<D=FN!
M?RA#2G^5("N_7&T]O<OZ>9%4>LQP\9C!.=;Q3S+?3[\Y4_3.,0.++4X+[/FJ
M;Z%JG9.Y)' TTHB[J2'-E;ND>("G?OU@=V@;4:.B[9]R)ZFH1^3NJP9?C'?S
MC@JH&WBMAL]^!ALR,R4FP=*?]G72VC^I@YU97[_?<Y3S!UR" ^HR+&/#2GAQ
MX\8>R)>@=G[-X6')*J_LE<7T38C00_3.HM>(] K\SSDN;T1HOK *2403JD2V
M.V)21-).:=&N9[%>9+JGXRA4NB*"WP)@R49->7QHT^A\B-N//4GR'.$HM?LN
M[0^+Q_"W@1 IXHVM1T6]"4DN$21__L(OI,6(5\I&)%L;8)<M#[WS$7(KT9'-
M+'<B5FF=J13L6LX.1FSEDWK<'J@)2WO<Q/V8.PMX)%)(<NP$L4-5+)+:#W[M
M7M'U%#S#R@8P#(\9%=,MO%K8'+*7*I;AYC2-!3N66JG(:>@I8SV^'C7LV<FL
MIFPBUK-6]%=LTK:%.B38S2D2,W;M@6MG=.J&$GO-P:4B5KM'U!^HS:%CANGR
M0$M*)BFC0_56=I<<,EA8;N],7VK[A=]6RF/'#%EOZW2WAIN4NOB5R8SQ%=B]
M#N[\@\]+LD7IP<;\47EO5)/?E0S?5S/\U7W*V -4<%TJHHL)UU-L:^:\G=1<
MOA/< 'Q8D:%MA) O OCTE%>:-J=,IU<881'QT>FJ123QE;:+8'=(21]<-K<4
MZ77OZE)C3\^M/+)99^P#4PI@!G71/*B*!:S6D.A?.(&X/R5[7Z'/OX?47[%;
M#$=5N06/7/*O:O\MNPW:N!K'V.SPVRR/^3) @P\B'G2 <&OH/DL>BS5NZ$YU
MC<1OU#<ZSHGL>_-PR31FP'WUP[P3K9@:PUXD__G;(TAD28*)^IQB-0.X"HR"
M*I3XE0Q*Z\5?6#T_XFX-$05-#2"@+?<N:PJ>B2^Z3K8(XC6<SW!^-3PD?5@Q
M"I-Z71]J+;(0I;>>@2FB;Q;TFN)+I8_LVW#XU<;;H]'P<KA7GT9'DF)OX9MA
M2R7>=]>/"!/L/2M OB:9&59F"K@=R#*\NSZ@BSY?Y/O515,@,.W!WJ.X$/99
MO=F^9U3I+'K';Y_3+8>[T>V[WA%.J5RQD.G6N%O4)_%J0E]?6V[/>\C&5Z>_
M^Z7U=)%H4)2VMK"XZ:C>SAHL;3NNDJQ$4*V?9<KFM)GR*X0\6I3J(03-0V(Z
M8 ,/\9ZJF'X_N=G%4)GL,V!^1G(?8BTNUAOJMEI1,[30_/G]T7 ^M9W7+")F
M]^S1.0&?\HAY8V,%A8*"LHTR" (U,WWDZMF$K<X&BGHW;P_A X\9OB,:^.>\
MR0*$T5#O^'.6?B"]QFS0D!MV]]"RX:WI^@KC>LGB&Y4'9F4T93^?B0X\.^)\
M&*5U-L,GJN-"V+S@,0/G /O,);^<$E35DE9@'Q(Q,3J[0!U=TNX3Z9R^=SMP
M7.S&9U3"RBZ*JTQZX&TP@(1(MY:(\&JV/]34'(H78OC-,MX/N[2R$Q\).$_U
MGBV%\5&B^%SXO UL-_Z,.A<86/S1?F,Q]$Z+6[[(YJ)S=X6+Q\\EK7IUPVA7
M_>7QPXD*4.\70KIIE$&BH988=\.>3S JV\BJ2W%;58BLFE=BN4Q:EAU]P!'5
M/_GLINU/U>0U7P";*@_5G(0/FR-3&UIBX4OWF>R4]-XZZ/PP^Z( O%>1+1RH
MI!/[:%8IT%RPONX#X5:DS@/ 0T;+97A(D>E]3&>[0U:ICC=*?U&&]Z6V85:4
M=F!A30"^H&%7Q0,407(!\$J+N7VWY0V2Z@:E<(J5K<W]2OQRT^)WM\_YQNP)
MS\X4G5D6B=:#)[>&^SM9=M!,@]8Z6[)!G7Y%;ZE:<Q+ABJ&T(L*0;]'D1%&R
MM^+$^J9&W@MH83W<WKR%?+[(L]C%S- 6;ZW@[YA6U=]=+]/.VR#!I5^%%),?
M=YF [&UC)]9]>N\GMAGG;O09F@4()MHT>Z%RUFCRE#E"_!4+BI#=R%_H-:@S
M86PFI"?!;#6N&+W>[Q&<7 DC<\QT1T#= !TBVZ-PQ-2*IVS(=>'!WM>,!G?\
M#/TK,I2&L:CQZ]>-G]U3'[54C3=M!K)/]AY:HAY\G.,(5#$SR0U&A:P&G:/W
M,K@'&DUDQ_@-97O'@ ;?*,*F^?*8LQ@Z:/!4EU_9QD7J4Y+*WEMO0'B6,'>^
M*K<.MF'86\<)L_Y'S])REJ<M3SHW?%X^R-\-$.Y8'54%[L==J7ZE_AD;N(XT
M]'7>MS.:;GI,UB$<H=Y[P<+3&3!6;2)0"6^(H=/#^GH!BJ$R"<B]9+?[==!;
MS\B U)67]TOU1M\+47B90*3N[KQ&[WVNP_&5/FBGNIK#YBO1Y"*?'5\WJV9_
M5&?AD:QZM'Q'Y_0-*Y';!:GCVYO$0-EDLN<3TD#KE$Y;NG-3J@%M0D^]W__F
MI3!I!9YZ0G-I&595@,I#B9RU O)0LL1<)VSCI.4:1*^(INQY?/FNM/5=?J'%
M-;\TQ43=T#.F@$MV?634RB9 26*P7P'NU/G(("8W<0@NW9Q=7K$CIPR997*[
M[E=J@!&M6?+*4(K4>?R2H:TC,_2Y@5H *:J(_<)J_!T/;\%%L3&CXAIBGJQ,
MP]!C[]RR#R>_/(8V4&,([I&1_8S&T:R!1>:XEZII>M>D/J$/[$TNQJ@LU\Q-
M9QAK\9QT&JKOJV0+$0K%A?"+V>)4MJ/L)HL98+SB1K2,YEJJ5M,6M3#.9F"K
M5EU-:?<+A7$6%77,<)4J 7=R?K5K"=5,XBK C5\+D^>C5!19%:A/@=&T0?A:
M<I!"(O+')K_5XS%EU28X?@%:3Q[9#:2+@";I!^Y(-S:M*#37<*WF>HG#"YP>
MXUQHR3#/BS\G\$2>6').VSDYU/K)RJ,K*4.F&GJBTG?U/>,V?1VSJ 'TUIX]
MF).(8S[%LOWV)<)9_K2)LN=$LU_J:OOA TH2H2C.5>:8X7JTQ]"$OVF+<<LS
M9C^AB=,MY1L&W+@4*;CPM?9N0D*H-0LW9BXB<2\7NE(&O4D&QL*<>T'L*[*1
M@-":_-._:MY&L_/R-5?Y5YA0JDFC( IBIA'/2A3J90O>9 KE<GH!\ [UB=4M
M$#71DM=R_EE69GR_9HZK<Z5_PG=+5;B2<H]\^-T22N,AK==6?/EA89+[^=RE
M@#D!$8J9&VEQ5Z^15-%><1V'=]&DW1N%Q*A"_<<O]/LL%O<0P<M=A3-FUEO"
M6Z959IAQ-]?%ZU)E*G(^$U55C;BC^%BH$ DX6QY.VC(G/;&\$P*!>)G7P@5<
M,UMI#$%'@::8[-6MN0LP1Q[\V2;9TK*>KTP?^7U_&*U$'90GE!2DF28U)V*/
M&:3OSAL_A_MLN^/S]OE9 DDA'6S!OZY2V U9US"15RK2#IO">O9+4^N/4G=
M5Z#GAI1E I5E;6\/._C/>$.&,KO7DS;L0#-&7&I/W#%YI+V%_?1>B1Q@I-W4
M_#XL;?,)BHFFZ#>-UR+1&DNLEKG%LQYE]&J=_D&4[Q'IY373(0?N>F,VO/L8
M._F9ZZ/TW'2BY&UY5MGKQNYS)J&S]BORXBUC]N# &N&M>VJWP4LIZ1N>$JLX
MY7(I"!)BA;$" Y0HGJVH&U23.28>_%795 *$>_QMRHA>Y,5L0'A (NC=M "P
MII5<%X<_9/7Q]<]NZOH5A#NX_&F*&%ROU&*<C*E=ZM[A]M'6:Y3>"7K:OQVK
MHXGI"A#4&S1R[ALT<OGP";MAP(\1\?T:[^+TR,@9C<OEXC&R*E HA@^G7^4Q
MXLY"=Y4NB8=8?IIR7M-U13Q)0 :\5&D<67LUW_))X]KO/=6/&Y#VH N/:F+8
M3SFH,,#7)-KH3;<.ZFL\%6RF,S0[@N9ES&C,7K9D[U;L6V8KN6ZZ*:")E;D4
MQ:[Q3'.*WF95,IS6<QI?<A/G]C" -4[76W_T=M2.#N22[-J211LN#EX:KAU\
MD73>=$R% ^[Z&,Q>=2[V=+Q+L B7B9O]2SUO8:MEGUT*+DT5WE-J]7"Y4XP]
M=&)R]%EA8DIB]L-+Z@7Y+A^N1=TM/74CZD;*NPOI]ZGWF5565+?^1#2<?;^9
M<=AC:6QDZ#ZF)U3?8TOQF<7?D<!+("U[$BRT3,^9>Y\URS$1Z9.=W@=]2G/;
MN(S 7-I8X]2..A1BM6A A:_)1/Q(ENW!J1%%"M'27*N;9-JNQ%,%]E2;;]FX
M:/E%_D2-%' P?_V0G;CR#]!4@@8@ON"E0W.BGZ'3N.#3I?9SY@YUH&M^*G!?
M:XM[?@$U0:/+M@C>1ZF-*@/"M7S=YJ\\( 9(2_]".<OMJZW__]VK)/")_/N.
M'8OU'$73#=OD,9/Y9K29:&K_M+(.Z9IXTY+4V&L6YOS7!\B+Y_D %^I>U-VZ
MT5#;6*OU8X9PH!K!\J>QL $QDW;,0+&7^*54BJ3XD@8L*"&O@SLYDEZ$7[/5
MOO#GJHK>GZ1NPB3^BK(9R]LIOL^PIOJ/L$N7\49VCDX'*EDAA:WV]J<G<&V-
M!M>#49:4I/7+#[[#SGM)G"T!S1\S.+G8P]%S2K IOE+4R7,'OF!TFK5%9#7[
ME^_ &J_;B\(.T*? ,F=32=W>?/70 :&;##W=Q=LE$VX5EVU"/]M-V:4=,ZAB
M'/J[>.Y/&U+7]C+K'0[2&2K5KC]E_!@\Y',+QCBASW:'YXUOP&E).[FP"@14
M[<N$7X9&_8CKZ/W^1JWUEO=!(@M?6]B)EG(=+$K:S6_S:Q)GKM>9_-1\LUAA
M'X?^ONOV/IC9C8DBRW&IDFA6<B=ARK.&/X3$/DB\9N.\PHW78M^);8^X;2=Z
MSV;2<=(TK,K&:S?NS*V?8YI-.3]<\:&.Q(GR<NE>!0M?=;6^WLMO[M**]@W/
M_%1F):!) QT@MF42K+M)MT#E[>]+.Z7Z[YJV").+'?Q_D-416*7H 6'9'1/V
MY2N%'#)[^\;6KX?<#M 49JRV>;'5P6#Z?TZ=O"!W[, '+E.B5&XIP->-$67A
MP?/$<+[@3V6*OT:][NY0[-\%1A*0+*EQ'!,+K(^"[GX4,/#H?9YC:(R7EI.5
M$=-OMXUU%76U7!BV2^-29R^Y,.*T5P9C6O+P\P4%L@$S(;SAJ^T-&N.@<A&7
M8K7'3W1+M NK3+G-?KW4S_@D!NDAU!6.Q=V/:C+E<?Q*O*SFV\ \Y/>N=Q[0
M$O/\R0#0KL!S]..7CRG=KM<D,]P#LV!W/F%]!RY=&[HOM+RAQ?-2S<M6M:&*
ME!+MZXE8+T_V^ O9KECAN>]3H40Z9HC;CK\Z*<@=.'#SQ73Y8%7>J5%F=1$7
M,72\2HU"I;#T[YP@_7?>#K'O9+L%PKI>!X'C1Z15[/7(D)J]@.0NN.ONYAF!
M-]%G7O RJ, *?/3T5$2\5CUD@M0W\?[107IBUXV$U]:E:JD"7SHK7/21S&VX
MZUN\]UI=OYM)E-A:C^/2Q%ZETVR^^]\EZ*MXN.#;@1'85$M$AP[$^Y(TA'E-
MU,\\GW$]:?)(1/AG<%^=*_C/=EPGR'[88<1KXKH(>YF+2I>>1\-\<EE.UCGS
M>5OM"JY2R_"(<\E;:<$;)D(Y[/W61"F7],3>*Q/7/E?[=+H;O!]M&B=B/W+/
M5]HXLVCX!YV+<9/IZ#FKXJOTE]FI64 TUB=P=N26G,?VEM5[P)SM%+>,B-*?
MUOM$1/$097SIFO:'KA>^QFJ_JWE/44;99EFC#AQ26Y0D=_?# 1(7L^'N#>SQ
MD:KBX-[G29H]>_D3'>X5Y2+8HJ,LJ$KA<HOUB)Y8/S[]K['%91O/.)Z+MWEU
M*X2&@HND^46X.$2E(>P86G@HF":/:7K8 7K]_$W6S?!Y YK,P,&HVIS;^8&9
MHR=/!A8M>Y*8VRGA.7OE/BWI\=6O]5-^[5O2AHQ=RI?JOTS>+JRWET:YWS'$
M9P8YYRQ+3NHB=97'\AGB=LA[\(#1=E3<,.5YOY*8X?F&,$G$;5!S_&-;4_#[
MTHAWF7R62X$6ZN(I_/KLF4G$((!];M'$V9(,8R_V3?R:2([%&%2_\<H?,3W<
MFIWR-RMM4V&'QF,6;?J9A4U;]O-;?D^#5KXK6\R"\9S@5$7$X7I]':2;C_$+
M^\(\)[.>XCK<#R=;6U3TV9Z$<1(VONUONZ#8/?^52RQN(<K3JW 4![C^SYDD
M32/N;#W7FE/-,QL1TW<HOC*_:-Q8<>E(U^NB%:>X_E(\8_<4&D 9FH.Q4!]0
M7L(**''K_5M&WYPE[L3$_)KTF#3KCMW3"RSJSN9VRA*D.).ZVG70SYJ;1EYQ
M*]79]S][KL$817K S"=<UZ0\);WCZX,:]T%1V?#?9XG#;<__*)')K6IN&6Y&
MS?"+*8\&[):]2$@G'FRZ6C0TQ<"*9=;VLL] SQ'XS/1)^&BHHW\1I7!3VO\&
M;LH2._3YI:DZ$.X7%U\L&U\V9I<;#K88_JNET9S7;&A:B;3Q5O6!W^9HMY3?
MHNYPC=77V2"0?J,HTKTJ1NI67'TW>Z%J@;;1>^//-QW+3*8P9;7!P8U<?]UK
M*Q,28K\WY2ST$N*Z9VN;\5DB'.7848=M,KE37?&8,90JKX'SA@#9]@];9B*8
MWX&6#8GX"U[F7GP275G,F T9R#46?1ZK']Y,,.% 7W'91,:SW&LT-JHIJ?#=
MM HI-1SA0 K++M:N<FHHV-R/*OL<O"7P!F,TRQI7+EW!B'-6'.B(:#(JM7&Y
MTB-6F%BZ*Y]CQNCYS2#EP.P3F7/YN0(/V*0 &9L\]=&R>6.W)B#@ ,SZ-@Z0
M*;B'/=0^$*D7 ENM$A';.PH#5+N-R/SX_8_=;@>.MC<+J0RDKN@9E3,=+?='
M9?QN85N=,C2KM@BUUG-22)=MK19ABB;5D;Q;(C-A5(3W>V5I9?UB+<7FTYC\
M2GH[!5+!(M<:(. G,IM9^&XE>\V&K:/(2WC\=U?^%>,XS.+3@W[^]->NW$8M
M\?FVJ37PBM2$9=.#VEMY1C6(3(3-"P0"L[VUI0HE[X5[X9DHZ<1V#>P,^7)Z
MG9/;E[.,1F,A@W$[VQST71D+Y<[*K@G9NS^OV/K)PJR KT>MRR:]^!!7]ACK
M*R2/"I35"# VJ&8@B@G>: 5ON(WI_&QK_:"?L7^I^:W,,!5 9@R7D7@;+$_2
M+YUELF,E*KX?LI[H]8NQ?_TY>:XYL*[;M.5TK,:O;&F>$1O,>N+^VN:2GSSH
MY6,^R_1Y<(HSN+ ?"Z$B]]/2W5IA3'Z^K8J.4<K^LR)]PJ-F/K2^ZI&9:R#!
MA\<,9:^VV0>@SRB/4"PC:ACI/EUP,!<VYX$Y_M58-Y])]W.1H9WB)@4RGE#T
M?GN HKV-O^P7W6Z ^%A)C#'DB?#LB, /UV_$3TN3#OV K5FG2--?&C#(\%F?
M>G2"9IQ%QE?=W>O?QF*,*Z_$9$!^6@^!IPS,YITG1LJ1]AT$4F5[OX'6;<[-
M'A7KF@876K-TY1#MARV 5%X,GM.2 =>S'"P;AB-E>V^IL5)W#&$1 :9RH3!'
MU"6_C-8 5 R@RVB, M9KV>2?#?Q+T*_YT3$#-(NA;&,\L!,'"(.JS>KH!1K%
M:R(QVVFBN8UI6K%\#:[=+FBT3 4KQ6W7E2P4DD-FSRHN@4$T1($.DV?)<>5?
MXK(MNZ]42I.33>[U>#8$B<.K:U,&)RZ3,/>]ILS5-HMWJEN(!WC#V*)6V'F+
M)2E*M07Y3I$;0:0T!3D<W.?$O[YTN;QWZ&$)3? H^]5V]A6_9_ FD&O+%?)I
M+LA.X_QF4S+ WP;6)-),<23K[6R\.] (]<KF-J>(= 1(KWH6?]ETS7%3_V,F
M:@04$7PY:19()YV#TDUC$U&Z*PC.J"< QDDV]]M>/55X&I#>.5NY3>R3Q4O(
MIK1$!L(#:QN'\&EX,(^H^.D">>G$A7GL+@;Q*[LYT!7^$]Y\2 *0<JELLWT<
M'8E^(IW<607%3K)KG@]L+<_69IJ5=P,*?#BFN4CWCN)7Q3.,ZS0./:6FX.G[
M<'?DD19P<B!@35EDMA<,H.A*5UR%&I+6T 'P]]^<L3XB\Q.=GV<J+S'(=[/_
M3G>M)&3"=AWJ22^[(U=KFMVTT;^;S-?9HZ;N<IZ68@P>+V.WUO-7TS>L<60,
MM%//I/UL /4^SAEN'S3\'>-V5\]R%R/C5K.ZME@\2SM+"MKH8.5P#@9\:YO"
M_[IEZAI-[%X2698(I7>!_'Z.<X7A^<O!THW-Y#MIWH>_ZVJ9( ^^[B=P>F;#
M_21:[7C_)"W.AKV=94*(.3L#-VIC,F/N:U)7IJ /"$ &/_LY&U2\N*J \P.*
M_P;+?'.352QVX;=(N>K3B[]'*S+0I7V*T&&#US[S9@LI#2H '>><W_/2RQYM
M1:+6'S'K:T[+)1COEH9/#<@P;[UGP7+$&\%_U(V(EFW AJ4I:,[US<GS*I5/
MB8#J[!!E#OM<M=D--N(N1P.BROKV#CP\[=EYP@=N74!7F17U$0FW!.3)"3)E
M.>@;;HXZ[>G16.5#7K9)?0<UN1SO3-B'*I$=]?BO:.;1!H>4]97'GW<?=)@(
M)(QR5DAYNWO9.\FQ>P^/[@F,IEA.'\)]6L*++IEK#S<E)E5/34]3&SS%Q"!9
M&1-&74T DH0^)CS2.].L PP(D59XHE=B_N0%N%!H_FKQ>M!RBRQ%)'^"\JB[
MD\:*=94!7N[S$2V_7,":))8?GA,\$;0R3E4AH]I\S6R!I.Y01 ;LW..O4_#I
MI&+0A4,%][V/,7Q?1D7(9[I]L(KG8W,IV;.7*/V!L>H*WDPJ]SA6#2:*:;>N
MN[HL%\5T]UZI3[*L\(;/]?K60 +QMB\="^)</BF??;V17)2W5U%37X;P:(9#
M%&RP2"DOX!O49>^I@(&VE&"%%G23GO>59RJA7U(Z!44R0\/EU])SZ!7QLPO$
M0@FW(ZL7?17/S,,C0O[,M3S*]7DI+ZKQLL)C1-DSUPG 5C-EVSL+#/>J8'@)
MC14 O1$=$WE3]<Q#@:A5SJ/=,B*-O^K72A4CJ^/;6X0R#,'O_0N%])K>QFFX
M-2GRCO*ZCXW?NZT@B+;!!8!+&MXA=<:UNU]\D[];A[Q0^SDYR7(Y#ZF$LK+I
M6DQT03%ZQ8*[I@%#RA=GU49'S.7'W:]&!3Z>U*Y;%8''[P:13%$E1'X.TD;T
MQCKUV4L>9*J[8]4P81#Z(W84:+E.-2 WMDVSDT?;IVQG-_1&F_2*E,H1I4[?
MSD;./8N3YXE8,=L! ;2*5KC+F]W)6?UVS(H]8IE9:9>B=T55S7],;,[ER)21
MT][G,7EJZ(DC4Q]8XBX3L;4)#;Y28:RGN/2I%3:085DKVP"EZ?7-ZD'*-!%K
MQ5,,+[))>K0@9Z?.>#ZWU#)SSH4[&3.BI.F0G#]YS.#W>U%HNM1L6GW7;)*B
M8+D^<>ZZ@>Z'(B-G],58UYJG4TZE@B>/H_,^>8I^E=[)]ZE0J:S+6-DT4*'1
MDYA"&=5/F$?VK $0^;U"S#5U]$>XEN[_XTM:0<1<=?Z:G_XKND6#*4(!<?D;
M!IB;+"XO58J3GT2<W$'GG",E##8JAAN?-H;0NVUCS:X5 Z1V0@,:,EQ\K6N$
MIUGUTQ0QPOX>=TI"R9O(ADL0A8;_+Z=< D9PV<Z.M[=7N"^#C)9!D,Z6-@OG
M31>V]S'N4XV75E:E*64W+W(>(#WU*[_%=9WB9BWUE7D68,:B'1<@%H?SVO<F
MLH"0B,1-O<KR(- S(_.QYBV8CR2F] L2J6-\D7O&3+2HMW*$$V_87)C!]XF1
M!W_8!1]&W/:4"^I;>R%@Y-RGEW_R,*$SSG=5P"GDO?BR)J:BBPX=HQ[N+'7*
MR/IM]N2 ;1)ZRK)\R$;K8]Z%>JTEK[5;705I[[X2S6=,&,GG4^ U1-F<9F7,
MR1<&?3OMKL@,W- =MIEJ>NTX_^Z6"2.R.2 UI.6"4RI.)O-HIZ]S;E*]"F(V
MEB=0Q+[I]^J@W-[2^)NT:ZJ%4O -QTSF%Z5:73$^ZP.F(88U#?)A1"Y0KB:+
M>9\?J@/T_L M;%LIUDZKL;XR\#5K\L(-EH$*E[FF>^0D6]**H.^U3.W>G#C/
ME#/CI9;CQPQH< GG 12))4-_XCWL4QZ,#2360):+M]M&2AG;;"5'J,^*Q# Q
MV;) ?Z:@;=7WIFM!)L+?X.<,,YIL?ZW'?$R5]N%1NVZ:=^DE$"&5?HJ[$J%W
M6JFLY[) ZD@E/"6_-.:SS9!45&*U/%.$8.V';N'D9VCN]W-W&F-U]*(-HL$Q
M\H=EBE%S%64%E9^Z;QWQ5%8\RE134?S,?J\N@-<QHHD;^79=M)*W.PGP$$^P
MOMW95)LD[2F@OH(Q-ZLZ(O9AI7ELGHM5W^$-&K\.;6O6ED_E$RI1_CGF+6:?
MIYS<B(98*2Z&K=>8W0[/8'2^[D[!WE,1&8WYF#PTKRTN/LPY190MYFE6QY1(
M_N^;:1KB"]25,+G\<\*R1!?MV(;TZCN2Q;$@%WN36UP\7C)GCG"9#=QO:6M@
MMHL):._;ZB[8!8GG"JH[9DG-YDD;)KX;5KP>DU%-B_0Y#5I_OO@T-7;S%Z/]
MBFVLP11.(Q LUE3"K7"]](RU0MQE>>*U K$#_P>-HEV]9R)BG=9&^WBS5_=F
MG6HDN#,L)C58J,&F<R-^\V B3UIL@^N5GGO+M?<?V+&"%5^U ##Y(:*Q/*ZQ
MHR%Q'6;#^%.T6]9^O6I9W4_=I&C?[VZ!J#6/![,#J X%"H89[S'IDT?EF9J8
M=\6,7CM*RS)6/_8AMSRR2F\E[1LWN%:#2UROU%L84X<T91N.U*S2G=;FG 6]
MXV1.VF'K\ @)L1TF$\PJ>\CXKZ(U[?N"UH0W.^QI.6/6VC?#M%B?&':3V.,)
M?M"5!U][MJRGKG7&/ZTG:"!<K-4E1*=.?4^1>K"<8%*S)K':H"LKA?HD8%.0
M&C-XKC<Z8NV9LX/[=1<IB[AS'MB6^ZD=W-^KAW+QX*M'1ZLA\V>&@O0L4*3+
MF<4 ?)\?^9AAX,'K3K"CWC!$.O!);?7;OT)AH1I$I]-3)S\4(I/'_*?P1=Z8
MN(_$NZ?#<DIX#)]'<=VI%_AM8O<QVQ/7M#([$ DD,)'*R)%-4V!C?EL"503/
M_\:K?,N<[)#\97S2>MKN8?0%I22_J6S=@-%? 875_F2CV7/U01-":<_#Q'LX
M@003SGHM->\[A@;12>/\4Z34QXK M]O;SR+OG'<\J#QFN+3:?>;ZA-6+:F34
MA:YK,A<8OQ6-$J\[EQC/G1L"I&*^_A^^WCJLZ?9] YX%2HB*M#"5$BDE):>B
MI'3GE X!Z6:*A)(BI2!,I',2HV'2"M(E.0;2-7JPX/U,G^?Y?=_C/8[W/]AV
MG_<5YQ4W?';=J\-)2B-AC]"^PTCZH'G3?9$KD;<*+VD_OGI%O'Y(/U6B2_3&
MOFZD@9Q#=-?G]_?/U*[HL5UR9'RM559;96M#WS&00KG(PMRCAUV,.P&=)T78
MY/F%N%8\XMP]O=$K,U?@2)(>J'S18HI,?G "$L <Q;BEYG6PP-U7#M28UW>O
MP;OJ^3!.^A;KGO<*Y^R'?!*1<H^+Y/'F0WO[$/N&<&%;MU0LT; C=;18.>/X
ML>:FHG?<X-??MN^2;04"DJ40#S.,2%--\[T9UDUMP;L3KL%\]A)^U&+5 I!P
MYAV(J!$3G*7SYMB3>^M#*L1S?DFTY@/?M&)7EZ[N4NV,_SJ$GL-%SK>S/DK1
MO:G LQ-5\7F^Q-Y>^O:RM_OC)?&V]UU#:OQ8XP\[3I$XKSEJ6KJ6]RH![N](
M1U]KC^+Z]=D#YO:&7*)47_^PR/!LJ)Z5,4P1X%9-LF'5+J]=4V#02+_5E8VL
M_KE'5(-6#V[X0,T>Q0MK2B(P%EYSFM&M3@^RFN.'>M\]@YU#B ^+4Z=KV*:N
M^O&^V[>3*@PUS%(2S-$T245]VUVS32H,^#H0S#UM:H8:X]D5=N'Z=* 3K+W'
M -?(K?8_L$S4?R_K(,GKW:>!.[5-U?J-=#M#4.-Q>"\)PO53<^HY5A,9T%M;
MTA E/%YE]OC6D8W!.;<U*)/9.%>;!.C=)9\@?AU!5^WP\<^Q),R-E86W%_E;
MVQ?4&$PG>6T#<++C&/L BM+8R;G#-R6(34'/;CMZ-AT3%:;<^5^&GP:K"Z1X
M$6))ZUI?\G7UYONQVPPY;_)7U?(O[HVN\K4VBM>-:?>*[><BI>J&3 I DJI_
MZFOHOW]V,2V13IVV/RVMOZ:BBGQHZ7-U5'OL#$35QTUYN#]\?ZU'TE[[6Z?8
ML0.ILHV',N>&UO1]2)C@U;:.$MJ'_=/VESGZ?WVG2*JY&48>:)!Y0?F;6[MT
MZO /VLP(3K$[;&ZQ?(8YM/=I)E#3X"0:RAQ!3L^B4Y69BM)T7>_3"6(78CJ1
M/ /+?/:%EZSD\K^Q4]SZ$F*4IO0Y,]&*.2?;T9)M*(=-R<Q#[?'U_ZX^]Y)(
MO__A__.D_D//%-+Q #'V!(1F\-B KP\&U<"\48E'OV$Z.]]RB-' ZU='^W]O
M7"_JP,$\]G-/0/9QF\&5Q.S7R>? ZWR0I2\DO8C["21_X07#$U!EQ"'$Q/7@
M,WCG)\DS0(4Z^1P=3BG[!)11=*0#:Y'A)>Q#NRHA2$.2'[PWC5@*6?I(6,&K
M1"5_S B4Y#L!)?_YF*CPWX]5,9$_EH!W@ $?6SY(8!(4E2%=]H,ME9/TX-C(
M[A.07,I."7W)*R LXY;423/@W>\D3V)EZ_OX=""0/Z%VIV&W';#1G213Q(*)
M4AL59"&>L +!W( "VDG+5;:OK["@L!%DG+$=0+$6-DG"(;#Q"0C#"3V:@TDK
MS#T&1.?=S=O(%5)5M"/<2 !294NP'AKWT.X$! \EQ#C Z?,!L2E)QX"2H9FP
MI=<PM%Z XZL?C[I=S_:=@" 7R K100@$W@63B'9 1?F-$U"0KF;455AW[0FH
MJ0#OG]Z^OOPQXEL%@-U%QG[@ EE:@-P>EA?2/#IT[26/QPN!]=4#P$&6>6[N
MVB* ?*=J@/T_G( XE0//N ';W"4I(B$8$?("_.H[W !D:1RU50@S*IB22Z<7
M)EVBCCLZBML1&\(>S)."LP@QCH"VCO#==?3AB!AN!G*T#RR+*Q[9%+:[WP6Y
MN$E':%0BCS,SE 3O[H.).TZ&)/I08$<#LL0H;(82H$<)H(?V?F$C(#T+#%NR
M"5G:A.!_#]&UFL*/\'&D(_'B0#\PX5B2N$^>+?>**4 16!P&*=$'-HD006&,
M@3:[;PIV^",;0K.I26CL/ $%I@*-7%@8TY]52@2!6ZBE@1/05J$\TK F0%8J
M'J@$3<LGH.[?Y%7 )\T] -6!5]$\2,TV^PA"+8JXQP?!6 %>DW<EF_EXV@*S
MCEU4P9EZ]1U; ZO(7BZL S3YA=I*,%F:>P+=_?,4,_GUGU&D0#@)?S7(!>$6
M(" %^)HJ=XL$LP+$5I<D,<BA"2>@QV0AQR#TE@ $+_!&^QV"%K ,"BPCU9K6
M-"8S=T$NN/01FCH@LSR YZAB 80O9 0G<*0VK"\*$-8R@<28#=V=!?;]E;66
M5!]1WLH"QN:[TA%0?^ 5L,'K@))[T,,?)1[;)I=/0$)78']6-4!V,;S$ SZB
M=[5;P#7)?8]K!(X&0!(<69D):*N4V+(W,5?B'7%QTB0Y6-8T_U%X3Q;E9T%=
M0#OKO]Y^4N:573R>;=]O\B6.<+T"?.2GV16&O=8<OI;$CSY=Z4PP$>(ZGURR
MZ>-9A)Y4(/F!>RN.VS46"]-Y#.):<YE;.&]I;VB26H!XITK!OX#U<1X-$&L@
M2_&$5;GL&*FG"L37O(0]:%<"GD+S:!F5I/GWS37A-O@E 5G![)Y\*&F3N?.,
M;-DZ9>.C-?R]VI[Q&VKC[>;KI@D*UCH](C=?O3=]R?]ZF[>=CLK7UB[<V5RH
ME*G8NVC1:ON:(3?M">A-DY0ZUQC3E64+)H,;G*\CTE:=DG E6/_N%G\!Z=BH
M@[<WHS=J=]/<EK(,N^=V STR!10OPFOJFHKJS!O&?X^V:8[7)=[8+$408FM(
M_1G7=N_^MF#HF_D%Z:@3I)P;"_4Z>L\]$I;8,^#R[C/AV#"%(([SPT#?<+"[
MBJC5FYM,S4%OW]<[EJ!5FA,>7]*M,$Q0K8_3BG;G?/<<AD5()-MD2&NW*=XM
MH)P\1BVZ=Y0*)^EIZSPYYMD9I587"GHTW790IF@M<N/[=9I]Q'MQZAB%N8C8
M4#=ZKFJ=(S=AZR< I_43C+=YPYP18L9Y=>4A-N."Q;7-'..DI&5PA8F1PIQ:
M]V1*3.E\W/-+R:W7]F\V3!G8R!XW7KN6$()J *B B78T,)IXE^.B/YPV[]-:
M!#N-4WL8_HOOU\]R94JA-G=U_\X6=:E]:$2J6(L^N&[RZ)JA%%[9/#=G]@-;
M-V=7#:74/D,6]DS;;?C%C6>WC-HYA:'^AU_CC<P6/5>*>,_AC+;RSNMV=%$[
M70H,+@OBQ4QWLYS:Y5;&RB,["-PX0Z?YOO#JA_//=>5:F>TZ?X;2+9C3;=Q%
M"/:%/B\)N8IV9]Y=YO>9?;SJ +THP+GS5N@G,4A=W4B))5V507\PSQ5%NJ:3
M1U4SQB)X53-C/L40IS2O<N.=F(=IT[@5B45W;)MAGR/&[UFQKPO:U!3WM#Q9
M;F'A:6;0@T.&!:#T9-=)9-K9O#"^,:JUH4<IL(T?"Y_H*5B-;\XQ;6QOLT'Y
M.(8F_3A 7,F01]!9WGYV8ZMY->G ]7AX]@"N771;Q4,H8J!NJ0-Z87E']@7Z
M1_[W!EA6ARK)]BL$DUGIP3.09YZTSUS<=S;PC.'.9J *9Z$7GKVV^5@4%N9
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M9ED25S #&M;R*X+T:N=O;AR&[-$ED/!@C(G"G39=G^AHN[ 6O4&U7=E.$DL
MD  _MZ.(>#$TSJ91D_1: LB]ZV/YL):)OP!6!'Y) ]SH\?-@:W^N,64I&6X6
M<#@_;",0NAM\OG65F6%H5Y9 ZI;.(U((HK;&<\G?)UV%[[%4GX!0MG6,Q'QG
M0ZG^Q>\;BW%8\GLZ)K!^*E<\ =(2MQ%M"$!TKW[TV??(2#C0'S$E64F@#]>'
M8)C$?<UC6E,8NL(<3!#GSB."%@&T5@)?Q$%^!7CW=!IY6!0VCU@117)MIE[U
M P" KB9<:P2V+.Y\ @KNX0S^<9QY OHP4DW$BP_ 6O6-3T#_;)M 8BWO([T4
M!:H-AG3U!%15!NO!W0S.23X!J7]:(HA8%)V 'M2[X@\<2O#<JXW((N!'IRP(
MT@MH*3[0H ]QL#!>@G@8G BR_2/3+=)$!TQR-FQ?H.+X^6+:@=*()J%C [!$
M?M]Z1!'\*-8$V*G"'$(03P+6\/[5@V[#P1:R> I"/ &!,?K$VFA CTM8%E/T
MKMW=$Q#-ZR)8O_L8B9AJ1[A[ #03#[JA^(.18?C$Q'>Z(Y &;.,K4#Z?$4N+
M.PG=0P#\-NDJS,4* L<^.@'9+4"'[ 3093.EZ%UV)-D)6:Z_T$:N1[$3?P1Q
M)8B/I!"I=_\NBSBH+P?O"FN>@&"=.'V8JQ4L/>A[1+*-<-Y<[_W@#O].(F4)
M;&M2!_ <Z]H9DM4H"B"'$<QI[<8)2&0/H H!%G:#B%B'+5O  :?$ 4Y!Q9*\
M#F\:&"8*P:-DA>?SUEU+[3.H&[9ID7NLB<>.+!8SS-^]XW!E>VL6$+R(XZ7F
MN1+%\4FGJ4G:C_/WI&XV]=802RO7WEB'0VG5N73X#!4_7'HP&YN$[8M+"F3;
MYFM0^#SQPR97W6.I^8+4>$)RW,V&)P8W?0MC2]3']YAYP[/.17S>,W4]AC^R
M\.5@5]/:18A3UQ<]=1?D@KV#[1<>OA5\#Z&!*K *N!7S.N9_8RZ2OEC"6)]M
M@FX^Y(V6E[LH=;6/'O8=E4]W;(GNJNG3@ZM8\:38=^*^Z![KU^5\^2HM]Y9=
M-HFD[R$&JOWR-4$+3J+GK3"F2>X85OXQS@89K;8'?8F\!<JM/VM@Z7N&)UT+
M[68#M*%FDT>L(-Q0^_&KX0;MPJGWRLD+DRSS)4&G\#<"*5"XE\=Q;QO:D$@D
MQ*[:[^J[S>!M\(-V7Z$4S!J*P??KRJA;Q0^!C9I7ATRR90>(?G0$Y(H8-#R8
M=DA6+G>Y7+#QTP.UMQ36L#FK3ATG?W%VOH).3[<Y;I7VH?P]&Q3.SER)%/(.
MAJ9((+$,:0/Q7@P^;"[IP]F;0H_/ BT^C!*G VM]"/"C_R84CX.T-,(VG@.Q
M21FU+XLZKGT+,'(-:.7[== DG%@K_MXJ9(_A-0DGWG@"HJ4ECWI\"]N:)7\/
MF"#VN)IX"B@XJ"P@+D;;@;AXO>H'V_>@([%T_KMQUO_\7(+"V:>Y'I]5^R.$
M@6T9WL!^@B9@2^PP^B"NYUQ<OV7<'TG.-O"8,_@<E:,(HK%90#P80;9>*_W/
MSV9M\&K%U/++X'"7=-%6EF&[O5Q8JY?#"6B/'VBE9^\#PD&0V] >''. 0!%J
MT=417!%<\^QFGT'%%8Z=K$L0JCDOUU]+'2;S]%[SU,[I6<H?]8)!HV7$>K%M
M@.?(/M)9.BQY9N,F$&W+!L#AY%L8 #F3$1"=4VS=]/N9+G6BWJ .+#!6D\0L
M;+8&'$NXX<1C1TW<TT8?4K@I!+^#GC>W(TB&PT] #\EPPF2+^Y$%O#T-^R/?
MR@G(>!>\!'67@E6("*]\_QVW3H^ ]?\ 3E/!IN1IOZ_VMXY9G@,]?S<LQ@N.
MG4E]<0+Z: #L=9J)< N0;7\(M:S_KVBP-7DKPMHFD ]L?T.'XG_ 6L^LH?9$
MQH&H3\XB,3-9G( RD[M)!*27,S[0 0 1R0&D0N!T89BFRG78]P+@^/"*'T@K
MQ4=QNXA:R@,7!:+4M3S"'8X&?USJ]Q/0)..?49%/Y0)(X4["^)V1$5AKL -Z
M[[8Y;%85Z-5X"9('0$Y^F#[V!_8$9"(J?(1K^BV\/A5Q["X%Q3UE#X#C"HI1
M6]V )4!KZ#U18Q@ZN;2(Q'$J-[:)'CB(?$L"%-'$^5Y,^P]'FU1I"^TEHZR_
M_H/B0P)(J"">0CP"C.US\-\OJWV$J]3JX%V^Z;_B2)(X+@#EIS_'ZZ]>)Z#1
MZ.ZCL:DP8OH[F(:2X GH(G$,M6Q;#G!74.7/;X"G__YJ_N $%!+J\'F>=)D?
M0;@ )3,A(M0!M7?K'W#(?AYY+&84V=QV6,"GO]W1V*U&P#(!PF3/ ^R^B ?0
M[?[" 1D^)-SA=1SND0L*RPUK287-9M991@,'$<Y_I(.5L, !JU/C(1'U)!$I
M.,ZG%P5H)A?W5\V^-Y!EN[(_6)($60C0&F<^)// $"@LA*L*3\"[M\S_3S(@
M&U\_CJ#S(5A[0+!;03! *C!^9QB,XZUJ@BW^(Q,O05;S?W'82%2"N7R=A!N'
M,-P5%$:3Z- # 2I#RBO,S DH.M:5Q+Z% ,PY )P @TWB<#Y5?^0C6WYYDKST
M5A^P%$I>"IQP(V(<X'N\TT @ZOR52>R/M1X"^=D4U:$D#9O-J#L"R)Q!)B0O
M0::O#;PG9D2F:FD<B4,T%]8/]_EK&#3.=S$%8(,7FLP& ,VD0O,/JPI>+,$Z
ME.0 0^]N4Q)I&2&'"ZB.!!+[TAS=,:L C!PSKM6$JZ_5=.-P"BXG("P?#.@$
M.![G $JDD<'52 S0-0TG<LP$Z8:?@-*VX_N HM<@"SA?X3'9\!#,#,=UP$1?
M.@$I724)5Q/4H$<)_V"].@&=XQX$DL5-FR72.6$R41=19*(68L=@'8IT!!G4
M?TI]/@$URQ#NPQ;M__C0%"CPYW@&QTC6DR@"%?1/E]0EACJF%X:0D>''(ZDG
M(&E\/$0? U\D6#\#WJ[?/P']54L'<*,K0 >'OU!P[$Z),"FT^P]0%HE#GZS?
MQ[_Z :PR1I!C><37[@C%P@S%;J(OP?J'_G7A_QNF!X"I[R/#D-F>O +=XYZ!
M_>._(O$_G$+0G( DYSGI2.QC9"L_!\0!\OK%-;(#)  '%'F0.$QS8/TI?G_W
M!U W^/]%S2(Z]I![#>C_:5472+:U^E];3Y/GH6?FDFWM FOMWD,<7]F"_..U
M9_\#BAHM'CL:(YU^O=H@2D!'1P/AH?F?(LIHK$;<)?!1*EDV S1!MA,(BDPA
MH/<YG4+.F1$?R'I9_-%K&R#E:,,D*5B8<(YZ]=/=_\"4"#UD;8 "&.&)BR"%
M%P'1,P(T5G2B@ZAEU0;R5YC(Y06S:&)(O. #QUU%$=3!:Q9 780P347L6S"3
M7#L4 5;# 0*(_R$ V:(>_T$!*9M.!(!2(T,!_IJSAV!UY6[!?B:1570Z ;4-
MD*ILT;O;L-E;@+7BR-:"M=8&*@#&TB<;"\B"D#>P?WT'P^ZJ U8NZB-00TD\
MY%&OZIZ \1 0K" ,EPH9_?E71=@[@.80@.51@,L6R2XS^!,S !$D ?LY_@$C
MB9/UE/@?/>?(\VW3'/Y:#>ALM\6A:[9_5"6=#MO7^%?7E#;(/[J2![IZ^ *Z
MII%U_8K&ZL;PP1;_#PX,O !XXF?"'V7)_ISZ*R#ER#TKU#PGF,3>,P?^RRXR
MV87?:!)ZR*(6V9$XW  B_+LP@D3ED4-W]-Z5K&A+RO$D$#5][0!-X31 ZK,"
M+"9+MIAY'!$'T&LJ VA@,PO)] )*:FMO)6 BUW],A%DB>U(2CF/\XTF7?]1#
M?8?I8F*![!?MBO/A!0S^UT9*!)FX_[0M@>/\1H&R]5 =R ) @J17(LBN >4D
MDX?,N3$RYTP]7(]P*.Q5X0)L)Y 9) DR"?\1(XO$_H,<2L5DNO;][]*_=$UW
M@.QQ_1.&@&!._PHFG]<"G"18F-'83<U+0,2/_(GIE'],5PP!T "6A:0[*)"L
MT_X2 P@CO_^L!W!LZ#_)&$@/]N69MG#?@2H?X8[[QW7H>:6_;A7[1984*/Y
M@8S( )A %HC,!#$X=K<'8%[4WPWB]JLE_J3Y?]!^_/^CC?Z+]@^OQ&"M?6*
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M@;\;/+?B*S$YE@S=C[NL%'ALF^;FGWSW8^D3/C@WI8'K _416?YB^V/U\+P
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M=*K_IF\F2]";4"7F:4V:I!^"I%O;,]KV;(<\S7Y<L9V]DJX^WL1O:Q-$@J1
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M=S]\T,5D2';T.H]L;\@A5EB,%'C.X1@F-'50O2\)XM2M>_X*XAIKF?(UX'Y
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MSV&KVK_%+P'PEK)WP:H#X,'@#.YJ7,<4FR6/Y]T!\N:W.F8,K[2RI^:9]+
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M+1%PQZ)Q,^]3ODR9^K8N7X<XTR>%,4G3MLX^7Z<:[WOP]>!!C4T28H6S76C
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MI,&-3+S!LO@>S[)B^KI?'_[4\J"\AQ8C%)!3L,BW;_$%?L<#_D6.24-<\Y7
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MA#<ETJ1)+.+,1_HRJEC*#J) 9="H\<0)N0Z:\N3CG.9@"?ZQ@0<PI(4'72:
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MDK3[<KG0EQ= /XXQG.7'&'X;3L?*70%N1X1*4SYX(Y9T//S#@&LY(SR="F/
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MF!42[S,H*M4$&IA-G*P'^OBS80+"H@.?.:2SCN]S5B$;O;[EAC$E_-D::@Y
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M?MRR$OLY0.5F0SNJ(NN(OC<=56)&904>M1U;LU_JPH@,F,:T30P(YV0JRIJ
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MOU45C7/@EU%>PA)2F^K77Q9PT6S*,6!^#:9B,[2QE%]!8UB./KQ9A:B9YO2
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M^<@9D".E'#$_I.PW[0C7+@.,2XU6@TRC2G5BSZ/PF^J.\2418>#+'>RAWK9
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MW*J$0S0(MI[=;/RYA^:!@M;8VC& TW.;"$^.E:C<_&SV'2:((1&/,NJ>]VU
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MP3YZ#>!J[Q^E@]<O";9T7*!7'A(4;<V?# 0;6#R_WZDT>C]?3=XU*$A*7X(
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M!&&6))1E6/1&]\NF7=])QD60V7 :51-)+5AQN*Y$:RZRV/+-=L1YXF$#A^+
MY(#>PP3LF%O@C18@MN;0F"@S67!Q":>1[FW/-[9H%3DBW'[_<;([1XWZ-#2@
M%D282W_JF_OC3ME5^)**D@Z=<VM.TF4M;=QJKD]H$MVO"S9I*C$"_5$S69>
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M:0M5^[VL:D>ZS\> XJN1C,%I(4:"MT>-I9+'"H<Q\Z4(G _D4)(HTNB5YDZ
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M%_+T=P4X&(/#I'5)LX/I1;YDR_R?'FY]/N*4(XLM:RQ9;_CFT\CH-I(3(GR
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M^_$<N1NHF6EQ(_A[1%#ZI@<E*+NWJ_N@2=VX[,PB*1:A7 BCGV"K"D(:,;P
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MXNRNJ\IIQ,-$^F$>"D![J?%';?UG_%I#5%['!8VYO#]YBU('4DS0(GVK_ZW
M6;1M+A+PV7SGPT\8"&&B1!#SL?8<'+I'4G)EJH&V2)KFR.810?VG_VO E2;.
M:;]'%8X!?2BC!%QVAM0!@ :9?1H%Q_ :*%AQ>8 ,@$,C5C^P$"M!S,(G*H@
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M[^;(UTOG FZ/ KU2YTFWXJO!;)J[1]MC$O.BOJJH(JJ:YE:*PKS^,>%%[/3
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M.#C:5?=C%G!-1B1,$![<4=(S2QX0)TH9)504!_ZK%=<3=P5?!+"L488 WB&
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MP[/]2X-GE5#Q.ANT@E_07;QQ]5<"%/]$#8KD^F*K9-O=^QH$?W]*?2..Q#]
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MI2X'F%<2"$"YIMH5 2R"K2L*[T]5C-/I38O*;T>&R7.I][\ZAF?5B#MM436
M9-T+UA/JJ#.@37='NVTD/QD-J:N:L2UQD C(5;<]-ZJ J.W547_;BK7U>Y+W
M+5!A>(_[6P2/K%C%R@@?-4<CVGV?/HJ&"HA_BT?; :YEFDJ5RN<W%H<LY7DO
M;*:Y#:HQLQKG#\U#%]$46XU9ERK>6PFIE9=469E9/!D.X@")DH;_G%\Z$!"8
M9\\^+MFI<QKKW$4 JC.DETD^\G$+0B)6.TH];,G2#2Z66NC34YZE3$;^E 1D
MSS91Z VK [;P/SKNG4ON.@:JA/0)'?O9/)*B\,!RTUUR'I1>8TI>BQP>8WG4
MSP-+F-5;JG31<>ZO?V&Q[585+Y1FEI%DFK0,AW+S!C"EV__Q 1159B:T4V!_
M[;H>NCZD.!QK"XL,O0.=&H.'\#QP'>]?:HA9#I70%2%9?H^,%,[G-T%2,T/]
M<F@WGYLO<0ZB*\?9XU(T2\@K2"5X)ZI3K3SIX^YV2G$(TSQMZ\S2=&;$1)_;
MV6E! $$FF9Z5PCG+,4\&4^8>5"N.CXJBE'?2KS?/(R6:/[$S,&DFVBLO,]'.
M=8U[;KOWL; :]WVC:MX+TZU>6RXWN:GBA._CK4;BBQ3C96[' RM?'GE=O'%A
MI(%E"N,%Q, )/-(<V6^7%T[Y>HB.%5<>MVV;V=C/$0WLF)L/[GB)V 2[;5AD
MG@RS<DOZ:'URXJ?7%58HWGT@(]$=;^;R#'\T3V==67?SKKB5B:VM!7<!7<U[
M9>;/F!'M'G> /OX\IDR.:>RO:DIW9+KX,$[Z+WK-I1=QYTJ:P:9J3:32S!5Y
MF](BTH8M27W%0=D.Y0QP4_LH(<VTM)AG VMUQ1&C&+)JY=$KD1ZFKZM^T"=R
M)8[GK0R551L.%)I6NJ;5F85(T3B(.7G>T8A V>L?&LT))=F,RY<5;)CXF8)?
M[9L<].!".,F;N=0J@GLT",Q:E_O4\R-@]U&ZT[8^ K)I9:&:?*KOGPF[+RT?
M-^%-E;3_\H HG5B4IK:B7(&-=!Q=)S($$Z)9#E$9CE.ML\I._O!8/X;#YB*T
MD!X>)5^UR5]=^2#$;:)SG"DUH"?LY@B33TV,/).'!", />3904RF#]D!_4O[
M4OX! O"X@'Y9@6'#&K@AW(KBWKYN#V]>W<EDXF&CO!7!=Y=A0JV$WK&P*L1=
M>==0A !*X3.E$,CADNGVFM!'$:^<NAI*8A=B8N))D^\I+L*X]AQ5-1QF+B^#
M;/6^B+A065&>1US4<7,_I[UZ*C!7MM>V,P6)-Q(=82@,8,OOC>NVLG+B^8AK
MR]W5N*0XX*U&AEH!"8I=/'6*F$4 H&H$\'5NAXFOO&;GK/"0]Q@?;^.RMVQ
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ME/ =,0HL4YJ@^_WZ[@$*!/+]IG1E91]P!8(.IMKRZ,P8!02LD[[93Y:H;&Y
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M<M,EC"&7ZT?QM.!'S1+LU_A=\O)2)SQ16C;V)? RGDQ12<B$#;AL1KL13G]
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MS"->IZE:@?9RTRS0UAK<Y,KDVK.A8^H<:2N&%]H(H* ;Z4E6!QZ(XB@/J^[
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M3ZS1@J"T(;L9*-"[/*7% IY6L#U[>%D&JG/G\;$M1L6:4_7O]"3^UIMF./&
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MSPWN+J+:!>J0)<5NFB4;Z:(QDYCF@-4GZ[N3S\83THRI4PNS*'\&^MT)7+P
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MX'S?\4PX2G7_S!62%%>7>QB=%2FF6]W/RO*H?H"V1?%$ZR$?>IY,9_I#HDO
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M0,_+RD/19SYSPX6KQS-7R[BB^YK,Q4@]@J3!V84*VHQG.-3?TR.Y-W,?+%>
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M?=8S\2IAGVUS:/#BV!@Y_><GER:HQ#PMZQ)>Q%VPXE<A_E2J+B@T?ZV.U>B
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M>(]B(\\[RN&\I4*C]-W'1 __:L]P[2B!(U=WG?LNWF@16A:  7*T^$W<\GA
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M:69@NO=^O/,=N''?_4_ICO^'17H[_1]02P,$%     @ #X!R6OC^:0:2J@$
MP? ! !,   !I;F\M,C R-#$R,S%?9S0N:G!G[+MY.)3A_R\^LH5D)^LDA)#L
MA4SV+:%"B$EV0@BCQDQEWT,H8A*AT-B7DK%+$B'+$#.#%ID\TS(]-8OS]/G^
M?N?\<Z[K_'[G.G^>VW4_N.:YYWZ_[_?V>CWW_>PN[I)@P@XV]C8PCCT<L$O0
M#VSW&VR_>4#4Y4!8( QJ'+O+,$O8'HY_[=]US[_&Q?GORLW%Q<G%P\W#\Y_.
MR[<7ZKP\/'L%]O+Q_VO07_L$^/?]^^??E_S7T#W<G)S<_+P\O/S_O]MN/TQD
M+^=!KHN<'(=@>T0X.$4X=H=A<$A&[O^(QP'[?QK''DXN;AY>2 P!Z(8.84A\
M3DY(:&Y(8NC3).AS&)<(MZBBCCF/F*L?[Z%H<=U;!55[E2Q:!B3.O@.4]2['
MW.;CEY0Z("VC<EA53?V(OH&AT?$3QI96UC:V=O8.Y\Z[N7M<\/3R#P@,"@X)
M#8N]%A>?@$J\GIR2FI:>D9E56'2WN*3TWOVR1]4UCVOKZI\\;6UK[^CLZNYY
M/C@T/#(Z]FK\]<SLW/OYA<4E(IFROK'Y\=/G+UNT[S]^_J+_!O_\_:<7!XR3
MX_]M_U.]1""]]ORS >\_O3CV)/R[082+6U&'1]3<E=<O6NR0[JV]XA8%52T#
M?$IZ9P&)RS'O^"65]<DJM'^J_4>S_V^*W?[?TNR_*_8_]"+"]G%R0,;C%($A
M8"SFHRPUV/_M_Z=[8/_]AW&=@9[\<*T' 3QCTO1)&#J:L@L#-7+,$*SVN*E%
M(3HO"-N%'>B]0>I&KV7*3/[.6K  IE+-KE9:OWVH]>QQ(>D$T>_VJL4!W4_7
M8C)82@/83OAH""(,*\@>1\@3 AB$?6&KRL!\7=,B.'2*=OXZ(5TU:[QIWA'U
MS%<@O"A&\$W F$&C4J2GUVEAA!:6]%;J/5.1IDWO EUI52I=8%T@A7786=+\
MB9ROH_+9K8*+DE-O1HZ>+I\*NH_MU:!KTQ\ \_AU^&W?8\#8385WIE$W2$EA
M<)XWV]G1@ALE4:+V8O#[.LH%/'XYD1<KK6%H%G".S3\@17W"L  9I'2FV%=2
M4^FP/)P<-[@(3E$\,GLO$0_?C),\*OEVT.[*3E#?5?^DF;V%!Z6NQ@M*%R70
MK7=AMQ\S3[ >[\)"L!G(%JG</O@JVA3\ KR1-MA)__NQIF@H*6Q"=B3)+U&&
MLO6^,$0V.NN$6Y#%9=C"( ((1!.#BAB\3!\06T\TJ,MLS\^-[>SRBY;.HZRJ
MSFPK9098IEUTY)XA_3PRU/+,<H0(SS)3W(4-;%TW^#VP66C'E"==^ 0FQX86
MR7>T !LM!68F.B]:<H*KQ^%U,+@7^@@DWM]0XRFFA.0LFR^)]H/N]1Q0:&M$
M;L6;R=$>H4:B?G[PHLQXWSMO)3/#RZ?9F2"B> 6NXV:X>0MO"8T=@>;R8\)W
M85RY8#!Y%R8?ML9EH)TA5?9AHQ)37/M5_;*FYO28=$^)1Y9Y25F(OQU]\X<&
M9T89 8$@O5QK]<B)(RR2L ,.;,Y,3?9!]MNU]OS,#FVJQO%=&+HLH$\Q1F6]
MQ/!W9K@:;ZIM=R1/N!!;H(*FX<-Z1B"E%&('K'N#21.Y>QB4WSEH.32B:A7;
M./-3PS&<<%AI?)]*;_=<Y/LQ+<$5V/>[''^%&#[8 23F(&9L%P8X(?D@R1UZ
M_1EJH<]K4RDG$;9]+X"W%33ID<T4F0?1)_%O_X;87TQ\VJI&%&?-WXDYP<""
MVL$I;&G4 AT[C;BBO51Z'DRLPLRLPEOF^F104_8T*^.W#_#72IZ5+"REK8:'
MBOL2T_WD,FHO)8CO^_JCCBG%RW9S WA9F?#]B)].Q0EK;5%,$>)7^E_P)$,*
M,[/6:4N5BGJ&LB3]'M3>MV4&@];3F=NP5*KB<$7=:5G7WK*_7W;X##M?LR_&
M;U$4)(S,2$+3:\0I^ET0RY!G3RH<9]5CU%:N3#.%R!,5[M\5#]KVZ%1]ITY7
MFHX'J(M>[\TZ,K4]SC '>>EX5J6I%,.!J=7[XR=<%HQ<N#";<%Q+=/) K,!Z
M34%+R$K\-3]B7PADWGN?,0(L?.]%0G-Z/D8&-31BQI4_:%0V-GP>B,^EC^9]
M_Z;>^#-$^<_<GGSZY*G8YR?:&5*C<C+@&EOP.*O6] 8PND!98(JLT3,=FQ"C
M"%Y3R[BGJ/ S<]4Z3JQRK=&)5VZRQ7;?*D^,7<RU/7A'C?,+@1,R2W"?+M,6
MFOT!Z@>;SYNLO?C"(DH!Q6G)7ICKN+&6K6M=ZT/\XWY.2''TSHPT/W(P_OFA
MC>-'C_']1"QJL/FIP )]#5RGV=*M7H+V34P$. X4)E;3C&Z;VB;M ]X43&R4
M9X=/1'S5/.2>ZTE7WQ.RY);L\=%^CA"6*\3>W\9J1%LS#H2NBLYA%+_@>,P6
MJD(J#5JZRR;<"T\J#;W1_&T>RVFIG-NNF9J5/ 23O7Z=P)09><H483TR.XK&
MLMHQ&F"V>Q2QRY<F_[YT!+D_;%KE@?')E"Y,F%9NL^R\9*%XEK/._?4;^A;B
MPC,WDSP9TI#*06A_AB]VP(:MBATP]F,5-?:>;$ K&>52UL0<:8+/(@*S!%XU
M.7K9Z&\D>A(#XSQ-J]H-[8[SO@#E=V'<RF !P]>+>0I,9<BR)Z_;YO;R 8S1
M4K94^;DY,Z5GY0WA7?-'TKYN2QX>O; OX)6DY/,7G3^N-V?NC06DF"+Y;/=X
M5C?VZX3;+FQVLCB& 'TEJ1C9A=S.I%0DL/DG=V$\#/:<AX?9/MIS>\H'+%EP
M[N:?=SV)G]),$HV\UXY(WK<2Y>I.%Y2+_'[Y)N(T6PO2YR(V"+<TQN;[\@@[
M8$4(-1$,'R!*$OSVE44E?VN:<0J[\27YWL_A])@GSX>C7CIRY4_<:4NU^#7%
MA&2X?9<]BVS;V2X2HKZC+= Y2L^ V"@_G@:*#]P"S"I=/3+=WI-U>2O)V/&
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MB XWC9#+K'Q8['_[!"_7I5NG%'0 ?_HN[)V9$936#-NA;*.&2_TI)#16MZ7
M4SI<;5L^4E@>'ICI6=M>1KLRH4D[L)'Y/F)9S,8E\D 8#0NJ)3 EM==5H56C
M:T)N4L XQ1ZBLY'9<=E.&N> B/SAWBUC^<W)CI$WK@Z3=7MK-.3;-,N]-^Y0
MD3HV?T$]MN 7 #DBQ(%9(<@A2#D84S#'8!>6BMS#/N2#&G)*NR!4_F35<TVE
MHUTT@*S5NQZ.>:?6W]-V6C3_(/;:+BQY&K$ICH&25>MF#?8+WN.AT+.CN[ H
M/)$Q]-QY2%L!54W?_R[25(DF,(R1GL7_RA=@^D@M^,IVSG\C=72^?-Y>?KHK
M.#>@VV7P<*3Y.+^ 4%V?$M,"P XZIS_?&7'.\-HP#KI%;E+XY#;_2S8YI:.]
M*_-QF3O]O(WJ%Z0,=L ,K4W;(5F@/JWO4/-IR?8+?0KC@!*9N@M+B7-$"AI6
MA#ZZL.C]5<S'J]W&,V=V<,;6Y/2!MC\TOW-A#W\B0+7\C)_:F5Z$%(1_4A09
MGX'V(^^(KQAVT"QM@+?W(C>CA#R;=;Q>/YUH.;K#GA3AHGBCM,]57N588_<C
M.KN&X*!:U'8!:8?XB:S2V_G<(VO;9W/F6ZT'SNE%ED<:9=ZB5S+OPH?86SWQ
MS0?\D$;HLU!.?\UT@:JS1/@_ N'PF=#*D_L$-3%,U"02TGOM8VD6CA&ZWE:M
M+WI9=/TG*FGGY!\T-"L]^UZ-F;F ]H0J]GNT%\UH6Q!R3PYP$XJO<^" 9%OM
MXE3#% 6?>@Q5MKS]^YQ-2X-N>\ #^^BZ<N^*I_%/.G"%]O78R+UL'<==&"\6
M#1DH#3-G>B)BW0#4N\Y6B)*ZX!Q;^W(0Q/KZ20QZ3XK?DMM3>;G/7Q,>4([N
MA+'VL4JA:,)7<H"S#!0XP>8KI^%(?1W PKI4BB:B76D&'W?<0-[(JTW'^GC)
MV^_RCZ>*]&.V4>\Z)=G*<<A&4R1E1P#D'+R.RV-&402<5*W?7?N#[T@ZRX[+
M$C )<1G7G#&Y=.B(AHY_/ZR,":U1,K;7@XPEKK/Y-R'B4LDB.'U,95P"8^RO
MX<%37'RA-5_*K*+-_346ASTA*F3ER"E5,%9J_&I?6M U1CI[OPFP,X(0QPY(
M])F$XO9>?EYTSFG/ZX]_30ZB1V<5YZB'YW3RR9*9)[#G]YM,<^<O0<GF":V:
MS7^(.#7LO BGZ[4OF(F'&K?_C< -$S)W8<(;P)OKK&%5T0KCUX*Z[,3+7+<^
M.FWL*ZS;_RR[:GT*/((=AG-A(#0ESS;9PK6D==2$(=LV=XHI.WP@?L3%RZG^
M5-DUCYF+BRM>(W'BM .?<H8OU-TSBOQ^[\HS9[;@/9KJ[5[(&;@<P,.5?(6"
M97%Y#<%/S?EDJU[Z> %OY/;GO%D--BTN<+;0> =9H4T&DYL W?V851<XK4D-
M($"Q:MLDZ$85.;U</4L\I:+QUOWP/LYK-KQ5#P60P.DI4$T;RD6DQ[B6XE)J
M+AE^TQB9>J7C3]1EH#/S*6K5?J/GAO>3I@#&Z8)%CBNU=MZAUO>*-^J_7-S)
MP9)JUMJ-DJ'!N G&-?CBTR'7BHZ,*X_ &[5HAU #:2;5Z^01$7'<TB/5XF_*
MYS8W!%/D-_,&/L*!L)H6>TA&4_!TP2N^_+.T0]V\WW#4Y?5D4!@KLV,J^04J
M?UR]H%M]/YG4!_:0O"?LSV\X<JT)_QR_?$=AZ]56_V\N%UX_Z*9L*$KJ_CGL
M[2[V1!'F'58(+1U-OC&I-^QA;)1AJG'CB<H*$4U+*33\(2%VW7Y?2W?$S8#G
MWUW*:-CD-<!W(HK(R>:OJ(<RJPY;G/VZS=X@V]>9-]\ )Y,=[OC!;%7[V*HU
M5WS,"^6&M)3(X8S/C&+O_'2,$&BT3F"*^K,%WD.(BN\3P_3S]51""B%<GI=A
M2>X8+3\@ L:$;I0X4PW.?<_X^=ZX>_%$P&VY7WN>Y]]<Y0&ZAH1 TV0O,)P4
M<>@DP@KX/3 AKV?;G&T2T70)>%8A[II#/V\-3X4E-41!<5Q.VQQC2KS&@LH6
MF''CJS0K&2R]"-7-M,-NKP>R*KL&Z-B@/WW!)0.FO?YO7JUU?<)7]\8R+)G!
MP!0UE8Q8*K4 I:NVC!%93(T&U&V$E/-ZIM9&>\=L\*S6MX+MD>2/YXXV7%%R
MN]M0'S.I< RKI76H<(HMY/G\1KM.-B&-HRD[)_$A*I1#X^MKB)S?Q#FP$+19
M90)P%IGZ1"PM''N+?5+OZ8-[PV5CR72Q+R\FBA1>R,H+PM LAND_?L.,H_V
M5G@=!ZJ@D:UG<(]1^>1YG.%C"D(<,1Q?-MY8':[3]X&GK-5>2>#SWMP4_YT]
M0]((U (%RQ1[P?;@934@MN]]V(5]QLCAEV3QF7V"[6!%*(#Q\3Q#2'QX\:M]
M0+69SUTQ<TZ[3R!'(=GBT\Z5(GAT,\<&H@/.%$>2A+9+&:?1(JP2S.$M##(#
M<QS,VW&8/G#F:8FO4X^Z9G51YK-*XKS.Z*<'#RB&$O.8!81"GR)F"KGO"MH-
MJ"8%3@U'B6RMJLU><U(=["2N7$^H4%FAZ.FMV,MERT4?_N.3]4#YR@V/=5NF
M5 -I)PL;@5P*O@AY8Q%3'W2C\4,L6V T^NLN;'^O3WB5\>( 24-%77QZA9>L
M<I4X,]$NX9V;_BT'TX8=T")$X(6@!;,B7%I+1W1@RNCK+@L_K?*'YZ_Z2WJ-
M]!SS'99Z6E\A7W3\L)'-Y\&;9G&[L/0%- H.G.. XJ 6T=QWTTRE@I?A35T#
MNG$,U7&&T'+\GUW8(CMH%Z:=DWCAPVCT9"AF'@MXP;/A+77;1O48(EP:X>>I
MB1LB"'\S5:(0N(V&SS,"*P97]%U6!G07VSV..50I"]XU4;'@#%C?@+!I\?PY
M]G@Z^ZO-RUGV_B]N2%#)-B.K7IKV\?89WG/TY%,*R0R/?T2>K<D>7P.<"##L
MP.E><X;0"![E./H\OJ@^3,8FDR97_I)G]GQ77KCZ,QDG ]=;NLJZ$0CE5AN.
M.SJ!?U7)^=1;230DG7L6$8D01'D,'9)']MM3)GR.1DF_ZM3Q+(^.&3?XO=AE
M]442@/QB0S/C_(,]0Y/8(,)26S^V$\X4?D$.WGY).RI,U,[#!B$$0XUB_OB5
M+=5,-UDE[!52"#C+57Q2QL#@SRQ4+K\SSX%KE+5TC"YD-"%F+$#]'@;GQ:A?
M=%H7Z,K-;<=(I&W91[9/;T1$1S\9DU/9;[I\TH%<=$CI%#P"L[(+ SRC<K"
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M= D;['P3HP3B:\"(7TU!\TM:O7H/+83N-WXUTE7IQ%WN_J3GX\CER1;>J.3
M0^%$'(.@/F#];ZNBKC\?5'=.[Q5:G]08\#5J31_"RG?@)3X+!L5-GKGDX3;'
MW] <JFI12M')F0KY5$7B_%7$%I"""O#9.0*I +=''TDT\6+AE&AK:;^08MZ?
MQ4:"*3O;C.7PGH<]%0=LY@NK1UJ7;D4=.Q;DVIS3_%>;G@ 64]9R<%Q,/5KP
M*(:_!?BUEGG-T>?LR4-#WA'F$8^Z4U6L0LOVZI+,#G 1]Y+OQ2+O(8#$.&KE
M8RB0BX#:ZCJ?D>BH:%J=32$?^8ZN76YMV&//"U?-N81M+RY\QO7O9$!<W9+!
M!9I0QH:U@DZ:G *F!K5,W.8[^/(G(D*C'H]IML(#K?Q!%]ZGX6WA)7]/OF'+
MS#8=_<65FEO1].NK]Y#F/;+O^3R;7/NM ;G\;V7,OZQT JD+H8" <(<8.A1(
MZ,]?Y!]T\B#Y-DF64W(AF$79&C%['*M<^N[1!<E9TR>Z?]'5>O:P/^N_(@A5
MG;/9#2'?K,Y47N99.D0N53JNU(+_^(+-UT-K8/-S,@R)4&6P9YM!I*P709:/
M\@4(P^&.35AKFF1J;&("7:@+S'_SLD7GXFA:>*"0>MJ%#4]QT1/Y$_<XZ=5L
MOA'($#[_O(_;A57>L9.SUCIU&Z^%=B3GGOYR_?>MWNA$%DXKESZ]U>K,E<#Y
M.F[EK)N-<K7&D>)+IMYLOC%HW" (U6%N:S!V'9Z);,-NPZN\O$!5KVR'N4:F
M!ZU\.W;E@T-YM9UAJ*[-<IZXU+4_&0J_WD(B/UD3@M@?+YNOTTR-_<97Y_TO
M@A@X=M$(+E5+XQZ.2 S$6\LT>&[GP.X<Z2KG.Q'LF+L=,R+V8X<M6 >Z,CR8
MCJQ*IE\BP$M)*L&17PK1&X&CCVF<@PWD^;+?WK,'YZ@JY:][17=AU;:B#RNM
MOV=>NS40=];M)N(R6@>2=R^KAID$Q)*CLM!B#*XUN!S3G):>H2]_HY^XD*_8
MGC]H:_OB94=/S_,^1T_)"[T3QSCR]+I7;*0PYF8(ABEV((*-8$.%KM-H9&HQ
MF.RQ+5CMM(Y+=EDA9'+OC"(.O_WUL-L[IJ2P0O7HI-*S-8/+%V,<%M84Q&A1
MM]'V]5^?JZ9$46MQ0]<G0O^NN-/6MQ=:S;G7;5 #_O)SNJ)Z;Q[\>( Q@-9(
M'+$92%BN8U'/[<*<W7]R_$R@0F2$^R\-N:W(,&;*LAYA#F&&/!)<T#ZB7OG[
M=V&#F,Z_:<E/AJ7>MO6XMZ@-7"C^(?%';<F-A&LBA D1-=;QVY\ *6>PPP\0
M&EI5?K_F/?/SI?=0)]NLA'A<A3 7\1.4$2B=S:]\Y'AOZ?>8R'EWHMQ-H<TI
MID(FISG@3(^?*],JF4:[](HYY1R2[,Q-<[Z2ZK\+XS#X>PN2:_\U1%M21]55
MY1=@-<DD/$YU9T(UNSW%6F'SG@OO+>R %8+4"A=&D"J1[:4#44OXD;76R&**
MR2XLSZO1V"/UEY,)Y?2=Y:4UV6R34/<-LQ*?RYY1_L,9\O<Y(K+65"*WX,"%
M"#AIC,H@38&J2.I]AAD2?9(6/'SCP$= */-GOJAU4XAQ[[,=T>4_;+=>X-7,
MZ#LU%,^%VOAT=\0_$#C=_-4# G9"H.J<@NR<5H2!%%AQ9-$'Z=DQ+/PVK@*F
M-"YJ+^MPJ]F!3[B9B_?B-SG\ $$2E4QO@KAQZ14V'#L0)%B:9J;$5&S-84]Y
M2253O::&O'X,:2ZX?)#J3@PN\129WU+\")OQ;G?J>"3<S;N$ UR%0.U1B,QQ
M#;!:>W48Q]ESB%;J3XP S=C+QY9F.\169UPT3BH>_M'?NK)4;G6MP*G][71C
MGH/2 :+%X_ M1,XNK'T7-HS<BVHC:Y4."*5B9&EKZ7V:7ZM/S_8ZH*_/NQ(_
M.?:]MYZ^L/U,\D9\>_/=ANK-BG6?J@NO3*OI!%9Z'P^T\)ACZ%!6"39$7H!J
M;-@#( ><@K'\>&)[]L9[4X\-I+<.7/E=RZOMUYX'Q.//_>GYS_YC!2,4,X0
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MWV_\_<04^4%'T[H&*E3ION!C6A%E*ALC$I)[1=-,\NNJ_KE:?<DW31'AIL"
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M-/O.VM3HBI\_6#2 ,OK/NX?<)@ \$T&J6)-DJV+>$:4R>Q$,MZ]UEC3\[8,
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M8@SH+M^'*6/AP-U_?Q)J:[ID9%Z(!5F^_^ ]3,Y>>*C\N]_'(^VB53%W8M7
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M-KQ_D' .R*"6R/2SB428(O/G6;^6QL)9A2#0+AHJXP.SDH5XSS[EMEKSXKO
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MODG:7I%7@!CYC_)M7^2/ LC/G"P2\X($&=6/9[KDI.*93J"'I"A9N9<O<Q4
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MS<MU@EQV)MJ/=7AYO(C4:JM25_9V3Y'%]ZE391H_$H9^\#B<4]O-)<RW-Z
M(8XJ5AO83:W1H/_I&T^3#(8),?]D:;!0GL.&3XD-+?$\%\-*AQG:]=68LCWM
ML9\@N P7I#Q6>#O084\!4R#N\@*V^R>\*:+NRJI<A^[&*K=]+Z*SZ&L!*>ZF
M1@2MC@L][#.HL,JGQ0N7O2LM1/=)HE9!N 1E1FY!&)[;76#^KFP"ND,)<&I)
MES)B%U>+1?Y::O6Z%6C4][G2?>9>T.M+4]8QF<L:]H$F+RLG2T.,-""\J*==
M>D 6^.^/ 6<\';K03LO9^%+A\0VFPZO\93O'-39.CS9^[0'@3Z>_K=/I(/GO
M'3S_0M,AX@'%(*+R-%GL%KP_!SAR#BF,[S'KP'.B,2AVU.1OO!16':C3N0O3
MQ*AR YD]JK]B7!9YE>]8X?O&!?Y^&$ZBGQ.K=7!Z+;P6'8F4@8<@%J:H+34A
M3[@@F*'6[48B:[^I&,M@7K[O]8I['&A6>L;(= @RUTU0@8,1N^5/(LEO"Y*V
M!6D1!/WC E>&^;F/JEJ4 5/$VLQTN(??CCZ!.E\XN3RK%.9B,R"):CSB:=&:
MON24H7).^AB4&6:Y0:$BE$ G:P"G/B$H&5QE$0<VL]KXS2\PQ*$NG31TLYXZ
M<3K"0*/)<U4H;[_AGF3S[B4]0=^+NL)KV?ETM/BWR5N7H:D&:*^-ZTN,IG8'
MB855HP-%JSJ?\$;.-1,M%KM[JF=8E$$)$>X.4+\F6"W>$SPZ)X$D$*UJY\02
M5#Y7]Q)KR805RKR?\;O9=+C[N:C7@%YKLD/Z4"JW];/Z2$&M(U6!*Z\RB-M.
MM2@,1C+/0;/@0K^<X1=8I-YB]#Z,3;^:\FQM@/Q;P_:/JC ^^3M9Z>I#OW2;
M=@CS858,#0)C/249=FRWZ%SA-<",/7$S][#JO+M<:%0,1QME^1IXO^("U!VS
MJ?;R='ZN-30_<V/<I,I_JA(ST5OYX3].BP9O"+3%O[QF_K[MEC!XOTTAW#Q4
MK*F]Y+@3ZTYBCE%^[($.<O1'4P=T5-C&$^$%LPNZ6/%U.:; #FO5Y&;.6?Y[
M'Y69[S<DI+!XIG,2[_&8^&K!9OHK^J/=LK3<B6=[7DD(2N5Z0Q.Y*"H%&J*!
M9!IGW!@+'7CP<GG-DO6QUR-:9>5:ZZ>8360:&'-5[7J6);<@"?7X0+P44-VC
M\&BY9+L:F5*SLXX]\U-;Q=@69)Q^<4>X;]8R[?7S0W+9LC=]MIN![OWUU0HT
M%:%AW@O<$=S[N<O(7K2 CX>WYR)_W.? XY#+,S,_S)\H_/S:C6Y("G),VY-D
M.<2>4+QB/[V#XT@EI6Y!)&":BQ1O[G'6YXRZ@8KU_];(C]N,7HA/DGU.6Q>2
M764.95\<7E+Q+=+8[S;VOT+T!B1JY1:D7F%C^[(,C5=%"AL7YP\9,OL<F4&#
M^M7AZ-Y_=CE&T6^Q#C6C+:S>>\XQLH'+%GF7K./.#BEWI!SQ15[":F\?Z@&#
M?>SG@ [G(&X6*F0&%UM'-EGV!7,O,3?=F'-I@1W$YK;@RS<G-D_/LN3NVT*\
M4G\TV/<(HN[9"R]==%^%<J7Q?%$Y3@1_8KM3TJ+E)=X3 ^[N<"HIL4M[JL.4
MKJC!BMZXCG%%3*ZR!'&!)5+U&N</OY5M0)@Q0OL%U6\F)L.^T8JX^^1HFRI?
MH<+XX#LQ-/FB2BP46&7=_M:M)@U"KT3"*&M7R?Y2%.K$N7_C[Z2&!'\NGJM3
M'KXL.,]9_7@1@LMU$R3(=2F<62D _(S[2W9@SZ[HT3[/[E<8XY!,4RUOI?SQ
MPR]Q.GY][I("%D ]O08:YBAJ(*J<KV9;XS/4U'C%6.]*3,R0!?M19^\Z^?>O
M/^+BOVX'-'>^HFCE7O!QV$U)$WUB_X<X2F*"U%T%\WV%OS>6EPW3Y!X$[+3+
MZ>&NU("/_]!)7!NL695G($@'-#H?/*M<\I4V=6S6BO;XM'M?3K.B +LTG<OD
MY8&$@,BWXI7C??%D=W;:'#RP1L>.M079>!M5,T0GB)RA+VA.-;M4+H[\]UEL
MO%$AL\WKXWYQ&?'A9_?V;?P@B>)[A@E*W[L4^*.$IJ%^XWDO^P]=2OP/74?>
M,.L6P[LT5<80B+8<%Y1&U+Z=;Z48<Q&;);-VP:O>N<^S':SA'M^$AZ"R78I<
MDW3R"MV]/URX;V+9U+#\VZ,.B_C_WAA(OAMYDYFY4FE7@ZU@!?%%<^A+7GS1
M[:0R[9R-+&:U#<LRBRO&',0K ]_<6&[MY@59>1*-=XJ=4FWVU&GU4\*:H]1[
M3^<EI)V[A <)%K4-RG212"0P+TD EAHG>34P1>#:%]N?78?6"I7'4YJ5\FXU
M>9\3J2T,MIJ!V%O89^=!*LH?.ES4? +A+20'1Z@[9MQRLU^RT2CW/V05+[*N
M-\.RS "-_W).(@F%3H0R'3<7YKHOVY)8T/XMR)ZI?C*_AN[LYA5NVD<.<\N<
M$)8\HYD_;GKZHJV%H+N=5H)0G=8L.*I54ES7]C:M/]#(9LSA=H6&T#=W84^C
M(2CD'M_9@EX@5?_82\HM&YYXF8.FS ,;'&-JQ. HA&?ZM$M\.[GZ);+99_O2
MJM;VQ0J!(4K#9A\%<,0Z,"?ARB?I&>BTHEEV2%COF;P9T$$T!(9HIWMH*X5<
M<\\^3*V64NKF99.H1((L/ 2]!S=%UNDW7@@ZQ;3LSUEHKDC^V6V*64<-S5;E
M, X*1HF)##MH$7_X^3LXFM5?%ZBD2GSX5EV-T@\Q1D> ".C4CQ']I(OG#WOD
M=T.B'JW\@I./LV^Q8,W"R5Q+UDK/H^3R:-UT<N_0@'S>F'[ISI>:20\X.QXM
M,PV_9/Z&[@J)V8)(W= 7-_9YU*LS:[9DQ*NM842()FBZC$X,!EP*N[NJ<-.T
M*4CN?Q>?KD^:5>.!8PCV;)ZXA6!PTQW?IP&).Y.=_9R#-++%U! OOEE#B6;N
MJ[OJMR#"XOSIN38$(Y@OR(NWTH\RWBB@F_C2&>=^TA]7HYY[U?S^_2SOI.)4
M8F6@1?@!6VOG4M];<H5'/K.A.4BF=XXH1IA]G/<8=I2K!ZAK=X* A5SL.OFK
M+GEYQ_3O"91X,V/*1G8L^F;]T4->8Y&R 7DG)I5D1._F/8%&!.,5^-) \4"1
MSTXF90"Z=UV9D7&6V&:8310DWF2HA-^S.KCZH1I;<^\0YDAM.DD1'^AL0T^B
M<%7'5E#C65VB'YHDI(PW_I5?R.E[U+<\?R4I!;$[2K:A;\\#?[&"O$/#%VN]
M+_FCT2G\O?I,K<V^:@1Y$P$$E!.[JTG9(4RZH3?WG&T7\W NR)PD&W^TB*D?
M6OBD\-/I5OY^_OI=N./7NG%C<A5?+(#EQ3ZZO<V_M@5YG3.XN>#J\'K2RH\V
M,N9(B\FIZ?"-NEZJU>H1P#%Z8'BASV1I+%J9_-?W8\HCU7;N]/@27*09F=[V
MI:]$QP-8I#*@?<NZK4T.YG=D3LX27)H;[F<^R%NE)8X1R]"&)_>O9 <+/'N:
MK@OY?_D(Z ^6"C'M^G/VCM,D4DOW3C;SM#^]:)W\70/3K[YU]G6 X;Z7[^:O
MB@Q3[X82^S:3"'MPTFO2&#S-O:]$N,]"YEQ@X5 ?V<KB?$<BY,JS@R^]('M6
MK$27_V_W9OC_\>.P0[?G-I5>F [A?IN#">$6*$U!7.E)B?EBOJ@0:/Z_I_@:
MV#-;D"3<(^>JM UL0/F5$+$7=_+?MDS7&AG5'NAH;$]KZ=A$"74OUW[HB.N5
MD.8U@(XB!=H<DPC^/J8T2'37+:1P+.F(3'A@CIH7JNU[?M2KH4JC%LU6RQA'
MU(F)BZ<=^*>EY6 NPBI%OKRXIW?AIEL07_0\BLU@"G,5HE;07-D@=CR@41[L
M(PXT,G_,.4S!7W?XAC^W*(Z45;8=_N*Z.CP4GIC;/IC9%:(28XM]Q_T.&ID-
M5W=[+*$(0!W)4.(H;[>)&"M*@]+=A_0[CV!:?@[*%UJ0I3BP]#^(F#VK_L']
M4E6%L_2@H)@]J5).A(DN8D5M:[GWUQI\=*@1XUGBQ_GWUQZIOG/'1ARU4QKV
M_7 7U0>.4V+[W*?Y?[W9"INI$@O'3\V9>4OT*U>'/BHM> X4?CN?M'GYR HJ
MB>/8ZNZ?;JZI=FKOD2<2XVAR-5\DB^/)W35-\B.05=CJ3$(27Q_DU&',*VHR
MK)PXK/,+&U\T'76JCIT6_JF--QI+_@Q<L[DOW?MN7YGK-Y#07D+,U[$_\-I(
MU'R<+J^$OP_W#B;.1&=CT?02[1^+/9<E4C>2NC)"4%:F[3X4N?CC#^=[^_Y(
M%2!-)!5$)HEK6K([?G[/YVBL_:]1RL/;R T'CB, ^W(VQ1UP#J$A9$,FEGH,
M9EWM E1;"Y4.A&@8Y-EJI<5I'$RZO^_YWR#^[I.<$_@>.SSU'ESXM_$\>HC0
M:$51P4&#^?L[24 TZ,!2U PF#6H/-+?=&V436Y0[5\M2_PY\6I+-AP0&J,0G
MPRMDSPL/$XC0I.TD0*CB=K-1DHS9^,)33I^:$$"B"X1#XVZ4Z%_6OJ-Q[F>9
M@NZ_^^GUO"Y[[ _-T_8T@^=YIOM;T9DD_QQ <YPKJT*=X\IYL3&\9JP#YRC7
M:L+*DD9(\.N#2E[]T'7 ?&F@Z^D$4NM]>93![(CA[]6^I3MEZ6D"]JMJ4<1Q
M]'QZV(O/MA.; 1^?1;C&GQB X 3P/2<T>"^PSBPB7[23B6?[\$JFALAU.3#=
M_\/>FT>S_7YMHU&44E5%S=+65&/,:JAT^**JJ+G&5-5<5%%!)*VQ-19%4;04
M-<8\DQI3557S5$,H:DX,$3*=^)YUSCK/\[SG?<:UGO<]Y_?'_L=:DCOWY][7
MOJ[]V??>GCG"D>B8S?V13[/V\]#D.8&,M*TDL083F0J*;<;->&XG1Q$M1"D*
MJ\<^J=<-Q!J>S GJFI]2ZFT^R"E:E+TPM[W7W=#LIV1;1YX=;3!%<SQD%86[
MO5*@@>+STYML@U- RIE4H@RE&\RM%8)+Q\-'6O6=D##CT1\%2U,'8.[9>;TR
MAPS7K"U%/<WJLASG[UM-IZB <I\GH8PW@*FH^L--/N)SV,G[%B+I9'1<.DF:
MG&7[@!"*+>U4<+.)XX2B#.K:1Z<>C_4/>G&E\YZ)UU7,LXQ/3/L2\;5T'H!8
M2(7439S,C6UTN$S[]Q'X$$7@)XFI<*U9JQ[.3G#"# 1?-[ 8NS/T(ZT\5./5
MUOW:)\, T8>"?T6&H5?4UFGGBA".9:4PLQ$?$W8H9P*(]^#="&$8J)  ZD&<
M;Y>22-067!]89/6<H??EBRLH[ZL/3+[>J1:?Y<@B?D[M[=508B<8:PB91N(_
MD%$(9Y^3_J$$(RJ C:1$5"+)UE>.EB%)-QU#_!:!'**Z6M:Q?"NLCQ*J^E=^
M/$KMW-RU\G4FWZ#AB +8,9<@AMYR)6K#9W+KQU-PX(Y@[OE.Q'16MU5P05'"
M$RVCL)7.X>6Z]!#GZMWO\4_/E;RRCM'-XWGXXVXQS;O#E."=N5@3U*1$1S3^
M(F&5* "[.@&3QJ!X[1R@3DN_VB_7OLM6M$W4OC-AQ*'RJX$Q+DI$Y%951M1B
MYR51LA5M"9((9^0DC4_2!#7#R4NC-%( +G$3C67O1%VDL, 0."7":^\ R*LW
M?_R@D/LAKU>%H<E\!?ZZS3GBY[LDDU4B=X7NN=:2::K'$3BCMP@F\13A VB?
M$^8.9MD\@)PBR1)@QSQQ 9Y"'C^FMD'>7@</?F<.CWN&2[Q)_*Q[YSE[Q!L
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MKCYY*6YYOTN"+2YN?*RM]>(;L?*R,UPFE^XLQ=\JN<H+H/M)-YW[?_;LYL;
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MU&BO1ZT2>AM3],K%NM7P=+J7YA<)U9V".]["#Q;5;$U=6<0M9-YUOH"/FD
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MKO!@HKIZ]_J]TQ9A_>G;^4'7?Q^D'""&6:[FM5?N_U\X<=INQG;.MJU@MMF
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M>PUS*B2H]AQ/N?F&%FXB#VU<C^Y3 ;6YJ>Y05[P'P0Q#W-DJ-[Z3!1GM8SP
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M53 OTBX@,&.1^WUM$0_><7[<%@6RI;DJI RH^Y_Q-5@@T17>+RQ!@"Q6$1_
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M\S!L5(5^D!FAXF@_M3PG0+0]-=R^5,@]$G+.P7!%9LCS#5O'S/_+NU2WYI1
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M3HH,\O]&N?(CW1X2C$2/;.1>MP=F)<F, #]00@:#!E4Y[B6=GUF<DT*8:5O
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M [[GHNUX!7R$TZ+(G<!GK"S0QZ6EYP3.^V;TBI!S\Q2@N)PC#.T0W3@OF+%
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MU+T%;KKA[1818,PT>O)-$T'=O&R5/FS=<]V,5_ !H,"#&<9PFWA9[_@(RC0
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MIP6JC"1%%]/6O.XXR4\HH!C&;?OKB95@!><>-X3IYKU:'$#<31UJ7:?O<W*
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M\[0<<-+R5:S.JT0AY+C)7V<S,*MYW8(\J7:H2=GN3^(OU*1LR X2[BZH,^)
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MJ(CC: BO)VV3WAD"5F,- TP:<I4!:@\<\[B;P2F_M<HJ@QI Q9AC&XG]:R_
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MZ)%GU3#8=W W4B9KGZI ZK#K8W@^=!2;C>)*;M@ASS,9H;'75+C[X:T?]^^
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M&B+'@O*JC_U^+#XG,@>  29/M-30GG1O5E\&R^1+!J[-3#ML9P<?R5,_]"M
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M\J,7U^YKOY=T._382"V:PYIR\Q#/Y8(12?"$[,9["&$.4\M#B,*M=K%ZX7O
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M6@-ADBATM4Y!0G*.G7Y*3CWT1QU>X^UVC56AZ__5]5&W&RC$XNN@\CM3<2U
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M@P?T[(?:TT_W)?U^QN^\Z?,]YN27'KH?.8,51B#A@ I"!.!%Q-:F+7MO![>
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MNB7,AI27*CIIRD:P>^^^R(6]21PYA4] D%XC*??>E=!WH<_Y7%AB\790]=H
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M.^O634;@L7"_%VW1G37@-8F8-^N_[\&:Q<Z<:<,8W-CUBTHHXQL";18X:6X
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MC/:%H[70DEG3;?""MC;]VE MDX#^"W33(NL-2/S=!B".C&<H"7  'N <7'R
MA?F8($;&?4YVS@P<X8H6="4,>^2/[1Q6T+Y:;?5'%((\"PI UW86T&:)$\=Z
MO0$3J(XP6 ?MU>^N<8!VWG&.4LK$M+IYR%X;O;FUS>?\O7#K^QFI9BBAX"\
M]1F!Z3 T^8<O[A= 6R:153O>#>"3N9H6>>VMAYFX:O*MNA>AE_KO#[YNRZI-
M%%^BN8?ZE&0?M7;KFJU6^F TI4)AMX UU"&R7,^,/HAGQ5-+R\K!/W:L7>2
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MTP;-O57.DJX=UM_*[/F>-6C..,@XJ>\G]K:NC 8#M9-6PFG E&87J2;Q!77
MK=-7@<4UM(YZ!99WFIO_&TK6N6JGY.;VRR)__IB\K]>68J/]9KIW4R'<#0B/
M9+J:_FJSUZA%BP,=+0'ZM=E(Q[.?@L!E*CJIP''HY9*ES9/+E"TSUVM/E8?I
M3(T<PERYHVM&6YB&$'U7.0*[^-0^6PWGI<W*P=?;@]^^%RAL*[^C8*$=O16K
MR\I+:S4,7F7.=>:J],19NU1P7;YHCYL:U6Q79.>Z:4RL*'X2_6N0N[?_7"/C
M<W?O#\+FJ.Y'R"TV>W&"M+F#=#V(&SZ7 >N"B:Z_-5U-+"\./M<3])3<&V)0
MFGK8_^[X97T/-Y._+^+]-(Z_A/RU99<(LI)\&EN!]]K&!#=#8B(&S 6\7)VO
MB!ER:6P6$'Q[E\+*WY4ZYZI'#1BE#\X^$9Z7"Y;4]].@!.M6R&(K;(8W*VO8
M4%".8X<3Q'=QG &NOVA7\S!V6RRUV0HI&1@U]X?LTU#,>[ 2>I-2H'BW>%I,
MZOLWV1W!JA<V#Q)A3AJE$*1Q.EP+WG.^'JB+3HU:CIY[K]/AJU%O9GFO>%S/
MB=43%611F]4F&7BM(?":AOS??!>]9<+65G&N(>])JRPFANK6AA#Q!('V(L61
MN=%U _7^&L= Z4M2_8Y6<KD!5SP>Y5YQT+J#BQ HK:<$:!_@)0I8XV,2<X*?
M>9J\.>H;U&M7/\RK)5WZ*M+MN[-F+ 0-#_0P(.K_EG#)U4M6'S=F659K##<:
M?K-P%1?:ZC9":&SBRJY1X8S?<W QS-#<YF8SUNN#Y;?;0W$5UG"Z\CHG%G8.
MH5_Y!7=1X]M#T^MM+Z+(CMO(.W319!A?K)Q)9+]@#74@4@!E_@'NB?<3-C)+
M':[,([Q<8D 0V^F$,:'A8Q99/_SC\3WW]]2BG,VPJV^$%V#D!V=&ZY&@A2W;
M9<PT;5]EU2&CN-8#M:3<K>*CE [Y;#LYO]?/ZPZ(W$$HP+C2;G2WI%:+8QPD
M!DZ?:XMF:?)5XCN96+O10W+OOOWX6>/I?N(#=_:J.^I[4PIN*5D+$OY@O:?3
M"-R[ 6G'I\PV#,630J$*6!<6!WN,N>.Q&8'FN(SR'=?STO.XGTW7#&ELO5A\
M;K7E8\7L@3:?E*;!#4@0"=1 K]ARG'"C)OP)YR6D-!\&+K@TG;)V><W58PUT
M"T*;F/QI^9 6Z3@OW=2=SP_6H50?98E"V*1)@(I>J>0<Y(KBV;=X&:;RH]90
MZM>H\Z/4ZK3S[UHR)6;K6YKN5W;U??SU\$WNQ1"KK??5;21#RI?'UB88@K"U
MM8WW0"  <G((P8MK6(4N\57 \))I=\?2H!FI<?5NC%1)>V!/@6V^^6%]QM[Y
M6WX::),=-G?K&U,_C>L=EEA)/'1B3<MP4EA8OS/7YEMVX);3_YV*O77\G+F
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M%?A7MPU(;M+_=$F^VT@N;4"4(TE;[0%67[O*V22B:KZBHY32.?,#HG?_*EM
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M_J4P;.WR\H=LBMWXP_B(1KD.3<,IU6_7=,_N,'Z*?V,CA>O9@-1%K4!90]V
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M.LL^]3NSV-<V"BA=]*RXI7/^34+.L^QH68,-B.:6MG/%H1:ZMTJG\11SOAC
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MZ\-S' FK58GW7SM?/O#R>1H3=,U/77_$Q2IK6KG)\!15!?+/.95)V"R*.VU
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MN!/P5M@ /DU-!9BNW_V\'",_Q-5H+7 .>*4<+?5I (5":S\+/J_H\\-UYJK
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M@2M*W@7K.\6;=0#OAB=\*!WZ8WD=Q)G$.\/7*S_9;K94!7:@O::[O9CB8 3
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M:7O"4/6R[O#W=]^5-Y._X2LN\OJF6,F5O):+N5O5Q:K:/OJ%*[GDXFY]G]L
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MCH,KT%('OW?_=>J5M1/<D<6J2716H]4,B$.[U?!M._5Q<'QN2R'>BJXM2!M
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M1UKY%)@D;EPOXQQ>>@O6#0IFBW8?@ \] -X. 6!3(6-$-G?5,<X1FKLRQHC
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M1$DH5T?B0^Q%"9-_08%(=*VX46I3+YE-1?I[Q0 0+0=MJ6N\X4'?*!@';]P
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M]5RHSE7(O-U6A,[;3J;5AU7;=/FO/+]_J#F[EIL1ON=[UP<+QI!  <4P3K(
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M)/6O7LRQ'+^/FA0A4W<KJ7OM*J[ EALHV8&*'] '\+<9 -2_T)H42+M;KA%
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M&P[@,QY(M2,U;+^?%M@@8#H@N7Z4U X"9J%1X*L'14/'Y1H(@0X\/%G<<UR
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MOZ>-)E7'"J3/!Z1'BRYFXXK%"1(PG=-GH6MJWC*!U%RU+1M&S6QT@8(TM'$
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M-(^T6C ,$7&L3'=DT88NH%W*.6#&=:4-<6%J\82D)AUBSHD,: UC073#GC"
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ML-2;$8K.\VXZ^HU;0_<X@&W_,>1XDGM!4!#,H]#'Q*<4IQ$3F(6,)#S.DZ0
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M*P<!<91E#GL:/@[EH>+75;4C</WX>*WVU/7S2G< RL 2CO6PI%0U&@5=;_2
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MO AP1GWIY_$PPBG)*$[RB'+/*_* D@L&%]83C< X'.!7&T_ .(N49E3'@OS
M8(Z)Z)?.+CR2R\WPPOI]!F","3LROO#X\X:;MHGO-A&@KVL5ZY'_:')L;NMZ
M+?AMV2O[GS$F:)YFJA&'2#%)$X&S*/:P2#)*?3]E24I!&QE W/'F;NFK2XJZ
M3?":-RRH4VW5ZTVANM2U'X!&="$X:ZH!1^@!58,J MWT(+Y".QR[1+G;+8X]
M=BSJ# ,0;.D1".EI=8L!*$?ZQF0-,QVD7,-325@B4]&6W,-Y$$N[H2A2G&69
MCW.:!8(*+PIR4">Q,W0F#+@H#F!ZXQPV>BK"@L30L&^^<I\2-B*6I?U]CLJD
M6WE$U,-=._9QLPVZG9K>S]3<_O(_Y]+1J-C3VV:"  O#D+(,IT6084)X@JFO
MQI9'>>3%N4BHKY4R943=\6;N9:UN"3<)E%^O?S<<-0 #5V_?.X,,I@TN0PNL
M%HRDMJ0L8+0G52%&L!PJ%K-%X$5JWP1;RN/R[:ZXJ2K5(G6GS;YH]K;37<;=
M]WY#79G!DOZR%,MUO>B*F@\;)/=/RR\V.]]!<3"J]](B,%GI%T3<?A48Z#GX
MK453S/=G-5^M1/E-/,YK>?((_FE>";:Z*PJA@G&;^C O)"07#!=1'&+"H@)G
ML8BQ-'6C6(09X7&B>UNA3];QJ=EG!.TX02TK:,.+?@P> .CX!88;F& :0Q.A
M\:2I2Z#2OZ9P YG9]<2E7R[0701<\($[",!BD]T]P 7LWSD8/&T>,K@MZU75
M?&$^4R;:TNA93@M1Q"+% 24"$^$G:M*DP#Q/4X]%?B8\K6%)8X0<:\S&CYYO
MZ5ZA0E)&=+C\&X:4?@3A4OD-0@BW/=$546N5[[IR68PAG"0S>1!A2-A3483!
MS\.KJFZ:E,=KSN6;K^^7]8HN_K_YR\<E%S,_)'F>))XT=$B""2UB3#F+,$_\
MO"CBS!=$ZU9AF(SC#=L21AWE*]321I(X4M3U"[ &@!K>L?;$A^U74\E!M5KC
M@AD5;@TL.UD5U[AH_9(NC4^;G:@/\K&[HM?J[OK'O)YE*6<%S^1QJKK(DL"C
M.(LB@4,B8C]*B<<\T-7]22K. _ +R<*RZY3<GT?4-%+N_?MN]20JM'JB)=I_
MZ _%)C"N=QI0O5/W8IA@6]@]0N#S>1 !2X?S:1J3GLR#8AX>R\,?AH<E[BOQ
M0N?\5UJNI7FY6BOKO.M6O4GHS8(X(ZF78,_S"29,M3JFGL!)X1-"?)^'5"OE
M68^<8T70,8">^QP@T;)PA1BT-$$#O_'H@UU48/M^ \@>\4TO>8-:#0U ]&,,
M=H$QBRU<"! HM* O[T!(06.1R4()^@+U0PB IPR+.VC]I!I)R/]1E:RO=-&D
M4[5S226QYD)C%H1%F@@A<.&%*@[+<YSR7'6 R&.6Y[Y?A"&LB8\67<A7VJ@C
MCR+?G.I,_2!VC #K/[1 U#-VK ,#-'XVB#0_]#BX0K0;)ZPV?<.%Q8(1B-"V
MZD>T:$Y;3@*!X:BZ!/2P8=L+55PFQ'=Y<*SKQH+/O3 OA$]QP.5_2!P74C-$
M*?;SC.1)PD*2@5RB(PJ.K:".'FH)&KDVQZ#H[?2+1(7M:IB4\#X3YR2QU5+B
M:/UINT><$^^H4<39#QH>SBI3KIA+^$5]5WP23?>0[GHJ#$,2Y41Z(%S((SGS
M$TQ3(C#U12YX$&91!$H''*#E.B+1HZQR!'A+&W@$#T"E>?#: 0!XW![(WI%U
MT Y"0SQ;!^L I6F/TW&1CPY1C4?@:3P?GU1YT6>5'717W*U7-2\?Y5']6_E:
MK_BV#?W?JG+%;\O[JOI'!1R_8$S \=96=518Y9)@]1/Z^*1B-2K[O9<+I[*"
M]J8<M%JT29*_KU1%MGJV1@]/T@"EE4!*OA5M&TPH2_6WIFN>X/H]L,W?Q[ J
MF>Q5P)3,I&_!\F"*B^$TRN,RISI9<M?%P/0SOBY?S*"SY)K/Y7O_2I_%+"2%
M)XAT(,)$Y7GY0:S:!5/L>WZ1I87T,/2FI!^LZUB[=920(@7H*=F3>UB=7" -
M3$%H"0+K)GG,MEDOR=XZTW62/&9^KX_DB3\;EANJ$J(/M%8SA=^:*XS=;<;7
M92F>7Q;+-R&ZLX>*)",\"#"G/,:$^@SGL9]*ISO@.<D2^5<!JC>$4'>\E7KT
M@)6$( CU/ %GP,!V9<,&;OA '2/[P]=ZO+CH'V>"@JUB0A#M::L)36 Y*B<T
M6@3N>/RCNBEY=ZP?'N,?7RO^C^KPL(?Y':;K3^%VB/VV^D,&[D=E',L?&_-X
M9<_/,(9_W,V8 GD#+\,9Z);=BDOA,_(JC(E.YE1<"DO?I[AX+<-10_WFO'+I
M;7_>WVI1K!=?YH68,9YZ6<($]H-<S221EE1*:2K=C9@G7ISX-$E!8X?&:3I/
MYF@YN$(OBH>K9N^(#1M7:-TP@A:2$^!L(@TX]:PJRR#!E-,.G[;9MH+G9@=/
MRP+Z,@0/?(21OL"VQAEI4)QVM)$^!$=CC@"/7NI]]2L0>Y;8A[=C.TT=8W<O
MZH-U[ZCZMEPL/K?]I&9QDL0B]F*<<4*D<Y9RG'EA@6-&4Y+%&96OS<Q-L\FF
M:W_NH/&)J5-G]<U O;_WPMO<3=PKI>UGJN9OZ*0[J5B[0AWG5WO6UQ^*>]2Q
M[\2O=(&O=0?4*I/OY*FZ /J\2^N$FL& 5_[/A^6]6"IV/I>[7C&ZXUU//^XZ
MI+R=\(T>ENC^YFYO2U_)[;A<J0;%@'FO9V 8=S$M(  ,0VL*;[F/CH:L9L-?
MSZPYW>C78:'V!K^.?-3,PFKJ([H4UL/,9RZHEZ49%GY08!))/RP+O 3'-,A#
M1O),<%!;G/.D'._8M@;DI4N-[M+GH:/0S^.D9[/8D1ZV6UO!-SGA]K/ ]66S
M-1?]/*%I1Z./"GPT'7W\"=/"\G:HP /]T0T7['YQ6[+ELYAYC"<B%A2S(%87
M4;G :1![F,<^"9(@BY(,Y.N,T'.\E;>3*2KQ*LJ!_&8CK/1VLD4$8-MY*[RD
MW(TSO4+;7[;4;1:<:XEIK>Y\F-K$Y>=:HA]7H>L]!B]\,[;<?Z4_YL_KYX_+
MLNF]NZ:+!U$]S]*"1S1+J"J+BS A+,.9YX<X]-4<(Q8S2C*]8A$'W$$VD%E)
MR8X>>FNN-M2\YV6A!B!)UE1UJ K1-KUSU=]U6^>Z>%/#*NF=T3>(@J!\. KR
MH8N"=)_;BX*@CF/4?X&*Y_=[/?K5@>_XFLQ*"?NO@?5?%]T/6M6]S[UTKXLV
MK^NY>UVL][K45ONKG?I#1X@.%"O:ICA99:,CJ/IED*Y(&*1R2_K7S4*+MWMI
M;O]>-\9WUP<2'&727,ZQX;NO,#MVD.('O=9_[=H<=#P!LJPUH1J/1#E "7:Z
M0 !R$)T"RF^6\JQ)8[H$9YC0>^G,P$<-[P_9D^#K;5_X#V\?%[2N'VB^$#,6
MT22)(J:2"U2&01YCFM$<4^DB\YA*2[C(0)> YVDYU@W=)(.&WG:R@?R.*]+0
M02\#@&G>S=F! 6A:&B$ OQ<;E\W6Y=8 I6EOJ,9%/KIFTG@$?JK_7J_*QT^K
MD]E*UZ74'[ND)5B")'AAQ[OY=U$WL\L^T9702M13B3*_MQEX!SE[^H8 '-UQ
MD\ IL##]8!%3RUF.QB 961!P:I/9$L9 ]*T*\T7,[(LVS#<C85RDH<@QCU-U
M4T9RG!+Y3R\E/.8\"%@4SU;+%5WHF1+MLB ]LUU<>T\\J$<0;4C!C(1.:CU[
M "X+;&M?#PL /N/W^;5TG'>+3GIR[PMR>$@?_-6@%]OB[7FY7CW]*H12K?>B
M+.NWQ2LMY[0[(3Q!BB"*8NP%?B!W!5.MV&**XR3B(A2$ADRK[X@6-<>'\H8^
MZABX0GT6  W'1E$;#_A:Q0*VV89A,&CV/HX'H/^:35P,VZ]=B ^L_YJNO$/M
MUT;7F*[[FJXX>\W7M!\R+%5H Y7UP_*:24.Q$F=SGF=>ZH4YCP3.0Z8ZSQ8A
MSOS QS$G1<*\N*"1/RO%HS1!N9X9H$]<ZYN=M=_L/@OZ7VSY^R=:MQU0&'V9
MF]H. $#U[ O+()FIQ8X'M%JBC@MT4,YPM5_/8+&$ 2R_K4H&?<+3%C2  3FJ
M:X"O (]G?);R+4NQ&>3S:2T>EK_/EXOFP+DK_G/Y+#ZJ%O;5VQ?ZY_7S2C><
M 5W7L>'4L8.V$Z:X=+OE-MFRI!2*8@IU7"')UM78](3+T1P/7[@$$J9>W& (
M"E.8@F$4I0 3FRQ(80I#/T9AO(9A@[KE\_.\R=BN5>O)9:GL)%&RN:AGO$@Y
M#1*..>$%)BD)<.[Y%&>A_&64I;D?@]I5#-!R?SVZH=PVB^W3!K:I&P!,SR2Q
M! -,21PB\%$+ 7B/NG'9;/6H&Z T;8^Z<9&/>M1I/'+IC>9-40BFDM7:[,('
M^N.;M.N56I%T%O-&G327+KMK_(B(R"MBCK.X\#$A0F7T4^FBQ)1G(D["5*\Y
MO@UF7-^)=JRANP)MF>MR9)O\6<4?VF?0]*K4X$WH*9*I\(5IFBVT2WUHN[M8
MY&2ZM@V8K-_;&K#R3A>[YJ"=O_F]8$TSO?AE6=<[/?OVB3[31U$WF25-9W<:
M<D:]@N&$T5!=T7 L_RFP*%)?R/\+J33- *IOA)YC[=:10ZJ:!*:UQG#24TP6
MI8?I'D6X9]J\7:$-%(KXE>VF]YIR6E(>8]0FU0^:HA^J -W'X &3AXI?5Y7*
M#9V7C?Y0E_FZ49&3#SO>I#UJ3>*!?C3CM*CC(8N+I81MQH>*-FT(^OG[VD*#
MP@^#@AG%&$ZO.%D@85"@?K1@^(-F9^57NEI7\I"^>Q%5LV8](UDN#T?/QT$H
MI&>0Y 13/Z X#DF<)EX0BU1KBO=Y$JXWVY-HBDIH^08[$$^ H7<&7B8B;*>U
MM)3!O:-F.8EY7"Q+I]P) I,>;.<%/#S+!CYYJ?/^32S4)=P]K59O4HV6-64-
M@0]O>W]I\FY%0N.B"#F.,ZG%2!RI*)TGL$_]@D59%OL9K*FL"1>.MV]'#S4$
M48^72].8(4!#G7)'\,%4@SER%_C9!I);=[ A/+R39VT TWF7VF0Q0U]:U+40
MG=8K'[\(*K?SG.;2<5^];2Y'/ZV%2H=]^',Y*SR:AT5(L-1&JL6 EV+*LD1:
M$/+7<9CF@H!:# #I.U9-\BL8 WUL('Z:/K<[5( ^>,/(%=JR@AI>KM"6FRMU
M.YF+SB=OLJ8E1Q;=<C,H;+GI0.K3NNUFT!RY\8;+&-I%JD[DMJ[7@G]JYF?>
MBVJ^Y&U?PO;WGY?5=U&]SIFH9WD>B"#W*"ZBC&(24*EOBB+%:11[219Y/B$,
M9!"!R#M6-XH>E:^Z2;1:/C_+@[QNJIF*9846XI$N4"U6JT7K;JL6!4T!MFZ/
M D/(-4TC9T ";R@:P%J"J.4$M:Q<=<TNKS9_5:AN&+)H*1D!8<M$@A&?UC8R
M N;(*#);Q;3!4KZZ+>M5M=Y,,)\%E*?2LLDQ#1."24X]3(,LP](?$R3/$C^.
M09W1CDFXOC^0!-&.HM%,S1.XZ&F)RZ2%:0*@H 9-DL[)8JTOTA&!B5LAG1/P
MN/O1V4\:ABDEAZHIQ'(A/_1X6\KON:A7UWG=](G0C=(-+N(P8K='%VT(RR]@
M1]IFR$Y+1EOANV%BTX;RM 0_"NOI/04OB3JX^[JI5_-GZ9C?%??R#W/IEZL/
M--=@=T5[5LWBD-"$>A'.2-R,.8AQ7G@%9C0.DY#$@@9:U])FY!V?,AL.E"G;
M&JD]TU6_1L@ UF'=X!XLH$-]=*G=1V[#$%(?N]H5+D.ZMAO"J%][Y19.LV(L
M)[""*K3,41DHV3)8=+(:+G.!^T5=%ZQB:&F(59NGI!:>A5&29T% ,&7$QR0+
M8YS&(L1>0421>CZ/$U U]][J()4++^J6M-!"D@'>@>[+[[."%)F4.HW5?9-T
M<?*$$,R+M"@2/Z-^"O)NS.4W&&IA0?XDX &E18:C@D:8%%&$\RR.,/,9B3+B
MAU1$L$(^. *7U.IM,$!J;Z+E]O+R$DPTC6W3-PVTK<5JDV[ZBZ+T%W2]6E7S
M?+UJ<DQ72W499K7([J1@M@SJO;6GM9]/B75D+I_\D$G^5I,M=%U53:Q .W&K
M_Y3K))+CA*;_!<G:VA-P>,M<)AMLOYS*T[(5"#DOAV%:UMY2$^9CG1)A/Q'K
MY"?@7N+?Q?SQ22KUZU>IF!]%.X9I8\CT1JS,(BX\CP8)]M7I2Y)0X$SX 0[2
M,(PX28(PU1J!!R'J>(-MV,"TY6-[P]%ZA\O>;"/PS08(VW$'T05BL&V[X0!U
M+*!N8M?=QDGISX)R@)&^]^<"*S.?SPYF("</*OR :Z>]U&0.'52XOAL'?A9N
M4]R_OAP45FF:%4</.E9\]_0-O=;J$K)85L_-_>ZG><VDF;ZNQ!5J>-&W-([%
M'C<V+I(8IKA.".NB_&M0*B/KXWBUR0R0LX+T;9#S'X*;(1]%M:+S\@-=J!?T
M_4E(,W\EGFO-^Q6=)=Q]PSK*J".-&MJH(:YSPP('0_\LM F*V1DX (Z=$T]7
MQ(&3;G2)R4XX76'Z)YOV,_!M>31#YE:^_O)113V[MHMI*I(@EQX!HRH=G%*&
MTX1R' 9QD>9IE%*B5<2M1<WQL=CUUU%-5C=T 3<:XUB-ZS"K","4V,EQ3COR
M:*2SI0$<^EK,*BQF:NQ">$ :35O< 94VOL9D.DU;G+Y2TW\(;J=O._%>\W_6
M-S_8XO%WNOCV4JEVO-_7S\_5FZK=JE?E0[Z =>^&K^SZTGNOG_1N7JK\\BKV
MUDUPH[UM_"9>EM6VQ71O? 70'3! =]Q?< LL3%,:8KKJ:@+W<;7<P-L<)R,7
MQ8#<9#Z,.11])^>"56"*B8OY[*9<R6_6Y_FB"T_,BB)F?I1YV%/=(4@<49SG
M\C\)H87/:)H%>L5VIQ9WK7D:<DC1Z\)>>BKD) [#"N)2Z8#;7U\P[:T[),'
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M",RFV!!Q^PH.NL]EQGS/GKQYWE_2)@[7U='U'SI6HLS/K2B+-0\6"4\2RDB
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M(S4[>/2LBG5*J&-5.GF-I0^](9LZE;@93:#SC-<K'=>JOZ.48\8EXXA3HM9
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MY-;_\UI9FN8%RKBVXGA[>?3OZO=?/^7'>]OFR]T/^-;M5LD?[^V#5MF9W\/
MXCP7)[.MZ3-#V]\*S$WZLI[6URO^3GP3R_53[6Q^UPR+V_6R8,\+R>(X9"1
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MB:3P*4&Y\-7"2YE$&<94_2T6 F.24VI4F.*$FXD729TPT>LGJ9CT6)]+;_-
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MJ7)/816&QR0F5K,ND%I3A-82OH##;(V[3$B8>AW(-T&G\O.R."L0?$%@YJK
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M/(W)P+-+X;A_$-Y*;#QUR7:YJ0^*-NI7S: F#:G^B>V0EJ0HO6\=W/K?1JS
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MEKS#KL4&\QY=X @XF)T43\LCV$EPA1VU6L,R=*@*?^A\QZ?6 A\<E-H_Q;J
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MUAN*?JSVIK==U$:L6'V]72\+5HCJFBJ7E;#-0D8L\4.&49)&#&$2<)111E#
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M*S6#:"W1MK*;E ,&W&P3-R6,,'/SHNW@70>98J?)?;]J!U@63*V'?,L&"P_
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MS]L8UO'PPQ1@P32_PZEW:MG@=-WBI!GQ:DZ:?YD )_. Q11XV<4OW.$&"FY
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M&(Z5B-W-CH>QNWM2U5WOU_>KC?H&5;K<JVM_4ZVJC5A6/P1?8!)C0LL<*OU
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MB:(H*5;V4R;T9 ;U#T[4D;&D*<IE2B,<6467Q\D%WOH[XMWA\ HTW8F&[!@
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M4L:UI0<"3@NV=X&?#[@.TSGF5V$Y)\-M]2RETY/339.(EUBF:;J>*!F)2[Q
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M%YQ_5W89J*L)8RXZQ @,BR7.:0$!.8+525L36,FV]=U]+T'C%I9U!\YVPNL
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M<MV[N34H]*A%>VMRWA1JPXI@Y!?N>WAW6^[QYGMG!^D'>8L3[Z46D?1\D+F
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MM;Z#"RR)26'W,*GN66(_M/PLT?66_.Q -6T[LOP=UU\6^5*[\)V>#59[+[@
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MC<_!DVQLW,#&$YV/_B#2T[G90T/\/E_$%3D8=<-OYE]/U]>NS$M]!*,G7R@
M-[K6& 4&3M1&2A9Y[6QL!&L=U1YB'^.VEWGJ4S$6 /IT.E_@<AVF\^=A%N8)
M/WY!7+]9X\GA#N8#']ABLN,C2#[2<:P)\7<M=S% -!3)N/9@7$)0FN0?77+@
M0Q1,LVBDW*?*X*%UCBF2N#"9WB_Q:YCF78[LZJR@^P6AOP;"-S?&-4TO;?!.
M\UPC*_4Y!QGXA(%\@J*T2<8P$_?8WS$TC..\-9?^Y3J+)Q-)!Y?O);=TUSC@
M??A1=T1[I>\L3_&RB7)MKR;'R'D2@,&0H6%Y?3=7=>NE#I)*DJGA<AX>3^\X
M+MA@4'UR$?9Y3;Z>?L=\Z2@><C/>_(P&E^$#A#4*G-[9C>'"--/*1%4#1R84
M<@<(8)$)#I)5S"6366P=+WV0J,&Z@UP@FZR]P!!5'1[N0 ERA0)/#!C3P6E1
M;&X^]OAAJL8-=;;%RMY]00Z329_:YN98^</?>^[ZJ!:O.GN1V6I4Q(W%WB[6
M%],FLY=)H8B '@W=;5Y!R%A *OHVLX$%UWK>UOT4-<Q)JNL\_W$MIU"%+#Q'
M":R>)&5KDG9,'AR!WV (6?+F&[Z?I)%'2+3#QSV90T>+HK-'DXM4J,OE(YOO
MKIZ=KK\LEM/_QOP[G=_EI?RHJGQ7SW^\^H[+-%WA^^4TX8?:T.)2J7@2Q4<5
MP)90G^-3@."L!^'IZX@J<-NZ-]OPNQKW>>5I$-X#(+IR6>_@R*5LP6=I/?UV
M=OM=[!AS$;5!$&TV9% E)G JDH)0B<N<2E'-"Y&.IWK<%Y(Q(=Y6H#\!A#\@
ML76:UKA-??U]/EVO-IFP=VR_-F1@0COB?CW!EAG:ON2 622,NK!P/0XX.)X?
MN85Q'SI&!/>0HAZY_\_M&[[48.OYC]OSO;<BN-36>Q-U_?0ES!^1!,Z]#])*
M")%S4,$5B,HC%%X5@M<JNO* @S;V'L8=#S# F1B;H8\"19_QAUK$-CW/TJS)
MP%/BV_RH6M:'/[/%T^#C"&\4FMBV=3@'+9(=8+FQ$(I!4)$C^* *V%B$#E(X
MT[R%_E4*VC0+>?<5:Y'$_//FP\^"^S_^'M;U6?[ZC6$2*X9K \GY^A*N"/Y<
M&/JCR,Q5O3U:!T(/('/<$,41.+F]G\AP(NI3+YUW:3U"#]W\C 9ZYP'"FJ6O
M[U:Y&(1\ :;DHS01@=E2:N*N)8O-QMKNF&[)I&KE9?-\]3O):>>Z;!=YCF6Q
MQ(L%Z3^K]30]F^?7]/WIY^MIS :=-;YF,!O-:O-G!U'X!%D&J1A*HTKKWGY'
MDCQV>GH;9-WMEPPOQZX\[E>E8'6M+O;Z(:SQWM1[YR5JS+0Y#!I4"J2>30I0
M5,+ 8\G*M#[!Q] [=JKYT( =6()=H?7EC@#:Y&TYP]># T''8+F&9&L6)IU"
MLF!L!I=8U*%(Q4WKI_X#21T[W7MHC XGM[&#.KLM+LJ%B;M859^.MKHMV7X1
MELL?=)MLO/;O7Z?;@N[K>P[*\\B+JOVL6)W15@-9="0]2R5F:X0W^0&#L24]
M8V=:MP7D:)+J2GG^7DLG:H.!_]X<Q.<XQS)=KSXL9K/7VTU?CP\Q+V@W!FJ3
ML[K3#%$*NC R.A55[9(R7!S]L=2.&QX<7H4.*KT^O>C=R.9+9?>'9Q?=]5$M
MLHOV(K-5=M&U,=;G*%-9R%Q00([6@'(NDDWG)22'I)>8KI&:UH?U#EH:O@=>
M6^$2CY__V/WPDEFKE!5:Z^J$$>(+<G"E]ECPUF<5HL+0NI'K@:2.G('4 D/W
MO.P-)K1.U=1>S2C?UOE?U4U[B>LPG0W79?/&0D_6;_/^+0[?>;,4FTK*!5AR
M]9Y+Y#(8Q6J/%8S<9"]9Z_/_%)TW[\XDKM?,A!L7N,0"IDZ-4W2>('AN@#.A
M35$^R^:UG?O2UFUOS<<@Y6Y%UU P/3@*))G-D_/V:;F^1R_F]8'RV??I:E)K
M5@T1#$Y$4M.21?#2"$BI6!Z0:V]4:Y3=1]#(-^@@&+@.M&8"Z0!=U_;P<G$2
MIO.)$B8R*1&P. M*D%<4JOT1##-2".=%:AU*OI60L3/"FPGZUJ%&QW"] ^AL
M.Q5O$G#^CB<1EQ/BAG6>#I0P(M=I3 %BS JD<3;**%(LK6?+W"!B7,@T$.S-
MJ0Q'<+D#F.P&[.Z(C]%7;R6!=[KFP6;B0O$*Z M+CD;)4;5VAZ\0,.ZK4WMX
M',[=#J#Q\32NIGE*'DSM,+:KCMDH5Z,"W<XB@L5$AJ!P#$*(&8+R@FN>;&S?
M ?DN8D8NVG@2DZ:)('I U 7Y;\,)??F)3L>*7 N2UNZT62E)>TH/.3I/]W:A
M&YQ9!K9XZ[U&CZKU)?4P52,;.FW$?QU4;64Q\HOB2TP;'5N%^Z[0\N2_[K2N
M#HX'$SV(4)OX*.*4UV0.9F.=$RH)[JXE"]WZ1GCW"B.CH[$<%\V9.C(TGGU=
M3F>W;,&PY(3P :S".K6#+F(G%5W.*6A;N _D/^R!BSL^?N1K:3A0M&#GV.D'
MQ)W5L\]+W+B/._I5L.B99I#DIA8!8[7;:QNR(G.Q11J^5ZW'+9\]<M'=<%@X
MFI$=V"2;8N]W96>IOUM^F'[^LM[<KB3;D -CM:--3:BQA<"<&3"9L[-*L&*;
M3SB\BYB1(?045FX;0?2*J-U)2^0O8F063$HU#<9K")QGH!VJZ&6@(_(DF.K!
MKFTD\'U@= #W.S1H=WM:G=VXEBD60P')1=JVRXQ9" A2:VY25"*% PW;JRMU
M")-#!/J 97L$=WNS<*]MQ8I2&24 F:CW,")$NH8A8RK&&%UXWJ?#XP/+C&OQ
M#H&2EGP=$2*KY7JRZ=:QT:WHA2*[3D"T=#&KFHWIHZ$]6.:*<<K(M%?G%OK4
M2[</_>WBYKFRX,A%^4-:+H<SM@<TG 6EG22#7090O#Z4!1L@:IX@!*V2Y+4?
M<S,\C'F='"&LZ^(^@',C"_SOT_GTY/1D1WAAM5"=)9 UJU9I92'$;*!(80T/
MRH:P5V^Q!T1^9=&1A7Z(R!8M^#>VX,/W2X1K&82*M.E2@JRCO2(X)R3PF!-#
MHU''O5+3'Q+\Y47',0N:"?Y@_G7@B-YYY?TVG>.F=_!$RJ@*,PB!(2<H$YZ#
M21RR)F8E]%&9UMV7'Z9JY)XE3Q'L:"R:#L#V%M?;<HY:'S3!K(6VQ8&,OH B
M3PJ"$PQTR$PE9XJ1K5^(KQ#0:8_< Z6[:,7JQ^/$;W$RQ\]AO?O=8US5?RR6
M_R1'ZD7X.EV'V418YDW-J& \A9H1D2$&8X$KQCTS/I6]&BQ=_=1Q'=&!9'\D
M\SI0$!]J>OL<\]E@\6<IG9Z<SBJL7F*9INEZDG0L6"PCQM36SLC)*C<E@PC1
MEI2D#J5UT]N'J1HW]#ZP*FDLE%'URWDH**R^U/]55GT+LTU*Z#QO9I1^NCJC
MM);N*%9< (]TCI3A""[05SYKSE!K*W/K3-K]J1LW<C(P\ 824@=Z[O)[ZVEU
M&W9=&U=O5JM3S&_FE]Y?)]P&P;*UP*RJO:6=()?$:MH;=\D644+[3+I'T#>N
M)3XP! <35 <@O)27_#XLWRTWR?)Y,R#M/2XWVYSX4E_C?0 ,@7B'K*IXK:'H
M*&V2QF;;^K;=@ZR](&=^4LBU%DL/2+OMX>7\/)T/^7L19C/,SW^</:'L?G$U
MB8D;@Z& +ZF.FQ<:@@@.HM+)*$><3JTC$$>2O!="[<^*T"<49P?HO70';+K:
MGY]"K91 5H=/BDA&1]*D[STYV3[+X#UYUD(T'TMV!RU[X<W]I'AK(H .@'3K
MN;DR,.'\A^>'A4^\Y=(EE.!KXTYE,D*,)8!$1D?':!2V=;W-083N!4'_DT)P
M>-%U@,]+Y^S%8KZ:9ESN6L<GG'ZK,W(O6[OH9'W-2$"J7()2F&AS-010!]]*
M%WUH[A<_BL#]PKOL)P7D<++J (C$NX285Z^)J]71JL,LWY5+AO%$%6VYR@XP
MRCI*)FMP)A@0):5L<@H>6S?0>I"H_0#WLSXHM)5)!R"[?>[ YKL?O\ZF:SI6
MW^A']4Q5(?))<#&E6N2942,HQR2XZ#BDP*S6,N0@VC=J>!R-^T'P9WO7>!*)
M=8#(,Q=JV]^IOA_O>CJM)DYJ*YEGY.%7AU_0=IRD4Q:L,,R2/B_:-\;>W=3L
MA[*?];FCD10ZP-.SV6SQ1]73KQ?+EXO3N"ZGL[/1S5L[H>YN-V1\(NA J"S)
MF6)8R"N7!F*I+;>)EY89Z;1M;<\]BL#]4/>SOG4,)ZL.@'@G[WY?(>WSMVG!
MB42171$!C*@E84+7YJ_6TN9\X=Y8KINWE=B#K/U ][.^;K262P=0N]$/^V):
MT]D)F]B<T"$SD&1RH'Q2$$3VX*.5+M.)XJYU@=4>9.T'M9_U5:.U7'[FAI47
M#;.?AU7]G?QR.CM=8WZ+ZYJN=1;?'+J?Y6/I>+)VET<QJ%$WS+-LE[.USCL<
M<A,\XT* ]$:"RJP.I#,:T!M7@JA%TJT'R]Q%2]-\S&??B)>;1M>+2U[]SMW:
M\?^<"<FI;+B6D&)1H# 6B,9Z8$;(HIAEQ;4> '$PL2/W$VN!HWNS.P<37 ?7
M^=4T5I&%M]9)\K]J6V-!%F^0.H$@;]Y[U-K8UHU_.LH8?B*AWYM(_!@)= "?
M?V!]B2%.?,-E^(Q74WC>G:Y7:[I;Z'3N&'8Q8F!C\)SSCUPJ'=%D$'7@L\*2
MP(4L0#CZLKXRLN:-@-M0/G*OO"%4WP@B';ET>]\=3V0,A45I0 ==1Y)O"A8M
MHU,O73%*<W6]3//V3/D]UQM7&XZ!@\7 0AD9:*3GEYLN/6&VNU,VNWFV7B^G
M\72]O6TV%OFSG44^_8;;(6FU$ I?GU:[^^P9?!)UM$(J#R$D ZI>$TX)^HK7
M\2E,,Z?W*=QH2]6X&G%DT(XHX)_(&-@P8!*5P.*9!9NU *6MHLUY!9(%99-@
MW#1/[GH4@>.6G(P(Y.'%>3A6%W2RAL3JCITW;YD<DU613/+ :D?IXCF$6!"2
M=4$8)8((K8,2CR1QW$J5?O':1*0C(K;>*]<-_2M7".97[S]>S =A-@0,"(S7
M%I Q)P@V:7!<1J%S%(A\#Z-@_Q7'+4\9^<(?2# =7.:W[FR2C$F<S@;0'ZKV
M<2!CNY!WJ8OS0I=<C&C]B'@K(>.X1D-*_/KXBZ/9WR&&=CR:)(XE)V<@JLQ!
M>8;@9:GU"<'QE$3610^,HATIXW@K(^+H$!'\S$^!S^AO>>=H753.;'J'#/WZ
MM\?23_;@]U@V##_QSGK$+.G&-2QJNG&]A9BX!8WDUHILM8FM=<!33+R[G=&O
MOJ?9*;&SYO;6T2:G6SF_*]>/Y[:I339,BR(8%)\D*&<S1!$B!.&M3J@3$\WG
M+S3=0;?3\QZ#NKNGYSVYD#NXRX_<\_,?MW_ =DZ8\PZ3"9 P!%#))O J& AT
MO_$L<\34&N\#;J>7^7Y/C]+K*9>=0*;;TU-' 9RUQ^7%A%R'=[A<QU)Q!LZY
M!"D'P4.IJJEU'X"':!I9B?<"GKU ?: D.T#FU>EHJHY6RSY!- E!6?HCH! 0
MBY":);H]8^L2G,?/GGMBS!TJVWO'T#V&T1V@Y!5Y18L?N*T%>O>U"N2L_S9+
M(5K'("7R2Y4CE]+;FG00BQ6U5:=/K0L%[R1FW+?'0='31@ '(^D;+N.BQ=0?
M7'Z;IAKLP/P!R2B?IAJ;KYOZ?3X];^I.VMG:$A$,'0_:B:;3X84F*"@46QW]
MD(^^_VKC/O0-@IJ!6-V!(KIM)Q\^_GZF58MQQ;$"P<@,*M<N9708(&;'@Q-!
MW<B(:-"[\!Z"QGV3&U0AM1-$!ZC:%K:NI^3QO#\CX?(\X1RD#)HQR(9XI$2*
M$-6FWZ<VTO"HK6[]^OL 2>.^N@V*K);"&/7"NV5#+S&N+QAV=EA,DC*Y#-X8
M3S>XD'1L8@!F7 @NIZ)4ZUS_!T@:M__;4Z'K:&%T@:ZZBS=S4L:G-?%L.[HK
M873>,[ A1-I#+N"%K'\E^ZAPH95J'5N_244O,Z%'#X,=*: .KL>K.[AT$-'+
M@E)S<"70-5][GWLF:VM8K4I2)A.3!@5:+]&J8V5\+V0.9/C8 ]',7S6[I&T_
MXGRZ6-:&(JN7IUCE>N:!L.RDT!OG@_Z064-0M==FX,8Q6Y7]/FG,^Z[7$U .
ME>QB8#9WH'..5-N_G1=5:YL22C(2;1T/I-#[.B^&+G1G5'3::Q]:%Z.WHKV7
M@;.C7Z&C@.'G/P3/3NH[^(0K+YPJ&KS2%E0BD];[X"!Y+5"C=*KYO-LFA/?X
M&# TYMH"_P  -/1IQNC\</Y;-6"PB7U6!N%\M<7-:G5ZL@F>KP;O_?!H2IZN
M^\-Q3!H^-RPE7ANZ>C!&"%!!TRU!%A#H8M!$):P-K0,B3Y$;=I;G>8W=]5GP
M\Z9J;/7\Q\7OO \_-K[$'V&9MS>HQH ^60EH'"F20B?8:;I+I?#%I-HJ*+:N
MDFY&?+<988_!VMT984\IVI&G67Z:KNN.W\SS]-LTGX;9QMN-/OLZ"@O09K+N
MB&D0?6#@G1?<A,R)I_M@\X&IEK<NWDO"U9."8-%2(KU!ZA_3]9</.-OP;_5E
M^O73XA6=WO6/G:\<BU+,2$O.<1T+KVL6IRP9)#D4*+R3LLFXY$>2-=YTW08
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M*!5*SUL[[+M1UG_I\5Z >%AZW%X[/6'N[COS(W_7V^')@JG1!S">#!>5DH2
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M+<14<^ZZKEE47+G8NBKG*7HZ=3P&OC;W540':YWO'J0+ZX64V7MPAM<1XRZ
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M/43(&BE\%Q@=(/V1_=77F%;!F:K.:^/BVG;8A&V83<+R5, (INML)KJQO?6
MZ)!\&V?8PXC'5C_T^2]U")-#%#H;3+H=7#HWX>;UTTY6*/D?M;%[?:!\8B)8
M!5FZ!,J2RQ.-1<C6>::3TJ'YP-8G">K"(VS]@+5300=X>L##YKP9A3)9<F!-
M(5=6E42"2MZ!M:XDI0K2"6F,HZV$C&U)-U/TK+74.X#.YEQM[E'R'!2/W$-6
MO.XZ90X\8Q:,E\)Y)9@TK0N6[Q$P+E0:*'362KH=0.-.<&3# /F9U;Y+Y&?F
MVI<;; W2)N#)%UM0DZG2O(?G(1'COD;M(7*<E#N R8>KN)CD29A_7V]2OLV=
MYXPI&BZ@%%5SYW4F6PD(R()17,9(;D)K0^8Q8D:N Q[(B&DB^AXP=$M^':#]
MMGPD.2U"JOK9G#&L?1A.,A HR,274D'(@4-"ZQD=DN1-\R6NSU(ULFG31OT/
M0=56%R.[YG].20?_F4^62YR^QT^319UBDU]/YIB6U\[D]3AU9W5,QH"6+()2
M,8'/V4+Q6D:5)./R0;AGJXN^^Q='1D]C/<\&%WH'%]76B_PV4:F<-2$X :Z$
MRHW*Q(TKP)PW@?GBK&A]23U-T<B]""<,/A^FA%XA]<M?.$^3!:Z*)&Y^<['Y
MW06_\"6ATI'7DD0)*CD.(462I/%6,E0LYN;%!(<0VF$X\D"D[ +"IFH;NPAK
M&X-WO)6W_YG2=SY/OFXFXEX$;3DF4>>!%PO*%P8Q,0$!639.:9=V*[7:\[L=
MAB>/0]C@PC\;8,TGL_G'V?7$W&M6T=8MD9Z!0TXR=;4"-D5)QFU$FY![5W9)
MI1Q)1H<.Y2EA=[QJS@6%OX>_)E^NOMP<-"$X5XE$FRW=X,44\%)QR-D8A8YE
MKD1+]-W_?(?VW E1=X0JSJ5,[\7RXV?\/<S_C<OJH"U>?)KC*GW1M![O^:\,
M4GBW)W.GJ;"STFLFI <C62:33$@(GLGJY!83M8\<V\]2'*OKU'F/,64$2[X]
MV0H"(;J2 (LQ/H=DF6\>DCW3KM-]<+%/U^D^*NC /7TZ?VJ2U<[F>L>G6ID=
MR.(,7$.P9 &PK POS8?:'EVK,$KWZ5YJWZM881\== "H[2FTD*4H27G2MZ;3
M5M!6RY'3/Y:0G>;%L-9 .KMBA;T4O5.QPCY2[P Z/^9*8]!L-16 :*53I:R'
M&+V'E$L4Q3-DI?5[=EA&^L1%"WLI]MF,]#Y2[@ FC^?%!$87F5'TB$=5]ULD
M<-QKNI.+YS%FA[EU?<MQ&>E1>D^/>JJ:R+X'$#V?'F.V%,Q8P'H>Z#Z.!IPM
MY(E&KI7EAL7<>O34^::D]U+__BGI?70Q]AKUJM7[_N_FGDW!>Y&\ A?K0N]8
M QJ),0B2+F_O68YII[WICWV@^X3S7EJ<M19I![C@6YD0)3!F48#@=;GE:OY(
MC@423X)GYHQ3<D=<;/W R$_1L+@X7J0=O$;;^Z*U1.>$C)!L'53K91T6;A!*
M-L9J9ESPS6=>'SQ&8[!<R%"FS/$R'_E"6;>YWT?_.H)^.W=VLS[7%RY$I!.5
M9:!CQ50&Y^BH>>]2*9S;Y/,.-\SN7^RB+N 8U<X&E_/8Z+F]EE>\72\Q?5M>
M3+_?\1'O+,0M,CA;]Q;DH$B H6Y^UW6A <^9,TY>I^2[H&CO+W=1 ] *3</*
M?6Q47?-U<U1>?**_^Q26N!Y7.ROWIA4+QTW*H3[,Q9 44Z +'#-(-(99HSWQ
MN<_%M-MGNTCNM[Z=!I!X=V#Z%];<,5VWWW!.)^/!C"'%3"#+#H1D9/,EDF#0
MSH.,2:B0N8D/NYMVQ-)37^TB8S\8E)K)NSLDW1R2[<N[5__"11V732>D3JVJ
M'$H?P 5DH$4D!]-KC#N5C!_V]7%7$Y_LDFHE_^X0]AZK;SN9?GH5OH94RR,V
M-F+2B<M4.U$%J\T;!GPA0U$SIIV(/.2R2X71SA\<=U?QT#AJ(>5S*1Y:S?6_
M/B.+>^.MFD[S>OXSP\SMVI.]$TVM-Z&$K#PD4U-MP=57SDL012CON<JY^?CD
M$>N'@O.R) '2<DY/.@KR7YD%5GA0.:S<C?_6#^V-B[WJA_90P8AOWF*^O/AM
MLIQ\6NGC55C@9KUJTE$K#LP@O=@B"@A1(B1O8[$I9]RM0XI^_!WPT#_= F?[
MESNN#-I'H;-FTNT*&Q_IW[@N74A*&R$5,%MWT*!&"&3C@3&UC]5GR^1.<\7W
M0LCM]\?!20M]/@J- X4[LL'\>WJ-\R^3_,\W*\/@';F47T+"J^4DA<O%FVEZ
M,<W_ZW_-%OCU\_\W^;))ZV095&%> )T:7?NKR"$P*8+BD@E71+#)[V ['_+M
M7H!SJ+9G)Q1]MQDU;TM6KD3PVB.1KFO1K]<@0W:"%QM,:#U[Z\P&TQ_R6K63
M^<AWTNU)^X#+Y>4Z4+'R)U_\)Y!2\L?9RDEY%^;+[^NHZ@4K4FHC$P1'%[D*
M64/T0D&*RA;#4[%L%W?^@$_WF&/;2]FSTTG^7%S\=4/4U_ICZZCJ]TC>QB0M
M-S/-_YQ.VC8*[?&Y05S^0]D]4>N00736.'!%TD/'Z"_TY'%P7*,(F%"W[Z89
MS?6WDC%K%0-KDJH;&CQ$QPJDX(+G(D?NF^_[.5/7?Q]<[./Z[Z."#DRL=Y=A
M6BNZ5JY,4EGF[#PP822Y,BF#L\+2M>RY,FBTR<VW M_Y?K_N_UY*?;AS]5 )
M=X2.C:]2=$1.7@/83,RKJ!E1KS4X0>?%FDB>1?,UY?<H&!<AAVOR$4@<(-8.
MZE\E.9<DK<DWK'QL/$OR8;/(-D*H6]%5+AY<K/7C)@FN+4_BX>*<1\M?M_W\
M/A1_B+YFC84W/@"XV<:#C4YK1:Z"Q+JR/+/5#'%+/H3)44:RXU78#0!;?_ZX
MSG8[ !POO/$!(,2;:;Y**__N#A.<)X>29XBQ,L$Q@3>,0S#H!;(Z8W77SHBM
M'QBWX*OA'7"\^,;' +/;<.SI0^@SH5<2Y8J8@.!S!&E\3CZ)C&F7.,IC/W_<
M.JUV"#A>>!W8AL3"[ O>=$/_5O^%JHEJ'(488^W= 6LMR4;P D%J0?<9YYB+
MS*IYI_@3Y/0;J#W&KV@E_WZAM#EHPBE4LD[&35;4 C('T3*Z'65.$C73(;?N
MH'F2H'%MT69JWPU.!^B@ T"])YT0 9]?3/-K_(:7LZ^K@0U_?<7I J^O6^V\
M8RY!J']1/-5XM\A@4K2\T'G,KG4::0>RN@37(2"8#:N1#D#V#YSB/%P21R_R
ME\ET4@.+]4F_SQ0W=?DI<9%"'?,=M"(S0?EJ)M0R6!%1M7X*=R)LW$=Q.*"U
MUTH'4%OESVK1P'IRO"XY!F8 HY!ULR2'F)D&*2USA<7 >>LH_ST"^FTE/<:>
M.ES&'0!DE4U]&1:8ZY09 OI&'?,P_;2>WO?R^^V?>1>^KW*SE>-;MJ?Y@8<3
MDU:"O _0B'4:,MD4SHNZ-5 GP]#K\K!SXOALT@!\C/ND'@&KAUFGL77< <ZW
M)9???_CSNKRI*+(4# ?RHCU)%SW9O[6B@"Q?KKG)P;7.3SQ)T,@)K='Q\J,-
MV$AY'2#Q'W4.+JY,F*O%9GJ.$TR1+$1=,Z5R)O.U8 %OLG!6%J4?3H8YWM)[
M2,2X$;*AGN;C9-T;6#8G*6-*52202K:@7#'@G$A0#.=DYA:N=>LY9UO(&/>*
M.E*Q3\'D "EW )0?[^/;Z_J/V12_?+V<?<=K+R;3 ;(>(S!6Q]\R0;<E,PQD
MBLXD[;4W:C #;0<".P+7(7!XU/YJK9N1VSP^3I;USGXSS9-ODWQ%SG,]B3QY
MY#X1[:KN:V91UTV8='4GALP')[7="5S/]'AL_?BX;=.MG[$V,NX-)/^:+#^_
MQ\N55NK@_X^S7Z;+R?+[YJ2E$ JS6 =3U!B.4 G(NT&2&\;LLY)H=W(>]X7/
MTV2-UP#2  !/P:FA-D9.+O\ZFW_!^3M2S2372W::7WV>8/GE+TQ7-9#WMI1)
MPOGFF@W$"@97IX6Y0.<Q._"!><B"VV0-U]+L4G>TUT<[ E%+M<].H8,.;*SM
M30_"FIAS;7JHLRI4U!PB)Q_49RVBCR['W5H:3])5--BDAZ$\N.-EW@%PG@VH
M/!9/6<]P>KN9X70[<.Y"H^.J\ BVE&HDDCD:M<Y@G.$EH&4\-I]UW9J)'CN8
M]@+6OF'60;5\,,R_X3S..@/ZMS"YK%<'/2<K9^P"I<J:?"$026/=CE"+IIV%
M@BG*$$0TO/D>GX%XZ7&<80^P/TKGYXW^=9?1F^EB.;]:Q==7W8X?/X?IICON
MC]GT&RZ6N)'9A;?:HY()I*#'5$6,X*+C4!RJD WZI)OWIIV*N1[',XYR/@9%
M10=6T=TE@)6S]3WP]FJY6 ;R4Z:?+GB1+LFZD]RE6MAJL2I @:>7+P?%K6O>
M@ODL43V.?#P&GFVU<-[W\.HO_Z0C16R_P_EDEOD%]Y)ISVVM(:K<E^H3:P$8
M+'<LAV)#\Z%8#>GO<8[D*+?IL;H=>\+D<:_(PZ?C=K[T>N)"?E/'RWR^,+$H
MYS)"2CZ TA+!.0P@C1'&26%5>F[.P.FH[7&VY2'8[E2_YXKXS7C^5[/IJF'_
M*EQ^Q/F7BY**6?7=.I_K'/4H(51GVG,=4W%<2[?3Y-6V9.V$8?N38[B!QD8U
M/"KS][W9M^6?*\O\0>72';/JSRFIMM9(723A8S*, ?.._%SO'(3$D?X1C2O(
MF.9V!V >3,!.$'3G <'3:*$+*_?%Y>K/$$];C]VF;/U"6568HJ/C5;5QN(@0
MK6"@92;60A*YM"YMW(VRG6#G^X?=@/KHP$G_95.<\@'GWR8)M_-V$XA8W>:+
MC[-EN+S[^Z]FB^4?L^7_QN5[3+-/TU5P.P1E>.U:#PX='3A?P*,LD'T*PGJ9
MC&T-S,&8V2V5P<X'S'VH_6?&_]H'_74VW_Q2_7/\PGO.4XD.;)"*=,9B;>HF
MG3E-=KJ(6>MX+H=B*X>[G90SROIU#) .CL_!+L'&C[UCJFV"W(D+MIJW+E3T
M=>QMA,"RA>2"B-R6S'DWJ8_'F-CM$/P=<H!-U#RZ[]>0_9O-.&_(%YY,%Y/T
MSW!YA73N9>#(#62#M<K/(D2R%LDA-LDDQ9A_&(9N&[W8F=+=L'T&^;L.%=O+
MA1Z?ETA\1"*__(7S-%G41/]]0?"+$'W.24J0Q<>ZSC6#,RZ"L,QI);PTOK7M
M,QPWNQV#,\H3=J+X<PU*KZ5P1P@/ENO=;K)Z$ 0E!4G)G07+32V>E!I<" XT
MRY&;J)1[6%XZQ,6_/^&['8 SR#SVK_9S?A:>+7)YY-V\\:C(4@R<-,?H]E@-
M?V$"0MUK:H7-) SRA\P@"?I1N-WM5)U!SG-\4>X%G+_C$5OG3BY<0,^D$)!#
M2K7\A_2<4DW*(7=%HF/#E-Z>GM7=#M<9)&//"3(]&'1/B2@^9]9^Q9I87,XJ
M[S_&,8IW HO5$$OAH+*0$#63D&.J^P-LSDKN:KX-1^9NR#^3''!/*CU;=#\X
M[\_))&65B]$"BC%UE+T+)!U.9]]J[@MS+L9=AGB?BM[=\'X&R>=NE=R+P730
M&*-;>4SFZP[9-]-U.N:!^[9Q[/#=?)+PP@?!D\8"+.G:SAKIQ5,B@I*BZ%1L
M<@_O^A''GAW&XV[-2V>4Z.X:).=PB/87SX7PQ>L@#5A%<E Z('@4 8R-]+"B
M+;(T7S;5GHW=CL(99;+'5O5/@/95X^)C]\#J-U^3S_1KF,S7R1_'L) 5J<#'
MFN7D)!FO9 $C. O12E9B-VVMA[&XVRGY&Z6ZAX3(.9^@9T,.^PJ.D6.FC4)0
MM;Q,!>XAD(4*RK/H+<?(U' SSD9F?K=3=P9)^.XDNQ>LNJ@3?S>?)<2\^)74
M='?CZK59FB\T\\(*7R=,. VJIEX]J02$459)E:W$UG[+LT3MAN SRI^W5<,Y
MW_0/&+\Y>ZNJR ?5,4H9=-IXX$HD4 +)?G0I@0[.*I-MSK*;2WP/OG9#]QDD
MQ[L%P]FL_-[,S9J5NY?"G=A;TX7?NWYLF'7?![%ZFF7?Q6E'V$<0.1#V-6/@
MC'20,/.(.5K/FCMBIUKVO?5H/IPUM6J$NZ.7VA.W>/G]7NSJ?3W,ZY%NHA3O
M9=+@+3GWB@X@!!\B^?4E\DA'TS5?3C,L1UVO'-\'G4^L'!\;"-T:+0?+8+V:
M(\?B)>DD!VOJG*JZ$+YNGS)!.U:,)Z&<Q$8YBHUN=JB/CM*=3)O30>:\3\V/
M MA,F.6J&,=R)I7PFDPLF:Q-S: X+T-6PMJ'7>]CGIK'V.AQ4<L)H=GNJ#3!
MR<C5%BNRWY9[K"S>3F^V%"JOR9,G>2(*4#D*<#(H<,(G;FQ4)>U2(_'T5\X6
MD&T ,!M$&SWBZN-_9AM.1-!$;M#@?.#D%H<"44L./KF(Y,LCFH-Q=?.5D5<A
M]XZKP[31):X((C?++IG1/-;<4\JU"=,%""H6P,15"(HKCO%@9-U^9^2UD-UC
MZT"-](BN7V=7U\/_N0@V9"M %U<'H6ABA=@#(<@JYR&6C.E0<-U^9N2]9KUC
MZT!]= FMR;?K4^)T+K&0IQ=2#D#RJM-V:E>AE=RH+#P]]P=#Z^8S(^\:ZAY:
MA^FC1VA]F/QUS0GC$5-QP$RJNR8]0O2! 6?H8U!8LMQEB.#37QEYDT?OP#I,
M&S];&.4V;T<>BV->1HB*A;KYD(%WRD'Q(03DP:ITFASIL9R,[&/\E"'(5L#Y
MZ8[/[#\XW\CCRV1YH83WUEA#%P@3I!Z2190V0191I:BQ,-\\H34@/S]1&.A
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MEOI1'$_=4G0K>5>"UPZ,-IQ<=-00O> DNI!\S7)9+7I^,O?D=]S]7+V>R7,
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MH*S5$#1SD$U*4C >66[>D_<X.5TG(_?!Q1/)R*-4T($)<#_KH+/QQFL%6(H
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M&35PKAU>\$2;)'Q0!"62RR#"1D(N.(]B4BJZJ((MWJ/M,#6M7I9E3K="4F@
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MO"+R:< "/E; +)K(O8N@E.JLE!J)'",161LH6&+ 3OEZH5N-%1<9'7V%Y=-
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M"#I(T,]8=(@GJ9 F1J"(8]188.%"Z1SGO83T@]&OZ;@^G_,-P>?2WN05P):
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MJC^SMGE&"9(#(Y4H0-*'R%+E1Y[,=><YCXPXN(H$TM@:Q"F%$\?1W+F0*L-
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M*GZG"^?9XEN0R%]R:>]W=A7O:G^?+YH]8_:240/OD(?945E8CW?VS5__L=I
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M/__K_P-02P$"% ,4    "  /@'):+5^JW+$G   U(0$ &0
M@ $     :6YO+3$R,S$R,#(T>#$P:V5X,3DQ+FAT;5!+ 0(4 Q0    (  ^
M<EJV]QNFU@(  +D,   9              "  >@G  !I;F\M,3(S,3(P,C1X
M,3!K97@R,3$N:'1M4$L! A0#%     @ #X!R6D8F^\FG P  PQ(  !D
M         ( !]2H  &EN;RTQ,C,Q,C R-'@Q,&ME>#(S,2YH=&U02P$"% ,4
M    "  /@'):1IK%S!8(  !J*@  &0              @ '3+@  :6YO+3$R
M,S$R,#(T>#$P:V5X,S$Q+FAT;5!+ 0(4 Q0    (  ^ <EIER._!! @  #,K
M   9              "  2 W  !I;F\M,3(S,3(P,C1X,3!K97@S,3(N:'1M
M4$L! A0#%     @ #X!R6@4(>]TJ!0  !!X  !D              ( !6S\
M &EN;RTQ,C,Q,C R-'@Q,&ME>#,R,2YH=&U02P$"% ,4    "  /@'):M\IF
M%9<L P @UAT $               @ &\1   :6YO+3(P,C0Q,C,Q+FAT;5!+
M 0(4 Q0    (  ^ <EHXT8E]%AH  ( P 0 0              "  8%Q P!I
M;F\M,C R-#$R,S$N>'-D4$L! A0#%     @ #X!R6DEE4R'S)0  H'<! !0
M             ( !Q8L# &EN;RTR,#(T,3(S,5]C86PN>&UL4$L! A0#%
M  @ #X!R6H?+T7=W@@  ML@% !0              ( !ZK$# &EN;RTR,#(T
M,3(S,5]D968N>&UL4$L! A0#%     @ #X!R6L$@5?$>*08 AP4' !,
M         ( !DS0$ &EN;RTR,#(T,3(S,5]G,2YJ<&=02P$"% ,4    "  /
M@'):QSC@K'NC 0!$Q $ $P              @ 'B70H :6YO+3(P,C0Q,C,Q
M7V<R+FIP9U!+ 0(4 Q0    (  ^ <EJ6!\.&"IH  ,?)   3
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52P4&     !  $  R!   G800

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>ino-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ino="http://www.inovio.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ino-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-16</startDate>
            <endDate>2024-12-16</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:December2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-16</startDate>
            <endDate>2024-12-16</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:April2024OfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:April2024OfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:April2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-16</startDate>
            <endDate>2024-12-16</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-16</startDate>
            <endDate>2024-12-16</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-16</startDate>
            <endDate>2024-12-16</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-16</startDate>
            <endDate>2024-12-16</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ino:December2024OfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenRegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-13</startDate>
            <endDate>2024-08-13</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2021SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2023IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis">ino:PerformanceRSUsSpecifiedThresholdPercentileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis">ino:PerformanceRSUsTargetPercentileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdAxis">ino:PerformanceRSUsSpecifiedMaximumPercentileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMilestoneBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsRSUsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ino:December2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">ino:December2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:StockOptionsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ino:StockOptionsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:BehestiVKimEtAlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3107Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO3107Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO5401AndOtherImmunoOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:INO5401AndOtherImmunoOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:EngineeringAndDeviceRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:EngineeringAndDeviceRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherUnallocatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ino:ReportableSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ino:ResearchAndDevelopmentCostAxis">ino:OtherUnallocatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-12</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:A2024SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ino:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>ino:position</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="defendent">
        <measure>ino:defendent</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName contextRef="c-1" id="f-36">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-37">0001055726</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-49" id="f-355">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-67" decimals="4" id="f-417" unitRef="number">0.0833</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-574">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash
      contextRef="c-222"
      decimals="INF"
      id="f-826"
      unitRef="number">0.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash>
    <us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-1019">http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense</us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-67" decimals="4" id="f-1057" unitRef="number">0.0833</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">208000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">36667221</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#x2019;s 2025 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x2019;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#x2019;s fiscal year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-38">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data (including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data) (collectively, &#x201c;Information Systems and Data&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Information Technology department (&#x201c;IT Department&#x201d;) (including its Senior Director), with support from service providers, helps identify, assess and manage our cybersecurity threats and risks. The IT Department identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment and our risk profile using various methods. For example, the methods include manual and automated tools; subscriptions to reports and services that identify cybersecurity threats; analysis of threat and threat actor reports; threat environment scans; law enforcement coordination; audits; threat assessments; and vulnerability assessments.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: security incident response strategies; tools designed to detect and respond to security incidents; data encryption strategies; access controls; physical security controls; asset management strategies; systems monitoring; personnel training; penetration testing; and cybersecurity insurance.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes.  For example, the IT Department works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business and our management evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example: professional services firms (including legal counsel); cybersecurity consultants; cybersecurity software providers; managed cybersecurity service providers; and penetration testing firms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use service providers to perform a variety of functions throughout our business, such as application providers; hosting providers; and contract research organizations. Depending on the nature of the services provided, in order to analyze the cybersecurity processes of certain vendors we review their internal security assessment reports and certifications, if available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including in particular under the caption &#x201c;if our information technology systems or those of third parties upon which we rely or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to, regulatory investigations and actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse consequences.&#x201d;&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-39">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data (including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data) (collectively, &#x201c;Information Systems and Data&#x201d;).  &lt;/span&gt;&lt;/div&gt;Our Information Technology department (&#x201c;IT Department&#x201d;) (including its Senior Director), with support from service providers, helps identify, assess and manage our cybersecurity threats and risks. The IT Department identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment and our risk profile using various methods. For example, the methods include manual and automated tools; subscriptions to reports and services that identify cybersecurity threats; analysis of threat and threat actor reports; threat environment scans; law enforcement coordination; audits; threat assessments; and vulnerability assessments.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-42">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-43">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-45">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including the Senior Director of the IT Department. This individual has previously held roles as a head of cybersecurity, cybersecurity consultant and information security specialist for other organizations. This individual holds several certifications related to cybersecurity including Certified Information Systems Security Professional (CISSP).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IT Department reports to our Chief Financial Officer (CFO) who is responsible for helping the IT Department hire appropriate personnel, integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The Senior Director of the IT Department is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CFO.   The Senior Director of IT and the CFO work with our incident response team to help mitigate and remediate cybersecurity incidents of which they &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are notified.  In addition, our incident response and vulnerability management processes include reporting to the audit committee of the board of directors for certain cybersecurity incidents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As indicated above, the audit committee receives reports from the Senior Director of IT or other designee concerning significant cybersecurity threats and risk and the processes we have implemented to address them. The audit committee also receives various written reports, summaries or presentations related to cybersecurity threats, risk and mitigation. In turn, the audit committee routinely provides reports to the board on cybersecurity matters.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-46">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-44">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; audit committee is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-47">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including the Senior Director of the IT Department. This individual has previously held roles as a head of cybersecurity, cybersecurity consultant and information security specialist for other organizations. This individual holds several certifications related to cybersecurity including Certified Information Systems Security Professional (CISSP).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IT Department reports to our Chief Financial Officer (CFO) who is responsible for helping the IT Department hire appropriate personnel, integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The Senior Director of the IT Department is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity incident response and vulnerability management processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the CFO.   The Senior Director of IT and the CFO work with our incident response team to help mitigate and remediate cybersecurity incidents of which they &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are notified.  In addition, our incident response and vulnerability management processes include reporting to the audit committee of the board of directors for certain cybersecurity incidents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As indicated above, the audit committee receives reports from the Senior Director of IT or other designee concerning significant cybersecurity threats and risk and the processes we have implemented to address them. The audit committee also receives various written reports, summaries or presentations related to cybersecurity threats, risk and mitigation. In turn, the audit committee routinely provides reports to the board on cybersecurity matters.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-48">This individual has previously held roles as a head of cybersecurity, cybersecurity consultant and information security specialist for other organizations. This individual holds several certifications related to cybersecurity including Certified Information Systems Security Professional (CISSP).</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-49">The IT Department reports to our Chief Financial Officer (CFO) who is responsible for helping the IT Department hire appropriate personnel, integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The Senior Director of the IT Department is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-50">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-51">As indicated above, the audit committee receives reports from the Senior Director of IT or other designee concerning significant cybersecurity threats and risk and the processes we have implemented to address them.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-52">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-53">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-54">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-55">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-56">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-57">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-58">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-59">Ernst&#160;&amp; Young&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-60">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="0" id="f-61" unitRef="usd">65813297</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="0" id="f-62" unitRef="usd">14310862</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="0" id="f-63" unitRef="usd">28300232</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-6" decimals="0" id="f-64" unitRef="usd">130982913</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="0" id="f-65" unitRef="usd">1199056</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="0" id="f-66" unitRef="usd">2405228</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="0" id="f-67" unitRef="usd">2517465</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="0" id="f-68" unitRef="usd">5414097</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="0" id="f-69" unitRef="usd">97830050</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="0" id="f-70" unitRef="usd">153113100</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="0" id="f-71" unitRef="usd">3659818</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="0" id="f-72" unitRef="usd">4960986</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-5" decimals="0" id="f-73" unitRef="usd">1613844</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-6" decimals="0" id="f-74" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="0" id="f-75" unitRef="usd">8113840</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="0" id="f-76" unitRef="usd">9491735</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="0" id="f-77" unitRef="usd">1979654</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="0" id="f-78" unitRef="usd">605315</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="0" id="f-79" unitRef="usd">113197206</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="0" id="f-80" unitRef="usd">170951423</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-81" unitRef="usd">16200013</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-8" decimals="0" id="f-82" unitRef="usd">19847744</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-9" decimals="0" id="f-83" unitRef="usd">1351163</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-10" decimals="0" id="f-84" unitRef="usd">1070519</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent contextRef="c-5" decimals="0" id="f-85" unitRef="usd">2021860</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent contextRef="c-6" decimals="0" id="f-86" unitRef="usd">2365382</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-5" decimals="0" id="f-87" unitRef="usd">13255188</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-6" decimals="0" id="f-88" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="0" id="f-89" unitRef="usd">2497360</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="0" id="f-90" unitRef="usd">2406522</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent contextRef="c-5" decimals="0" id="f-91" unitRef="usd">0</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent contextRef="c-6" decimals="0" id="f-92" unitRef="usd">109407</ino:DeferredGrantFundingCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-5" decimals="0" id="f-93" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent contextRef="c-6" decimals="0" id="f-94" unitRef="usd">16770654</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="0" id="f-95" unitRef="usd">35325584</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="0" id="f-96" unitRef="usd">42570228</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="0" id="f-97" unitRef="usd">9367827</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="0" id="f-98" unitRef="usd">11032066</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="0" id="f-99" unitRef="usd">44693411</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="0" id="f-100" unitRef="usd">53602294</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-101" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-102" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-103"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-104"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-105" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-106" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-107" unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-108" unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-109" unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-110" unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="0" id="f-111" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="0" id="f-112" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-113"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-114"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-115" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-116" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-117" unitRef="shares">36099991</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-118" unitRef="shares">36099991</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-119" unitRef="shares">22793075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-120" unitRef="shares">22793075</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="0" id="f-121" unitRef="usd">36099</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="0" id="f-122" unitRef="usd">22792</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="0" id="f-123" unitRef="usd">1799362625</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="0" id="f-124" unitRef="usd">1740954074</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="0" id="f-125" unitRef="usd">-1730219262</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="0" id="f-126" unitRef="usd">-1622965136</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="0" id="f-127" unitRef="usd">-675667</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="0" id="f-128" unitRef="usd">-662601</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="0" id="f-129" unitRef="usd">68503795</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="0" id="f-130" unitRef="usd">117349129</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="0" id="f-131" unitRef="usd">113197206</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="0" id="f-132" unitRef="usd">170951423</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-133" unitRef="usd">217756</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="0" id="f-134" unitRef="usd">832010</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-135" unitRef="usd">75620340</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-11" decimals="0" id="f-136" unitRef="usd">86676563</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-137" unitRef="usd">36996338</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-11" decimals="0" id="f-138" unitRef="usd">47582104</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="0" id="f-139" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-11" decimals="0" id="f-140" unitRef="usd">10513371</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="0" id="f-141" unitRef="usd">112616678</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-11" decimals="0" id="f-142" unitRef="usd">144772038</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-143" unitRef="usd">-112398922</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="0" id="f-144" unitRef="usd">-143940028</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="0" id="f-145" unitRef="usd">4766993</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-11" decimals="0" id="f-146" unitRef="usd">8133290</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="0" id="f-147" unitRef="usd">177833</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-11" decimals="0" id="f-148" unitRef="usd">1222789</us-gaap:InterestExpenseNonoperating>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="0" id="f-149" unitRef="usd">-2808608</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-11" decimals="0" id="f-150" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-1" decimals="0" id="f-151" unitRef="usd">-1166443</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-11" decimals="0" id="f-152" unitRef="usd">773145</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-153" unitRef="usd">2077182</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-11" decimals="0" id="f-154" unitRef="usd">5850626</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="0" id="f-155" unitRef="usd">-3163711</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-11" decimals="0" id="f-156" unitRef="usd">-4711596</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-157" unitRef="usd">-107254126</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-158" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-159"
      unitRef="usdPerShare">-3.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-3.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">-6.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-162"
      unitRef="usdPerShare">-6.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-163" unitRef="shares">27160863</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-164" unitRef="shares">27160863</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-165" unitRef="shares">22173662</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-166" unitRef="shares">22173662</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-167" unitRef="usd">-107254126</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-168" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-169" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-11" decimals="0" id="f-170" unitRef="usd">-3920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-171" unitRef="usd">-45469</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-11" decimals="0" id="f-172" unitRef="usd">40060</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="0" id="f-173" unitRef="usd">-107267192</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-11" decimals="0" id="f-174" unitRef="usd">-135081212</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-175"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="0" id="f-176" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-177"
      unitRef="shares">21090938</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="0" id="f-178" unitRef="usd">21090</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="0" id="f-179" unitRef="usd">1710888191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="0" id="f-180" unitRef="usd">-1487847784</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="0" id="f-181" unitRef="usd">-698741</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="0" id="f-182" unitRef="usd">222362756</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c-18"
      decimals="INF"
      id="f-183"
      unitRef="shares">760083</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-18" decimals="0" id="f-184" unitRef="usd">760</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-19" decimals="0" id="f-185" unitRef="usd">13999240</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c-11" decimals="0" id="f-186" unitRef="usd">14000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-18"
      decimals="INF"
      id="f-187"
      unitRef="shares">875305</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-18" decimals="0" id="f-188" unitRef="usd">875</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="0" id="f-189" unitRef="usd">5460870</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-11" decimals="0" id="f-190" unitRef="usd">5461745</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-18"
      decimals="INF"
      id="f-191"
      unitRef="shares">66749</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-18" decimals="0" id="f-192" unitRef="usd">67</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-19" decimals="0" id="f-193" unitRef="usd">-466713</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-11" decimals="0" id="f-194" unitRef="usd">-466646</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="0" id="f-195" unitRef="usd">11072486</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="0" id="f-196" unitRef="usd">11072486</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="0" id="f-197" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-198" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-21" decimals="0" id="f-199" unitRef="usd">40060</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-11" decimals="0" id="f-200" unitRef="usd">40060</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-21" decimals="0" id="f-201" unitRef="usd">-3920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-11" decimals="0" id="f-202" unitRef="usd">-3920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-203"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="0" id="f-204" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-205"
      unitRef="shares">22793075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="0" id="f-206" unitRef="usd">22792</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="0" id="f-207" unitRef="usd">1740954074</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="0" id="f-208" unitRef="usd">-1622965136</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="0" id="f-209" unitRef="usd">-662601</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="0" id="f-210" unitRef="usd">117349129</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-27"
      decimals="INF"
      id="f-211"
      unitRef="shares">13213778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="0" id="f-212" unitRef="usd">13214</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="0" id="f-213" unitRef="usd">36020259</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="0" id="f-214" unitRef="usd">36033473</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-28" decimals="0" id="f-215" unitRef="usd">16146397</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-1" decimals="0" id="f-216" unitRef="usd">16146397</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-27"
      decimals="INF"
      id="f-217"
      unitRef="shares">93138</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-27" decimals="0" id="f-218" unitRef="usd">93</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-28" decimals="0" id="f-219" unitRef="usd">-353213</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="0" id="f-220" unitRef="usd">-353120</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="0" id="f-221" unitRef="usd">6595108</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="0" id="f-222" unitRef="usd">6595108</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="0" id="f-223" unitRef="usd">-107254126</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-224" unitRef="usd">-107254126</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-30" decimals="0" id="f-225" unitRef="usd">-45469</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-226" unitRef="usd">-45469</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-30" decimals="0" id="f-227" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="0" id="f-228" unitRef="usd">32403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-229"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="0" id="f-230" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-32"
      decimals="INF"
      id="f-231"
      unitRef="shares">36099991</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="0" id="f-232" unitRef="usd">36099</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="0" id="f-233" unitRef="usd">1799362625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="0" id="f-234" unitRef="usd">-1730219262</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="0" id="f-235" unitRef="usd">-675667</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="0" id="f-236" unitRef="usd">68503795</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-237" unitRef="usd">-107254126</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-238" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="0" id="f-239" unitRef="usd">1752147</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-11" decimals="0" id="f-240" unitRef="usd">2621649</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="0" id="f-241" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-11" decimals="0" id="f-242" unitRef="usd">145417</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="0" id="f-243" unitRef="usd">1377895</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-11" decimals="0" id="f-244" unitRef="usd">736472</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="0" id="f-245" unitRef="usd">-2808608</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-11" decimals="0" id="f-246" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="0" id="f-247" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-11" decimals="0" id="f-248" unitRef="usd">10513371</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="0" id="f-249" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-11" decimals="0" id="f-250" unitRef="usd">1984444</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-251" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-11" decimals="0" id="f-252" unitRef="usd">-32046</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-253" unitRef="usd">6595108</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-11" decimals="0" id="f-254" unitRef="usd">11072486</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestIncomeExpense contextRef="c-1" decimals="0" id="f-255" unitRef="usd">355654</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense contextRef="c-11" decimals="0" id="f-256" unitRef="usd">-155814</ino:NonCashInterestIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="0" id="f-257" unitRef="usd">1690527</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-11" decimals="0" id="f-258" unitRef="usd">4686144</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-1" decimals="0" id="f-259" unitRef="usd">-1905369</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="c-11" decimals="0" id="f-260" unitRef="usd">-4805804</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="0" id="f-261" unitRef="usd">22466</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-11" decimals="0" id="f-262" unitRef="usd">-317997</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-1" decimals="0" id="f-263" unitRef="usd">-1166443</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-11" decimals="0" id="f-264" unitRef="usd">773145</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-265" unitRef="usd">2077182</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-11" decimals="0" id="f-266" unitRef="usd">5850626</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="0" id="f-267" unitRef="usd">-1206172</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-11" decimals="0" id="f-268" unitRef="usd">-9332988</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="0" id="f-269" unitRef="usd">-1483393</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-11" decimals="0" id="f-270" unitRef="usd">-39020611</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="0" id="f-271" unitRef="usd">-38900</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-11" decimals="0" id="f-272" unitRef="usd">-78729</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="0" id="f-273" unitRef="usd">-3367087</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-11" decimals="0" id="f-274" unitRef="usd">-45989061</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-1" decimals="0" id="f-275" unitRef="usd">-343522</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="c-11" decimals="0" id="f-276" unitRef="usd">-8228691</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-1" decimals="0" id="f-277" unitRef="usd">-1573401</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="c-11" decimals="0" id="f-278" unitRef="usd">-2020971</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-1" decimals="0" id="f-279" unitRef="usd">-109407</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="c-11" decimals="0" id="f-280" unitRef="usd">-2453297</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-281" unitRef="usd">-104076553</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-11" decimals="0" id="f-282" unitRef="usd">-124365551</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-1" decimals="0" id="f-283" unitRef="usd">54138026</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-11" decimals="0" id="f-284" unitRef="usd">203475052</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-1" decimals="0" id="f-285" unitRef="usd">158637578</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-11" decimals="0" id="f-286" unitRef="usd">284932562</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-287" unitRef="usd">487832</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-11" decimals="0" id="f-288" unitRef="usd">320898</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-289" unitRef="usd">59319</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-11" decimals="0" id="f-290" unitRef="usd">6219263</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-291" unitRef="usd">104071039</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-11" decimals="0" id="f-292" unitRef="usd">87355875</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-1" decimals="0" id="f-293" unitRef="usd">16415000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-11" decimals="0" id="f-294" unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <ino:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts contextRef="c-1" decimals="0" id="f-295" unitRef="usd">16146397</ino:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts>
    <ino:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts contextRef="c-11" decimals="0" id="f-296" unitRef="usd">0</ino:ProceedsFromIssuanceOfWarrantsNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="0" id="f-297" unitRef="usd">36033473</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-11" decimals="0" id="f-298" unitRef="usd">5461745</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-1" decimals="0" id="f-299" unitRef="usd">16063796</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c-11" decimals="0" id="f-300" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="0" id="f-301" unitRef="usd">67675</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-11" decimals="0" id="f-302" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-1" decimals="0" id="f-303" unitRef="usd">-420795</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings contextRef="c-11" decimals="0" id="f-304" unitRef="usd">-466646</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-305" unitRef="usd">51475546</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-11" decimals="0" id="f-306" unitRef="usd">4995099</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="0" id="f-307" unitRef="usd">32403</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="0" id="f-308" unitRef="usd">-3920</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-309" unitRef="usd">51502435</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-11" decimals="0" id="f-310" unitRef="usd">-32018497</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="0" id="f-311" unitRef="usd">14310862</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="0" id="f-312" unitRef="usd">46329359</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="0" id="f-313" unitRef="usd">65813297</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="0" id="f-314" unitRef="usd">14310862</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="0" id="f-315" unitRef="usd">533487</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-11" decimals="0" id="f-316" unitRef="usd">1066975</us-gaap:InterestPaidNet>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="0" id="f-317" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-11" decimals="0" id="f-318" unitRef="usd">14000000</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-319">The Company&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body&#x2019;s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body's cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA),  HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID),  Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-320">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss of $107.3 million for the year ended December&#160;31, 2024. The Company had working capital of $62.5 million and an accumulated deficit of $1.7 billion as of December&#160;31, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $94.1 million as of December 31, 2024 are not sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of 10,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 10,000,000 shares of common stock (the &#x201c;Warrants&#x201d;), at an offering price of $3.00 per share and accompanying Warrant. The exercise price of the Warrants is $3.76 per share. The net proceeds from the December 2024 Offering were $27.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2024, the Company closed an underwritten registered direct offering (the &#x201c;April 2024 Offering&#x201d;), relating to the issuance and sale of 2,536,258 shares (the &#x201c;Shares&#x201d;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Going Concern &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $94.1 million as of December&#160;31, 2024 are expected to be sufficient to support the Company's planned operations through the fourth quarter of 2025. The Company's current &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $60.8&#160;million from equity offerings during the year ending December 31, 2024, and $6.1&#160;million and $5.5&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2024 and 2023, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the fourth quarter of 2025. The Company's consolidated financial statements as of and for the year ended December&#160;31, 2024 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is, and from time to time in the future may be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 24, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation, as previously amended, to effect a 1-for-12 reverse stock split of its common stock (the &#x201c;Reverse Stock Split&#x201d;).  As a result of the Reverse Stock Split, every 12 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The reverse stock split was reflected on the Nasdaq Capital Market beginning with the opening of trading on January 25, 2024. Accordingly, an amount equal to the par value of the decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock" on the balance sheet and statement of changes in stockholders&#x2019; equity. Any fractional post-split shares as a result of the reverse stock split were eliminated by the payment of cash for the value of such fractional share. As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and outstanding shares of Series C Cumulative Convertible Preferred Stock and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split did not change the par value of the Company's common stock or the authorized number of shares of the Company's common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM"), the President and Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States, as further described in Note 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses and common stock warrant liability. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The estimated fair value of the common stock warrant liability is determined by using the Black-Scholes pricing model, as discussed in Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Affiliated Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable from affiliated entities are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. There was no allowance for doubtful accounts for potential credit losses as of December&#160;31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:f-355"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. No impairment losses have been recognized related to long-lived assets for the years ended December 31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reporting period while the warrants are outstanding. The Pre-Funded Warrants issued in April 2024 met all the criteria for equity classification and were recorded as a component of additional paid-in capital on issuance. However, the Warrants issued in December 2024 did not meet all the criteria for equity classification and were recorded as a liability at fair value upon issuance. The Warrants met the definition of a derivative and did not meet any scope exceptions under ASC 815. As a result, the fair value of the liability associated with the Warrants will be remeasured at the end of each reporting period while the Warrants are outstanding, and any change in fair value between reporting periods will be recognized as gain or loss on the consolidated statement of operations for that reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs associated with the issuance of the Warrants classified as a liability were expensed at the time of issuance and have been included as part of other expense, net, on the consolidated statement of operations for the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carryforwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $349.2 million and $327.5 million at December&#160;31, 2024 and 2023, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. The outstanding Pre-Funded Warrants (see Note 10) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the year ended December 31, 2024 given their nominal exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 9) was considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024 and 2023, basic and diluted net loss per share are the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share for the year ended December 31, 2024 and 2023 are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,254,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,117,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,655,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,173,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,160,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,173,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-and market-based restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,804,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to service-based RSUs, performance-and market-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2023-07. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU expands public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company has adopted ASU 2023-07 and included the segment disclosures in Note 16 below.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2023-09. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2023-09 requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2024-03. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024-03 requires public business entities to disaggregate operating expenses into specific categories such as employee compensation, depreciation, and intangible asset amortization, by relevant expense caption on the statement of operations. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-321">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss of $107.3 million for the year ended December&#160;31, 2024. The Company had working capital of $62.5 million and an accumulated deficit of $1.7 billion as of December&#160;31, 2024. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $94.1 million as of December 31, 2024 are not sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2024, the Company closed an underwritten public offering (the "December 2024 Offering"), relating to the issuance and sale of 10,000,000 shares of its common stock, par value $0.001 per share, and warrants to purchase 10,000,000 shares of common stock (the &#x201c;Warrants&#x201d;), at an offering price of $3.00 per share and accompanying Warrant. The exercise price of the Warrants is $3.76 per share. The net proceeds from the December 2024 Offering were $27.6&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2024, the Company closed an underwritten registered direct offering (the &#x201c;April 2024 Offering&#x201d;), relating to the issuance and sale of 2,536,258 shares (the &#x201c;Shares&#x201d;) of its common stock, par value $0.001 per share, at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant. The net proceeds from the April 2024 Offering were $33.2&#160;million, after deducting the underwriting discounts and commissions and offering expenses paid by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Going Concern &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and short-term investments of $94.1 million as of December&#160;31, 2024 are expected to be sufficient to support the Company's planned operations through the fourth quarter of 2025. The Company's current &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;financial resources may not be sufficient to support its planned operations beyond this date without securing additional financing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings, including under At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $60.8&#160;million from equity offerings during the year ending December 31, 2024, and $6.1&#160;million and $5.5&#160;million from equity offerings under Sales Agreements during the years ending December 31, 2024 and 2023, respectively. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and may never achieve positive cash flow. In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the fourth quarter of 2025. The Company's consolidated financial statements as of and for the year ended December&#160;31, 2024 do not include any adjustments that might result from the outcome of this uncertainty. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company is, and from time to time in the future may be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-322" unitRef="usd">-107300000</us-gaap:NetIncomeLoss>
    <ino:WorkingCapital contextRef="c-5" decimals="-5" id="f-323" unitRef="usd">62500000</ino:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-8" id="f-324" unitRef="usd">-1700000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-5" decimals="-5" id="f-325" unitRef="usd">94100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-36"
      decimals="INF"
      id="f-326"
      unitRef="shares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-37"
      decimals="INF"
      id="f-327"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-38"
      decimals="INF"
      id="f-328"
      unitRef="shares">10000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-39"
      decimals="2"
      id="f-329"
      unitRef="usdPerShare">3.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-39"
      decimals="INF"
      id="f-330"
      unitRef="usdPerShare">3.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-40" decimals="-5" id="f-331" unitRef="usd">27600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-41"
      decimals="INF"
      id="f-332"
      unitRef="shares">2536258</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-42"
      decimals="INF"
      id="f-333"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-43"
      decimals="INF"
      id="f-334"
      unitRef="usdPerShare">7.693</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-44"
      decimals="INF"
      id="f-335"
      unitRef="shares">2135477</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-45"
      decimals="INF"
      id="f-336"
      unitRef="usdPerShare">7.692</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-45"
      decimals="INF"
      id="f-337"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-46" decimals="-5" id="f-338" unitRef="usd">33200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-5" decimals="-5" id="f-339" unitRef="usd">94100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-27" decimals="-5" id="f-340" unitRef="usd">60800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-47" decimals="-5" id="f-341" unitRef="usd">6100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-48" decimals="-5" id="f-342" unitRef="usd">5500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-343">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-344">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker ("CODM"), the President and Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States, as further described in Note 16.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-345"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-346">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-347">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-348">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, investments in affiliated entity, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses and common stock warrant liability. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The estimated fair value of the common stock warrant liability is determined by using the Black-Scholes pricing model, as discussed in Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-349">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain mutual funds and U.S. treasury securities at December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-350">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-351">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Affiliated Entities&lt;/span&gt;&lt;/div&gt;Accounts receivable from affiliated entities are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-6" decimals="INF" id="f-352" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="INF" id="f-353" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-354">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets include property and equipment and leasehold improvements. Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:f-355"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;The Company evaluates the carrying value of long-lived assets, which includes fixed assets and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-50" id="f-356">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <ino:WarrantsPolicyPolicyTextBlock contextRef="c-1" id="f-357">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent &lt;/span&gt;&lt;/div&gt;reporting period while the warrants are outstanding. The Pre-Funded Warrants issued in April 2024 met all the criteria for equity classification and were recorded as a component of additional paid-in capital on issuance. However, the Warrants issued in December 2024 did not meet all the criteria for equity classification and were recorded as a liability at fair value upon issuance. The Warrants met the definition of a derivative and did not meet any scope exceptions under ASC 815. As a result, the fair value of the liability associated with the Warrants will be remeasured at the end of each reporting period while the Warrants are outstanding, and any change in fair value between reporting periods will be recognized as gain or loss on the consolidated statement of operations for that reporting period.</ino:WarrantsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-358">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carryforwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $349.2 million and $327.5 million at December&#160;31, 2024 and 2023, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-359" unitRef="usd">349200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-5" id="f-360" unitRef="usd">327500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-362">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;).</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-361">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements and Revenue Recognition&lt;/span&gt;&lt;/div&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;).</us-gaap:CollaborativeArrangementAccountingPolicy>
    <ino:GrantRevenuePolicyTextBlock contextRef="c-1" id="f-363">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-research and development expense as opposed to revenue on the consolidated statement of operations.</ino:GrantRevenuePolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-364">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-365">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing its proprietary device technology and DNA medicine candidates. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-366">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. The outstanding Pre-Funded Warrants (see Note 10) are included in the weighted-average common shares outstanding in the basic net loss per share calculation for the year ended December 31, 2024 given their nominal exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding Warrants, stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the Notes previously issued by the Company (discussed in Note 9) was considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024 and 2023, basic and diluted net loss per share are the same, as the assumed exercise or settlement of common stock warrants, stock options, service-based RSUs, performance-and market-based RSUs and the potentially dilutive shares issuable upon conversion of the Notes prior to their repayment on March 1, 2024 would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="c-1" id="f-367">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share for the year ended December 31, 2024 and 2023 are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,254,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,117,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares used to compute net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,655,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,173,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Weighted-average shares underlying pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Weighted-average common shares outstanding used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,160,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,173,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-368" unitRef="usd">-107254126</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="0" id="f-369" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <ino:WeightedAverageNumberOfSharesOutstanding contextRef="c-1" decimals="0" id="f-370" unitRef="shares">25655527</ino:WeightedAverageNumberOfSharesOutstanding>
    <ino:WeightedAverageNumberOfSharesOutstanding contextRef="c-11" decimals="0" id="f-371" unitRef="shares">22173662</ino:WeightedAverageNumberOfSharesOutstanding>
    <ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants contextRef="c-1" decimals="0" id="f-372" unitRef="shares">1505336</ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants>
    <ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants contextRef="c-11" decimals="0" id="f-373" unitRef="shares">0</ino:IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-374" unitRef="shares">27160863</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-375" unitRef="shares">27160863</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-376" unitRef="shares">22173662</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-377" unitRef="shares">22173662</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-378"
      unitRef="usdPerShare">-3.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-379"
      unitRef="usdPerShare">-3.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-380"
      unitRef="usdPerShare">-6.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-381"
      unitRef="usdPerShare">-6.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-and market-based restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,804,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-51" decimals="0" id="f-383" unitRef="shares">10000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-52" decimals="0" id="f-384" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-53" decimals="0" id="f-385" unitRef="shares">1337228</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-54" decimals="0" id="f-386" unitRef="shares">1128864</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-55" decimals="0" id="f-387" unitRef="shares">337911</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-56" decimals="0" id="f-388" unitRef="shares">274794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-57" decimals="0" id="f-389" unitRef="shares">128800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-58" decimals="0" id="f-390" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-59" decimals="0" id="f-391" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="0" id="f-392" unitRef="shares">275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-393" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-394" unitRef="shares">254165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-395" unitRef="shares">11804214</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-11" decimals="0" id="f-396" unitRef="shares">1658098</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-397">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to service-based RSUs, performance-and market-based RSUs  and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Capital Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;The Company recognizes forfeitures as they occur.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-399">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.22%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.929%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-63" decimals="4" id="f-400" unitRef="number">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-64" decimals="4" id="f-401" unitRef="number">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-63" decimals="2" id="f-402" unitRef="number">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-64" decimals="2" id="f-403" unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-63" id="f-404">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-64" id="f-405">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-63"
      decimals="INF"
      id="f-406"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-64"
      decimals="INF"
      id="f-407"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-65" decimals="4" id="f-408" unitRef="number">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-66" decimals="4" id="f-409" unitRef="number">0.0390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-65" decimals="2" id="f-410" unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-66" decimals="2" id="f-411" unitRef="number">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-65" id="f-412">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-66" id="f-413">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-65"
      decimals="INF"
      id="f-414"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-66"
      decimals="INF"
      id="f-415"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-416">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements.  Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2023-07. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU expands public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the Chief Operating Decision Maker (CODM) and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The ASU also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. All disclosure requirements under ASU 2023-07 are also required for public entities with a single reportable segment. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. The Company has adopted ASU 2023-07 and included the segment disclosures in Note 16 below.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2023-09. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ASU 2023-09 requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASU No. 2024-03. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024-03 requires public business entities to disaggregate operating expenses into specific categories such as employee compensation, depreciation, and intangible asset amortization, by relevant expense caption on the statement of operations. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, and may be applied either prospectively or retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-418">Revenue Recognition and Concentration of Credit Risk&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the years ended December&#160;31, 2024 and 2023, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ApolloBio Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No revenue recognized during the years ended December&#160;31, 2024 and 2023 was in deferred revenue as of December 31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2024 and 2023, the Company had no accounts receivable balance.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-419">The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ApolloBio Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-68" decimals="0" id="f-420" unitRef="usd">217756</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-69" decimals="2" id="f-421" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-70" decimals="0" id="f-422" unitRef="usd">245056</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="2" id="f-423" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="0" id="f-424" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="2" id="f-425" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-74" decimals="0" id="f-426" unitRef="usd">586954</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-427" unitRef="number">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-428" unitRef="usd">217756</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-429" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="0" id="f-430" unitRef="usd">832010</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="2" id="f-431" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="INF" id="f-432" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-433">Collaborative Agreements  &lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated in 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. The 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#x2019;s clinical trial of INO-4800 that was planned. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine continues to develop INO-4800 with its own resources under the terms of the Advaccine Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounts for the 2021 amendment under ASC Topic 808. Reimbursements from Advaccine are recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility is assured.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024 and 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company received funding of $0 and $3.6&#160;million respectively, from Advaccine that was recorded as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contra-research and development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), which was amended in June 2023. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2024 and 2023, the Company received $218,000 and $245,000, respectively, from the ApolloBio Agreement that was recorded as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations (CEPI)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56&#160;million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, the Company received funding of $1.6 million in connection with the final close-out of these grants, which was recorded as contra-research and development expense. During the year ended December 31, 2023, the Company received funding of $1.8 million in connection with these grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Gates awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2024 and 2023, the Company recorded $39,000 and $70,000, respectively, as contra-research and development expense related to the Gates dMAb grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-78" decimals="-5" id="f-434" unitRef="usd">0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-79" decimals="-5" id="f-435" unitRef="usd">3600000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved contextRef="c-80" decimals="-5" id="f-436" unitRef="usd">20000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod contextRef="c-80" id="f-437">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-80" decimals="-3" id="f-438" unitRef="usd">218000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived contextRef="c-81" decimals="-3" id="f-439" unitRef="usd">245000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-82" decimals="-6" id="f-440" unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment contextRef="c-83" id="f-441">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-84" decimals="-5" id="f-442" unitRef="usd">1600000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="c-85" decimals="-5" id="f-443" unitRef="usd">1800000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-86" decimals="-5" id="f-444" unitRef="usd">2200000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-87" decimals="-5" id="f-445" unitRef="usd">1100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-88" decimals="-3" id="f-446" unitRef="usd">39000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived contextRef="c-89" decimals="-3" id="f-447" unitRef="usd">70000</ino:CollaborativeAgreementFundingToBeReceived>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-449">Short-term Investments and Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,167,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,876,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024 and 2023, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $900 and $1,000, respectively, and gross realized loss on investments of $1.9 million and $4.8 million, respectively. During the years ended December&#160;31, 2024 and 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $2.1&#160;million and $5.9&#160;million, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2024 and&#160;2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2024, the Company had&#160;19&#160;available-for-sale securities with an aggregate total unrealized loss of $1.9 million. All of the securities had been in a loss position for longer than 12 months as of December&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2024&#160;were primarily due to changes in interest rates, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, at December&#160;31, 2024, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,914,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,094,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2024 consisted of mutual funds and the Company&#x2019;s investment in its affiliated entity, PLS. Level 1 assets at December 31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or as a gain or loss on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2024 and 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of December&#160;31, 2024 or 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 liabilities held as of December 31, 2024 consisted of liabilities associated with the Warrants to purchase  common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 10 for additional information about the liability-classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. The following assumptions were used to estimate the fair value of the warrant liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;On Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#x2019;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $2.8&#160;million on the consolidated statement of operations for the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company&#x2019;s total Level 3 financial liabilities for the year ended December 31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of common stock warrants in December 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,063,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-574"&gt;Decrease in fair value of liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,808,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-448">Short-term Investments and Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,167,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,876,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024 and 2023, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $900 and $1,000, respectively, and gross realized loss on investments of $1.9 million and $4.8 million, respectively. During the years ended December&#160;31, 2024 and 2023, the Company recorded net unrealized gain on available-for-sale equity securities of $2.1&#160;million and $5.9&#160;million, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2024 and&#160;2023. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2024, the Company had&#160;19&#160;available-for-sale securities with an aggregate total unrealized loss of $1.9 million. All of the securities had been in a loss position for longer than 12 months as of December&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2024&#160;were primarily due to changes in interest rates, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, at December&#160;31, 2024, the Company did not record an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,914,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,094,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2024 consisted of mutual funds and the Company&#x2019;s investment in its affiliated entity, PLS. Level 1 assets at December 31, 2023 consisted of mutual funds and U.S. treasury securities held by the Company that are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or as a gain or loss on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2024 and 2023 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of December&#160;31, 2024 or 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 liabilities held as of December 31, 2024 consisted of liabilities associated with the Warrants to purchase  common stock issued in the Company's underwritten public offering that closed in December 2024. See Note 10 for additional information about the liability-classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reassesses the fair value of the common stock warrant liability at each reporting date utilizing a Black-Scholes pricing model. The following assumptions were used to estimate the fair value of the warrant liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;On Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in these assumptions as well as fluctuations in the Company's stock price between the valuation dates can have a &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant impact on the fair value of the common stock warrant liability. Expected volatility was based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company&#x2019;s expectations of future volatility over the expected term. Expected term is calculated based on the remaining contractual term of the Warrants. The risk-free rate was based on the U.S. Treasury rate that corresponds to the expected term of the Warrants. As a result of these calculations, the Company recorded a decrease in fair value of the liability of $2.8&#160;million on the consolidated statement of operations for the year ended December 31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company&#x2019;s total Level 3 financial liabilities for the year ended December 31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of common stock warrants in December 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,063,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-574"&gt;Decrease in fair value of liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,808,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,926,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445,706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,980,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,167,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,876,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,389,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,522,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,164,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,978,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,873,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-90" decimals="0" id="f-451" unitRef="usd">25926415</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-90" decimals="0" id="f-452" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-90" decimals="0" id="f-453" unitRef="usd">1445706</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="0" id="f-454" unitRef="usd">24480709</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-91" id="f-455">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-92" decimals="0" id="f-456" unitRef="usd">2980273</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-92" decimals="0" id="f-457" unitRef="usd">9750</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-92" decimals="0" id="f-458" unitRef="usd">281</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="0" id="f-459" unitRef="usd">2989742</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-93" decimals="0" id="f-460" unitRef="usd">1260745</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-93" decimals="0" id="f-461" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-93" decimals="0" id="f-462" unitRef="usd">430964</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-93" decimals="0" id="f-463" unitRef="usd">829781</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="0" id="f-464" unitRef="usd">30167433</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="0" id="f-465" unitRef="usd">9750</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="0" id="f-466" unitRef="usd">1876951</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="0" id="f-467" unitRef="usd">28300232</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-94" decimals="0" id="f-468" unitRef="usd">55389289</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-94" decimals="0" id="f-469" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-94" decimals="0" id="f-470" unitRef="usd">3522888</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-94" decimals="0" id="f-471" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-95" id="f-472">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-96" decimals="0" id="f-473" unitRef="usd">75164782</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-96" decimals="0" id="f-474" unitRef="usd">24938</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-96" decimals="0" id="f-475" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-96" decimals="0" id="f-476" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="c-95" id="f-477">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-97" decimals="0" id="f-478" unitRef="usd">2978917</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-97" decimals="0" id="f-479" unitRef="usd">11709</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-97" decimals="0" id="f-480" unitRef="usd">300</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-97" decimals="0" id="f-481" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-98" decimals="0" id="f-482" unitRef="usd">1340439</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-98" decimals="0" id="f-483" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-98" decimals="0" id="f-484" unitRef="usd">403973</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-98" decimals="0" id="f-485" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-6" decimals="0" id="f-486" unitRef="usd">134873427</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-6" decimals="0" id="f-487" unitRef="usd">36647</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-6" decimals="0" id="f-488" unitRef="usd">3927161</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="0" id="f-489" unitRef="usd">130982913</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-1" decimals="-2" id="f-490" unitRef="usd">900</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-11" decimals="-3" id="f-491" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-1" decimals="-5" id="f-492" unitRef="usd">1900000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-11" decimals="-5" id="f-493" unitRef="usd">4800000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-494" unitRef="usd">2100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-11" decimals="-5" id="f-495" unitRef="usd">5900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-5"
      decimals="INF"
      id="f-496"
      unitRef="position">19</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-5" id="f-497" unitRef="usd">-1900000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-498">&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,989,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,300,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,480,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,914,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,094,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,819,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.565%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,866,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,189,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,982,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,056,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,763,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,836,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-99" decimals="0" id="f-499" unitRef="usd">24480709</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-100" decimals="0" id="f-500" unitRef="usd">24480709</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-101" decimals="0" id="f-501" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-102" decimals="0" id="f-502" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-103" decimals="0" id="f-503" unitRef="usd">2989742</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-104" decimals="0" id="f-504" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-105" decimals="0" id="f-505" unitRef="usd">2989742</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="0" id="f-506" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-107" decimals="0" id="f-507" unitRef="usd">829781</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-108" decimals="0" id="f-508" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="0" id="f-509" unitRef="usd">829781</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="0" id="f-510" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="0" id="f-511" unitRef="usd">28300232</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-112" decimals="0" id="f-512" unitRef="usd">24480709</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="0" id="f-513" unitRef="usd">3819523</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-114" decimals="0" id="f-514" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-111" decimals="0" id="f-515" unitRef="usd">1613844</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-112" decimals="0" id="f-516" unitRef="usd">1613844</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-113" decimals="0" id="f-517" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-114" decimals="0" id="f-518" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-111" decimals="0" id="f-519" unitRef="usd">29914076</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-112" decimals="0" id="f-520" unitRef="usd">26094553</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-113" decimals="0" id="f-521" unitRef="usd">3819523</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-114" decimals="0" id="f-522" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-111" decimals="0" id="f-523" unitRef="usd">13255188</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-112" decimals="0" id="f-524" unitRef="usd">0</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-113" decimals="0" id="f-525" unitRef="usd">0</ino:CommonStockWarrantLiabilityFairValue>
    <ino:CommonStockWarrantLiabilityFairValue contextRef="c-114" decimals="0" id="f-526" unitRef="usd">13255188</ino:CommonStockWarrantLiabilityFairValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-111" decimals="0" id="f-527" unitRef="usd">13255188</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-112" decimals="0" id="f-528" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-113" decimals="0" id="f-529" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-114" decimals="0" id="f-530" unitRef="usd">13255188</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="0" id="f-531" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-116" decimals="0" id="f-532" unitRef="usd">51866401</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-117" decimals="0" id="f-533" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-118" decimals="0" id="f-534" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-119" decimals="0" id="f-535" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-120" decimals="0" id="f-536" unitRef="usd">75189720</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-121" decimals="0" id="f-537" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="0" id="f-538" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-123" decimals="0" id="f-539" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-124" decimals="0" id="f-540" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-125" decimals="0" id="f-541" unitRef="usd">2990326</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-126" decimals="0" id="f-542" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-127" decimals="0" id="f-543" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-128" decimals="0" id="f-544" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-129" decimals="0" id="f-545" unitRef="usd">936466</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-130" decimals="0" id="f-546" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-131" decimals="0" id="f-547" unitRef="usd">130982913</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-132" decimals="0" id="f-548" unitRef="usd">127056121</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-133" decimals="0" id="f-549" unitRef="usd">3926792</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-134" decimals="0" id="f-550" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-131" decimals="0" id="f-551" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-132" decimals="0" id="f-552" unitRef="usd">2780287</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-133" decimals="0" id="f-553" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-134" decimals="0" id="f-554" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-131" decimals="0" id="f-555" unitRef="usd">133763200</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-132" decimals="0" id="f-556" unitRef="usd">129836408</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-133" decimals="0" id="f-557" unitRef="usd">3926792</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-134" decimals="0" id="f-558" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-135"
      decimals="INF"
      id="f-559"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-136"
      decimals="INF"
      id="f-560"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-561">The following assumptions were used to estimate the fair value of the warrant liability:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.467%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;On Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;4.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;111%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-137" decimals="3" id="f-562" unitRef="number">0.043</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-138" decimals="3" id="f-563" unitRef="number">0.044</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-139" decimals="3" id="f-564" unitRef="number">1.11</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-140" decimals="3" id="f-565" unitRef="number">1.11</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-141" decimals="0" id="f-566" unitRef="y">5</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-142" decimals="0" id="f-567" unitRef="y">5</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-143" decimals="3" id="f-568" unitRef="number">0</ino:WarrantLiabilityMeasurementInput>
    <ino:WarrantLiabilityMeasurementInput contextRef="c-144" decimals="3" id="f-569" unitRef="number">0</ino:WarrantLiabilityMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-5" id="f-570" unitRef="usd">2800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-571">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company&#x2019;s total Level 3 financial liabilities for the year ended December 31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of common stock warrants in December 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,063,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-574"&gt;Decrease in fair value of liability&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,808,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,255,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-6" decimals="0" id="f-572" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-1" decimals="0" id="f-573" unitRef="usd">16063796</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="0" id="f-575" unitRef="usd">2808608</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="0" id="f-576" unitRef="usd">13255188</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c-1" id="f-577">Certain Balance Sheet Items&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets at December&#160;31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical expenses (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,410,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,091,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses (b) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,432,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,200,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,847,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt"&gt;As of December 31, 2024 and 2023, balance included $0 and $1.5&#160;million, respectively, of prepaid manufacturing expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;As of December 31, 2024 and 2023, balance included $0 and $4.3&#160;million, respectively, of liability for unused grant funding.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-578">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets at December&#160;31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical expenses (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,410,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,003,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,414,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <ino:PrepaidClinicalExpensesCurrent contextRef="c-5" decimals="0" id="f-579" unitRef="usd">627962</ino:PrepaidClinicalExpensesCurrent>
    <ino:PrepaidClinicalExpensesCurrent contextRef="c-6" decimals="0" id="f-580" unitRef="usd">3410442</ino:PrepaidClinicalExpensesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-5" decimals="0" id="f-581" unitRef="usd">1889503</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-6" decimals="0" id="f-582" unitRef="usd">2003655</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="0" id="f-583" unitRef="usd">2517465</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="0" id="f-584" unitRef="usd">5414097</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-585">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,091,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,007,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses (b) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,432,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,200,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,847,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt"&gt;As of December 31, 2024 and 2023, balance included $0 and $1.5&#160;million, respectively, of prepaid manufacturing expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;As of December 31, 2024 and 2023, balance included $0 and $4.3&#160;million, respectively, of liability for unused grant funding.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c-7" decimals="0" id="f-586" unitRef="usd">5091503</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="c-8" decimals="0" id="f-587" unitRef="usd">3577826</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-7" decimals="0" id="f-588" unitRef="usd">10007180</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-8" decimals="0" id="f-589" unitRef="usd">9837104</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-7" decimals="0" id="f-590" unitRef="usd">1101330</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-8" decimals="0" id="f-591" unitRef="usd">6432814</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-7" decimals="0" id="f-592" unitRef="usd">16200013</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-8" decimals="0" id="f-593" unitRef="usd">19847744</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ino:PrepaidManufacturingExpenseCurrent contextRef="c-5" decimals="-5" id="f-594" unitRef="usd">0</ino:PrepaidManufacturingExpenseCurrent>
    <ino:PrepaidManufacturingExpenseCurrent contextRef="c-6" decimals="-5" id="f-595" unitRef="usd">1500000</ino:PrepaidManufacturingExpenseCurrent>
    <ino:GrantLiability contextRef="c-5" decimals="-5" id="f-596" unitRef="usd">0</ino:GrantLiability>
    <ino:GrantLiability contextRef="c-6" decimals="-5" id="f-597" unitRef="usd">4300000</ino:GrantLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-598">Fixed Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,761,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,390,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,370,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,835,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,571,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,431,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,416,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,093,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,083,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,122,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,462,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,659,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,917,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,753,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,164,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,078,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,816,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,204,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,812,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,851,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,960,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense for the years ended December&#160;31, 2024 and 2023 was $1.8 million and $2.6 million, respectively. The Company determined that the carrying value of its fixed assets was not impaired during the periods presented. During the year ended December 31, 2024, the Company sold fixed assets with no net book value for a gain of $59,000 and disposed of fixed assets with a net book value of $37,000. During the year ended December 31, 2023, the Company sold fixed assets with no net book value for a gain of $148,000 and disposed of fixed assets with a net book value of $466,000.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-599">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,761,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,390,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,370,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,835,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,571,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,431,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,416,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,093,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,083,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,122,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,462,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,659,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,917,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,753,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,164,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,538,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,078,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,816,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,204,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,812,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,851,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,960,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-145" decimals="0" id="f-600" unitRef="usd">11761522</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-145" decimals="0" id="f-601" unitRef="usd">8390612</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-145" decimals="0" id="f-602" unitRef="usd">3370910</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-146" decimals="0" id="f-603" unitRef="usd">2835298</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-146" decimals="0" id="f-604" unitRef="usd">2571747</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-146" decimals="0" id="f-605" unitRef="usd">263551</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-147" decimals="0" id="f-606" unitRef="usd">2431633</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-147" decimals="0" id="f-607" unitRef="usd">2416232</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-147" decimals="0" id="f-608" unitRef="usd">15401</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-148" decimals="0" id="f-609" unitRef="usd">3093812</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-148" decimals="0" id="f-610" unitRef="usd">3083856</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-148" decimals="0" id="f-611" unitRef="usd">9956</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="0" id="f-612" unitRef="usd">20122265</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="0" id="f-613" unitRef="usd">16462447</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="0" id="f-614" unitRef="usd">3659818</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-149" decimals="0" id="f-615" unitRef="usd">15917596</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-149" decimals="0" id="f-616" unitRef="usd">11753081</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-149" decimals="0" id="f-617" unitRef="usd">4164515</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-150" decimals="0" id="f-618" unitRef="usd">3538698</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-150" decimals="0" id="f-619" unitRef="usd">3078165</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-150" decimals="0" id="f-620" unitRef="usd">460533</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-151" decimals="0" id="f-621" unitRef="usd">2827476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-151" decimals="0" id="f-622" unitRef="usd">2816577</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-151" decimals="0" id="f-623" unitRef="usd">10899</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-152" decimals="0" id="f-624" unitRef="usd">3529129</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-152" decimals="0" id="f-625" unitRef="usd">3204090</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-152" decimals="0" id="f-626" unitRef="usd">325039</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="0" id="f-627" unitRef="usd">25812899</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="0" id="f-628" unitRef="usd">20851913</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="0" id="f-629" unitRef="usd">4960986</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-630" unitRef="usd">1800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-11" decimals="-5" id="f-631" unitRef="usd">2600000</us-gaap:Depreciation>
    <ino:GainLossOnSaleOfFixedAssetsNoNetBookValue contextRef="c-1" decimals="-3" id="f-632" unitRef="usd">59000</ino:GainLossOnSaleOfFixedAssetsNoNetBookValue>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c-1" decimals="-3" id="f-633" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <ino:GainLossOnSaleOfFixedAssetsNoNetBookValue contextRef="c-11" decimals="-3" id="f-634" unitRef="usd">148000</ino:GainLossOnSaleOfFixedAssetsNoNetBookValue>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c-11" decimals="-3" id="f-635" unitRef="usd">466000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-636">Goodwill and Intangible Assets &lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2023, as a result of the sustained decline in the Company&#x2019;s stock price and related market capitalization, and a general decline in equity values in the biotechnology industry, the Company performed a quantitative impairment assessment of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;its goodwill and long-lived assets. The goodwill was determined to be fully impaired as of September 30, 2023, and the Company recorded an impairment charge of $10.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2023, the Company also recorded an impairment charge of $2.0&#160;million to research and development expense for the remaining book value of intangible assets acquired in 2016 from Bioject Medical Technologies, as the Company had no plans to further develop or utilize this technology.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-11" decimals="-5" id="f-637" unitRef="usd">10500000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-153" decimals="-5" id="f-638" unitRef="usd">2000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-639">Convertible Debt&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Notes were senior unsecured obligations of the Company and accrued interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes matured on March 1, 2024 and the Company paid the then remaining $16.9&#160;million obligation in full, including accrued interest.&lt;/span&gt;&lt;/div&gt;For the years ended December&#160;31, 2024 and 2023, &#160;the Company recognized $178,000 and $1.2&#160;million, respectively, of interest expense related to the Notes, of which $178,000 and $1.1 million, respectively, related to the contractual interest coupon.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-154" decimals="INF" id="f-640" unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-154"
      decimals="INF"
      id="f-641"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-154"
      decimals="INF"
      id="f-642"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-155" decimals="-5" id="f-643" unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-154"
      decimals="INF"
      id="f-644"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c-156" decimals="-5" id="f-645" unitRef="usd">16900000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:InterestExpenseNonoperating contextRef="c-157" decimals="-3" id="f-646" unitRef="usd">178000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-158" decimals="-5" id="f-647" unitRef="usd">1200000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseDebt contextRef="c-157" decimals="-3" id="f-648" unitRef="usd">178000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-158" decimals="-5" id="f-649" unitRef="usd">1100000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-650">Stockholders&#x2019; Equity&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#x2019;s option, to convert all or any lesser portion of such holder&#x2019;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2024, the conversion value w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;as $326.40 per share, such&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; that the outstanding shares of Series C preferred stock were convertible into an aggregate of 275 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Offerings of Common Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2024, the Company closed the December 2024 Offering (see &#x201c;Basis of Presentation and Liquidity&#x201d; in Note 2 above). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Warrant issued in the December 2024 Offering has an initial exercise price per share of $3.76, subject to certain adjustments. The Warrants may be exercised at any time, in whole or in part, until expiration on December 16, 2029. In the event there is no effective registration statement covering the shares of common stock underlying a Warrant exercise, the Warrants may be exercised via cashless exercise. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 4.99% (or, for certain holders who so elected prior to the issuance of the Warrants, 9.99%) of the Company&#x2019;s outstanding Common Stock immediately after exercise, which percentage may be changed at the holder&#x2019;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#x2019; notice to the Company subject to the terms of the Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Warrants are not indexed to the Company&#x2019;s common stock, the Company recorded a liability for the Warrants at fair value upon issuance on the Company's consolidated balance sheet. The common stock warrant liability is remeasured to fair value at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, no Warrants issued in the December 2024 Offering had been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 18, 2024, the Company closed the April 2024 Offering (see &#x201c;Basis of Presentation and Liquidity&#x201d; in Note 2 above). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Pre-Funded Warrant issued in the April 2024 Offering has an initial exercise price per share of $0.001, subject to certain adjustments. The Pre-Funded Warrants may be exercised at any time until exercised in full. A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the Company&#x2019;s outstanding Common &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock immediately after exercise, which percentage may be changed at the holder&#x2019;s election to a lower or higher percentage not in excess of 19.99% upon 61 days&#x2019; notice to the Company subject to the terms of the Pre-Funded Warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Pre-Funded Warrants issued in the April 2024 Offering are indexed to the Company's own shares of common stock (and otherwise meet the requirements to be classified in equity), the Company recorded the consideration received from the issuance of the Pre-Funded Warrants as additional paid-in capital on the Company's condensed consolidated balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, no Pre-Funded Warrants had been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;At-The-Market Sales Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 13, 2024, the Company entered into an Equity Distribution Agreement (the "2024 Sales Agreement") with an outside sales agent (the "Sales Agent") for the offer and sale of its common stock for an aggregate offering price of up to $60.0&#160;million. The 2024 Sales Agreement provides that the Sales Agent is entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agent under the 2024 Sales Agreement, and the Company has provided the Sales Agent with certain indemnification rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, the Company sold 133,900 shares of its common stock under the 2024 Sales Agreement. The sales were made at a weighted average price of $7.02 per share, resulting in aggregate net proceeds of $925,000. As of December 31, 2024, there was $59.1&#160;million of remaining capacity under the 2024 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2021, the Company entered into an ATM Equity Offering Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with outside sales agents for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the sales agents were entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold under the 2021 Sales Agreement. During the three months ended March 31, 2024, the Company sold 543,620 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $9.76 per share, resulting in aggregate net proceeds of $5.2&#160;million. During the year ended December 31, 2023, the Company sold 875,305 shares of its common stock under the 2021 Sales Agreement at a weighted average price of $6.33 per share, resulting in aggregate net proceeds of $5.5&#160;million. The 2021 Sales Agreement was terminated in August 2024 in connection with the entry into the 2024 Sales Agreement described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Issuances of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company issued 760,083 shares of common stock pursuant to a securities class action litigation settlement, as described in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors adopted the 2023 Omnibus Incentive Plan (the &#x201c;2023 Plan&#x201d;) on March 24, 2023, pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Plan was approved by stockholders on May 16, 2023. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2023 Plan will not exceed the sum of 1,166,666 shares plus any shares that may return from time to time from the 2016 Omnibus Incentive Plan (as amended, the &#x201c;2016 Plan&#x201d;) as a result of expirations, terminations or forfeitures of awards outstanding under the 2016 Plan as of May 16, 2023. At December&#160;31, 2024, the Company had 800,526 shares of common stock available for future grant under the 2023 Plan, 188,082 shares underlying outstanding but unvested RSUs and 282,579 shares underlying options outstanding to purchase common stock under the 2023 Plan. The awards granted and available for future grant under the 2023 Plan generally vest over three years and have a maximum contractual term of ten years. The 2023 Plan terminates by its terms on March&#160;24, 2033.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following adoption of the 2023 Plan, no further awards may be made under the 2016 Plan, but outstanding awards continue to be governed by their existing terms. At December&#160;31, 2024, the Company had 129,000 shares underlying outstanding but unvested RSU and options outstanding to purchase 904,669 shares of common stock under the 2016 Plan. The outstanding awards granted under the 2016 Plan generally vest over three years and have a maximum contractual term of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2022 Inducement Plan will not exceed 166,666 shares. At December&#160;31, 2024 the Company had 84,328 shares of common stock available for future grant under the 2022 Inducement Plan, 20,829 shares underlying outstanding but unvested RSUs and options outstanding to purchase 53,684 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2024, the Company had options outstanding to purchase 96,296 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vested over three years and have a maximum contractual term of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2024 and 2023 was $6.4 million and $10.4 million, respectively, of which $2.8 million and $4.5 million was included in research and development expenses and $3.6 million and $5.9 million was included in general and administrative expenses, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024 and 2023, there was $2.1 million and $4.3 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.5 years and 1.3 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2024 and 2023, there was $2.0 million and $3.5 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.6 years and 1.5 years, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2024 and 2023 was $226,000 and $669,000, respectively. As of December&#160;31, 2024, options to purchase 66,056 shares of common stock granted to non-employees remained outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.78-$18.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.01-$39.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$39.01-$52.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$52.01-$90.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$90.01-$130.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.01-$233.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, the aggregate intrinsic value of options outstanding was $1,000, the aggregate intrinsic value of options exercisable was $0, and the weighted average remaining contractual term of options exercisable was 5.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2024, the aggregate intrinsic value of unvested RSUs was $618,000 and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2024 was $1.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2024, options to purchase 1,337,228 shares of common stock and 337,911 RSUs were expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2024 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2024 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price per share was $139.02 for the 38,503 options which expired during the year ended December&#160;31, 2024 and $38.86 for the 9,357 options which expired during the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $6.69 and $11.19 for options granted during the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value was $8.30 and $10.34 per share for RSUs granted during the years ended December&#160;31, 2024 and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received $68,000 in proceeds from the exercise of stock options during the years ended December&#160;31, 2024. No stock options were exercised during the year ended December 31, 2023. The aggregate intrinsic value of options exercised was $39,000 during the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance- and Market-Based RSUs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company granted performance- and-market-based RSUs (such performance-based grants, the "PSU Awards") to key employees under the 2023 Plan. Each PSU was expressed as a target number of RSUs. With respect to the PSU Awards, the Company's Board of Directors established specified performance goals and corresponding performance periods over which the goals must be attained, the satisfaction of which are conditions to earning the PSU Awards and vesting of the underlying RSUs. As of December 31, 2024, 83,800 performance- and market-based RSUs were outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the target number of RSUs underlying each PSU Award, up to 70% (the "Milestone-based RSUs") will vest based on the achievement of specified milestones relating to the development, regulatory status and commercialization of the Company&#x2019;s lead product candidate INO-3107 (each, a "Milestone," and collectively, the "Milestones"). Each Milestone has a specified deadline for achievement ranging between the end of 2025 and the end of 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining 30% of the target number of RSUs underlying each PSU Award (the "Market-based RSUs") will be eligible to vest based on the Company&#x2019;s achievement of total stockholder return relative to a peer group consisting of companies in the Russell 2000 Biotechnology Subsector index (the &#x201c;Relative TSR&#x201d;) over the period beginning on June 1, 2024 and ending on December 31, 2027 (the &#x201c;Performance Period&#x201d;), expressed as a percentile ranking.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of Market-based RSUs, if any, actually earned based on the achievement of the Relative TSR goal may range from 50% of the target number of RSUs for performance at a specified threshold percentile, to 100% of the target number of RSUs for performance at the target percentile, and up to 150% of the target number of RSUs for performance at or above a specified maximum percentile. In the event that actual Relative TSR performance is between the threshold and target levels or between the target and maximum levels, the number of RSUs earned based on Relative TSR will be determined based on linear interpolation between the specified percentiles. If the Company&#x2019;s actual Relative TSR performance is below the threshold percentile, then no RSUs would be earned based on Relative TSR. The number of RSUs earned based on Relative TSR may not exceed the target number of RSUs eligible to vest based on Relative TSR if the Company&#x2019;s total stockholder return is negative for the Performance Period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company valued the Milestone-based RSUs based on the grant date closing price per share. The Company recognizes stock-based compensation expense over the performance period, if it is probable that the performance condition will be achieved. Adjustments to stock-based compensation expense are made, as needed, each reporting period based on changes in the Company's estimate of the number of units that are probable of vesting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company valued the Market-based RSUs on the grant date using the Monte Carlo simulation method, a generally accepted statistical technique used to simulate a range of possible future stock prices for the Company and the peer group. The determination of fair value was affected by the Company's stock price and a number of assumptions including the expected volatility and the risk-free interest rate. The Company will recognize stock-based compensation expense ratably over the performance period of the award. The market-based RSUs will cliff-vest at the end of the three-year period ranging from zero to 150% of the target number of awards granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant assumptions used in the Monte Carlo simulation method were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the Milestone-based RSUs was $643,000 based on the grant date closing price per share of $10.96. As of December 31, 2024, the underlying performance milestones of the Milestone-based RSUs were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the year then ended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the Market-based RSUs was $269,000 based on the fair value of $10.69 per share as determined using the Monte Carlo simulation method. For the year ended December 31, 2024, the Company recognized $44,000 in stock-based compensation for the Market-based RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2024 Performance-Based Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2024, the Company granted performance-based stock options and RSUs (such performance-based grants, the "December 2024 Awards") to key employees under the 2023 Plan. Each award was expressed as a target number of stock options and RSUs. With respect to the December 2024 Awards, the Company's Board of Directors established specified performance goals and a corresponding performance period over which the goals must be attained, the satisfaction of which are conditions to earning the December 2024 Awards and vesting of the underlying stock options and RSUs. As of December 31, 2024, December 2024 Awards were outstanding covering 25,686 shares of common stock underlying stock options and 19,314 shares of common stock underlying RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of the performance-based RSUs was $34,000 based on the grant date closing price per share of $1.78. The grant date fair value of the performance-based stock options was $38,000 based on the Black-Scholes per share value of $1.46. As of December 31, 2024, the underlying performance milestones of the December 2024 Awards were determined to be not probable of achievement, and no stock-based compensation expense was recognized for the year then ended.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-651">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-159"
      decimals="INF"
      id="f-652"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-160"
      decimals="INF"
      id="f-653"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-159"
      decimals="INF"
      id="f-654"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-159"
      decimals="INF"
      id="f-655"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-159"
      decimals="INF"
      id="f-656"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-160"
      decimals="INF"
      id="f-657"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare
      contextRef="c-161"
      decimals="2"
      id="f-658"
      unitRef="usdPerShare">326.40</ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-162"
      decimals="INF"
      id="f-659"
      unitRef="shares">275</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-163"
      decimals="INF"
      id="f-660"
      unitRef="usdPerShare">3.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPercent contextRef="c-163" decimals="4" id="f-661" unitRef="number">0.0499</ino:ClassOfWarrantOrRightCommonStockOwnershipPercent>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent contextRef="c-163" decimals="4" id="f-662" unitRef="number">0.0999</ino:ClassOfWarrantOrRightCommonStockOwnershipPriorToIssuancePercent>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent contextRef="c-163" decimals="4" id="f-663" unitRef="number">0.1999</ino:ClassOfWarrantOrRightCommonStockOwnershipMaximumPercent>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-164"
      decimals="INF"
      id="f-664"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPercent contextRef="c-165" decimals="4" id="f-665" unitRef="number">0.0999</ino:ClassOfWarrantOrRightCommonStockOwnershipPercent>
    <ino:ClassOfWarrantOrRightCommonStockOwnershipPercent contextRef="c-166" decimals="4" id="f-666" unitRef="number">0.1999</ino:ClassOfWarrantOrRightCommonStockOwnershipPercent>
    <ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="c-167" decimals="-5" id="f-667" unitRef="usd">60000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage contextRef="c-167" decimals="3" id="f-668" unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-168"
      decimals="INF"
      id="f-669"
      unitRef="shares">133900</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-168"
      decimals="2"
      id="f-670"
      unitRef="usdPerShare">7.02</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-168" decimals="-3" id="f-671" unitRef="usd">925000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSaleAgreementRemainingCapacityAmount contextRef="c-169" decimals="-5" id="f-672" unitRef="usd">59100000</ino:StockSaleAgreementRemainingCapacityAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="c-170" decimals="INF" id="f-673" unitRef="usd">300000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage
      contextRef="c-170"
      decimals="INF"
      id="f-674"
      unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-171"
      decimals="INF"
      id="f-675"
      unitRef="shares">543620</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-171"
      decimals="2"
      id="f-676"
      unitRef="usdPerShare">9.76</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-171" decimals="-5" id="f-677" unitRef="usd">5200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="c-172"
      decimals="INF"
      id="f-678"
      unitRef="shares">875305</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="c-172"
      decimals="2"
      id="f-679"
      unitRef="usdPerShare">6.33</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="c-172" decimals="-5" id="f-680" unitRef="usd">5500000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:LitigationSettlementAmountAwardedToOtherPartyShares
      contextRef="c-173"
      decimals="INF"
      id="f-681"
      unitRef="shares">760083</ino:LitigationSettlementAmountAwardedToOtherPartyShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-174"
      decimals="INF"
      id="f-682"
      unitRef="shares">1166666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-175"
      decimals="INF"
      id="f-683"
      unitRef="shares">800526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-175"
      decimals="INF"
      id="f-684"
      unitRef="shares">188082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-175"
      decimals="INF"
      id="f-685"
      unitRef="shares">282579</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-176" id="f-686">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-176" id="f-687">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan
      contextRef="c-177"
      decimals="INF"
      id="f-688"
      unitRef="shares">129000</ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-178"
      decimals="INF"
      id="f-689"
      unitRef="shares">904669</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-177" id="f-690">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-177" id="f-691">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-179"
      decimals="INF"
      id="f-692"
      unitRef="shares">166666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-180"
      decimals="INF"
      id="f-693"
      unitRef="shares">84328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-180"
      decimals="INF"
      id="f-694"
      unitRef="shares">20829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-180"
      decimals="INF"
      id="f-695"
      unitRef="shares">53684</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="c-181"
      decimals="INF"
      id="f-696"
      unitRef="shares">96296</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-182" id="f-697">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="c-182" id="f-698">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-699" unitRef="usd">6400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-5" id="f-700" unitRef="usd">10400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-183" decimals="-5" id="f-701" unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-184" decimals="-5" id="f-702" unitRef="usd">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-185" decimals="-5" id="f-703" unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-186" decimals="-5" id="f-704" unitRef="usd">5900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-5" decimals="-5" id="f-705" unitRef="usd">2100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-6" decimals="-5" id="f-706" unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-707">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-11" id="f-708">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-187" decimals="-5" id="f-709" unitRef="usd">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-188" decimals="-5" id="f-710" unitRef="usd">3500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-189" id="f-711">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-190" id="f-712">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-713" unitRef="usd">226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-192" decimals="-3" id="f-714" unitRef="usd">669000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-193"
      decimals="INF"
      id="f-715"
      unitRef="shares">66056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-716">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.78-$18.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$18.01-$39.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$39.01-$52.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$52.01-$90.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$90.01-$130.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.01-$233.28&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-194"
      decimals="INF"
      id="f-717"
      unitRef="usdPerShare">1.78</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-194"
      decimals="INF"
      id="f-718"
      unitRef="usdPerShare">18.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-195"
      decimals="INF"
      id="f-719"
      unitRef="shares">568085</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-194" id="f-720">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-195"
      decimals="2"
      id="f-721"
      unitRef="usdPerShare">10.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-195"
      decimals="INF"
      id="f-722"
      unitRef="shares">205698</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-195"
      decimals="2"
      id="f-723"
      unitRef="usdPerShare">12.08</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-196"
      decimals="INF"
      id="f-724"
      unitRef="usdPerShare">18.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-196"
      decimals="INF"
      id="f-725"
      unitRef="usdPerShare">39.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-197"
      decimals="INF"
      id="f-726"
      unitRef="shares">249917</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-196" id="f-727">P6Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-197"
      decimals="2"
      id="f-728"
      unitRef="usdPerShare">35.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-197"
      decimals="INF"
      id="f-729"
      unitRef="shares">191644</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-197"
      decimals="2"
      id="f-730"
      unitRef="usdPerShare">35.28</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-198"
      decimals="INF"
      id="f-731"
      unitRef="usdPerShare">39.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-198"
      decimals="INF"
      id="f-732"
      unitRef="usdPerShare">52.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-199"
      decimals="INF"
      id="f-733"
      unitRef="shares">152066</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-198" id="f-734">P3Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-199"
      decimals="2"
      id="f-735"
      unitRef="usdPerShare">44.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-199"
      decimals="INF"
      id="f-736"
      unitRef="shares">151949</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-199"
      decimals="2"
      id="f-737"
      unitRef="usdPerShare">44.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-200"
      decimals="INF"
      id="f-738"
      unitRef="usdPerShare">52.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-200"
      decimals="INF"
      id="f-739"
      unitRef="usdPerShare">90.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-201"
      decimals="INF"
      id="f-740"
      unitRef="shares">126336</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-200" id="f-741">P3Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-201"
      decimals="2"
      id="f-742"
      unitRef="usdPerShare">76.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-201"
      decimals="INF"
      id="f-743"
      unitRef="shares">123316</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-201"
      decimals="2"
      id="f-744"
      unitRef="usdPerShare">77.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-202"
      decimals="INF"
      id="f-745"
      unitRef="usdPerShare">90.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-202"
      decimals="INF"
      id="f-746"
      unitRef="usdPerShare">130.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-203"
      decimals="INF"
      id="f-747"
      unitRef="shares">112293</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-202" id="f-748">P3Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-203"
      decimals="2"
      id="f-749"
      unitRef="usdPerShare">98.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-203"
      decimals="INF"
      id="f-750"
      unitRef="shares">112293</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-203"
      decimals="2"
      id="f-751"
      unitRef="usdPerShare">98.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-204"
      decimals="INF"
      id="f-752"
      unitRef="usdPerShare">130.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-204"
      decimals="INF"
      id="f-753"
      unitRef="usdPerShare">233.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-205"
      decimals="INF"
      id="f-754"
      unitRef="shares">128531</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-204" id="f-755">P5Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-205"
      decimals="2"
      id="f-756"
      unitRef="usdPerShare">137.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-205"
      decimals="INF"
      id="f-757"
      unitRef="shares">128531</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-205"
      decimals="2"
      id="f-758"
      unitRef="usdPerShare">137.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c-5" decimals="INF" id="f-759" unitRef="shares">1337228</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-760">P6Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-5"
      decimals="2"
      id="f-761"
      unitRef="usdPerShare">45.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c-5" decimals="INF" id="f-762" unitRef="shares">913431</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-5"
      decimals="2"
      id="f-763"
      unitRef="usdPerShare">59.52</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue contextRef="c-1" decimals="-3" id="f-764" unitRef="usd">1000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-765" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm contextRef="c-1" id="f-766">P5Y6M</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="c-187" decimals="-3" id="f-767" unitRef="usd">618000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-189" decimals="-5" id="f-768" unitRef="usd">1300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber contextRef="c-5" decimals="INF" id="f-769" unitRef="shares">1337228</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber
      contextRef="c-187"
      decimals="INF"
      id="f-770"
      unitRef="shares">337911</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-771">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2024 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.539%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.659%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-772" unitRef="shares">1128864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-773"
      unitRef="usdPerShare">58.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-774" unitRef="shares">328376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-775"
      unitRef="usdPerShare">8.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-776" unitRef="shares">8159</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-777"
      unitRef="usdPerShare">8.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-778" unitRef="shares">111853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-779"
      unitRef="usdPerShare">76.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-780" unitRef="shares">1337228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-781"
      unitRef="usdPerShare">45.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-782">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2024 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-188"
      decimals="INF"
      id="f-783"
      unitRef="shares">274794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-189"
      decimals="INF"
      id="f-784"
      unitRef="shares">214207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-189"
      decimals="INF"
      id="f-785"
      unitRef="shares">126133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-189"
      decimals="INF"
      id="f-786"
      unitRef="shares">24957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-187"
      decimals="INF"
      id="f-787"
      unitRef="shares">337911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-788"
      unitRef="usdPerShare">139.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-789" unitRef="shares">38503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-790"
      unitRef="usdPerShare">38.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-11"
      decimals="INF"
      id="f-791"
      unitRef="shares">9357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-792"
      unitRef="usdPerShare">6.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-11"
      decimals="2"
      id="f-793"
      unitRef="usdPerShare">11.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-189"
      decimals="2"
      id="f-794"
      unitRef="usdPerShare">8.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-190"
      decimals="2"
      id="f-795"
      unitRef="usdPerShare">10.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-796" unitRef="usd">68000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-11" decimals="-3" id="f-797" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-798" unitRef="usd">39000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-206"
      decimals="INF"
      id="f-799"
      unitRef="shares">83800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased contextRef="c-207" decimals="2" id="f-800" unitRef="number">0.70</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMilestoneBased>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased contextRef="c-207" decimals="2" id="f-801" unitRef="number">0.30</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPercentageMarketBased>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-208" decimals="2" id="f-802" unitRef="number">0.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-209" decimals="2" id="f-803" unitRef="number">1</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage contextRef="c-210" decimals="2" id="f-804" unitRef="number">1.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-211" id="f-805">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards contextRef="c-212" decimals="2" id="f-806" unitRef="number">0</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards contextRef="c-213" decimals="2" id="f-807" unitRef="number">1.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardsGrantedPercentageOfTargetAwards>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-808">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant assumptions used in the Monte Carlo simulation method were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.760%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-211" decimals="4" id="f-809" unitRef="number">0.0460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-211" decimals="2" id="f-810" unitRef="number">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-211" id="f-811">P3Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-211"
      decimals="INF"
      id="f-812"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue contextRef="c-214" decimals="-3" id="f-813" unitRef="usd">643000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-215"
      decimals="2"
      id="f-814"
      unitRef="usdPerShare">10.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-215" decimals="INF" id="f-815" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue contextRef="c-216" decimals="-3" id="f-816" unitRef="usd">269000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-211"
      decimals="2"
      id="f-817"
      unitRef="usdPerShare">10.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-211" decimals="-3" id="f-818" unitRef="usd">44000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock contextRef="c-217" decimals="0" id="f-819" unitRef="shares">25686</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock contextRef="c-218" decimals="0" id="f-820" unitRef="shares">19314</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardUnderlyingCommonStock>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue contextRef="c-219" decimals="-3" id="f-821" unitRef="usd">34000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice
      contextRef="c-219"
      decimals="2"
      id="f-822"
      unitRef="usdPerShare">1.78</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantDateClosingSharePrice>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue contextRef="c-220" decimals="-3" id="f-823" unitRef="usd">38000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-221"
      decimals="2"
      id="f-824"
      unitRef="usdPerShare">1.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-215" decimals="INF" id="f-825" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-827">Commitments and Contingencies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 56,600 square feet of office, laboratory, and manufacturing space in San Diego, California and approximately 57,400 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2024 of 2.4 to 5.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The base rent adjusts periodically throughout the term of the leases. Rent payments under the leases include base rent with annual increases of approximately two to three percent, and additional monthly fees to cover the Company's share of certain facility expenses, including utilities, property taxes, insurance and maintenance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,555,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,310,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,435,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,570,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,865,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,497,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,368,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2024 and 2023 were $2.6 million and $3.5 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, the Company entered into agreements to sublease a total of approximately 11,400 square feet in its Plymouth Meeting headquarters with sublease terms through December 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2024, the Company amended the sublease agreements for its Plymouth Meeting headquarters to extend one sublease term through December 31, 2027 and the other through December 31, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, a purported shareholder class action complaint was filed naming the Company and its former President and Chief Executive Officer as defendants and alleging that the Company made materially false and misleading statements in violation of certain federal securities laws. In 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint, which was approved by the court in January 2023. Under the settlement, the Company agreed to pay $30.0&#160;million in cash and issued 760,083 shares of its common stock, with a value of $14.0&#160;million at the time, to settle all outstanding claims. The Company's insurance carriers paid the $30.0&#160;million cash component of the settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, a purported shareholder derivative complaint was filed naming eight current and former directors of the Company as defendants. The lawsuit asserted state and federal claims and was based on the same alleged misstatements as the shareholder class action complaint described above. The lawsuit accused the Company&#x2019;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#x2019;s management, policies, practices, and internal controls. The plaintiff sought unspecified monetary damages on behalf of the Company as well as governance reforms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between 2020 and 2022, additional shareholder derivative complaints were filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, the court entered an order preliminarily approving a proposed settlement of the derivative claims, in accordance with a Stipulation of Settlement. The Stipulation of Settlement contemplated that, following the settlement hearing and the final approval of the settlement by the court, the Company would implement certain corporate governance reforms described in the Stipulation of Settlement. The preliminary order also approved the form and manner of the notice of the Settlement. As part of the Settlement, in July 2023 the Company paid $1.2&#160;million to plaintiffs&#x2019; counsel for their fees and expenses. In October 2023, the court entered an order and final judgment approving the Settlement, which became effective in November 2023. The Company has implemented the corporate governance reforms in response to the provisions of the Stipulation of Settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VGXI Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#x2019;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#x2019; fees, interest, costs and other relief from VGXI. In June 2020, the Company filed a petition for preliminary injunction, which was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following an appeal by the Company, in July 2020, VGXI filed counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#x2019; fees, interest, costs and other relief from the Company. VGXI also filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI, but VGXI later discontinued its third-party claims. The Company filed an answer to VGXI&#x2019;s counterclaims, disputing the allegations and the claims raised in VGXI&#x2019;s filing. In October 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#x2019;s counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement in October 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#x2019; fees, interest, and other relief from the Company. The Company filed preliminary objections to the complaint, which were overruled by the court. In September 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#x2019;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The counterclaims seek damages, interest, expenses, attorney&#x2019;s fees, and costs. In October 2021, GeneOne filed its answer to the Company&#x2019;s counterclaims and new matter. On February 29, 2024, the Company filed a motion for summary judgment. On April 1, 2024, GeneOne filed an opposition to the Company&#x2019;s motion for summary judgment. On June 28, 2024, the court denied the motion for summary judgment. A trial date for this litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#x2019;s complaint. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-223" decimals="0" id="f-828" unitRef="sqft">56600</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-224" decimals="0" id="f-829" unitRef="sqft">57400</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-49" id="f-830">P2Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-50" id="f-831">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease contextRef="c-225" decimals="2" id="f-832" unitRef="number">0.02</ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease>
    <ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease contextRef="c-226" decimals="2" id="f-833" unitRef="number">0.03</ino:LesseeOperatingLeaseBaseRatePercentageIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-834">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,555,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,310,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,435,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,570,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,865,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,497,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,368,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-835" unitRef="usd">3483000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-836" unitRef="usd">3555000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-837" unitRef="usd">2955000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-838" unitRef="usd">2310000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-5" decimals="-3" id="f-839" unitRef="usd">2132000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-840" unitRef="usd">14435000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-841" unitRef="usd">2570000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-842" unitRef="usd">11865000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-843" unitRef="usd">2497000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-844" unitRef="usd">9368000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-845">P4Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-846" unitRef="number">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-5" id="f-847" unitRef="usd">2600000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-11" decimals="-5" id="f-848" unitRef="usd">3500000</us-gaap:LeaseCost>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="c-227" decimals="-2" id="f-849" unitRef="sqft">11400</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-228" decimals="-5" id="f-850" unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LitigationSettlementAmountAwardedToOtherPartyShares contextRef="c-228" decimals="0" id="f-851" unitRef="shares">760083</ino:LitigationSettlementAmountAwardedToOtherPartyShares>
    <ino:LossContingencyEstimateOfPossibleLossValueOfShares contextRef="c-228" decimals="-5" id="f-852" unitRef="usd">14000000</ino:LossContingencyEstimateOfPossibleLossValueOfShares>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-228" decimals="-5" id="f-853" unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="c-229"
      decimals="INF"
      id="f-854"
      unitRef="defendent">8</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyDamagesPaidValue contextRef="c-230" decimals="-5" id="f-855" unitRef="usd">1200000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-856">Income Taxes &lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,254,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,979,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,254,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,117,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no provision for or benefit from income taxes for the years ended December 31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2024 and 2023, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,523,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,375,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,543,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,922,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,749,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,394,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,846,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,139,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,056,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2024 and 2023 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,143,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,336,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,734,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,492,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,822,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,808,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,928,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,486,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349,224,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(327,493,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,704,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,993,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,704,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,993,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2024, the Company had federal, California and other state tax net operating loss (NOL) carryforwards of $1.1 billion, $259.9 million and $88.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $801.9 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2025, and the California and other state NOL carryforwards will begin and have begun to expire in 2028 and 2025, respectively, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also had Korean NOL carryforward of $1.0&#160;million as of December 31, 2024.  The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2035, unless previously utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as of December 31, 2024, the Company had federal and state research and development (R&amp;amp;D) tax credit carryforwards of $46.1 million and $7.9 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#x2019;s NOL and R&amp;amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;amp;D credit carryforwards as of December&#160;31, 2024. As a result of the analysis, the Company estimates that approximately $5.3 million of tax benefits related to NOL and R&amp;amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes, could further limit the ability to use the NOL and R&amp;amp;D carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2024 and 2023, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,608,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $22.9 million and $20.5 million as of December&#160;31, 2024 and 2023, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2021 and state and local income tax examinations before 2020. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#x201c;IRS&#x201d;), state, local or foreign tax examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-857">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,254,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(134,979,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,254,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,117,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="0" id="f-858" unitRef="usd">-107254126</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-11" decimals="0" id="f-859" unitRef="usd">-134979579</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="0" id="f-860" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-11" decimals="0" id="f-861" unitRef="usd">-137772</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="0" id="f-862" unitRef="usd">-107254126</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="0" id="f-863" unitRef="usd">-135117351</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="INF" id="f-864" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-161" decimals="INF" id="f-865" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-866" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-867">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2024 and 2023, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,523,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,375,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,543,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,922,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,749,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,394,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,846,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,139,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,099,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,056,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-868" unitRef="usd">-22523000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-11" decimals="-3" id="f-869" unitRef="usd">-28375000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-870" unitRef="usd">-1543000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-11" decimals="-3" id="f-871" unitRef="usd">-3922000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-872" unitRef="usd">21749000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-873" unitRef="usd">28394000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ino:IncomeTaxReconciliationStatuteLimitations contextRef="c-1" decimals="-3" id="f-874" unitRef="usd">-5846000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations contextRef="c-11" decimals="-3" id="f-875" unitRef="usd">-2139000</ino:IncomeTaxReconciliationStatuteLimitations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-876" unitRef="usd">1579000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-11" decimals="-3" id="f-877" unitRef="usd">2099000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-3" id="f-878" unitRef="usd">2344000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-11" decimals="-3" id="f-879" unitRef="usd">861000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-1" decimals="-3" id="f-880" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses contextRef="c-11" decimals="-3" id="f-881" unitRef="usd">1962000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits contextRef="c-1" decimals="-3" id="f-882" unitRef="usd">4687000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits contextRef="c-11" decimals="-3" id="f-883" unitRef="usd">1352000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits contextRef="c-1" decimals="-3" id="f-884" unitRef="usd">-2056000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits contextRef="c-11" decimals="-3" id="f-885" unitRef="usd">-997000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-886" unitRef="usd">403000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-11" decimals="-3" id="f-887" unitRef="usd">365000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-888" unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-11" decimals="-3" id="f-889" unitRef="usd">-4000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-890" unitRef="usd">1206000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-11" decimals="-3" id="f-891" unitRef="usd">404000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-892" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-893" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-894">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2024 and 2023 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,143,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250,336,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,734,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,492,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,822,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,720,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,808,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,928,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,486,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349,224,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(327,493,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,704,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,993,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,704,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,993,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,704,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,993,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-895" unitRef="usd">54204000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-896" unitRef="usd">50143000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-897" unitRef="usd">250336000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-898" unitRef="usd">235624000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="c-5" decimals="-3" id="f-899" unitRef="usd">31250000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="c-6" decimals="-3" id="f-900" unitRef="usd">27734000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-3" id="f-901" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-6" decimals="-3" id="f-902" unitRef="usd">22000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-903" unitRef="usd">3060000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-904" unitRef="usd">3683000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ino:DeferredTaxAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-905" unitRef="usd">774000</ino:DeferredTaxAssetsIntangibleAssets>
    <ino:DeferredTaxAssetsIntangibleAssets contextRef="c-6" decimals="-3" id="f-906" unitRef="usd">907000</ino:DeferredTaxAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-5" decimals="-3" id="f-907" unitRef="usd">1651000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-6" decimals="-3" id="f-908" unitRef="usd">1406000</us-gaap:DeferredTaxAssetsInvestments>
    <ino:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-909" unitRef="usd">2492000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <ino:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-910" unitRef="usd">2822000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-911" unitRef="usd">441000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-912" unitRef="usd">337000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-913" unitRef="usd">6720000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-914" unitRef="usd">6808000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-915" unitRef="usd">350928000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-916" unitRef="usd">329486000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-917" unitRef="usd">349224000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-918" unitRef="usd">327493000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-919" unitRef="usd">1704000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-920" unitRef="usd">1993000</us-gaap:DeferredTaxAssetsNet>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-921" unitRef="usd">1704000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-922" unitRef="usd">1993000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-923" unitRef="usd">1704000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-924" unitRef="usd">1993000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-925" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-926" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="c-231" decimals="-5" id="f-927" unitRef="usd">1100000000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="c-232" decimals="-5" id="f-928" unitRef="usd">259900000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="c-233" decimals="-5" id="f-929" unitRef="usd">88600000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-234" decimals="-5" id="f-930" unitRef="usd">801900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-235" decimals="-5" id="f-931" unitRef="usd">1000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-236" decimals="-5" id="f-932" unitRef="usd">46100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-237" decimals="-5" id="f-933" unitRef="usd">7900000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock contextRef="c-1" id="f-934">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock>
    <ino:OperatingLossCarryforwardsExpiringInNextFiscalYear contextRef="c-238" decimals="-5" id="f-935" unitRef="usd">16000000.0</ino:OperatingLossCarryforwardsExpiringInNextFiscalYear>
    <ino:OperatingLossCarryforwardsExpiringInNextFiscalYear contextRef="c-239" decimals="-5" id="f-936" unitRef="usd">5200000</ino:OperatingLossCarryforwardsExpiringInNextFiscalYear>
    <ino:OperatingLossCarryforwardsExpiringInNextFiscalYear contextRef="c-235" decimals="-5" id="f-937" unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringInNextFiscalYear>
    <ino:TaxCreditCarryforwardExpiringInNextFiscalYear contextRef="c-240" decimals="-5" id="f-938" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInNextFiscalYear>
    <ino:TaxCreditCarryforwardExpiringInNextFiscalYear contextRef="c-237" decimals="-5" id="f-939" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInNextFiscalYear>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears contextRef="c-238" decimals="-5" id="f-940" unitRef="usd">17100000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears contextRef="c-239" decimals="-5" id="f-941" unitRef="usd">7100000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears contextRef="c-235" decimals="-5" id="f-942" unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears contextRef="c-240" decimals="-5" id="f-943" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears contextRef="c-237" decimals="-5" id="f-944" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears contextRef="c-238" decimals="-5" id="f-945" unitRef="usd">6100000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears contextRef="c-239" decimals="-5" id="f-946" unitRef="usd">1900000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears contextRef="c-235" decimals="-5" id="f-947" unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:TaxCreditCarryforwardExpiringInThreeYears contextRef="c-240" decimals="-5" id="f-948" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInThreeYears>
    <ino:TaxCreditCarryforwardExpiringInThreeYears contextRef="c-237" decimals="-5" id="f-949" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears contextRef="c-238" decimals="-5" id="f-950" unitRef="usd">245900000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears contextRef="c-239" decimals="-5" id="f-951" unitRef="usd">333600000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears contextRef="c-235" decimals="-5" id="f-952" unitRef="usd">1000000.0</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:TaxCreditCarryforwardExpiringInFourYears contextRef="c-240" decimals="-5" id="f-953" unitRef="usd">46100000</ino:TaxCreditCarryforwardExpiringInFourYears>
    <ino:TaxCreditCarryforwardExpiringInFourYears contextRef="c-237" decimals="-5" id="f-954" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInFourYears>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward contextRef="c-238" decimals="-5" id="f-955" unitRef="usd">801900000</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward contextRef="c-239" decimals="-5" id="f-956" unitRef="usd">700000</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward contextRef="c-235" decimals="-5" id="f-957" unitRef="usd">0</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely contextRef="c-240" decimals="-5" id="f-958" unitRef="usd">0</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely contextRef="c-237" decimals="-5" id="f-959" unitRef="usd">7900000</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <us-gaap:OperatingLossCarryforwards contextRef="c-238" decimals="-5" id="f-960" unitRef="usd">1087000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-239" decimals="-5" id="f-961" unitRef="usd">348500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-235" decimals="-5" id="f-962" unitRef="usd">1000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-240" decimals="-5" id="f-963" unitRef="usd">46100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-237" decimals="-5" id="f-964" unitRef="usd">7900000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:TaxBenefitsExpired contextRef="c-5" decimals="-5" id="f-965" unitRef="usd">5300000</ino:TaxBenefitsExpired>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-966">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(841,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,608,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,114,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-967" unitRef="usd">22114000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-17" decimals="-3" id="f-968" unitRef="usd">21139000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-969" unitRef="usd">2297000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-11" decimals="-3" id="f-970" unitRef="usd">1816000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-971" unitRef="usd">197000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-11" decimals="-3" id="f-972" unitRef="usd">841000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-973" unitRef="usd">24608000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-974" unitRef="usd">22114000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-5" decimals="-5" id="f-975" unitRef="usd">22900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-6" decimals="-5" id="f-976" unitRef="usd">20500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-977">401(k) Plan&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#x2019; contributions, up to 6% of their annual compensation. The Company&#x2019;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $961,000 and $1.4 million for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="c-1" decimals="INF" id="f-978" unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c-1" decimals="INF" id="f-979" unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-3" id="f-980" unitRef="usd">961000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-11" decimals="-5" id="f-981" unitRef="usd">1400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-982">Related Party Transactions&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company owned 597,808 shares of common stock in PLS as of December 31, 2024 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, representing a 17.3% and 17.8% ownership interest, respectively. The Company's investment in PLS is recorded as investment in affiliated entity on the consolidated balance sheet as of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and was valued at $1.6&#160;million and $2.8&#160;million, respectively, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on the closing price of the shares on the Korea New Exchange Market at the applicable balance sheet date&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. One &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dr.&#160;Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar") and an Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into collaborative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;upon expiration of the 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the exclusive right to in-license new intellectual property developed under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $13.6&#160;million,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19. In August 2024,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the sub-grant was amended to a total of $12.5&#160;million in funding through September 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company received a $1.2&#160;million sub-grant through Wistar, which was amended in 2024 to $2.4&#160;million with funding through November 2024, with an option for an additional $4.2&#160;million in funding that extends the sub-grant through November 2027. The Company will support the Wistar lead consortium in the research and development of synthetic DNA-launched nanoparticles (dLNPs) for vaccination against HIV infection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2024 and 2023, the Company recorded $482,000 and $1.0 million, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements. Research and development expenses recorded from Wistar for the years ended December&#160;31, 2024 and 2023 were $1.5 million and $1.8 million, respectively. At December&#160;31, 2024 and 2023, the Company had an accounts receivable balance of $1.2 million and $2.4 million, respectively, and an accounts payable and accrued liability balance of $1.4 million and $1.1 million, respectively, related to Wistar. As of December&#160;31, 2024 and 2023, the Company had a prepaid expense balance of $0 and $20,000, respectively, and recorded $0 and $22,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-241"
      decimals="INF"
      id="f-983"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-242"
      decimals="INF"
      id="f-984"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-241" decimals="3" id="f-985" unitRef="number">0.173</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-242" decimals="3" id="f-986" unitRef="number">0.178</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-243" decimals="-5" id="f-987" unitRef="usd">1600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-244" decimals="-5" id="f-988" unitRef="usd">2800000</us-gaap:AccountsReceivableNetCurrent>
    <ino:CollaborativeAgreementExpensesToReimburse contextRef="c-245" decimals="-5" id="f-989" unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm contextRef="c-245" id="f-990">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-246" decimals="-5" id="f-991" unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount contextRef="c-247" decimals="-5" id="f-992" unitRef="usd">13600000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAmendedAmount contextRef="c-248" decimals="-5" id="f-993" unitRef="usd">12500000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedAmount contextRef="c-249" decimals="-5" id="f-994" unitRef="usd">1200000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount contextRef="c-250" decimals="-5" id="f-995" unitRef="usd">2400000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount contextRef="c-249" decimals="-5" id="f-996" unitRef="usd">4200000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:GrantProceedsReceived contextRef="c-251" decimals="-3" id="f-997" unitRef="usd">482000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived contextRef="c-252" decimals="-5" id="f-998" unitRef="usd">1000000.0</ino:GrantProceedsReceived>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-250" decimals="-5" id="f-999" unitRef="usd">1500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-253" decimals="-5" id="f-1000" unitRef="usd">1800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNet contextRef="c-254" decimals="-5" id="f-1001" unitRef="usd">1200000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-255" decimals="-5" id="f-1002" unitRef="usd">2400000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-254" decimals="-5" id="f-1003" unitRef="usd">1400000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c-255" decimals="-5" id="f-1004" unitRef="usd">1100000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c-254" decimals="-3" id="f-1005" unitRef="usd">0</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="c-255" decimals="-3" id="f-1006" unitRef="usd">20000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate contextRef="c-254" decimals="-3" id="f-1007" unitRef="usd">0</ino:DeferredGrantFundingFromAffiliate>
    <ino:DeferredGrantFundingFromAffiliate contextRef="c-255" decimals="-3" id="f-1008" unitRef="usd">22000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-1009">Geneos Therapeutics, Inc. &lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company formed Geneos Therapeutics ("Geneos") to develop and commercialize neoantigen-based personalized cancer therapies. The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2024, the Company held 23% of the outstanding equity of Geneos, on an as-converted to common stock basis. The Company accounts for its common stock investment in Geneos as an equity method investment under ASC 323. Due to continuing net losses of Geneos, the Company&#x2019;s investment had been reduced to $0 as of each of December 31, 2024 and 2023. The Company has not made any further investment in Geneos. The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos, as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;The Company continues to exclusively license its immunotherapy platform and CELLECTRA&#160;technology to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c-256"
      decimals="2"
      id="f-1010"
      unitRef="number">0.23</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestments contextRef="c-256" decimals="-3" id="f-1011" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-257" decimals="-3" id="f-1012" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <ino:EquityMethodInvestmentsMinimum contextRef="c-256" decimals="-3" id="f-1013" unitRef="usd">0</ino:EquityMethodInvestmentsMinimum>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1014">Segment Information&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,  &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative arrangements and other contracts, including affiliated entity&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1019"&gt;Research and development:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;INO-3107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,930,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,840,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;INO-5401 and other Immuno-oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other programs (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,701,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Engineering and device-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,393,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,863,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,606,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other unallocated expenses (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,259,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,905,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,996,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,582,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,616,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,772,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,766,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,133,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,222,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,808,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) gain on investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,166,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain on available-for-sale equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,077,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,163,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,711,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,254,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,117,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;          (b) Includes impairment of intangible assets of $2.0&#160;million recorded in 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1015"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1016">&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,  &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative arrangements and other contracts, including affiliated entity&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1019"&gt;Research and development:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;INO-3107&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,930,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,840,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;INO-5401 and other Immuno-oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,293,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,758,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other programs (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,701,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Engineering and device-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,393,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,863,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,821,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,606,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other unallocated expenses (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,259,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,905,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,996,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,582,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,616,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,772,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,766,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,133,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,222,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,808,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) gain on investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,166,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain on available-for-sale equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,077,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,850,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,163,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,711,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,254,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,117,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;          (b) Includes impairment of intangible assets of $2.0&#160;million recorded in 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-258" decimals="0" id="f-1017" unitRef="usd">217756</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-259" decimals="0" id="f-1018" unitRef="usd">832010</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-260" decimals="0" id="f-1020" unitRef="usd">29930344</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-261" decimals="0" id="f-1021" unitRef="usd">17840728</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-262" decimals="0" id="f-1022" unitRef="usd">6293401</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-263" decimals="0" id="f-1023" unitRef="usd">11758935</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-264" decimals="0" id="f-1024" unitRef="usd">-77955</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-265" decimals="0" id="f-1025" unitRef="usd">18701675</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-266" decimals="0" id="f-1026" unitRef="usd">19393929</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-267" decimals="0" id="f-1027" unitRef="usd">8863170</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-268" decimals="0" id="f-1028" unitRef="usd">2821226</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-269" decimals="0" id="f-1029" unitRef="usd">4606341</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-270" decimals="0" id="f-1030" unitRef="usd">17259395</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-271" decimals="0" id="f-1031" unitRef="usd">24905714</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-258" decimals="0" id="f-1032" unitRef="usd">36996338</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-259" decimals="0" id="f-1033" unitRef="usd">47582104</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-258" decimals="0" id="f-1034" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-259" decimals="0" id="f-1035" unitRef="usd">10513371</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingExpenses contextRef="c-258" decimals="0" id="f-1036" unitRef="usd">112616678</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-259" decimals="0" id="f-1037" unitRef="usd">144772038</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest contextRef="c-258" decimals="0" id="f-1038" unitRef="usd">4766993</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-259" decimals="0" id="f-1039" unitRef="usd">8133290</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-258" decimals="0" id="f-1040" unitRef="usd">177833</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-259" decimals="0" id="f-1041" unitRef="usd">1222789</us-gaap:InterestExpenseNonoperating>
    <ino:ChangeInFairValueOfCommonStockWarrants contextRef="c-258" decimals="0" id="f-1042" unitRef="usd">2808608</ino:ChangeInFairValueOfCommonStockWarrants>
    <ino:ChangeInFairValueOfCommonStockWarrants contextRef="c-259" decimals="0" id="f-1043" unitRef="usd">0</ino:ChangeInFairValueOfCommonStockWarrants>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-258" decimals="0" id="f-1044" unitRef="usd">-1166443</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="c-259" decimals="0" id="f-1045" unitRef="usd">773145</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-258" decimals="0" id="f-1046" unitRef="usd">2077182</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-259" decimals="0" id="f-1047" unitRef="usd">5850626</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-258" decimals="0" id="f-1048" unitRef="usd">-3163711</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-259" decimals="0" id="f-1049" unitRef="usd">-4711596</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-258" decimals="0" id="f-1050" unitRef="usd">-107254126</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-259" decimals="0" id="f-1051" unitRef="usd">-135117352</us-gaap:NetIncomeLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-271" decimals="-5" id="f-1052" unitRef="usd">2000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1053">Subsequent Events&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From January 1, 2025 through the date of these financial statements, the Company sold 512,518 shares of common stock under the 2024 Sales Agreement at a weighted average price of $2.16 per share, for net proceeds of $1.1&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-272"
      decimals="INF"
      id="f-1054"
      unitRef="shares">512518</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-273"
      decimals="2"
      id="f-1055"
      unitRef="usdPerShare">2.16</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-272" decimals="-5" id="f-1056" unitRef="usd">1100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
